FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Kahn, HS Bullard, KM Barker, LE Imperatore, G AF Kahn, Henry S. Bullard, Kai McKeever Barker, Lawrence E. Imperatore, Giuseppina TI Differences between Adiposity Indicators for Predicting All-Cause Mortality in a Representative Sample of United States Non-Elderly Adults SO PLOS ONE LA English DT Article ID LIPID-ACCUMULATION PRODUCT; BODY-MASS INDEX; INSULIN-RESISTANCE; ABDOMINAL ADIPOSITY; PROSPECTIVE COHORT; METABOLIC SYNDROME; AFRICAN-AMERICAN; FAT DISTRIBUTION; HEART-DISEASE; RISK-FACTORS AB Background: Adiposity predicts health outcomes, but this relationship could depend on population characteristics and adiposity indicator employed. In a representative sample of 11,437 US adults (National Health and Nutrition Examination Survey, 1988-1994, ages 18-64) we estimated associations with all-cause mortality for body mass index (BMI) and four abdominal adiposity indicators (waist circumference [WC], waist-to-height ratio [WHtR], waist-to-hip ratio [WHR], and waist-to-thigh ratio [WTR]). In a fasting subsample we considered the lipid accumulation product (LAP; [WC enlargement* triglycerides]). Methods and Findings: For each adiposity indicator we estimated linear and categorical mortality risks using sex-specific, proportional-hazards models adjusted for age, black ancestry, tobacco exposure, and socioeconomic position. There were 1,081 deaths through 2006. Using linear models we found little difference among indicators (adjusted hazard ratios [aHRs] per SD increase 1.2-1.4 for men, 1.3-1.5 for women). Using categorical models, men in adiposity midrange (quartiles 2+3; compared to quartile 1) were not at significantly increased risk (aHRs<1.1) unless assessed by WTR (aHR 1.4 [95% CI 1.0-1.9]). Women in adiposity midrange, however, tended toward elevated risk (aHRs 1.2-1.5), except for black women assessed by BMI, WC or WHtR (aHRs 0.7-0.8). Men or women in adiposity quartile 4 (compared to midrange) were generally at risk (aHRs>1.1), especially black men assessed by WTR (aHR 1.9 [1.4-2.6]) and black women by LAP (aHR 2.2 [1.4-3.5]). Quartile 4 of WC or WHtR carried no significant risk for diabetic persons (aHRs 0.7-1.1), but elevated risks for those without diabetes (aHRs>1.5). For both sexes, quartile 4 of LAP carried increased risks for tobacco-exposed persons (aHRs>1.6) but not for non-exposed (aHRs<1.0). Conclusions: Predictions of mortality risk associated with top-quartile adiposity vary with the indicator used, sex, ancestry, and other characteristics. Interpretations of adiposity should consider how variation in the physiology and expandability of regional adipose-tissue depots impacts health. C1 [Kahn, Henry S.; Bullard, Kai McKeever; Barker, Lawrence E.; Imperatore, Giuseppina] US Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. RP Kahn, HS (reprint author), US Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. EM hkahn@cdc.gov OI Kahn, Henry/0000-0003-2533-1562 NR 63 TC 19 Z9 19 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 30 PY 2012 VL 7 IS 11 AR e50428 DI 10.1371/journal.pone.0050428 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 054WM UT WOS:000312376100095 PM 23226283 ER PT J AU Rose, J Parashar, UD AF Rose, Johnie Parashar, Umesh D. TI Should India launch a national immunisation programme against rotavirus? Yes SO BRITISH MEDICAL JOURNAL LA English DT Editorial Material ID COST-EFFECTIVENESS; VACCINE; MORTALITY; EFFICACY; DIARRHEA; INFANTS; SAFETY; IMPACT C1 [Rose, Johnie] Case Western Reserve Univ, Div Res, Dept Family Med & Community Hlth, Cleveland, OH 44106 USA. [Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Rose, J (reprint author), Case Western Reserve Univ, Div Res, Dept Family Med & Community Hlth, Cleveland, OH 44106 USA. EM johnie.rose@case.edu NR 15 TC 2 Z9 2 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BRIT MED J JI Br. Med. J. PD NOV 30 PY 2012 VL 345 AR e7818 DI 10.1136/bmj.e7818 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 048FS UT WOS:000311896500002 PM 23203999 ER PT J AU Buzard, GS Baker, D Wolcott, MJ Norwood, DA Dauphin, LA AF Buzard, Gregory S. Baker, Daniel Wolcott, Mark J. Norwood, David A. Dauphin, Leslie A. TI Multi-platform comparison of ten commercial master mixes for probe-based real-time polymerase chain reaction detection of bioterrorism threat agents for surge preparedness SO FORENSIC SCIENCE INTERNATIONAL LA English DT Article DE Master mix; Real-time PCR; Bioterrorism; Surge preparedness; Select agents ID BURKHOLDERIA-MALLEI; DNA-POLYMERASES; PCR ASSAY; PERFORMANCE; GENOME; QUANTITATION; ANTHRACIS; SEQUENCE; DISEASE; SYSTEMS AB The Centers for Disease Control and Prevention and United States Army Research Institute for Infectious Diseases have developed real-time PCR assays for the detection of bioterrorism threat agents. These assays all rely on a limited number of approved real-time PCR master mixes. Because the availability of these reagents is a critical element of bioterrorism preparedness, we undertook a joint national preparedness exercise to address the potential surge needs resulting from a large-scale bio-emergency. We identified 9 commercially-available potential alternatives to an existing approved master mix (LightCycler FastStart DNA Master HybProbes): the TaqMan Fast Universal PCR master mix, OmniMix HS, FAST qPCR master mix, EXPRESS qPCR SuperMix kit, QuantiFast Probe PCR kit, LightCycler FastStart DNA Master(PLUS) HybProbe, Brilliant II FAST qPCR master mix, ABsolute Fast QPCR Mix and the HotStart IT Taq master mix. The performances of these kits were evaluated by the use of real-time PCR assays for four bioterrorism threat agents: Bacillus anthracis, Brucella melitensis, Burkholderia mallei and Francisella tularensis. The master mixes were compared for target-specific detection levels, as well as consistency of results among three different real-time PCR platforms (LightCycler, SmartCycler and 7500 Fast Dx). Real-time PCR analysis revealed that all ten kits performed well for agent detection on the 7500 Fast Dx instrument; however, the QuantiFast Probe PCR kit yielded the most consistently positive results across multiple real-time PCR platforms. We report that certain combinations of commonly used master mixes and instruments are not as reliable as others at detecting low concentrations of target DNA. Furthermore, our study provides laboratories the option to select from the commercial kits we evaluated to suit their preparedness needs. Published by Elsevier Ireland Ltd. C1 [Buzard, Gregory S.; Dauphin, Leslie A.] Ctr Dis Control & Prevent, BRRAT Lab, LPRB, DPEI,NCEZID,CDC, Atlanta, GA 30333 USA. [Buzard, Gregory S.; Wolcott, Mark J.; Norwood, David A.] USAMRIID, DSD, Ft Detrick, MD 21702 USA. RP Dauphin, LA (reprint author), Ctr Dis Control & Prevent, BRRAT Lab, LPRB, DPEI,NCEZID,CDC, Mail Stop G-42,1600 Clifton Rd, Atlanta, GA 30333 USA. EM Ldauphin@CDC.GOV NR 21 TC 9 Z9 9 U1 0 U2 17 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0379-0738 J9 FORENSIC SCI INT JI Forensic Sci.Int. PD NOV 30 PY 2012 VL 223 IS 1-3 BP 292 EP 297 DI 10.1016/j.forsciint.2012.10.003 PG 6 WC Medicine, Legal SC Legal Medicine GA 041WJ UT WOS:000311432100058 PM 23107058 ER PT J AU Caudill, SP AF Caudill, Samuel P. TI Use of pooled samples from the national health and nutrition examination survey SO STATISTICS IN MEDICINE LA English DT Article DE 2,2 ',4,4 ',5,5 '-hexachlorobiphenyl; log normal; NHANES; polychlorinated and polybrominated compounds; pooled-samples AB The National Centers for Disease Control and Prevention (CDC) provides an ongoing assessment of the US population's exposure to environmental chemicals by using biomonitoring in conjunction with CDC's National Health and Nutrition Examination Survey (NHANES). Characterizing the distributions of concentrations of environmental compounds or their metabolites in the US population is a primary objective of CDC's biomonitoring program. Historically, this characterization has been based on individual measurements of these compounds in body fluid or tissue from representative samples of the population. Pooling samples before making analytical measurements can reduce the costs of biomonitoring by reducing the number of analyses. For the first time in NHANES 2005-2006, a weighted pooled-sample design was implemented to facilitate pooling samples before making analytical measurements. This paper describes this design and the estimation method being developed in the National Center for Environmental Health, Division of Laboratory Sciences (NCEH/DLS) to characterize concentrations of polychlorinated and polybrominated compounds. We present percentile estimates for 2,2',4,4',5,5'-hexachlorobiphenyl (PCB153) in specific subpopulations of the US based on the NHANES 2005-2006 pooled-sample design. We also compare estimates based on individual samples from NHANES 2003-2004 with estimates based on artificially created pools from NHANES 2003-2004 using a pooled-sample design similar to the one used for NHANES 2005-2006. For NHANES 2005-2006 the number of analyses required to characterize the levels of 61 polychlorinated and 13 polybrominated compounds in the US population was reduced from 2201 to 228. At a cost of $1400 per analytical measurement, this represents a savings of approximately $2.78 million. Published 2012. This article is a US Government work and is in the public domain in the USA. C1 [Caudill, Samuel P.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Publ Hlth Serv,US Dept HHS, Atlanta, GA 30333 USA. RP Caudill, SP (reprint author), Ctr Dis Control, Div Sci Lab, Atlanta, GA 30333 USA. EM spc1@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 9 Z9 9 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD NOV 30 PY 2012 VL 31 IS 27 SI SI BP 3269 EP 3277 DI 10.1002/sim.5341 PG 9 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 034PR UT WOS:000310885900004 PM 22492247 ER PT J AU Chen, MP Shang, N Winston, CA Becerra, JE AF Chen, Michael P. Shang, Nong Winston, Carla A. Becerra, Jose E. TI A Bayesian analysis of the 2009 decline in tuberculosis morbidity in the United?States SO STATISTICS IN MEDICINE LA English DT Article DE tuberculosis trends; time series analysis; seasonality; ARIMA; intervention models; change point; Bayesian analysis ID REGRESSION; STATES AB Although annual data are commonly used to model linear trends and changes in trends of disease incidence, monthly data could provide additional resolution for statistical inferences. Because monthly data may exhibit seasonal patterns, we need to consider seasonally adjusted models, which can be theoretically complex and computationally intensive. We propose a combination of methods to reduce the complexity of modeling seasonal data and to provide estimates for a change in trend when the timing and magnitude of the change are unknown. To assess potential changes in trend, we first used autoregressive integrated moving average (ARIMA) models to analyze the residuals and forecast errors, followed by multiple ARIMA intervention models to estimate the timing and magnitude of the change. Because the variable corresponding to time of change is not a statistical parameter, its confidence bounds cannot be estimated by intervention models. To model timing of change and its credible interval, we developed a Bayesian technique. We avoided the need for computationally intensive simulations by deriving a closed form for the posterior distribution of the time of change. Using a combination of ARIMA and Bayesian methods, we estimated the timing and magnitude of change in trend for tuberculosis cases in the United States. Published 2012. This article is a US Government work and is in the public domain in the USA. C1 [Chen, Michael P.; Shang, Nong; Winston, Carla A.; Becerra, Jose E.] Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. RP Chen, MP (reprint author), CDC, Div TB Eliminat, Atlanta, GA 30329 USA. EM mchen1@cdc.gov RI Becerra, Jose/C-4071-2014 NR 14 TC 2 Z9 3 U1 0 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD NOV 30 PY 2012 VL 31 IS 27 SI SI BP 3278 EP 3284 DI 10.1002/sim.5343 PG 7 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 034PR UT WOS:000310885900005 PM 22415632 ER PT J AU Furlow-Parmley, C Singleton, JA Bardenheier, B Bryan, L AF Furlow-Parmley, Carolyn Singleton, James A. Bardenheier, Barbara Bryan, Leah TI Combining estimates from two surveys: An example from monitoring 2009 influenza A (H1N1) pandemic vaccination SO STATISTICS IN MEDICINE LA English DT Article DE H1N1; vaccination; combining estimates AB During the 2009 influenza A (H1N1) pandemic, there was an ongoing need to monitor 2009 H1N1 vaccination coverage at the national and state level to evaluate the vaccination campaign; thus, precise vaccination coverage estimates were needed in a timely fashion. The current objective is to describe and evaluate the methodology used to combine 2009 H1N1 vaccination coverage estimates from the Behavioral Risk Factor Surveillance System (BRFSS) and the National 2009 H1N1 Flu Survey (NHFS). H1N1 state level vaccination coverage estimates were combined by taking weighted averages of the BRFSS and NHFS estimates, with more weight given to the estimate with the larger effective sample size (sample size/design effect). The impact of the choice of weights was evaluated by comparing estimates when the design effect was removed from the weights. Combined vaccination coverage estimates for children generally fell midway between NHFS and BRFSS estimates because of larger NHFS sample sizes but smaller BRFSS design effects. Adult estimates were more closely weighted to BRFSS estimates because of larger BRFSS sample sizes. Combined standard errors were smaller than the survey-specific standard errors. When removing the design effect from the weights, the child combined estimates were more closely weighted to those from NHFS, resulting in larger standard errors. Adult combined estimates were similar regardless of choice of weight because of similar design effects across the two surveys. Combining estimates by weighting by the effective sample size allowed timely release of more precise estimates in all states during the 2009 H1N1 pandemic. Copyright (C) 2012 John Wiley & Sons, Ltd. C1 [Furlow-Parmley, Carolyn; Bryan, Leah] Sci Applicat Int Corp, Atlanta, GA USA. [Singleton, James A.] Ctr Dis Control & Prevent, Assessment Branch, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Bardenheier, Barbara] Ctr Dis Control & Prevent, Epidemiol & Stat Branch, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Furlow-Parmley, C (reprint author), Sci Applicat Int Corp, Atlanta, GA USA. EM cfurlow@cdc.gov NR 6 TC 2 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 J9 STAT MED JI Stat. Med. PD NOV 30 PY 2012 VL 31 IS 27 SI SI BP 3285 EP 3294 DI 10.1002/sim.5333 PG 10 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 034PR UT WOS:000310885900006 PM 22859268 ER PT J AU Chai, SJ Rao, CY Varma, JK AF Chai, Shua J. Rao, Carol Y. Varma, Jay K. TI Multidrug-Resistant Tuberculosis SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID CHINA C1 [Chai, Shua J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Rao, Carol Y.] US Ctr Dis Control & Prevent, Beijing, Peoples R China. [Varma, Jay K.] New York City Dept Hlth & Mental Hyg, New York, NY USA. RP Chai, SJ (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM schai@cdc.gov NR 5 TC 0 Z9 0 U1 1 U2 7 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 29 PY 2012 VL 367 IS 22 BP 2154 EP 2155 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 044MS UT WOS:000311624400017 PM 23190230 ER PT J AU Shults, RA Olsen, EO AF Shults, Ruth A. Olsen, Emily O'Malley TI Vital Signs: Drinking and Driving Among High School Students Aged >= 16 Years-United States, 1991-2011 (Reprinted from MMWR, vol 61, pg 796-800, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID BINGE DRINKING; RISK; ADULTS; YOUTH C1 [Olsen, Emily O'Malley] CDC, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM rshults@cdc.gov NR 22 TC 1 Z9 1 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 28 PY 2012 VL 308 IS 20 BP 2074 EP 2077 DI 10.1001/jama.2012.14817 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 043IV UT WOS:000311537200008 ER PT J AU Leshem, E AF Leshem, Eyal TI Severe Respiratory Illness Associated With a Novel Coronavirus - Saudi Arabia and Qatar, 2012 (Reprinted from MMWR, vol 61, pg 820, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 CDC, Atlanta, GA 30333 USA. RP Leshem, E (reprint author), CDC, Atlanta, GA 30333 USA. EM eleshem@cdc.gov NR 7 TC 1 Z9 1 U1 0 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 28 PY 2012 VL 308 IS 20 BP 2077 EP 2078 DI 10.1001/jama.2012.31393 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 043IV UT WOS:000311537200009 ER PT J AU Misegades, LK Winter, K Harriman, K Talarico, J Messonnier, NE Clark, TA Martin, SW AF Misegades, Lara K. Winter, Kathleen Harriman, Kathleen Talarico, John Messonnier, Nancy E. Clark, Thomas A. Martin, Stacey W. TI Association of Childhood Pertussis With Receipt of 5 Doses of Pertussis Vaccine by Time Since Last Vaccine Dose, California, 2010 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID UNITED-STATES; CHILDREN; EFFICACY; DIPHTHERIA; SEVERITY; OUTBREAK; TETANUS AB Context In 2010, California experienced its largest pertussis epidemic in more than 60 years; a substantial burden of disease was noted in the 7- to 10-year-old age group despite high diphtheria, tetanus, and acellular pertussis vaccine (DTaP) coverage, indicating the possibility of waning protection. Objective To evaluate the association between pertussis and receipt of 5 DTaP doses by time since fifth DTaP dose. Design, Setting, and Participants Case-control evaluation conducted in 15 California counties. Cases (n=682) were all suspected, probable, and confirmed pertussis cases among children aged 4 to 10 years reported from January through December 14, 2010; controls (n=2016) were children in the same age group who received care from the clinicians reporting the cases. Three controls were selected per case. Vaccination histories were obtained from medical records and immunization registries. Main Outcome Measures Primary outcomes were (1) odds ratios (ORs) for the association between pertussis and receipt of the 5-dose DTaP series and (2) ORs for the association between pertussis and time since completion (<12, 12-23, 24-35, 36-47, 48-59, or >= 60 months) of the 5-dose DTaP series. Logistic regression was used to calculate ORs, accounting for clustering by county and clinician, and vaccine effectiveness (VE) was estimated as (1-OR) x 100%. Results Among cases and controls, 53 (7.8%) and 19 (0.9%) had not received any pertussis-containing vaccines, respectively. Compared with controls, children with pertussis had a lower odds of having received all 5 doses of DTaP (OR, 0.11; 95% CI, 0.06-0.21 [estimated VE, 88.7%; 95% CI, 79.4%-93.8%]). When children were categorized by time since completion of the DTaP series, using an unvaccinated reference group, children with pertussis compared with controls were less likely to have received their fifth dose within the prior 12 months (19 [2.8%] vs 354 [17.6%], respectively; OR, 0.02; 95% CI, 0.01-0.04 [estimated VE, 98.1%; 95% CI, 96.1%-99.1%]). This association was evident with longer time since vaccination, with ORs increasing with time since the fifth dose. At 60 months or longer (n=231 cases [33.9%] and n=288 controls [14.3%]), the OR was 0.29 (95% CI, 0.15-0.54 [estimated VE, 71.2%; 95% CI, 45.8%-84.8%]). Accordingly, the estimated VE declined each year after receipt of the fifth dose of DTaP. Conclusion Among children in 15 California counties, children with pertussis, compared with controls, had lower odds of having received the 5-dose DTaP series; as time since last DTaP dose increased, the odds increased, which is consistent with a progressive decrease in estimated vaccine effectiveness each year after the final dose of pertussis vaccine. JAMA. 2012;308(20):2126-2132 www.jama.com C1 [Misegades, Lara K.; Messonnier, Nancy E.; Clark, Thomas A.; Martin, Stacey W.] US Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Misegades, Lara K.] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Winter, Kathleen; Harriman, Kathleen; Talarico, John] Calif Dept Publ Hlth, Immunizat Branch, Richmond, VA USA. RP Misegades, LK (reprint author), US Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS C25, Atlanta, GA 30329 USA. EM lmisegades@cdc.gov NR 31 TC 119 Z9 121 U1 0 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 28 PY 2012 VL 308 IS 20 BP 2126 EP 2132 DI 10.1001/jama.2012.14939 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 043IV UT WOS:000311537200027 PM 23188029 ER PT J AU Etienne, KA Gillece, J Hilsabeck, R Schupp, JM Colman, R Lockhart, SR Gade, L Thompson, EH Sutton, DA Neblett-Fanfair, R Park, BJ Turabelidze, G Keim, P Brandt, ME Deak, E Engelthaler, DM AF Etienne, Kizee A. Gillece, John Hilsabeck, Remy Schupp, Jim M. Colman, Rebecca Lockhart, Shawn R. Gade, Lalitha Thompson, Elizabeth H. Sutton, Deanna A. Neblett-Fanfair, Robyn Park, Benjamin J. Turabelidze, George Keim, Paul Brandt, Mary E. Deak, Eszter Engelthaler, David M. TI Whole Genome Sequence Typing to Investigate the Apophysomyces Outbreak following a Tornado in Joplin, Missouri, 2011 SO PLOS ONE LA English DT Article ID ELEGANS; ZYGOMYCOSIS; EPIDEMIOLOGY AB Case reports of Apophysomyces spp. in immunocompetent hosts have been a result of traumatic deep implantation of Apophysomyces spp. spore-contaminated soil or debris. On May 22, 2011 a tornado occurred in Joplin, MO, leaving 13 tornado victims with Apophysomyces trapeziformis infections as a result of lacerations from airborne material. We used whole genome sequence typing (WGST) for high-resolution phylogenetic SNP analysis of 17 outbreak Apophysomyces isolates and five additional temporally and spatially diverse Apophysomyces control isolates (three A. trapeziformis and two A. variabilis isolates). Whole genome SNP phylogenetic analysis revealed three clusters of genotypically related or identical A. trapeziformis isolates and multiple distinct isolates among the Joplin group; this indicated multiple genotypes from a single or multiple sources. Though no linkage between genotype and location of exposure was observed, WGST analysis determined that the Joplin isolates were more closely related to each other than to the control isolates, suggesting local population structure. Additionally, species delineation based on WGST demonstrated the need to reassess currently accepted taxonomic classifications of phylogenetic species within the genus Apophysomyces. C1 [Etienne, Kizee A.; Lockhart, Shawn R.; Gade, Lalitha; Neblett-Fanfair, Robyn; Park, Benjamin J.; Brandt, Mary E.; Deak, Eszter] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Gillece, John; Hilsabeck, Remy; Schupp, Jim M.; Colman, Rebecca; Keim, Paul; Engelthaler, David M.] Translat Genom Res Inst, Flagstaff, AZ USA. [Thompson, Elizabeth H.; Sutton, Deanna A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Turabelidze, George] Missouri Dept Hlth, St Louis, MO USA. RP Etienne, KA (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM ketienne@cdc.gov NR 31 TC 21 Z9 22 U1 2 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 27 PY 2012 VL 7 IS 11 AR e49989 DI 10.1371/journal.pone.0049989 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 048BS UT WOS:000311885800039 PM 23209631 ER PT J AU Kerkhoff, AD Kranzer, K Samandari, T Nakiyingi-Miiro, J Whalen, CC Harries, AD Lawn, SD AF Kerkhoff, Andrew D. Kranzer, Katharina Samandari, Taraz Nakiyingi-Miiro, Jessica Whalen, Christopher C. Harries, Anthony D. Lawn, Stephen D. TI Systematic Review of TST Responses in People Living with HIV in Under-Resourced Settings: Implications for Isoniazid Preventive Therapy SO PLOS ONE LA English DT Article ID TUBERCULIN SKIN-TEST; HUMAN-IMMUNODEFICIENCY-VIRUS; GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MYCOBACTERIUM-TUBERCULOSIS; ANTIRETROVIRAL THERAPY; INFECTED INDIVIDUALS; POSITIVE INDIVIDUALS; CONTROLLED TRIAL; SOUTH-AFRICA AB Background: People living with HIV (PLWH) who have positive tuberculin skin tests (TST) benefit from isoniazid preventive therapy (IPT) whereas those testing TST-negative do not. Revised World Health Organization guidelines explicitly state that assessment of TST is not a requirement for initiation of IPT. However, it is not known what proportions of patients will benefit from IPT if implemented without targeting according to TST status. We therefore determined the proportions of PLWH who test TST-positive. Methodology/Principal Findings: We systematically reviewed the literature published between January 1990 and February 2012 to determine the proportions of patients without active tuberculosis attending HIV care services in low and middle-income countries who tested TST-positive (>= 5 mm induration). Proportions were also determined for different CD4 count strata. Data from 19 studies with 9,478 PLWH from sub-Saharan Africa, Asia and Central and South America were summarized. The vast majority were not receiving antiretroviral therapy (ART). A sub-analysis was conducted of 5 studies (5,567 subjects) from high TB prevalence countries of PLWH with negative TB screens attending HIV care and treatment settings for whom CD4 stratified data were available. The median proportion of PLWH testing TST-positive overall was 22.8% (range, 19.5-32.6%). The median (range) proportions with CD4 cell counts of < 200, 200-499 or >= 500 cells/mL who tested positive were 12.4% (8.2-15.3%), 28.4% (20.1-36.9%) and 37.4% (31.3-56.3%), respectively. Heterogeneity in the data precluded calculation of pooled summary estimates. Conclusions/Significance: In most settings, if IPT is administered to PLWH pre-ART without assessment of TST status, only a minority of those treated are likely to benefit, especially among those with the lowest CD4 cell counts. This may be inefficient use of resources and cost-effectiveness analyses should take this into account. Local knowledge of TST response rates may help inform policies. New simple means of identifying those who will benefit from IPT are needed to permit appropriate targeting of this intervention. C1 [Kerkhoff, Andrew D.; Kranzer, Katharina; Lawn, Stephen D.] Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa. [Kerkhoff, Andrew D.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Kranzer, Katharina; Harries, Anthony D.; Lawn, Stephen D.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1E 7HT, England. [Samandari, Taraz] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Nakiyingi-Miiro, Jessica] Uganda Virus Res Inst, MRC, Uganda Res Unit AIDS, Entebbe, Uganda. [Whalen, Christopher C.] Univ Georgia, Dept Epidemiol & Biostat, Coll Publ Hlth, Athens, GA 30602 USA. [Harries, Anthony D.] Int Union TB & Lung Dis, Paris, France. RP Lawn, SD (reprint author), Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa. EM stephen.lawn@lshtm.ac.uk RI Kranzer, Katharina/O-8845-2014 OI Kranzer, Katharina/0000-0001-5691-7270 FU Wellcome Trust FX SDL and KK were funded by the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 60 TC 11 Z9 11 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 27 PY 2012 VL 7 IS 11 AR e49928 DI 10.1371/journal.pone.0049928 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 048BS UT WOS:000311885800034 PM 23209621 ER PT J AU Streicker, DG Altizer, SM Velasco-Villa, A Rupprecht, CE AF Streicker, Daniel G. Altizer, Sonia M. Velasco-Villa, Andres Rupprecht, Charles E. TI Variable evolutionary routes to host establishment across repeated rabies virus host shifts among bats SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE comparative; phylogeny; chiroptera; Lyssavirus ID RNA VIRUSES; TRANSMISSION; VIRULENCE; GLYCOPROTEIN; EMERGENCE; SELECTION; PATHOGENICITY; EPIDEMIOLOGY; CONSTRAINTS; MUTATIONS AB Determining the genetic pathways that viruses traverse to establish in new host species is crucial to predict the outcome of cross-species transmission but poorly understood for most host-virus systems. Using sequences encoding 78% of the rabies virus genome, we explored the extent, repeatability and dynamic outcome of evolution associated with multiple host shifts among New World bats. Episodic bursts of positive selection were detected in several viral proteins, including regions associated with host cell interaction and viral replication. Host shifts involved unique sets of substitutions, and few sites exhibited repeated evolution across adaptation to many bat species, suggesting diverse genetic determinants over host range. Combining these results with genetic reconstructions of the demographic histories of individual viral lineages revealed that although rabies viruses shared consistent three-stage processes of emergence in each new bat species, host shifts involving greater numbers of positively selected substitutions had longer delays between cross-species transmission and enzootic viral establishment. Our results point to multiple evolutionary routes to host establishment in a zoonotic RNA virus that may influence the speed of viral emergence. C1 [Streicker, Daniel G.; Altizer, Sonia M.] Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA. [Streicker, Daniel G.; Velasco-Villa, Andres; Rupprecht, Charles E.] US Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. RP Streicker, DG (reprint author), Univ Georgia, Odum Sch Ecol, Athens, GA 30602 USA. EM dstrike@uga.edu OI Streicker, Daniel/0000-0001-7475-2705 FU University of Georgia; National Science Foundation [DEB-1020966] FX We thank Ivan Kuzmin for providing some of the oligonucleotide sequences, Sergei Kosakovsky Pond for suggestions on detection of positive selection, and Eric Crandall for help with the two-epoch demographic models. We thank many colleagues in the US state health departments and abroad for submission of samples for diagnostic confirmation and viral characterization. D. G. S. was supported by a Dissertation Completion Award from the University of Georgia and National Science Foundation Grant DEB-1020966. NR 39 TC 17 Z9 17 U1 2 U2 42 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 27 PY 2012 VL 109 IS 48 BP 19715 EP 19720 DI 10.1073/pnas.1203456109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 053ZN UT WOS:000312313900047 PM 23150575 ER PT J AU Loughlin, AM Marchant, CD Adams, W Barnett, E Baxter, R Black, S Casey, C Dekker, C Edwards, KM Klein, J Klein, NP LaRussah, P Sparks, R Jakob, K AF Loughlin, Anita M. Marchant, Colin D. Adams, William Barnett, Elizabeth Baxter, Roger Black, Steve Casey, Christine Dekker, Cornelia Edwards, Katherine M. Klein, Jerold Klein, Nicola P. LaRussah, Philip Sparks, Robert Jakob, Kathleen TI Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) SO VACCINE LA English DT Article DE Causality; Vaccine safety; VAERS ID SAFETY; NETWORK AB Adverse events following immunization (AEFI) reported to the national Vaccine Adverse Event Reporting System (VAERS) represent true causally related events, as well as events that are temporally, but not necessarily causally related to vaccine. Objective: We sought to determine if the causal relationships between the vaccine and the AEFI reported to VAERS could be assessed through expert review. Design: A stratified random sample of 100 VAERS reports received in 2004 contained 13 fatal cases, 19 cases with non-fatal disabilities, 39 other serious non-fatal cases and 29 non-serious cases. Experts knowledgeable about vaccines and clinical outcomes, reviewed each VAERS report and available medical records. Main outcome measures: Modified World Health Organization criteria were used to classify the causal relationship between vaccines and AEFI as definite, probable, possible, unlikely or unrelated. Five independent reviewers evaluated each report. If they did not reach a majority agreement on causality after initial review, the report was discussed on a telephone conference to achieve agreement. Results: 108 AEFIs were identified in the selected 100 VAERS reports. After initial review majority agreement was achieved for 83% of the AEFI and 17% required further discussion. In the end, only 3 (3%) of the AEFI were classified as definitely causally related to vaccine received. Of the remaining AEFI22 (20%) were classified as probably and 22(20%) were classified as possibly related to vaccine received: a majority (53%) were classified as either unlikely or unrelated to a vaccine received. Conclusions: Using VAERS reports and additional documentation, causality could be assessed by expert review in the majority of VAERS reports. Assessment of VAERS reports identified that causality was thought to be probable or definite in less than one quarter of reports, and these were dominated by local reactions, allergic reactions, or symptoms known to be associated with the vaccine administered. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Loughlin, Anita M.; Marchant, Colin D.; Adams, William; Barnett, Elizabeth; Klein, Jerold] Boston Med Ctr, Boston, MA USA. [Loughlin, Anita M.; Marchant, Colin D.; Adams, William; Barnett, Elizabeth; Klein, Jerold] Boston Univ, Sch Med, Boston, MA 02118 USA. [Loughlin, Anita M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Baxter, Roger; Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA. [Black, Steve] Cincinnati Childrens Hosp Cincinnati, Ctr Global Health, Cincinnati, OH USA. [Casey, Christine] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dekker, Cornelia] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Edwards, Katherine M.; Sparks, Robert] Vanderbilt Univ, Nashville, TN USA. [LaRussah, Philip; Jakob, Kathleen] Columbia Univ, Med Ctr, New York, NY USA. RP Loughlin, AM (reprint author), Boston Med Ctr, Boston, MA USA. EM aloughli@bu.edu OI Casey, Christine/0000-0002-6163-2277; Barnett, Elizabeth/0000-0003-4822-5949 FU Centers for Disease Control and Prevention through America's Health Insurance Plans [200-2002-00732]; Sanofi Pasteur; Intercell; Novartis; Merck; GSK; MedImmune; Wyeth; Merck Co; GlaxoSmithKline FX Financial support for this study was provided by the Centers for Disease Control and Prevention (contract 200-2002-00732) through America's Health Insurance Plans, this funding covered the costs of design and conduct of the study, collection, management, analysis, and interpretation of data, and the preparation, review, and approval of the manuscript. The principal investigator, Colin Marchant and first author, Anita Loughlin had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the analysis. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention.; The CISA Causality working group includes all co-authors. Their contributions include but are not limited to (1) the refinement of study protocol and modified causality criteria definitions, (2) the review of records and participation in the adjudication process for each case report, and (3) the critical review and editing of the submitted manuscript. Co-authors' financial disclosures are the following. Elizabeth Barnett has received research support Sanofi Pasteur and Intercell; Roger Baxter has received research grants from Novartis, Sanofi Pasteur, Merck, GSK, MedImmune, and Wyeth; Steven Black is a consultant for Novartis and serves on DSMBs for GSK and Novartis; Cornelia Dekker is a member of the Scientific Advisory Board of PharmaJet; Jerome Klein has been a member of the Pediatric Scientific Advisory Committee of Merck; Nicola Klein has received research support from Merck, Sanofi Pasteur, GSK, Novartis and Pfizer. Philip LaRussa serves on DSMBs for Novartis and his laboratory receives research support from Merck & Co; Colin Marchant has received research funding, and/or has been a speaker or consultant to the following companies: GlaxoSmithKline, Merck, MedImmune, Novartis, Sanofi-Pasteur, and Pfizer. Authors without conflicts of interest are William Adams, Christine Casey, Kathryn Edwards, Kathleen Jakobs, Anita Loughlin, and Robert Sparks. NR 30 TC 16 Z9 17 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 26 PY 2012 VL 30 IS 50 BP 7253 EP 7259 DI 10.1016/j.vaccine.2012.09.074 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 056XB UT WOS:000312523600024 PM 23063829 ER PT J AU Phillips, CD Adepoju, O Stone, N Moudouni, DKM Nwaiwu, O Zhao, HW Frentzel, E Mehr, D Garfinkel, S AF Phillips, Charles D. Adepoju, Omolola Stone, Nimalie Moudouni, Darcy K. McMaughan Nwaiwu, Obioma Zhao, Hongwei Frentzel, Elizabeth Mehr, David Garfinkel, Steven TI Asymptomatic bacteriuria, antibiotic use, and suspected urinary tract infections in four nursing homes SO BMC GERIATRICS LA English DT Article DE Nursing home; Antibiotic stewardship; Urinary tract infection; Asymptomatic bacteriuria; Antibiotics ID LONG-TERM-CARE; MINIMUM DATA SET; COGNITIVE PERFORMANCE SCALE; ANTIMICROBIAL RESISTANCE; RESIDENTS; FACILITIES; MDS; EPIDEMIOLOGY; DEPRESSION; DEMENTIA AB Background: Urinary tract infections (UTIs) are the most commonly treated infection among nursing home residents. Even in the absence of specific (e. g., dysuria) or non-specific (e. g., fever) signs or symptoms, residents frequently receive an antibiotic for a suspected infection. This research investigates factors associated with the use of antibiotics to treat asymptomatic bacteriuria (ASB) among nursing home residents. Methods: This was a cross-sectional study involving multi-level multivariate analyses of antibiotic prescription data for residents in four nursing homes in central Texas. Participants included all nursing home residents in these homes who, over a six-month period, received an antibiotic for a suspected UTI. We investigated what factors affected the likelihood that a resident receiving an antibiotic for a suspected UTI was asymptomatic. Results: The most powerful predictor of antibiotic treatment for ASB was the presence of an indwelling urinary catheter. Over 80 percent of antibiotic prescriptions written for catheterized individuals were written for individuals with ASB. For those without a catheter, record reviews identified 204 antibiotic prescriptions among 151 residents treated for a suspected UTI. Almost 50% of these prescriptions were for residents with no documented UTI symptoms. Almost three-quarters of these antibiotics were ordered after laboratory results were available to clinicians. Multivariate analyses indicated that resident characteristics did not affect the likelihood that an antibiotic was prescribed for ASB. The only statistically significant factor was the identity of the nursing home in which a resident resided. Conclusions: We confirm the findings of earlier research indicating frequent use of antibiotics for ASB in nursing homes, especially for residents with urinary catheters. In this sample of nursing home residents, half of the antibiotic prescriptions for a suspected UTI in residents without catheters occurred with no documented signs or symptoms of a UTI. Urine studies were performed in almost all suspected UTI cases in which an antibiotic was prescribed. Efforts to improve antibiotic stewardship in nursing homes must address clinical decision-making solely on the basis of diagnostic testing in the absence of signs or symptoms of a UTI. C1 [Phillips, Charles D.; Adepoju, Omolola; Moudouni, Darcy K. McMaughan; Nwaiwu, Obioma; Zhao, Hongwei] Texas A&M Hlth Sci Ctr, College Stn, TX 77843 USA. [Stone, Nimalie] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Frentzel, Elizabeth; Garfinkel, Steven] Amer Inst Res, Chapel Hill, NC 27517 USA. [Mehr, David] Univ Missouri Columbia, Sch Med, Curtis W & Ann H Long Dept Family & Community Med, Columbia, MO 65212 USA. RP Phillips, CD (reprint author), Texas A&M Hlth Sci Ctr, 1266 TAMU, College Stn, TX 77843 USA. EM phillipscd@srph.tamhsc.edu; nwaiwu@srph.tamhsc.edu FU Agency for Healthcare Research and Quality/sub to American Institutes for Research [00530-02434.008, HHSA2902006000191 T.0.8] FX Funding provided by the Agency for Healthcare Research and Quality/sub to American Institutes for Research, Award No. 00530-02434.008, Prime award: HHSA2902006000191 T.0.8. NR 49 TC 20 Z9 20 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2318 J9 BMC GERIATR JI BMC Geriatr. PD NOV 23 PY 2012 VL 12 AR 73 DI 10.1186/1471-2318-12-73 PG 8 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 070FE UT WOS:000313490700001 PM 23176555 ER PT J AU Smith, DH Schneider, J Thorp, ML Vupputuri, S Weiss, JW Johnson, ES Feldstein, A Petrik, AF Yang, X Snyder, SR AF Smith, David H. Schneider, Jennifer Thorp, Micah L. Vupputuri, Suma Weiss, Jessica W. Johnson, Eric S. Feldstein, Adrianne Petrik, Amanda F. Yang, Xuihai Snyder, Susan R. TI Clinician's use of automated reports of estimated glomerular filtration rate: A qualitative study SO BMC NEPHROLOGY LA English DT Article DE Estimated glomerular filtration rate; Qualitative; Serum creatinine ID CHRONIC KIDNEY-DISEASE; PREDICTION EQUATION; SERUM CREATININE; PHYSICIANS; PREVALENCE; IMPROVE AB Background: There is a growing awareness in primary care of the importance of identifying patients with chronic kidney disease (CKD) so that they can receive appropriate clinical care; one method that has been widely embraced is the use of automated reporting of estimated glomerular filtration rate (eGFR) by clinical laboratories. We undertook a qualitative study to examine how clinicians use eGFR in clinical decision making, patient communication issues, barriers to use of eGFR, and suggestions to improve the clinical usefulness of eGFR reports. Methods: Our study used qualitative methods with structured interviews among primary care clinicians including both physicians and allied health providers, recruited from Kaiser Permanente Northwest, a non-profit health maintenance organization. Results: We found that clinicians generally held favorable views toward eGFR reporting but did not use eGFR to replace serum creatinine in their clinical decision-making. Clinicians used eGFR as a tool to help identify CKD, educate patients about their kidney function and make treatment decisions. Barriers noted by several clinicians included a desire for greater education regarding care for patients with CKD and tools to facilitate discussion of eGFR findings with patients. Conclusions: The manner in which clinicians use eGFRs appears to be more complex than previously understood, and our study illustrates some of the efforts that might be usefully undertaken (e. g. specific clinician education) when encouraging further promulgation of eGFR reporting and usage. C1 [Smith, David H.; Schneider, Jennifer; Thorp, Micah L.; Weiss, Jessica W.; Johnson, Eric S.; Feldstein, Adrianne; Petrik, Amanda F.; Yang, Xuihai] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. [Thorp, Micah L.] Kaiser Permanente NW, Dept Nephrol, Portland, OR USA. [Vupputuri, Suma] Kaiser Permanente SE, Ctr Heath Res, Atlanta, GA USA. [Weiss, Jessica W.] Oregon Hlth & Sci Univ, Div Nephrol, Portland, OR 97201 USA. [Snyder, Susan R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Smith, DH (reprint author), Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. EM David.h.smith@kpchr.org NR 25 TC 0 Z9 1 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD NOV 23 PY 2012 VL 13 AR 154 DI 10.1186/1471-2369-13-154 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA 064HW UT WOS:000313065800001 PM 23173944 ER PT J AU Elshabrawy, HA Coughlin, MM Baker, SC Prabhakar, BS AF Elshabrawy, Hatem A. Coughlin, Melissa M. Baker, Susan C. Prabhakar, Bellur S. TI Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing SO PLOS ONE LA English DT Article ID ACUTE RESPIRATORY SYNDROME; RECEPTOR-BINDING DOMAIN; CORONAVIRUS-LIKE VIRUS; IN-VITRO; ESCAPE MUTANTS; STRUCTURAL-CHARACTERIZATION; CELL RESPONSES; FUSION PEPTIDE; CATHEPSIN-L; S2 DOMAIN AB Immune sera from convalescent patients have been shown to be effective in the treatment of patients infected with Severe Acute Respiratory Syndrome Virus (SARS-CoV) making passive immune therapy with human monoclonal antibodies an attractive treatment strategy for SARS. Previously, using Xenomouse (Amgen British Columbia Inc), we produced a panel of neutralizing Human monoclonal antibodies (HmAbs) that could specifically bind to the ectodomain of the SARS-CoV spike (S) glycoprotein. Some of the HmAbs were S1 domain specific, while some were not. In this study, we describe non-S1 binding neutralizing HmAbs that can specifically bind to the conserved S2 domain of the S protein. However, unlike the S1 specific HmAbs, the S2 specific HmAbs can neutralize pseudotyped viruses expressing different S proteins containing receptor binding domain sequences of various clinical isolates. These data indicate that HmAbs which bind to conserved regions of the S protein are more suitable for conferring protection against a wide range of SARS-CoV variants and have implications for generating therapeutic antibodies or subunit vaccines against other enveloped viruses. C1 [Elshabrawy, Hatem A.; Prabhakar, Bellur S.] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA. [Coughlin, Melissa M.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Virus Lab Branch, Atlanta, GA USA. [Baker, Susan C.] Loyola Univ Chicago, Stritch Sch Med, Dept Microbiol & Immunol, Maywood, IL USA. RP Prabhakar, BS (reprint author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA. EM bprabhak@uic.edu FU Public Health Service [1U01AI082296] FX This work was supported by Public Health Service grant 1U01AI082296. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 16 Z9 17 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 21 PY 2012 VL 7 IS 11 AR e50366 DI 10.1371/journal.pone.0050366 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 047ER UT WOS:000311821000222 PM 23185609 ER PT J AU Ball, SW Walker, DK Donahue, SMA Izrael, D Zhang, J Euler, GL Greby, SM Lindley, MC Graitcer, SB Bridges, C Williams, WW Singleton, JA MacCannell, TF AF Ball, Sarah W. Walker, Deborah K. Donahue, Sara M. A. Izrael, David Zhang, Jun Euler, Gary L. Greby, Stacie M. Lindley, Megan C. Graitcer, Samuel B. Bridges, Carolyn Williams, Walter W. Singleton, James A. MacCannell, Taranisia F. TI Influenza Vaccination Coverage Among Health-Care Personnel-2011-12 Influenza Season, United States (Reprinted from MMWR vol, 38, pg 753, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID HOME STAFF; RESIDENTS; WORKERS; TRIAL C1 [Zhang, Jun; Euler, Gary L.; Greby, Stacie M.; Lindley, Megan C.; Graitcer, Samuel B.; Bridges, Carolyn; Williams, Walter W.; Singleton, James A.] CDC, Immunizat Svcs Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Ball, Sarah W.; Walker, Deborah K.; Donahue, Sara M. A.; Izrael, David] ABT Associates Inc, Cambridge, MA USA. [MacCannell, Taranisia F.] CDC, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Euler, GL (reprint author), CDC, Immunizat Svcs Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jzhang5@cdc.gov; geuler@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 21 PY 2012 VL 308 IS 19 BP 1964 EP 1966 DI 10.1001/jama.2012.14337 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 040AQ UT WOS:000311291400008 ER PT J AU Grant, J Kammerer, S Baker, B Kim, L AF Grant, Juliana Kammerer, Steve Baker, Brian Kim, Lindsay TI Tuberculosis Genotyping-United States, 2004-2010 (Reprinted form MMWR vol 36, pg 723, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID MYCOBACTERIUM-TUBERCULOSIS; MOLECULAR EPIDEMIOLOGY C1 [Baker, Brian; Kim, Lindsay] CDC, Atlanta, GA 30333 USA. [Grant, Juliana; Kammerer, Steve] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA USA. RP Kim, L (reprint author), CDC, Atlanta, GA 30333 USA. EM lkim@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 21 PY 2012 VL 308 IS 19 BP 1966 EP 1968 DI 10.1001/jama.2012.13502 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 040AQ UT WOS:000311291400009 ER PT J AU Lobue, PA Castro, KG AF LoBue, Philip A. Castro, Kenneth G. TI Interferon-gamma-Release Assays for Latent Tuberculosis Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID INFECTION; ANERGY C1 [LoBue, Philip A.; Castro, Kenneth G.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. RP Lobue, PA (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM plobue@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 21 PY 2012 VL 308 IS 19 BP 1971 EP 1971 DI 10.1001/jama.2012.12826 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 040AQ UT WOS:000311291400014 ER PT J AU Ye, XY Zhou, XL Wong, LY Calafat, AM AF Ye, Xiaoyun Zhou, Xiaoliu Wong, Lee-Yang Calafat, Antonia M. TI Concentrations of Bisphenol A and Seven Other Phenols in Pooled Sera from 3-11 Year Old Children: 2001-2002 National Health and Nutrition Examination Survey SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID TANDEM MASS-SPECTROMETRY; URINARY CONCENTRATIONS; ENVIRONMENTAL PHENOLS; BIOLOGICAL SAMPLES; RISK-ASSESSMENT; US POPULATION; UNITED-STATES; HUMAN BLOOD; EXPOSURE; PARABENS AB Concerns exist regarding children's exposure to bisphenol A (BPA) and other phenols because of the higher sensitivity, compared to adults, of children's developing organs to endocrine disruptors. Several studies reported the urinary concentrations of these phenols in children, but data on levels of these compounds in children's serum are limited. We present here the total (free plus conjugated) and free concentrations of BPA and seven other phenols in 24 pooled serum samples prepared from individual specimens collected from 936 children 3-11 years old who participated in the 2001-2002 National Health and Nutrition Examination Survey. We detected benzophenone-3, triclosan, 2,4-dichlorophenol, 2,5- dichlorophenol, and three parabens in at least 60% of the pools suggesting children's exposure to these compounds or their precursors. Conjugated phenols were the major species. However, although many previous studies have shown widespread detection of BPA in children's urine, we only detected total or free BPA in 3 and 2 pooled serum samples, respectively, at concentrations of 0.1-0.2 mu g/L. The nonpersistent nature of BPA and the phenols examined and the likely episodic nature of the exposures to these compounds (or their precursors) suggest that for general population biomonitoring of these nonpersistent phenols, urine, not serum or plasma, is the preferred matrix. C1 [Ye, Xiaoyun; Zhou, Xiaoliu; Wong, Lee-Yang; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Ye, XY (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Hwy,Mailstop F53, Atlanta, GA 30341 USA. EM xay5@cdc.gov FU Intramural CDC HHS [CC999999] NR 62 TC 21 Z9 25 U1 1 U2 46 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD NOV 20 PY 2012 VL 46 IS 22 BP 12664 EP 12671 DI 10.1021/es303109c PG 8 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 047WZ UT WOS:000311873500052 PM 23102149 ER PT J AU Canfell, K Chesson, H Kulasingam, SL Berkhof, J Diaz, M Kim, JJ AF Canfell, Karen Chesson, Harrell Kulasingam, Shalini L. Berkhof, Johannes Diaz, Mireia Kim, Jane J. TI Modeling Preventative Strategies against Human Papillomavirus-Related Disease in Developed Countries SO VACCINE LA English DT Review DE HPV; Intraepithelial neoplasia; Uterine cervical neoplasms; Vulvar; Vaginal; Anal; Oral cavity and oropharyngeal cancer; Anogenital warts; Recurrent Respiratory Papillomatosis; Vaccines; Mathematical models; Cervical cancer screening; Cost-effectiveness analysis; Developed countries ID COST-EFFECTIVENESS ANALYSIS; QUADRIVALENT HPV VACCINE; CERVICAL-CANCER VACCINATION; UNITED-STATES; ECONOMIC-EVALUATION; PARTICLE VACCINE; PREDICTED IMPACT; ANAL CANCER; NETHERLANDS; WOMEN AB Over the last 5 years, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females has been introduced in most developed countries, supported by modeled evaluations that have almost universally found vaccination of pre-adolescent females to be cost-effective. Studies to date suggest that vaccination of pre-adolescent males may also be cost-effective at a cost per vaccinated individual of similar to US$400-500 if vaccination coverage in females cannot be increased above similar to 50%; but if it is possible, increasing coverage in females appears to be a better return on investment. Comparative evaluation of the quadrivalent (HPV16,18,6,11) and bivalent (HPV16,18) vaccines centers around the potential trade-off between protection against anogenital warts and vaccine-specific levels of cross-protection against infections not targeted by the vaccines. Future evaluations will also need to consider the cost-effectiveness of a next generation nonavalent vaccine designed to protect against similar to 90% of cervical cancers. The timing of the effect of vaccination on cervical screening programs will be country-specific and will depend on vaccination catch-up age range and coverage and the age at which screening starts. Initial evaluations suggest that if screening remains unchanged, it will be less cost-effective in vaccinated compared to unvaccinated women but, in the context of current vaccines, will remain an important prevention method. Comprehensive evaluation of new approaches to screening will need to consider the population-level effects of vaccination over time. New screening strategies of particular interest include delaying the start age of screening, increasing the screening interval and switching to primary HPV screening. Future evaluations of screening will also need to focus on the effects of disparities in screening and vaccination uptake, the potential effects of vaccination on screening participation, and the effects of imperfect compliance with screening recommendations. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Canfell, Karen] NSW Canc Council, Canc Epidemiol Res Unit, Sydney, NSW, Australia. [Canfell, Karen] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia. [Chesson, Harrell] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kulasingam, Shalini L.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Berkhof, Johannes] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostatist, Amsterdam, Netherlands. [Diaz, Mireia] Inst Catala Oncol, CERP, Unit Infect & Canc UNIC, Lhospitalet De Llobregat, Barcelona, Spain. [Kim, Jane J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA. RP Canfell, K (reprint author), NSW Canc Council, Canc Epidemiol Res Unit, Sydney, NSW, Australia. EM karenc@nswcc.org.au RI DIAZ SANCHIS, MIREIA/H-6335-2014 FU National Health and Medical Research Council, Australia [CDF APP1007994, 1007518]; non-commercial government and academic consulting agreements in Australia, New Zealand and the UK; Cancer Council NSW, Australia; U.S. National Cancer Institute [U54 CA164336, R01 CA160744-01A1]; Bill and Melinda Gates Foundation [30505]; European Commission [HEALTH-F3-2010-242061]; Instituto de Salud Carlos III (Spanish Government) [FIS PI10/02995, FIS PI11/02090, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, CIBERESP]; Agencia de Gestio d'Ajuts Universitaris i de Recerca-Generalitat de Catalunya (Catalonian Government) [AGAUR 2005SGR00695, AGAUR 2009SGR126]; GlaxoSmithKline; Merck; Sanofi Pasteur MSD; Qiagen FX We thank Megan Smith and Leonardo Simonella of Cancer Council NSW, Australia, for repeating and checking the accuracy of data extraction from the primary studies reviewed in this paper. Karen Canfell is supported by grants from the National Health and Medical Research Council, Australia (CDF APP1007994 and Project Grant #1007518), by non-commercial government and academic consulting agreements in Australia, New Zealand and the UK, and by Cancer Council NSW, Australia. Jane J. Kim is supported in part by grants from the U.S. National Cancer Institute (U54 CA164336, R01 CA160744-01A1) and the Bill and Melinda Gates Foundation (30505) for modeling of HPV and cervical cancer in developing countries.; The work of Mireia Diaz and the Unit of Infections and Cancer regarding this chapter, was partially supported by public grants from the European Commission (7th Framework Programme grant HEALTH-F3-2010-242061, PREHDICT), from the Instituto de Salud Carlos III (Spanish Government) (grants FIS PI10/02995, FIS PI11/02090, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095 and CIBERESP) and from the Agencia de Gestio d'Ajuts Universitaris i de Recerca-Generalitat de Catalunya (Catalonian Government) (grants AGAUR 2005SGR00695 and AGAUR 2009SGR126), who had no role in data collection, analysis or interpretation of results.; MD: Has disclosed no potential conflicts of interest. The Unit of Infections and Cancer at the ICO is involved in HPV vaccine trials and epidemiological studies sponsored by GlaxoSmithKline, Merck and Sanofi Pasteur MSD and screening and HPV testing trials partially supported by Qiagen. NR 89 TC 50 Z9 52 U1 0 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 20 PY 2012 VL 30 SU 5 BP F157 EP F167 DI 10.1016/j.vaccine.2012.06.091 PG 11 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 063CX UT WOS:000312974900017 PM 23199959 ER PT J AU Markowitz, LE Tsu, V Deeks, SL Cubie, H Wang, SA Vicari, AS Brotherton, JML AF Markowitz, Lauri E. Tsu, Vivien Deeks, Shelley L. Cubie, Heather Wang, Susan A. Vicari, Andrea S. Brotherton, Julia M. L. TI Human Papillomavirus Vaccine Introduction - The First Five Years SO VACCINE LA English DT Review DE HPV; vaccine introduction; vaccine acceptability ID HPV VACCINATION; UNITED-STATES; IMPLEMENTATION; PROGRAM; SURVEILLANCE; IMMUNIZATION; COVERAGE; AUSTRALIA; SCHEDULES; INFECTION AB The availability of prophylactic human papillomavirus (HPV) vaccines has provided powerful tools for primary prevention of cervical cancer and other HPV-associated diseases. Since 2006, the quadrivalent and bivalent vaccines have each been licensed in over 100 countries. By the beginning of 2012, HPV vaccine had been introduced into national immunization programs in at least 40 countries. Australia, the United Kingdom, the United States, and Canada were among the first countries to introduce HPV vaccination. In Europe, the number of countries having introduced vaccine increased from 3 in 2007 to 22 at the beginning of 2012. While all country programs target young adolescent girls, specific target age groups vary as do catch-up recommendations. Different health care systems and infrastructure have resulted in varied implementation strategies, with some countries delivering vaccine in schools and others through health centers or primary care providers. Within the first 5 years after vaccines became available, few low- or middle-income countries had introduced HPV vaccine. The main reason was budgetary constraints due to the high vaccine cost. Bhutan and Rwanda implemented national immunization after receiving vaccine through donation programs in 2010 and 2011, respectively. The GAVI Alliance decision in 2011 to support HPV vaccination should increase implementation in low-income countries. Evaluation of vaccination programs includes monitoring of coverage, safety, and impact. Vaccine safety monitoring is part of routine activities in many countries. Safety evaluations are important and communication about vaccine safety is critical, as events temporally associated with vaccination can be falsely attributed to vaccination. Anti-vaccination efforts, in part related to concerns about safety, have been mounted in several countries. In the 5 years since HPV vaccines were licensed, there have been successes as well as challenges with vaccine introduction and implementation. Further progress is anticipated in the coming years, especially in low- and middle-income countries where the need for vaccine is greatest. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. Published by Elsevier Ltd. C1 [Markowitz, Lauri E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Tsu, Vivien] PATH, Seattle, WA 98109 USA. [Deeks, Shelley L.] Publ Hlth Ontario, Toronto, ON M5G 1V2, Canada. [Cubie, Heather] Royal Infirm Edinburgh NHS Trust, Natl HPV Reference Lab, Edinburgh EH16 4SA, Midlothian, Scotland. [Wang, Susan A.] WHO, Expanded Programme Immunizat, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Vicari, Andrea S.] Pan Amer Hlth Org, Comprehens Family Immunizat Project, San Jose, Costa Rica. [Brotherton, Julia M. L.] Victorian Cytol Serv Registries, Melbourne, Vic 8002, Australia. RP Markowitz, LE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM Lem2@cdc.gov FU Australian Research Council; Cooperative Research Centre for Aboriginal Health; GlaxoSmithKline; CSL Limited FX JB is an investigator on an Australian Research Council Linkage Grant, for which CSL Biotherapies is a partner organization and was a chief investigator (2005-2008) on a study of HPV prevalence in Australian women, which was funded by a grant from the Cooperative Research Centre for Aboriginal Health, as well as education grants from GlaxoSmithKline and CSL Limited.; HC has been on Expert Advisory Boards for SPMSD and GlaxoSmithKline and currently holds a GlaxoSmithKline educational grant. NR 67 TC 134 Z9 137 U1 7 U2 51 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD NOV 20 PY 2012 VL 30 SU 5 BP F139 EP F148 DI 10.1016/j.vaccine.2012.05.039 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 063CX UT WOS:000312974900015 PM 23199957 ER PT J AU Knaack, JS Zhou, YT Abney, CW Prezioso, SM Magnuson, M Evans, R Jakubowski, EM Hardy, K Johnson, RC AF Knaack, Jennifer S. Zhou, Yingtao Abney, Carter W. Prezioso, Samantha M. Magnuson, Matthew Evans, Ronald Jakubowski, Edward M. Hardy, Katelyn Johnson, Rudolph C. TI High-Throughput Immunomagnetic Scavenging Technique for Quantitative Analysis of Live VX Nerve Agent in Water, Hamburger, and Soil Matrixes SO ANALYTICAL CHEMISTRY LA English DT Article ID CHEMICAL WARFARE AGENTS; ACETYLCHOLINESTERASE BIOSENSOR; DEGRADATION-PRODUCTS; BUTYRYLCHOLINESTERASE; EXTRACTION; PROTECTION; ELECTRODE; TOXICITY; EXPOSURE; SENSORS AB We have developed a novel immunomagnetic scavenging technique for extracting cholinesterase inhibitors from aqueous matrixes using biological targeting and antibody-based extraction. The technique was characterized using the organophosphorus nerve agent VX. The limit of detection for VX in high-performance liquid chromatography (HPLC)-grade water, defined as the lowest calibrator concentration, was 25 pg/mL in a small, 500 mu L sample. The method was characterized over the course of 22 sample sets containing calibrators, blanks, and quality control samples. Method precision, expressed as the mean relative standard deviation, was less than 9.2% for all calibrators. Quality control sample accuracy was 102% and 100% of the mean for VX spiked into HPLC-grade water at concentrations of 2.0 and 0.25 ng/mL, respectively. This method successfully was applied to aqueous extracts from soil, hamburger, and finished tap water spiked with VX. Recovery was 65%, 81%, and 100% from these matrixes, respectively. Biologically based extractions of organophosphorus compounds represent a new technique for sample extraction that provides an increase in extraction specificity and sensitivity. C1 [Knaack, Jennifer S.; Zhou, Yingtao; Hardy, Katelyn; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Emergency Response & Air Toxicants Branch, Chamblee, GA 30341 USA. [Abney, Carter W.] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ, Chamblee, GA 30341 USA. [Prezioso, Samantha M.] Ctr Dis Control & Prevent, IHRC Inc, Atlanta, GA USA. [Magnuson, Matthew] US EPA, Cincinnati, OH 45268 USA. [Evans, Ronald; Jakubowski, Edward M.] USA, Edgewood Chem Biol Ctr, Aberdeen Proving Ground, MD 21010 USA. RP Johnson, RC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Emergency Response & Air Toxicants Branch, 4770 Buford Highway,MS F44, Chamblee, GA 30341 USA. EM RJohnson6@cdc.gov RI Abney, Carter/A-6710-2013; OI Abney, Carter/0000-0002-1809-9577 NR 22 TC 4 Z9 4 U1 1 U2 37 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 J9 ANAL CHEM JI Anal. Chem. PD NOV 20 PY 2012 VL 84 IS 22 BP 10052 EP 10057 DI 10.1021/ac3025224 PG 6 WC Chemistry, Analytical SC Chemistry GA 055RP UT WOS:000312434800054 PM 23126363 ER PT J AU Fang, J Yang, QH Hong, YL Loustalot, F AF Fang, Jing Yang, Quanhe Hong, Yuling Loustalot, Fleetwood TI Status of Cardiovascular Health among Adult Americans in 50 States and District of Columbia, 2009 SO CIRCULATION LA English DT Meeting Abstract DE Epidemiology; Population science; Risk factors C1 [Fang, Jing; Yang, Quanhe; Hong, Yuling; Loustalot, Fleetwood] CDC, Div Heart Dis & Stroke Prevent, NCCDPHP, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 11897 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885002045 ER PT J AU Huffman, MD Lloyd-Jones, DM Ning, HY Labarthe, DR Ford, ES Capewell, S AF Huffman, Mark D. Lloyd-Jones, Donald M. Ning, Hongyan Labarthe, Darwin R. Ford, Earl S. Capewell, Simon TI Quantifying Options for Reducing Coronary Heart Disease Mortality by 2020 SO CIRCULATION LA English DT Meeting Abstract DE 2020 Goals; Coronary heart disease; Epidemiology C1 [Huffman, Mark D.; Lloyd-Jones, Donald M.; Ning, Hongyan; Labarthe, Darwin R.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Ford, Earl S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Capewell, Simon] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13229 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003143 ER PT J AU Brophy, JT Keith, MM Watterson, A Park, R Gilbertson, M Maticka-Tyndale, E Beck, M Abu-Zahra, H Schneider, K Reinhartz, A DeMatteo, R Luginaah, I AF Brophy, James T. Keith, Margaret M. Watterson, Andrew Park, Robert Gilbertson, Michael Maticka-Tyndale, Eleanor Beck, Matthias Abu-Zahra, Hakam Schneider, Kenneth Reinhartz, Abraham DeMatteo, Robert Luginaah, Isaac TI Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case-control study SO ENVIRONMENTAL HEALTH LA English DT Article DE Agriculture; Breast cancer; Canning; Casino; Carcinogen; Endocrine disruptor; Metals; Occupational; Plastics ID DATA-COLLECTION; YOUNG-WOMEN; BISPHENOL-A; HEALTH; EPIDEMIOLOGY; CHEMICALS; SHANGHAI; INDUSTRY; WORKERS; ENVIRONMENT AB Background: Endocrine disrupting chemicals and carcinogens, some of which may not yet have been classified as such, are present in many occupational environments and could increase breast cancer risk. Prior research has identified associations with breast cancer and work in agricultural and industrial settings. The purpose of this study was to further characterize possible links between breast cancer risk and occupation, particularly in farming and manufacturing, as well as to examine the impacts of early agricultural exposures, and exposure effects that are specific to the endocrine receptor status of tumours. Methods: 1005 breast cancer cases referred by a regional cancer center and 1146 randomly-selected community controls provided detailed data including occupational and reproductive histories. All reported jobs were industry- and occupation-coded for the construction of cumulative exposure metrics representing likely exposure to carcinogens and endocrine disruptors. In a frequency-matched case-control design, exposure effects were estimated using conditional logistic regression. Results: Across all sectors, women in jobs with potentially high exposures to carcinogens and endocrine disruptors had elevated breast cancer risk (OR = 1.42; 95% CI, 1.18-1.73, for 10 years exposure duration). Specific sectors with elevated risk included: agriculture (OR = 1.36; 95% CI, 1.01-1.82); bars-gambling (OR = 2.28; 95% CI, 0.94-5.53); automotive plastics manufacturing (OR = 2.68; 95% CI, 1.47-4.88), food canning (OR = 2.35; 95% CI, 1.00-5.53), and metalworking (OR = 1.73; 95% CI, 1.02-2.92). Estrogen receptor status of tumors with elevated risk differed by occupational grouping. Premenopausal breast cancer risk was highest for automotive plastics (OR = 4.76; 95% CI, 1.58-14.4) and food canning (OR = 5.70; 95% CI, 1.03-31.5). Conclusions: These observations support hypotheses linking breast cancer risk and exposures likely to include carcinogens and endocrine disruptors, and demonstrate the value of detailed work histories in environmental and occupational epidemiology. C1 [Brophy, James T.; Keith, Margaret M.; Watterson, Andrew; Gilbertson, Michael] Univ Stirling, Occupat & Environm Hlth Res Grp, Ctr Publ Hlth & Populat Hlth Res, Stirling FK9 4LA, Scotland. [Brophy, James T.; Keith, Margaret M.; Maticka-Tyndale, Eleanor] Univ Windsor, Dept Sociol Anthropol & Criminol, Windsor, ON N9B 3P4, Canada. [Park, Robert] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. [Beck, Matthias] Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland. [Abu-Zahra, Hakam; Schneider, Kenneth] Windsor Reg Canc Ctr, Windsor, ON N8W 2X3, Canada. [Reinhartz, Abraham; DeMatteo, Robert] Occupat Hlth Clin Ontario Workers, Don Mills, ON M3C 1Y8, Canada. [Luginaah, Isaac] Univ Western Ontario, Dept Geog, Social Sci Ctr, London, ON N6A 5C2, Canada. RP Brophy, JT (reprint author), Univ Stirling, Occupat & Environm Hlth Res Grp, Ctr Publ Hlth & Populat Hlth Res, Stirling FK9 4LA, Scotland. EM jim.brophy@stir.ac.uk FU Department of Sociology, Anthropology and Criminology, University of Windsor; National Network on Environments and Women's Health; Health Canada through the Women's Health Contribution Program; Canadian Breast Cancer Foundation - Ontario Region; Breast Cancer Society of Canada; Windsor Essex County Cancer Centre Foundation; Green Shield Foundation FX This work was supported by the Department of Sociology, Anthropology and Criminology, University of Windsor (host institution) and the National Network on Environments and Women's Health, which received funding from Health Canada through the Women's Health Contribution Program. Partners included the Windsor Regional Cancer Centre (Windsor Regional Hospital) and Occupational Health Clinics for Ontario Workers (OHCOW). Funding was provided by Canadian Breast Cancer Foundation - Ontario Region, Breast Cancer Society of Canada, Windsor Essex County Cancer Centre Foundation, and Green Shield Foundation. The Canada Research Chair for Social Justice and Sexual Health provided software and data support. The authors received support for their time from their employing institutions or volunteered their time. The funding bodies played no role of the design, collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to submit the manuscript for publication. NR 70 TC 29 Z9 29 U1 3 U2 45 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1476-069X J9 ENVIRON HEALTH-GLOB JI Environ. Health PD NOV 19 PY 2012 VL 11 AR 87 DI 10.1186/1476-069X-11-87 PG 17 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 068BF UT WOS:000313338800001 PM 23164221 ER PT J AU Abedi, GR Mutuc, JD Lawler, J Leroy, ZC Hudson, JM Blog, DS Schulte, CR Rausch-Phung, E Ogbuanu, IU Gallagher, K Kutty, PK AF Abedi, Glen R. Mutuc, Jeffry D. Lawler, Jacqueline Leroy, Zanie C. Hudson, Jean M. Blog, Debra S. Schulte, Cynthia R. Rausch-Phung, Elizabeth Ogbuanu, Ikechukwu U. Gallagher, Kathleen Kutty, Preeta K. TI Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak SO VACCINE LA English DT Article DE Mumps; MMR; Vaccine; Adverse event; Outbreak ID HEALTHY-CHILDREN; REACTOGENICITY; IMMUNOGENICITY AB During a 2009-2010 mumps outbreak in a New York State village, a third dose of measles, mumps, and rubella (MMR) vaccine was administered to children in three schools as a control measure. Information on local and systemic adverse events (AE) was collected by a self-report survey distributed to all children in grades 6-12. A comprehensive search for AE following MMR vaccination was conducted using physician records and the Vaccine Adverse Events Reporting System (VAERS). A literature search was performed for published reports pertaining to AE associated with mumps-containing vaccine, using the Jeryl-Lynn strain, from 1969 to 2011. A total of 1755 individuals received the third dose; 1597 (91.0%) returned the survey. Of those, 115 (7.2%) reported at least one local or systemic AE in the 2 weeks following vaccination. The most commonly reported AE were "pain, redness, or swelling at the injection site" (3.6%) and "joint or muscle aches" (1.8%). No serious AE were reported in the survey, physician records or through VAERS. The proportions of AE found in the present study were lower than or within the range of those reported in prior studies of first- and second-dose MMR vaccine studies. The results of this study suggest that a third dose of MMR vaccine administered in an outbreak setting is safe, with injection site reactions reported more frequently than systemic reactions. However, to assess risk for rare or serious AE after a third dose of MMR vaccine, longer term studies would be required. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Abedi, Glen R.; Mutuc, Jeffry D.; Gallagher, Kathleen; Kutty, Preeta K.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Leroy, Zanie C.] Ctr Dis Control & Prevent, Natl Ctr Zoonot & Emerging Infect Dis, Atlanta, GA 30333 USA. [Ogbuanu, Ikechukwu U.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Ctr Global Hlth, Atlanta, GA 30333 USA. [Lawler, Jacqueline; Hudson, Jean M.] Orange Cty Dept Hlth, Goshen, NY 10924 USA. [Blog, Debra S.; Schulte, Cynthia R.; Rausch-Phung, Elizabeth] New York State Dept Hlth, Albany, NY 12237 USA. RP Abedi, GR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM gabedi@cdc.gov NR 26 TC 4 Z9 5 U1 0 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 19 PY 2012 VL 30 IS 49 BP 7052 EP 7058 DI 10.1016/j.vaccine.2012.09.053 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 050LC UT WOS:000312053800015 PM 23041123 ER PT J AU Bartsch, SM Lopman, BA Hall, AJ Parashar, UD Lee, BY AF Bartsch, Sarah M. Lopman, Benjamin A. Hall, Aron J. Parashar, Umesh D. Lee, Bruce Y. TI The potential economic value of a human norovirus vaccine for the United States SO VACCINE LA English DT Article DE Norovirus; Vaccine; Economics ID INFECTIOUS INTESTINAL DISEASE; COST-EFFECTIVENESS; ACUTE GASTROENTERITIS; COMMUNITY; OUTBREAKS; ENGLAND; ILLNESS; IMPACT; ADULTS AB Vaccines against human norovirus are currently under development. We developed a simulation model to determine their potential economic value. Vaccination prevented 100-6125 norovirus gastroenteritis cases per 10,000 vaccinees. Low vaccine cost (<=$50) garnered cost-savings and a more expensive vaccine led to costs per case averted comparable to other vaccines. In the US, vaccination could avert approximately 1.0-2.2 million cases (efficacy 50%, 12 month duration), costing an additional $400 million to $1.0 billion, but could save <=$2.1 billion (48 month duration). Human norovirus vaccination can offer economic value while averting clinical outcomes, depending on price, efficacy, and protection duration. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Lee, Bruce Y.] Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, Sch Med, Pittsburgh, PA 15213 USA. [Bartsch, Sarah M.; Lee, Bruce Y.] Univ Pittsburgh, Dept Biomed Informat, Sch Med, Pittsburgh, PA 15213 USA. [Bartsch, Sarah M.; Lee, Bruce Y.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [Lopman, Benjamin A.; Hall, Aron J.; Parashar, Umesh D.] Ctr Dis Control & Prevent CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Diseases, Atlanta, GA USA. RP Lee, BY (reprint author), Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, Sch Med, 200 Meyran Ave,Suite 200, Pittsburgh, PA 15213 USA. EM BYL1@pitt.edu FU National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [1U54GM088491-0109]; Vaccine Modeling Initiative; Bill and Melinda Gates Foundation FX This study was supported by the National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) grant 1U54GM088491-0109 and the Vaccine Modeling Initiative funded by the Bill and Melinda Gates Foundation. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 39 TC 37 Z9 37 U1 2 U2 20 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 19 PY 2012 VL 30 IS 49 BP 7097 EP 7104 DI 10.1016/j.vaccine.2012.09.040 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 050LC UT WOS:000312053800022 PM 23026689 ER PT J AU Engelgau, MM Gregg, EW AF Engelgau, Michael M. Gregg, Edward W. TI Tackling the global diabetes burden: will screening help? SO LANCET LA English DT Editorial Material ID COST-EFFECTIVENESS ANALYSIS; RANDOMIZED-TRIAL; TYPE-2; ADULTS; PREVENTION; PREVALENCE; TASK C1 [Engelgau, Michael M.; Gregg, Edward W.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Engelgau, MM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. EM mxe1@cdc.gov NR 15 TC 5 Z9 5 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD NOV 17 PY 2012 VL 380 IS 9855 BP 1716 EP 1718 DI 10.1016/S0140-6736(12)61682-1 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 038CV UT WOS:000311153700006 PM 23040423 ER PT J AU Go, JT Belisle, SE Tchitchek, N Tumpey, TM Ma, WJ Richt, JA Safronetz, D Feldmann, H Katze, MG AF Go, Jennifer T. Belisle, Sarah E. Tchitchek, Nicolas Tumpey, Terrence M. Ma, Wenjun Richt, Juergen A. Safronetz, David Feldmann, Heinz Katze, Michael G. TI 2009 pandemic H1N1 influenza virus elicits similar clinical course but differential host transcriptional response in mouse, macaque, and swine infection models SO BMC GENOMICS LA English DT Article DE Pandemic; Influenza virus; Genomics; Inflammation; Lipid metabolism; Glucocorticoid receptor; LXR/RXR ID INNATE IMMUNE-RESPONSE; GENE-EXPRESSION; VITAMIN-D; A H1N1; IN-VITRO; RECEPTOR; PIGS; MACROPHAGES; CIRCULATION; METABOLISM AB Background: The 2009 pandemic H1N1 influenza virus emerged in swine and quickly became a major global health threat. In mouse, non human primate, and swine infection models, the pH1N1 virus efficiently replicates in the lung and induces pro-inflammatory host responses; however, whether similar or different cellular pathways were impacted by pH1N1 virus across independent infection models remains to be further defined. To address this we have performed a comparative transcriptomic analysis of acute phase responses to a single pH1N1 influenza virus, A/California/04/2009 (CA04), in the lung of mice, macaques and swine. Results: Despite similarities in the clinical course, we observed differences in inflammatory molecules elicited, and the kinetics of their gene expression changes across all three species. We found genes associated with the retinoid X receptor (RXR) signaling pathway known to control pro-inflammatory and metabolic processes that were differentially regulated during infection in each species, though the heterodimeric RXR partner, pathway associated signaling molecules, and gene expression patterns varied among the three species. Conclusions: By comparing transcriptional changes in the context of clinical and virological measures, we identified differences in the host transcriptional response to pH1N1 virus across independent models of acute infection. Antiviral resistance and the emergence of new influenza viruses have placed more focus on developing drugs that target the immune system. Underlying overt clinical disease are molecular events that suggest therapeutic targets identified in one host may not be appropriate in another. C1 [Go, Jennifer T.; Belisle, Sarah E.; Tchitchek, Nicolas; Katze, Michael G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. [Katze, Michael G.] Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA. [Ma, Wenjun; Richt, Juergen A.] Kansas State Univ, Dept Diagnost Med Pathobiol, Coll Vet Med, Manhattan, KS 66506 USA. [Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Safronetz, David; Feldmann, Heinz] NIAID, Lab Virol, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT 59840 USA. RP Go, JT (reprint author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. EM tisoncik@u.washington.edu OI Tchitchek, Nicolas/0000-0003-3307-0446 FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200800060C, HHSN266200700005C]; Intramural research Program of the NIAID, NIH FX We thank Elizabeth Rosenzweig, Sara Kelly, and Jean Chang for microarray technical support. We are grateful to Marcus Korth, Lynn Law, and Janine Bryan for their critical review of the manuscript. This work was supported by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract HHSN272200800060C (M. G. K.) and contract HHSN266200700005C (J.A.R.). We thank the staff of the Rocky Mountain Veterinary Branch (Division of Intramural Research (DIR), NIAID, NIH) for their assistance with the nonhuman primate work. In addition, we thank Friederike Feldmann (DIR, NIAID, NIH) for technical assistance in biocontainment. The study was partially funded by the Intramural research Program of the NIAID, NIH. We thank Deborah Clouser, Darlene Sheffer, Xi Li, Qinfang Liu, and Chuanling Qiao of Kansas State University for their assistance with the pig work. NR 50 TC 20 Z9 21 U1 0 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2164 J9 BMC GENOMICS JI BMC Genomics PD NOV 15 PY 2012 VL 13 AR 627 DI 10.1186/1471-2164-13-627 PG 15 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA 061UJ UT WOS:000312873600001 PM 23153050 ER PT J AU Connor, TH MacKenzie, BA DeBord, DG AF Connor, Thomas H. MacKenzie, Barbara A. DeBord, D. Gayle TI Clarification about hazardous drugs SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Letter C1 [Connor, Thomas H.; MacKenzie, Barbara A.; DeBord, D. Gayle] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Connor, TH (reprint author), NIOSH, Div Appl Res & Technol, 4676 Columbia Pkwy MS R-2, Cincinnati, OH 45226 USA. EM tmc6@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD NOV 15 PY 2012 VL 69 IS 22 BP 1949 EP 1950 DI 10.2146/ajhp120585 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 038ME UT WOS:000311178000009 PM 23135559 ER PT J AU Sauber-Schatz, EK Sappenfield, W Grigorescu, V Kulkarni, A Zhang, YJ Salihu, HM Rubin, LP Kirby, RS Jamieson, DJ Macaluso, M AF Sauber-Schatz, Erin K. Sappenfield, William Grigorescu, Violanda Kulkarni, Aniket Zhang, Yujia Salihu, Hamisu M. Rubin, Lewis P. Kirby, Russell S. Jamieson, Denise J. Macaluso, Maurizio TI Obesity, Assisted Reproductive Technology, and Early Preterm Birth-Florida, 2004-2006 SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE body mass index; Florida; obesity; preterm birth; reproductive techniques; assisted ID IN-VITRO FERTILIZATION; BODY-MASS INDEX; DELAYED CHILDBEARING; UNITED-STATES; PERINATAL OUTCOMES; SINGLETON INFANTS; MULTIPLE BIRTHS; RISK; WEIGHT; TWINS AB Florida resident birth certificates for 20042006 were linked to the Centers for Disease Control and Preventions National ART Surveillance System and were used to investigate 1) whether the association of assisted reproductive technology (ART) with preterm birth varies by prepregnancy body mass index and 2) whether the association varies by plurality. Preterm birth was defined as early preterm birth (gestation 34 weeks) and late preterm birth (gestation 3436 weeks). Descriptive statistics and multinomial logistic regression were used to explore maternal and infant differences by ART status and plurality. Of 581,403 women included in the study, 24.0 were overweight, 18.6 were obese, 7.3 had late preterm birth, 2.6 had early preterm birth, and 0.67 conceived through ART. Among singleton births, ART was associated with increased early preterm birth risk among underweight (odds ratio (OR) 2.94, 95 confidence interval (CI): 1.27, 6.81), overweight (OR 1.75, 95 CI: 1.12, 2.72), and obese (OR 2.37, 95 CI: 1.51, 3.71) women. Among twins, ART was significantly associated with increased risk among overweight (OR 1.61, 95 CI: 1.12, 2.32) and obese (OR 1.85, 95 CI: 1.18, 2.90) women. Differences in the associations between ART and early preterm birth by body mass index and plurality warrant further investigation. C1 [Sauber-Schatz, Erin K.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30341 USA. [Sauber-Schatz, Erin K.; Sappenfield, William] Florida Dept Hlth, Div Family Hlth Serv, Bur Family & Community Hlth, Tallahassee, FL USA. [Grigorescu, Violanda] Michigan Dept Community Hlth, Div Genom Perinatal Hlth & Chron Dis Epidemiol, Bur Epidemiol, Lansing, MI USA. [Kulkarni, Aniket; Zhang, Yujia; Jamieson, Denise J.; Macaluso, Maurizio] Ctr Dis Control & Prevent, Womens Hlth & Fertil Branch, Div Reprod Hlth, Atlanta, GA 30341 USA. [Salihu, Hamisu M.] Univ S Florida, Coll Publ Hlth, Dept Epidemiol & Biostat, Tampa, FL USA. [Rubin, Lewis P.] Univ S Florida, Coll Med, Div Neonatol, Tampa, FL USA. [Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Tampa, FL USA. [Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. RP Sauber-Schatz, EK (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 4770 Buford Highway NE,Mailstop F62, Atlanta, GA 30341 USA. EM ESauberSchatz@cdc.gov RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 NR 49 TC 8 Z9 8 U1 2 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD NOV 15 PY 2012 VL 176 IS 10 BP 886 EP 896 DI 10.1093/aje/kws155 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 034SH UT WOS:000310892700006 PM 23097258 ER PT J AU Shulman, ST Bisno, AL Clegg, HW Gerber, MA Kaplan, EL Lee, G Martin, JM Van Beneden, C AF Shulman, Stanford T. Bisno, Alan L. Clegg, Herbert W. Gerber, Michael A. Kaplan, Edward L. Lee, Grace Martin, Judith M. Van Beneden, Chris TI Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID GRADE; RECOMMENDATIONS; CONSENSUS; QUALITY AB The guideline is intended for use by healthcare providers who care for adult and pediatric patients with group A streptococcal pharyngitis. The guideline updates the 2002 Infectious Diseases Society of America guideline and discusses diagnosis and management, and recommendations are provided regarding antibiotic choices and dosing. Penicillin or amoxicillin remain the treatments of choice, and recommendations are made for the penicillin-allergic patient, which now include clindamycin. C1 [Shulman, Stanford T.] Northwestern Univ, Dept Pediat, Div Infect Dis, Ann & Robert H Lurie Childrens Hosp,Feinberg Sch, Chicago, IL 60611 USA. [Bisno, Alan L.] Univ Miami, Miller Sch Med, Dept Med, Miami Vet Affairs Healthcare Syst, Miami, FL 33136 USA. [Clegg, Herbert W.] Hemby Childrens Hosp, Dept Pediat, Charlotte, NC USA. [Clegg, Herbert W.] Eastover Pediat, Charlotte, NC USA. [Gerber, Michael A.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA. [Kaplan, Edward L.] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA. [Lee, Grace] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA. [Martin, Judith M.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA. [Van Beneden, Chris] Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Shulman, ST (reprint author), Northwestern Univ, Dept Pediat, Div Infect Dis, Ann & Robert H Lurie Childrens Hosp,Feinberg Sch, 225 E Chicago Ave, Chicago, IL 60611 USA. EM sshulman@northwestern.edu FU Infectious Diseases Society of America (IDSA); Quidel FX This work was supported by the Infectious Diseases Society of America (IDSA).; The following list is a reflection of what has been reported to the IDSA. To provide thorough transparency, the IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. S. S. has served as a consultant to Novartis Vaccines and Merck Vaccines and received research support from Quidel. A. B. has served as a consultant for SPD Development, Cornerstone BioPharma, and Rib-X Pharmaceuticals. All other authors report no potential conflicts. NR 8 TC 99 Z9 103 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2012 VL 55 IS 10 BP 1279 EP 1282 DI 10.1093/cid/cis847 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 027SV UT WOS:000310374600007 PM 23091044 ER PT J AU Weber, IB Turabelidze, G Patrick, S Griffith, KS Kugeler, KJ Mead, PS AF Weber, Ingrid B. Turabelidze, George Patrick, Sarah Griffith, Kevin S. Kugeler, Kiersten J. Mead, Paul S. TI Clinical Recognition and Management of Tularemia in Missouri: A Retrospective Records Review of 121 Cases SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID UNITED-STATES; FRANCISELLA-TULARENSIS; EPIDEMIOLOGY; CIPROFLOXACIN; DIAGNOSIS; AGENTS AB Background. Clinical recognition of tularemia is essential for prompt initiation of appropriate antibiotic treatment. Although fluoroquinolones have desirable attributes as a treatment option, limited data on efficacy in the US setting exist. Methods. To define the epidemiology of tularemia in Missouri, and to evaluate practices and outcomes of tularemia management in general, we conducted a detailed retrospective review and analysis of clinical records for patients reported to the state from 2000 to 2007. Results. We reviewed records of 121 of 190 patients (64%) reported with tularemia; 79 (65%) were males; the median age was 37 years. Most patients presented with ulceroglandular (37%) and glandular (25%) forms of tularemia, followed by pneumonic (12%), typhoidal (10%), oculoglandular (3%), and oropharyngeal (2%) forms. Most cases (69%) were attributed to tick bites. Median incubation period was 3 days (range, 1-9 days), and patients sought care after a median of 3 days of illness (range, 0-44 days). Systemic disease occurred more commonly in older patients. Patients were prescribed tetracyclines (49%), aminoglycosides (47%), and fluoroquinolones (41%). Nine of 10 patients treated with ciprofloxacin for >= 10 days recovered uneventfully, without accompanying aminoglycosides or tetracyclines. Conclusions. Tularemia is frequently initially misdiagnosed. A thorough exposure history, particularly for tick bites, and awareness of clinical features may prompt clinicians to consider tularemia and facilitate appropriate testing. Promising success with oral fluoroquinolones could provide an acceptable alternative to intravenous aminoglycosides or long courses of tetracyclines where clinically appropriate. C1 [Weber, Ingrid B.; Griffith, Kevin S.; Kugeler, Kiersten J.; Mead, Paul S.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Weber, Ingrid B.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Turabelidze, George; Patrick, Sarah] Missouri Dept Hlth & Senior Serv, Jefferson, AR USA. RP Weber, IB (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM iweber@cdc.gov NR 26 TC 23 Z9 23 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2012 VL 55 IS 10 BP 1283 EP 1290 DI 10.1093/cid/cis706 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 027SV UT WOS:000310374600008 PM 22911645 ER PT J AU Patel, MK Konde, MK Didi-Ngossaki, BH Ndinga, E Yogolelo, R Salla, M Shaba, K Everts, J Armstrong, GL Daniels, D Burns, C Wassilak, S Pallansch, M Kretsinger, K AF Patel, Minal K. Konde, Mandy Kader Didi-Ngossaki, Boris Hermann Ndinga, Edouard Yogolelo, Riziki Salla, Mbaye Shaba, Keith Everts, Johannes Armstrong, Gregory L. Daniels, Danni Burns, Cara Wassilak, Steve Pallansch, Mark Kretsinger, Katrina TI An Outbreak of Wild Poliovirus in the Republic of Congo, 2010-2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID POLIOMYELITIS; IDENTIFICATION; TRANSMISSION; INTERRUPTION AB Background. The Republic of Congo has had no cases of wild poliovirus type 1 (WPV1) since 2000. In October 2010, a neurologist noted an abnormal number of cases of acute flaccid paralysis (AFP) among adults, which were later confirmed to be caused by WPV1. Methods. Those presenting with AFP underwent clinical history, physical examination, and clinical specimen collection to determine if they had polio. AFP cases were classified as laboratory-confirmed, clinical, or nonpolio AFP. Epidemiologic features of the outbreak were analyzed. Results. From 19 September 2010 to 22 January 2011, 445 cases of WPV1 were reported in the Republic of Congo; 390 cases were from Pointe Noire. Overall, 331 cases were among adults; 378 cases were clinically confirmed, and 64 cases were laboratory confirmed. The case-fatality ratio (CFR) was 43%. Epidemiologic characteristics differed among polio cases reported in Pointe Noire and cases reported in the rest of the Republic of Congo, including age distribution and CFR. The outbreak stopped after multiple vaccination rounds with oral poliovirus vaccine, which targeted the entire population. Conclusions. This outbreak underscores the need to maintain high vaccination coverage to prevent outbreaks, the need to maintain timely high-quality surveillance to rapidly identify and respond to any potential cases before an outbreak escalates, and the need to perform ongoing risk assessments of immunity gaps in polio-free countries. C1 [Patel, Minal K.; Daniels, Danni; Wassilak, Steve; Kretsinger, Katrina] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30329 USA. [Armstrong, Gregory L.; Burns, Cara; Pallansch, Mark] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30329 USA. [Didi-Ngossaki, Boris Hermann; Ndinga, Edouard] WHO, Reg Off Africa, Minist Hlth, Brazzaville, Congo. [Salla, Mbaye; Shaba, Keith] WHO, Reg Off Africa, Expanded Programme Immunizat, Brazzaville, Congo. [Yogolelo, Riziki] Minist Publ Hlth, Inst Natl Rech Biomed, Kinshasa, Zaire. [Everts, Johannes] WHO, CH-1211 Geneva, Switzerland. RP Patel, MK (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS A-04, Atlanta, GA 30329 USA. EM hgo9@cdc.gov FU Republic of Congo Ministry of Health; World Health Organization; US Centers for Disease Control and Prevention; United Nations Children's Fund; Medecin Sans Frontieres; Bill & Melinda Gates Foundation; Rotary Club International; European Union FX This work was supported by the Republic of Congo Ministry of Health; the World Health Organization; the US Centers for Disease Control and Prevention; United Nations Children's Fund; Medecin Sans Frontieres; the Bill & Melinda Gates Foundation; Rotary Club International; and the European Union. NR 20 TC 19 Z9 19 U1 0 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2012 VL 55 IS 10 BP 1291 EP 1298 DI 10.1093/cid/cis714 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 027SV UT WOS:000310374600009 PM 22911642 ER PT J AU Gregory, CJ Ndiaye, S Patel, M Hakizamana, E Wannemuehler, K Ndinga, E Chu, S Talani, P Kretsinger, K AF Gregory, Christopher J. Ndiaye, Serigne Patel, Minal Hakizamana, Elisaphan Wannemuehler, Kathleen Ndinga, Edouard Chu, Susan Talani, Pascal Kretsinger, Katrina TI Investigation of Elevated Case-Fatality Rate in Poliomyelitis Outbreak in Pointe Noire, Republic of Congo, 2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID DRINKING-WATER WELLS; PARALYTIC POLIOMYELITIS; ENTERIC VIRUSES; RISK FACTOR; TRANSMISSION; CONTAMINATION; INTERRUPTION; WISCONSIN; VACCINE; DISEASE AB Background. Multiple cases of paralysis, often resulting in death, occurred among young adults during a wild poliovirus (WPV) type 1 outbreak in Pointe Noire, Republic of Congo, in 2010. We conducted an investigation to identify factors associated with fatal outcomes among persons with poliomyelitis in Pointe Noire. Methods. Polio cases were defined as acute flaccid paralysis (AFP) cases reported from 7 October to 7 December 2010 with either a stool specimen positive for WPV or clinically classified as polio-compatible. Data were obtained from medical records, hospital databases, AFP case investigation forms and, when possible, via interviews with persons with polio or surrogates using a standard questionnaire. Results. A total of 369 polio cases occurred in Pointe Noire between 7 October and 7 December 2010. Median age was 22 years for nonsurvivors and 18 years for survivors (P = .01). Small home size, as defined by = 2 rooms, use of a well for drinking water during a water shortage, and age = 15 years were risk factors for death in multivariate analysis. Conclusions. Consideration should be given during polio risk assessment planning and outbreak response to water/sanitation status and potential susceptibility to polio in older children and adults. Serosurveys to estimate immunity gaps in older age groups in countries at high risk of polio importation might be useful to guide preparedness and response planning. C1 [Gregory, Christopher J.; Ndiaye, Serigne; Patel, Minal; Wannemuehler, Kathleen; Chu, Susan; Kretsinger, Katrina] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30329 USA. [Hakizamana, Elisaphan] WHO, Country Off, Brazzaville, Congo. [Ndinga, Edouard] Minist Hlth, Brazzaville, Congo. [Talani, Pascal] Fac Hlth Sci, Dept Publ Hlth, Brazzaville, Congo. RP Gregory, CJ (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM hgk4@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. NR 36 TC 12 Z9 12 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2012 VL 55 IS 10 BP 1299 EP 1306 DI 10.1093/cid/cis715 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 027SV UT WOS:000310374600010 PM 22911644 ER PT J AU Cleveland, AA Farley, MM Harrison, LH Stein, B Hollick, R Lockhart, SR Magill, SS Derado, G Park, BJ Chiller, TM AF Cleveland, Angela Ahlquist Farley, Monica M. Harrison, Lee H. Stein, Betsy Hollick, Rosemary Lockhart, Shawn R. Magill, Shelley S. Derado, Gordana Park, Benjamin J. Chiller, Tom M. TI Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID BLOOD-STREAM INFECTIONS; INTENSIVE-CARE-UNIT; FLUCONAZOLE PROPHYLAXIS; INVASIVE CANDIDIASIS; ACTIVE SURVEILLANCE; RISK-FACTORS; STATES; EPIDEMIOLOGY; MORTALITY; ALBICANS AB Background. Candidemia is common and associated with high morbidity and mortality; changes in population-based incidence rates have not been reported. Methods. We conducted active, population-based surveillance in metropolitan Atlanta, Georgia, and Baltimore City/County, Maryland (combined population 5.2 million), during 2008-2011. We calculated candidemia incidence and antifungal drug resistance compared with prior surveillance (Atlanta, 1992-1993; Baltimore, 1998-2000). Results. We identified 2675 cases of candidemia with 2329 isolates during 3 years of surveillance. Mean annual crude incidence per 100 000 person-years was 13.3 in Atlanta and 26.2 in Baltimore. Rates were highest among adults aged >= 65 years (Atlanta, 59.1; Baltimore, 72.4) and infants (aged <1 year; Atlanta, 34.3; Baltimore, 46.2). In both locations compared with prior surveillance, adjusted incidence significantly declined for infants of both black and white race (Atlanta: black risk ratio [RR], 0.26 [95% confidence interval {CI}, .17-.38]; white RR: 0.19 [95% CI, .12-.29]; Baltimore: black RR, 0.38 [95% CI, .22-.64]; white RR: 0.51 [95% CI: .29-.90]). Prevalence of fluconazole resistance (7%) was unchanged compared with prior surveillance; 32 (1%) isolates were echinocandin-resistant, and 9 (8 Candida glabrata) were multidrug resistant to both fluconazole and an echinocandin. Conclusions. We describe marked shifts in candidemia epidemiology over the past 2 decades. Adults aged >= 65 years replaced infants as the highest incidence group; adjusted incidence has declined significantly in infants. Use of antifungal prophylaxis, improvements in infection control, or changes in catheter insertion practices may be contributing to these declines. Further surveillance for antifungal resistance and efforts to determine effective prevention strategies are needed. C1 [Cleveland, Angela Ahlquist; Lockhart, Shawn R.; Derado, Gordana; Park, Benjamin J.; Chiller, Tom M.] Ctr Dis Control & Prevent, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Farley, Monica M.; Stein, Betsy] Atlanta Vet Affairs Med Ctr, Georgia Emerging Infect Program, Atlanta, GA USA. [Farley, Monica M.; Stein, Betsy] Emory Univ, Atlanta, GA 30322 USA. [Harrison, Lee H.; Hollick, Rosemary] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Magill, Shelley S.] Ctr Dis Control & Prevent, Surveillance Branch, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Cleveland, AA (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd,MS C-09, Atlanta, GA 30333 USA. EM ara0@cdc.gov FU Intramural CDC HHS [CC999999] NR 43 TC 99 Z9 104 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2012 VL 55 IS 10 BP 1352 EP 1361 DI 10.1093/cid/cis697 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 027SV UT WOS:000310374600016 PM 22893576 ER PT J AU Misegades, LK Martin, SW Messonnier, NE Clark, TA AF Misegades, Lara K. Martin, Stacey W. Messonnier, Nancy E. Clark, Thomas A. TI Estimating the Effectiveness of Acellular Pertussis Vaccines SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID VACCINATION C1 [Misegades, Lara K.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. RP Misegades, LK (reprint author), Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30329 USA. EM lmisegades@cdc.gov NR 3 TC 4 Z9 4 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2012 VL 55 IS 10 BP 1432 EP U220 DI 10.1093/cid/cis669 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 027SV UT WOS:000310374600030 PM 22871824 ER PT J AU Shulman, ST Bisno, AL Clegg, HW Gerber, MA Kaplan, EL Lee, G Martin, JM Van Beneden, C AF Shulman, Stanford T. Bisno, Alan L. Clegg, Herbert W. Gerber, Michael A. Kaplan, Edward L. Lee, Grace Martin, Judith M. Van Beneden, Chris TI Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UPPER RESPIRATORY-TRACT; BETA-HEMOLYTIC STREPTOCOCCI; APPROPRIATE ANTIBIOTIC USE; 5-DAY CEFDINIR TREATMENT; TWICE-DAILY PENICILLIN; ANTIGEN-DETECTION TEST; ACUTE SORE THROAT; OF-THE-LITERATURE; RHEUMATIC-FEVER; FUSOBACTERIUM-NECROPHORUM AB The guideline is intended for use by healthcare providers who care for adult and pediatric patients with group A streptococcal pharyngitis. The guideline updates the 2002 Infectious Diseases Society of America guideline and discusses diagnosis and management, and recommendations are provided regarding antibiotic choices and dosing. Penicillin or amoxicillin remain the treatments of choice, and recommendations are made for the penicillin-allergic patient, which now include clindamycin. C1 [Shulman, Stanford T.] Northwestern Univ, Dept Pediat, Div Infect Dis, Ann & Robert H Lurie Childrens Hosp,Feinberg Sch, Chicago, IL 60611 USA. [Bisno, Alan L.] Univ Miami, Miller Sch Med, Dept Med, Miami Vet Affairs Healthcare Syst, Miami, FL 33136 USA. [Clegg, Herbert W.] Hemby Childrens Hosp, Dept Pediat, Charlotte, NC USA. [Clegg, Herbert W.] Eastover Pediat, Charlotte, NC USA. [Gerber, Michael A.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA. [Kaplan, Edward L.] Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA. [Lee, Grace] Boston Childrens Hosp, Div Infect Dis, Boston, MA USA. [Martin, Judith M.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA. [Van Beneden, Chris] Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Shulman, ST (reprint author), Northwestern Univ, Dept Pediat, Div Infect Dis, Ann & Robert H Lurie Childrens Hosp,Feinberg Sch, 225 E Chicago Ave, Chicago, IL 60611 USA. EM sshulman@northwestern.edu FU Infectious Diseases Society of America (IDSA); Quidel FX This work was supported by the Infectious Diseases Society of America (IDSA).; The following list is a reflection of what has been reported to the IDSA. To provide thorough transparency, the IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. S. S. has served as a consultant to Novartis Vaccines and Merck Vaccines and received research support from Quidel. A. B. has served as a consultant for SPD Development, Cornerstone BioPharma, and Rib-X Pharmaceuticals. All other authors report no potential conflicts. NR 135 TC 70 Z9 76 U1 1 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 15 PY 2012 VL 55 IS 10 BP E86 EP E102 DI 10.1093/cid/cis629 PG 17 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 027SV UT WOS:000310374600005 PM 22965026 ER PT J AU Hladik, W Pellett, PE Hancock, J Downing, R Gao, HJ Packel, L Mimbe, D Nzaro, E Mermin, J AF Hladik, Wolfgang Pellett, Philip E. Hancock, John Downing, Robert Gao, Hongjiang Packel, Laura Mimbe, Derrick Nzaro, Esau Mermin, Jonathan TI Association Between Transfusion With Human Herpesvirus 8 Antibody-Positive Blood and Subsequent Mortality SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; PRIMARY INFECTION; TRANSMISSION; TRANSPLANTATION; PATIENT; DISEASE AB Background. Human herpesvirus 8 (HHV-8) is endemic in Uganda and transmissible by blood. We evaluated mortality following transfusion of HHV-8 antibody-positive blood. Methods. In a hospital-based, observational, prospective cohort study with a 6-month follow-up, we examined the effect of HHV-8 antibody-positive blood on transfusion recipients surviving at least 7 days. Results. Of 1092 recipients, 471 (43.1%) were transfused with HHV-8 antibody-positive blood. Median age was 1.8 years (range, 0.1-78); 111 (10.2%) died during follow-up. After adjusting for confounders (increasing age, human immunodeficiency virus infection, illness other than malaria, receipt of multiple transfusions), recipients of HHV-8 antibody-positive blood stored <= 4 days ("short-stored") were more likely to die than recipients of HHV-8 antibody-negative blood (adjusted hazards ratio [AHR], 1.92; 95% confidence interval [CI], 1.21-3.05; P = .01). The AHR of the effect of each additional short-stored HHV-8 antibody-positive transfusion was 1.79 (95% CI, 1.33-2.41; P = .001). Conclusions. Transfusion with short-stored HHV-8 antibody-positive blood was associated with an increased risk of death. Further research is warranted to determine if a causal pathway exists and to verify the observed association between acute HHV-8 infection and premature mortality. C1 [Hladik, Wolfgang; Hancock, John; Downing, Robert; Mimbe, Derrick] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Ctr Global Hlth, Entebbe, Uganda. [Nzaro, Esau] Mulago Hosp, Dept Haematol, Kampala, Uganda. [Hladik, Wolfgang] Univ Amsterdam, Dept Clin Epidemiol, Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands. [Pellett, Philip E.] Wayne State Univ, Dept Immunol & Microbiol, Detroit, MI USA. [Gao, Hongjiang] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Mermin, Jonathan] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Natl Ctr Hepatitis HIV STD & TB Prevent, Atlanta, GA USA. [Packel, Laura] Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94143 USA. RP Hladik, W (reprint author), Uganda Virus Res Inst, POB 49, Entebbe, Uganda. EM wfh3@cdc.gov RI Mermin, Jonathan/J-9847-2012 FU CDC FX This work was funded by the CDC. CDC staff were involved in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; and in the preparation, review, and approval of the manuscript. NR 18 TC 5 Z9 5 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 15 PY 2012 VL 206 IS 10 BP 1497 EP 1503 DI 10.1093/infdis/jis543 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 025UI UT WOS:000310220000005 PM 22949307 ER PT J AU Kuehn, BM Petersen, L AF Kuehn, Bridget M. Petersen, Lyle TI Record Heat May Have Contributed to a Banner Year for West Nile Virus SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT News Item C1 [Petersen, Lyle] CDC, Div Vector Borne Dis, Atlanta, GA 30333 USA. NR 0 TC 6 Z9 6 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 14 PY 2012 VL 308 IS 18 BP 1846 EP 1848 DI 10.1001/jama.2012.13495 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 035NA UT WOS:000310952700002 PM 23149988 ER PT J AU del Rio, C Hall, G Holmes, K Soge, O Hook, EW Kirkcaldy, RD Workowski, KA Kidd, S Weinstock, HS Papp, JR Trees, D Peterman, TA Bolan, G AF del Rio, Carlos Hall, Geraldine Holmes, King Soge, Olusegun Hook, Edward W. Kirkcaldy, Robert D. Workowski, Kimberly A. Kidd, Sarah Weinstock, Hillard S. Papp, John R. Trees, David Peterman, Thomas A. Bolan, Gail TI Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections (Reprinted from MMWR, vol 61, pg 590, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Kirkcaldy, Robert D.; Workowski, Kimberly A.; Kidd, Sarah; Weinstock, Hillard S.; Papp, John R.; Trees, David; Peterman, Thomas A.; Bolan, Gail] CDC, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [del Rio, Carlos] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Hall, Geraldine] Cleveland Clin, Dept Clin Pathol, Cleveland, OH 44106 USA. [Holmes, King; Soge, Olusegun] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Hook, Edward W.] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA. RP Kirkcaldy, RD (reprint author), CDC, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM rkirkcaldy@cdc.gov RI del Rio, Carlos/B-3763-2012 OI del Rio, Carlos/0000-0002-0153-3517 NR 1 TC 0 Z9 0 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 14 PY 2012 VL 308 IS 18 BP 1850 EP 1853 DI 10.1001/2012.jama.11292 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 035NA UT WOS:000310952700007 ER PT J AU O'Keefe, A Frederick, J Harmon, B Safranek, T Buss, BF Park, BJ Yeoman, K AF O'Keefe, Anne Frederick, Justin Harmon, Bonnie Safranek, Tom Buss, Bryan F. Park, Benjamin J. Yeoman, Kristin TI Notes from the Field: Histoplasmosis Outbreak Among Day Camp Attendees-Nebraska, June 2012 (Reprinted from MMWR, vol 61, pg 747, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Yeoman, Kristin] CDC, Atlanta, GA 30333 USA. RP Yeoman, K (reprint author), CDC, Atlanta, GA 30333 USA. EM vij6@cdc.gov NR 4 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 14 PY 2012 VL 308 IS 18 BP 1853 EP 1854 DI 10.1001/jama.2012.14070 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 035NA UT WOS:000310952700008 ER PT J AU Scanlon, KS Dietz, WH AF Scanlon, Kelley S. Dietz, William H. TI Reduction of trans-Fatty Acids From Food Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Scanlon, Kelley S.; Dietz, William H.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. RP Scanlon, KS (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. EM kscanlon@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 14 PY 2012 VL 308 IS 18 BP 1858 EP 1859 DI 10.1001/jama.2012.14231 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 035NA UT WOS:000310952700015 ER PT J AU Zhu, XY Yang, H Guo, Z Yu, WL Carney, PJ Li, Y Chen, LM Paulson, JC Donis, RO Tong, SX Stevens, J Wilson, IA AF Zhu, Xueyong Yang, Hua Guo, Zhu Yu, Wenli Carney, Paul J. Li, Yan Chen, Li-Mei Paulson, James C. Donis, Ruben O. Tong, Suxiang Stevens, James Wilson, Ian A. TI Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE enzyme; mechanism; receptor; glycoprotein; infection ID SIALIC-ACID; 3-DIMENSIONAL STRUCTURE; H1N1 NEURAMINIDASE; 2.2-A RESOLUTION; DRUG DESIGN; BINDING; ATTACHMENT; INHIBITOR; MECHANISM; SUBSTRATE AB Recently, we reported a unique influenza A virus subtype H17N10 from little yellow-shouldered bats. Its neuraminidase (NA) gene encodes a protein that appears to be highly divergent from all known influenza NAs and was assigned as a new subtype N10. To provide structural and functional insights on the bat H17N10 virus, X-ray structures were determined for N10 NA proteins from influenza A viruses A/little yellow-shouldered bat/Guatemala/164/2009 (GU09-164) in two crystal forms at 1.95 angstrom and 2.5 angstrom resolution and A/little yellow-shouldered bat/Guatemala/060/2010 (GU10-060) at 2.0 angstrom. The overall N10 structures are similar to each other and to other known influenza NA structures, with a single highly conserved calcium binding site in each monomer. However, the region corresponding to the highly conserved active site of influenza A N1-N9 NA subtypes and influenza B NA differs substantially. In particular, most of the amino acid residues required for NA activity are substituted, and the putative active site is much wider because of displacement of the 150-loop and 430-loop. These structural features and the fact that the recombinant N10 protein exhibits no, or extremely low, NA activity suggest that it may have a different function than the NA proteins of other influenza viruses. Accordingly, we propose that the N10 protein be termed an NA-like protein until its function is elucidated. C1 [Yang, Hua; Guo, Zhu; Carney, Paul J.; Chen, Li-Mei; Donis, Ruben O.; Stevens, James] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Li, Yan; Tong, Suxiang] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Zhu, Xueyong; Yu, Wenli; Paulson, James C.; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA. [Paulson, James C.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA. [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA. RP Stevens, J (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM wilson@scripps.edu FU National Institutes of Health (NIH) [AI058113]; Skaggs Institute for Chemical Biology; DOE Office of Biological and Environmental Research; NIH National Center for Research Resources, Biomedical Technology Program [P41RR001209]; National Institute of General Medical Sciences; National Cancer Institute [Y1CO-1020]; National Institute of General Medical Sciences [Y1-GM-1104]; DOE, Basic Energy Sciences, Office of Science [DE-AC02-06CH11357, W-31-109-Eng-38] FX We thank Henry Tien of the Robotics Core at the Joint Center for Structural Genomics for automated crystal screening and Ryan McBride and Corwin Nycholat for assistance in analysis of the NA enzymatic activity of the N10 NAL proteins. X-ray diffraction data sets were collected at the Stanford Synchrotron Radiation Lightsource (SSRL) beamline 11-1 and the Advanced Photon Source beamlines 23ID-D and 22-ID. This work was supported in part by National Institutes of Health (NIH) Grant AI058113 (to I.A.W.) and the Skaggs Institute for Chemical Biology. Portions of this research were carried out at the SSRL, a national user facility operated by Stanford University on behalf of the US Department of Energy (DOE), Office of Basic Energy Sciences. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by NIH National Center for Research Resources, Biomedical Technology Program Grant P41RR001209, and the National Institute of General Medical Sciences. The GM/CA CAT 23-ID-D beamline has been funded in whole or in part with federal funds from the National Cancer Institute (Y1CO-1020) and National Institute of General Medical Sciences (Y1-GM-1104). Supporting institutions for SER-CAT 22-ID may be found at www.ser-cat.org/members.html. Use of the Advanced Photon Source was supported by the DOE, Basic Energy Sciences, Office of Science, under Contracts DE-AC02-06CH11357 and W-31-109-Eng-38. This is publication 21882 from The Scripps Research Institute. NR 36 TC 54 Z9 55 U1 1 U2 18 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 13 PY 2012 VL 109 IS 46 BP 18903 EP 18908 DI 10.1073/pnas.1212579109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 043UY UT WOS:000311576300059 PM 23012478 ER PT J AU Kandeel, AM Talaat, M Afifi, SA El-Sayed, NM Fadeel, MAA Hajjeh, RA Mahoney, FJ AF Kandeel, Amr M. Talaat, Maha Afifi, Salma A. El-Sayed, Nasr M. Fadeel, Moustafa A. Abdel Hajjeh, Rana A. Mahoney, Frank J. TI Case control study to identify risk factors for acute hepatitis C virus infection in Egypt SO BMC INFECTIOUS DISEASES LA English DT Article DE Acute Hepatitis C; Risk factor; Egypt ID TRANSMISSION; EPIDEMIOLOGY; SURVEILLANCE; COLONOSCOPY; CHALLENGES; COMMUNITY; EXPOSURE AB Background: Identification of risk factors of acute hepatitis C virus (HCV) infection in Egypt is crucial to develop appropriate prevention strategies. Methods: We conducted a case-control study, June 2007-September 2008, to investigate risk factors for acute HCV infection in Egypt among 86 patients and 287 age and gender matched controls identified in two infectious disease hospitals in Cairo and Alexandria. Case-patients were defined as: any patient with symptoms of acute hepatitis; lab tested positive for HCV antibodies and negative for HBsAg, HBc IgM, HAV IgM; and 7-fold increase in the upper limit of transaminase levels. Controls were selected from patients' visitors with negative viral hepatitis markers. Subjects were interviewed about previous exposures within six months, including community-acquired and health-care associated practices. Results: Case-patients were more likely than controls to have received injection with a reused syringe (OR=23.1, CI 4.7-153), to have been in prison (OR=21.5, CI 2.5-479.6), to have received IV fluids in a hospital (OR=13.8, CI 5.3-37.2), to have been an IV drug user (OR=12.1, CI 4.6-33.1), to have had minimal surgical procedures (OR=9.7, CI 4.2-22.4), to have received IV fluid as an outpatient (OR=8, CI 4-16.2), or to have been admitted to hospital (OR=7.9, CI 4.2-15) within the last 6 months. Multivariate analysis indicated that unsafe health facility practices are the main risk factors associated with transmission of HCV infection in Egypt. Conclusion: In Egypt, focusing acute HCV prevention measures on health-care settings would have a beneficial impact. C1 [Talaat, Maha; Afifi, Salma A.; Fadeel, Moustafa A. Abdel] USN, Med Res Unit NAMRU 3 3, FPO, AE 09835 USA. [Kandeel, Amr M.; El-Sayed, Nasr M.] Minist Hlth & Populat, Prevent & Endem Dis Sect, Cairo, Egypt. [Hajjeh, Rana A.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Mahoney, Frank J.] Ctr Dis Control & Prevent, Jakarta, Indonesia. RP Afifi, SA (reprint author), USN, Med Res Unit NAMRU 3 3, PSC 452,Box 5000, FPO, AE 09835 USA. EM salma.afifi.eg@med.navy.mil FU US Agency for International Development (USAID) [80000.000.000.E0022] FX This work was supported by US Agency for International Development (USAID), [Work Unit no. 80000.000.000.E0022]. NR 31 TC 10 Z9 12 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD NOV 12 PY 2012 VL 12 AR 294 DI 10.1186/1471-2334-12-294 PG 8 WC Infectious Diseases SC Infectious Diseases GA 048EO UT WOS:000311893200001 PM 23145873 ER PT J AU Emanuele, VA Panicker, G Gurbaxani, BM Lin, JMS Unger, ER AF Emanuele, Vincent A., II Panicker, Gitika Gurbaxani, Brian M. Lin, Jin-Mann S. Unger, Elizabeth R. TI Sensitive and Specific Peak Detection for SELDI-TOF Mass Spectrometry Using a Wavelet/Neural-Network Based Approach SO PLOS ONE LA English DT Article ID SERUM BIOMARKERS; BREAST-CANCER; VALIDATION; MS AB SELDI-TOF mass spectrometer's compact size and automated, high throughput design have been attractive to clinical researchers, and the platform has seen steady-use in biomarker studies. Despite new algorithms and preprocessing pipelines that have been developed to address reproducibility issues, visual inspection of the results of SELDI spectra preprocessing by the best algorithms still shows miscalled peaks and systematic sources of error. This suggests that there continues to be problems with SELDI preprocessing. In this work, we study the preprocessing of SELDI in detail and introduce improvements. While many algorithms, including the vendor supplied software, can identify peak clusters of specific mass (or m/z) in groups of spectra with high specificity and low false discover rate (FDR), the algorithms tend to underperform estimating the exact prevalence and intensity of peaks in those clusters. Thus group differences that at first appear very strong are shown, after careful and laborious hand inspection of the spectra, to be less than significant. Here we introduce a wavelet/neural network based algorithm which mimics what a team of expert, human users would call for peaks in each of several hundred spectra in a typical SELDI clinical study. The wavelet denoising part of the algorithm optimally smoothes the signal in each spectrum according to an improved suite of signal processing algorithms previously reported (the LibSELDI toolbox under development). The neural network part of the algorithm combines those results with the raw signal and a training dataset of expertly called peaks, to call peaks in a test set of spectra with approximately 95% accuracy. The new method was applied to data collected from a study of cervical mucus for the early detection of cervical cancer in HPV infected women. The method shows promise in addressing the ongoing SELDI reproducibility issues. C1 [Emanuele, Vincent A., II; Panicker, Gitika; Gurbaxani, Brian M.; Lin, Jin-Mann S.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Chron & Viral Dis Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Emanuele, VA (reprint author), Ctr Dis Control & Prevent, Chron & Viral Dis Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. EM VEmanueleII@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 FU National Cancer Institute's (NCI) Early Detection Research Network [IAA Y1-CN-5005-01, Y1-CN-0101-01]; Oak Ridge Institute for Science and Education through U.S. Department of Energy; Oak Ridge Institute for Science and Education through Centers for Disease Control and Prevention (CDC) FX This work was supported in part by the National Cancer Institute's (NCI) Early Detection Research Network through IAA Y1-CN-5005-01 and Y1-CN-0101-01. This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an inter-agency agreement between the U.S. Department of Energy and the Centers for Disease Control and Prevention (CDC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 3 Z9 3 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 12 PY 2012 VL 7 IS 11 AR e48103 DI 10.1371/journal.pone.0048103 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 039HA UT WOS:000311234000007 PM 23152765 ER PT J AU Calvert, AE Huang, CYH Blair, CD Roehrig, JT AF Calvert, Amanda E. Huang, Claire Y. -H. Blair, Carol D. Roehrig, John T. TI Mutations in the West Nile prM protein affect VLP and virion secretion in vitro SO VIROLOGY LA English DT Article DE Flavivirus; West Nile virus; prM protein; Flavivirus structure ID TICK-BORNE ENCEPHALITIS; RECOMBINANT SUBVIRAL PARTICLES; LINKED IMMUNOSORBENT ASSAYS; DENGUE VIRUS-INFECTION; JAPANESE ENCEPHALITIS; ENVELOPE PROTEIN; ENDOPLASMIC-RETICULUM; FLAVIVIRUS PARTICLES; PREMEMBRANE PROTEIN; GLYCOSYLATION SITE AB Mutation of the West Nile virus-like particle (WN VLP) prM protein (T20D, K31A, K31V, or K31T) results in undetectable VLP secretion from transformed COS-1 cells. K31 mutants formed intracellular prM-E heterodimers; however these proteins remained in the ER and ER-Golgi intermediary compartments of transfected cells. The T20D mutation affected glycosylation, heterodimer formation, and WN VLP secretion. When infectious viruses bearing the same mutations were used to infect COS-1 cells, K31 mutant viruses exhibited delayed growth and reduced infectivity compared to WT virus. Epitope maps of WN VLP and WNV prM were also different. These results suggest that while mutations in the prM protein can reduce or eliminate secretion of WN VLPs, they have less effect on virus. This difference may be due to the quantity of prM in WN VLPs compared to WNV or to differences in maturation, structure, and symmetry of these particles. Published by Elsevier Inc. C1 [Calvert, Amanda E.; Huang, Claire Y. -H.; Roehrig, John T.] Ctr Dis Control & Prevent, Arbovirus Dis Branch, Div Vector Borne Dis, Publ Hlth Serv,US Dept HHS, Ft Collins, CO 80521 USA. [Blair, Carol D.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Calvert, AE (reprint author), Ctr Dis Control & Prevent, Arbovirus Dis Branch, Div Vector Borne Dis, Publ Hlth Serv,US Dept HHS, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM zpz0@cdc.gov OI Roehrig, John/0000-0001-7581-0479 NR 47 TC 9 Z9 9 U1 2 U2 12 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV 10 PY 2012 VL 433 IS 1 BP 35 EP 44 DI 10.1016/j.virol.2012.07.011 PG 10 WC Virology SC Virology GA 020GS UT WOS:000309797600005 PM 22858174 ER PT J AU Beatman, E Oyer, R Shives, KD Hedman, K Brault, AC Tyler, KL Beckham, JD AF Beatman, Erica Oyer, Ryan Shives, Katherine D. Hedman, Karla Brault, Aaron C. Tyler, Kenneth L. Beckham, J. David TI West Nile virus growth is independent of autophagy activation SO VIROLOGY LA English DT Article DE Flavivirus; West Nile virus; Autophagy; Neuron; Viral encephalitis; p62 ID REPLICATION; MACHINERY; PROTEIN; INFECTION; PATHWAY; DEATH; MICE; ENCEPHALITIS; SUBVERSION; TREHALOSE AB West Nile virus (WNV) is an arthropod-borne virus with a worldwide distribution that causes neurologic disease and death. Autophagy is a cellular homeostatic mechanism involved in antiviral responses but can be subverted to support viral growth as well. We show that autophagy is induced by WNV infection in cell culture and in primary neuron cultures. Following WNV infection, lysosomes co-localize with autophagosomes resulting in LC3B-II turnover and autolysosomal acidification. However, activation or inhibition of autophagy has no significant effect on WNV growth but pharmacologic inhibition of PI3 kinases associated with autophagy reduce WNV growth. Basal levels of p62/sequestosome1(SQSTM1) do not significantly change following WNV-induced autophagy activation, but p62 is turned over or degraded by autophagy activation implying that p62 expression is increased following WNV-infection. These data show that WNV-induces autophagy but viral growth is independent of autophagy activation suggesting that WNV-specific interactions with autophagy have diverged from other flaviviruses. (C) 2012 Elsevier Inc. All rights reserved. C1 [Beatman, Erica; Oyer, Ryan; Hedman, Karla; Tyler, Kenneth L.; Beckham, J. David] Univ Colorado, Div Infect Dis, Dept Med, Aurora, CO 80045 USA. [Tyler, Kenneth L.; Beckham, J. David] Univ Colorado, Dept Neurol, Aurora, CO 80045 USA. [Shives, Katherine D.; Tyler, Kenneth L.; Beckham, J. David] Univ Colorado, Dept Microbiol, Aurora, CO 80045 USA. [Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Beckham, JD (reprint author), Univ Colorado, Div Infect Dis, Dept Med, Anschutz Med Campus,Bldg Res 2,12700 E 19th Ave,B, Aurora, CO 80045 USA. EM david.beckham@ucdenver.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU National Institute of Allergy and Infectious Diseases (NIAID) [K08AI076518, U54AI065357]; VA Merit award [R21AI101064]; NIH NINDS [R01NS076512]; Neurovirology molecular biology training grant [5T32NS007321] FX We would like to thank Dr. Mizushima for providing Atg5 knockout and wildtype MEF cells. We appreciate the assistance of the University of Colorado Boulder Electron Microscopy Core and Dr. Thomas Perkins in the preparation and imaging of samples using electron microscopy. We also appreciate the use of the University of Colorado AMC Advanced Light Microscopy Core for confocal imaging studies. We would like to thank Dohun Pyeon and Laura Griffin for assistance with reagents. This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) Grant K08AI076518 and the NIAID supported Rocky Mountain Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research Grant U54AI065357. K.L.T. is supported by a VA Merit award, R21AI101064 and NIH NINDS R01NS076512. R.O. is supported by 5T32NS007321, Neurovirology molecular biology training grant. We would also like to thank Micayla Medek for her work on our campus and dedicate this work to her memory and the memory of the other 11 victims from 7/20/12. NR 34 TC 21 Z9 22 U1 2 U2 14 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV 10 PY 2012 VL 433 IS 1 BP 262 EP 272 DI 10.1016/j.virol.2012.08.016 PG 11 WC Virology SC Virology GA 020GS UT WOS:000309797600030 PM 22939285 ER PT J AU Esposito, DH Freedman, DO Neumayr, A Parola, P AF Esposito, D. H. Freedman, D. O. Neumayr, A. Parola, P. TI Ongoing outbreak of an acute muscular Sarcocystis-like illness among travellers returning from Tioman Island, Malaysia, 2011-2012 SO EUROSURVEILLANCE LA English DT Article AB As of 4 November, 2012, 100 patients with an acute muscular Sarcocystis-like illness associated with travel to Tioman Island, Malaysia, have been identified. Thirty-five travelled there mostly during July and August 2011 and 65 mostly during July and August 2012, suggesting an ongoing outbreak. Epidemiological investigations are ongoing. Public health agencies and practicing clinicians should be aware of this rarely-reported disease in humans and consider it as differential diagnosis in travellers returning from Tioman Island. From 27 July to 4 November 2012, GeoSentinel [1], working with EuroTravNet [2] and TropNet [3], has identified 65 patients with an acute muscular Sarcocystis-like illness after recent travel to Tioman Island. All of these patients had traveled to Tioman, located off the east coast of peninsular Malaysia, mostly during July and August, 2012. Reports originated from Germany (n = 25), France (n = 20), the Netherlands (n = 12), Switzerland (n = 3), Belgium (n = 2), Spain (n = 2), and Singapore (n = 1). These patients appear to represent the second wave of an outbreak that started in 2011 [4]. An epidemiologic investigation, initiated in November 2011, is ongoing. C1 [Esposito, D. H.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA 30329 USA. [Freedman, D. O.] Univ Alabama Birmingham, Div Infect Dis, GeoSentinel Program Off, Birmingham, AL USA. [Neumayr, A.] Swiss Trop & Publ Hlth Inst, TropNet Coordinating Ctr, Basel, Switzerland. [Parola, P.] Aix Marseille Univ, Univ Hosp, Inst Infect & Trop Dis, EuroTravNet Coordinating Ctr, Marseille, France. [Parola, P.] Assisitance Publ Hop Marseille, Marseille, France. RP Esposito, DH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Global Migrat & Quarantine, Atlanta, GA 30329 USA. EM desposito@geosentinel.org FU EuroTravNet through the European Centre for Disease Prevention and Control's public tenders [OJ/2008/07/08-PROC/2008/019, OJ/2010/03/16-PROC/2010/011]; Cooperative Agreement from United States Centers for Disease Control and Prevention [5U50CK000189]; US Centers for Disease Control and Prevention's Parasitic Diseases Branch Reference Laboratory and Infectious Diseases Pathology Branch; US Department of Agriculture Agricultural Research Services FX We are grateful to all clinicians and members of the EuroTravNet/GeoSentinel and TropNet networks who contributed to this alert by providing early reports of their patients. EuroTravNet (http://www.eurotravnet.eu) has been funded through the European Centre for Disease Prevention and Control's public tenders OJ/2008/07/08-PROC/2008/019 and OJ/2010/03/16-PROC/2010/011 and has been supported by Cooperative Agreement 5U50CK000189 from the United States Centers for Disease Control and Prevention. It has been created by grouping the European surveillance sites and network members of GeoSentinel (http://www.geosentinel.org), the global surveillance program of the International Society of Travel Medicine. TropNet (http://www.tropnet.net) is a European network for tropical medicine and travel health.; We also thank the US Centers for Disease Control and Prevention's Parasitic Diseases Branch Reference Laboratory and Infectious Diseases Pathology Branch and to the US Department of Agriculture Agricultural Research Services for diagnostic expertise and support. NR 10 TC 5 Z9 6 U1 0 U2 2 PU EUR CENTRE DIS PREVENTION & CONTROL PI STOCKHOLM PA TOMTEBODAVAGEN 11A, STOCKHOLM, 171 83, SWEDEN SN 1560-7917 J9 EUROSURVEILLANCE JI Eurosurveillance PD NOV 8 PY 2012 VL 17 IS 45 BP 2 EP 4 AR 20310 PG 3 WC Infectious Diseases SC Infectious Diseases GA 038GZ UT WOS:000311164500001 ER PT J AU Althomsons, SP Kammerer, JS Shang, N Navin, TR AF Althomsons, Sandy P. Kammerer, J. Steven Shang, Nong Navin, Thomas R. TI Using Routinely Reported Tuberculosis Genotyping and Surveillance Data to Predict Tuberculosis Outbreaks SO PLOS ONE LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; CONTACT INVESTIGATIONS; UNITED-STATES; URBAN-COMMUNITY; TRANSMISSION; CLASSIFICATION; TREE AB We combined routinely reported tuberculosis (TB) patient characteristics with genotyping data and measures of geospatial concentration to predict which small clusters (i.e., consisting of only 3 TB patients) in the United States were most likely to become outbreaks of at least 6 TB cases. Of 146 clusters analyzed, 16 (11.0%) grew into outbreaks. Clusters most likely to become outbreaks were those in which at least 1 of the first 3 patients reported homelessness or excess alcohol or illicit drug use or was incarcerated at the time of TB diagnosis and in which the cluster grew rapidly (i.e., the third case was diagnosed within 5.3 months of the first case). Of 17 clusters with these characteristics and therefore considered high risk, 9 (53%) became outbreaks. This retrospective cohort analysis of clusters in the United States suggests that routinely reported data may identify small clusters that are likely to become outbreaks and which are therefore candidates for intensified contact investigations. C1 [Althomsons, Sandy P.; Shang, Nong; Navin, Thomas R.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Kammerer, J. Steven] Northrop Grumman Corp, Ctr Dis Control Program, Atlanta, GA USA. [Kammerer, J. Steven] Northrop Grumman Corp, Ctr Prevent Program, Atlanta, GA USA. RP Althomsons, SP (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. EM Salthomsons@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX The Centers for Disease Control and Prevention (CDC) provides funding to state and local health departments to conduct surveillance of TB disease in accordance with their own disease reporting regulations. CDC provides technical guidance for the collection of data by the state and local health departments and data are sent to CDC for national-level analyses. The analysis methods for this manuscript were developed by CDC. CDC makes all decisions regarding the publication of national surveillance data as a means to describe the TB epidemic. Northrop Grumman Corporation, Atlanta, Georgia, United States of America, employs JSK and provided scientific analysis services as directed by CDC through a contract with CDC. NR 32 TC 13 Z9 14 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 7 PY 2012 VL 7 IS 11 AR e48754 DI 10.1371/journal.pone.0048754 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 048TK UT WOS:000311935800121 PM 23144956 ER PT J AU Menzies, NA Berruti, AA Blandford, JM AF Menzies, Nicolas A. Berruti, Andres A. Blandford, John M. TI The Determinants of HIV Treatment Costs in Resource Limited Settings SO PLOS ONE LA English DT Article ID ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; MODELS; HEALTH; PREVENTION; EFFICIENCY; DELIVERY; OUTCOMES; IMPROVE AB Background: Governments and international donors have partnered to provide free HIV treatment to over 6 million individuals in low and middle-income countries. Understanding the determinants of HIV treatment costs will help improve efficiency and provide greater certainty about future resource needs. Methods and Findings: We collected data on HIV treatment costs from 54 clinical sites in Botswana, Ethiopia, Mozambique, Nigeria, Uganda, and Vietnam. Sites provided free HIV treatment funded by the U. S. President's Emergency Plan for AIDS Relief (PEPFAR), national governments, and other partners. Service delivery costs were categorized into successive six-month periods from the date when each site began HIV treatment scale-up. A generalized linear mixed model was used to investigate relationships between site characteristics and per-patient costs, excluding ARV expenses. With predictors at their mean values, average annual per-patient costs were $177 (95% CI: 127-235) for pre-ART patients, $353 (255-468) for adult patients in the first 6 months of ART, and $222 (161-296) for adult patients on ART for >6 months (excludes ARV costs). Patient volume (no. patients receiving treatment) and site maturity (months since clinic began providing treatment services) were both strong independent predictors of per-patient costs. Controlling for other factors, costs declined by 43% (18-63) as patient volume increased from 500 to 5,000 patients, and by 28% (6-47) from 5,000 to 10,000 patients. For site maturity, costs dropped 41% (28-52) between months 0-12 and 25% (15-35) between months 12-24. Price levels (proxied by per-capita GDP) were also influential, with costs increasing by 22% (4-41) for each doubling in per-capita GDP. Additionally, the frequency of clinical follow-up, frequency of laboratory monitoring, and clinician-patient ratio were significant independent predictors of per-patient costs. Conclusions: Substantial reductions in per-patient service delivery costs occur as sites mature and patient cohorts increase in size. Other predictors suggest possible strategies to reduce per-patient costs. C1 [Menzies, Nicolas A.; Berruti, Andres A.; Blandford, John M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Menzies, Nicolas A.] ICF Macro Inc, Atlanta, GA USA. [Menzies, Nicolas A.] Harvard Univ, Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA 02115 USA. RP Menzies, NA (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA USA. EM nick.menzies@gmail.com FU PEPFAR FX The PEPFAR ART Costing Project is a PEPFAR-funded public health evaluation (PHE) study led by the U.S. Centers for Disease Control and Prevention (CDC) and implemented with ICF Macro, in collaboration with the U.S. Agency for International Development (USAID). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 35 TC 27 Z9 27 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 7 PY 2012 VL 7 IS 11 AR e48726 DI 10.1371/journal.pone.0048726 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 048TK UT WOS:000311935800112 PM 23144946 ER PT J AU Taylor, AB Kurbatova, EV Cegielski, JP AF Taylor, Allison B. Kurbatova, Ekaterina V. Cegielski, J. Peter TI Prevalence of Anti-Tuberculosis Drug Resistance in Foreign-Born Tuberculosis Cases in the US and in Their Countries of Origin SO PLOS ONE LA English DT Article ID UNITED-STATES; INFECTION AB Background: Foreign-born individuals comprise > 50% of tuberculosis (TB) cases in the U.S. Since anti-TB drug resistance is more common in most other countries, when evaluating a foreign-born individual for TB, one must consider the risk of drug resistance. Naturally, clinicians query The Global Project on Anti-tuberculosis Drug Resistance Surveillance (Global DRS) which provides population-based data on the prevalence of anti-TB drug resistance in 127 countries starting in 1994. However, foreign-born persons in the U.S. are a biased sample of the population of their countries of origin, and Global DRS data may not accurately predict their risk of drug resistance. Since implementing drug resistance surveillance in 1993, the U.S. National TB Surveillance System (NTSS) has accumulated systematic data on over 130,000 foreign-born TB cases from more than 200 countries and territories. Our objective was to determine whether the prevalence of drug resistance among foreign-born TB cases correlates better with data from the Global DRS or with data on foreign-born TB cases in the NTSS. Methods and Findings: We compared the prevalence of resistance to isoniazid and rifampin among foreign-born TB cases in the U.S., 2007-2009, with US NTSS data from 1993 to 2006 and with Global DRS data from 1994-2007 visually with scatterplots and statistically with correlation and linear regression analyses. Among foreign-born TB cases in the U.S., 2007-2009, the prevalence of isoniazid resistance and multidrug resistance (MDR, i.e. resistance to isoniazid and rifampin), correlated much better with 1993-2006 US surveillance data (isoniazid: r = 0.95, P <.001, MDR: r = 0.75, P <.001) than with Global DRS data, 1994-2007 (isoniazid: r = 0.55, P = .001; MDR: r = 0.50, P <.001). Conclusion: Since 1993, the US NTSS has accumulated sufficient data on foreign-born TB cases to estimate the risk of drug resistance among such individuals better than data from the Global DRS. C1 [Taylor, Allison B.; Kurbatova, Ekaterina V.; Cegielski, J. Peter] US Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Cegielski, JP (reprint author), US Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. EM pcegielski@cdc.gov NR 14 TC 4 Z9 4 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 7 PY 2012 VL 7 IS 11 AR e49355 DI 10.1371/journal.pone.0049355 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 048TK UT WOS:000311935800252 PM 23145161 ER PT J AU Fang, J Ayala, C Loustalot, F Dai, SF AF Fang, Jing Ayala, Carma Loustalot, Fleetwood Dai, Shifan TI Prevalence of Cholesterol Screening and High Blood Cholesterol Among Adults-United States, 2005, 2007, and 2009 (Reprinted from MMWR, vol 35, pg 697, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID RISK-FACTORS; DISEASE C1 [Fang, Jing; Ayala, Carma; Loustalot, Fleetwood; Dai, Shifan] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Fang, J (reprint author), CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM jfang@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 7 PY 2012 VL 308 IS 17 BP 1730 EP + DI 10.1001/jama.2012.13022 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 032NR UT WOS:000310726500008 ER PT J AU Hunt, A Bohm, SR Bidol, SA Achen, M Cui, J Denny, L Brandt, E Davis, S Woody, D Reimschuessel, R Tuite, C Rotstein, D Schwensohn, C Behravesh, CB Imanishi, M AF Hunt, April Bohm, Susan R. Bidol, Sally A. Achen, Maya Cui, Jing Denny, Lynn Brandt, Eric Davis, Sam Woody, Dillard Reimschuessel, Renate Tuite, Carla Rotstein, David Schwensohn, Colin Behravesh, Casey Barton Imanishi, Maho CA Public Hlth Agcy Canada TI Notes From the Field: Human Salmonella Infantis Infections Linked to Dry Dog Food-United States and Canada, 2012 (Reprinted from MMWR, vol 23, pg 436, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Imanishi, Maho] CDC, EIS, Atlanta, GA 30333 USA. [Denny, Lynn; Brandt, Eric] Ohio Dept Hlth, Columbus, OH 43266 USA. [Woody, Dillard; Reimschuessel, Renate] US FDA, Ctr Vet Med, Rockville, MD 20857 USA. [Tuite, Carla; Rotstein, David] US FDA, Coordinated Outbreak Response & Evaluat Network, Rockville, MD 20857 USA. [Schwensohn, Colin; Behravesh, Casey Barton] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Imanishi, M (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM hwl2@cdc.gov NR 1 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 7 PY 2012 VL 308 IS 17 BP 1736 EP 1736 DI 10.1001/jama.2012.10060 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 032NR UT WOS:000310726500009 ER PT J AU Samuel, V Benjamin, C Renwick, O Hilliard, A Arnwine, S Spike, D Zabala, J McConnell, K Salfinger, M Mitruka, K Gardner, T Johns, E Luo, R de Rochars, MB Dantes, R AF Samuel, Vincy Benjamin, Cynthia Renwick, Ozzie Hilliard, Aaron Arnwine, Sherrie Spike, Debra Zabala, Jose McConnell, Kateesha Salfinger, Max Mitruka, Kiren Gardner, Tracie Johns, Emma Luo, Robert de Rochars, Madsen Beau Dantes, Raymund TI Notes From the Field: Tuberculosis Cluster Associated With Homelessness-Duval County, Florida, 2004-2012 (Reprinted from MMWR, vol 28, pg 539, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Luo, Robert; de Rochars, Madsen Beau; Dantes, Raymund] CDC, EIS, Atlanta, GA 30333 USA. EM max_salfinger@doh.state.fl.us NR 5 TC 0 Z9 0 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 7 PY 2012 VL 308 IS 17 BP 1736 EP 1737 DI 10.1001/jama.2012.10046 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 032NR UT WOS:000310726500010 ER PT J AU Monte, TCC Simoes, RO Oliveira, APM Novaes, CF Thiengo, SC Silva, AJ Estrela, PC Maldonado, A AF Monte, Taina C. C. Simoes, Raquel O. Oliveira, Ana Paula M. Novaes, Clodoaldo F. Thiengo, Silvana C. Silva, Alexandre J. Estrela, Pedro C. Maldonado Junior, Arnaldo TI Phylogenetic relationship of the Brazilian isolates of the rat lungworm Angiostrongylus cantonensis (Nematoda: Metastrongylidae) employing mitochondrial COI gene sequence data SO PARASITES & VECTORS LA English DT Article DE Rattus norvegicus; Achatina fulica; Eosinophilic meningoencephalitis; Molecular phylogeny; Cytochrome c oxidase subunit I; Brazil ID SNAIL ACHATINA-FULICA; GIANT AFRICAN SNAIL; RIO-DE-JANEIRO; INVASIVE SNAIL; SOUTH-AMERICA; DNA; PERNAMBUCO; INFERENCE; LINEAGES; MOLLUSCA AB Background: The rat lungworm Angiostrongylus cantonensis can cause eosinophilic meningoencephalitis in humans. This nematode's main definitive hosts are rodents and its intermediate hosts are snails. This parasite was first described in China and currently is dispersed across several Pacific islands, Asia, Australia, Africa, some Caribbean islands and most recently in the Americas. Here, we report the genetic variability among A. cantonensis isolates from different geographical locations in Brazil using mitochondrial cytochrome c oxidase subunit I (COI) gene sequences. Methods: The isolates of A. cantonensis were obtained from distinct geographical locations of Brazil. Genomic DNAs were extracted, amplified by polymerase reaction, purified and sequenced. A partial sequence of COI gene was determined to assess their phylogenetic relationship. Results: The sequences of A. cantonensis were monophyletic. We identified a distinct clade that included all isolates of A. cantonensis from Brazil and Asia based on eight distinct haplotypes (ac1, ac2, ac3, ac4, ac5, ac6, ac7 and ac8) from a previous study. Interestingly, the Brazilian haplotype ac5 is clustered with isolates from Japan, and the Brazilian haplotype ac8 from Rio de Janeiro, Sao Paulo, Para and Pernambuco states formed a distinct clade. There is a divergent Brazilian haplotype, which we named ac9, closely related to Chinese haplotype ac6 and Japanese haplotype ac7. Conclusion: The genetic variation observed among Brazilian isolates supports the hypothesis that the appearance of A. cantonensis in Brazil is likely a result of multiple introductions of parasite-carrying rats, transported on ships due to active commerce with Africa and Asia during the European colonization period. The rapid spread of the intermediate host, Achatina fulica, also seems to have contributed to the dispersion of this parasite and the infection of the definitive host in different Brazilian regions. C1 [Monte, Taina C. C.; Simoes, Raquel O.; Estrela, Pedro C.; Maldonado Junior, Arnaldo] Inst Oswaldo Cruz, Lab Biol & Parasitol Mamiferos Silvestres Reserva, BR-21040360 Rio De Janeiro, Brazil. [Oliveira, Ana Paula M.; Thiengo, Silvana C.] Inst Oswaldo Cruz, Lab Referencia Nacl Malacol Med, BR-21040360 Rio De Janeiro, Brazil. [Novaes, Clodoaldo F.] Secretaria Saude Estado Rio de Janeiro, BR-20031142 Rio De Janeiro, Brazil. [Silva, Alexandre J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Maldonado, A (reprint author), Inst Oswaldo Cruz, Lab Biol & Parasitol Mamiferos Silvestres Reserva, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil. EM maldonad@ioc.fiocruz.br RI Maldonado Junior, Arnaldo/C-9641-2013; Thiengo, Silvana /I-2886-2015 FU Oswaldo Cruz Institute/FIOCRUZ, CAPES [3031/2011]; CNPq; CNPq-PDJ-FIOCRUZ [500091/2012-2] FX We are grateful to Oswaldo Cruz Institute/FIOCRUZ, CAPES (Program of Basic Parasitology - grant 3031/2011) and CNPq, which supported this work and also thank the Genomic Platform-DNA Sequencing (PDTIS/FIOCRUZ). PCE was funded by CNPq-PDJ-FIOCRUZ grant 500091/2012-2. We also thank Franklyn Enrique Samudio Acosta for valuable suggestions and Nilson J Melo, Geronimo N Costa and Jorge M Silva for technical support. NR 31 TC 13 Z9 13 U1 4 U2 18 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD NOV 6 PY 2012 VL 5 AR 248 DI 10.1186/1756-3305-5-248 PG 9 WC Parasitology SC Parasitology GA 049GA UT WOS:000311969300001 PM 23130987 ER PT J AU O'Leary, ST Suh, CA Marin, M AF O'Leary, Sean T. Suh, Christina A. Marin, Mona CA Vaccine Policy Collaborative Initi TI Febrile seizures and measles-mumps-rubella-varicella (MMRV) vaccine: What do primary care physicians think? SO VACCINE LA English DT Article DE Febrile seizures; MMRV vaccine; MMR vaccine; Varicella vaccine; Immunizations ID IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; INFLUENZA VACCINE; RECOMMENDATIONS; SAFETY; CHILDREN; SIGNAL; RISK AB Purpose: Measles-mumps-rubella-varicella (MMRV) vaccine is associated with increased febrile seizure risk compared with measles-mumps-rubella and varicella vaccine given separately (MMR + V) in children 12-15-month old. We assessed knowledge regarding MMRV and febrile seizures, intended practices, and factors influencing the decision to recommend MMRV. Methods: National survey administered 10/2008-1/2009 of US pediatricians (Peds) and family physicians (FP). Results: Response rate was 73% (620/849). Twenty-nine percent of Peds and 74% of FP (p<0.001) were unaware of increased febrile seizure risk after MMRV. After reading an informational statement, 20% of Peds and 7% of FP (p<0.001) would recommend MMRV to a healthy 12-15-month-old child. The factor most frequently reported as "very important" in the decision to recommend MMRV or MMR + V was ACIP/AAFP/AAP recommendations (pediatricians, 77%, family physicians, 73%, p=0.08). Conclusions: After receiving data regarding febrile seizure risk after MMRV, few physicians report they would recommend MMRV to a healthy 12-15-month-old child. (C) 2012 Elsevier Ltd. All rights reserved. C1 [O'Leary, Sean T.; Suh, Christina A.] Univ Colorado Anschutz Med Campus, Dept Pediat, Aurora, CO USA. [O'Leary, Sean T.; Suh, Christina A.] Childrens Hosp Colorado, Childrens Outcomes Res Program, Aurora, CO USA. [Marin, Mona] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP O'Leary, ST (reprint author), Univ Colorado, Dept Pediat, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA. EM sean.o'leary@childrenscolorado.org RI Huang, Wan-Ting/E-3497-2010 OI Huang, Wan-Ting/0000-0002-4344-9567 FU Centers for Disease Control and Prevention PEP through the Association of American Medical Colleges, Washington, DC [MM-1040-08/08] FX The authors would like to thank all pediatricians and family physicians in the Networks for participating and responding to this survey. This investigation was funded by a grant from the Centers for Disease Control and Prevention PEP (MM-1040-08/08) through the Association of American Medical Colleges, Washington, DC. The findings and conclusions in this report are those of the authors, and do not necessarily represent the official position of the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. All authors are responsible for the reported research, had full access to the data, all have participated in the concept and design, analysis and interpretation of data, drafting or revising of the manuscript, and they have approved the manuscript NR 11 TC 6 Z9 7 U1 0 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 6 PY 2012 VL 30 IS 48 BP 6731 EP 6733 DI 10.1016/j.vaccine.2012.08.075 PG 3 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 050LA UT WOS:000312053600003 PM 22975026 ER PT J AU Wooten, KG Wortley, PM Singleton, JA Euler, GL AF Wooten, Karen G. Wortley, Pascale M. Singleton, James A. Euler, Gary L. TI Perceptions matter: Beliefs about influenza vaccine and vaccination behavior among elderly white, black and Hispanic Americans SO VACCINE LA English DT Article DE Influenza vaccination; Elderly; Beliefs; Race or ethnicity; Education ID UNITED-STATES; PNEUMOCOCCAL VACCINATION; IMMUNIZATION STATUS; TELEPHONE SURVEY; CONTROLLED-TRIAL; HEALTH-CARE; SELF-REPORT; ADULTS; DISPARITIES; VALIDATION AB Background: Knowledge and beliefs about influenza vaccine that differ across racial or ethnic groups may promote racial or ethnic disparities in vaccination. Objective: To identify associations between vaccination behavior and personal beliefs about influenza vaccine by race or ethnicity and education levels among the U.S. elderly population. Methods: Data from a national telephone survey conducted in 2004 were used for this study. Reponses for 3875 adults >= 65 years of age were analyzed using logistic regression methods. Results: Racial and ethnic differences in beliefs were observed. For example, whites were more likely to believe influenza vaccine is very effective in preventing influenza compared to blacks and Hispanics (whites, 60%; blacks, 47%, and Hispanics, 51%, p < 0.01). Among adults who believed the vaccine is very effective, self-reported vaccination was substantially higher across all racial/ethnic groups (whites, 93%; blacks, 76%; Hispanics, 78%) compared to adults who believed the vaccine was only somewhat effective (whites 67%; blacks 61%, Hispanics 61%). Also, vaccination coverage differed by education level and personal beliefs of whites, blacks, and Hispanics. Conclusions: Knowledge and beliefs about influenza vaccine may be important determinants of influenza vaccination among racial/ethnic groups. Strategies to increase coverage should highlight the burden of influenza disease in racial and ethnic populations, the benefits and safety of vaccinations and personal vulnerability to influenza disease if not vaccinated. For greater effectiveness, factors associated with the education levels of some communities may need to be considered when developing or implementing new strategies that target specific racial or ethnic groups. Published by Elsevier Ltd. C1 [Wooten, Karen G.; Wortley, Pascale M.; Singleton, James A.; Euler, Gary L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30030 USA. RP Singleton, JA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, 1600 Clifton Rd,MS A19, Atlanta, GA 30030 USA. EM KWooten@cdc.gov; PWortley@cdc.gov; JSingleton@cdc.gov; GEuler@cdc.gov FU Centers for Disease Control and Prevention FX The authors of this manuscript declare to have no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with or could be construed as influencing positions presented in this manuscript, and have no relevant financial interests in this manuscript. The research was sponsored by the Centers for Disease Control and Prevention. NR 45 TC 13 Z9 13 U1 1 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD NOV 6 PY 2012 VL 30 IS 48 BP 6927 EP 6934 DI 10.1016/j.vaccine.2012.08.036 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 050LA UT WOS:000312053600032 PM 22939908 ER PT J AU Mahamud, A Wiseman, R Grytdal, S Basham, C Asghar, J Dang, T Leung, J Lopez, A Schmid, DS Bialek, SR AF Mahamud, Abdirahman Wiseman, Rachel Grytdal, Scott Basham, Candyce Asghar, Jawaid Thi Dang Leung, Jessica Lopez, Adriana Schmid, D. Scott Bialek, Stephanie R. TI Challenges in confirming a varicella outbreak in the two-dose vaccine era SO VACCINE LA English DT Article DE Varicella outbreak; Varicella vaccination ID UNITED-STATES; ELEMENTARY-SCHOOL; ZOSTER-VIRUS; EPIDEMIOLOGY; CHILDREN; HOSPITALIZATIONS; IMMUNIZATION; FACILITY AB Background: A second dose of varicella vaccine was recommended for U.S. children in 2006. We investigated a suspected varicella outbreak in School District X, Texas to determine 2-dose varicella vaccine effectiveness (VE). Methods: A varicella case was defined as an illness with maculopapulovesicular rash without other explanation with onset during April 1-June 10, 2011, in a School District X student. We conducted a retrospective cohort in the two schools with the majority of cases. Lesion, saliva, and environmental specimens were collected for varicella-zoster virus (VZV) PCR testing. VE was calculated using historic attack rates among unvaccinated. Results: In School District X.82 varicella cases were reported, including 60 from Schools A and B. All cases were mild, with a median of 14 lesions. All 10 clinical specimens and 58 environmental samples tested negative for VZV. Two-dose varicella vaccination coverage was 66.4% in Schools A and B. Varicella VE in affected classrooms was 80.9% (95% CI; 67.2-88.9) among 1-dose vaccinees and 94.7% (95% CI: 89.2-97.4) among 2-dose vaccinees in School A, with a second dose incremental VE of 72.1% (95% CI: 39.0-87.3). Varicella VE among School B students did not differ significantly by dose (80.1% vs. 84.2% among 1-dose and 2-dose vaccinees, respectively). Conclusion: Laboratory testing could not confirm varicella as the etiology of this outbreak; clinical and epidemiologic data suggests varicella as the likely cause. Better diagnostics are needed for diagnosis of varicella in vaccinated individuals so that appropriate outbreak control measures can be implemented. Published by Elsevier Ltd. C1 [Mahamud, Abdirahman; Grytdal, Scott; Leung, Jessica; Lopez, Adriana; Schmid, D. Scott; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Mahamud, Abdirahman] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Wiseman, Rachel] Texas Dept State Hlth Serv, Austin, TX USA. [Basham, Candyce; Asghar, Jawaid; Thi Dang] Texas Dept State Hlth Serv, Reg Off 2 3, Arlington, TX USA. RP Mahamud, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop A-34, Atlanta, GA 30333 USA. EM Amahamud@cdc.gov NR 25 TC 11 Z9 12 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 6 PY 2012 VL 30 IS 48 BP 6935 EP 6939 DI 10.1016/j.vaccine.2012.07.076 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 050LA UT WOS:000312053600033 PM 22884663 ER PT J AU Liu, N Yen, C Fang, ZY Tate, JE Jiang, BM Parashar, UD Zeng, G Duan, ZJ AF Liu, Na Yen, Catherine Fang, Zhao-yin Tate, Jacqueline E. Jiang, Baoming Parashar, Umesh D. Zeng, Guang Duan, Zhao-jun TI Projected health impact and cost-effectiveness of rotavirus vaccination among children < 5 years of age in China SO VACCINE LA English DT Article DE Rotavirus; Vaccination; Impact; Cost-effectiveness; China ID CHILDHOOD DIARRHEA; UNITED-STATES; GASTROENTERITIS; EFFICACY; SAFETY; HOSPITALIZATIONS; DEATHS; BURDEN; MEXICO AB Introduction: Two rotavirus vaccines have been licensed globally since 2006. In China, only a lamb rotavirus vaccine is licensed and several new rotavirus vaccines are in development. Data regarding the projected health impact and cost-effectiveness of vaccination of children in China against rotavirus will assist policy makers in developing recommendations for vaccination. Methods: Using a Microsoft Excel model, we compared the national health and economic burden of rotavirus disease in China with and without a vaccination program. Model inputs included 2007 data on burden and cost of rotavirus outcomes (deaths, hospitalizations, outpatient visits), projected vaccine efficacy, coverage, and cost. Cost-effectiveness was measured in US dollars per disability-adjusted life-year (DALY) and US dollars per life saved. Results: A 2-dose rotavirus vaccination program could annually avert 3013 (62%) deaths, 194,794(59%) hospitalizations and 1,333,356 (51%) outpatient visits associated with rotavirus disease in China. The medical break-even price of the vaccine is $1.19 per dose. From a societal perspective, a vaccination program would be highly cost-effective in China at the vaccine price of $2.50 to $5 per dose, and be cost-effective at the price of $10 to $20 per dose. Conclusions: A national rotavirus vaccination program could be a cost-effective measure to effectively reduce deaths, hospitalizations, and outpatient visits due to rotavirus disease in China. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Liu, Na; Fang, Zhao-yin; Duan, Zhao-jun] Chinese Ctr Dis Control, Dept Viral Diarrhea, Inst Viral Dis Control & Prevent, Beijing 100052, Peoples R China. [Yen, Catherine; Tate, Jacqueline E.; Jiang, Baoming; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Zeng, Guang] Chinese Ctr Dis Control, Chinese Field Epidemiol Training Program, Beijing 100052, Peoples R China. RP Duan, ZJ (reprint author), Chinese Ctr Dis Control, Dept Viral Diarrhea, Inst Viral Dis Control & Prevent, 100 Yingxin St, Beijing 100052, Peoples R China. EM zhaojund@126.com NR 36 TC 9 Z9 11 U1 0 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD NOV 6 PY 2012 VL 30 IS 48 BP 6940 EP 6945 DI 10.1016/j.vaccine.2012.05.084 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 050LA UT WOS:000312053600034 PM 22705174 ER PT J AU Baggett, HC Chittaganpitch, M Thamthitiwat, S Prapasiri, P Naorat, S Sawatwong, P Ditsungnoen, D Olsen, SJ Simmerman, JM Srisaengchai, P Chantra, S Peruski, LF Sawanpanyalert, P Maloney, SA Akarasewi, P AF Baggett, Henry C. Chittaganpitch, Malinee Thamthitiwat, Somsak Prapasiri, Prabda Naorat, Sathapana Sawatwong, Pongpun Ditsungnoen, Darunee Olsen, Sonja J. Simmerman, James M. Srisaengchai, Prasong Chantra, Somrak Peruski, Leonard F. Sawanpanyalert, Pathom Maloney, Susan A. Akarasewi, Pasakorn TI Incidence and Epidemiology of Hospitalized Influenza Cases in Rural Thailand during the Influenza A (H1N1) pdm09 Pandemic, 2009-2010 SO PLOS ONE LA English DT Article ID UNITED-STATES; RESPIRATORY PATHOGENS; VIRUS-INFECTION; PNEUMONIA; BURDEN; SURVEILLANCE; CHILDREN; IMPACT AB Background: Data on the burden of the 2009 influenza pandemic in Asia are limited. Influenza A(H1N1)pdm09 was first reported in Thailand in May 2009. We assessed incidence and epidemiology of influenza-associated hospitalizations during 2009-2010. Methods: We conducted active, population-based surveillance for hospitalized cases of acute lower respiratory infection (ALRI) in all 20 hospitals in two rural provinces. ALRI patients were sampled 1: 2 for participation in an etiology study in which nasopharyngeal swabs were collected for influenza virus testing by PCR. Results: Of 7,207 patients tested, 902 (12.5%) were influenza-positive, including 190 (7.8%) of 2,436 children aged,5 years; 86% were influenza A virus (46% A(H1N1) pdm09, 30% H3N2, 6.5% H1N1, 3.5% not subtyped) and 13% were influenza B virus. Cases of influenza A(H1N1) pdm09 first peaked in August 2009 when 17% of tested patients were positive. Subsequent peaks during 2009 and 2010 represented a mix of influenza A(H1N1) pdm09, H3N2, and influenza B viruses. The estimated annual incidence of hospitalized influenza cases was 136 per 100,000, highest in ages <5 years (477 per 100,000) and >75 years (407 per 100,000). The incidence of influenza A(H1N1) pdm09 was 62 per 100,000 (214 per 100,000 in children <5 years). Eleven influenza-infected patients required mechanical ventilation, and four patients died, all adults with influenza A(H1N1) pdm09 (1) or H3N2 (3). Conclusions: Influenza-associated hospitalization rates in Thailand during 2009-10 were substantial and exceeded rates described in western countries. Influenza A(H1N1) pdm09 predominated, but H3N2 also caused notable morbidity. Expanded influenza vaccination coverage could have considerable public health impact, especially in young children. C1 [Baggett, Henry C.; Thamthitiwat, Somsak; Prapasiri, Prabda; Naorat, Sathapana; Sawatwong, Pongpun; Olsen, Sonja J.; Simmerman, James M.; Srisaengchai, Prasong; Peruski, Leonard F.; Maloney, Susan A.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth MOPH, Int Emerging Infect Program, Nonthaburi, Thailand. [Baggett, Henry C.; Peruski, Leonard F.; Maloney, Susan A.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Global Dis Detect & Emergency Response Div, Atlanta, GA USA. [Chittaganpitch, Malinee; Sawanpanyalert, Pathom] MOPH, Natl Inst Hlth, Nonthaburi, Thailand. [Ditsungnoen, Darunee] Nakhon Phanom Prov Hlth Off, Nakhon Phanom, Thailand. [Olsen, Sonja J.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Chantra, Somrak] MOPH, Sa Kaeo Prov Hlth Off, Sa Kaeo, Thailand. [Akarasewi, Pasakorn] MOPH, Bur Epidemiol, Nonthaburi, Thailand. RP Baggett, HC (reprint author), US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth MOPH, Int Emerging Infect Program, Nonthaburi, Thailand. EM hbaggett@cdc.gov FU U.S. Centers for Disease Control and Prevention FX This research was funded by the U.S. Centers for Disease Control and Prevention. The funders had a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. NR 30 TC 9 Z9 9 U1 0 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 6 PY 2012 VL 7 IS 11 AR e48609 DI 10.1371/journal.pone.0048609 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 040IE UT WOS:000311315300044 PM 23139802 ER PT J AU Knaack, JS Zhou, YT Abney, CW Jacob, JT Prezioso, SM Hardy, K Lemire, SW Thomas, J Johnson, RC AF Knaack, Jennifer S. Zhou, Yingtao Abney, Carter W. Jacob, Justin T. Prezioso, Samantha M. Hardy, Katelyn Lemire, Sharon W. Thomas, Jerry Johnson, Rudolph C. TI A High-Throughput Diagnostic Method for Measuring Human Exposure to Organophosphorus Nerve Agents SO ANALYTICAL CHEMISTRY LA English DT Article ID TANDEM MASS-SPECTROMETRY; RETROSPECTIVE DETECTION; TOKYO SUBWAY; HUMAN-PLASMA; BUTYRYLCHOLINESTERASE; SARIN; QUANTIFICATION; ACETYLCHOLINESTERASE; IMMUNOASSAY; METABOLITES AB An automated high-throughput immunomagnetic separation (IMS) method for diagnosing exposure to the organophosphorus nerve agents (OPNAs) satin (GB), cyclohexylsarin (GF), VX, and Russian VX (RVX) was developed to increase sample processing capacity for emergency response applications. Diagnosis of exposure to OPNAs was based on the formation of OPNA adducts to butyrylcholinesterase.(BuChE). Data reported with this method represent a ratio of the agent-specific BuChE adduct concentration, relative to the total BuChE peptide concentration that provides a nonactivity measurement expressed as percent adducted. All magnetic bead transfer steps and washes were performed using instrumentation in a 96-well format allowing for simultaneous extraction of 86 clinical samples plus reference materials. Automating extractions increased sample throughput 50-fold, as compared to a previously reported manual method. The limits of detection, determined using synthetic peptides, were 1 ng/mL, for unadducted BuChE and GB-, GF-, VX-, and RVX-adducted BuChE. The automated method was characterized using unexposed serum and serum pools exposed to GB, GF, VX, or RVX. Variation for the measurement of percent adducted was <12% for all characterized quality control serum pools. Twenty-six (26) serum samples from individuals asymptomatic for cholinesterase inhibitor exposure were analyzed using this method, and no background levels of OPNA exposure were observed: Unexposed BuChE serum concentrations measured using this method ranged from 2.8 mu g/mL to 10.6 mu g/mL, with an average concentration of 6.4 mu g/mL. C1 [Knaack, Jennifer S.; Zhou, Yingtao; Hardy, Katelyn; Lemire, Sharon W.; Thomas, Jerry; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Emergency Response & Air Toxicants Branch, Div Sci Lab, Chamblee, GA 30341 USA. [Abney, Carter W.; Jacob, Justin T.] Oak Ridge Inst Sci & Educ, Ctr Dis Control & Prevent, Chamblee, GA 30341 USA. [Prezioso, Samantha M.] IHRC Inc, Ctr Dis Control & Prevent, Atlanta, GA 30346 USA. RP Johnson, RC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Emergency Response & Air Toxicants Branch, Div Sci Lab, 4770 Buford Highway,MS F44, Chamblee, GA 30341 USA. EM RJohnson6@cdc.gov RI Abney, Carter/A-6710-2013; OI Abney, Carter/0000-0002-1809-9577 NR 31 TC 17 Z9 17 U1 2 U2 33 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 J9 ANAL CHEM JI Anal. Chem. PD NOV 6 PY 2012 VL 84 IS 21 BP 9470 EP 9477 DI 10.1021/ac302301w PG 8 WC Chemistry, Analytical SC Chemistry GA 031TG UT WOS:000310664600083 PM 23083472 ER PT J AU Cardemil, CV Cortese, MM Medina-Marino, A Jasuja, S Desai, R Leung, J Rodriguez-Hart, C Villarruel, G Howland, J Quaye, O Tam, KI Bowen, MD Parashar, UD Gerber, SI AF Cardemil, Cristina V. Cortese, Margaret M. Medina-Marino, Andrew Jasuja, Supriya Desai, Rishi Leung, Jessica Rodriguez-Hart, Cristina Villarruel, Gissela Howland, Julia Quaye, Osbourne Tam, Ka Ian Bowen, Michael D. Parashar, Umesh D. Gerber, Susan I. CA Rotavirus Invest Team TI Two Rotavirus Outbreaks Caused by Genotype G2P[4] at Large Retirement Communities Cohort Studies SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID NURSING-HOME; GERIATRIC INPATIENT; CARE FACILITIES; GASTROENTERITIS; INFECTION; VACCINE; ADULTS; SEVERITY; CHILDREN; DIARRHEA AB Background: Outbreaks of rotavirus gastroenteritis in elderly adults are reported infrequently but are often caused by G2P[4] strains. In 2011, outbreaks were reported in 2 Illinois retirement facilities. Objective: To implement control measures, determine the extent and severity of illness, and assess risk factors for disease among residents and employees. Design: Cohort studies using surveys and medical chart abstraction. Setting: Two large retirement facilities in Cook County, Illinois. Patients: Residents and employees at both facilities and community residents with rotavirus disease. Measurements: Attack rates, hospitalization rates, and rotavirus genotype. Results: At facility A, 84 of 324 residents (26%) were identified with clinical or laboratory-confirmed rotavirus gastroenteritis (median age, 84 years) and 11 (13%) were hospitalized. The outbreak lasted 7 weeks. At facility B, 90 case patients among 855 residents (11%) were identified (median age, 88 years) and 19 (21%) were hospitalized. The facility B outbreak lasted 9.3 weeks. Ill employees were identified at both locations. In each facility, attack rates seemed to differ by residential setting, with the lowest rates among those in more separated settings or with high baseline level of infection control measures. The causative genotype for both outbreaks was G2P[4]. Some individuals shed virus detected by enzyme immunoassay or genotyping reverse transcription polymerase chain reaction for at least 35 days. G2P[4] was also identified in 17 of 19 (89%) samples from the older adult community but only 15 of 40 (38%) pediatric samples. Limitation: Medical or cognitive impairment among residents limited the success of some interviews. Conclusion: Rotavirus outbreaks can occur among elderly adults in residential facilities and can result in considerable morbidity. Among older adults, G2P[4] may be of unique importance. Health professionals should consider rotavirus as a cause of acute gastroenteritis in adults. C1 [Cortese, Margaret M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. Cook Cty Dept Publ Hlth, Oak Forest, IL USA. Illinois Dept Publ Hlth, Chicago, IL USA. RP Cortese, MM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM mcortese@cdc.gov NR 53 TC 12 Z9 12 U1 0 U2 6 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 6 PY 2012 VL 157 IS 9 BP 621 EP + DI 10.7326/0003-4819-157-9-201211060-00006 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA 033GX UT WOS:000310783300003 PM 23128862 ER PT J AU Phillips-Howard, PA Odhiambo, FO Hamel, M Adazu, K Ackers, M van Eijk, AM Orimba, V van't Hoog, A Beynon, C Vulule, J Bellis, MA Slutsker, L deCock, K Breiman, R Laserson, KF AF Phillips-Howard, Penelope A. Odhiambo, Frank O. Hamel, Mary Adazu, Kubaje Ackers, Marta van Eijk, Anne M. Orimba, Vincent van't Hoog, Anja Beynon, Caryl Vulule, John Bellis, Mark A. Slutsker, Laurence deCock, Kevin Breiman, Robert Laserson, Kayla F. TI Mortality Trends from 2003 to 2009 among Adolescents and Young Adults in Rural Western Kenya Using a Health and Demographic Surveillance System SO PLOS ONE LA English DT Article ID TREATED BED NETS; PERENNIAL MALARIA TRANSMISSION; SUB-SAHARAN AFRICA; VERBAL AUTOPSY; ANTIRETROVIRAL THERAPY; SCHISTOSOMA-MANSONI; FALCIPARUM-MALARIA; INCOME COUNTRIES; HIV-1 INFECTION; CHILD-MORTALITY AB Background: Targeted global efforts to improve survival of young adults need information on mortality trends; contributions from health and demographic surveillance system (HDSS) are required. Methods and Findings: This study aimed to explore changing trends in deaths among adolescents (15-19 years) and young adults (20-24 years), using census and verbal autopsy data in rural western Kenya using a HDSS. Mid-year population estimates were used to generate all-cause mortality rates per 100,000 population by age and gender, by communicable (CD) and non-communicable disease (NCD) causes. Linear trends from 2003 to 2009 were examined. In 2003, all-cause mortality rates of adolescents and young adults were 403 and 1,613 per 100,000 population, respectively, among females; and 217 and 716 per 100,000, respectively, among males. CD mortality rates among females and males 15-24 years were 500 and 191 per 100,000 (relative risk [RR] 2.6; 95% confidence intervals [CI] 1.7-4.0; p<0.001). NCD mortality rates in same aged females and males were similar (141 and 128 per 100,000, respectively; p = 0.76). By 2009, young adult female all-cause mortality rates fell 53% (chi(2) for linear trend 30.4; p<0.001) and 61.5% among adolescent females (chi(2) for linear trend 11.9; p<0.001). No significant CD mortality reductions occurred among males or for NCD mortality in either gender. By 2009, all-cause, CD, and NCD mortality rates were not significantly different between males and females, and among males, injuries equalled HIV as the top cause of death. Conclusions: This study found significant reductions in adolescent and young adult female mortality rates, evidencing the effects of targeted public health programmes, however, all-cause and CD mortality rates among females remain alarmingly high. These data underscore the need to strengthen programmes and target strategies to reach both males and females, and to promote NCD as well as CD initiatives to reduce the mortality burden amongst both gender. C1 [Phillips-Howard, Penelope A.; van Eijk, Anne M.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Odhiambo, Frank O.; Adazu, Kubaje; Orimba, Vincent; van't Hoog, Anja; Vulule, John; Breiman, Robert; Laserson, Kayla F.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya. [Hamel, Mary; Ackers, Marta; Slutsker, Laurence; deCock, Kevin] Ctr Dis Control & Prevent, Atlanta, GA USA. [van't Hoog, Anja] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. [Beynon, Caryl; Bellis, Mark A.] Liverpool John Moores Univ, Ctr Publ Hlth, Liverpool L3 5UX, Merseyside, England. [Breiman, Robert; Laserson, Kayla F.] Ctr Dis Control & Prevent, Nairobi, Kenya. RP Phillips-Howard, PA (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. EM pennyph@liverpool.ac.uk OI Phillips-Howard, Penelope A/0000-0003-1018-116X FU The Health and Demographic Surveillance System (HDSS); Centers of Disease Control infrastructure grant FX The Health and Demographic Surveillance System (HDSS) and field staff support has been funded through the Centers of Disease Control infrastructure grant, with supplemental support from project-specific grants. Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 65 TC 6 Z9 6 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 5 PY 2012 VL 7 IS 11 AR e47017 DI 10.1371/journal.pone.0047017 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 032TG UT WOS:000310741400014 PM 23144796 ER PT J AU Hallal, PC Bauman, AE Heath, GW Kohl, HW Lee, IM Pratt, M AF Hallal, Pedro C. Bauman, Adrian E. Heath, Gregory W. Kohl, Harold W., III Lee, I-Min Pratt, Michael TI The challenge of assessing physical activity in populations Reply SO LANCET LA English DT Letter ID REACTIVITY; VALIDITY C1 [Hallal, Pedro C.] Univ Fed Pelotas, BR-96030002 Pelotas, Brazil. [Bauman, Adrian E.] Univ Sydney, Sch Publ Hlth, Prevent Res Collaborat, Sydney, NSW 2006, Australia. [Heath, Gregory W.] Univ Tennessee, Coll Med, Chattanooga, TN USA. [Kohl, Harold W., III] Univ Texas Hlth Sci Ctr, Houston Sch Publ Hlth, Austin, TX USA. [Kohl, Harold W., III] Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA. [Lee, I-Min] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA. [Pratt, Michael] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Hallal, PC (reprint author), Univ Fed Pelotas, BR-96030002 Pelotas, Brazil. EM prchallal@terra.com.br RI Epidemiologicas, Centro de pesquisas /D-4561-2013; Hallal, Pedro/A-3249-2011 OI Hallal, Pedro/0000-0003-1470-6461 NR 5 TC 0 Z9 0 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD NOV 3 PY 2012 VL 380 IS 9853 BP 1555 EP 1556 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 030VR UT WOS:000310598700024 ER PT J AU Modell, B Berry, RJ Boyle, CA Christianson, A Darlison, M Dolk, H Howson, CP Mastroiacovo, P Mossey, P Rankin, J AF Modell, Bernadette Berry, R. J. Boyle, Coleen A. Christianson, Arnold Darlison, Matthew Dolk, Helen Howson, Christopher P. Mastroiacovo, Pierpaolo Mossey, Peter Rankin, Judith TI Global, regional, and national causes of child mortality SO LANCET LA English DT Letter C1 [Modell, Bernadette; Darlison, Matthew] UCL, WHO Collaborating Ctr Community Control Hereditar, Ctr Hlth Informat & Multiprofess Educ, London N19 5LW, England. [Berry, R. J.; Boyle, Coleen A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Christianson, Arnold] Natl Hlth Lab Serv, Johannesburg, South Africa. [Christianson, Arnold] Univ Witwatersrand, Johannesburg, South Africa. [Dolk, Helen] Univ Ulster, WHO Collaborating Ctr Surveillance Congenital Ano, Newtownabbey, North Ireland. [Howson, Christopher P.] March Dimes Fdn, White Plains, NY USA. [Mastroiacovo, Pierpaolo] Alessandra Lisi Int Ctr Birth Defects & Prematur, Rome, Italy. [Mossey, Peter] Univ Dundee, Sch Dent, WHO Collaborating Ctr Craniofacial Anomalies, Dundee, Scotland. [Rankin, Judith] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. RP Modell, B (reprint author), UCL, WHO Collaborating Ctr Community Control Hereditar, Ctr Hlth Informat & Multiprofess Educ, London N19 5LW, England. EM b.modell@ucl.ac.uk NR 4 TC 4 Z9 4 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD NOV 3 PY 2012 VL 380 IS 9853 BP 1556 EP 1556 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 030VR UT WOS:000310598700025 PM 23122246 ER PT J AU Haaland, RE Sullivan, ST Evans-Strickfaden, T Lennox, JL Hart, CE AF Haaland, Richard E. Sullivan, Sharon T. Evans-Strickfaden, Tammy Lennox, Jeffrey L. Hart, Clyde E. TI Female Genital Tract Shedding of CXCR4-Tropic HIV Type 1 Is Associated with a Majority Population of CXCR4-Tropic HIV Type 1 in Blood and Declining CD4(+) Cell Counts SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; V3 LOOP; NEUTRALIZING ANTIBODIES; ANTIRETROVIRAL THERAPY; TREATMENT INTERRUPTION; SEXUAL TRANSMISSION; VAGINAL SECRETIONS; SEQUENCE VARIATION; CORECEPTOR USAGE; IMMUNE-RESPONSES AB This study compared HIV-1 genotypes shed over time (<= 3.5 years) in the vaginal secretions (VS) and blood plasma (BP) of 15 chronically infected women. Analysis of predicted coreceptor tropism (CCR5 = R5, CXCR4 = X4) for quasispecies shedding revealed three patterns: (1) viral quasispecies shed in both VS and BP were restricted to R5-tropism at all time points, (2) quasispecies shed in VS were restricted to R5-tropism at all time points but X4 quasispecies were identified in the BP at one or more time points, and (3) quasispecies shed in matched VS and BP both contained X4-tropic viruses. Overall, the frequency of X4 quasispecies circulation in VS was 2-fold less than in BP and detection of X4 virus in VS was more likely to occur when X4 quasispecies comprised more than 50% of BP viruses (p = 0.01) and when declines in blood CD4(+) lymphocyte levels were the greatest (p = 0.038). Additionally, the mean number of predicted N-glycosylation sites between matched VS and BP samples was strongly correlated (r = 0.86, p < 0.0001) with glycosylation densities in the following order (VS R5 = BP R5 > BP X4 > VS X4). The X4 glycosylation densities may result from compartmentalization pressures in the female genital tract or the delayed appearance of these viruses in VS. Our results suggest that the presence of X4 virus in VS is associated with a threshold population of X4 quasispecies in BP, which are increasing during the HIV-induced failure of the human immune system. C1 [Haaland, Richard E.; Sullivan, Sharon T.; Evans-Strickfaden, Tammy; Hart, Clyde E.] Ctr Dis Control & Prevent, Branch Lab, Div HIV & AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. [Lennox, Jeffrey L.] Emory Univ, Sch Med, Dept Med, Grady Infect Dis Program, Atlanta, GA USA. RP Haaland, RE (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV & AIDS Prevent, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd NE,Mailstop A25, Atlanta, GA 30333 USA. EM hyw9@cdc.gov RI Lennox, Jeffrey/D-1654-2014 OI Lennox, Jeffrey/0000-0002-2064-5565 NR 53 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD NOV PY 2012 VL 28 IS 11 BP 1524 EP 1532 DI 10.1089/aid.2012.0004 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 032XP UT WOS:000310754100017 PM 22369497 ER PT J AU Bush, T Zbikowski, SM Mahoney, L Deprey, M Mowery, P Cerutti, B AF Bush, Terry Zbikowski, Susan M. Mahoney, Lisa Deprey, Mona Mowery, Paul Cerutti, Barbara TI State Quitlines and Cessation Patterns Among Adults With Selected Chronic Diseases in 15 States, 2005-2008 SO PREVENTING CHRONIC DISEASE LA English DT Article ID SMOKING-CESSATION; RANDOMIZED-TRIAL; COST-EFFECTIVENESS; TOBACCO CESSATION; CIGARETTE-SMOKING; COTININE LEVELS; NICOTINE PATCH; UNITED-STATES; PRIMARY-CARE; HEALTH-CARE AB Introduction The death rate of people who have a chronic disease is lower among former smokers than current smokers. State tobacco cessation quitlines are available for free in every state. The objective of our study was to compare demographic characteristics, use of quitline services, and quit rates among a sample of quitline callers. Methods We used data from 15 states on tobacco users aged 18 or older who enrolled with a quitline between October 1, 2005, and May 31, 2008; 9 states also provided data from 7-month follow-up surveys. We used descriptive statistics and logistic regression to compare callers by disease status. Results Among 195,057 callers, 32.3% reported having 1 or more of the following chronic diseases: 17.7%, asthma; 5.9%, coronary artery disease; 11.1%, chronic obstructive pulmonary disease; and 9.3%, diabetes; 9.0% had 2 or more chronic diseases. Callers who had a chronic disease were older and better educated; more likely to be female, have Medicaid or other health insurance, and have used tobacco for 20 years or more; and less likely to quit smoking (22.3%) at 7 months than callers who had none of these chronic diseases (29.7%). Conclusion About one-third of tobacco users who call state quitlines have a chronic disease, and those who have a chronic disease are less likely to quit using tobacco. Continued efforts are needed to ensure cessation treatments are reaching tobacco users who have a chronic disease and to develop and test ways to increase quit rates among them. C1 [Bush, Terry; Zbikowski, Susan M.; Mahoney, Lisa; Deprey, Mona] Alere Wellbeing Inc, Seattle, WA 98104 USA. [Mowery, Paul] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cerutti, Barbara] Univ London Imperial Coll Sci Technol & Med, London, England. RP Bush, T (reprint author), Alere Wellbeing Inc, 999 3rd Ave,Ste 2100, Seattle, WA 98104 USA. EM terry.bush@alere.com FU Centers for Disease Control and Prevention Requisition [00HCUCLB-2008-59261] FX This study was funded by the Centers for Disease Control and Prevention Requisition no. 00HCUCLB-2008-59261. We acknowledge each state that participated in this study. NR 36 TC 5 Z9 5 U1 3 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD NOV PY 2012 VL 9 AR UNSP 120105 DI 10.5888/pcd9.120105 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 173AV UT WOS:000321051300004 PM 23137862 ER PT J AU Gibbs, FA Tong, VT Farr, SL Dietz, PM Babb, S AF Gibbs, Falicia A. Tong, Van T. Farr, Sherry L. Dietz, Patricia M. Babb, Stephen TI Smoke-Free-Home Rules Among Women With Infants, 2004-2008 SO PREVENTING CHRONIC DISEASE LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; UNITED-STATES; EXPOSURE; HOUSEHOLD; BANS; CHILDREN; LAWS AB Introduction Exposure to secondhand smoke increases risk for infant illness and death. The objective of this study was to estimate the prevalence of complete smoke-free-home rules (smoking not allowed anywhere in the home) among women with infants in the United States. Methods We analyzed 2004-2008 data from the Pregnancy Risk Assessment Monitoring System on 41,535 women who had recent live births in 5 states (Arkansas, Maine, New Jersey, Oregon, and Washington). We calculated the prevalence of complete smoke-free-home rules and partial or no rules by maternal smoking status, demographic characteristics, delivery year, and state of residence. We used adjusted prevalence ratios (APRs) to estimate associations between complete rules and partial or no rules and variables. Results During 2004-2008, the overall prevalence of complete rules was 94.6% (95% confidence interval [CI], 94.4-94.9), ranging from 85.4% (Arkansas) to 98.1% (Oregon). The prevalence of complete rules increased significantly in 3 states from 2004 to 2008. It was lowest among women who smoked during pregnancy and postpartum, women younger than 20 years, non-Hispanic black women, women with fewer than 12 years of education, women who had an annual household income of less than $10,000, unmarried women, and women enrolled in Medicaid during pregnancy. Conclusion The prevalence of complete smoke-free-home rules among women with infants was high overall and increased in 3 of 5 states, signifying a public health success. Sustained and targeted efforts among groups of women who are least likely to have complete smoke-free-home rules are needed to protect infants from exposure to secondhand smoke. C1 [Gibbs, Falicia A.; Tong, Van T.; Farr, Sherry L.; Dietz, Patricia M.; Babb, Stephen] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS-K22, Atlanta, GA 30341 USA. EM vtong@cdc.gov OI Tong, Van/0000-0002-3970-1440 NR 25 TC 2 Z9 2 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD NOV PY 2012 VL 9 AR UNSP 120108 DI 10.5888/pcd9.120108 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 173AV UT WOS:000321051300005 ER PT J AU McAfee, T Tynan, M AF McAfee, Tim Tynan, Michael TI Smoking in Movies: A New Centers for Disease Control and Prevention Core Surveillance Indicator SO PREVENTING CHRONIC DISEASE LA English DT Editorial Material C1 [McAfee, Tim] Ctr Dis Control & Prevent, Off Smoking Hlth, Atlanta, GA 30341 USA. [Tynan, Michael] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP McAfee, T (reprint author), Ctr Dis Control & Prevent, Off Smoking Hlth, 4770 Buford Hwy NE,Mailstop K50, Atlanta, GA 30341 USA. EM mtt4@cdc.gov NR 10 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD NOV PY 2012 VL 9 AR UNSP 120261 DI 10.5888/pcd9.120261 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 173AV UT WOS:000321051300003 ER PT J AU Mugavero, K Losby, JL Gunn, JP Levings, JL Lane, RI AF Mugavero, Kristy Losby, Jan L. Gunn, Janelle P. Levings, Jessica Lee Lane, Rashon I. TI Reducing Sodium Intake at the Community Level: The Sodium Reduction in Communities Program SO PREVENTING CHRONIC DISEASE LA English DT Article C1 [Mugavero, Kristy] Ctr Dis Control & Prevent, Chamblee, GA 30341 USA. [Losby, Jan L.; Gunn, Janelle P.; Levings, Jessica Lee; Lane, Rashon I.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Mugavero, K (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F-72, Chamblee, GA 30341 USA. EM Frc9@cdc.gov NR 11 TC 6 Z9 6 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD NOV PY 2012 VL 9 AR UNSP 120081 DI 10.5888/pcd9.120081 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 173AV UT WOS:000321051300009 ER PT J AU Adams, AP Navarro-Lopez, R Ramirez-Aguilar, FJ Lopez-Gonzalez, I Leal, G Flores-Mayorga, JM da Rosa, APAT Saxton-Shaw, KD Singh, AJ Borland, EM Powers, AM Tesh, RB Weaver, SC Estrada-Franco, JG AF Adams, A. Paige Navarro-Lopez, Roberto Ramirez-Aguilar, Francisco J. Lopez-Gonzalez, Irene Leal, Grace Flores-Mayorga, Jose M. da Rosa, Amelia P. A. Travassos Saxton-Shaw, Kali D. Singh, Amber J. Borland, Erin M. Powers, Ann M. Tesh, Robert B. Weaver, Scott C. Estrada-Franco, Jose G. TI Venezuelan Equine Encephalitis Virus Activity in the Gulf Coast Region of Mexico, 2003-2010 SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID NORTH-AMERICA; SOUTH-AMERICA; ENCEPHALOMYELITIS; EMERGENCE; PHYLOGENIES; ANTIBODIES; ALGORITHM; INFECTION; VECTORS; VERSION AB Venezuelan equine encephalitis virus (VEEV) has been the causative agent for sporadic epidemics and equine epizootics throughout the Americas since the 1930s. In 1969, an outbreak of Venezuelan equine encephalitis (VEE) spread rapidly from Guatemala and through the Gulf Coast region of Mexico, reaching Texas in 1971. Since this outbreak, there have been very few studies to determine the northward extent of endemic VEEV in this region. This study reports the findings of serologic surveillance in the Gulf Coast region of Mexico from 2003-2010. Phylogenetic analysis was also performed on viral isolates from this region to determine whether there have been substantial genetic changes in VEEV since the 1960s. Based on the findings of this study, the Gulf Coast lineage of subtype IE VEEV continues to actively circulate in this region of Mexico and appears to be responsible for infection of humans and animals throughout this region, including the northern State of Tamaulipas, which borders Texas. C1 [Adams, A. Paige; Leal, Grace; da Rosa, Amelia P. A. Travassos; Tesh, Robert B.; Weaver, Scott C.] Univ Texas Med Branch, Inst Human Infect & Immun, Ctr Trop Dis, Galveston, TX 77555 USA. [Adams, A. Paige; Leal, Grace; da Rosa, Amelia P. A. Travassos; Tesh, Robert B.; Weaver, Scott C.] Univ Texas Med Branch, Dept Pathol, Galveston, TX USA. [Navarro-Lopez, Roberto; Lopez-Gonzalez, Irene; Flores-Mayorga, Jose M.] Comis Mexico Estados Unidos Prevenc Fiebre Aftosa, Secretaria Agr Ganaderia Desarrollo Rural Pesca &, Tuxtla Gutierrez, Mexico. [Ramirez-Aguilar, Francisco J.] Univ Autonoma Chiapas, Fac Ciencias Quim, Lab Enfermedades Emergentes & Zoonot, Tapachula, Chiapas, Mexico. [Saxton-Shaw, Kali D.; Singh, Amber J.; Borland, Erin M.; Powers, Ann M.] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Estrada-Franco, Jose G.] Univ Autonoma Estado Mexico, Fac Med Vet & Zootecnia, Ctr Invest & Estudios Avanzados Salud Anim, Toluca, Mexico. RP Adams, AP (reprint author), Univ Texas Med Branch, Inst Human Infect & Immun, Ctr Trop Dis, Galveston, TX 77555 USA. EM apadams@utmb.edu RI Weaver, Scott/D-6490-2011 FU National Institutes of Health (NIH) [AI25489, AI077796]; Consejo Nacional de Ciencia y Tecnologia [69692] FX This research was supported by National Institutes of Health (NIH) grants AI25489 (RBT, SCW) and AI077796 (APA). The field work was also supported in part by a grant from Consejo Nacional de Ciencia y Tecnologia (grant no. 69692) to FJRA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 16 Z9 16 U1 1 U2 14 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD NOV PY 2012 VL 6 IS 11 AR e1875 DI 10.1371/journal.pntd.0001875 PG 15 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 048CX UT WOS:000311888900008 PM 23133685 ER PT J AU Goodhew, EB Priest, JW Moss, DM Zhong, GM Munoz, B Mkocha, H Martin, DL West, SK Gaydos, C Lammie, PJ AF Goodhew, E. Brook Priest, Jeffrey W. Moss, Delynn M. Zhong, Guangming Munoz, Beatriz Mkocha, Harran Martin, Diana L. West, Sheila K. Gaydos, Charlotte Lammie, Patrick J. TI CT694 and pgp3 as Serological Tools for Monitoring Trachoma Programs SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID CHLAMYDIA-TRACHOMATIS; MASS TREATMENT; INFECTION; ANTIGENS; AZITHROMYCIN; ELIMINATION; FILARIASIS; ANTIBODIES; CHILDREN; ASSAY AB Background: Defining endpoints for trachoma programs can be a challenge as clinical signs of infection may persist in the absence of detectable bacteria. Antibody-based tests may provide an alternative testing strategy for surveillance during terminal phases of the program. Antibody-based assays, in particular ELISAs, have been shown to be useful to document C. trachomatis genital infections, but have not been explored extensively for ocular C. trachomatis infections. Methodology/Principal Findings: An antibody-based multiplex assay was used to test two C. trachomatis antigens, pgp3 and CT694, for detection of trachoma antibodies in bloodspots from Tanzanian children (n = 160) collected after multiple rounds of mass azithromycin treatment. Using samples from C. trachomatis-positive (by PCR) children from Tanzania (n = 11) and control sera from a non-endemic group of U. S. children (n = 122), IgG responses to both pgp3 and CT694 were determined to be 91% sensitive and 98% specific. Antibody responses of Tanzanian children were analyzed with regard to clinical trachoma, PCR positivity, and age. In general, children with more intense ocular pathology (TF/TI = 2 or most severe) had a higher median antibody response to pgp3 (p = 0.0041) and CT694 (p = 0.0282) than those with normal exams (TF/TI = 0). However, 44% of children with no ocular pathology tested positive for antibody, suggesting prior infection. The median titer of antibody responses for children less than three years of age was significantly lower than those of older children. (p<0.0001 for both antigens). Conclusions/Significance: The antibody-based multiplex assay is a sensitive and specific additional tool for evaluating trachoma transmission. The assay can also be expanded to include antigens representing different diseases, allowing for a robust assay for monitoring across NTD programs. C1 [Goodhew, E. Brook; Martin, Diana L.; Lammie, Patrick J.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Priest, Jeffrey W.; Moss, Delynn M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Zhong, Guangming] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Munoz, Beatriz; West, Sheila K.] Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21218 USA. [Mkocha, Harran] Kongwa Trachoma Project, Kongwa, Tanzania. [Gaydos, Charlotte] Johns Hopkins Univ, Dept Infect Dis, Baltimore, MD USA. RP Goodhew, EB (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. EM plammie@cdc.gov FU USAID [OGH11-12021]; Bill and Melinda Gates Foundation FX Funding for this study was obtained in part from USAID (No. OGH11-12021) through an inter-agency agreement with the Centers for Disease Control and Prevention. The study also received operational support from Trachoma Control Programs in Tanzania and was funded in part by the Bill and Melinda Gates Foundation. Dr. West is the recipient of a Senior Scientific Investigator award from Research to Prevent Blindness. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 23 TC 18 Z9 18 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD NOV PY 2012 VL 6 IS 11 AR e1873 DI 10.1371/journal.pntd.0001873 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 048CX UT WOS:000311888900007 PM 23133684 ER PT J AU Stangl, AL Bunnell, R Wamai, N Masaba, H Mermin, J AF Stangl, Anne L. Bunnell, Rebecca Wamai, Nafuna Masaba, Humphrey Mermin, Jonathan TI Measuring quality of life in rural Uganda: reliability and validity of summary scores from the Medical Outcomes Study HIV Health Survey (MOS-HIV) SO QUALITY OF LIFE RESEARCH LA English DT Article DE Quality of life; HIV; Antiretroviral therapy; Construct validity; Uganda ID ACTIVE ANTIRETROVIRAL THERAPY; INFECTED WOMEN; QUESTIONNAIRE; PREDICTORS; DISEASE; ADULTS; ERA AB Purpose Summary scores derived from the Medical Outcomes Study HIV Health Survey (MOS-HIV) are used to assess treatment impacts among HIV-infected patients in Western settings, but have yet to be validated in rural, African settings. We examined the reliability, validity and responsiveness of scores among a prospective cohort of 947 HIV-1-infected adults initiating antiretroviral therapy between May 2003 and May 2004 in rural Uganda. Methods Physical (PHS) and mental health (MHS) summary scores were developed from baseline MOS-HIV sub-domains using exploratory factor analysis. Construct and discriminant validity were established by comparing mean summary scores across known groups of sociodemographic, clinical and health status characteristics. Effect sizes were calculated to assess responsiveness to therapy. Results Reliability of the PHS and MHS scores was 0.79 and 0.85, respectively. Mean baseline PHS and MHS scores varied significantly by CD4 cell count, HIV viral load, WHO stage of disease and Karnofsky performance status scores. By 12 months on antiretroviral therapy, PHS and MHS scores improved by 14.6 points (P < 0.001) and 13.9 points (P < 0.001), respectively. Conclusions PHS and MHS scores can be derived from the MOS-HIV and used to assess health status among cohorts of patients taking antiretroviral therapy in rural Uganda. C1 [Stangl, Anne L.] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Int Hlth & Dev, New Orleans, LA USA. [Stangl, Anne L.] Int Ctr Res Women, Washington, DC 20036 USA. [Stangl, Anne L.; Wamai, Nafuna; Masaba, Humphrey] CDC Uganda, Uganda Virus Res Inst, Entebbe, Uganda. [Bunnell, Rebecca; Mermin, Jonathan] Ctr Dis Control & Prevent CDC, CDC Uganda, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Stangl, AL (reprint author), Int Ctr Res Women, Washington, DC 20036 USA. EM alstangl@gmail.com; rrb7@cdc.gov; hmt6@ug.cdc.gov; jhm7@cdc.gov RI Mermin, Jonathan/J-9847-2012 FU Centers for Disease Control and Prevention; US Department of Health and Human Services FX This study was funded by the Centers for Disease Control and Prevention through the President's Emergency Plan for AIDS Relief and the US Department of Health and Human Services. The authors wish to thank the participants and study team in Tororo, especially Kenneth Khana. We also wish to thank Stevens Bechange for data management and Drs. Dominique Meekers, Paul Hutchinson and Lisanne Brown for providing comments on earlier versions of this manuscript. NR 27 TC 13 Z9 13 U1 2 U2 6 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0962-9343 J9 QUAL LIFE RES JI Qual. Life Res. PD NOV PY 2012 VL 21 IS 9 BP 1655 EP 1663 DI 10.1007/s11136-011-0075-5 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 089MH UT WOS:000314914200019 PM 22198741 ER PT J AU Kauffman, Y Nair, V Herist, K Thomas, V Weidle, PJ AF Kauffman, Yardlee Nair, Vidya Herist, Keith Thomas, Vasavi Weidle, Paul J. TI HIV medication therapy management services in community pharmacies SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION LA English DT Editorial Material DE Medication therapy management; HIV; community pharmacy; antiretroviral therapy ID MEDI-CAL BENEFICIARIES; ANTIRETROVIRAL THERAPY; PILOT PROGRAM; ADHERENCE; CARE; HIV/AIDS; OUTCOMES AB Objectives: To present a rationale and a proposed structure to support pharmacist-delivered medication therapy management (MTM) for human immunodeficiency virus (HIV) disease and to outline challenges to implementing and sustaining the service. Data sources: Professional literature. Summary: Historically, the effect of pharmacy services for HIV-infected persons has been demonstrated in inpatient and clinic-based settings. Developing similar programs adapted for community pharmacists could be a model of care to improve patient adherence to antiretroviral therapy and retention in care. Initiation of antiretroviral therapy and regular monitoring of CD4+ cell count, HIV RNA viral load, adverse drug events, and adherence form the backbone of successful medical management of HIV infection. Support for these services can be provided to HIV-infected patients through pharmacist-managed HIV MTM programs in community pharmacy settings in collaboration with primary providers and other health care professionals. Conclusion: Community pharmacists can help meet the growing need for HIV care through provision of MTM services. Although resources have been developed, including the general MTM framework, challenges of adequate training, education, and support of community pharmacists need to be addressed in order for HIV MTM to be a successful model. C1 [Kauffman, Yardlee] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Nair, Vidya] NE Georgia Med Ctr, Gainesville, FL USA. [Herist, Keith] Univ Georgia, Coll Pharm, Athens, GA 30602 USA. [Thomas, Vasavi; Weidle, Paul J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Kauffman, Y (reprint author), Kaiser Permanente Colorado, 16601 E Centretech Pkwy, Aurora, CO 80011 USA. EM yardlee.s.kauffman@kp.org FU Intramural CDC HHS [CC999999] NR 35 TC 6 Z9 6 U1 1 U2 6 PU AMER PHARMACEUTICAL ASSOC PI WASHINGTON PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA SN 1544-3191 J9 J AM PHARM ASSOC JI J. Am. Pharm. Assoc. PD NOV-DEC PY 2012 VL 52 IS 6 BP E287 EP E291 DI 10.1331/JAPhA.2012.12063 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 082OM UT WOS:000314401500021 PM 23229993 ER PT J AU Johnson, DP Stanforth, A Lulla, V Luber, G AF Johnson, Daniel P. Stanforth, Austin Lulla, Vijay Luber, George TI Developing an applied extreme heat vulnerability index utilizing socioeconomic and environmental data SO APPLIED GEOGRAPHY LA English DT Article DE Extreme heat; Urban heat island; Social vulnerability; Disaster preparation; Disaster mitigation; Heat-health vulnerability ID LAND-SURFACE TEMPERATURE; THERMAL COMFORT CONDITIONS; CLIMATE-CHANGE; SOCIAL VULNERABILITY; IMPERVIOUS SURFACE; UNITED-STATES; VEGETATION INDEX; HUMAN MORTALITY; HEALTH-RISK; URBAN AREAS AB Extreme heat is a leading cause of weather-related fatalities worldwide. Emphasis is currently being placed on the development of spatially specific vulnerability models, which are useful for decision support during extreme heat events (EHE). Research results concerning such spatially-explicit models lead efforts in preparation and mitigation of heat-related vulnerability and potential adaptation. The presented research analyzes the 1995 Chicago EHE in the context of a socio-environmental hazards approach, and fosters the development of an extreme heat vulnerability index (EHVI). The EHVI is a fused dataset consisting of census data and remotely sensed variables, which are examined in relation to geocoded mortality data. The presented analysis combines 25 well-known indicators of extreme risk into an applied index utilizing a principal components analysis. The developed EHVI presented a trend of higher rates of death in the highest risk zones to lower rates in lower zones of risk. The model explains nearly 80% of the total variance in the heat-health vulnerability variables utilized. This index could be utilized by city officials to assist in the mitigation of extreme heat events and is a further evolution of previously developed efforts. Our findings indicate extreme heat vulnerability models should likely be developed on a local level for a specific location, taking into account local variations in social and environmental vulnerability. (C) 2012 Published by Elsevier Ltd. C1 [Johnson, Daniel P.; Stanforth, Austin; Lulla, Vijay] Indiana Univ, Inst Res Social Issues, Indianapolis, IN 46202 USA. [Luber, George] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Druid Hills, GA USA. RP Johnson, DP (reprint author), Indiana Univ, Inst Res Social Issues, 425 Univ Blvd,Cavanaugh Hall 207C, Indianapolis, IN 46202 USA. EM dpjohnso@iupui.edu NR 79 TC 41 Z9 46 U1 2 U2 64 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0143-6228 J9 APPL GEOGR JI Appl. Geogr. PD NOV PY 2012 VL 35 IS 1-2 BP 23 EP 31 DI 10.1016/j.apgeog.2012.04.006 PG 9 WC Geography SC Geography GA 068QB UT WOS:000313380200003 ER PT J AU Bowen, MD Payne, DC AF Bowen, Michael D. Payne, Daniel C. TI Rotavirus vaccine-derived shedding and viral reassortants SO EXPERT REVIEW OF VACCINES LA English DT Article DE contraindication; reassortment; Rotarix (R) vaccine; RotaTeq (R) vaccine; rotavirus; severe combined immunodeficiency disorder; shedding; vaccine-derived virus; vaccine effectiveness ID SEVERE COMBINED IMMUNODEFICIENCY; GASTROENTERITIS; INFANTS; TRANSMISSION; PREVENTION; CHILDREN; STRAINS AB Evaluation of: Donato CM, Ch'ng LS, Boniface KF et al. Identification of strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J. Infect. Dis. 206(3), 377-383 (2012). Two live, attenuated rotavirus vaccines, RotaTeq (R) (Merck) and Rotarix (R) (GlaxoSmithKline), have been used in Australia since July 2007 to prevent severe rotavirus gastroenteritis in children. Using active postvaccination monitoring, passive surveillance and state-of-the-art laboratory techniques, Donato et al. report that RotaTeq rotavirus vaccine and vaccine-derived strains were detected actively in stool samples from 13 out of 61(21.3%) infants having diarrhea within 2 weeks of rotavirus vaccination, and among three out of 460(0.7%) cases with acute gastroenteritis captured via the Australian Rotavirus Surveillance Program. Six (37.5%) of these 16 vaccine-derived viral specimens were associated with a G1P[8] strain thought to be the result of genetic reassortment between two component RotaTeq strains. Although nearly half of these reassortant-associated cases had underlying medical conditions, such as severe combined immunodeficiency disorder, further study is needed to understand the relationship between shedding, viral reassortants and underlying medical conditions. C1 [Bowen, Michael D.; Payne, Daniel C.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM mkb6@cdc.gov NR 19 TC 8 Z9 8 U1 0 U2 3 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1476-0584 J9 EXPERT REV VACCINES JI Expert Rev. Vaccines PD NOV PY 2012 VL 11 IS 11 BP 1311 EP 1314 DI 10.1586/ERV.12.114 PG 4 WC Immunology SC Immunology GA 073VJ UT WOS:000313770900010 PM 23249230 ER PT J AU Flegal, KM Carroll, MD Ogden, CL AF Flegal, Katherine M. Carroll, Margaret D. Ogden, Cynthia L. TI Effects of trimming weight-for-height data on growth-chart percentiles SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID DISEASE-CONTROL; UNITED-STATES; PREVENTION; OVERWEIGHT; CHILDREN; HEALTH; AGE AB Background: Before estimating smoothed percentiles of weight-for-height and BMI-for-age to construct the WHO growth charts, WHO excluded observations that were considered to represent unhealthy weights for height. Objective: The objective was to estimate the effects of similar data trimming on empirical percentiles from the CDC growth-chart data set relative to the smoothed WHO percentiles for ages 24-59 mo. Design: We used the nationally representative US weight and height data from 1971 to 1994, which was the source data for the 2000 CDC growth charts. Trimming cutoffs were calculated on the basis of weight-for-height for 9722 children aged 24-71 mo. Empirical percentiles for 7315 children aged 24-59 mo were compared with the corresponding smoothed WHO percentiles. Results: Before trimming, the mean empirical percentiles for weight-for-height in the CDC data set were higher than the corresponding smoothed WHO percentiles. After trimming, the mean empirical 95th and 97th percentiles of weight-for-height were lower than the WHO percentiles, and the proportion of children in the CDC data set above the WHO 95th percentile decreased from 7% to 5%. The findings were similar for BMI-for-age. However, for weight-for-age, which had not been trimmed by the WHO, the empirical percentiles before trimming agreed closely with the upper percentiles from the WHO charts. Conclusion: WHO data-trimming procedures may account for some of the differences between the WHO growth charts and the 2000 CDC growth charts. Am J Clin Nutr 2012;96:1051-5. C1 [Flegal, Katherine M.; Carroll, Margaret D.; Ogden, Cynthia L.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Flegal, KM (reprint author), CDC, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4336, Hyattsville, MD USA. EM kmf2@cdc.gov OI Flegal, Katherine/0000-0002-0838-469X FU Intramural CDC HHS [CC999999] NR 11 TC 1 Z9 1 U1 0 U2 5 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD NOV PY 2012 VL 96 IS 5 BP 1051 EP 1055 DI 10.3945/ajcn.112.041822 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 062UX UT WOS:000312949600014 PM 22990032 ER PT J AU Gobel, VL Schlotthauer, AE Mahoney, JE Clemson, LM Mack, KA Shea, T Cech, SF AF Gobel, V. L. Schlotthauer, A. E. Mahoney, J. E. Clemson, L. M. Mack, K. A. Shea, T. Cech, S. F. TI USE OF THE DELPHI CONSENSUS TECHNIQUE TO DETERMINE KEY ELEMENTS OF STEPPING ON SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Gobel, V. L.; Mahoney, J. E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Clemson, L. M.] Univ Sydney, Sydney, Qld, Australia. [Schlotthauer, A. E.] Med Coll Wisconsin, Injury Res Ctr, Madison, WI USA. [Mack, K. A.] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Shea, T.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Cech, S. F.] Greater Wisconsin Agcy Aging Resources Inc, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 479 EP 479 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203542 ER PT J AU Schlotthauer, AE Layde, PM Mahoney, JE Mack, KA Shea, T Christiansen, AL Gobel, VL Clemson, LM AF Schlotthauer, A. E. Layde, P. M. Mahoney, J. E. Mack, K. A. Shea, T. Christiansen, A. L. Gobel, V. L. Clemson, L. M. TI RESEARCH ON THE TRANSLATION AND IMPLEMENTATION OF STEPPING ON IN THREE COMMUNITY SETTINGS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Schlotthauer, A. E.; Layde, P. M.; Christiansen, A. L.] Med Coll Wisconsin, Injury Res Ctr, Milwaukee, WI 53226 USA. [Mahoney, J. E.; Gobel, V. L.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. [Mack, K. A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Shea, T.] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA. [Clemson, L. M.] Univ Sydney Hlth Sci, Sydney, NSW, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 479 EP 479 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888203544 ER PT J AU Anderson, L AF Anderson, L. TI KEY INDICATORS OF HEALTH AND WELL-BEING FOR OLDER ADULTS: THE STATE OF AGING AND HEALTH IN AMERICA REPORT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Anderson, L.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2012 VL 52 SU 1 BP 552 EP 552 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 061ZG UT WOS:000312888204025 ER PT J AU Wattam, AR Inzana, TJ Williams, KP Mane, SP Shukla, M Almeida, NF Dickerman, AW Mason, S Moriyon, I O'Callaghan, D Whatmore, AM Sobral, BW Tiller, RV Hoffmaster, AR Frace, MA De Castro, C Molinaro, A Boyle, SM De, BK Setubal, JC AF Wattam, Alice R. Inzana, Thomas J. Williams, Kelly P. Mane, Shrinivasrao P. Shukla, Maulik Almeida, Nalvo F. Dickerman, Allan W. Mason, Steven Moriyon, Ignacio O'Callaghan, David Whatmore, Adrian M. Sobral, Bruno W. Tiller, Rebekah V. Hoffmaster, Alex R. Frace, Michael A. De Castro, Cristina Molinaro, Antonio Boyle, Stephen M. De, Barun K. Setubal, Joao C. TI Comparative Genomics of Early-Diverging Brucella Strains Reveals a Novel Lipopolysaccharide Biosynthesis Pathway (vol 3, e00246, 2012) SO MBIO LA English DT Correction C1 [Wattam, Alice R.; Mane, Shrinivasrao P.; Shukla, Maulik; Dickerman, Allan W.; Mason, Steven; Sobral, Bruno W.; Setubal, Joao C.] Virginia Tech, Virginia Bioinformat Inst, Blacksburg, VA USA. [Inzana, Thomas J.; Boyle, Stephen M.] Virginia Tech, Ctr Mol Med & Infect Dis, Virginia Maryland Reg Coll Vet Med, Blacksburg, VA 24061 USA. [Williams, Kelly P.] Sandia Natl Labs, Livermore, CA USA. [Almeida, Nalvo F.] Univ Fed Mato Grosso do Sul, Fac Comp, Campo Grande, MS, Brazil. [Moriyon, Ignacio] Univ Navarra, Inst Salud Trop, Fac Med, E-31080 Pamplona, Spain. [Moriyon, Ignacio] Univ Navarra, Dept Microbiol & Parasitol, Fac Med, E-31080 Pamplona, Spain. [O'Callaghan, David] INSERM, U1047, UFR Med, Nimes, France. [O'Callaghan, David] Univ Montpellier I, UFR Med, Nimes, France. [Whatmore, Adrian M.] Anim Hlth & Vet Labs Agcy, Dept Bacteriol, Addlestone, Surrey, England. [Tiller, Rebekah V.; Hoffmaster, Alex R.; Frace, Michael A.; De, Barun K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [De Castro, Cristina; Molinaro, Antonio] Univ Naples Federico II, Dept Chem Sci, Naples, Italy. [Setubal, Joao C.] Univ Sao Paulo, Dept Biochem, Inst Chem, Sao Paulo, Brazil. RP Inzana, TJ (reprint author), Virginia Tech, Ctr Mol Med & Infect Dis, Virginia Maryland Reg Coll Vet Med, Blacksburg, VA 24061 USA. EM tinzana@vt.edu RI Setubal, Joao/C-7305-2012; Moriyon, Ignacio/N-4764-2016 OI Setubal, Joao/0000-0001-9174-2816; Moriyon, Ignacio/0000-0002-4288-0195 NR 1 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD NOV-DEC PY 2012 VL 3 IS 6 AR e00388-12 DI 10.1128/mBio.00388 PG 1 WC Microbiology SC Microbiology GA 064UK UT WOS:000313100700014 ER PT J AU Self, WH McNaughton, CD Grijalva, CG Zhu, YW Chappell, JD Williams, JV Talbot, HK Shay, DK Griffin, MR AF Self, Wesley H. McNaughton, Candace D. Grijalva, Carlos G. Zhu, Yuwei Chappell, James D. Williams, John V. Talbot, H. Keipp Shay, David K. Griffin, Marie R. TI Diagnostic performance of the BinaxNow Influenza A&B rapid antigen test in ED patients SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID UNITED-STATES; H1N1 VIRUS; IMMUNOCHROMATOGRAPHIC ASSAY; SEASONAL INFLUENZA; YOUNG-CHILDREN; FLU-A; MANAGEMENT; INFECTION; IMPACT; HOSPITALIZATIONS AB Objective: The objective of this study is to evaluate the diagnostic performance of the BinaxNow Influenza A&B rapid antigen test (RAT) in emergency department (ED) patients. Methods: We prospectively enrolled a systematic sample of ED patients older than 6 months with acute respiratory symptoms or nonlocalizing fever during 3 consecutive influenza seasons (20082011). Nasal and throat swabs collected by research personnel were tested for influenza by real-time reverse transcription-polymerase chain reaction (RT-PCR). Clinicians independently ordered RATs during clinical care; these specimens were collected by clinical staff and tested for influenza using the BinaxNow RAT. Patients with both a research RT-PCR and clinical RAT were included in the study. Rapid antigen test diagnostic performance was evaluated using RT-PCR as a criterion standard, with preplanned, stratified analysis for subject age, duration of symptoms, influenza subtype, and polymerase chain reaction cycle threshold, which provides a semiquantitative estimate of viral load. Results: Of 561 subjects enrolled, 131 (23.4%) had a positive RT-PCR, and 37 (6.6%) had a positive RAT. Overall, RAT performance included sensitivity of 24.4% (95% confidence interval [CI], 17.5%-32.9%), specificity of 98.8% (95% CI, 97.1%-99.6%), positive predictive value of 86.5% (95% CI, 70.4%-94.9%), negative predictive value of 81.1% (95% CI, 77.4%-84.3%). Rapid antigen test sensitivities were low for all categories of subject age, symptom duration, influenza subtype, and cycle threshold. Conclusion: The BinaxNow RAT demonstrated high specificity and poor sensitivity in ED patients selected by treating clinicians for influenza testing. A negative RAT is a poor predictor for the absence of influenza in the ED and should not be used as a criterion to withhold antiviral medications. (C) 2012 Elsevier Inc. All rights reserved. C1 [Self, Wesley H.; McNaughton, Candace D.] Vanderbilt Univ, Sch Med, Dept Emergency Med, Nashville, TN 37232 USA. [McNaughton, Candace D.; Griffin, Marie R.] Tennessee Valley Healthcare Syst, Vet Affairs, Nashville, TN USA. [Grijalva, Carlos G.; Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA. [Zhu, Yuwei] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA. [Chappell, James D.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA. [Williams, John V.; Talbot, H. Keipp] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA. [Talbot, H. Keipp; Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA. [Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Self, WH (reprint author), Vanderbilt Univ, Sch Med, Dept Emergency Med, 221 Kirkland Hall, Nashville, TN 37232 USA. EM wesley.self@vanderbilt.edu RI Williams, John/F-6962-2010; OI Williams, John/0000-0001-8377-5175; Shay, David/0000-0001-9619-4820 FU CDC [U01 IP000184]; Office of Academic Affiliations, Department of Veterans Affairs, VA National Quality Scholars Program FX Supported by CDC Cooperative Agreement U01 IP000184. Supported by the Office of Academic Affiliations, Department of Veterans Affairs, VA National Quality Scholars Program with resources and the use of facilities at VA Tennessee Valley Healthcare System, Nashville, TN (CD McNaughton). NR 34 TC 9 Z9 9 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD NOV PY 2012 VL 30 IS 9 BP 1955 EP 1961 DI 10.1016/j.ajem.2012.04.018 PG 7 WC Emergency Medicine SC Emergency Medicine GA 049QD UT WOS:000311997600042 PM 22795995 ER PT J AU Bush, T Levine, MD Beebe, LA Cerutti, B Deprey, M McAfee, T Boeckman, L Zbikowski, S AF Bush, Terry Levine, Michele D. Beebe, Laura A. Cerutti, Barbara Deprey, Mona McAfee, Tim Boeckman, Lindsay Zbikowski, Susan TI Addressing Weight Gain in Smoking Cessation Treatment: A Randomized Controlled Trial SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Smoking; Weight Concerns; Quidines; Effectiveness; Prevention Research ID COGNITIVE-BEHAVIORAL THERAPY; CONCERNED WOMEN; COST-EFFECTIVENESS; REAL-WORLD; PROGRAM; SMOKERS; TOBACCO; QUITLINE; POPULATION; BUPROPION AB Purpose. To evaluate the effectiveness of a cognitive behavioral treatment (CBT) addressing cessation-related weight concerns delivered via a tobacco quitline that does not address weight concerns. Design. Randomized controlled trial, blinded 6-month follow-up. Setting. The Oklahoma Tobacco Helpline (OKHL). Subjects. All 7998 smokers who called the OKHL were screened; 4240 were eligible; 2000 were randomized to the standard quitline (STD) or the brief version of the CBT weight concerns program (WCP). Intervention. Telephone counseling to help people quit smoking and address concerns about cessation-related weight gain. Measures. Demographics, weight, tobacco status, weight concerns, self-efficacy in quitting, and quitting without weight gain. Analysis. Descriptive statistics and logistic regression. Results. Of those randomized, 1002 participants completed the 6-month survey (response rates = 53.2% for STD, 47% for WCP). Compared with STD, WCP led to reduced weight concerns (p < .01) and less weight gain among quitters (1.8 vs. -3.4 pounds; p = .01). Although not significant, participants in the WCP were more likely to report 30-day abstinence (33.3 % vs. 36.8%, p = .24; intent to treat = 17.7 vs. 17.3). Conclusion. The WCP was successfully delivered via a quitline and resulted in improved attitudes about weight and decreased cessation-related weight gain without harming quit rates. Promotion of a quitline focused on addressing weight in conjunction with quitline treatment for smoking cessation may improve cessation and weight outcomes. Study limitations include use of self-report and survey response. (Am J Health Promot 2012;27[2]:94-102.) C1 [Bush, Terry; Cerutti, Barbara; Deprey, Mona; McAfee, Tim; Zbikowski, Susan] Alere Wellbeing, Seattle, WA 98104 USA. [Levine, Michele D.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Beebe, Laura A.; Boeckman, Lindsay] Univ Oklahoma, Coll Publ Hlth, Oklahoma City, OK USA. [McAfee, Tim] Ctr Dis Control, Off Smoking & Hlth, Atlanta, GA 30333 USA. RP Bush, T (reprint author), Alere Wellbeing, 999 3rd St,Suite 2100, Seattle, WA 98104 USA. EM Terry.Bush@alere.com OI levine, michele/0000-0002-1054-3856 NR 36 TC 11 Z9 11 U1 5 U2 12 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD NOV-DEC PY 2012 VL 27 IS 2 BP 94 EP 102 DI 10.4278/ajhp.110603-QUAN-238 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 052VP UT WOS:000312227200008 PM 23113779 ER PT J AU Hawkins, NA McCarty, F Peipins, LA Rodriguez, JL AF Hawkins, Nikki A. McCarty, Frances Peipins, Lucy A. Rodriguez, Juan L. TI Measuring the degree of closeness to the cancer experience: Development and initial validation of the CONNection to the Experience of Cancer Scale (CONNECS) SO PATIENT EDUCATION AND COUNSELING LA English DT Article DE Lived experience of cancer; Cancer connection; Scale development ID BREAST-CANCER; FAMILY-HISTORY; RISK PERCEPTION; OVARIAN-CANCER; DECISION-MAKING; PERCEIVED RISK; WOMEN; HEURISTICS; MASTECTOMY; JUDGMENT AB Objective: To describe the development and psychometric testing of items measuring connection to the cancer experience through a close friend or relative. Methods: Ten items assess four aspects of connection to cancer: emotional and cognitive involvement, kind and amount of shared experience, perceived similarity to the affected person, and negative change witnessed. Interviews were conducted with 2200 women close to someone with cancer. The sample was split into two samples for exploratory and confirmatory factor analysis. Sample 1 (n = 1342) was used to examine the underlying structure of the items. Sample 2 (n = 858) was used for CFA. Internal consistency and reliability analysis were also conducted. Results: Three factors with moderate correlation were extracted: general closeness, resemblance, and cognitive processing. Results from the CFA analysis confirmed a good fit of the three-factor model (Bentler-Bonett NIF = 0.973, Bentler-Bonett NNFI = 0.975, RMSEA = 0.040 and CFI = 0.984) and all path coefficients were statistically significant. Conclusion: Findings provide preliminary evidence for the reliability and construct validity of the CONNECS scale in measuring individuals' connection to the cancer experience through a close friend or relative. Practice Implications: CONNECS may be a useful tool for examining the impact of the cancer experience on risk perceptions, cancer worry, and medical decision making. Published by Elsevier Ireland Ltd. C1 [Hawkins, Nikki A.; Peipins, Lucy A.; Rodriguez, Juan L.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA USA. [McCarty, Frances] Georgia State Univ, Inst Publ Hlth, Atlanta, GA 30303 USA. RP Hawkins, NA (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K-55, Atlanta, GA 30341 USA. EM nhawkins@cdc.gov FU Centers for Disease Control and Prevention [200-2002-00574] FX Funding support was provided by the Centers for Disease Control and Prevention (Contract No. 200-2002-00574, Task order 0015). NR 25 TC 5 Z9 5 U1 0 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0738-3991 J9 PATIENT EDUC COUNS JI Patient Educ. Couns. PD NOV PY 2012 VL 89 IS 2 BP 292 EP 299 DI 10.1016/j.pec.2012.08.009 PG 8 WC Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 046LO UT WOS:000311766700012 PM 22940373 ER PT J AU Wallander, JL Fradkin, C Chien, AT Mrug, S Banspach, SW Davies, S Elliott, MN Franzini, L Schuster, MA AF Wallander, Jan L. Fradkin, Chris Chien, Alyna T. Mrug, Sylvie Banspach, Stephen W. Davies, Susan Elliott, Marc N. Franzini, Luisa Schuster, Mark A. TI Racial/Ethnic Disparities in Health-Related Quality of Life and Health in Children Are Largely Mediated by Family Contextual Differences SO ACADEMIC PEDIATRICS LA English DT Article DE disparities; ethnicity; family context; quality of life; race ID SOCIAL-CLASS GRADIENTS; GENERIC CORE SCALES; SOCIOECONOMIC-STATUS; RISK-FACTORS; ETHNIC DISPARITIES; INSURANCE PROGRAM; UNITED-STATES; ADOLESCENTS; RACE; CARE AB OBJECTIVE: To examine (1) racial/ethnic disparities in health-related quality of life (HRQOL), and overall health status among African-American, Hispanic, and white 5th graders in the general population and (2) the extent to which socioeconomic status (SES) and other family contextual variables mediate any disparities. METHODS: A total of 4824 African-American, Hispanic, and white fifth-graders participating in a population-based, cross-sectional survey conducted in 3 U.S. metropolitan areas reported their own HRQOL by using the Pediatric Quality of Life Inventory Version 4.0 and supplemental personal and social wellbeing scales. Parents reported these children's overall health status. SES was indexed by parent education and household income. Other family contextual variables included family structure and degree to which English is spoken at home. RESULTS: Marked racial/ethnic disparities were observed across all measures of HRQOL and health status, favoring white children and especially disfavoring Hispanic children. Most of these disparities were no longer significant after adjusting for SES and other family contextual differences that were observed among these racial/ethnic groups. Only disparities in parent-reported overall health status and self-reported global self-worth remained. CONCLUSIONS: Racial/ethnic disparities in children's health status are substantial but may be mediated by corresponding disparities in SES and other family contextual variables. Race/ethnicity and family context are related to one another and should be considered jointly in efforts to reduce health disparities in children. C1 [Wallander, Jan L.] UC Merced, SSHA, Ctr Excellence Hlth Dispar, Merced, CA 95343 USA. [Wallander, Jan L.; Fradkin, Chris] UC Merced, Hlth Sci Res Inst, Merced, CA 95343 USA. [Chien, Alyna T.; Schuster, Mark A.] Childrens Hosp Boston, Div Gen Pediat, Boston, MA USA. [Chien, Alyna T.; Schuster, Mark A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Mrug, Sylvie] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA. [Banspach, Stephen W.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Davies, Susan] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA. [Elliott, Marc N.; Schuster, Mark A.] RAND Corp, Santa Monica, CA USA. [Franzini, Luisa] Univ Texas Sch Publ Hlth, Houston, TX USA. RP Wallander, JL (reprint author), UC Merced, SSHA, Ctr Excellence Hlth Dispar, 5200 N Lake Rd, Merced, CA 95343 USA. EM jwallander@ucmerced.edu OI Fradkin, Chris/0000-0002-8195-269X FU Centers for Disease Control and Prevention (CDC) [U19DP002663, U19DP002664, U19DP002665] FX This research was funded through cooperative agreements (U19DP002663, U19DP002664, and U19DP002665) from the Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. The contributions made to this research by study participants in the Birmingham, Houston, and Los Angeles areas, other Healthy Passages investigators, field teams at each site, and the CDC Division of Adolescent and School Health are gratefully acknowledged. NR 50 TC 6 Z9 6 U1 1 U2 19 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD NOV-DEC PY 2012 VL 12 IS 6 BP 532 EP 538 PG 7 WC Pediatrics SC Pediatrics GA 048OA UT WOS:000311920600010 PM 22884796 ER PT J AU Matjasko, JL Vivolo-Kantor, AM Massetti, GM Holland, KM Holt, MK Dela Cruz, J AF Matjasko, Jennifer L. Vivolo-Kantor, Alana M. Massetti, Greta M. Holland, Kristin M. Holt, Melissa K. Dela Cruz, Jason TI A systematic meta-review of evaluations of youth violence prevention programs: Common and divergent findings from 25 years of meta-analyses and systematic reviews SO AGGRESSION AND VIOLENT BEHAVIOR LA English DT Review DE Youth violence; Prevention; Intervention; Meta-review ID COGNITIVE-BEHAVIORAL THERAPY; ANTISOCIAL-BEHAVIOR; DISRUPTIVE BEHAVIOR; CONFLICT-RESOLUTION; INTERVENTIONS; CHILDREN; DELINQUENCY; DISORDERS; OUTCOMES; ANGER AB Violence among youth is a pervasive public health problem. In order to make progress in reducing the burden of injury and mortality that result from youth violence, it is imperative to identify evidence-based programs and strategies that have a significant impact on violence. There have been many rigorous evaluations of youth violence prevention programs. However, the literature is large, and it is difficult to draw conclusions about what works across evaluations from different disciplines, contexts, and types of programs. The current study reviews the meta-analyses and systematic reviews published prior to 2009 that synthesize evaluations of youth violence prevention programs. This meta-review reports the findings from 37 meta-analyses and 15 systematic reviews; the included reviews were coded on measures of the social ecology, prevention approach, program type, and study design. A majority of the meta-analyses and systematic reviews were found to demonstrate moderate program effects. Meta-analyses yielded marginally smaller effect sizes compared to systematic reviews, and those that included programs targeting family factors showed marginally larger effects than those that did not. In addition, there are a wide range of individual/family, program, and study moderators of program effect sizes. Implications of these findings and suggestions for future research are discussed. Published by Elsevier Ltd. C1 [Matjasko, Jennifer L.; Vivolo-Kantor, Alana M.; Massetti, Greta M.; Holland, Kristin M.; Holt, Melissa K.; Dela Cruz, Jason] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Matjasko, JL (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS-F64, Atlanta, GA 30341 USA. EM JMatjasko@cdc.gov OI Massetti, Greta/0000-0002-3813-9839 NR 70 TC 22 Z9 23 U1 3 U2 54 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1359-1789 J9 AGGRESS VIOLENT BEH JI Aggress. Violent Behav. PD NOV-DEC PY 2012 VL 17 IS 6 BP 540 EP 552 DI 10.1016/j.avb.2012.06.006 PG 13 WC Criminology & Penology; Psychology, Multidisciplinary SC Criminology & Penology; Psychology GA 035KM UT WOS:000310945400008 ER PT J AU Cardemil, CV Gilroy, KE Callaghan-Koru, JA Nsona, H Bryce, J AF Cardemil, Cristina V. Gilroy, Kate E. Callaghan-Koru, Jennifer A. Nsona, Humphreys Bryce, Jennifer TI Comparison of Methods for Assessing Quality of Care for Community Case Management of Sick Children: An Application with Community Health Workers in Malawi SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ACUTE RESPIRATORY-INFECTIONS; DEVELOPING-COUNTRIES; SIAYA DISTRICT; PERFORMANCE; BANGLADESH; KENYA; VALIDATION; GUIDELINES; ADHERENCE; ILLNESSES AB Direct observation (DO) with re-examination (RE) by a skilled clinician is a rigorous method for assessing health worker performance, but is not always feasible. We assessed the performance of 131 community health workers in Malawi in community case management of sick children with cough and fast breathing, fever, and diarrhea. We compared estimates of correct treatment measured through DO with RE (n = 382 cases) to DO only (n = 382 cases), register review (n = 1,219 cases), and case scenarios (n = 91.7 cases). Estimates of correct treatment of uncomplicated fever and diarrhea measured through DO only, register review, and case scenarios were within 9 percentage points of DO with RE estimates, while estimates for uncomplicated cough and fast breathing, and severe illness were substantially higher than DO with RE (12-51 percentage points above the estimate). Those planning for community health worker assessments in community case management can use these results to make an informed choice of methods on the basis of their objectives and the local context. C1 Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA. [Gilroy, Kate E.; Callaghan-Koru, Jennifer A.; Bryce, Jennifer] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Inst Int Programs, Baltimore, MD USA. [Nsona, Humphreys] Minist Hlth, Integrated Management Childhood Illnesses Unit, Lilongwe, Malawi. RP Cardemil, CV (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ccardemil@cdc.gov; kgilroy@jhsph.edu; jcallagh@jhsph.edu; hnsona@gmail.com; jbryce@jhsph.edu FU Bill and Melinda Gates Foundation; Child Health Center Board; Robert H. Parrott REACH Program FX This study was supported by the Bill and Melinda Gates Foundation through a contract to the World Health Organization to support the independent evaluation of the Maternal New-born Child Health Rapid Scale-Up in Malawi. Cristina V. Cardemil received additional support from the Child Health Center Board and the Robert H. Parrott REACH Program. NR 36 TC 10 Z9 10 U1 0 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2012 VL 87 IS 5 SU S BP 127 EP 136 DI 10.4269/ajtmh.2012.12-0389 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 036VJ UT WOS:000311060100019 PM 23136288 ER PT J AU Bean, CJ Boulet, SL Ellingsen, D Pyle, ME Barron-Casella, EA Casella, JF Payne, AB Driggers, J Trau, HA Yang, GY Jones, K Ofori-Acquah, SF Hooper, WC DeBaun, MR AF Bean, Christopher J. Boulet, Sheree L. Ellingsen, Dorothy Pyle, Meredith E. Barron-Casella, Emily A. Casella, James F. Payne, Amanda B. Driggers, Jennifer Trau, Heidi A. Yang, Genyan Jones, Kimberly Ofori-Acquah, Solomon F. Hooper, W. Craig DeBaun, Michael R. TI Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease SO BLOOD LA English DT Article ID MICROSATELLITE POLYMORPHISM; ALPHA-THALASSEMIA; POPULATION; SUSCEPTIBILITY; ENDOTHELIUM; PREVALENCE; FERRITIN; SUPPORT; VARIANT; ASTHMA AB Sickle cell disease is a common hemolytic disorder with a broad range of complications, including vaso-occlusive episodes, acute chest syndrome (ACS), pain, and stroke. Heme oxygenase-1 (gene HMOX1; protein HO-1) is the inducible, rate-limiting enzyme in the catabolism of heme and might attenuate the severity of outcomes from vaso-occlusive and hemolytic crises. A(GT)(n) dinucleotide repeat located in the promoter region of the HMOX1 gene is highly polymorphic, with long repeat lengths linked to de-creased activity and inducibility. We examined this polymorphism to test the hypothesis that short alleles are associated with a decreased risk of adverse outcomes (hospitalization for pain or ACS) among a cohort of 942 children with sickle cell disease. Allele lengths varied from 13 to 45 repeats and showed a trimodal distribution. Compared with children with longer allele lengths, children with 2 shorter alleles (4%; <= 25 repeats) had lower rates of hospitalization for ACS (incidence rate ratio 0.28, 95% confidence interval, 0.10-0.81), after adjusting for sex, age, asthma, percentage of fetal hemoglobin, and alpha-globin gene deletion. No relationship was identified between allele lengths and pain rate. We provide evidence that genetic variation in HMOX1 is associated with decreased rates of hospitalization for ACS, but not pain. This study is registered at www.clinicaltrials.gov as #NCT00072761. (Blood. 2012;120(18):3822-3828) C1 [DeBaun, Michael R.] Vanderbilt Univ, Sch Med, Matthew Walker Ctr Excellence Sickle Cell Dis, Nashville, TN 37232 USA. [Bean, Christopher J.; Boulet, Sheree L.; Ellingsen, Dorothy; Pyle, Meredith E.; Payne, Amanda B.; Driggers, Jennifer; Trau, Heidi A.; Yang, Genyan; Hooper, W. Craig] Ctr Dis Control & Prevent, Clin & Mol Hemostasis Lab Branch, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Barron-Casella, Emily A.; Casella, James F.; Jones, Kimberly] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Hematol, Baltimore, MD 21205 USA. [Ofori-Acquah, Solomon F.] Emory Univ, Div Hematol Oncol BMT, Atlanta, GA 30322 USA. RP DeBaun, MR (reprint author), Vanderbilt Univ, Sch Med, Matthew Walker Ctr Excellence Sickle Cell Dis, 215 Light Hall, Nashville, TN 37232 USA. EM m.debaun@vanderbilt.edu FU National Heart, Lung, and Blood Institute [RO1-HL079937, 1U54HL090515]; Burroughs Wellcome Foundation; National Institute of Neurological Disorders and Stroke [U01-NS-042804]; Center for Translational Science Award [M01-RR00052, K02HL088026]; Johns Hopkins FX This work was supported by National Heart, Lung, and Blood Institute (RO1-HL079937, M. R. D.; and 1U54HL090515, J.F.C.), Burroughs Wellcome Foundation (M. R. D.), National Institute of Neurological Disorders and Stroke (U01-NS-042804; E. A. B.-C.), and Center for Translational Science Award (M01-RR00052, J.F.C.; and K02HL088026, S.F.O.-A.).; J.F.C. has received an honorarium and travel expenses in the past and presently receives salary support through Johns Hopkins for providing consultative advice to Adventrx Pharmaceuticals regarding a proposed clinical trial of an agent for treating vaso-occlusive crisis in SCD. The remaining authors declare no competing financial interests. NR 36 TC 28 Z9 29 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 1 PY 2012 VL 120 IS 18 BP 3822 EP 3828 DI 10.1182/blood-2011-06-361642 PG 7 WC Hematology SC Hematology GA 044MW UT WOS:000311624800026 PM 22966170 ER PT J AU Williams, BA Dorn, JM LaMonte, MJ Donahue, RP Trevisan, M Leonard, DA Greene, RS Merhige, ME AF Williams, Brent A. Dorn, Joan M. LaMonte, Michael J. Donahue, Richard P. Trevisan, Maurizio Leonard, Deborah A. Greene, Robert S. Merhige, Michael E. TI Evaluating the Prognostic Value of Positron-Emission Tomography Myocardial Perfusion Imaging Using Automated Software to Calculate Perfusion Defect Size SO CLINICAL CARDIOLOGY LA English DT Article ID CORONARY-ARTERY-DISEASE; NUCLEAR-CARDIOLOGY; LONG-TERM; PET; SPECT; RB-82; REVASCULARIZATION; DIAGNOSIS; OUTCOMES; METAANALYSIS AB Background: Myocardial perfusion imaging by positron-emission tomography (PET MPI) is regarded as a valid technique for the diagnosis of coronary artery disease (CAD), but the incremental prognostic value of PET MPI among individuals with known or suspected CAD is not firmly established. Hypothesis: Myocardial perfusion defect sizes as measured by PET MPI using automated software will provide incremental prognostic value for cardiac and all-cause mortality. Methods: This study included 3739 individuals who underwent rest-stress rubidium-82 PET MPI for the evaluation of known or suspected CAD. Rest, stress, and stress-induced myocardial perfusion defect sizes were determined objectively by automated computer software. Study participants were followed for a mean of 5.2 years for cardiac and all-cause mortality. Cox proportional hazards models were developed to evaluate the incremental prognostic value of PET MPI. Results: A strong correlation was observed between perfusion defect sizes assessed visually and by automated software (r = 0.76). After adjusting for cardiac risk factors, known CAD, noncoronary vascular disease, and use of cardioprotective medications, stress perfusion defect size was strongly associated with cardiac death (P < 0.001). Rest perfusion defects demonstrated a stronger association with cardiac death (P < 0.001) than stress-induced perfusion defects (P = 0.01), yet both were highly significant. Similar patterns held for all-cause death. Conclusions: The current study is the largest to date demonstrating PET MPI provides incremental prognostic value among individuals with known or suspected CAD. Automated calculation of perfusion defect sizes may provide valuable supplementary information to visual assessment. This work was partially funded by a predoctoral fellowship grant awarded to the first author by the American Heart Association's Founders' Affiliate. Additional funding was provided by Niagara Falls Memorial Medical Center, Positron Corporation, the University at Buffalo, and Niagara University. The authors have no other funding, financial relationships, or conflicts of interest to disclose. C1 [Williams, Brent A.] Geisinger Hlth Syst, Dept Ctr Hlth Res, Danville, PA 17822 USA. [Dorn, Joan M.] Ctr Dis Control, Atlanta, GA 30333 USA. [LaMonte, Michael J.; Donahue, Richard P.; Merhige, Michael E.] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA. [Trevisan, Maurizio] CUNY City Coll, New York, NY 10031 USA. [Leonard, Deborah A.; Greene, Robert S.] Niagara Univ, Dept Biol, Lewiston, NY USA. [Merhige, Michael E.] Ctr Niagara, Niagara Falls, NY USA. RP Williams, BA (reprint author), Geisinger Hlth Syst, Dept Ctr Hlth Res, 100 N Acad Ave, Danville, PA 17822 USA. EM bawilliams2@geisinger.edu FU American Heart Association's Founders' Affiliate; Niagara Falls Memorial Medical Center, Positron Corporation; University at Buffalo; Niagara University FX This work was partially funded by a predoctoral fellowship grant awarded to the first author by the American Heart Association's Founders' Affiliate. Additional funding was provided by Niagara Falls Memorial Medical Center, Positron Corporation, the University at Buffalo, and Niagara University. NR 36 TC 6 Z9 6 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-9289 J9 CLIN CARDIOL JI Clin. Cardiol. PD NOV PY 2012 VL 35 IS 11 BP E14 EP E21 DI 10.1002/clc.22058 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 037KO UT WOS:000311103200003 PM 22961671 ER PT J AU Lozano-Fuentes, S Welsh-Rodriguez, C Hayden, MH Tapia-Santos, B Ochoa-Martinez, C Kobylinski, KC Uejio, CK Zielinski-Gutierrez, E Delle Monache, L Monaghan, AJ Steinhoff, DF Eisen, L AF Lozano-Fuentes, Saul Welsh-Rodriguez, Carlos Hayden, Mary H. Tapia-Santos, Berenice Ochoa-Martinez, Carolina Kobylinski, Kevin C. Uejio, Christopher K. Zielinski-Gutierrez, Emily Delle Monache, Luca Monaghan, Andrew J. Steinhoff, Daniel F. Eisen, Lars TI Aedes (Ochlerotatus) epactius Along an Elevation and Climate Gradient in Veracruz and Puebla States, Mexico SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE Aedes (Ochlerotatus) epactius; Aedes aegypti; artificial container; climate; elevation ID INTERSPECIFIC COMPETITION; CONTAINER MOSQUITOS; ALBOPICTUS DIPTERA; AEGYPTI DIPTERA; SOUTH FLORIDA; CULICIDAE; TRANSMISSION; COEXISTENCE; RESISTANCE; EXCLUSION AB We report on the collection of immatures of Aedes (Ochlerotatus) epactius Dyar & Knab from artificial containers during July through September 2011 in 12 communities located along an elevation and climate gradient extending from sea level in Veracruz State to high elevations (>2,000 m) in Veracruz and Puebla States, Mexico. Ae. epactius was collected from 11 of the 12 study communities; the lone exception was the highest elevation community along the transect (>2,400 m). This mosquito species was thus encountered at elevations ranging from near sea level in Veracruz City on the Gulf of Mexico to above 2,100 min Puebla City in the central highlands. Collection sites included the city of Cordoba, located at approximate to 850 m, from which some of the first described specimens of Ae. epactius were collected in 1908. Estimates for percentage of premises in each community with Ae. epactius pupae present, and abundance of Ae. epactius pupae on the study premises, suggest that along the transect in central Mexico, the mosquito is present but rare at sea level, most abundant at mid-range elevations from 1,250-1,750 m and then decreases in abundance above 1,800 m. Statistically significant parabolic relationships were found between percentage of premises with Ae. epactius pupae present and average minimum daily temperature, cumulative growing degree-days, and rainfall. We recorded Ae. epactius immatures from a wide range of container types including cement water tanks, barrels/drums, tires, large earthen jars, small discarded containers, buckets, cement water troughs, flower pots, cement water cisterns, and larger discarded containers. There were 45 documented instances of co-occurrence of Ae. epactius and Aedes aegypti (L.) immatures in individual containers. C1 [Lozano-Fuentes, Saul; Kobylinski, Kevin C.; Eisen, Lars] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Welsh-Rodriguez, Carlos; Tapia-Santos, Berenice; Ochoa-Martinez, Carolina] Univ Veracruzana, Ctr Ciencias Tierra, Xalapa 91090, Veracruz, Mexico. [Hayden, Mary H.; Delle Monache, Luca; Monaghan, Andrew J.; Steinhoff, Daniel F.] Natl Ctr Atmospher Res, Boulder, CO 80307 USA. [Uejio, Christopher K.] Florida State Univ, Dept Geog, Tallahassee, FL 32306 USA. [Zielinski-Gutierrez, Emily] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. RP Eisen, L (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, 3195 Rampart Rd, Ft Collins, CO 80523 USA. EM lars.eisen@colostate.edu RI Lozano-Fuentes, Saul/H-4324-2011 OI Lozano-Fuentes, Saul/0000-0003-1517-6853 FU National Science Foundation [GEO-1010204]; Ministry of Public Health of Veracruz Government; Ministry of Education of Veracruz Government; Ministry of Civil Protection of Veracruz Government FX We thank Eric Hubron, Elena Rustrian, Selene Tejeda, Marco Aurelio Morales, Yair Zamora, students from Universidad Veracruzana's Geography Program, and students and personnel from Bachilleres Veracruz, Ilustre Instituto Veracruzano, Bachilleres Rio Blanco, and Bachilleres Ricardo Flores Magon (Oficial B) for field and laboratory assistance. We also thank the Ministries of Public Health, Education and Civil Protection of Veracruz Government for their support. Finally, we are grateful to the involved home owners for granting us access to collect mosquitoes from their properties. This study was funded by a grant from the National Science Foundation to the University Corporation for Atmospheric Research (GEO-1010204). NR 42 TC 2 Z9 2 U1 1 U2 5 PU ENTOMOLOGICAL SOC AMER PI LANHAM PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA SN 0022-2585 J9 J MED ENTOMOL JI J. Med. Entomol. PD NOV PY 2012 VL 49 IS 6 BP 1244 EP 1253 DI 10.1603/ME12067 PG 10 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 040EC UT WOS:000311303200008 PM 23270151 ER PT J AU Mutebi, JP Crabtree, MB Kading, RC Powers, AM Lutwama, JJ Miller, BR AF Mutebi, J. -P. Crabtree, M. B. Kading, R. C. Powers, A. M. Lutwama, J. J. Miller, B. R. TI Mosquitoes of Western Uganda SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE mosquito; species composition; Uganda; Mweya; Sempaya ID RIFT-VALLEY-FEVER; ONYONG-NYONG FEVER; YELLOW-FEVER; EAST-AFRICA; NILE VIRUS; CULICIDAE; EPIDEMIC; VECTORS; SENEGAL; DIPTERA AB The mosquito fauna in many areas of western Uganda has never been studied and is currently unknown. One area, Bwamba County, has been previously studied and documented but the species lists have not been updated for >40 yr. This paucity of data makes it difficult to determine which arthropod-borne viruses pose a risk to human or animal populations. Using CO2 baited-light traps, from 2008 through 2010, 67,731 mosquitoes were captured at five locations in western Uganda including Mweya, Sempaya, Maramagambo, Bwindi (BINP), and Kibale (KNP). Overall, 88 mosquito species, 7 subspecies, and 7 species groups in 10 genera were collected. The largest number of species was collected at Sempaya (65 species), followed by Maramagambo (45), Mweya (34), BINP (33), and KNP (22). However, species diversity was highest in BINP (Simpson's Diversity Index 1-D = 0.85), followed by KNP (0.80), Maramagambo (0.79), Sempaya (0.67), and Mweya (0.56). Only six species Aedes (Aedimorphus) cumminsii (Theobald), Aedes (Neomelaniconion) circumluteolus (Theobald), Culex (Culex) antennatus (Becker), Culex (Culex) decens group, Culex (Lutzia) tigripes De Grandpre and De Charmoy, and Culex (Oculeomyia) annulioris (Theobald), were collected from all five sites suggesting large differences in species composition among sites. Four species (Aedes (Stegomyia) metallicus (Edwards), Anopheles (Cellia) rivulorum Leeson, Uranotaenia (Uranotaenia) chorleyi (Edwards), and Uranotaenia (Uranotaenia) pallidocephala (Theobald) and one subspecies (Aedes (Stegomyia) aegypti formosus (Walker)) were collected in Bwamba County for the first time. This study represents the first description of the mosquito species composition of Mweya, Maramagambo, BINP, and KNP. A number of morphological variations were noted regarding the postspiracular scales, hind tibia, and sternites that make Culex (Culex) neavei (Theobald) challenging to identify. At least 50 species collected in this study have previously been implicated in the transmission of arboviruses of public health importance suggesting a high potential for maintenance and transmission of a wide variety of arboviruses in western Uganda. C1 [Mutebi, J. -P.; Crabtree, M. B.; Kading, R. C.; Powers, A. M.; Miller, B. R.] Ctr Dis Control & Prevent CDC, Ft Collins, CO 80512 USA. [Lutwama, J. J.] Uganda Virus Res Inst, Dept Arbovirol, Entebbe, Uganda. RP Mutebi, JP (reprint author), Ctr Dis Control & Prevent CDC, 3150 Rampart Rd, Ft Collins, CO 80512 USA. EM jmutebi@cdc.gov RI Kading, Rebekah/E-5633-2017 OI Kading, Rebekah/0000-0002-4996-915X FU USAID Emerging Pandemic Threat Program FX We thank the Uganda Wildlife Authority (UWA) for granting us access to Semliki National Park (SNP), Queen Elizabeth National Park (QENP), Bwindi Impenetrable National Park (BINP), Maramagambo Forest (MF), and Kibale National Park (KNP). We thank the park rangers at SNP, QENP, BINP, MF, and KNP for their assistance and for use of UWA facilities. We thank T. Okello and M. Driciru for use of laboratory facilities at QENP. We thank C. Tumwesigye and A. Musinguzi for use of BINP and KNP facilities. We thank G. Kalema-Zikusoka, L. Zikusoka, S. Rubanga, H. Kumanya, and other members of Conservation through Public Health (CTPH) for field assistance and for the use of CTPH facilities in BINP. We thank F. Ssenfunka, J.-B. Lwanga, S. Wakaalo J. Mugga, G. Kyazze, and D. Ssemwogerere of UVRI, and K. Saxton-Shaw, J. Lederman, and E. Borland of CDC Ft. Collins for field assistance during this project. We thank J. Pecor and Y.-M. Huang of the Smithsonian Institute for their assistance in verifying mosquito identifications. Lastly, we thank R. Rosenberg for his assistance and support during this project. This study was supported in part by funds from USAID Emerging Pandemic Threat Program. NR 58 TC 5 Z9 6 U1 2 U2 19 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD NOV PY 2012 VL 49 IS 6 BP 1289 EP 1306 DI 10.1603/ME12111 PG 18 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 040EC UT WOS:000311303200014 PM 23270157 ER PT J AU Graham, CB Black, WC Boegler, KA Montenieri, JA Holmes, JL Gage, KL Eisen, RJ AF Graham, Christine B. Black, William C. Boegler, Karen A. Montenieri, John A. Holmes, Jennifer L. Gage, Kenneth L. Eisen, Rebecca J. TI Combining Real-Time Polymerase Chain Reaction Using SYBR Green I Detection and Sequencing to Identify Vertebrate Bloodmeals in Fleas SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE bloodmeal identification; flea; real-time PCR; threshold cycle; cutoff ID EARLY-PHASE TRANSMISSION; PLAGUE-ENDEMIC REGION; WEST-NILE-VIRUS; YERSINIA-PESTIS; CTENOCEPHALIDES-FELIS; IXODES-RICINUS; CAT FLEA; MOSQUITO BLOODMEALS; MITOCHONDRIAL-DNA; FEEDING PATTERNS AB Programs that aim to control vector-borne zoonotic diseases require information on zoonotic hosts and on the feeding behavior of bridging vectors that are capable of transmitting pathogens from those hosts to humans. Here we describe an assay developed to identify bloodmeals in field-collected cat fleas (Ctenocephalides felis Bouche) to assess this species' potential role as a Yersinia pestis bridging vector in a plague-endemic region of Uganda. Our assay uses a single primer set and SYBR Green I-based real-time polymerase chain reaction to amplify a segment of the 12S mitochondrial ribosomal RNA gene for identification by sequencing. The assay capitalizes on the sensitivity of real-time polymerase chain reaction and the specificity of sequencing and can be used to differentiate vertebrate bloodmeals to the genus or species level without a priori knowledge of the host community. Because real-time assays that detect vertebrate DNA are highly sensitive to human DNA contamination, we analyzed detection in artificially fed and unfed fleas to establish a Ct cutoff that optimized specificity without completely sacrificing sensitivity. Using the established cutoff, our assay detected human, rat, and goat DNA in artificially fed C. felis up to 72 h postfeeding. C1 [Graham, Christine B.; Boegler, Karen A.; Montenieri, John A.; Holmes, Jennifer L.; Gage, Kenneth L.; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. [Black, William C.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Graham, CB (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM hyb4@cdc.gov FU Intramural CDC HHS [CC999999] NR 64 TC 5 Z9 6 U1 2 U2 24 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD NOV PY 2012 VL 49 IS 6 BP 1442 EP 1452 DI 10.1603/ME12071 PG 11 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 040EC UT WOS:000311303200031 PM 23270174 ER PT J AU Eremeeva, ME Karpathy, SE Krueger, L Hayes, EK Williams, AM Zaldivar, Y Bennett, S Cummings, R Tilzer, A Velten, RK Kerr, N Dasch, GA Hu, RJ AF Eremeeva, Marina E. Karpathy, Sandor E. Krueger, Laura Hayes, Erica K. Williams, Ashley M. Zaldivar, Yamitzel Bennett, Stephen Cummings, Robert Tilzer, Art Velten, Robert K. Kerr, Nelson Dasch, Gregory A. Hu, Renjie TI Two Pathogens and One Disease: Detection and Identification of Flea-Borne Rickettsiae in Areas Endemic for Murine Typhus in California SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE flea-borne rickettsiosis; Rickettsia typhi; Rickettsia felis; flea; opossum ID POLYMERASE-CHAIN-REACTION; LOS-ANGELES COUNTY; CTENOCEPHALIDES-FELIS; SOUTH TEXAS; CAT FLEAS; SPOTTED-FEVER; INFECTION; HUMANS; TRANSMISSION; ASSOCIATION AB Results of an environmental assessment conducted in a newly emergent focus of murine typhus in southern California are described. Opossums, Didelphis virginiana Kerr, infested with cat fleas, Ctenocephalides felis Buche, in the suburban area were abundant. Animal and flea specimens were tested for the DNA of two flea-borne rickettsiae, Rickettsia typhi and Rickettsia felis. R. felis was commonly detected in fleas collected throughout this area while R. typhi was found at a much lower prevalence in the vicinity of just 7 of 14 case-patient homes identified. DNA of R. felis, but not R. typhi, was detected in renal, hepatic, and pulmonary tissues of opossums. In contrast, there were no hematologic polymerase chain reaction findings of R. felis or R. typhi in opossums, rats, and cats within the endemic area studied. Our data suggest a significant probability of human exposure to R. felis in the area studied; however, disease caused by this agent is not recognized by the medical community and may be misdiagnosed as murine typhus using nondiscriminatory serologic methods. C1 [Eremeeva, Marina E.; Karpathy, Sandor E.; Hayes, Erica K.; Williams, Ashley M.; Zaldivar, Yamitzel; Dasch, Gregory A.] CDC, Div Vector borne Dis, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. [Krueger, Laura; Bennett, Stephen; Cummings, Robert; Tilzer, Art; Velten, Robert K.] Orange Cty Vector Control Dist, Garden Grove, CA 92843 USA. [Kerr, Nelson] Long Beach Vector Control Program, Long Beach, CA 90815 USA. RP Karpathy, SE (reprint author), CDC, Div Vector borne Dis, Rickettsial Zoonoses Branch, Mail Stop G 13,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM skarpathy@cdc.gov OI Dasch, Gregory/0000-0001-6090-1810 FU Centers for Disease Control and Prevention; James A. Ferguson Emerging Infectious Diseases Minority Program Fellows, CDC; Bevier Training Program of Agnes Scott College, Atlanta, GA; Department of State, Washington, DC FX We thank Maria L. Zambrano, Kyle F. Abramowicz, and Michele M. Sturgeon of the CDC for laboratory assistance; Wesley Moore, Lamar Rush, and John Holguin of City of Long Beach for assistance with field work, the CDC Biotechnology Core Facility Branch for synthesis of primers and probes, and cell culture. This research was supported in part by an appointment of S. E. K. to the Emerging Infectious Diseases Fellowship Program administered by the Association of Public Health Laboratories and funded by the Centers for Disease Control and Prevention. E. K. H. was supported through the James A. Ferguson Emerging Infectious Diseases Minority Program Fellows, CDC. A. M. W. was supported through the Bevier Training Program of Agnes Scott College, Atlanta, GA. Y.Z. was supported through the Partners of the Americas, Department of State, Washington, DC. Preliminary reports of this investigation were presented in 2007 at the 21st Meeting of the American Society for Rickettsiology (Colorado Springs, CO) and in 2008 at the fifth International Meeting on Rickettsiae and Rickettsial Diseases (Marseille, France). NR 48 TC 10 Z9 10 U1 3 U2 12 PU ENTOMOLOGICAL SOC AMER PI LANHAM PA 10001 DEREKWOOD LANE, STE 100, LANHAM, MD 20706-4876 USA SN 0022-2585 J9 J MED ENTOMOL JI J. Med. Entomol. PD NOV PY 2012 VL 49 IS 6 BP 1485 EP 1494 DI 10.1603/ME11291 PG 10 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 040EC UT WOS:000311303200037 PM 23270180 ER PT J AU Just, AC Whyatt, RM Miller, RL Rundle, AG Chen, QX Calafat, AM Divjan, A Rosa, MJ Zhang, HJ Perera, FP Goldstein, IF Perzanowski, MS AF Just, Allan C. Whyatt, Robin M. Miller, Rachel L. Rundle, Andrew G. Chen, Qixuan Calafat, Antonia M. Divjan, Adnan Rosa, Maria J. Zhang, Hanjie Perera, Frederica P. Goldstein, Inge F. Perzanowski, Matthew S. TI Children's Urinary Phthalate Metabolites and Fractional Exhaled Nitric Oxide in an Urban Cohort SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE airway inflammation; asthma; diethyl phthalate; butylbenzyl phthalate; fractional exhaled nitric oxide ID INNER-CITY CHILDREN; NEW-YORK-CITY; HEALTHY-CHILDREN; PREGNANT-WOMEN; AIR-POLLUTION; US POPULATION; EXPOSURE; ASTHMA; VARIABILITY; CHILDHOOD AB Rationale: Phthalates are used widely in consumer products. Exposure to several phthalates has been associated with respiratory symptoms and decreased lung function. Associations between children's phthalate exposures and fractional exhaled nitric oxide (FENO), a biomarker of airway inflammation, have not been examined. Objectives: We hypothesized that urinary concentrations of four phthalate metabolites would be positively associated with FENO and that these associations would be stronger among children with seroatopy or wheeze. Methods: In an urban ongoing birth cohort, 244 children had phthalate metabolites determined in urine collected on the same day as FENO measurement. Repeated sampling gathered 313 observations between ages 4.9 and 9.1 years. Seroatopy was assessed by specific IgE. Wheeze in the past year was assessed by validated questionnaire. Regression models used generalized estimating equations. Measurements and Main Results: Log-unit increases in urinary concentrations of metabolites of diethyl phthalate (DEP) and butylbenzyl phthalate (BBzP) were associated with a 6.6% (95% confidence interval [CI] 0.5-13.1%) and 8.7% (95% CI, 1.9-16.0%) increase in FENO, respectively, adjusting for other phthalate metabolites and potential covariates/confounders. There was no association between concentrations of metabolites of di(2-ethylhexyl) phthalate or di-n-butyl phthalate and FENO. There was no significant interaction by seroatopy. The BBzP metabolite association was significantly stronger among children who wheeze (P = 0.016). Conclusions: Independent associations between exposures to DEP and BBzP and FENO in a cohort of inner-city children were observed. These results suggest that these two ubiquitous phthalates, previously shown to have substantial contributions from inhalation, are positively associated with airway inflammation in children. C1 [Just, Allan C.; Whyatt, Robin M.; Miller, Rachel L.; Rundle, Andrew G.; Divjan, Adnan; Rosa, Maria J.; Perera, Frederica P.; Goldstein, Inge F.; Perzanowski, Matthew S.] Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, New York, NY USA. [Just, Allan C.; Whyatt, Robin M.; Miller, Rachel L.; Divjan, Adnan; Rosa, Maria J.; Perera, Frederica P.; Perzanowski, Matthew S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA. [Rundle, Andrew G.; Goldstein, Inge F.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Chen, Qixuan] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. [Miller, Rachel L.; Zhang, Hanjie] Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care, New York, NY 10032 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Just, AC (reprint author), 722 W 168th St,11th Floor, New York, NY 10032 USA. EM acj2109@columbia.edu RI Rundle, Andrew/A-5282-2009; OI Rundle, Andrew/0000-0003-0211-7707; Just, Allan/0000-0003-4312-5957 FU National Institute of Environmental Health Sciences [R01 ES014393, R01 ES013163, P01 ES09600, R01 ES008977, P30 ES009089]; U.S. Environmental Protection Agency [R827027, RD832141, RD834509]; EPA STAR graduate fellowship [FP-91712001]; John and Wendy Neu Family Foundation; Blanchette Hooker Rockefeller Fund; New York Community Trust; Educational Foundation of America; Millstream Fund FX Supported by the National Institute of Environmental Health Sciences grants R01 ES014393, R01 ES013163, P01 ES09600, R01 ES008977, and P30 ES009089; the U.S. Environmental Protection Agency grants R827027, RD832141, RD834509, and EPA STAR graduate fellowship FP-91712001 (A.C.J.); the John and Wendy Neu Family Foundation; Blanchette Hooker Rockefeller Fund; New York Community Trust; Educational Foundation of America; and the Millstream Fund. NR 54 TC 26 Z9 26 U1 0 U2 24 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2012 VL 186 IS 9 BP 830 EP 837 DI 10.1164/rccm.201203-0398OC PG 8 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 037TB UT WOS:000311128300009 PM 22923660 ER PT J AU Harshfield, E Lantagne, D Turbes, A Null, C AF Harshfield, Eric Lantagne, Daniele Turbes, Anna Null, Clair TI Evaluating the Sustained Health Impact of Household Chlorination of Drinking Water in Rural Haiti SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; POINT-OF-USE; DIARRHEA PREVENTION; FLOCCULANT-DISINFECTANT; SAFE STORAGE; INTERVENTIONS; COUNTRIES AB The Jolivert Safe Water for Families program has sold sodium hypochlorite solution (chlorine) and conducted household visits in rural Haiti since 2002. To assess the impact of the program on diarrheal disease, in 2010 we conducted a survey and water quality testing in 201 program participants and 425 control households selected at random. Fifty-six percent of participants (versus 10% of controls) had free chlorine residuals between 0.2 and 2.0 mg/L, indicating correct water treatment. Using intention-to-treat analysis, we found that significantly fewer children < 5 in participant households had an episode of diarrhea in the previous 48 hours (32% versus 52%; P < 0.001) with 59% reduced odds (odds ratio = 0.41, 95% confidence interval = 0.21-0.79). Treatment-on-treated estimates of the odds of diarrhea indicated larger program effects for participants who met more stringent verifications of participation. Diarrheal disease reduction in this long-term program was comparable with that seen in short-term randomized, controlled interventions, suggesting that household chlorination can be an effective long-term water treatment strategy. C1 [Turbes, Anna; Null, Clair] Emory Univ, Rollins Sch Publ Hlth, Sch Med, Atlanta, GA 30322 USA. [Lantagne, Daniele] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA USA. RP Null, C (reprint author), Emory Univ, Rollins Sch Publ Hlth, Sch Med, 1518 Clifton Rd, Atlanta, GA 30322 USA. EM eric.harshfield@gmail.com; dlantagne@cdc.gov; aturbes@gmail.com; clair.null@emory.edu OI Harshfield, Eric/0000-0001-8767-0928 FU Emory Global Health Institute, Emory Sustainability Initiatives; Gangarosa Endowment for Safe Water at the CDC Foundation FX This study was supported by the Emory Global Health Institute, Emory Sustainability Initiatives, and the Gangarosa Endowment for Safe Water at the CDC Foundation. NR 20 TC 14 Z9 14 U1 0 U2 22 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2012 VL 87 IS 5 BP 786 EP 795 DI 10.4269/ajtmh.2012.12-0010 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 036VI UT WOS:000311060000004 PM 22987657 ER PT J AU Rolfes, MA McCarra, M Magak, NG Ernst, KC Dent, AE Lindblade, KA John, CC AF Rolfes, Melissa A. McCarra, Matthew Magak, Ng'wena G. Ernst, Kacey C. Dent, Arlene E. Lindblade, Kim A. John, Chandy C. TI Development of Clinical Immunity to Malaria in Highland Areas of Low and Unstable Transmission SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ENTOMOLOGICAL INOCULATION RATE; PLASMODIUM-FALCIPARUM TRANSMISSION; POLYMERASE-CHAIN-REACTION; WESTERN KENYAN HIGHLANDS; CASE DEFINITIONS; NORTHEASTERN TANZANIA; SEASONAL TRANSMISSION; EXPERT MICROSCOPY; LOW-PREVALENCE; AGE-PATTERNS AB In highland areas of unstable, low malaria transmission, the extent to which immunity to uncomplicated malaria develops with age and intermittent parasite exposure has not been well characterized. We conducted active surveillance for clinical malaria during April 2003-March 2005 in two highland areas of western Kenya (Kapsisiywa and Kipsamoite). In both sites, annual malaria incidence was significantly lower in persons >= 15 years of age than in persons < 5 years of age (Kapsisiywa: incidence = 382.9 cases/1,000 persons among persons < 1-4 years of age versus 135.1 cases/1,000 persons among persons >= 15 years of age; Kipsamoite: incidence = 233.0 cases/1,000 persons in persons < 1-4 years of age versus 43.3 cases/1,000 persons in persons >= 15 years of age). In Kapsisiywa, among persons with malaria, parasite density and axillary body temperature were also significantly lower in persons >= 15 years of age than in persons < 5 years of age. Even in highland areas of unstable and low malaria transmission, age is associated with development of clinical immunity to malaria. C1 [Rolfes, Melissa A.; John, Chandy C.] Univ Minnesota, Dept Pediat, Ctr Global Pediat, Minneapolis, MN 55455 USA. [Lindblade, Kim A.] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Magak, Ng'wena G.] Moi Univ, Sch Med, Dept Med Physiol, Eldoret, Kenya. [Ernst, Kacey C.] Univ Arizona, Coll Publ Hlth, Tucson, AZ USA. [Dent, Arlene E.] Case Western Reserve Univ, Ctr Global Hlth & Dis, Case Western Reserve Sch Med, Cleveland, OH 44106 USA. RP Rolfes, MA (reprint author), Univ Minnesota, Dept Pediat, Ctr Global Pediat, 3-410 MTRF,2001 6th St SE, Minneapolis, MN 55455 USA. EM riede056@umn.edu; mcca0495@umn.edu; gngwena@hotmail.com; kernst@email.arizona.edu; arlene.dent@case.edu; kil2@cdc.gov; ccj@umn.edu RI Ernst, Kacey/M-5943-2013 FU National Institutes of Allergy and Infectious Diseases [U01 AI056270, K08 AI01572, D43 TW0080085] FX This study was supported in part by National Institutes of Allergy and Infectious Diseases grants U01 AI056270, K08 AI01572, and D43 TW0080085 to Chandy C. John. NR 42 TC 7 Z9 7 U1 0 U2 0 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2012 VL 87 IS 5 BP 806 EP 812 DI 10.4269/ajtmh.2012.11-0530 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 036VI UT WOS:000311060000006 PM 22987652 ER PT J AU Butler, SE Muok, EM Montgomery, SP Odhiambo, K Mwinzi, PMN Secor, WE Karanja, DMS AF Butler, Sara E. Muok, Erick M. Montgomery, Susan P. Odhiambo, Keziah Mwinzi, Pauline M. N. Secor, W. Evan Karanja, Diana M. S. TI Mechanism of Anemia in Schistosoma mansoni-Infected School Children in Western Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SERUM TRANSFERRIN RECEPTOR; ADULT MICROSOMAL ANTIGENS; IRON-DEFICIENCY ANEMIA; CHRONIC DISEASE; FERRITIN INDEX; YOUNG-ADULTS; JAPONICUM; INFLAMMATION; PHILIPPINES; DIAGNOSIS AB A better understanding of the mechanism of anemia associated with Schistosoma mansoni infection might provide useful information on how treatment programs are implemented to minimize schistosomiasis-associated morbidity and maximize treatment impact. We used a cross-sectional study with serum samples from 206 Kenyan school children to determine the mechanisms in S. mansoni-associated anemia. Serum ferritin and soluble transferrin receptor levels were measured by using an enzyme-linked immunosorbent assay. Results suggest that S. mansoni-infected persons are more likely (odds ratio = 3.68, 95% confidence interval = 1.33-10.1) to have levels of serum ferritin (> 100 ng/mL) that are associated with anemia of inflammation (Al) than S. mansoni-uninfected children. Our results suggest that Al is the most common form of anemia in S. mansoni infections. In contrast, the mechanism of anemia in S. mansoni-uninfected children was iron deficiency. Moreover, the prevalence of Al in the study participants demonstrated a significant trend with S. mansoni infection intensity (P < 0.001). Our results are consistent with those observed in S. japonicum-associated anemia. C1 [Butler, Sara E.; Montgomery, Susan P.; Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30341 USA. [Muok, Erick M.; Odhiambo, Keziah; Mwinzi, Pauline M. N.; Karanja, Diana M. S.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. RP Secor, WE (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 4770 Buford Highway,Mailstop F13, Atlanta, GA 30341 USA. EM saebutler@gmail.com; EMuok@kemricdc.org; zqu6@cdc.gov; kezahinyi@yahoo.com; PMwinzi@kemricdc.org; was4@cdc.gov; DKaranja@kemricdc.org FU Emerging Infectious Diseases Fellowship Program; Schistosomiasis Research Program at the DBL - Institute for Health Research and Development; Centers for Disease Control and Prevention FX This study was supported in part by an appointment to the Emerging Infectious Diseases Fellowship Program administered by the Association of Public Health Laboratories and funded by a grant from the Schistosomiasis Research Program at the DBL - Institute for Health Research and Development and the Centers for Disease Control and Prevention. NR 38 TC 5 Z9 5 U1 0 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2012 VL 87 IS 5 BP 862 EP 867 DI 10.4269/ajtmh.2012.12-0248 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 036VI UT WOS:000311060000013 PM 22987658 ER PT J AU Samuels, AM Matey, E Mwinzi, PNM Wiegand, RE Muchiri, G Ireri, E Hyde, M Montgomery, SP Karanja, DMS Secor, WE AF Samuels, Aaron M. Matey, Elizabeth Mwinzi, Pauline N. M. Wiegand, Ryan E. Muchiri, Geoffrey Ireri, Edmund Hyde, Molly Montgomery, Susan P. Karanja, Diana M. S. Secor, W. Evan TI Schistosoma mansoni Morbidity among School-Aged Children: A SCORE Project in Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SHUTTLE RUN TEST; UGANDAN SCHOOLCHILDREN; HAEMATOBIUM INFECTION; FALCIPARUM-MALARIA; PHYSICAL-FITNESS; DIETARY-INTAKE; WESTERN KENYA; LAKE VICTORIA; CANE CUTTERS; PRAZIQUANTEL AB Schistosomiasis control programs aim to reduce morbidity but are evaluated by infection prevalence and intensity reduction. We present baseline cross-sectional data from a nested cohort study comparing indicators of morbidity for measuring program impact. Eight hundred twenty-two schoolchildren 7-8 years of age from Nyanza Province, Kenya, contributed stool for diagnosis of Schistosoma mansoni and soil-transmitted helminths (STH) and blood smears for malaria, and were evaluated for anemia, quality of life, exercise tolerance, anthropometry, and ultrasound abnormalities. Schistosoma mansoni, STH, and malaria infection prevalence were 69%, 25%, and 8%, respectively. Only anemia and S. mansoni infection (adjusted odds ratio [aOR] = 1.70; confidence interval [CI] = 1.03-2.80), and hepatomegaly and heavy S. mansoni infection (aOR = 2.21; CI = 1.19-4.11) were associated. Though anemia and hepatomegaly appeared most useful at baseline, additional morbidity indicators may be sensitive longitudinal measures to evaluate schistosomiasis program health impact. C1 [Samuels, Aaron M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. RP Samuels, AM (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,MS A06, Atlanta, GA 30329 USA. EM iyp2@cdc.gov; Ematey@kemricdc.org; PMwinzi@kemricdc.org; FWK2@cdc.gov; Geoffmosh@yahoo.com; Eikareko@hotmail.com; Molly1013@hotmail.com; ZQU6@cdc.gov; DKaranja@kemricdc.org; WAS4@cdc.gov FU University of Georgia Research Foundation, Inc.; Bill and Melinda Gates Foundation FX This study received financial support from the University of Georgia Research Foundation, Inc., which is funded by the Bill and Melinda Gates Foundation for this SCORE project. NR 60 TC 14 Z9 14 U1 0 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2012 VL 87 IS 5 BP 874 EP 882 DI 10.4269/ajtmh.2012.12-0397 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 036VI UT WOS:000311060000015 PM 22987651 ER PT J AU Lozano-Fuentes, S Hayden, MH Welsh-Rodriguez, C Ochoa-Martinez, C Tapia-Santos, B Kobylinski, KC Uejio, CK Zielinski-Gutierrez, E Delle Monache, L Monaghan, AJ Steinhoff, DF Eisen, L AF Lozano-Fuentes, Saul Hayden, Mary H. Welsh-Rodriguez, Carlos Ochoa-Martinez, Carolina Tapia-Santos, Berenice Kobylinski, Kevin C. Uejio, Christopher K. Zielinski-Gutierrez, Emily Delle Monache, Luca Monaghan, Andrew J. Steinhoff, Daniel F. Eisen, Lars TI The Dengue Virus Mosquito Vector Aedes aegypti at High Elevation in Mexico SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID CLIMATE-CHANGE; EPIDEMIC DENGUE; FEVER; TRANSMISSION; DIPTERA; TEMPERATURE; CULICIDAE; AUSTRALIA; MODELS; IMPACT AB Mexico has cities (e.g., Mexico City and Puebla City) located at elevations > 2,000 m and above the elevation ceiling below which local climates allow the dengue virus mosquito vector Aedes aegypti to proliferate. Climate warming could raise this ceiling and place high-elevation cities at risk for dengue virus transmission. To assess the elevation ceiling for Ae. aegypti and determine the potential for using weather/climate parameters to predict mosquito abundance, we surveyed 12 communities along an elevation/climate gradient from Veracruz City (sea level) to Puebla City (similar to 2,100 m). Ac. aegypti was commonly encountered up to 1,700 m and present but rare from 1,700 to 2,130 m. This finding extends the known elevation range in Mexico by > 300 m. Mosquito abundance was correlated with weather parameters, including temperature indices. Potential larval development sites were abundant in Puebla City and other high-elevation communities, suggesting that Ae. aegypti could proliferate should the climate become warmer. C1 [Lozano-Fuentes, Saul; Kobylinski, Kevin C.; Eisen, Lars] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Hayden, Mary H.; Delle Monache, Luca; Monaghan, Andrew J.; Steinhoff, Daniel F.] Natl Ctr Atmospher Res, Boulder, CO 80307 USA. [Welsh-Rodriguez, Carlos; Ochoa-Martinez, Carolina; Tapia-Santos, Berenice] Univ Veracruzana, Ctr Ciencias Tierra, Xalapa 91000, Veracruz, Mexico. [Uejio, Christopher K.] Florida State Univ, Dept Geog, Tallahassee, FL 32306 USA. [Zielinski-Gutierrez, Emily] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO USA. RP Eisen, L (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. EM slozano@colostate.edu; mhayden@ucar.edu; cwelsh@uv.mx; orac8a@gmail.com; beretap@gmail.com; kobylinskikevin@yahoo.com; cuejio@admin.fsu.edu; ebz0@CDC.GOV; lucadm@ucar.edu; monaghan@ucar.edu; steinhof@ucar.edu; lars.eisen@colostate.edu RI Lozano-Fuentes, Saul/H-4324-2011; OI Lozano-Fuentes, Saul/0000-0003-1517-6853; Monaghan, Andrew/0000-0002-8170-2359 FU Ministries of Public Health, Education and Civil Protection of Veracruz Government; National Science Foundation [GEO-1010204] FX The authors thank Eric Hubron, Elena Rustrian, Selene Tejeda, Marco Aurelio Morales, Yair Zamora, students from Universidad Veracruzana's Geography Program, and students and personnel from Bachilleres Veracruz, Ilustre Instituto Veracruzano, Bachilleres Rio Blanco, and Bachilleres Ricardo Flores Magon (Oficial B) for field and laboratory assistance. We also thank the Ministries of Public Health, Education and Civil Protection of Veracruz Government for their support. Finally, we are grateful to the involved home owners for granting us access to collect mosquitoes from their properties.; This study was funded by National Science Foundation Grant GEO-1010204 to the University Corporation for Atmospheric Research. NR 47 TC 27 Z9 27 U1 2 U2 14 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD NOV PY 2012 VL 87 IS 5 BP 902 EP 909 DI 10.4269/ajtmh.2012.12-0244 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 036VI UT WOS:000311060000019 PM 22987656 ER PT J AU Wang, ML Kelly, KJ Klancnik, M Petsonk, EL AF Wang, Mei Lin Kelly, Kevin J. Klancnik, Meribeth Petsonk, Edward L. TI Self-reported hand symptoms: a role in monitoring health care workers for latex sensitization? SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Article ID TEST RESPONSES; PRICK TEST; SKIN; QUESTIONNAIRE; ALLERGY; EXPOSURE AB Background: The use of powdered natural rubber latex (NRL) gloves increased greatly in the 1980s because of concerns about transmission of blood-borne infections and the subsequent implementation of universal precautions. The most common clinical reactions to glove use are irritant and T-cell-mediated contact dermatitis. However, IgE-mediated immediate reactions to latex have become a serious concern for health care workers (HCWs). The diagnosis of latex allergy requires a comprehensive medical history and diagnostic tests. The skin prick test is the preferred diagnostic method, although it can be time-consuming. Objective: To determine the role of hand symptoms reported on questionnaires in monitoring HCWs for latex sensitization. Methods: Questionnaires were completed by 804 HCWs at 2 hospitals. Using a positive skin prick test (SPT) result as a criterion standard of latex sensitization, the diagnostic performance of hand symptoms was evaluated. Results: Increasing latex glove use was strongly related to increasing reports of hand symptoms. Hand symptoms were highly associated with glove-related respiratory and systemic symptoms. A positive SPT result was seen in 5% of HCWs and increased with the number of hand symptoms: 0 (1.6%), 1 to 2 (3.4%), and 3 to 7 (19.0%). Participants reporting more than 2 hand symptoms were 11 times more likely to have positive SPT results compared with those with 2 or fewer hand symptoms. Conclusion: Hand symptoms are closely associated with latex sensitization. Questionnaires should be useful in health monitoring for HCWs who use latex gloves. (C) 2012 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. C1 [Wang, Mei Lin; Petsonk, Edward L.] Ctr Dis Control & Prevent, Div Resp Dis Studies, NIOSH, Morgantown, WV 26505 USA. [Kelly, Kevin J.; Klancnik, Meribeth] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Childrens Hosp Wisconsin, Dept Pediat Allergy Immunol & Med, Milwaukee, WI 53226 USA. RP Wang, ML (reprint author), Ctr Dis Control & Prevent, Div Resp Dis Studies, NIOSH, Mail Stop H-G900-2,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM mlw4@cdc.gov FU Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health [U60/CCU14541] FX This study was supported by grant U60/CCU14541 from the Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health. NR 18 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD NOV PY 2012 VL 109 IS 5 BP 314 EP 318 DI 10.1016/j.anai.2012.08.007 PG 5 WC Allergy; Immunology SC Allergy; Immunology GA 041VK UT WOS:000311429100008 PM 23062385 ER PT J AU Fleming, ST Kimmick, GG Sabatino, SA Cress, RD Wu, XC Trentham-Dietz, A Huang, B Hwang, W Liff, JM AF Fleming, Steven T. Kimmick, Gretchen G. Sabatino, Susan A. Cress, Rosemary D. Wu, Xiao-Cheng Trentham-Dietz, Amy Huang, Bin Hwang, Wenke Liff, Jonathan M. CA Patterns Care Study Grp TI Defining care provided for breast cancer based on medical record review or Medicare claims: information from the Centers for Disease Control and Prevention Patterns of Care Study SO ANNALS OF EPIDEMIOLOGY LA English DT Review DE Breast neoplasm; Medicare; Claims analysis; Medical records; Patterns; Clinical practice ID ADMINISTRATIVE DATA; HOSPITAL DISCHARGE; REGISTRY DATA; QUALITY; SURGERY AB Background: Description of care patterns is important as evidence-based guidelines increasingly dictate care. We explore the level of agreement between claims and record abstraction for guideline concordant multidisciplinary breast cancer care. Methods: From the U.S. Centers for Disease Control and Prevention's National Program of Cancer Registries Patterns of Care study, in which medical record abstraction of breast cancer and treatment was accomplished, cases include breast cancer where Medicare claims were available. Components of care were breast-conserving surgery (BCS), mastectomy, node assessment, radiation (RT), and chemotherapy (CTX), including specific chemotherapeutic agents, and combinations. We compared Medicare claims with record abstraction, and measured concordance using the kappa statistic and sensitivity. Results: The study sample consisted of 1762 women with stage 0 to 4 breast cancer. Level of agreement was excellent for surgery type (kappa = 0.84) and CTX (kappa = 0.89); agreement for RT therapy was slightly lower (kappa = 0.79). For standard multicomponent strategies, sensitivities and specificities were high; for example, 88.8%/93.5% for mastectomy plus nodes and 86.6%/95.4% for BCS plus nodes and RT. For selected, standard, multi-agent, adjuvant CTX regimens, sensitivities ranged from 66.3% to 68.8% (kappa 0.63-0.73). Conclusions: Medicare claims, compared with chart abstraction, is a reliable method for determining patterns of multicomponent care for breast cancer. (C) 2012 Elsevier Inc. All rights reserved. C1 [Fleming, Steven T.] Univ Kentucky, Dept Epidemiol, Coll Publ Hlth, Lexington, KY 40536 USA. [Kimmick, Gretchen G.] Duke Univ, Med Ctr, Durham, NC USA. [Sabatino, Susan A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Cress, Rosemary D.] Calif Canc Registry, Sacramento, CA USA. [Wu, Xiao-Cheng] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA. [Trentham-Dietz, Amy] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Huang, Bin] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA. [Hwang, Wenke] Penn State Univ, Coll Med, Hershey, PA USA. [Liff, Jonathan M.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Fleming, ST (reprint author), Univ Kentucky, Dept Epidemiol, Coll Publ Hlth, 121 Washington Ave, Lexington, KY 40536 USA. EM stflem2@uky.edu FU Centers for Disease Control and Prevention; California Cancer Registry (Public Health Institute) [1-U01-DP000260]; Emory University [1-U01-DP000258]; Louisiana State University Health Sciences Center [1-U01-DP000253]; Minnesota Cancer Surveillance System (Minnesota Department of Health) [1-U01-DP000259]; Medical College of Wisconsin [1-U01-DP000261]; University of Kentucky [1-U01-DP000251]; Wake Forest University [1-U01-DP000264] FX The Breast and Prostate Cancer Data Quality and Patterns of Care Study was supported by the Centers for Disease Control and Prevention through cooperative agreements with the California Cancer Registry (Public Health Institute) (1-U01-DP000260), Emory University (1-U01-DP000258), Louisiana State University Health Sciences Center (1-U01-DP000253), Minnesota Cancer Surveillance System (Minnesota Department of Health) (1-U01-DP000259), Medical College of Wisconsin (1-U01-DP000261), University of Kentucky (1-U01-DP000251), and Wake Forest University (1-U01-DP000264). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 24 TC 2 Z9 2 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD NOV PY 2012 VL 22 IS 11 BP 807 EP 813 DI 10.1016/j.annepidem.2012.08.001 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 036YI UT WOS:000311067800009 PM 22948184 ER PT J AU Mcclean, MD Osborn, LV Snawder, JE Olsen, LD Kriech, AJ Sjodin, A Li, Z Smith, JP Sammons, DL Herrick, RF Cavallari, JM AF Mcclean, Michael D. Osborn, Linda V. Snawder, John E. Olsen, Larry D. Kriech, Anthony J. Sjoedin, Andreas Li, Zheng Smith, Jerome P. Sammons, Deborah L. Herrick, Robert F. Cavallari, Jennifer M. TI Using Urinary Biomarkers of Polycyclic Aromatic Compound Exposure to Guide Exposure-Reduction Strategies Among Asphalt Paving Workers SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE asphalt; biodiesel; biomarkers; dermal; polycyclic aromatic compounds ID DERMAL EXPOSURE; CANCER MORTALITY; BITUMEN FUME; HYDROCARBONS; PREDICTORS; INHALATION; AIRBORNE; EMISSION; PAVERS AB Paving workers are exposed to polycyclic aromatic compounds (PACs) while working with hot-mix asphalt (HMA). Further characterization of the source and route of these exposures is necessary to guide exposure-reduction strategies. Personal air (n 144), hand-wash (n 144), and urine (n 480) samples were collected from 12 paving workers over 3 workdays during 4 workweeks. Urine samples were collected at preshift, postshift, and bedtime and analyzed for 10 hydroxylated PACs (1-OH-pyrene; 1-, 2-, 3-, 4-OH-phenanthrene; 1-, 2-OH-naphthalene; 2-, 3-, 9-OH-fluorene) by an immunochemical quantification of PACs (I-PACs). The air and hand-wash samples were analyzed for the parent compounds corresponding to the urinary analytes. Using a crossover study design, each of the 4 weeks represented a different exposure scenario: a baseline week (normal conditions), a dermal protection week (protective clothing), a powered air-purifying respirator (PAPR) week, and a biodiesel substitution week (100% biodiesel provided to replace the diesel oil normally used by workers to clean tools and equipment). The urinary analytes were analyzed using linear mixed-effects models. Postshift and bedtime concentrations were significantly higher than preshift concentrations for most urinary biomarkers. Compared with baseline, urinary analytes were reduced during the dermal protection (29% for 1-OH-pyrene, 15% for I-PACs), the PAPR (24% for 1-OH-pyrene, 15% for I-PACs), and the biodiesel substitution (15% for 1-OH-pyrene) weeks. The effect of PACs in air was different by exposure scenario (biodiesel substitution > dermal protection > PAPR and baseline) and was still a significant predictor of most urinary analytes during the week of PAPR use, suggesting that PACs in air were dermally absorbed. The application temperature of HMA was positively associated with urinary measures, such that an increase from the lowest application temperature (121C) to the highest (154C) was associated with a 72% increase in SigmaOH-fluorene and 1-OH-pyrene and an 82% increase in SigmaOH-phenanthrene. Though PACs in hand-wash samples were not predictors of urinary analytes, the effects observed during the PAPR scenario and the week of increased dermal protection provide evidence of dermal absorption. Our results provide evidence that PACs in air are dermally absorbed. Reducing the application temperature of asphalt mix appears to be a promising strategy for reducing PAC exposure among paving workers. Additional reductions may be achieved by requiring increased dermal coverage of workers and by substituting biodiesel for diesel oil as a cleaning agent. C1 [Mcclean, Michael D.] Boston Univ, Sch Publ Hlth, Boston, MA 02218 USA. [Osborn, Linda V.; Kriech, Anthony J.] Heritage Res Grp, Indianapolis, IN 46231 USA. [Snawder, John E.; Olsen, Larry D.; Smith, Jerome P.; Sammons, Deborah L.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Sjoedin, Andreas; Li, Zheng] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Herrick, Robert F.; Cavallari, Jennifer M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA. RP Mcclean, MD (reprint author), Boston Univ, Sch Publ Hlth, 715 Albany St, Boston, MA 02218 USA. EM mmcclean@bu.edu RI Sjodin, Andreas/F-2464-2010; McClean, Michael/J-2934-2015; OI McClean, Michael/0000-0002-3902-8823 FU National Asphalt Pavement Association (NAPA); State Asphalt Pavement Association (SAPA) FX National Asphalt Pavement Association (NAPA); the State Asphalt Pavement Association (SAPA). NR 26 TC 8 Z9 8 U1 2 U2 23 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD NOV PY 2012 VL 56 IS 9 BP 1013 EP 1024 DI 10.1093/annhyg/mes058 PG 12 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 044TC UT WOS:000311645500004 PM 23002274 ER PT J AU Johnson, CY Honein, MA Flanders, WD Howards, PP Oakley, GP Rasmussen, SA AF Johnson, Candice Y. Honein, Margaret A. Flanders, W. Dana Howards, Penelope P. Oakley, Godfrey P., Jr. Rasmussen, Sonja A. TI Pregnancy termination following prenatal diagnosis of anencephaly or spina bifida: A systematic review of the literature SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Review DE anencephaly; metaanalysis; prenatal diagnosis; spina bifida; termination of pregnancy ID NEURAL-TUBE DEFECTS; FOLIC-ACID FORTIFICATION; BIRTH-DEFECTS; ELECTIVE TERMINATION; MATERNAL OBESITY; CONGENITAL-MALFORMATIONS; ULTRASOUND DETECTION; FETAL ANEUPLOIDY; NATURAL-HISTORY; IMPACT AB BACKGROUND In regions where prenatal screening for anencephaly and spina bifida is widespread, many cases of these defects are diagnosed prenatally. The purpose of this study was to estimate the frequency of termination of pregnancy (TOP) following prenatal diagnosis of anencephaly or spina bifida and to investigate factors associated with TOP that might lead to selection bias in epidemiologic studies. METHODS We included articles indexed in Medline or Embase between 1990 and May 2012 reporting the frequency of TOP following prenatal diagnosis of anencephaly or spina bifida with English-language abstracts, 20 or more prenatally diagnosed cases, and at least half of the study years in 1990 or later. We summarized the frequency of TOP across studies using random-effects metaanalysis and stratified results by fetal and study characteristics. RESULTS Among the 17 studies identified, 9 included anencephaly and 15 included spina bifida. Nine were from Europe, six were from North America, and one each was from South America and Asia. The overall frequency of TOP following prenatal diagnosis was 83% for anencephaly (range, 59100%) and 63% for spina bifida (range, 3197%). There were insufficient data to stratify the results for anencephaly; TOP for spina bifida was more common when the prenatal diagnosis occurred at less than 24 weeks' gestation, with defects of greater severity, and in Europe versus North America. CONCLUSIONS Because underascertainment of birth defects might be more likely when the pregnancy ends in TOP and TOP is associated with fetal characteristics, selection bias is possible in epidemiologic studies of anencephaly or spina bifida. (c) 2012 Wiley Periodicals, Inc. C1 [Johnson, Candice Y.; Honein, Margaret A.; Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Johnson, Candice Y.; Flanders, W. Dana; Howards, Penelope P.; Oakley, Godfrey P., Jr.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA. RP Johnson, CY (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,MS R-15, Cincinnati, OH 45226 USA. EM cyjohnson@cdc.gov FU Intramural CDC HHS [CC999999] NR 42 TC 16 Z9 16 U1 0 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD NOV PY 2012 VL 94 IS 11 BP 857 EP 863 DI 10.1002/bdra.23086 PG 7 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 039HD UT WOS:000311234400001 PM 23097374 ER PT J AU Chandler, AL Hobbs, CA Mosley, BS Berry, RJ Canfield, MA Qi, YP Siega-Riz, AM Shaw, GM AF Chandler, Angela L. Hobbs, Charlotte A. Mosley, Bridget S. Berry, Robert J. Canfield, Mark A. Qi, Yan Ping Siega-Riz, Anna Maria Shaw, Gary M. CA Natl Birth Defects Prevention Stud TI Neural tube defects and maternal intake of micronutrients related to one-carbon metabolism or antioxidant activity SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE dietary periconceptional micronutrients; maternal nutrition; National Birth Defects Prevention Study; neural tube defects; one-carbon metabolism ID BIRTH-DEFECTS; UNITED-STATES; SPINA-BIFIDA; FOLIC-ACID; FORTIFIED POPULATION; AFFECTED PREGNANCIES; DIETARY-INTAKE; RISK-FACTOR; VITAMIN; OBESITY AB BACKGROUND Maternal nutritional status has been evaluated to clarify its role in development of neural tube defects (NTDs). Maternal folate intake during pregnancy has been closely evaluated for its association with NTDs. The study objective was to examine associations between NTDs and other dietary periconceptional micronutrient intake, particularly nutrients involved in one-carbon metabolism or antioxidant activity. METHODS Using data from the National Birth Defects Prevention Study, 19972005, logistic regression models were used to estimate the relative risk of NTDs based on maternal micronutrient intake. RESULTS Results were stratified according to folic acid supplement use, race/ethnicity, and maternal body mass index. Analyses included 954 cases (300 with anencephaly, 654 with spina bifida) and 6268 controls. Higher intakes of folate, thiamin, betaine, iron, and vitamin A were associated with decreased risk of anencephaly among some ethnic and clinical groups. In some groups, higher intakes of thiamin, riboflavin, vitamin B6, vitamin C, vitamin E, niacin, and retinol were associated with decreased risk of spina bifida. CONCLUSION In addition to folic acid, other micronutrients, including thiamin, betaine, riboflavin, vitamin B6, vitamin C, vitamin E, niacin, iron, retinol, and vitamin A, may decrease the risk of NTD occurrence. Birth Defects Research (Part A) 2012. (c) 2012 Wiley Periodicals, Inc. C1 [Chandler, Angela L.; Hobbs, Charlotte A.; Mosley, Bridget S.] Univ Arkansas Med Sci Hosp, Dept Pediat, Coll Med, Arkansas Childrens Hosp Res Inst, Little Rock, AR 72202 USA. [Berry, Robert J.; Qi, Yan Ping] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Canfield, Mark A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. [Siega-Riz, Anna Maria] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Siega-Riz, Anna Maria] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA. [Shaw, Gary M.] Stanford Univ, Sch Med, Dept Pediat, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA. RP Hobbs, CA (reprint author), Univ Arkansas Med Sci Hosp, Dept Pediat, Coll Med, Arkansas Childrens Hosp Res Inst, 13 Childrens Way,Slot 512-40, Little Rock, AR 72202 USA. EM HobbsCharlotte@uams.edu OI Berry, Robert/0000-0002-7162-5046 FU Centers for Disease Control and Prevention [5U01DD000491]; National Institutes of Health [RO1NS050249, DK56350] FX This research was supported by the Centers for Disease Control and Prevention (5U01DD000491); and partially supported by the National Institutes of Health (RO1NS050249 to G.M.S.). Funds for part of the nutrient database work were provided by NIH DK56350 granted to the University of North Carolina Department of Nutrition Clinical Research Center, Nutrition Epidemiology Core. NR 45 TC 20 Z9 20 U1 1 U2 24 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD NOV PY 2012 VL 94 IS 11 BP 864 EP 874 DI 10.1002/bdra.23068 PG 11 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 039HD UT WOS:000311234400002 PM 22933447 ER PT J AU Lupo, PJ Symanski, E Langlois, PH Lawson, CC Malik, S Gilboa, SM Lee, LJ Agopian, AJ Desrosiers, TA Waters, MA Romitti, PA Correa, A Shaw, GM Mitchell, LE AF Lupo, Philip J. Symanski, Elaine Langlois, Peter H. Lawson, Christina C. Malik, Sadia Gilboa, Suzanne M. Lee, Laura J. Agopian, A. J. Desrosiers, Tania A. Waters, Martha A. Romitti, Paul A. Correa, Adolfo Shaw, Gary M. Mitchell, Laura E. CA Natl Birth Defects Prevention Stud TI Maternal occupational exposure to polycyclic aromatic hydrocarbons and congenital heart defects among offspring in the national birth defects prevention study SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE birth defects; congenital heart defects; epidemiology; maternal occupation; polycyclic aromatic hydrocarbons ID IN-VITRO; RISK; ABNORMALITIES; ASSOCIATION; PLACENTA; CANCER AB BACKGROUND:There is evidence in experimental model systems that exposure to polycyclic aromatic hydrocarbons (PAHs) results in congenital heart defects (CHDs); however, to our knowledge, this relationship has not been examined in humans. Therefore, we conducted a case-control study assessing the association between estimated maternal occupational exposure to PAHs and CHDs in offspring. METHODS:Data on CHD cases and control infants were obtained from the National Birth Defects Prevention Study for the period of 1997 to 2002. Exposure to PAHs was assigned by industrial hygienist consensus, based on self-reported maternal occupational histories from 1 month before conception through the third month of pregnancy. Logistic regression was used to evaluate the association between maternal occupational PAH exposure and specific CHD phenotypic subtypes among offspring. RESULTS:The prevalence of occupational PAH exposure was 4.0% in CHD case mothers (76/1907) and 3.6% in control mothers (104/2853). After adjusting for maternal age, race or ethnicity, education, smoking, folic acid supplementation, and study center, exposure was not associated with conotruncal defects (adjusted odds ratio [AOR], 0.98; 95% confidence interval [CI], 0.581.67), septal defects (AOR, 1.28; 95% CI, 0.861.90), or with any isolated CHD subtype. CONCLUSIONS:Our findings do not support an association between potential maternal occupational exposure to PAHs and various CHDs in a large, population-based study. For CHD phenotypic subtypes in which modest nonsignificant associations were observed, future investigations could be improved by studying populations with a higher prevalence of PAH exposure and by incorporating information on maternal and fetal genotypes related to PAH metabolism. Birth Defects Research (Part A), 2012. (c) 2012 Wiley Periodicals, Inc. C1 [Lupo, Philip J.; Symanski, Elaine; Lee, Laura J.; Agopian, A. J.; Mitchell, Laura E.] Univ Texas Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA. [Langlois, Peter H.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. [Lawson, Christina C.; Waters, Martha A.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Malik, Sadia] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA. [Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Desrosiers, Tania A.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Romitti, Paul A.] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Shaw, Gary M.] Stanford Sch Med, Dept Pediat, Palo Alto, CA USA. RP Lupo, PJ (reprint author), Univ Texas Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, 1200 Herman Pressler Dr,RAS 511, Houston, TX 77030 USA. EM Philip.J.Lupo@uth.tmc.edu OI Lupo, Philip/0000-0003-0978-5863 FU American Heart Association [10BGIA3060022]; Centers for Disease Control and Prevention (CDC) [PA 96043, PA 02081, FOA DD09-001]; CDC [200-2000-08018]; National Institute for Occupational Safety and Health; [U01DD000494] FX Supported by the American Heart Association (to P.J.L., grant no. 10BGIA3060022); cooperative agreements under PA 96043, PA 02081, and FOA DD09-001 from the Centers for Disease Control and Prevention (CDC) to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study; Grant number: U01DD000494. The CDC to the Texas Department of State Health Services. Contract 200-2000-08018 from the CDC and the National Institute for Occupational Safety and Health. NR 32 TC 13 Z9 13 U1 1 U2 22 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD NOV PY 2012 VL 94 IS 11 BP 875 EP 881 DI 10.1002/bdra.23071 PG 7 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 039HD UT WOS:000311234400003 PM 22945317 ER PT J AU Suarez, L Felkner, M Brender, JD Canfield, M Zhu, HP Hendricks, KA AF Suarez, Lucina Felkner, Marilyn Brender, Jean D. Canfield, Mark Zhu, Huiping Hendricks, Katherine A. TI Neural tube defects on the Texas-Mexico border: What we've learned in the 20 years since the Brownsville cluster SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Review DE neural tube defects; Mexican American; folic acid; fumonisins; environment; case-control study ID INFANT METHYLENETETRAHYDROFOLATE REDUCTASE; MATERNAL VITAMIN USE; FUMONISIN B-1; AFFECTED PREGNANCIES; HYDROLYSIS PRODUCT; AMERICAN WOMEN; DIETARY-FOLATE; SPINA-BIFIDA; FOLIC-ACID; RISK AB We reviewed the published findings from the Texas Neural Tube Defect Project, a 6-year case-control study (19952000) of neural tube defects (NTDs) on the Texas-Mexico border. In this review, we highlight what was learned about environmental, genetic, and nutritional factors (i.e., those related to the folate and other metabolic pathways) and the novel putative risk factors that emerged from this study of Mexican American women living on the Texas-Mexico border. Our investigations of the micronutrients and metabolic pathways involved confirmed the findings of other researchers that increased folate intake has a protective effect and that low serum B12, high serum homocysteine levels, and obesity independently contribute to risk. Studies of this population also have implicated hyperinsulinemia and low ferritin, metabolic risk factors, which require additional study to elucidate their physiologic mechanism. Environmental contaminants such as heavy metals, pesticides, and polychlorinated biphenyls (PCBs), which were of community concern, did little to explain NTD risk. Studies in this folic acid deficit-population also revealed several novel risk factors, namely, diarrhea, stress, fumonisins, and the combination of nitrosatable drug exposure with high nitrate/nitrite intake. In conclusion, the 23 studies among the Mexican American women living along the Texas-Mexico border have demonstrated the multifactorial nature of NTDs and that a population deficient in folic acid will be vulnerable to a variety of insults whether brought on by individual behaviors (e.g., obesity) or through the surrounding environment (e.g., fumonisins). Birth Defects Research (Part A), 2012. (c) 2012 Wiley Periodicals, Inc. C1 [Suarez, Lucina; Felkner, Marilyn; Canfield, Mark] Calif Dept Hlth Serv, Prevent & Preparedness Div, Austin, TX 78756 USA. [Brender, Jean D.] Texas A&M Hlth Sci Ctr, Sch Rural Publ Hlth, College Stn, TX USA. [Zhu, Huiping] Univ Texas Austin, Dell Pediat Res Inst, Dept Nutr Serv, Austin, TX 78712 USA. [Hendricks, Katherine A.] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Suarez, L (reprint author), Calif Dept Hlth Serv, Prevent & Preparedness Div, 1100 W 49th St, Austin, TX 78756 USA. EM lucina.suarez@dshs.state.tx.us NR 54 TC 14 Z9 14 U1 1 U2 29 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD NOV PY 2012 VL 94 IS 11 BP 882 EP 892 DI 10.1002/bdra.23070 PG 11 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 039HD UT WOS:000311234400004 PM 22945287 ER PT J AU Nassar, N Leoncini, E Amar, E Arteaga-Vazquez, J Bakker, MK Bower, C Canfield, MA Castilla, EE Cocchi, G Correa, A Csaky-Szunyogh, M Feldkamp, ML Khoshnood, B Landau, D Lelong, N Lopez-Camelo, JS Lowry, RB McDonnell, R Merlob, P Metneki, J Morgan, M Mutchinick, OM Palmer, MN Rissmann, A Siffel, C Sipek, A Szabova, E Tucker, D Mastroiacovo, P AF Nassar, Natasha Leoncini, Emanuele Amar, Emmanuelle Arteaga-Vazquez, Jazmin Bakker, Marian K. Bower, Carol Canfield, Mark A. Castilla, Eduardo E. Cocchi, Guido Correa, Adolfo Csaky-Szunyogh, Melinda Feldkamp, Marcia L. Khoshnood, Babak Landau, Danielle Lelong, Nathalie Lopez-Camelo, Jorge S. Lowry, R. Brian McDonnell, Robert Merlob, Paul Metneki, Julia Morgan, Margery Mutchinick, Osvaldo M. Palmer, Miland N. Rissmann, Anke Siffel, Csaba Sipek, Antonin Szabova, Elena Tucker, David Mastroiacovo, Pierpaolo TI Prevalence of esophageal atresia among 18 international birth defects surveillance programs SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE esophageal atresia; congenital anomalies; prevalence; epidemiology ID TRACHEOESOPHAGEAL FISTULA; PRENATAL-DIAGNOSIS; CONGENITAL-MALFORMATIONS; UNITED-STATES; EPIDEMIOLOGY; CLEARINGHOUSE; TERMINATIONS; ANOMALIES; REGIONS; IMPACT AB BACKGROUND: The prevalence of esophageal atresia (EA) has been shown to vary across different geographical settings. Investigation of geographical differences may provide an insight into the underlying etiology of EA. METHODS: The study population comprised infants diagnosed with EA during 1998 to 2007 from 18 of the 46 birth defects surveillance programs, members of the International Clearinghouse for Birth Defects Surveillance and Research. Total prevalence per 10,000 births for EA was defined as the total number of cases in live births, stillbirths, and elective termination of pregnancy for fetal anomaly (ETOPFA) divided by the total number of all births in the population. RESULTS: Among the participating programs, a total of 2943 cases of EA were diagnosed with an average prevalence of 2.44 (95% confidence interval [CI], 2.352.53) per 10,000 births, ranging between 1.77 and 3.68 per 10,000 births. Of all infants diagnosed with EA, 2761 (93.8%) were live births, 82 (2.8%) stillbirths, 89 (3.0%) ETOPFA, and 11 (0.4%) had unknown outcomes. The majority of cases (2020, 68.6%), had a reported EA with fistula, 749 (25.5%) were without fistula, and 174 (5.9%) were registered with an unspecified code. CONCLUSIONS: On average, EA affected 1 in 4099 births (95% CI, 1 in 39544251 births) with prevalence varying across different geographical settings, but relatively consistent over time and comparable between surveillance programs. Findings suggest that differences in the prevalence observed among programs are likely to be attributable to variability in population ethnic compositions or issues in reporting or registration procedures of EA, rather than a real risk occurrence difference. Birth Defects Research (Part A), 2012. (c) 2012 Wiley Periodicals, Inc. C1 [Leoncini, Emanuele; Mastroiacovo, Pierpaolo] Ctr Int Clearinghouse Birth Defects Surveillance, I-00195 Rome, Italy. [Nassar, Natasha] Univ Sydney, Kolling Inst Med Res, Sydney, NSW 2006, Australia. [Amar, Emmanuelle] Rhone Alps Registry Birth Defects REMERA, Lyon, France. [Arteaga-Vazquez, Jazmin; Mutchinick, Osvaldo M.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Genet Registro & Vigilancia Epidemiol Malfor, Mexico City, DF, Mexico. [Bakker, Marian K.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, EUROCAT No Netherlands, Groningen, Netherlands. [Bower, Carol] Western Australian Register Dev Anomalies, Perth, WA, Australia. [Canfield, Mark A.] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. [Castilla, Eduardo E.; Lopez-Camelo, Jorge S.] Inst Nacl Genet Med & Populac, Rio De Janeiro, Brazil. [Castilla, Eduardo E.; Lopez-Camelo, Jorge S.] Ctr Educ Med & Invest Clin, Estudio Colaborativo Latino Amer Malformac Cogeni, Buenos Aires, DF, Argentina. [Castilla, Eduardo E.] Fundaco Oswaldo Cruz, Inst Oswaldo Cruz, Lab Epidemiol Malformacoes Congeitas, Estudio Colaborativo Latino Amer Malformac Cogeni, Rio De Janeiro, Brazil. [Cocchi, Guido] Univ Bologna, Dept Pediat, Indagine Malformazioni Congenite Emilia Romagna R, Bologna, Italy. [Correa, Adolfo; Siffel, Csaba] Ctr Dis Control & Prevent, Metropolitan Atlanta Congenital Defects Program, Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Csaky-Szunyogh, Melinda; Metneki, Julia] Natl Ctr Healthcare Audit & Inspect, Dept Hungarian Congenital Abnormal Registry & Sur, Budapest, Hungary. [Feldkamp, Marcia L.] Univ Utah, Hlth Sci Ctr, Div Med Genet, Salt Lake City, UT USA. [Feldkamp, Marcia L.; Palmer, Miland N.] Utah Dept Hlth, Utah Birth Defect Network, Salt Lake City, UT 84116 USA. [Khoshnood, Babak; Lelong, Nathalie] Hop Cochin, Inst Natl Sante & Rech Med, Unite Mixte Rech Epidemiol Res Perinatal Hlth & W, F-75674 Paris, France. [Khoshnood, Babak; Lelong, Nathalie] UPMC Univ, Paris, France. [Landau, Danielle] Soroka Univ Med Ctr, Dept Neonatol, Beer Sheva, Israel. [Lowry, R. Brian] Alberta Congenital Anomalies Surveillance Syst, Alberta Hlth & Wellness, Calgary, AB, Canada. [McDonnell, Robert] Dublin EUROCAT Registry, Dublin, Ireland. [Merlob, Paul] Rabin Med Ctr, Dept Neonatol, Petah Tiqwa, Israel. [Morgan, Margery; Tucker, David] Singleton Hosp, Congenital Anomaly Register Wales, Swansea SA2 8QA, W Glam, Wales. [Rissmann, Anke] Univ Magdeburg, Malformat Monitoring Ctr Saxony Anhalt, D-39106 Magdeburg, Germany. [Sipek, Antonin] Thomayer Univ Hosp, Dept Med Genet, Natl Registry Congenital Anomalies Czech Republ, Prague, Czech Republic. [Szabova, Elena] Slovak Med Univ, Slovak Teratol Informat Ctr, Bratislava, Slovakia. RP Mastroiacovo, P (reprint author), Ctr Int Clearinghouse Birth Defects Surveillance, Via Carlo Mirabello 14, I-00195 Rome, Italy. EM centre@icbdsr.org RI , emanuele/A-5466-2010; OI , emanuele/0000-0002-7669-8535; Khoshnood, Babak/0000-0002-4031-4915 FU Centers for Disease Control and Prevention (CDC), National Center on Birth Defects and Developmental Disabilities [1U50DD000524-01]; Australian National Health and Medical Research Council [632955] FX Supported by the Centers for Disease Control and Prevention (CDC), National Center on Birth Defects and Developmental Disabilities (Project Collaborative International Birth Defects Surveillance and Program, grant no. 1U50DD000524-01). Natasha Nassar is supported by an Australian National Health and Medical Research Council Career Development Fellowship (no. 632955). NR 41 TC 13 Z9 14 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD NOV PY 2012 VL 94 IS 11 BP 893 EP 899 DI 10.1002/bdra.23067 PG 7 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 039HD UT WOS:000311234400005 PM 22945024 ER PT J AU Hirve, S Chadha, M Lele, P Lafond, KE Deoshatwar, A Sambhudas, S Juvekar, S Mounts, A Dawood, F Lal, R Mishra, A AF Hirve, Siddhivinayak Chadha, Mandeep Lele, Pallavi Lafond, Kathryn E. Deoshatwar, Avinash Sambhudas, Somnath Juvekar, Sanjay Mounts, Anthony Dawood, Fatimah Lal, Renu Mishra, Akhilesh TI Performance of case definitions used for influenza surveillance among hospitalized patients in a rural area of India SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID CLINICAL SIGNS; INFECTION AB Objective To assess case definitions for influenza in a rural community in India. Methods Residents of the study area who were hospitalized for any acute medical condition for at least one night between May 2009 and April 2011 were enrolled. Respiratory specimens were collected and tested for influenza viruses in a reverse-transcription polymerase chain reaction (PCR). The PCR results were taken as the "gold standard" in evaluating the performance of several case definitions. Findings Of the 3179 patients included in the final analysis, 21% (665) were PCR-positive for influenza virus, 96% reported fever and 4% reported shortness of breath. The World Health Organization (WHO) case definition for severe acute respiratory illness had a sensitivity of 11% among patients aged <5 years and of 3% among older patients. When shortness of breath was excluded from the definition, sensitivities increased (to 69% and 70%, respectively) and corresponding specificities of 43% and 53% were recorded. Among patients aged 5 years, WHO's definition of a case of influenza-like illness had a sensitivity of 70% and a specificity of 53%. The addition of "cough and reported or measured fever" increased sensitivity to 80% but decreased specificity to 42%. Conclusion The inclusion of shortness of breath in WHO's case definition for severe acute respiratory illness may grossly underestimate the burden posed by influenza in hospitals. The exclusion of shortness of breath from this definition or, alternatively, the inclusion of "cough and measured or reported fever" may improve estimates of the burden. C1 [Hirve, Siddhivinayak; Lele, Pallavi; Sambhudas, Somnath; Juvekar, Sanjay] KEM Hosp Res Ctr, Pune 411011, Maharashtra, India. [Chadha, Mandeep; Deoshatwar, Avinash; Mishra, Akhilesh] Natl Inst Virol, Pune, Maharashtra, India. [Lafond, Kathryn E.; Mounts, Anthony; Dawood, Fatimah; Lal, Renu] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hirve, S (reprint author), KEM Hosp Res Ctr, Sardar Moodliar Rd, Pune 411011, Maharashtra, India. EM sidbela@vsnl.com FU Centers for Disease Control and Prevention [1U01IP000206] FX The study reported forms part of a larger investigation (the Influenza Disease Burden, India, study), which was supported by the Centers for Disease Control and Prevention via a cooperative agreement (1U01IP000206). NR 31 TC 16 Z9 17 U1 0 U2 3 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD NOV PY 2012 VL 90 IS 11 BP 804 EP 812 DI 10.2471/BLT.12.108837 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 039KY UT WOS:000311245900008 PM 23226892 ER PT J AU Weaver, KE Forsythe, LP Reeve, BB Alfano, CM Rodriguez, JL Sabatino, SA Hawkins, NA Rowland, JH AF Weaver, Kathryn E. Forsythe, Laura P. Reeve, Bryce B. Alfano, Catherine M. Rodriguez, Juan L. Sabatino, Susan A. Hawkins, Nikki A. Rowland, Julia H. TI Mental and Physical Health-Related Quality of Life among US Cancer Survivors: Population Estimates from the 2010 National Health Interview Survey SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION LA English DT Article ID BREAST-CANCER; PSYCHOLOGICAL DISTRESS; IMPACT; INTERVENTIONS; METAANALYSIS; DISPARITIES; BEHAVIORS; OUTCOMES; SCORES; ADULTS AB Background: Despite extensive data on health-related quality of life (HRQOL) among cancer survivors, we do not yet have an estimate of the percentage of survivors with poor mental and physical HRQOL compared with population norms. HRQOL population means for adult-onset cancer survivors of all ages and across the survivorship trajectory also have not been published. Methods: Survivors (N = 1,822) and adults with no cancer history (N = 24,804) were identified from the 2010 National Health Interview Survey. The PROMIS (R) Global Health Scale was used to assess HRQOL. Poor HRQOL was defined as 1 SD or more below the PROMIS (R) population norm. Results: Poor physical and mental HRQOL were reported by 24.5% and 10.1% of survivors, respectively, compared with 10.2% and 5.9% of adults without cancer (both P < 0.0001). This represents a population of approximately 3.3 million and 1.4 million U.S. survivors with poor physical and mental HRQOL. Adjusted mean mental and physical HRQOL scores were similar for breast, prostate, and melanoma survivors compared with adults without cancer. Survivors of cervical, colorectal, hematologic, short-survival, and other cancers had worse physical HRQOL; cervical and short-survival cancer survivors reported worse mental HROOL. Conclusion: These data elucidate the burden of cancer diagnosis and treatment among U.S. survivors and can be used to monitor the impact of national efforts to improve survivorship care and outcomes. Impact: We present novel data on the number of U.S. survivors with poor HRQOL. Interventions for high-risk groups that can be easily implemented are needed to improve survivor health at a population level. Cancer Epidemiol Biomarkers Prev; 21(11); 2108-17. (C) 2012 AACR. C1 [Weaver, Kathryn E.] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC 27157 USA. [Forsythe, Laura P.; Alfano, Catherine M.; Rowland, Julia H.] NCI, Off Canc Survivorship, NIH, DHHS, Bethesda, MD 20892 USA. [Forsythe, Laura P.] NCI, Ctr Canc Training, NIH, DHHS, Bethesda, MD 20892 USA. [Reeve, Bryce B.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC USA. [Rodriguez, Juan L.; Sabatino, Susan A.; Hawkins, Nikki A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Weaver, KE (reprint author), Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Med Ctr Blvd, Winston Salem, NC 27157 USA. EM keweaver@wakehealth.edu FU National Cancer Institute at the NIH [HHSN 261201100189P] FX This work was supported by the National Cancer Institute at the NIH. Contract no. HHSN 261201100189P. NR 36 TC 62 Z9 63 U1 5 U2 17 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1055-9965 J9 CANCER EPIDEM BIOMAR JI Cancer Epidemiol. Biomarkers Prev. PD NOV PY 2012 VL 21 IS 11 BP 2108 EP 2117 DI 10.1158/1055-9965.EPI-12-0740 PG 10 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA 035GP UT WOS:000310931700026 PM 23112268 ER PT J AU Smith, KW Braun, JM Williams, PL Ehrlich, S Correia, KF Calafat, AM Ye, XY Ford, J Keller, M Meeker, JD Hauser, R AF Smith, Kristen W. Braun, Joe M. Williams, Paige L. Ehrlich, Shelley Correia, Katharine F. Calafat, Antonia M. Ye, Xiaoyun Ford, Jennifer Keller, Myra Meeker, John D. Hauser, Russ TI Predictors and Variability of Urinary Paraben Concentrations in Men and Women, Including before and during Pregnancy SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE biomarker; exposure science; female; male; parabens; partners; predictors; pregnancy; variability ID MALE REPRODUCTIVE-SYSTEM; BISPHENOL-A CONCENTRATIONS; PHTHALATE METABOLITE; TEMPORAL VARIABILITY; BUTYL PARABEN; HUMAN HEALTH; HUMANS; PRESERVATIVES; BUTYLPARABEN; EXPOSURE AB BACKGROUND: Parabens are suspected endocrine disruptors and ubiquitous preservatives used in personal care products, pharmaceuticals, and foods. No studies have assessed the variability of parabens in women, including during pregnancy. OBJECTIVE: We evaluated predictors and variability of urinary paraben concentrations. METHODS: We measured urinary concentrations of methyl (MP), propyl (PP), and butyl paraben (BP) among couples from a fertility center. Mixed-effects regression models were fit to examine demographic predictors of paraben concentrations and to calculate intraclass correlation coefficients (ICCs). RESULTS: Between 2005 and 2010, we collected 2,721 spot urine samples from 245 men and 408 women. The median concentrations were 112 mu g/L (MP), 24.2 mu g/L (PP), and 0.70 mu g/L (BP). Urinary MP and PP concentrations were 4.6 and 7.8 times higher in women than men, respectively, and concentrations of both MP and PP were 3.8 times higher in African Americans than Caucasians. MP and PP concentrations we CI re slightly more variable in women (ICC = 0.42, 0.43) than men (ICC = 0.54, 0.51), and were weakly correlated between partners (r = 0.27-0.32). Among 129 pregnant women, urinary paraben concentrations were 25-45% lower during pregnancy than before pregnancy, and MP and PP concentrations were more variable (ICCs of 0.38 and 0.36 compared with 0.46 and 0.44, respectively). CONCLUSIONS: Urinary paraben concentrations were more variable in women compared with men, and during pregnancy compared with before pregnancy. However, results for this study population suggest that a single urine sample may reasonably represent an individual's exposure over several months, and that a single sample collected during pregnancy may reasonably classify gestational exposure. C1 [Smith, Kristen W.; Braun, Joe M.; Ehrlich, Shelley; Ford, Jennifer; Keller, Myra; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Correia, Katharine F.] Brigham & Womens Hosp, Div Reprod Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Meeker, John D.] Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Boston, MA 02114 USA. RP Hauser, R (reprint author), 665 Huntington Ave,Bldg 1,14th Floor, Boston, MA 02115 USA. EM rhauser@hsph.harvard.edu RI Braun, Joseph/H-8649-2014; Ehrlich , Shelley/L-6991-2015; OI Meeker, John/0000-0001-8357-5085 FU National Institute of Environmental Health Sciences, National Institutes of Health [ES009718, ES000002, T32ES007069] FX The work was supported by grants ES009718, ES000002, and T32ES007069 from the National Institute of Environmental Health Sciences, National Institutes of Health. NR 29 TC 53 Z9 53 U1 4 U2 59 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD NOV PY 2012 VL 120 IS 11 BP 1538 EP 1543 DI 10.1289/ehp.1104614 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 036ZE UT WOS:000311070000022 PM 22721761 ER PT J AU Lin, S Hsu, WH Van Zutphen, AR Saha, S Luber, G Hwang, SA AF Lin, Shao Hsu, Wan-Hsiang Van Zutphen, Alissa R. Saha, Shubhayu Luber, George Hwang, Syni-An TI Excessive Heat and Respiratory Hospitalizations in New York State: Estimating Current and Future Public Health Burden Related to Climate Change SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE climate change; extreme heat; morbidity; projection; public health burden; respiratory disease ID HIGH-TEMPERATURES; AIR-POLLUTION; UNITED-STATES; MORTALITY; ADMISSIONS; DISEASES; IMPACTS; MODELS AB BACKGROUND: Although many climate-sensitive environmental exposures are related to mortality and morbidity, there is a paucity of estimates of the public health burden attributable to climate change. OBJECTIVE: We estimated the excess current and future public health impacts related to respiratory hospitalizations attributable to extreme heat in summer in New York State (NYS) overall, its geographic regions, and across different demographic strata. METHODS: On the basis of threshold temperature and percent risk changes identified from our study in NYS, we estimated recent and future attributable risks related to extreme heat due to climate change using the global climate model with various climate scenarios. We estimated effects of extreme high apparent temperature in summer on respiratory admissions, days hospitalized, direct hospitalization costs, and lost productivity from days hospitalized after adjusting for inflation. RESULTS: The estimated respiratory disease burden attributable to extreme heat at baseline (1991-2004) in NYS was 100 hospital admissions, US$644,069 in direct hospitalization costs, and 616 days of hospitalization per year. Projections for 2080-2099 based on three different climate scenarios ranged from 206-607 excess hospital admissions, US$26-$76 million in hospitalization costs, and 1,299-3,744 days of hospitalization per year. Estimated impacts varied by geographic region and population demographics. CONCLUSIONS: We estimated that excess respiratory admissions in NYS due to excessive heat would be 2 to 6 times higher in 2080-2099 than in 1991-2004. When combined with other heat-associated diseases and mortality, the potential public health burden associated with global warming could be substantial. C1 [Lin, Shao; Hsu, Wan-Hsiang; Van Zutphen, Alissa R.; Hwang, Syni-An] New York State Dept Hlth, Ctr Environm Hlth, Albany, NY 12237 USA. [Lin, Shao; Hsu, Wan-Hsiang; Van Zutphen, Alissa R.; Hwang, Syni-An] Univ Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, Rensselaer, NY USA. [Saha, Shubhayu; Luber, George] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Lin, S (reprint author), New York State Dept Hlth, Ctr Environm Hlth, Empire State Plaza,Corning Tower,Room 1203, Albany, NY 12237 USA. EM sxl05@health.state.ny.us OI Lin, Shao/0000-0002-5535-7504 FU Centers for Disease Control and Prevention [5U01EH000396-02, 1U38EH000184-05] FX This study was supported by grants 5U01EH000396-02 and 1U38EH000184-05 from the Centers for Disease Control and Prevention. NR 45 TC 23 Z9 24 U1 2 U2 35 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD NOV PY 2012 VL 120 IS 11 BP 1571 EP 1577 DI 10.1289/ehp.1104728 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 036ZE UT WOS:000311070000027 PM 22922791 ER PT J AU Buttke, DE Sircar, K Martin, C AF Buttke, Danielle E. Sircar, Kanta Martin, Colleen TI Exposures to Endocrine-Disrupting Chemicals and Age of Menarche in Adolescent Girls in NHANES (2003-2008) SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE 2,4-dichlorophenol; endocrine disruptors; menarche; NHANES; reproductive health ID IN-UTERO EXPOSURE; PHTHALATE METABOLITES; UNITED-STATES; ENVIRONMENTAL PHENOLS; PRECOCIOUS PUBERTY; ENDOMETRIAL CANCER; SEXUAL-MATURATION; MASS-SPECTROMETRY; BREAST-CANCER; RISK-FACTORS AB BACKGROUND: The observed age of menarche has fallen, which may have important adverse social and health consequences. Increased exposure to endocrine-disrupting compounds (EDCs) has been associated with adverse reproductive outcomes. OBJECTIVE: Our objective was so assess the relationship between EDC exposure and the age of menarche in adolescent girls. METHODS: We used data from female participants 12-16 years of age who had completed the reproductive health questionnaire and laboratory examination for the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey (NHANES) for years 2003-2008 (2005-2008 for analyses of phthalates and parabens). Exposures were assessed based on creatinine-corrected natural log urine concentrations of selected environmental chemicals and metabolites found in at least 75% of samples in our study sample. We used Cox proportional hazards analysis in SAS 9.2 survey procedures to estimate associations after accounting for censored data among participants who had not reached menarche. We evaluated body mass index (BMI; kilograms per meter squared), family income-to-poverty ratio, race/ethnicity, mother's smoking status during pregnancy, and birth weight as potential confounders. RESULTS: The weighted mean age of menarche was 12.0 years of age. Among 440 girls with both reproductive health and laboratory data, after accounting for BMI and race/ethnicity, we found that 2,5-dichlorophenol (2,5-DCP) and summed environmental phenols (2,5-DCP and 2,4-DCP) were inversely associated with age of menarche [hazard ratios of 1.10; 95% confidence interval (CI): 1.01, 1.19 and 1.09; 95% CI: 1.01, 1.19, respectively]. Other exposures (total parabens, bisphenol A, triclosan, benzophenone-3, total phthalates, and 2,4-DCP) were not significantly associated with age of menarche. CONCLUSIONS: Our findings suggest an association between 2,5-DCP, a potential EDC, and earlier age of menarche in the general U.S. population. C1 [Buttke, Danielle E.; Sircar, Kanta; Martin, Colleen] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Buttke, DE (reprint author), Natl Ctr Environm Hlth, Epidem Intelligence Serv, 4770 Buford Hwy,Mailstop F-57, Chamblee, GA 30341 USA. EM iyk7@cdc.gov FU National Center for Environmental Health, Centers for Disease Control and Prevention (CDC) FX This work was supported by the National Center for Environmental Health, Centers for Disease Control and Prevention (CDC). NR 71 TC 40 Z9 40 U1 7 U2 69 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD NOV PY 2012 VL 120 IS 11 BP 1613 EP 1618 DI 10.1289/ehp.1104748 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 036ZE UT WOS:000311070000033 PM 23124194 ER PT J AU Lenaway, D Perry, HN AF Lenaway, D. Perry, H. N. TI A New Conceptual Model for Public Health System Strengthening SO EUROPEAN JOURNAL OF PUBLIC HEALTH LA English DT Meeting Abstract C1 [Lenaway, D.; Perry, H. N.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. EM DLenaway@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1101-1262 J9 EUR J PUBLIC HEALTH JI Eur. J. Public Health PD NOV PY 2012 VL 22 SU 2 BP 26 EP 26 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 027RH UT WOS:000310370400059 ER PT J AU Perry, HN Lenaway, DD AF Perry, H. N. Lenaway, D. D. TI Capacity Development to Address International Health Regulations (IHR) in Africa SO EUROPEAN JOURNAL OF PUBLIC HEALTH LA English DT Meeting Abstract C1 [Perry, H. N.; Lenaway, D. D.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. EM DLenaway@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1101-1262 J9 EUR J PUBLIC HEALTH JI Eur. J. Public Health PD NOV PY 2012 VL 22 SU 2 BP 26 EP 27 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 027RH UT WOS:000310370400060 ER PT J AU Fekedulegn, D Burchfiel, CM Violanti, JM Hartley, TA Charles, LE Andrew, ME Miller, DB AF Fekedulegn, Desta Burchfiel, Cecil M. Violanti, John M. Hartley, Tara A. Charles, Luenda E. Andrew, Michael E. Miller, Diane B. TI Associations of Long-term Shift Work with Waking Salivary Cortisol Concentration and Patterns among Police Officers SO INDUSTRIAL HEALTH LA English DT Article DE Shift work; Waking; Cortisol; Police; Saliva; HPA-axis ID CARDIOVASCULAR-DISEASE MORBIDITY; LAW-ENFORCEMENT COHORT; PITUITARY-ADRENAL AXIS; CHRONIC STRESS; NURSES; RHYTHM; SLEEP; TOLERANCE; EMERGENCY; RESPONSES AB The objective of this study was to evaluate whether long-term shift work is associated with both the total hormonal secretion after awakening and the pattern of the cortisol levels during the first hour following awakening, among 65 randomly selected police officers who represent a high stress occupation. Dominant shift (Day, Afternoon, or Midnight) was ascertained using daily payroll records of each participant's work activities during the 6-8 yrs prior to saliva sampling. Four salivary samples were collected at 15 min intervals upon first awakening. After accounting for potential confounders, salivary cortisol concentrations averaged across all four time points and total area under the curve differed significantly across shift with midnight shift workers showing suppressed awakening cortisol response relative to the afternoon and day shift. The percent of hours worked on midnight shift was inversely correlated with total awakening cortisol output. In contrast, the pattern of cortisol secretion during the first hour following waking appeared not to be affected as no significant interaction effect was found between time since awakening and shift work. The results show that long-term midnight shift work is associated with decreased absolute mean level and total volume of cortisol released over the waking period. C1 [Fekedulegn, Desta; Burchfiel, Cecil M.; Hartley, Tara A.; Charles, Luenda E.; Andrew, Michael E.] Ctr Dis Control & Prevent, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. [Violanti, John M.] SUNY Buffalo, Dept Social & Prevent Med, Sch Publ Hlth & Hlth Profess, Buffalo, NY 14260 USA. [Miller, Diane B.] Ctr Dis Control & Prevent, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Natl Inst Occupat Safety & Hlth, Atlanta, GA USA. RP Fekedulegn, D (reprint author), Ctr Dis Control & Prevent, Biostat & Epidemiol Branch, Hlth Effects Lab Div, Natl Inst Occupat Safety & Hlth, Atlanta, GA 30333 USA. EM djf7@cdc.gov RI Miller, Diane/O-2927-2013 FU Intramural CDC HHS [CC999999] NR 49 TC 8 Z9 8 U1 1 U2 14 PU NATL INST OCCUPATIONAL SAFETY & HEALTH, JAPAN PI KAWASAKI KANAGAWA PA 21-1 NAGAO 6-CHOME TAMA-KU, KAWASAKI KANAGAWA, 214, JAPAN SN 0019-8366 J9 IND HEALTH JI Ind. Health PD NOV PY 2012 VL 50 IS 6 BP 476 EP 486 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 044CY UT WOS:000311598200003 PM 23047078 ER PT J AU Lowther, SA Johnson, G Hendel-Paterson, B Nelson, K Mamo, B Krohn, K Pessoa-Brandao, L O'Fallon, A Stauffer, W AF Lowther, Sara A. Johnson, Glenise Hendel-Paterson, Brett Nelson, Kailey Mamo, Blain Krohn, Kristina Pessoa-Brandao, Luisa O'Fallon, Ann Stauffer, William TI HIV/AIDS and Associated Conditions among HIV-Infected Refugees in Minnesota, 2000-2007 SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE HIV; acquired immunodeficiency syndrome; refugees; emigration and immigration; epidemiology ID RHODE-ISLAND; TUBERCULOSIS; PREVALENCE AB In 2010, the requirement for human immunodeficiency virus (HIV) testing of adult refugees prior to US resettlement was removed, thus leading to a potential for missed diagnosis. We reviewed refugee health assessment data and medical charts to evaluate the health status of HIV-infected refugees who arrived in Minnesota during 2000-2007, prior to this 2010 policy change. Among 19,292 resettled adults, 174 were HIV-infected; 169 (97%) were African (median age 26.4 (range: 17-76) years). Charts were abstracted for 157 (124 (79%) with >= 1 year of follow-up). At initial presentation, two of 74 (3%) women were pregnant; 27% became pregnant during follow-up. HIV clinical stage varied (59%, asymptomatic; 11%, mild symptoms; 10%, advanced symptoms; 3%, severe symptoms; 17%, unknown); coinfections were common (51 tuberculosis, 13 hepatitis B, 13 parasites, four syphilis). Prior to arrival 4% had received antiretrovirals. Opportunistic infections were diagnosed among 13%; 2% died from AIDS-related causes. Arrival screening may be needed to identify these HIV-infected refugees and prevent HIV-related morbidity and mortality. C1 [Lowther, Sara A.; Nelson, Kailey; Stauffer, William] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Lowther, Sara A.; Johnson, Glenise; Nelson, Kailey; Mamo, Blain; Pessoa-Brandao, Luisa; O'Fallon, Ann] Minnesota Dept Hlth MDH, St Paul, MN 55164 USA. [Hendel-Paterson, Brett; Krohn, Kristina; Stauffer, William] Univ Minnesota, Dept Med Global Hlth, Minneapolis, MN 55455 USA. [Hendel-Paterson, Brett] HealthPartners Reg Hosp, St Paul, MN 55104 USA. RP Lowther, SA (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd,MS A-04, Atlanta, GA 30333 USA. EM sgl6@cdc.gov; glenise.johnson@state.mn.us; bhendel1@gmail.com; kailey.nelson@state.mn.us; blain.mamo@state.mn.us; kmkrohn@gmail.com; lpessoa-brandao@nastad.org; ann.ofallon@gmail.com; stauf005@umn.edu FU CDC [5U38HM000414-04] FX The authors thank David Boulware, Susan B. Reynolds, Kay C. Smith, Donald Stiepan, Ruth Lynfield, and Richard Danila, for their input on this analysis and review of this manuscript. K. Nelson was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists and funded by CDC Cooperative Agreement 5U38HM000414-04. NR 19 TC 2 Z9 2 U1 0 U2 8 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD NOV PY 2012 VL 9 IS 11 BP 4197 EP 4209 DI 10.3390/ijerph9114197 PG 13 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 041TH UT WOS:000311423600026 PM 23202841 ER PT J AU Praamsma, ML Jones, DR Jarrett, JM Dumas, P Cirtiu, CM Parsons, PJ AF Praamsma, Meredith L. Jones, Deanna R. Jarrett, Jeffery M. Dumas, Pierre Cirtiu, Ciprian Mihai Parsons, Patrick J. TI A comparison of clinical laboratory data for assigning a consensus value for manganese in a caprine blood reference material SO JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY LA English DT Article ID ICP-MS; INTELLECTUAL FUNCTION; EXPOSURE; BIOMARKERS; CHILDREN; COEXPOSURE; WATER; LEAD AB Biomonitoring for manganese (Mn) exposure is important due to its potential to cause adverse health effects. In this study, we investigate how different sample preparation methods (dilution, digestion), calibration protocols (aqueous, blood-based, standard additions), and instrumental techniques affect Mn method bias and analytical imprecision. The techniques used included graphite furnace atomic absorption spectrometry (GFAAS), dynamic reaction cell inductively coupled plasma mass spectrometry (DRC-ICP-MS), and sector field (SF-) ICP-MS. We analyzed NIST SRM 1643e Trace Elements in Water and SRM 1598a Inorganic Constituents in Animal Serum (both certified for Mn), and SRM 955c Toxic Metals in Caprine Blood - Level I (not certified for Mn). Various matrix effects in ICP-MS produced inaccurate results for SRM 1643e and discrepant results for SRM 955c. In the absence of a certified value for Mn in SRM 955c, we assigned a "consensus" value by combining data from the New York State Department of Health (NYS), the Centers for Disease Control and Prevention (CDC) and the Centre de toxicologie du Quebec (CTQ). With this interlaboratory approach, we established an "all-lab" consensus value of 16.3 +/- 0.8 mu g L-1 based on data from DRC-ICP-MS with dilution sample preparation and blood-based calibration. We also assigned an "all-method" consensus value of 16.3 +/- 0.9 mu g L-1 based on GFAAS and SF-ICP-MS data from the NYS lab and the DRC-ICP-MS all-lab consensus value. Although the expanded uncertainty (U) calculated for the consensus values may not fully account for all sources of uncertainty, it does show the relative variation that might be expected from one study to the next for the determination of Mn in blood. C1 [Praamsma, Meredith L.; Parsons, Patrick J.] New York State Dept Hlth, Lab Inorgan & Nucl Chem, Wadsworth Ctr, Albany, NY 12201 USA. [Praamsma, Meredith L.; Parsons, Patrick J.] SUNY Albany, Dept Environm Hlth Sci, Sch Publ Hlth, Albany, NY 12201 USA. [Jones, Deanna R.; Jarrett, Jeffery M.] Ctr Dis Control, Inorgan & Radiat Analyt Toxicol Branch, Atlanta, GA 30341 USA. [Dumas, Pierre; Cirtiu, Ciprian Mihai] Inst Natl Sante Publ Quebec, Ctr Toxicol Quebec, Quebec City, PQ G1V 5B3, Canada. RP Parsons, PJ (reprint author), New York State Dept Hlth, Lab Inorgan & Nucl Chem, Wadsworth Ctr, POB 509, Albany, NY 12201 USA. EM pparsons@wadsworth.org OI Jarrett, Jeffery/0000-0001-5755-3552; Parsons, Patrick/0000-0001-9133-875X FU US CDC [U38 EH000464-02] FX The authors are grateful to the staff of the NYS DOH Laboratory of Inorganic and Nuclear Chemistry's Clinical Trace Elements section for advice and technical assistance, and we thank Dr John Arnason for his assistance with SF-ICP-MS. We acknowledge NIST for providing SRM 1643e and 1598a materials for this study, and we are especially grateful to Karen Murphy and Will Guthrie of NIST for many helpful discussions. We also thank Dr Ryszard Gajek of the California Department of Public Health for sharing his insights on SRM 955c. This work was supported in part by Cooperative Agreement Number U38 EH000464-02 from the US CDC. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. NR 23 TC 4 Z9 4 U1 1 U2 13 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0267-9477 J9 J ANAL ATOM SPECTROM JI J. Anal. At. Spectrom. PD NOV PY 2012 VL 27 IS 11 BP 1975 EP 1982 DI 10.1039/c2ja30142e PG 8 WC Chemistry, Analytical; Spectroscopy SC Chemistry; Spectroscopy GA 029FJ UT WOS:000310479900019 PM 26290619 ER PT J AU Mechtler, TP Metz, TF Muller, HG Ostermann, K Ratschmann, R De Jesus, VR Shushan, B Di Bussolo, JM Herman, JL Herkner, KR Kasper, DC AF Mechtler, Thomas P. Metz, Thomas F. Mueller, Hannes G. Ostermann, Katharina Ratschmann, Rene De Jesus, Victor R. Shushan, Bori Di Bussolo, Joseph M. Herman, Joseph L. Herkner, Kurt R. Kasper, David C. TI Short-incubation mass spectrometry assay for lysosomal storage disorders in newborn and high-risk population screening SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES LA English DT Article DE Short-incubation; Lysosomal storage disorders; Multiplex assay; Tandem mass spectrometry; Newborn screening; Turbulent flow chromatography ID DRIED BLOOD SPOTS; POMPE-DISEASE; MUCOPOLYSACCHARIDOSIS-I; KRABBE-DISEASE; ENZYME ASSAYS; FABRY AB The interest in early detection strategies for lysosomal storage disorders (LSDs) in newborns and high-risk population has increased in the last years due to the availability of novel treatment strategies coupled with the development of diagnostic techniques. We report the development of a short-incubation mass spectrometry-based protocol that allows the detection of Gaucher, Niemann-Pick A/B, Pompe, Fabry and mucopolysaccharidosis type I disease within 4h including sample preparation from dried blood spots. Optimized sample handling without the need of time-consuming offline preparations, such as liquid-liquid and solid-phase extraction, allows the simultaneous quantification of five lysosomal enzyme activities using a cassette of substrates and deuterated internal standards. Applying incubation times of 3 h revealed in intra-day CV% values ranging from 4% to 11% for all five enzyme activities, respectively. In a first clinical evaluation, we tested 825 unaffected newborns and 16 patients with LSDs using a multiplexed, turbulent flow chromatography-ultra high performance liquid chromatography-tandem mass spectrometer assay. All affected patients were identified accurately and could be differentiated from non-affected newborns. In comparison to previously published two-day assays, which included an overnight incubation, this protocol enabled the detection of lysosomal enzyme activities from sample to first result within half a day. (C) 2012 Elsevier BM. All rights reserved. C1 [Mechtler, Thomas P.; Metz, Thomas F.; Mueller, Hannes G.; Ostermann, Katharina; Herkner, Kurt R.; Kasper, David C.] Med Univ Vienna, Dept Pediat & Adolescent Med, Res Core Unit Pediat Biochem & Analyt, A-1090 Vienna, Austria. [De Jesus, Victor R.] Ctr Dis Control & Prevent, Newborn Screening & Mol Biol Branch, Atlanta, GA 30341 USA. [Shushan, Bori] Clin Mass Spec Consultants, Toronto, ON M4W 2W6, Canada. [Di Bussolo, Joseph M.; Herman, Joseph L.] Thermo Fisher Sci, Franklin, MA 02038 USA. RP Kasper, DC (reprint author), Med Univ Vienna, Dept Pediat & Adolescent Med, Res Core Unit Pediat Biochem & Analyt, Wahringer Gurtel 18-20, A-1090 Vienna, Austria. EM david.kasper@meduniwien.ac.at RI Kasper, David/B-9054-2012 FU Austrian Mucopolysaccharidosis Research and Patient's Organization FX Support of this work by the Austrian Mucopolysaccharidosis Research and Patient's Organization is gratefully acknowledged. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 27 TC 15 Z9 15 U1 1 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1570-0232 J9 J CHROMATOGR B JI J. Chromatogr. B PD NOV 1 PY 2012 VL 908 BP 9 EP 17 DI 10.1016/j.jchromb.2012.09.012 PG 9 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 038ST UT WOS:000311195100002 PM 23122395 ER PT J AU Michaliszyn, SF Sjaarda, LA Mihalik, SJ Lee, S Bacha, F Chace, DH De Jesus, VR Vockley, J Arslanian, SA AF Michaliszyn, Sara F. Sjaarda, Lindsey A. Mihalik, Stephanie J. Lee, SoJung Bacha, Fida Chace, Donald H. De Jesus, Victor R. Vockley, Jerry Arslanian, Silva A. TI Metabolomic Profiling of Amino Acids and beta-Cell Function Relative to Insulin Sensitivity in Youth SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID OBESE YOUTH; GLUCOSE DYSREGULATION; SECRETION; RESISTANCE; PLASMA; CHILDREN; RANGE; ONSET; MEN AB Context: In longitudinal studies of adults, elevated amino acid (AA) concentrations predicted future type 2 diabetes mellitus (T2DM). Objective: The aim of the present investigation was to examine whether increased plasma AA concentrations are associated with impaired beta-cell function relative to insulin sensitivity [i.e. disposition index (DI)], a predictor of T2DM development. Design, Setting, and Participants: Metabolomic analysis for fasting plasma AAs was performed by tandem mass spectrometry in 139 normal-weight and obese adolescents with and without dysglycemia. First-phase insulin secretion was evaluated by a hyperglycemic (similar to 225 mg/dl) clamp and insulin sensitivity by a hyperinsulinemic-euglycemic clamp. DI was calculated as the product of first-phase insulin and insulin sensitivity. Results: DI was positively associated with branched-chain AAs (leucine/isoleucine and valine; r = 0.27 and 0.29, P = 0.001), neutrally transported AAs (phenylalanine and methionine; r = 0.30 and 0.35, P = 0.001), basic AAs (histidine and arginine; r = 0.28 and 0.23, P <= 0.007), serine (r = 0.35, P < 0.001), glycine (r = 0.26, P = 0.002), and branched-chain AAs-derived intermediates C3, C4, and C5 acylcarnitine (range r = 0.18-0.19, P <= 0.04). Conclusion: In youth, increased plasma AA concentrations are not associated with a heightened metabolic risk profile for T2DM; rather, they are positively associated with beta-cell function relative to insulin sensitivity. These contrasting observations between adults and youth may be a reflection of developmental differences along the lifespan dependent on the combined impact of the aging process together with the impact of progressive obesity. (J Clin Endocrinol Metab 97: E2119-E2124, 2012) C1 [Michaliszyn, Sara F.; Sjaarda, Lindsey A.; Lee, SoJung; Arslanian, Silva A.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Div Weight Management, Med Ctr, Pittsburgh, PA 15224 USA. [Arslanian, Silva A.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Div Pediat Endocrinol Metab & Diabet Mellitus, Med Ctr, Pittsburgh, PA 15224 USA. [Vockley, Jerry] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat & Human Genet, Med Ctr, Pittsburgh, PA 15224 USA. [Vockley, Jerry] Univ Pittsburgh, Grad Sch Publ Hlth, Sch Med, Pittsburgh, PA 15261 USA. [Mihalik, Stephanie J.] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15261 USA. [Bacha, Fida] Baylor Coll Med, Houston, TX 77030 USA. [Chace, Donald H.] Pediatrix Med Grp, Sunrise, FL 33323 USA. [De Jesus, Victor R.] Ctr Dis Control & Prevent, Newborn Screening Qual Assurance Program, Atlanta, GA 30333 USA. RP Arslanian, SA (reprint author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Div Weight Management, Med Ctr, 4401 Penn Ave, Pittsburgh, PA 15224 USA. EM Silva.arslanian@chp.edu FU National Institutes of Health [UL1 RR024153, UL1TR000005, DK54936, R01 HD-27503, K24HD-01357, ROI DK-78775]; Richard L. Day Endowed Chair; Department of Defense FX The project described was supported by the National Institutes of Health through Grants UL1 RR024153 and UL1TR000005, DK54936 (to J.V.), R01 HD-27503 (to S.A.A.), K24HD-01357 (to S.A.A.), ROI DK-78775 (to J.V.), Richard L. Day Endowed Chair (to S.A.A.), and Department of Defense (to S.A. A., S.J.M., L.A.S., and S.L.). NR 24 TC 15 Z9 15 U1 0 U2 17 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0021-972X J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD NOV PY 2012 VL 97 IS 11 BP E2119 EP E2124 DI 10.1210/jc.2012-2170 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 032IT UT WOS:000310710500014 PM 22977272 ER PT J AU Corrigan, JD Cuthbert, JP Whiteneck, GG Dijkers, MP Coronado, V Heinemann, AW Harrison-Felix, C Graham, JE AF Corrigan, John D. Cuthbert, Jeffrey P. Whiteneck, Gale G. Dijkers, Marcel P. Coronado, Victor Heinemann, Allen W. Harrison-Felix, Cynthia Graham, James E. TI Representativeness of the Traumatic Brain Injury Model Systems National Database SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE craniocerebral trauma; methodology; rehabilitation; traumatic brain injury ID FUNCTIONAL INDEPENDENCE MEASURE; INPATIENT REHABILITATION; PROSPECTIVE-PAYMENT; FOLLOW-UP; TBI; HOSPITALIZATION; IMPAIRMENT; DISABILITY; ADULTS AB Objective: To determine whether the Traumatic Brain Injury Model Systems National Database (TBIMS-NDB) is representative of individuals aged 16 years and older admitted for acute, inpatient rehabilitation in the United States with a primary diagnosis of traumatic brain injury (TBI). Design: Secondary analysis of existing data sets. Setting: Acute inpatient rehabilitation facilities. Participants: Patients aged 16 years and older with a primary rehabilitation diagnosis of TBI. Main Outcome Measures: Demographic characteristics, functional status, and hospital length of stay. Results: Patients included in the TBIMS-NDB from October 2001 through December 2007 were largely representative of all individuals 16 years and older admitted for rehabilitation in the United States with a primary diagnosis of TBI. The major difference in distribution was age-the TBIMS-NDB cohort did not include as large a proportion of patients older than 65 years as were admitted for rehabilitation with a primary diagnosis of TBI in the United States. Distributional differences for age-related characteristics were observed; however, groups of patients partitioned at aged 65 years differed minimally, especially within the younger than 65 years subset. Regardless of age, the proportion of patients with a rehabilitation stay of 1 to 9 days was larger nationwide. Nationwide admissions showed an age distribution similar to patients discharged alive from acute care with moderate, severe or penetrating TBI. The proportion of patients aged 70 years and older admitted for TBI rehabilitation in the United States increased every year, a trend that was not evident in the general population, TBIMS-NDB or among TBI patients in acute care. Conclusions: These results provide substantial empirical evidence that the TBIMS-NDB is representative of patients receiving inpatient rehabilitation for TBI in the United States. Researchers utilizing the TBIMS-NDB may want to adjust statistically for the lower percentage of patients older than 65 years or those with stays less than 10 days. C1 [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA. [Cuthbert, Jeffrey P.; Whiteneck, Gale G.; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO USA. [Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. [Coronado, Victor] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA. [Heinemann, Allen W.] Rehabil Inst Chicago, Chicago, IL 60611 USA. [Graham, James E.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX USA. RP Corrigan, JD (reprint author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA. EM corrigan.1@osu.edu RI Corrigan, John/E-2921-2011; Heinemann, Allen /K-6283-2012; OI Heinemann, Allen /0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596 FU National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services; US Department of Education [H133A060038]; TBI Model System Center grants [H133A070022]; Ohio State University [H133A070029]; Mount Sinai School of Medicine [H133A070033]; Rehabilitation Institute of Chicago [H133A080045] FX This research was supported by supplemental grant funding to the Traumatic Brain Injury Model Systems National Data and Statistical Center from the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grant no. H133A060038), as well as TBI Model System Center grants to Craig Hospital (H133A070022), Ohio State University (H133A070029), Mount Sinai School of Medicine (H133A070033), and the Rehabilitation Institute of Chicago (H133A080045). However, the contents do not necessarily represent the policy of the Department of Education, and the reader should not assume endorsement by the Federal Government. This article does not reflect the official policy or opinions of the Centers for Disease Control and Prevention (CDC) or the US Department of Health and Human Services (HHS) and does not constitute an endorsement of the individuals or their programs-by CDC, HHS, or other components of the federal government-and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. NR 24 TC 19 Z9 19 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD NOV-DEC PY 2012 VL 27 IS 6 BP 391 EP 403 DI 10.1097/HTR.0b013e3182238cdd PG 13 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 039CU UT WOS:000311221200010 PM 21897288 ER PT J AU Cuthbert, JP Corrigan, JD Whiteneck, GG Harrison-Felix, C Graham, JE Bell, JM Coronado, VG AF Cuthbert, Jeffrey P. Corrigan, John D. Whiteneck, Gale G. Harrison-Felix, Cynthia Graham, James E. Bell, Jeneita M. Coronado, Victor G. TI Extension of the Representativeness of the Traumatic Brain Injury Model Systems National Database: 2001 to 2010 SO JOURNAL OF HEAD TRAUMA REHABILITATION LA English DT Article DE methodology; rehabilitation; traumatic brain injury AB Objective: To extend the representativeness of the Traumatic Brain Injury Model Systems National Database (TBIMS-NDB) for individuals 16 years and older, admitted for acute, inpatient rehabilitation in the United States with a primary diagnosis of traumatic brain injury (TBI) analyses completed by Corrigan and colleagues by comparing this data set to national data for patients admitted to inpatient rehabilitation with identical inclusion criteria that included 3 additional years of data and 2 new demographic variables. Design: Secondary analysis of existing data sets and extension of previously published analyses. Setting: Acute inpatient rehabilitation facilities. Participants: Patients 16 years and older with a primary rehabilitation diagnosis of TBI; the US TBI Rehabilitation population, n = 156 447; and the TBIMS-NDB population, n = 7373. Interventions: None. Main Outcome Measures: Demographics, functional status, and length of stay in hospital. Results: The TBIMS-NDB was largely representative of patients 16 years and older, admitted for rehabilitation in the United States with a primary diagnosis of TBI on or after October 1, 2001, and discharged as of December 31, 2010. The results of the extended analyses were similar to those reported by Corrigan and colleagues. Age accounted for the largest difference between the samples, with the TBIMS-NDB including a smaller proportion of patients 65 years and older than all those admitted for rehabilitation with a primary diagnosis of TBI in the United States. After partitioning each data set at age 65, most distributional differences found between samples were markedly reduced; however, differences in the preinjury vocational status of the employed and rehabilitation lengths of stay between 1 and 9 days remained robust. The subsamples of patients 64 years and younger were found to differ only slightly on all remaining variables, whereas those 65 years and older were found to have meaningful differences in insurance type and age distribution. Conclusions: These results reconfirm that the TBIMS-NDB is largely representative of patients with TBI receiving inpatient rehabilitation in the United States. Differences between the 2 data sets were found to be stable across the 3 additional years of data, and new differences were limited to those involving newly introduced variables. To use these data for population-based research, it is strongly recommended that statistical adjustment be conducted to account for the lower percentage of patients older than 65 years, inpatient rehabilitation stays less than 10 days, and preinjury vocational status in the TBIMS-NDB. C1 [Cuthbert, Jeffrey P.; Whiteneck, Gale G.; Harrison-Felix, Cynthia] Craig Hosp, Dept Res, Englewood, CO 80113 USA. [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA. [Graham, James E.] Univ Texas Med Branch, Div Rehabil Sci, Galveston, TX USA. [Bell, Jeneita M.; Coronado, Victor G.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Cuthbert, JP (reprint author), Craig Hosp, Dept Res, 3425 S Clarkson St, Englewood, CO 80113 USA. EM JCuthbert@Craighospital.org RI Corrigan, John/E-2921-2011 FU US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention (CDC); National Institute on Disability and Rehabilitation Research (NIDRR) [H133A110006]; US Department of Education; Office of Special Education and Rehabilitative Services; TBI Model System Centers grant from NIDRR [H133A070029]; National Institutes of Health National Center for Medical Rehabilitation Research within the National Institute of Child Health and Human Development [R24 HD065702] FX This research was supported by an intra-agency agreement between the US Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), and the National Institute on Disability and Rehabilitation Research (NIDRR), US Department of Education, Office of Special Education and Rehabilitative Services, with supplemental funding to the NIDRR-funded Traumatic Brain Injury (TBI) Model Systems National Data and Statistical Center (grant H133A110006). It was also supported by a TBI Model System Centers grant (H133A070029) from the NIDRR to Ohio State University and by a grant (R24 HD065702) from the National Institutes of Health National Center for Medical Rehabilitation Research within the National Institute of Child Health and Human Development. This article does not reflect the official policy or opinions of the CDC or the US Department of HHS and does not constitute an endorsement of the individuals or their programs-by CDC, HHS, or other components of the federal government-and none should be inferred. No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors or upon any organization with which the authors are associated. The TBI Model Systems National Database is supported by the NIDRR and created and maintained by the TBI Model Systems Centers Program. However, these contents do not necessarily reflect the opinions or views of the TBI Model Systems Centers, the NIDRR, or the US Department of Education. NR 6 TC 14 Z9 14 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-9701 J9 J HEAD TRAUMA REHAB JI J. Head Trauma Rehabil. PD NOV-DEC PY 2012 VL 27 IS 6 BP E15 EP E27 DI 10.1097/HTR.0b013e31826da983 PG 13 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 039CU UT WOS:000311221200002 PM 23131967 ER PT J AU Hannon, PA Garson, G Harris, JR Hammerback, K Sopher, CJ Clegg-Thorp, C AF Hannon, Peggy A. Garson, Gayle Harris, Jeffrey R. Hammerback, Kristen Sopher, Carrie J. Clegg-Thorp, Catherine TI Workplace Health Promotion Implementation, Readiness, and Capacity Among Midsize Employers in Low-Wage Industries A National Survey SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CLINICAL PREVENTIVE SERVICES; DIRECTIONS-SMALL-BUSINESS; BLUE-COLLAR WORKSITES; REDUCE TOBACCO USE; UNITED-STATES; ORGANIZATIONAL READINESS; WORKING-CLASS; PROGRAMS; OBESITY; INTERVENTIONS AB Objective: To describe workplace health promotion (WHP) implementation, readiness, and capacity among midsize employers in low-wage industries in the United States. Methods: A cross-sectional survey of a national sample of midsize employers (100 to 4999 employees) representing five low-wage industries. Results: Employers' WHP implementation for both employees and employees' spouses and partners was low. Readiness scales showed that employers believe WHP would benefit their employees and their companies, but they were less likely to believe that WHP was feasible for their companies. Employers' capacity to implement WHP was very low; nearly half the sample reported no capacity. Conclusion: Midsize employers in low-wage industries implement few WHP programs; their responses to readiness and capacity measures indicate that low capacity may be one of the principal barriers to WHP implementation. C1 [Hannon, Peggy A.; Garson, Gayle; Harris, Jeffrey R.; Hammerback, Kristen; Sopher, Carrie J.; Clegg-Thorp, Catherine] Univ Washington, Hlth Promot Res Ctr, Ctr Dis Control & Prevent, Res Ctr,Sch Publ Hlth, Seattle, WA 98105 USA. RP Hannon, PA (reprint author), Univ Washington, Hlth Promot Res Ctr, Ctr Dis Control & Prevent, Res Ctr,Sch Publ Hlth, 1107 NE 45th St,Ste 200, Seattle, WA 98105 USA. EM peggyh@uw.edu OI Harris, Jeffrey/0000-0001-8728-7195 FU National Cancer Institute [R21CA136435]; University of Washington Health Promotion Research Center (HPRC); Centers for Disease Control and Prevention research centers [U48 DP001911-01] FX This research was supported by grant R21CA136435 from the National Cancer Institute. Additional research support was provided by the University of Washington Health Promotion Research Center (HPRC), one of the Centers for Disease Control and Prevention research centers (HPRC cooperative agreement number U48 DP001911-01). NR 49 TC 20 Z9 20 U1 1 U2 17 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD NOV PY 2012 VL 54 IS 11 BP 1337 EP 1343 DI 10.1097/JOM.0b013e3182717cf2 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 035BD UT WOS:000310915900005 PM 23090160 ER PT J AU Dunning, KK Adjei, S Levin, L Rohs, AM Hilbert, T Borton, E Kapil, V Rice, C LeMasters, GK Lockey, JE AF Dunning, Kari K. Adjei, Stephen Levin, Linda Rohs, Amy M. Hilbert, Tim Borton, Eric Kapil, Vikas Rice, Carol LeMasters, Grace K. Lockey, James E. TI Mesothelioma Associated With Commercial Use of Vermiculite Containing Libby Amphibole SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID ASBESTOS-CONTAMINATED VERMICULITE; TABLE ANALYSIS SYSTEM; MORTALITY; MONTANA; EXPOSURE; TREMOLITE; MINERS; COHORT; HEALTH AB Objectives: To describe asbestos-related mortality among manufacturing workers who expanded and processed Libby vermiculite that contained amphibole fiber. Methods: Standardized mortality ratio was calculated for 465 white male workers 31 years after last Libby vermiculite exposure. Results: Two workers died from mesothelioma, resulting in a significantly increased standardized mortality ratio of 10.5 (95% confidence interval, 1.3 to 38.0). These workers were in the upper 10th percentile of cumulative fiber exposure, that is, 43.80 and 47.23 fiber-years/cm(3), respectively. One additional worker with cumulative fiber exposure of 5.73 fiber-years/cm(3) developed mesothelioma but is not deceased. There were no other significantly increased standardized mortality ratios. Conclusions: Workers expanding and processing Libby vermiculite in a manufacturing setting demonstrated an increased risk for the development of mesothelioma following exposure to the amphibole fiber contained within this vermiculite ore source. C1 [Dunning, Kari K.; Adjei, Stephen; Levin, Linda; Rohs, Amy M.; Hilbert, Tim; Borton, Eric; Rice, Carol; LeMasters, Grace K.; Lockey, James E.] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA. [Dunning, Kari K.] Univ Cincinnati, Coll Allied Hlth Sci, Dept Rehabil Sci, Cincinnati, OH 45267 USA. [Adjei, Stephen; Rohs, Amy M.; Lockey, James E.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Pulm, Cincinnati, OH 45267 USA. [Kapil, Vikas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Kapil, Vikas] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Atlanta, GA USA. RP Lockey, JE (reprint author), Univ Cincinnati, Coll Med, Dept Environm Hlth, 3223 Eden Ave,ML 0056, Cincinnati, OH 45267 USA. EM james.lockey@uc.edu FU Comprehensive Environmental Response Compensation and Liability Act trust fund; Agency for Toxic Substances and Disease Registry (ATSDR), US Department of Health and Human Services, Centers for Disease Control and Prevention [U50/ATU573006s, 1R01TS000098-1]; National Institute of Environmental Health Sciences [ES10957]; US Environmental Protection Agency Region 8; ATSDR FX This study was supported by funds from the Comprehensive Environmental Response Compensation and Liability Act trust fund through a cooperative agreement with the Agency for Toxic Substances and Disease Registry (ATSDR), US Department of Health and Human Services, Centers for Disease Control and Prevention ATSDR grants U50/ATU573006s and 1R01TS000098-1. In addition, this study was partially supported by the National Institute of Environmental Health Sciences grant ES10957 and by the US Environmental Protection Agency Region 8, as part of the management of the Libby Asbestos Superfund Site.; Drs Lockey, Dunning, and Levin, Mr Hilbert, and Mr Borton received partial funding by a grant from ATSDR. Dr Lockey served as a fact and state-of-the-art witness for the US Department of Justice for the District of Montana, Missoula Division, in the case of United States of America v WR Grace et al. NR 23 TC 10 Z9 10 U1 9 U2 27 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD NOV PY 2012 VL 54 IS 11 BP 1359 EP 1363 DI 10.1097/JOM.0b013e318250b5f5 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 035BD UT WOS:000310915900008 PM 22544163 ER PT J AU Gu, JK Charles, LE Burchfiel, CM Fekedulegn, D Sarkisian, K Andrew, ME Ma, C Violanti, JM AF Gu, Ja K. Charles, Luenda E. Burchfiel, Cecil M. Fekedulegn, Desta Sarkisian, Khachatur Andrew, Michael E. Ma, Claudia Violanti, John M. TI Long Work Hours and Adiposity Among Police Officers in a US Northeast City SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID BODY-MASS INDEX; CORONARY-HEART-DISEASE; METABOLIC SYNDROME; RISK-FACTORS; HEALTHY-MEN; WAIST CIRCUMFERENCE; CARDIOVASCULAR RISK; CORTISOL PATTERNS; SLEEP DURATION; GHRELIN LEVELS AB Objective: To investigate the associations between long work hours and adiposity measures in police officers. Methods: Participants included 408 officers from the Buffalo Cardio-Metabolic Occupational Police Stress study who were examined between 2004 and 2009. Total work hours were abstracted from payroll records and questionnaires. Analysis of variance and covariance models were used. Results: Among male officers who worked the midnight shift, mean values of waist circumference and body mass index increased with longer work hours after adjustment for age, physical activity, energy intake, sleep duration, smoking status, police rank, activities after work (eg, child/family care, sports), and household income. Adiposity measures were not associated with work hours among women on any shift. Conclusion: Working longer hours was significantly associated with larger waist circumferences and higher body mass index among male police officers working the midnight shift. C1 [Gu, Ja K.; Charles, Luenda E.; Burchfiel, Cecil M.; Fekedulegn, Desta; Sarkisian, Khachatur; Andrew, Michael E.; Ma, Claudia] NIOSH, HELD, BEB, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Violanti, John M.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Social & Prevent Med, Buffalo, NY 14260 USA. RP Gu, JK (reprint author), NIOSH, HELD, BEB, Ctr Dis Control & Prevent, Mailstop L-4050,1095Willowdale Rd, Morgantown, WV 26505 USA. EM jgu@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH) [200-2003-01580] FX This work was supported by the National Institute for Occupational Safety and Health (NIOSH), contract 200-2003-01580. NR 65 TC 9 Z9 9 U1 2 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD NOV PY 2012 VL 54 IS 11 BP 1374 EP 1381 DI 10.1097/JOM.0b013e31825f2bea PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 035BD UT WOS:000310915900010 PM 23013913 ER PT J AU Spangler, NW Koesten, J Fox, MH Radel, J AF Spangler, Nancy W. Koesten, Joy Fox, Michael H. Radel, Jeff TI Employer Perceptions of Stress and Resilience Intervention SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID POSITIVE PSYCHOLOGY; HEALTH; WORK; ORGANIZATIONS; DEPRESSION; STRATEGY; EXERCISE; BEHAVIOR; PROGRESS AB Objective: To understand employers' perceived organizational strengths in addressing stress and resilience-building to help expand theoretical knowledge and guide interventions. Methods: Interviews and discussion groups with 46 employer representatives using grounded theory methodology for sampling and analysis of narrative data. Results: Participants detailed three levels of approaches: (1) preventing stress/building resilience; (2) providing information, resources, and benefits to employees; and (3) intervening actively with troubled employees. Preventing stress through trusting work relationships and trust in stability of organizational structures emerged as a core concept explaining effectiveness of these approaches. Results are discussed using positive organizational scholarship, systems, and well-being frameworks. Conclusions: Psychosocial distress has unfavorable effects on human health and work performance. Greater attention to the systemic development and maintenance of trust in workplace relationships and systems is suggested. C1 [Spangler, Nancy W.; Radel, Jeff] Univ Kansas, Med Ctr, Dept Occupat Therapy, Kansas City, KS 66103 USA. [Koesten, Joy] Univ Kansas, Dept Commun Studies, Lawrence, KS 66045 USA. [Fox, Michael H.] Univ Kansas, Med Ctr, Dept Hlth Policy & Management, Kansas City, KS 66103 USA. Ctr Dis Control & Prevent, Div Human Dev & Disabil, Atlanta, GA USA. RP Spangler, NW (reprint author), Spangler Associates Inc, 3401 W 87th St, Leawood, KS 66206 USA. EM nspangler@kc.rr.com NR 78 TC 2 Z9 2 U1 2 U2 27 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD NOV PY 2012 VL 54 IS 11 BP 1421 EP 1429 DI 10.1097/JOM.0b013e3182619038 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 035BD UT WOS:000310915900017 PM 23047656 ER PT J AU Eke, PI Thornton-Evans, G Dye, B Genco, R AF Eke, Paul I. Thornton-Evans, Gina Dye, Bruce Genco, Robert TI Advances in Surveillance of Periodontitis: The Centers for Disease Control and Prevention Periodontal Disease Surveillance Project SO JOURNAL OF PERIODONTOLOGY LA English DT Article DE Chronic periodontitis; nutrition surveys; population surveillance ID POPULATION; VALIDITY; PREVALENCE; VALIDATION; QUESTIONS; HEALTH; NHANES; STATES AB The Centers for Disease Control and Prevention (CDC) has as one of its strategic goals to support and improve surveillance of periodontal disease. In 2003, the CDC initiated the CDC Periodontal Disease Surveillance Project in collaboration with the American Academy of Periodontology to address population-based surveillance of periodontal disease at the local, state, and national levels. This initiative has made significant advancements toward the goal of improved surveillance, including developing valid self-reported measures that can be obtained from interview-based surveys to predict prevalence of periodontitis in populations. This will allow surveillance of periodontitis at the state and local levels and in countries where clinical resources for surveillance are scarce. This work has produced standard case definitions for surveillance of periodontitis that are now widely recognized and applied in population studies and research. At the national level, this initiative has evaluated the validity of previous clinical examination protocols and tested new protocols on the National Health and Nutrition Examination Survey (NHANES), recommending and supporting funding for the gold-standard full-mouth periodontal examination in NHANES 2009 to 2012. These examinations will generate accurate estimates of the prevalence of periodontitis in the US adult population and provide a superior dataset for surveillance and research. Also, this data will be used to generate the necessary coefficients for our self-report questions for use in subsets of the total US population. The impact of these findings on population-based surveillance of periodontitis and future directions of the project are discussed along with plans for dissemination and translation efforts for broader public health use. J Periodontol 2012;83:1337-1342. C1 [Eke, Paul I.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Thornton-Evans, Gina] Ctr Dis Control & Prevent, Div Oral Hlth, Atlanta, GA 30341 USA. [Dye, Bruce] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Hyattsville, MD USA. [Genco, Robert] SUNY Buffalo, Buffalo, NY 14260 USA. RP Eke, PI (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis & Hlth Promot, 4770 Buford Highway,Mailstop E45, Atlanta, GA 30341 USA. EM peke@cdc.gov FU American Academy of Periodontology (AAP); CDC/Division of Oral Health (DOH) FX The authors are grateful to the American Academy of Periodontology (AAP) for its support, contributions, and active role in collaborating with Centers for Disease Control and Prevention (CDC) on this project. In particular, we are grateful to past and present AAP presidents and executive staff who have participated in this project. Also, we are grateful for support from past and present CDC/Division of Oral Health (DOH) leadership for their support on this project. We are most grateful to individual members of the workgroup for volunteering their time and expertise and for providing guidance as the project evolved. Active members of the workgroup have included Robert Genco (State University of New York, Buffalo, New York) workgroup Chair, Paul I. Eke (CDC/DOH) Co-Chair, James Beck (University of North Carolina, Chapel Hill, North Carolina), Gordon Douglass (Past President, AAP, Private practice, Sacramento, California), Roy Page (University of Washington, Seattle, Washington), Gary Slade (University of North Carolina, Chapel Hill, North Carolina), George W. Taylor (University of Michigan, Ann Arbor, Michigan), Bruce Dye (CDC/National Center for Health Statistics [NCHS]), Gina Thornton-Evans (CDC/DOH), Wenche Borgnakke (University of Michigan,), and representatives of AAP executive staff Alice Deforest and Erin O'Donnell Dotzler. Others who have served on this workgroup include Scott Tomar (University of Florida, Gainesville, Florida), Karen Falkner (State University of New York, Buffalo), Kaumudi Joshipura (University of Puerto Rico, San Juan, Puerto Rico), Jeff Hyman (NCHS), Gregg Gilbert (University of Alabama, Birmingham, Alabama), and Lisa LaVange (University of North Carolina). Dr. Eke is the Project Officer for the CDC Periodontal Diseases Surveillance Project, and Dr. Thornton-Evans is the Technical Monitor. NR 29 TC 29 Z9 29 U1 0 U2 14 PU AMER ACAD PERIODONTOLOGY PI CHICAGO PA 737 NORTH MICHIGAN AVENUE, SUITE 800, CHICAGO, IL 60611-2690 USA SN 0022-3492 J9 J PERIODONTOL JI J. Periodont. PD NOV PY 2012 VL 83 IS 11 BP 1337 EP 1342 DI 10.1902/jop.2012.110676 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 039SI UT WOS:000311266400001 PM 22324489 ER PT J AU Carlberg, MM Shapiro-Mendoza, CK Goodman, M AF Carlberg, Michelle M. Shapiro-Mendoza, Carrie K. Goodman, Michael TI Maternal and Infant Characteristics Associated With Accidental Suffocation and Strangulation in Bed in US Infants SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Accidents; Infant sleep position; Asphyxia; SIDS; Infant mortality; Injury ID DEATH-SYNDROME; UNITED-STATES; ADULT BEDS; SUDDEN; SLEEP; RISK; TRENDS; CLASSIFICATION; ENVIRONMENT; PREVENTION AB To identify maternal and infant characteristics associated with accidental suffocation and strangulation in bed (ASSB) in US infants. Using 2000-2002 US linked infant birth and death certificate cohort files, we compared ASSB deaths to survivors. Adjusted odds ratios (aOR) from logistic regression were used to analyze associations between selected maternal and infant characteristics and ASSB mortality. During 2000-2002, 1,064 infants died from ASSB, resulting in an ASSB mortality rate of 9.2 per 100,000 live births. Most ASSB deaths (71%) occurred before an infant reached 4 months old. Maternal factors associated with an increased risk of ASSB were younger age (using maternal age of 25-29 years as reference aOR 2.6 for mothers < 20 years old and 1.6 for mothers 20-24 years old), lower educational attainment (aOR 4.3 for < 12 years and 3.3 for 12 years compared to a parts per thousand yen16 years), multiparity (aOR 1.7, 2.2, and 3.5 for parity 2, 3, and 4 or higher, respectively) and smoking during pregnancy (aOR 2.8). Compared to non-Hispanic whites, non-Hispanic blacks (aOR 1.8) and American Indians (aOR 1.8) were more likely to have an ASSB death. Being male and born preterm were also associated with a higher ASSB mortality risk. Younger, less educated, mulitparous, non-Hispanic black or American Indian women and their families who smoke during their pregnancy and deliver male or preterm infants, may need more intense safe sleeping education during the infant's first year of life, especially during the first 4 months of age. C1 [Shapiro-Mendoza, Carrie K.] Ctr Dis Control & Prevent, Maternal & Infant Hlth Branch, Div Reprod Hlth, Atlanta, GA 30341 USA. [Carlberg, Michelle M.; Goodman, Michael] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Shapiro-Mendoza, CK (reprint author), Ctr Dis Control & Prevent, Maternal & Infant Hlth Branch, Div Reprod Hlth, Mailstop K-23,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM ayn9@cdc.gov NR 25 TC 8 Z9 9 U1 0 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD NOV PY 2012 VL 16 IS 8 BP 1594 EP 1601 DI 10.1007/s10995-011-0855-0 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 042YN UT WOS:000311508900006 PM 21769585 ER PT J AU Lynch, MM Mitchell, EW Williams, JL Brumbaugh, K Jones-Bell, M Pinkney, DE Layton, CM Mersereau, PW Kendrick, JS Medina, PE Smith, LR AF Lynch, Molly M. Mitchell, Elizabeth W. Williams, Jennifer L. Brumbaugh, Kelly Jones-Bell, Michelle Pinkney, Debra E. Layton, Christine M. Mersereau, Patricia W. Kendrick, Juliette S. Medina, Paula Eguino Smith, Lucia Rojas TI Pregnant and Recently Pregnant Women's Perceptions about Influenza A Pandemic (H1N1) 2009: Implications for Public Health and Provider Communication SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE H1N1 virus; Influenza vaccine; Pregnant women; Social marketing ID VACCINATION; PREVENTION; VACCINES AB The objective of this study was to explore pregnant and recently pregnant women's perceptions of influenza vaccine and antivirals during the 2009 H1N1 pandemic. We conducted 18 focus groups with pregnant and recently pregnant women in three US cities in September 2009. Participants were segmented into groups by insurance status (no or public insurance vs. private insurance), vaccine attitudes (higher vs. lower likelihood of acceptance of any vaccines, not only influenza vaccines), and parity (first child vs. other children in the home) based on information they provided on the screening questionnaire at the time of recruitment. We found that women are not well informed about influenza vaccinations and antiviral medicine and have significant concerns about taking them during pregnancy. An interest in their infant's well-being, however, can be strong motivation to adopt preventive recommendations, including vaccination. A woman's health care provider is a highly trusted source of information about the 2009 H1N1. Pregnant women have unique communication needs for influenza. Messages directing pregnant women to adopt public health recommendations, particularly for vaccination or prophylactic medication should include a detailed description of the benefits or lack of risk to the fetus and the safety of breastfeeding. Additionally, messages should recognize that pregnant women are taught to be selective about taking medication and provide a clear rationale for why the medicine or vaccine is necessary. C1 [Lynch, Molly M.; Jones-Bell, Michelle; Pinkney, Debra E.; Layton, Christine M.; Medina, Paula Eguino; Smith, Lucia Rojas] RTI Int, Res Triangle Pk, NC 27709 USA. [Mitchell, Elizabeth W.; Williams, Jennifer L.; Brumbaugh, Kelly; Kendrick, Juliette S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mersereau, Patricia W.] SciMetrika, Durham, NC USA. RP Lynch, MM (reprint author), RTI Int, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA. EM mlynch@rti.org FU PHS HHS [0210637] NR 20 TC 17 Z9 17 U1 0 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD NOV PY 2012 VL 16 IS 8 BP 1657 EP 1664 DI 10.1007/s10995-011-0865-y PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 042YN UT WOS:000311508900012 PM 21822963 ER PT J AU Ahluwalia, IB Morrow, B D'Angelo, D Li, RW AF Ahluwalia, Indu B. Morrow, Brian D'Angelo, Denise Li, Ruowei TI Maternity Care Practices and Breastfeeding Experiences of Women in Different Racial and Ethnic Groups: Pregnancy Risk Assessment and Monitoring System (PRAMS) SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Maternity care practices; PRAMS; Breastfeeding; Race/ethnicity ID UNITED-STATES; COGNITIVE-DEVELOPMENT; RANDOMIZED-TRIAL; HISPANIC WOMEN; 1ST YEAR; HOSPITALS; DURATION; FORMULA; METAANALYSIS; PROMOTION AB Research shows that maternity care practices are important to promoting breastfeeding in the early post partum period; however, little is known about the association between maternity care practices and breastfeeding among different racial and ethnic groups. We examined the association between maternity care practices and breastfeeding duration to a parts per thousand yen10 weeks overall and among various racial and ethnic groups using data from the Pregnancy Risk Assessment and Monitoring System (PRAMS). PRAMS is a state, population-based surveillance system that collects information on maternal behaviors. We used maternity care practices data from 11 states and New York City with response rates a parts per thousand yen70% from 2004 to 2006. Multiple maternity care practices were examined and the analysis adjusted for demographic characteristics, participation in the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), lifestyle, and infant variables. The outcome variable for multivariable analysis was breastfeeding duration to < 10 weeks or a parts per thousand yen10 weeks. PRAMS data show that 22.1% of women did not breastfeed, about 27.7% breastfed for < 10 weeks and 50.2% breastfed for a parts per thousand yen10 weeks. Breastfeeding patterns varied with white and Hispanic women reporting highest breastfeeding initiation and duration prevalence. Overall, practices positively associated with a parts per thousand yen10 duration were: breastfeeding initiated within the first hour after birth (adjusted OR [AOR] = 1.29; 95% CI: 1.16-1.45); fed breast milk only (AOR = 2.40; 95% CI: 2.15-2.68); breastfed on demand (AOR = 1.23; 95% CI 1.08-1.40) and receiving telephone support (AOR = 1.20; 95% CI: 1.03-1.39). Maternity care practices associated with breastfeeding to a parts per thousand yen10 weeks varied across three racial/ethnic groups. One practice, that of giving newborns breast milk only, was positively associated with breastfeeding duration of a parts per thousand yen10 weeks across all three groups. Maternity care practices associated with breastfeeding continuation to a parts per thousand yen10 weeks varied by race/ethnicity. For example: breastfeeding within the first hour, baby given a pacifier, and assistance from hospital staff, were significantly associated with breastfeeding duration among black and white women and not Hispanics. The practice of breastfeeding on demand was significantly associated with breastfeeding to a parts per thousand yen10 weeks for black and Hispanic women and not for whites. Hospitals may want to examine the implementation of specific practices in relation to the cultural backgrounds of women to promote breastfeeding. C1 [Ahluwalia, Indu B.; Morrow, Brian; D'Angelo, Denise] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Li, Ruowei] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ahluwalia, IB (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mail Stop K-22, Atlanta, GA 30341 USA. EM Iahluwalia@cdc.gov NR 33 TC 14 Z9 15 U1 0 U2 20 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD NOV PY 2012 VL 16 IS 8 BP 1672 EP 1678 DI 10.1007/s10995-011-0871-0 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 042YN UT WOS:000311508900014 PM 21847676 ER PT J AU Hwang, SS Smith, VC McCormick, MC Barfield, WD AF Hwang, Sunah S. Smith, Vincent C. McCormick, Marie C. Barfield, Wanda D. TI The Association between Maternal Oral Health Experiences and Risk of Preterm Birth in 10 States, Pregnancy Risk Assessment Monitoring System, 2004-2006 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Maternal oral health; Preterm birth; Dental care during pregnancy ID PERIODONTAL-DISEASE; DENTAL-CARE; BACTERIAL VAGINOSIS; UNITED-STATES; DELIVERY; POPULATION; WOMEN; CORONARY; PRAMS AB The aim of this study is to investigate the association between oral health experiences of women in the peripartum period and the risk of preterm delivery (< 37 weeks). We analyzed 2004-2006 data from the CDC Pregnancy Risk Assessment Monitoring System (PRAMS), a population-based surveillance system that collects data on pregnancy and postpartum experiences of mothers who have recently delivered a live infant. Ten states included in the analysis had a a parts per thousand yen70% weighted response rate and three standard questions pertaining to oral health. White non-Hispanic (WNH), Black non-Hispanic (BNH), and Hispanic women were selected for analysis. Chi-squared analysis was performed for our bivariate analysis and multivariate logistic regression models were created to calculate adjusted odds ratios, controlling for socio-demographic characteristics and peripartum morbidities. Weighted percentages and standard errors were used for all analyses. Among the 35,267 women studied, in the multivariate analysis, mothers who did not receive dental care during pregnancy and did not have a teeth cleaning during pregnancy were at higher risk for delivering a preterm infant (OR 1.15, CI 1.02-1.30; OR 1.23, CI 1.08-1.41). In this population-based study, women who did not receive dental care or have a teeth cleaning during pregnancy were at slightly higher risk for preterm delivery after adjustment for pertinent confounders. C1 [Hwang, Sunah S.; Smith, Vincent C.] Childrens Hosp, Div Newborn Med, Dept Neonatol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [McCormick, Marie C.] Harvard Univ, Dept Soc Human Dev & Hlth, Harvard Sch Publ Hlth, Sch Med, Boston, MA 02115 USA. [Barfield, Wanda D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Hwang, SS (reprint author), Childrens Hosp, Div Newborn Med, Dept Neonatol, Beth Israel Deaconess Med Ctr, 300 Longwood Ave,Enders 961, Boston, MA 02115 USA. EM sunah.hwang@childrens.harvard.edu; Vsmith1@bidmc.harvard.edu; mmccormi@hsph.harvard.edu; wbarfield@cdc.gov OI McCormmick, Marie/0000-0002-3938-1707 FU Intramural CDC HHS [CC999999] NR 30 TC 2 Z9 2 U1 1 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD NOV PY 2012 VL 16 IS 8 BP 1688 EP 1695 DI 10.1007/s10995-011-0870-1 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 042YN UT WOS:000311508900016 PM 21847677 ER PT J AU Zhang, YJ Cohen, B Macaluso, M Zhang, Z Durant, T Nannini, A AF Zhang, Yujia Cohen, Bruce Macaluso, Maurizio Zhang, Zi Durant, Tonji Nannini, Angela TI Probabilistic Linkage of Assisted Reproductive Technology Information with Vital Records, Massachusetts 1997-2000 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Assisted reproductive technology; Birth-infant death file; Probabilistic linkage ID BIRTH AB To assess the validity of probabilistic linkage (PL) in combining national surveillance data on assisted reproductive technology (ART) with Massachusetts birth and infant death data, for the purpose of monitoring maternal and child health outcomes of ART. A study conducted in 2006 utilized direct identifiers to match Massachusetts birth records with records on ART procedures performed to Massachusetts residents in fertility clinics located in Massachusetts and Rhode Island, achieving a linkage rate of 87.5%. The present study employed PL using the program Link Plus, without access to direct identifiers. The primary linking variables were maternal and infant dates of birth, and plurality. Ancillary variables such as maternal ZIP code and gravidity helped resolve duplicate matches and capture additional matches. PL linked 5,390 (87.8%) of 6,139 deliveries, correctly identifying 96.4% of the matches previously obtained using deterministic linkage methods. PL yielded a high linkage rate with satisfactory validity; this method may be applied in other states to help monitor the maternal and child health outcomes of ART. C1 [Zhang, Yujia; Macaluso, Maurizio; Durant, Tonji] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Cohen, Bruce; Zhang, Zi; Nannini, Angela] Massachusetts Dept Publ Hlth, Boston, MA USA. [Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. [Zhang, Zi] Univ Massachusetts, Sch Med, Shrewsbury, MA USA. [Durant, Tonji] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30341 USA. [Nannini, Angela] Univ Massachusetts, Lowell, MA USA. RP Zhang, YJ (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway NE,MS K34, Atlanta, GA 30341 USA. EM YZhang2@cdc.gov RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 NR 16 TC 20 Z9 20 U1 0 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD NOV PY 2012 VL 16 IS 8 BP 1703 EP 1708 DI 10.1007/s10995-011-0877-7 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 042YN UT WOS:000311508900018 PM 21909704 ER PT J AU Gargis, AS Kalman, L Berry, MW Bick, DP Dimmock, DP Hambuch, T Lu, F Lyon, E Voelkerding, KV Zehnbauer, BA Agarwala, R Bennett, SF Chen, B Chin, ELH Compton, JG Das, S Farkas, DH Ferber, MJ Funke, BH Furtado, MR Ganova-Raeva, LM Geigenmuller, U Gunselman, SJ Hegde, MR Johnson, PLF Kasarskis, A Kulkarni, S Lenk, T Liu, CSJ Manion, M Manolio, TA Mardis, ER Merker, JD Rajeevan, MS Reese, MG Rehm, HL Simen, BB Yeakley, JM Zook, JM Lubin, IM AF Gargis, Amy S. Kalman, Lisa Berry, Meredith W. Bick, David P. Dimmock, David P. Hambuch, Tina Lu, Fei Lyon, Elaine Voelkerding, Karl V. Zehnbauer, Barbara A. Agarwala, Richa Bennett, Sarah F. Chen, Bin Chin, Ephrem L. H. Compton, John G. Das, Soma Farkas, Daniel H. Ferber, Matthew J. Funke, Birgit H. Furtado, Manohar R. Ganova-Raeva, Lilia M. Geigenmueller, Ute Gunselman, Sandra J. Hegde, Madhuri R. Johnson, Philip L. F. Kasarskis, Andrew Kulkarni, Shashikant Lenk, Thomas Liu, C. S. Jonathan Manion, Megan Manolio, Teri A. Mardis, Elaine R. Merker, Jason D. Rajeevan, Mangalathu S. Reese, Martin G. Rehm, Heidi L. Simen, Birgitte B. Yeakley, Joanne M. Zook, Justin M. Lubin, Ira M. TI Assuring the quality of next-generation sequencing in clinical laboratory practice SO NATURE BIOTECHNOLOGY LA English DT Letter C1 [Gargis, Amy S.; Kalman, Lisa; Zehnbauer, Barbara A.; Chen, Bin; Lubin, Ira M.] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Atlanta, GA 30333 USA. [Berry, Meredith W.; Lu, Fei] SeqWright Inc, Houston, TX USA. [Bick, David P.; Dimmock, David P.] Med Coll Wisconsin, Dept Pediat, Div Genet, Milwaukee, WI 53226 USA. [Hambuch, Tina] Illumina Clin Serv, San Diego, CA USA. [Lyon, Elaine; Voelkerding, Karl V.] Univ Utah, Dept Pathol, Salt Lake City, UT USA. [Lyon, Elaine; Voelkerding, Karl V.] ARUP Labs, Inst Clin & Expt Pathol, Salt Lake City, UT USA. [Agarwala, Richa] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20892 USA. [Bennett, Sarah F.] Ctr Medicare & Medicaid Serv, Div Lab Serv, Baltimore, MD USA. [Chin, Ephrem L. H.; Hegde, Madhuri R.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA. [Compton, John G.] GeneDx Inc, Gaithersburg, MD USA. [Das, Soma] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA. [Farkas, Daniel H.] Sequenom Ctr Mol Med Inc, Grand Rapids, MI USA. [Ferber, Matthew J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Funke, Birgit H.; Rehm, Heidi L.] Partners Healthcare Ctr Personalized Genet Med, Mol Med Lab, Cambridge, MA USA. [Funke, Birgit H.; Rehm, Heidi L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Furtado, Manohar R.] Life Technol, Foster City, CA USA. [Ganova-Raeva, Lilia M.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Geigenmueller, Ute] Correlagen Diagnost Inc, Waltham, MA USA. [Gunselman, Sandra J.] Kailos Genet Inc, Huntsville, AL USA. [Johnson, Philip L. F.] Emory Univ, Dept Biol, Atlanta, GA 30322 USA. [Kasarskis, Andrew] Pacific Biosci, Menlo Pk, CA USA. [Kulkarni, Shashikant] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA. [Kulkarni, Shashikant] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA. [Kulkarni, Shashikant] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA. [Lenk, Thomas] Celera Corp, Alameda, CA USA. [Liu, C. S. Jonathan; Manion, Megan] Softgenet LLC, State Coll, PA USA. [Manolio, Teri A.] NHGRI, NIH, Bethesda, MD 20892 USA. [Mardis, Elaine R.] Washington Univ, Genome Ctr, St Louis, MO USA. [Mardis, Elaine R.] Washington Univ, Dept Genet & Mol Microbiol, St Louis, MO USA. [Merker, Jason D.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA. [Rajeevan, Mangalathu S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Reese, Martin G.] Omica Inc, Emeryville, CA USA. [Simen, Birgitte B.] A Roche Co, Life Sci 454, Branford, CT USA. [Yeakley, Joanne M.] Illumina Inc, San Diego, CA USA. [Zook, Justin M.] Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA. RP Gargis, AS (reprint author), Ctr Dis Control & Prevent, Div Lab Sci & Stand, Atlanta, GA 30333 USA. EM ILubin@cdc.gov RI Zook, Justin/B-7000-2008; Dimmock, David/I-7913-2015 OI Zook, Justin/0000-0003-2309-8402; Dimmock, David/0000-0001-6690-2523 FU NHGRI NIH HHS [R44 HG006579] NR 4 TC 180 Z9 183 U1 0 U2 30 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD NOV PY 2012 VL 30 IS 11 BP 1033 EP 1036 DI 10.1038/nbt.2403 PG 4 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA 037FL UT WOS:000311087500014 PM 23138292 ER PT J AU Ahmed, SA Awosika, J Baldwin, C Bishop-Lilly, KA Biswas, B Broomall, S Chain, PSG Chertkov, O Chokoshvili, O Coyne, S Davenport, K Detter, JC Dorman, W Erkkila, TH Folster, JP Frey, KG George, M Gleasner, C Henry, M Hill, KK Hubbard, K Insalaco, J Johnson, S Kitzmiller, A Krepps, M Lo, CC Luu, T McNew, LA Minogue, T Munk, CA Osborne, B Patel, M Reitenga, KG Rosenzweig, CN Shea, A Shen, XH Strockbine, N Tarr, C Teshima, H van Gieson, E Verratti, K Wolcott, M Xie, G Sozhamannan, S Gibbons, HS AF Ahmed, Sanaa A. Awosika, Joy Baldwin, Carson Bishop-Lilly, Kimberly A. Biswas, Biswajit Broomall, Stacey Chain, Patrick S. G. Chertkov, Olga Chokoshvili, Otar Coyne, Susan Davenport, Karen Detter, J. Chris Dorman, William Erkkila, Tracy H. Folster, Jason P. Frey, Kenneth G. George, Matroner Gleasner, Cheryl Henry, Matthew Hill, Karen K. Hubbard, Kyle Insalaco, Joseph Johnson, Shannon Kitzmiller, Aaron Krepps, Michael Lo, Chien-Chi Truong Luu McNew, Lauren A. Minogue, Timothy Munk, Christine A. Osborne, Brian Patel, Mohit Reitenga, Krista G. Rosenzweig, C. Nicole Shea, April Shen, Xiaohong Strockbine, Nancy Tarr, Cheryl Teshima, Hazuki van Gieson, Eric Verratti, Kathleen Wolcott, Mark Xie, Gary Sozhamannan, Shanmuga Gibbons, Henry S. CA Threat Characterization Consortium TI Genomic Comparison of Escherichia coli O104:H4 Isolates from 2009 and 2011 Reveals Plasmid, and Prophage Heterogeneity, Including Shiga Toxin Encoding Phage stx2 SO PLOS ONE LA English DT Article ID HEMOLYTIC-UREMIC SYNDROME; SALMONELLA-TYPHIMURIUM; AGGREGATIVE ADHERENCE; GADE YHIE; BACTERIOPHAGES; RESISTANCE; PATHOGENS; SEQUENCES; ALIGNMENT; OUTBREAK AB In May of 2011, an enteroaggregative Escherichia coli O104:H4 strain that had acquired a Shiga toxin 2-converting phage caused a large outbreak of bloody diarrhea in Europe which was notable for its high prevalence of hemolytic uremic syndrome cases. Several studies have described the genomic inventory and phylogenies of strains associated with the outbreak and a collection of historical E. coli O104: H4 isolates using draft genome assemblies. We present the complete, closed genome sequences of an isolate from the 2011 outbreak (2011C-3493) and two isolates from cases of bloody diarrhea that occurred in the Republic of Georgia in 2009 (2009EL-2050 and 2009EL-2071). Comparative genome analysis indicates that, while the Georgian strains are the nearest neighbors to the 2011 outbreak isolates sequenced to date, structural and nucleotide-level differences are evident in the Stx2 phage genomes, the mer/tet antibiotic resistance island, and in the prophage and plasmid profiles of the strains, including a previously undescribed plasmid with homology to the pMT virulence plasmid of Yersinia pestis. In addition, multiphenotype analysis showed that 2009EL-2071 possessed higher resistance to polymyxin and membrane-disrupting agents. Finally, we show evidence by electron microscopy of the presence of a common phage morphotype among the European and Georgian strains and a second phage morphotype among the Georgian strains. The presence of at least two stx2 phage genotypes in host genetic backgrounds that may derive from a recent common ancestor of the 2011 outbreak isolates indicates that the emergence of stx2 phage-containing E. coli O104: H4 strains probably occurred more than once, or that the current outbreak isolates may be the result of a recent transfer of a new stx2 phage element into a pre-existing stx2-positive genetic background. C1 [Broomall, Stacey; Hubbard, Kyle; Insalaco, Joseph; Krepps, Michael; McNew, Lauren A.; Rosenzweig, C. Nicole; Gibbons, Henry S.] USA, Edgewood Chem Biol Ctr, Aberdeen Proving Ground, MD USA. [Ahmed, Sanaa A.; Chain, Patrick S. G.; Chertkov, Olga; Davenport, Karen; Detter, J. Chris; Erkkila, Tracy H.; Gleasner, Cheryl; Hill, Karen K.; Johnson, Shannon; Lo, Chien-Chi; Munk, Christine A.; Reitenga, Krista G.; Shen, Xiaohong; Teshima, Hazuki; Xie, Gary] Los Alamos Natl Lab, Los Alamos, NM USA. [Awosika, Joy; Bishop-Lilly, Kimberly A.; Biswas, Biswajit; Frey, Kenneth G.; George, Matroner; Henry, Matthew; Truong Luu; Patel, Mohit; Verratti, Kathleen; Sozhamannan, Shanmuga] USN, Med Res Ctr, Frederick, MD USA. [Awosika, Joy; Bishop-Lilly, Kimberly A.; Biswas, Biswajit; Frey, Kenneth G.; George, Matroner; Henry, Matthew; Truong Luu; Patel, Mohit; Verratti, Kathleen; Sozhamannan, Shanmuga] Henry M Jackson Fdn Mil Med, Frederick, MD USA. [Baldwin, Carson; Coyne, Susan; Dorman, William; Minogue, Timothy; Shea, April; Wolcott, Mark] USA, Res Inst Infect Dis, Frederick, MD USA. [Chokoshvili, Otar] Natl Ctr Dis Control & Publ Hlth, S Caucasus Field Epidemiol & Lab Training Program, Tbilisi, Rep of Georgia. [Folster, Jason P.; Strockbine, Nancy; Tarr, Cheryl] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. [Hubbard, Kyle; Krepps, Michael] Excet Inc, Springfield, VA USA. [Insalaco, Joseph] Sci Applicat Int Corp, Abingdon, MD USA. [Kitzmiller, Aaron; Osborne, Brian] BioTeam Inc, Middleton, MA USA. [Shea, April] Team Keaki Tech, Frederick, MD USA. [van Gieson, Eric] Def Threat Reduct Agcy, Alexandria, VA USA. RP Gibbons, HS (reprint author), USA, Edgewood Chem Biol Ctr, Aberdeen Proving Ground, MD USA. EM henry.s.gibbons.civ@mail.mil RI chain, patrick/B-9777-2013; OI Johnson, Shannon/0000-0002-3972-9208; Chain, Patrick/0000-0003-3949-3634; xie, gary/0000-0002-9176-924X FU Defense Threat Reduction Agency [CB2847, IB06RSQ002] FX The work presented here was supported by the Defense Threat Reduction Agency (www.dtra.mil) Transformational Medical Technologies program under project numbers CB2847 to HSG and CNR; IB06RSQ002 to SS; and to JCD. The funding agency participated in the formation of the consortium but did not impact the collection of data, analysis, decision to publish, or preparation of the manuscript. NR 90 TC 38 Z9 40 U1 1 U2 36 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 1 PY 2012 VL 7 IS 11 AR e48228 DI 10.1371/journal.pone.0048228 PG 22 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 030WR UT WOS:000310601300006 PM 23133618 ER PT J AU Margulis, AV Mitchell, AA Gilboa, SM Werler, MM Mittleman, MA Glynn, RJ Hernandez-Diaz, S AF Margulis, Andrea V. Mitchell, Allen A. Gilboa, Suzanne M. Werler, Martha M. Mittleman, Murray A. Glynn, Robert J. Hernandez-Diaz, Sonia CA Natl Birth Defects Prevention TI Use of topiramate in pregnancy and risk of oral clefts SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE antiepileptic drugs; birth defects; cleft lip; oral clefts; topiramate ID MAJOR CONGENITAL-MALFORMATIONS; BIRTH-DEFECTS PREVENTION; FOLIC-ACID ANTAGONISTS; ANTIEPILEPTIC DRUGS; UK-EPILEPSY; PRELIMINARY EXPERIENCE; IN-UTERO; EXPOSURE; REGISTER; WOMEN AB OBJECTIVE: The objective of this study was to evaluate the association between the use of monotherapy topiramate in pregnancy and cleft lip with or without cleft palate (CL/P) in the offspring. STUDY DESIGN: Data from the Slone Epidemiology Center Birth Defects Study (BDS) from 1997 to 2009 and the National Birth Defects Prevention Study (NBDPS) from 1997 to 2007 were analyzed. Conditional logistic regression was used to compare the first-trimester use of topiramate monotherapy to no antiepileptic drug use during the periconceptional period between the mothers of infants with CL/P and the mothers of controls for each study separately and in pooled data. RESULTS: The BDS contained 785 CL/P cases and 6986 controls; the NBDPS contained 2283 CL/P cases and 8494 controls. The odds ratios (exact 95% confidence intervals) for the association between topiramate use and CL/P were 10.1 (1.1-129.2) in the BDS, 3.6 (0.7-20.0) in the NBDPS, and 5.4 (1.5-20.1) in the pooled data. CONCLUSION: First-trimester use of topiramate may be associated with CL/P. C1 [Margulis, Andrea V.; Mittleman, Murray A.; Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Mitchell, Allen A.; Werler, Martha M.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Mittleman, Murray A.] Beth Israel Deaconess Med Ctr, Cardiovasc Epidemiol Res Unit, Boston, MA 02215 USA. [Glynn, Robert J.] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA. [Gilboa, Suzanne M.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Margulis, AV (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave,Kresge Bldg, Boston, MA 02115 USA. EM andreamargulis@post.harvard.edu RI Margulis, Andrea/G-2833-2013; OI Margulis, Andrea/0000-0001-7388-6082; Mitchell, Allen/0000-0003-0950-6799; Werler, Martha/0000-0003-3392-6814 FU Centers for Disease Control and Prevention through the Massachusetts Department of Public Health [U50/CCU113247]; Centers for Disease Control and Prevention [PA 96043, PA 02081, FOA DD09-001]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01 HD 046595] FX This study was supported by cooperative agreement number U50/CCU113247 from the Centers for Disease Control and Prevention to the Slone Epidemiology Center through the Massachusetts Department of Public Health; cooperative agreements under PA 96043, PA 02081, and FOA DD09-001 from the Centers for Disease Control and Prevention to the Centers for Birth Defects Research and Prevention participating in the National Birth Defects Prevention Study; and grant R01 HD 046595 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 36 TC 9 Z9 9 U1 0 U2 9 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD NOV PY 2012 VL 207 IS 5 AR 405.e1 DI 10.1016/j.ajog.2012.07.008 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 030JM UT WOS:000310567000027 PM 22917484 ER PT J AU Okoroh, EM Hooper, WC Atrash, HK Yusuf, HR Boulet, SL AF Okoroh, Ekwutosi M. Hooper, W. Craig Atrash, Hani K. Yusuf, Hussain R. Boulet, Sheree L. TI Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003-2008 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE polycystic ovary syndrome; prevalence; venous thromboembolism ID DEEP-VEIN THROMBOSIS; CORONARY-ARTERY-DISEASE; PULMONARY-EMBOLISM; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; METABOLIC SYNDROME; WHITE WOMEN; POPULATION; PREVALENCE; ASSOCIATION AB OBJECTIVE: We sought to determine prevalence and likelihood of venous thromboembolism (VTE) among women with and without polycystic ovary syndrome (PCOS). STUDY DESIGN: We performed a cross-sectional analysis using Thomson Reuters MarketScan Commercial databases for the years 2003 through 2008. The association between VTE and PCOS among women aged 18-45 years was assessed using age-stratified multivariable logistic regression models. RESULTS: Prevalence of VTE per 100,000 was 374.2 for PCOS women and 193.8 for women without PCOS. Compared with women without PCOS, those with PCOS were more likely to have VTE (adjusted odds ratio [aOR] 18-24 years, 3.26; 95% confidence interval [CI], 2.61-4.08; aOR 25-34 years, 2.39; 95% CI, 2.12-2.70; aOR 35-45 years, 2.05; 95% CI, 1.84 -2.38). A protective association (odds ratio, 0.8; 95% CI, 0.73-0.98) with oral contraceptive use was noted for PCOS women. CONCLUSION: PCOS might be a predisposing condition for VTE, particularly among women aged 18-24 years. Oral contraceptive use might be protective. C1 [Okoroh, Ekwutosi M.; Hooper, W. Craig; Atrash, Hani K.; Yusuf, Hussain R.; Boulet, Sheree L.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Okoroh, EM (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E64, Atlanta, GA 30333 USA. EM Eokoroh@cdc.gov FU Intramural CDC HHS [CC999999] NR 39 TC 0 Z9 0 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD NOV PY 2012 VL 207 IS 5 AR 377.e1 DI 10.1016/j.ajog.2012.08.007 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 030JM UT WOS:000310567000015 PM 22959762 ER PT J AU Styn, MA Wang, J Acharya, SD Yang, K Chasens, ER Choo, J Ye, L Burke, LE AF Styn, Midi A. Wang, Jing Acharya, Sushama D. Yang, Kyeongra Chasens, Eileen R. Choo, Jina Ye, Lei Burke, Lora E. TI Health-related quality of life among participants in the SMART weight loss trial SO APPLIED NURSING RESEARCH LA English DT Article ID OVERWEIGHT AB Obesity has been associated with a decreased health-related quality of life (HRQoL); however, the association between weight change and HRQoL is unclear. This secondary analysis of the SMART (Self Monitoring And Recording using Technology) trial, a clinical trial of behavioral weight loss treatment, provides evidence that quality of life improves with weight loss. (C) 2012 Elsevier Inc. All rights reserved. C1 [Styn, Midi A.; Wang, Jing; Yang, Kyeongra; Chasens, Eileen R.; Ye, Lei; Burke, Lora E.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [Acharya, Sushama D.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30341 USA. [Choo, Jina] Korea Univ, Coll Nursing, Seoul 136705, South Korea. RP Styn, MA (reprint author), Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. EM mimst31@pitt.edu; Jing.Wang@uth.tmc.edu; Vgk3@cdc.gov; yangk@pitt.edu; chasense@pitt.edu; jinachoo@gmail.com; Ley9@pitt.edu; Lbu100@pitt.edu FU National Institutes of Health (NIH) [RO1-DK71817]; NIH [NR010742]; Data Management Core of the Center for Research in Chronic Disorders, NIH-NINR [P30-NR03924]; General Clinical Research Center, NIH-NCRR-GCRC [5MO1-RR00056]; Clinical Translational Research Center, NIH/NCRR/CTSA at the University of Pittsburgh [UL1 RR024153] FX This study was supported by National Institutes of Health (NIH) Grant RO1-DK71817 and partial support for L. E. Burke by NIH K24 Award (NR010742). The conduct of the study was also supported by the Data Management Core of the Center for Research in Chronic Disorders, NIH-NINR #P30-NR03924; the General Clinical Research Center, NIH-NCRR-GCRC #5MO1-RR00056; and the Clinical Translational Research Center, NIH/NCRR/CTSA Grant UL1 RR024153, at the University of Pittsburgh. NR 16 TC 4 Z9 4 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0897-1897 J9 APPL NURS RES JI Appl. Nurs. Res. PD NOV PY 2012 VL 25 IS 4 BP 276 EP 279 DI 10.1016/j.apnr.2011.08.001 PG 4 WC Nursing SC Nursing GA 035FJ UT WOS:000310928400009 PM 22079745 ER PT J AU Zhang, P Brown, MB Bilik, D Ackermann, RT Li, R Herman, WH AF Zhang, Ping Brown, Morton B. Bilik, Dori Ackermann, Ronald T. Li, Rui Herman, William H. TI Health Utility Scores for People With Type 2 Diabetes in U.S. Managed Care Health Plans Results from Translating Research Into Action for Diabetes (TRIAD) SO DIABETES CARE LA English DT Article ID QUALITY-OF-LIFE; UNITED-STATES; EQ-5D; VALUES; COMPLICATIONS; SAMPLE AB OBJECTIVE-To estimate the health utility scores associated with type 2 diabetes, its treatments, complications, and comorbidities. RESEARCH DESIGN AND METHODS-We analyzed health-related quality-of-life data, collected at baseline during Translating Research Into Action for Diabetes, a multicenter, prospective, observational study of diabetes care in managed care, for 7,327 individuals with type 2 diabetes. We measured quality-of-life using the EuroQol (EQ)-5D, a standardized instrument for which 1.00 indicates perfect health. We used multivariable regression to estimate the independent impact of demographic characteristics, diabetes treatments, complications, and comorbidities on health-related quality-of-life. RESULTS-The mean EQ-5D-derived health utility score for those individuals with diabetes was 0.80. The modeled utility score for a nonobese, non-insulin-treated, non-Asian, non-Hispanicman with type 2 diabetes, with an annual household income of more than $40,000, and with no diabetes complications, risk factors for cardiovascular disease, or comorbidities, was 0.92. Being a woman, being obese, smoking, and having a lower household income were associated with lower utility scores. Arranging complications from least to most severe according to the reduction in health utility scores resulted in the following order: peripheral vascular disease, other heart diseases, transient ischemic attack, cerebral vascular accident, nonpainful diabetic neuropathy, congestive heart failure, dialysis, hemiplegia, painful neuropathy, and amputation. CONCLUSIONS-Major diabetes complications and comorbidities are associated with decreased health-related quality-of-life. Utility estimates from our study can be used to assess the impact of diabetes on quality-of-life and conduct cost-utility analyses. Diabetes Care 35: 2250-2256, 2012 C1 [Zhang, Ping; Li, Rui] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30329 USA. [Brown, Morton B.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Bilik, Dori; Herman, William H.] Univ Michigan Hlth Syst, Dept Internal Med & Epidemiol, Ann Arbor, MI USA. [Ackermann, Ronald T.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA. RP Zhang, P (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30329 USA. EM paz2@cdc.gov FU Centers for Disease Control and Prevention, Division of Diabetes Translation [04005]; National Institute of Diabetes and Digestive and Kidney Diseases; Biostatistics and Economic Modeling Core of the Michigan Diabetes Research Training Center from the National Institute of Diabetes and Digestive and Kidney Diseases [P60DK020572] FX This study was jointly funded by Program Announcement No. 04005 from the Centers for Disease Control and Prevention, Division of Diabetes Translation, and the National Institute of Diabetes and Digestive and Kidney Diseases. Additional support was provided by the Biostatistics and Economic Modeling Core of the Michigan Diabetes Research Training Center, Grant No. P60DK020572 from the National Institute of Diabetes and Digestive and Kidney Diseases. NR 23 TC 19 Z9 20 U1 2 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD NOV PY 2012 VL 35 IS 11 BP 2250 EP 2256 DI 10.2337/dc11-2478 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 041TM UT WOS:000311424100027 PM 22837369 ER PT J AU Salmon, D Yih, WK Lee, G Rosofsky, R Brown, J Vannice, K Tokars, J Roddy, J Ball, R Gellin, B Lurie, N Koh, H Platt, R Lieu, T AF Salmon, Daniel Yih, W. Katherine Lee, Grace Rosofsky, Robert Brown, Jeffrey Vannice, Kirsten Tokars, Jerome Roddy, James Ball, Robert Gellin, Bruce Lurie, Nicole Koh, Howard Platt, Richard Lieu, Tracy CA PRISM Program Grp TI Success Of Program Linking Data Sources To Monitor H1N1 Vaccine Safety Points To Potential For Even Broader Safety Surveillance SO HEALTH AFFAIRS LA English DT Article ID ADVERSE EVENTS; IMMUNIZATION; PROJECT; NETWORK; SYSTEM; FOOD AB In response to the 2009 H1N1 pandemic and subsequent vaccination program, the Department of Health and Human Services and collaborators developed the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) Program as a demonstration project to detect rare adverse events rapidly. The program monitored three million people who had received the H1N1 vaccine by linking data from large private health plans and from public immunization registries that had originally not been designed to share data, and on a larger scale than had been previously attempted. The program generated safety data in two weeks rather than three to six monty 10ths-the standard time frame achievable using health plan data. PRISM substantially contributed to the understanding of the safety of H1N1 vaccines. Its use in the case of H1N1 highlights the necessity of proactive planning, scalable infrastructure, and public-private partnerships in tracking adverse events after vaccination in epidemics. It also illustrates how data could be integrated to produce policy-relevant information for other medical products. C1 [Salmon, Daniel] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21205 USA. [Yih, W. Katherine; Brown, Jeffrey; Platt, Richard] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Rosofsky, Robert] Hlth Informat Syst Consulting, Milton, MA USA. [Vannice, Kirsten] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Tokars, Jerome] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Roddy, James] Consulting firm CSC, Falls Church, VA USA. [Ball, Robert] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA. [Gellin, Bruce] Dept Hlth & Human Serv HHS, Washington, DC USA. [Lurie, Nicole; Koh, Howard] HHS, Washington, DC USA. [Lieu, Tracy] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. RP Salmon, D (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21205 USA. EM dsalmon@jhsph.edu NR 19 TC 6 Z9 6 U1 1 U2 4 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD NOV PY 2012 VL 31 IS 11 BP 2518 EP 2527 DI 10.1377/hlthaff.2012.0104 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 036LH UT WOS:000311026900020 PM 23129683 ER PT J AU Auchincloss, AH Moore, KAB Moore, LV Roux, AVD AF Auchincloss, Amy H. Moore, Kari A. B. Moore, Latetia V. Roux, Ana V. Diez TI Improving retrospective characterization of the food environment for a large region in the United States during a historic time period SO HEALTH & PLACE LA English DT Article DE Residence characteristics; Validity; Reliability; Food; Geography; Environment ID COMMERCIAL DATA SOURCES; BODY-MASS INDEX; NEIGHBORHOOD CHARACTERISTICS; STORE AVAILABILITY; PHYSICAL-ACTIVITY; HEALTHY FOODS; ASSOCIATIONS; DISPARITIES; VALIDATION; ACCURACY AB Access to healthy foods has received increasing attention due to growing prevalence of obesity and diet-related health conditions yet there are major obstacles in characterizing the local food environment. This study developed a method to retrospectively characterize supermarkets for a single historic year, 2005, in 19 counties in 6 states in the USA using a supermarket chain-name list and two business databases. Data preparation, merging, overlaps, added-value amongst various approaches and differences by census tract area-level socio-demographic characteristics are described. Agreement between two food store databases was modest: 63%. Only 55% of the final list of supermarkets were identified by a single business database and selection criteria that included industry classification codes and sales revenue >=$2 million. The added-value of using a supermarket chain-name list and second business database was identification of an additional 14% and 30% of supermarkets, respectively. These methods are particularly useful to retrospectively characterize access to supermarkets during a historic period and when field observations are not feasible and business databases are used. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Auchincloss, Amy H.] Drexel Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Moore, Kari A. B.; Roux, Ana V. Diez] Univ Michigan, Dept Epidemiol, Ctr Social Epidemiol & Populat Hlth, Ann Arbor, MI 48109 USA. [Moore, Latetia V.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Auchincloss, AH (reprint author), Drexel Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA. EM aha27@drexel.edu; kbrunn@umich.edu; lvmoore@cdc.gov; adiezrou@umich.edu FU National Heart, Lung, and Blood Institute at the National Institutes of Health [2R01 HL071759] FX this research was supported by Grant 2R01 HL071759 from National Heart, Lung, and Blood Institute at the National Institutes of Health. NR 53 TC 16 Z9 16 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8292 J9 HEALTH PLACE JI Health Place PD NOV PY 2012 VL 18 IS 6 BP 1341 EP 1347 DI 10.1016/j.healthplace.2012.06.016 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 037XW UT WOS:000311140800017 PM 22883050 ER PT J AU Cox, CR Rees, JC Voorhees, KJ AF Cox, Christopher R. Rees, Jon C. Voorhees, Kent J. TI Modeling bacteriophage amplification as a predictive tool for optimized MALDI-TOF MS-based bacterial detection SO JOURNAL OF MASS SPECTROMETRY LA English DT Article DE bacteriophage amplification; bacterial detection; in silico modeling; MALDI-TOF MS; Yersinia pestis; Escherichia coli ID FLIGHT-MASS-SPECTROMETRY; ASSISTED-LASER-DESORPTION/IONIZATION; MYCOBACTERIUM-TUBERCULOSIS; THERAPY; IDENTIFICATION; PATHOGENS AB Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is a valuable tool for rapid bacterial detection and identification but is limited by the need for relatively high cell count samples, which have been grown under strictly controlled conditions. These requirements can be eliminated by the natural infection of a viable bacterial species of interest with a host-specific phage. This produces a rapid increase in phage protein concentrations in comparison to bacterial concentrations, which can in turn be exploited as a method for signal amplification during MALDI-TOF MS. One drawback to this approach is the requirement for repetitive, time-consuming sample preparation and analysis applied over the course of a phage infection to monitor phage concentrations as a function of time to determine the MALDI-TOF MS detection limit. To reduce the requirement for repeated preparation and analysis, a modified phage therapy model was investigated as a means for predicting the time during a given phage infection when a detectable signal would occur. The modified model used a series of three differential equations composed of predetermined experimental parameters including phage burst size and burst time to predict progeny phage concentrations as a function of time. Using Yersinia pestis with plague diagnostic phage phi A1122 and Escherichia coli with phage MS2 as two separate, well-characterized model phagehost pairs, we conducted in silico modeling of the infection process and compared it with experimental infections monitored in real time by MALDI-TOF MS. Significant agreement between mathematically calculated phage growth curves and those experimentally obtained by MALDI-TOF MS was observed, thus verifying this method's utility for significant time and labor reduction. Copyright (c) 2012 John Wiley & Sons, Ltd. C1 [Cox, Christopher R.; Voorhees, Kent J.] Colorado Sch Mines, Dept Chem & Geochem, Golden, CO 80401 USA. [Rees, Jon C.] Ctr Dis Control, Atlanta, GA 30333 USA. RP Voorhees, KJ (reprint author), Colorado Sch Mines, Dept Chem, Golden, CO 80401 USA. EM kvoorhee@mines.edu FU Armed Forces Institute of Pathology; Defense Threat Reduction Agency [W81XWH-07-C-0061] FX We wish to thank the Armed Forces Institute of Pathology and the Defense Threat Reduction Agency for funding this work (W81XWH-07-C-0061). The authors also thank the Centers for Disease Control Division of Vector-borne Infectious Diseases for kindly providing Yersinia pestis A1122 and bacteriophage phi A1122. We also wish to thank Drs. Mark Eberhart and Travis Jones for their generous assistance with computational analysis. NR 26 TC 2 Z9 2 U1 0 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1076-5174 J9 J MASS SPECTROM JI J. Mass Spectrom. PD NOV PY 2012 VL 47 IS 11 BP 1435 EP 1441 DI 10.1002/jms.3087 PG 7 WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy GA 037HP UT WOS:000311093400007 PM 23147819 ER PT J AU Schrijver, I Aziz, N Farkas, DH Furtado, M Gonzalez, AF Greiner, TC Grody, WW Hambuch, T Kalman, L Kant, JA Klein, RD Leonard, DGB Lubin, IM Mao, R Nagan, N Pratt, VM Sobel, ME Voelkerding, KV Gibson, JS AF Schrijver, Iris Aziz, Nazneen Farkas, Daniel H. Furtado, Manohar Gonzalez, Andrea Ferreira Greiner, Timothy C. Grody, Wayne W. Hambuch, Tina Kalman, Lisa Kant, Jeffrey A. Klein, Roger D. Leonard, Debra G. B. Lubin, Ira M. Mao, Rong Nagan, Narasimhan Pratt, Victoria M. Sobel, Mark E. Voelkerding, Karl V. Gibson, Jane S. TI Opportunities and Challenges Associated with Clinical Diagnostic Genome Sequencing A Report of the Association for Molecular Pathology SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Article ID QUALITY ASSESSMENT SCHEME; RECOMBINANT-DNA; CANCER GENOME; COMMON DISEASE; BREAST-CANCER; MUTATIONS; RISK; MEDICINE; GENES; ELECTROPHORESIS AB This report of the Whole Genome Analysis group of the Association for Molecular Pathology illuminates the opportunities and challenges associated with clinical diagnostic genome sequencing. With the reality of clinical application of next-generation sequencing, technical aspects of molecular testing can be accomplished at greater speed and with higher volume, while much information is obtained. Although this testing is a next logical step for molecular pathology laboratories, the potential impact on the diagnostic process and clinical correlations is extraordinary and clinical interpretation will be challenging. We review the rapidly evolving technologies; provide application examples; discuss aspects of clinical utility, ethics, and consent; and address the analytic, postanalytic, and professional implications. (J Mol Diagn 2012, 14:525-540; http://dx.doi.org/10.1016/j.jmoldx.2012.04.006) C1 [Schrijver, Iris] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA. [Schrijver, Iris] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA. [Schrijver, Iris; Aziz, Nazneen; Farkas, Daniel H.; Furtado, Manohar; Gonzalez, Andrea Ferreira; Greiner, Timothy C.; Grody, Wayne W.; Hambuch, Tina; Kalman, Lisa; Kant, Jeffrey A.; Klein, Roger D.; Leonard, Debra G. B.; Lubin, Ira M.; Mao, Rong; Nagan, Narasimhan; Pratt, Victoria M.; Sobel, Mark E.; Voelkerding, Karl V.; Gibson, Jane S.] Assoc Mol Pathol Clin Practice Comm, Whole Genome Anal Working Grp, Bethesda, MD USA. [Aziz, Nazneen] Coll Amer Pathologists, Dept Transformat, Program Off, Northfield, IL USA. [Farkas, Daniel H.] Sequenom Ctr Mol Med, Dept Clin Diagnost, Grand Rapids, MI USA. [Furtado, Manohar] Life Technol, Dept Mol Med, Foster City, CA USA. [Gonzalez, Andrea Ferreira] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA USA. [Greiner, Timothy C.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA. [Grody, Wayne W.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles Sch Med, Los Angeles, CA USA. [Hambuch, Tina] Illumina Clin Serv Lab, San Diego, CA USA. [Kalman, Lisa; Lubin, Ira M.] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Atlanta, GA USA. [Kant, Jeffrey A.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA. [Klein, Roger D.] Med Coll Wisconsin, BloodCtr Wisconsin, Milwaukee, WI 53226 USA. Med Coll Wisconsin, Depanment Pathol, Milwaukee, WI 53226 USA. [Leonard, Debra G. B.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA. [Mao, Rong] Univ Utah, Dept Pathol, ARUP Labs, Salt Lake City, UT USA. [Nagan, Narasimhan] Esoterix Genet Labs LLC, Westborough, MA USA. [Pratt, Victoria M.] Nichols Inst, Chantilly, VA USA. [Sobel, Mark E.] Amer Soc Invest Pathol, Bethesda, MD USA. [Voelkerding, Karl V.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA. [Voelkerding, Karl V.] ARUP Inst Expt & Clin Pathol, Salt Lake City, UT USA. [Gibson, Jane S.] Univ Cent Florida, Coll Med, Dept Clin Sci Pathol, Orlando, FL 32816 USA. RP Schrijver, I (reprint author), Stanford Univ, Dept Pathol, Sch Med, 300 Pasteur Dr,Room L235, Stanford, CA 94305 USA. EM ischrijver@stanfordmed.org FU Association for Molecular Pathology FX Supported by the Association for Molecular Pathology. NR 80 TC 55 Z9 56 U1 2 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2012 VL 14 IS 6 BP 525 EP 540 DI 10.1016/j.jmoldx.2012.04.006 PG 16 WC Pathology SC Pathology GA 025HG UT WOS:000310178600001 PM 22918138 ER PT J AU Morton, S Saydah, S Cleary, SD AF Morton, Suzanne Saydah, Sharon Cleary, Sean D. TI Consistency with the Dietary Approaches to Stop Hypertension Diet among Adults with Diabetes SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Diabetes; Hypertension; Dietary Approaches to Stop Hypertension (DASH) diet ID CARDIOVASCULAR-DISEASE RISK; BLOOD-PRESSURE; MICROVASCULAR COMPLICATIONS; DASH DIET; TRIAL; ASSOCIATION; MANAGEMENT; HABITS; SODIUM; WOMEN AB Few studies have documented whether the dietary patterns of adults with diabetes are similar to the Dietary Approaches to Stop Hypertension (DASH) diet. Our objective was to determine differences in the degree of consistency with the DASH diet among adults with self-reported diabetes (with and without self-reported high blood pressure) compared with those without either disease. It was a cross-sectional study using data from 5,867 nonpregnant, noninstitutionalized adults aged >= 20 years with two reliable 24-hour recall dietary interviews in the National Health and Nutrition Examination Survey during 2003-2004 and 2005-2006. Diabetes and hypertension status were obtained from a questionnaire, and degree of consistency with the DASH diet was calculated based on nine nutrient targets (0- to 9-point DASH score). Multiple linear regression (adjusting for age, energy intake, and other covariates such as education, race, and body mass index) was performed to compare mean DASH scores and mean nutrient intakes among adults with diabetes, with and without high blood pressure, to those without either disease. No statistically significant differences were seen in mean DASH score among the three groups in the unadjusted or fully adjusted multivariable models. Compared with adults without either disease, those with only diabetes had higher intakes of fiber (8.1 g/1,000 kcal vs 7.6 g/1,000 kcal; P=0.02) and total fat as a percentage of total energy (35.3% vs 34.1%; P=0.006), and those with both diabetes and hypertension had higher sodium intake (153.0% of DASH target vs 146.6%; P=0.04). This information about individual nutrients could help guide the development of education programs. J Acad Nutr Diet. 2012;112:1798-1805. C1 [Saydah, Sharon] Ctr Dis Control & Prevent, Div Diabet Translat, Hyattsville, MD 20782 USA. [Morton, Suzanne; Cleary, Sean D.] George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC USA. [Morton, Suzanne] Natl Comm Qual Assurance, Washington, DC USA. RP Saydah, S (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM Ssaydah@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 2 Z9 2 U1 1 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD NOV PY 2012 VL 112 IS 11 BP 1798 EP 1805 DI 10.1016/j.jand.2012.06.364 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 033RT UT WOS:000310819200012 PM 23102178 ER PT J AU Hall, IJ Rim, SH Johnson-Turbes, CA Vanderpool, R Kamalu, NN AF Hall, Ingrid J. Rim, Sun Hee Johnson-Turbes, C. Ashani Vanderpool, Robin Kamalu, Ngozi N. TI The African American Women and Mass Media Campaign: A CDC Breast Cancer Screening Project SO JOURNAL OF WOMENS HEALTH LA English DT Article ID PREVENTIVE SERVICES; INTERVENTIONS; DISPARITIES; RADIO AB For decades, black radio has reached African American communities with relevant, culturally appropriate information, and it continues to be an ideal communication channel to use for contemporary health promotion. In an effort to combat excess breast cancer mortality rates and help eliminate cancer disparities among low-income African American women, the Centers for Disease Control and Prevention's (CDC) Division of Cancer Prevention and Control designed, implemented, and evaluated the African American Women and Mass Media (AAMM) pilot campaign. The AAMM campaign uses black radio, radio stations with broad African American listenership, as a platform for targeted, culturally competent health promotion and outreach to low-income, African American women. The AAMM campaign uses radio advertisements and print materials disseminated in predominantly African American neighborhoods to promote awareness of breast cancer, early detection, and the CDC's National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Evaluation of the AAMM campaign found that the campaign successfully reached its target audience of low-income, African American women and increased women's awareness of breast cancer screening services through the Breast and Cervical Cancer Program in Savannah and Macon, Georgia. C1 [Hall, Ingrid J.; Rim, Sun Hee] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Johnson-Turbes, C. Ashani; Kamalu, Ngozi N.] ICF Macro, Atlanta, GA USA. [Vanderpool, Robin] Univ Kentucky, Coll Publ Hlth, Dept Hlth Behav, Lexington, KY USA. RP Hall, IJ (reprint author), Ctr Dis Prevent, Div Canc Prevent & Control, 4770 Buford Highway,MS K-55, Atlanta, GA 30341 USA. EM ihall@cdc.gov FU Centers for Disease Control and Prevention, Division of Cancer Prevention and Control [200-2002-00574] FX We acknowledge the assistance of Yasmine Zavahir for her contribution to AAMM campaign implementation and evaluation, Devon Welsh and Heather Ryan for creation and finalization of figures, and local health department staff in Savannah and Macon, GA, for recruitment of screened women into focus groups. This work was supported by Centers for Disease Control and Prevention, Division of Cancer Prevention and Control (contract No. 200-2002-00574). NR 21 TC 9 Z9 10 U1 1 U2 17 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD NOV PY 2012 VL 21 IS 11 BP 1107 EP 1113 DI 10.1089/jwh.2012.3903 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 034BI UT WOS:000310844700001 PM 23072329 ER PT J AU Saraiya, M Watson, M Benard, VB AF Saraiya, Mona Watson, Meg Benard, Vicki B. TI Cervical Cancer Screening Measures Need to Evolve to Continue to Tell the Story SO JOURNAL OF WOMENS HEALTH LA English DT Editorial Material ID NEOPLASIA; SOCIETY C1 [Saraiya, Mona; Watson, Meg; Benard, Vicki B.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30341 USA. RP Saraiya, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, 4770 Buford Highway,NE MS K-55, Atlanta, GA 30341 USA. EM msaraiya@cdc.gov NR 12 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD NOV PY 2012 VL 21 IS 11 BP 1128 EP 1129 DI 10.1089/jwh.2012.3994 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 034BI UT WOS:000310844700003 PM 23072328 ER PT J AU SteelFisher, GK Blendon, RJ Ward, JRM Rapoport, R Kahn, EB Kohl, KS AF SteelFisher, Gillian K. Blendon, Robert J. Ward, Johanna R. M. Rapoport, Robyn Kahn, Emily B. Kohl, Katrin S. TI Public response to the 2009 influenza A H1N1 pandemic: a polling study in five countries SO LANCET INFECTIOUS DISEASES LA English DT Article ID TELEPHONE SURVEY; UNITED-STATES; VACCINATION; ATTITUDES; BEHAVIOR; INTERVENTIONS; NONRESPONSE; IMPACT AB Background Many important strategies to reduce the spread of pandemic influenza need public participation. To assess public receptivity to such strategies, we compared adoption of preventive behaviours in response to the 2009 H1N1 influenza pandemic among the public in five countries and examined whether certain non-pharmaceutical behaviours (such as handwashing) were deterrents to vaccination. We also assessed public support for related public health recommendations. Methods We used data from simultaneous telephone polls (mobile telephone and landline) in Argentina, Japan, Mexico, the UK, and the USA. In each country, interviews were done in a nationally representative sample of adults, who were selected by the use of random digit dial techniques. The questionnaire asked people whether or not they had adopted each of various preventive behaviours (non-pharmaceutical such as personal protective and social distancing behaviour or vaccinations) to protect themselves or their family from H1N1 at any point during the pandemic. Two-tailed t tests were used for statistical analysis. Findings 900 people were surveyed in each country except the USA where 911 people were contacted. There were wide differences in the adoption of preventive behaviours between countries, although certain personal protective behaviours (eg, handwashing) were more commonly adopted than social distancing behaviours (eg, avoiding places where many people gather) across countries (53-89% vs 11-69%). These non-pharmaceutical behaviours did not reduce the likelihood of getting vaccinated in any country. There was also support across all countries for government recommendations related to school closure, avoiding places where many people gather, and wearing masks in public. Interpretation There is a need for country-specific approaches in pandemic policy planning that use both non-pharmaceutical approaches and vaccination. C1 [SteelFisher, Gillian K.; Blendon, Robert J.; Ward, Johanna R. M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Blendon, Robert J.] Harvard Univ, John F Kennedy Sch Govt, Malcolm Wiener Ctr Social Policy, Cambridge, MA 02138 USA. [Rapoport, Robyn] Social Sci Res Solut, Media, PA USA. [Kahn, Emily B.] Ctr Dis Control & Prevent, Div State & Local Readiness, Off Preparedness, Off Publ Hlth Preparedness & Emergency Response, Atlanta, GA USA. [Kohl, Katrin S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP SteelFisher, GK (reprint author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. EM gsteel@hsph.harvard.edu OI Kahn, Emily/0000-0001-7812-7958 FU US Centers for Disease Control and Prevention; National Public Health Information Coalition FX Funding US Centers for Disease Control and Prevention and the National Public Health Information Coalition. NR 30 TC 20 Z9 22 U1 4 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD NOV PY 2012 VL 12 IS 11 BP 845 EP 850 DI 10.1016/S1473-3099(12)70206-2 PG 6 WC Infectious Diseases SC Infectious Diseases GA 029JT UT WOS:000310492300023 PM 23041199 ER PT J AU He, XQ Ma, Q AF He, Xiaoqing Ma, Qiang TI Redox Regulation by Nuclear Factor Erythroid 2-Related Factor 2: Gatekeeping for the Basal and Diabetes-Induced Expression of Thioredoxin-Interacting Protein SO MOLECULAR PHARMACOLOGY LA English DT Article ID ADENOSINE-CONTAINING MOLECULES; ANTIOXIDANT RESPONSE ELEMENT; BETA-CELL APOPTOSIS; OXIDATIVE STRESS; NAD(P)H-QUINONE OXIDOREDUCTASE; KEAP1-NRF2 PATHWAY; TXNIP EXPRESSION; GLUCOSE; NRF2; COMPLICATIONS AB Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor activated by a range of oxidants and electrophiles. The transcriptional response to endogenous oxidative cues by Nrf2 plays an important role in mammalian redox physiology and oxidative pathology. Hyperglycemia induces oxidative stress in the heart where it leads to apoptosis and ultimately cardiomyopathy. Here we investigated the mechanism by which Nrf2 suppresses oxidative stress in diabetic mouse heart. Knockout (KO) of Nrf2 induced oxidative stress and apoptosis in KO heart; diabetes further increased oxidative damage. A pathway-focused gene array revealed that Nrf2 controls the expression of 24 genes in the heart, including the gene encoding thioredoxin-interacting protein (TXNIP). Nrf2 suppressed the basal expression of Txnip in the heart and blocked induction of Txnip by high glucose by binding to an antioxidant response element (ARE) (-1286 to -1276) of the Txnip promoter. Binding of Nrf2 to ARE also suppressed the binding of MondoA to the carbohydrate response element with or without high glucose. TXNIP promoted reactive oxygen species production and apoptosis by inhibiting thioredoxin. On the other hand, Nrf2 boosted thioredoxin activity by inhibiting Txnip. The findings revealed, for the first time, that Nrf2 is a key gatekeeper of Txnip transcription, suppressing both its basal expression and MondoA-driven induction to control the thioredoxin redox signaling in diabetes. C1 [He, Xiaoqing; Ma, Qiang] NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Morgantown, WV USA. RP Ma, Q (reprint author), Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM qam1@cdc.gov FU National Institute for Occupational Safety and Health FX This work was supported by the National Institute for Occupational Safety and Health. NR 46 TC 23 Z9 25 U1 2 U2 7 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0026-895X J9 MOL PHARMACOL JI Mol. Pharmacol. PD NOV PY 2012 VL 82 IS 5 BP 887 EP 897 DI 10.1124/mol.112.081133 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 037WS UT WOS:000311137800011 PM 22869588 ER PT J AU Taveras, EM McDonald, J O'Brien, A Haines, J Sherry, B Bottino, CJ Troncoso, K Schmidt, ME Koziol, R AF Taveras, Elsie M. McDonald, Julia O'Brien, Ashley Haines, Jess Sherry, Bettylou Bottino, Clement J. Troncoso, Karen Schmidt, Marie Evans Koziol, Renata TI Healthy Habits, Happy Homes: Methods and baseline data of a randomized controlled trial to improve household routines for obesity prevention SO PREVENTIVE MEDICINE LA English DT Article DE Routines; Behavior change; Home-based interventions; Obesity; Overweight; Children ID INCOME PRESCHOOL-CHILDREN; SUGAR-SWEETENED BEVERAGES; LIFE RISK-FACTORS; BODY-MASS INDEX; PHYSICAL-ACTIVITY; SLEEP DURATION; US CHILDREN; CHILDHOOD OBESITY; AGED CHILDREN; FAMILY DINNER AB Objective. To develop a home-based intervention for parents of 2-5 year old children to promote household routines to prevent overweight/obesity. Methods. We recruited 121 children from health centers in Boston between 2011 and 2012 and randomized 62 to intervention and 59 to the control condition. The 6-month intervention included 1) motivational coaching at home and by phone with a health educator, 2) mailed educational materials, and 3) weekly text messages. The intervention promoted three household routines: eating meals as a family, obtaining adequate sleep, and limiting screen time. Results. Of the 121 children, mean (SD) age was 4.0 (1.1) years; 52% were Hispanic, 34% Black, and 14% White/Other. Nearly 60% of the sample had annual household incomes <= $20,000. Approximately 64% of families reported eating together >= 7 times per week, however, many meals were eaten in front of a TV. Over half of the children slept less than the recommended 11 h/night and 78% viewed >= 2 h/day of screen time. Conclusions. Household routines that increase obesity risk were prevalent among low-income families in this study. If proven to be effective, promotion of household routines related to family meals, sleep, and screen time may prevent young children from becoming overweight/obese. Clinical Trials Registration Number: NCT01565161. (C) 2012 Elsevier Inc. All rights reserved. C1 [Taveras, Elsie M.] Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Obes Prevent Program,Dept Populat Med, Boston, MA 02215 USA. [Taveras, Elsie M.; Bottino, Clement J.; Schmidt, Marie Evans] Childrens Hosp Boston, Dept Med, Boston, MA USA. [Haines, Jess] Univ Guelph, Dept Family Relat & Appl Nutr, Guelph, ON N1G 2W1, Canada. [Sherry, Bettylou] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Taveras, EM (reprint author), Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Obes Prevent Program,Dept Populat Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA. EM Elsie_Taveras@harvardpilgrim.org FU NCCDPHP CDC HHS [1U48DP00194] NR 43 TC 10 Z9 10 U1 7 U2 53 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD NOV PY 2012 VL 55 IS 5 BP 418 EP 426 DI 10.1016/j.ypmed.2012.08.016 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 036VT UT WOS:000311061100014 PM 22960162 ER PT J AU Roberts, RM Hicks, LA AF Roberts, Rebecca M. Hicks, Lauri A. TI Appropriate Antibiotic Use: Family Physicians Have the Power of the Pen SO AMERICAN FAMILY PHYSICIAN LA English DT Editorial Material ID UNITED-STATES; PRIMARY-CARE; INFECTIONS C1 [Roberts, Rebecca M.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Roberts, RM (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM RMRoberts@cdc.gov NR 8 TC 2 Z9 2 U1 0 U2 2 PU AMER ACAD FAMILY PHYSICIANS PI KANSAS CITY PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA SN 0002-838X J9 AM FAM PHYSICIAN JI Am. Fam. Physician PD NOV 1 PY 2012 VL 86 IS 9 BP 810 EP 810 PG 1 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 033TO UT WOS:000310824200005 PM 23113459 ER PT J AU Bilous, RW Gonzalez-Campoy, JM Fradkin, JE Mauer, M Molitch, ME Narva, AS Nelson, RG Sharma, K Tuttle, KR Rocco, MV Berns, JS Wilt, TJ Ishani, A Rector, TS Slinin, Y Fitzgerald, P Carlyle, M AF Bilous, Rudolf W. Gonzalez-Campoy, J. Michael Fradkin, Judith E. Mauer, Michael Molitch, Mark E. Narva, Andrew S. Nelson, Robert G. Sharma, Kumar Tuttle, Katherine R. Rocco, Michael V. Berns, Jeffrey S. Wilt, Timothy J. Ishani, Areef Rector, Thomas S. Slinin, Yelena Fitzgerald, Patrick Carlyle, Maureen TI KDOQI CLINICAL PRACTICE GUIDELINE FOR DIABETES AND CKD: 2012 UPDATE SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Albuminuria; chronic kidney disease; Clinical Practice Guideline; diabetes; dyslipidemia; evidence-based recommendation; KDOQI ID CHRONIC KIDNEY-DISEASE; BLOOD-GLUCOSE CONTROL; PLACEBO-CONTROLLED TRIAL; IMPAIRED RENAL-FUNCTION; CONVERTING ENZYME-INHIBITION; RANDOMIZED CONTROLLED-TRIAL; IMPROVING GLOBAL OUTCOMES; ALBUMIN EXCRETION RATE; GLYCEMIC CONTROL; SEVERE HYPOGLYCEMIA AB The 2012 update of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for Diabetes and Chronic Kidney Disease (CKD) is intended to assist the practitioner caring for patients with diabetes and CKD. Substantial high-quality new evidence has emerged since the original 2007 KDOQI guideline that could significantly change recommendations for clinical practice. As such, revisions of prior guidelines are offered that specifically address hemoglobin A(1c) (HbA(1c)) targets, treatments to lower low-density lipoprotein cholesterol (LDL-C) levels, and use of angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) treatment in diabetic patients with and without albuminuria. Treatment approaches are addressed in each section and the stated guideline recommendations are based on systematic reviews of relevant trials. Appraisal of the quality of the evidence and the strength of recommendations followed the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach. Limitations of the evidence are discussed and specific suggestions are provided for future research. C1 [Bilous, Rudolf W.] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. [Bilous, Rudolf W.] James Cook Univ Hosp, Middlesbrough, Cleveland, England. [Bilous, Rudolf W.] NIH, Metab Med Unit, Bethesda, MD 20892 USA. [Bilous, Rudolf W.] Univ Minnesota, JDRF, Minneapolis, MN 55455 USA. [Gonzalez-Campoy, J. Michael; Mauer, Michael] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA. [Gonzalez-Campoy, J. Michael] NIDDK, Div Diabet Endocrinol & Metab Dis DEMD, NIH, Bethesda, MD 20892 USA. [Fradkin, Judith E.] Yale Univ, New Haven, CT 06520 USA. [Fradkin, Judith E.] Ctr Dis Control & Prevent, Natl Diabet Educ Program, Atlanta, GA USA. [Fradkin, Judith E.] Natl Naval Med Ctr, Bethesda, MD USA. [Molitch, Mark E.] Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Evanston, IL 60208 USA. [Molitch, Mark E.] Univ Calif Los Angeles, Harbor Gen Hosp, Los Angeles, CA 90024 USA. [Narva, Andrew S.] NIDDK, Natl Kidney Dis Educ Program, Bethesda, MD 20892 USA. [Nelson, Robert G.] NIDDK, Phoenix, AZ USA. [Sharma, Kumar] Univ Calif San Diego, Ctr Renal Translat Med, San Diego, CA 92103 USA. [Tuttle, Katherine R.] Providence Sacred Heart Med Ctr, Spokane, WA USA. [Tuttle, Katherine R.] Natl Diabet Educ Program NIH & CDC, Healthcare Profess Work Grp, Bethesda, MD 20892 USA. [Tuttle, Katherine R.] Inst Review Board, Spokane, WA USA. [Tuttle, Katherine R.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Tuttle, Katherine R.] Washington State Univ, Pullman, WA 99164 USA. [Rocco, Michael V.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Berns, Jeffrey S.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Berns, Jeffrey S.] Univ Penn, Sch Med, Penn Presbyterian Med Ctr Philadelphia, Philadelphia, PA 19104 USA. [Wilt, Timothy J.; Rector, Thomas S.] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Ishani, Areef] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Fitzgerald, Patrick] CCDOR, Minneapolis, MN USA. [Carlyle, Maureen] Minneapolis VA Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Carlyle, Maureen] Univ Minnesota, Minnesota Evidence Based Practice Ctr, Minneapolis, MN 55455 USA. NR 115 TC 0 Z9 0 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD NOV PY 2012 VL 60 IS 5 BP 858 EP + PG 30 WC Urology & Nephrology SC Urology & Nephrology GA 029PO UT WOS:000310508100041 ER PT J AU An, Q Prejean, J Hall, HI AF An, Qian Prejean, Joseph Hall, H. Irene TI Racial Disparity in US Diagnoses of Acquired Immune Deficiency Syndrome, 2000-2009 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HEALTH INEQUALITIES; AIDS SURVEILLANCE; CANCER INCIDENCE; COMPLETENESS; TRENDS; TIMELINESS AB Background: Increased attention has been focused on health disparities among racial/ethnic groups in the U.S. Purpose: To assess the extent of progress toward meeting the targets of Healthy People 2010 objectives and eliminating disparities. Methods: All diagnoses of AIDS during 2000-2009 among people aged >= 13years in the 50 states and District of Columbia, reported to national HIV surveillance through June 2010, together with census population data were used in this analysis (conducted in March 2011). This study assesses the trend in racial/ethnic disparities in rates of AIDS diagnoses both between particular groups using rate difference (RD) and rate ratio (RR) and across the entire range of racial/ethnic subgroups using three summary measures of disparity: between-group variance (BGV); Theil index (TI); and mean log deviation (MLD). Results: The overall racial/ethnic disparity, black-white disparity, and Hispanic-white disparity in rates of AIDS diagnoses decreased for those aged 25-64 years from 2000 to 2009. The black-white and Hispanic-white disparity in rates of AIDS diagnoses also decreased among men aged >= 65years; however, the black-white disparity increased among young men aged 13-24 years (BGV: p<0.001, black-white RD: p<0.01) from 2000 to 2009. Conclusions: Findings indicate overall decreases in racial/ethnic disparities in AIDS diagnoses except in young men, particularly young black men aged 13-24 years where the burden of AIDS is increasing. HIV testing, prevention, treatment and policy-making should be a priority for this group. (Am J Prev Med 2012;43(5):461-466) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [An, Qian; Prejean, Joseph; Hall, H. Irene] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP An, Q (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mailstop E-47, Atlanta, GA 30333 USA. EM FEI8@cdc.gov NR 26 TC 8 Z9 8 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2012 VL 43 IS 5 BP 461 EP 466 DI 10.1016/j.amepre.2012.07.040 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 032JI UT WOS:000310713100001 PM 23079167 ER PT J AU Guy, GP Ekwueme, DU Tangka, FK Richardson, LC AF Guy, Gery P., Jr. Ekwueme, Donatus U. Tangka, Florence K. Richardson, Lisa C. TI Melanoma Treatment Costs A Systematic Review of the Literature, 1990-2011 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID NONMELANOMA SKIN-CANCER; CUTANEOUS MALIGNANT-MELANOMA; INDOOR TANNING DEVICES; UNITED-STATES; ULTRAVIOLET-RADIATION; ECONOMIC-EVALUATION; BURDEN; EPIDEMIOLOGY; POPULATION; RISK AB Context: Melanoma is the most deadly form of skin cancer and an important public health concern. Given the substantial health burden associated with melanoma, it is important to examine the economic costs associated with its treatment. The purpose of the current study was to systematically review the literature on the direct medical care costs of melanoma. Evidence acquisition: A systematic review was performed using multiple databases including MEDLINE, Embase, CINAHL, and Econlit. Nineteen articles on the direct medical costs of melanoma were identified. Evidence synthesis: Detailed information on the study population, study country/setting, study perspective, costing approach, disease severity (stage), and key study results were abstracted. The overall costs of melanoma were examined as well as per-patient costs, costs by phase of care, stage of diagnosis, and setting/type of care. Among studies examining all stages of melanoma, annual treatment costs ranged from $44.9 million among Medicare patients with existing cases to $932.5 million among newly diagnosed cases across all age groups. Conclusions: Melanoma leads to substantial direct medical care costs, with estimates varying widely because of the heterogeneity across studies in terms of the study setting, populations studied, costing approach, and study methods. Melanoma treatment costs varied by phase of care and stage at diagnoses; costs were highest among patients diagnosed with late-stage disease and in the initial and terminal phases of care. Aggregate treatment costs were generally highest in the outpatient/office-based setting; per-patient/per-case treatment costs were highest in the hospital inpatient setting. Given the substantial costs of treating melanoma, public health strategies should include efforts to enhance both primary prevention (reduction of ultraviolet light exposure) and secondary prevention (earlier detection) of melanoma. (Am J Prey Med 2012;43(5):537-545) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Guy, Gery P., Jr.; Ekwueme, Donatus U.; Tangka, Florence K.; Richardson, Lisa C.] CDC, Div Canc Prewnt & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Guy, GP (reprint author), CDC, Div Canc Prewnt & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-55, Atlanta, GA 30341 USA. EM irm2@cdc.gov FU Intramural CDC HHS [CC999999] NR 59 TC 22 Z9 22 U1 3 U2 25 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2012 VL 43 IS 5 BP 537 EP 545 DI 10.1016/j.amepre.2012.07.031 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 032JI UT WOS:000310713100012 PM 23079178 ER PT J AU Brown, DR Soares, J Epping, JM Lankford, TJ Wallace, JS Hopkins, D Buchanan, LR Orleans, CT AF Brown, David R. Soares, Jesus Epping, Jacqueline M. Lankford, Tina J. Wallace, Jana S. Hopkins, David Buchanan, Leigh Ramsey Orleans, C. Tracy CA Community Preventive Serv Task TI Stand-Alone Mass Media Campaigns to Increase Physical Activity A Community Guide Updated Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID PREVENTIVE-SERVICES; SYSTEMATIC REVIEWS; VERB(TM) CAMPAIGN; HEALTH; IMPACT; COMMUNICATION; INTERVENTION; AWARENESS; CHILDREN; BEHAVIOR AB Context: The goal of the systematic review described in this summary was to determine the effectiveness of stand-alone mass media campaigns to increase physical activity at the population level. This systematic review is an update of a Community Guide systematic review and Community Preventive Services Task Force recommendation completed in 2001. Evidence acquisition: Updated searches for literature published from 1980 to 2008 were conducted in 11 databases. Of 267 articles resulting from the literature search, 16 were selected for full abstraction, including the three studies from the original 2001 review. Standard Community Guide methods were used to conduct the systematic evidence review. Evidence synthesis: Physical activity outcomes were assessed using a variety of self-report measures with duration intervals ranging from 6 weeks to 4 years. Ten studies using comparable outcome measures documented a median absolute increase of 3.4 percentage points (interquartile interval: 2.4 to 4.2 percentage points), and a median relative increase of 6.7% (interquartile interval: 3.0% to 14.1%), in self-reported physical activity levels. The remaining six studies used alternative outcome measures: three evaluated changes in self-reported time spent in physical activity (median relative change, 4.4%; range of values, 3.1%-18.2%); two studies used a single outcome measure and found that participants reported being more active after the campaign than before it; and one study found that a mass media weight-loss program led to a self-reported increase in physical activity. Conclusions: The findings of this updated systematic review show that intervention effects, based wholly on self-reported measures, were modest and inconsistent. These findings did not lead the Task Force to change its earlier conclusion of insufficient evidence to determine the effectiveness of stand-alone mass media campaigns to increase physical activity. This paper also discusses areas needing future research to strengthen the evidence base. Finally, studies published between 2009 and 2011, after the Task Force finding was reached, and briefly summarized here, are shown to support that finding. (Am J Prey Med 2012;43(5):551-561) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Brown, David R.; Soares, Jesus; Epping, Jacqueline M.; Lankford, Tina J.; Wallace, Jana S.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Phys Act & Hlth Branch, Atlanta, GA 30341 USA. [Hopkins, David; Buchanan, Leigh Ramsey] CDC, Off Surveillance Epidemiol & Lab Serv, Epidemiol & Anal Program Off, Community Guide Branch, Atlanta, GA 30341 USA. [Orleans, C. Tracy] Robert Wood Johnson Fdn, Princeton, NJ 08540 USA. RP Brown, DR (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Phys Act & Hlth Branch, MS K-46,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM dbrown@cdc.gov NR 38 TC 17 Z9 17 U1 1 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2012 VL 43 IS 5 BP 551 EP 561 DI 10.1016/j.amepre.2012.07.035 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 032JI UT WOS:000310713100014 PM 23079180 ER PT J AU Brown, DR AF Brown, David R. CA Community Preventive Serv Task TI Stand-Alone Mass Media Campaigns to Increase Physical Activity Updated Findings from the Community Preventive Services Task Force SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article AB The Community Preventive Services Task Force concludes there is insufficient evidence to determine the effectiveness of stand-alone mass media campaigns to increase physical activity at the population level. Additional research is needed to determine effectiveness. (Am J Prey Med 2012;43(5):562-564) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Brown, David R.] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Brown, DR (reprint author), CDC, Div Nutr Phys Act & Obes, MS K-46,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM dbrown@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD NOV PY 2012 VL 43 IS 5 BP 562 EP 564 DI 10.1016/j.amepre.2012.07.026 PG 3 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 032JI UT WOS:000310713100015 ER PT J AU Bowen, A Agboatwalla, M Luby, S Tobery, T Ayers, T Hoekstra, RM AF Bowen, Anna Agboatwalla, Mubina Luby, Stephen Tobery, Timothy Ayers, Tracy Hoekstra, R. M. TI Association Between Intensive Handwashing Promotion and Child Development in Karachi, Pakistan A Cluster Randomized Controlled Trial SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID BRAZILIAN SHANTYTOWN; DEVELOPING-COUNTRIES; DIARRHEA; GROWTH; INTERVENTIONS; MALNUTRITION; METAANALYSIS; INFECTION; INFANTS; WATER AB Objective: To evaluate associations between handwashing promotion and child growth and development. Design: Cluster randomized controlled trial. Setting: Informal settlements in Karachi, Pakistan. Participants: A total of 461 children who were enrolled in a trial of household-level handwashing promotion in 2003 and were younger than 8 years at reassessment in 2009. Interventions: In 2003, neighborhoods were randomized to control (n = 9), handwashing promotion (n = 9), or handwashing promotion and drinking water treatment (n = 10); intervention households received free soap and weekly handwashing promotion for 9 months. Main Outcome Measures: Anthropometrics and developmental quotients measured with the Battelle Developmental Inventory II at 5 to 7 years of age. Results: Overall, 24.9% (95% CI, 20.0%-30.6%) and 22.1% (95% CI, 18.0%-26.8%) of children had z scores that were more than 2 SDs below the expected z scores for height and body mass index for age, respectively; anthropometrics did not differ significantly across study groups. Global developmental quotients averaged 104.4 (95% CI, 101.9-107.0) among intervention children and 98.3 (95% CI, 93.1-103.4) among control children (P =. 04). Differences of similar magnitude were measured across adaptive, personal-social, communication, cognitive, and motor domains. Conclusions: Although growth was similar across groups, children randomized to the handwashing promotion during their first 30 months of age attained global developmental quotients 0.4 SDs greater than those of control children at 5 to 7 years of age. These gains are comparable to those of at-risk children enrolled in publicly funded preschools in the United States and suggest that handwashing promotion could improve child wellbeing and societal productivity. C1 [Bowen, Anna; Luby, Stephen; Ayers, Tracy; Hoekstra, R. M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Agboatwalla, Mubina] Hlth Oriented Prevent Educ, Karachi, Pakistan. [Luby, Stephen] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Tobery, Timothy] Procter & Gamble Co, Mason, OH USA. [Tobery, Timothy] Unilever, Englewood Cliffs, NJ USA. RP Bowen, A (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30333 USA. EM abowen@cdc.gov FU Procter Gamble Company; Centers for Disease Control and Prevention FX Most of the study funds were provided by the Procter & Gamble Company. The balance of the study funds was provided by the Centers for Disease Control and Prevention. NR 35 TC 13 Z9 13 U1 0 U2 17 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD NOV PY 2012 VL 166 IS 11 BP 1037 EP 1044 DI 10.1001/archpediatrics.2012.1181 PG 8 WC Pediatrics SC Pediatrics GA 032BI UT WOS:000310686400007 PM 22986783 ER PT J AU Quinn, CP Sabourin, CL Niemuth, NA Li, H Semenova, VA Rudge, TL Mayfield, HJ Schiffer, J Mittler, RS Ibegbu, CC Wrammert, J Ahmed, R Brys, AM Hunt, RE Levesque, D Estep, JE Barnewall, RE Robinson, DM Plikaytis, BD Marano, N AF Quinn, Conrad P. Sabourin, Carol L. Niemuth, Nancy A. Li, Han Semenova, Vera A. Rudge, Thomas L. Mayfield, Heather J. Schiffer, Jarad Mittler, Robert S. Ibegbu, Chris C. Wrammert, Jens Ahmed, Rafi Brys, April M. Hunt, Robert E. Levesque, Denyse Estep, James E. Barnewall, Roy E. Robinson, David M. Plikaytis, Brian D. Marano, Nina CA AVRP Lab Working Grp TI A Three-Dose Intramuscular Injection Schedule of Anthrax Vaccine Adsorbed Generates Sustained Humoral and Cellular Immune Responses to Protective Antigen and Provides Long-Term Protection against Inhalation Anthrax in Rhesus Macaques SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID RECEPTOR-BINDING REGION; IN-VITRO CORRELATE; CD4(+) T-CELLS; BACILLUS-ANTHRACIS; LETHAL FACTOR; MONOCLONAL-ANTIBODIES; PASSIVE PROTECTION; GUINEA-PIGS; NEUTRALIZING ANTIBODIES; TOXIN COMPONENTS AB A 3-dose (0, 1, and 6 months) intramuscular (3-IM) priming series of a human dose (HuAVA) and dilutions of up to 1:10 of anthrax vaccine adsorbed (AVA) provided statistically significant levels of protection (60 to 100%) against inhalation anthrax for up to 4 years in rhesus macaques. Serum anti-protective antigen (anti-PA) IgG and lethal toxin neutralization activity (TNA) were detectable following a single injection of HuAVA or 1:5 AVA or following two injections of diluted vaccine (1:10, 1:20, or 1:40 AVA). Anti-PA and TNA were highly correlated (overall r(2) = 0.89 for log(10)-transformed data). Peak responses were seen at 6.5 months. In general, with the exception of animals receiving 1:40 AVA, serum anti-PA and TNA responses remained significantly above control levels at 28.5 months (the last time point measured for 1:20 AVA), and through 50.5 months for the HuAVA and 1:5 and 1:10 AVA groups (P < 0.05). PA-specific gamma interferon (IFN-gamma) and interleukin-4 (IL-4) CD4(+) cell frequencies and T cell stimulation indices were sustained through 50.5 months (the last time point measured). PA-specific memory B cell frequencies were highly variable but, in general, were detectable in peripheral blood mononuclear cells (PBMC) by 2 months, were significantly above control levels by 7 months, and remained detectable in the HuAVA and 1:5 and 1:20 AVA groups through 42 months (the last time point measured). HuAVA and diluted AVA elicited a combined Th1/Th2 response and robust immunological priming, with sustained production of high-avidity PA-specific functional antibody, long-term immune cell competence, and immunological memory (30 months for 1:20 AVA and 52 months for 1:10 AVA). Vaccinated animals surviving inhalation anthrax developed high-magnitude anamnestic anti-PA IgG and TNA responses. C1 [Quinn, Conrad P.; Li, Han; Semenova, Vera A.; Schiffer, Jarad; Plikaytis, Brian D.; Marano, Nina] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Sabourin, Carol L.; Niemuth, Nancy A.; Rudge, Thomas L.; Mayfield, Heather J.; Brys, April M.; Hunt, Robert E.; Estep, James E.; Barnewall, Roy E.; Robinson, David M.] Battelle Biomed Res Ctr, Columbus, OH USA. [Mittler, Robert S.; Ibegbu, Chris C.; Wrammert, Jens; Ahmed, Rafi] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Mittler, Robert S.; Ibegbu, Chris C.; Levesque, Denyse] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA. RP Quinn, CP (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM cquinn@cdc.gov OI Akondy, Rama/0000-0003-4737-5240 FU Centers for Disease Control and Prevention, Atlanta, GA; DHHS CDC [200-2000-10065]; Atlanta Research and Education Foundation (AREF) through the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Atlanta, GA FX This study was funded through the Centers for Disease Control and Prevention, Atlanta, GA. The Battelle Biomedical Research Center was funded under DHHS CDC contract 200-2000-10065. The members of the AVRP Laboratory Working Group marked by asterisks were funded by the Atlanta Research and Education Foundation (AREF) through the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Atlanta, GA. NR 60 TC 24 Z9 25 U1 0 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD NOV PY 2012 VL 19 IS 11 BP 1730 EP 1745 DI 10.1128/CVI.00324-12 PG 16 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 030IF UT WOS:000310563700004 PM 22933399 ER PT J AU Ledgerwood, JE Hu, Z Gordon, IJ Yamshchikov, G Enama, ME Plummer, S Bailer, R Pearce, MB Tumpey, TM Koup, RA Mascola, JR Nabel, GJ Graham, BS AF Ledgerwood, J. E. Hu, Z. Gordon, I. J. Yamshchikov, G. Enama, M. E. Plummer, S. Bailer, R. Pearce, M. B. Tumpey, T. M. Koup, R. A. Mascola, J. R. Nabel, G. J. Graham, B. S. CA VRC 304 Study Team VRC 305 Study Team TI Influenza Virus H5 DNA Vaccination Is Immunogenic by Intramuscular and Intradermal Routes in Humans SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID I CLINICAL-TRIAL; HEALTHY-ADULTS; NEUTRALIZING ANTIBODY; CANDIDATE VACCINE; IMMUNE-RESPONSES; OPEN-LABEL; SAFETY; ANTIGENS AB Avian influenza virus causes outbreaks in domestic and wild birds around the world, and sporadic human infections have been reported. A DNA vaccine encoding hemagglutinin (HA) protein from the A/Indonesia/5/05 (H5N1) strain was initially tested in two randomized phase I clinical studies. Vaccine Research Center study 304 (VRC 304) was a double-blinded study with 45 subjects randomized to placebo, 1 mg of vaccine, or 4 mg of vaccine treatment groups (n = 15/group) by intramuscular (i.m.) Biojector injection. VRC 305 was an open-label study to evaluate route, with 44 subjects randomized to intradermal (i.d.) injections of 0.5 mg by needle/syringe or by Biojector or 1 mg delivered as two 0.5-mg Biojector injections in the same deltoid or as 0.5 mg in each deltoid (n = 11/group). Injections were administered at weeks 0, 4, and 8 in both studies. Antibody responses to H5 were assessed by hemagglutination inhibition (HAI) assay, enzyme-linked immunosorbent assay (ELISA), and neutralization assay, and the H5 T cell responses were assessed by enzyme-linked immunospot and intracellular cytokine staining assays. There were no vaccine-related serious adverse events, and the vaccine was well tolerated in all groups. At 1 mg, i.d. vaccination compared to i.m. vaccination induced a greater frequency and magnitude of response by ELISA, but there were no significant differences in the frequency or magnitude of response between the i.d. and i.m. routes in the HAI or neutralization assays. T cell responses were more common in subjects who received the 1- or 4-mg dose i.m. These studies demonstrated that the DNA vaccine encoding H5 is safe and immunogenic and served to define the proper dose and route for further studies. The i.d. injection route did not offer a significant advantage over the i.m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens. C1 [Ledgerwood, J. E.; Gordon, I. J.; Yamshchikov, G.; Enama, M. E.; Plummer, S.; Bailer, R.; Koup, R. A.; Mascola, J. R.; Nabel, G. J.; Graham, B. S.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Hu, Z.] NIAID, Biostat Res Branch, Div Clin Res, NIH, Bethesda, MD 20892 USA. [Pearce, M. B.; Tumpey, T. M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Ledgerwood, JE (reprint author), NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM ledgerwood@mail.nih.gov FU NIAID FX This clinical trial was funded by the NIAID Intramural program. NR 22 TC 26 Z9 26 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD NOV PY 2012 VL 19 IS 11 BP 1792 EP 1797 DI 10.1128/CVI.05663-11 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 030IF UT WOS:000310563700011 PM 22956656 ER PT J AU Mercader, S Garcia, P Bellini, WJ AF Mercader, Sara Garcia, Philip Bellini, William J. TI Measles Virus IgG Avidity Assay for Use in Classification of Measles Vaccine Failure in Measles Elimination Settings SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID IMMUNOGLOBULIN-G AVIDITY; LABORATORY CONFIRMATION; RECOMBINANT PROTEIN; ENZYME IMMUNOASSAYS; RUBELLA INFECTION; HIV-1 INFECTION; UNITED-STATES; DIAGNOSIS; SECONDARY; OUTBREAK AB In regions where endemic measles virus has been eliminated, diagnostic assays are needed to assist in correctly classifying measles cases irrespective of vaccination status. A measles IgG avidity assay was configured using a commercially available measles-specific IgG enzyme immunoassay by modifying the protocol to include three 5-min washes with diethylamine (60 mM; pH 10.25) following serum incubation; serum was serially diluted, and the results were expressed as the end titer avidity index. Receiver operating characteristic analysis was used for evaluation and validation and to establish low (<= 30%) and high (>= 70%) end titer avidity thresholds. Analysis of 319 serum specimens expected to contain either high-or low-avidity antibodies according to clinical and epidemiological data indicated that the assay is highly accurate, with an area under the curve of 0.998 (95% confidence interval [CI], 0.978 to 1.000), sensitivity of 91.9% (95% CI, 83.2% to 97.0%), and specificity of 98.4% (95% CI, 91.6% to 100%). The assay is rapid (<2 h) and precise (standard deviation [SD], 4% to 7%). In 18 samples from an elimination setting outbreak, the assay identified 2 acute measles cases with low-avidity results; both were IgM-positive samples. Additionally, 11 patients (15 samples) with modified measles who were found to have high-avidity IgG results were classified as secondary vaccine failures; one sample with an intermediate-avidity result was not interpretable. In elimination settings, measles IgG avidity assays can complement existing diagnostic tools in confirming unvaccinated acute cases and, in conjunction with adequate clinical and epidemiologic investigation, aid in the classification of vaccine failure cases. C1 [Mercader, Sara; Garcia, Philip; Bellini, William J.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Mercader, S (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM sjm7@cdc.gov NR 44 TC 10 Z9 15 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD NOV PY 2012 VL 19 IS 11 BP 1810 EP 1817 DI 10.1128/CVI.00406-12 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 030IF UT WOS:000310563700014 PM 22971778 ER PT J AU Garcia-Lerma, JG Heneine, W AF Garcia-Lerma, J. Gerardo Heneine, Walid TI Animal models of antiretroviral prophylaxis for HIV prevention SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE macaque models; microbicides; preexposure prophylaxis; tenofovir; emtricitabine ID SIMIAN IMMUNODEFICIENCY VIRUS; TENOFOVIR DISOPROXIL FUMARATE; HUMANIZED BLT MICE; ORAL PREEXPOSURE PROPHYLAXIS; PROTECT INFANT MACAQUES; DRUG-RESISTANT HIV-1; RHESUS MACAQUES; VAGINAL TRANSMISSION; MENSTRUAL-CYCLE; PRECLINICAL INTERVENTIONS AB Purpose of review Oral and topical pre-exposure prophylaxis (PrEP) with antiretroviral drugs are novel biomedical interventions recently found to prevent HIV transmission among high-risk populations. In this review, we outline lessons learned from animal studies and discuss next steps in preclinical PrEP research including the study of new PrEP modalities, pharmacologic correlates of protection, and biological factors that may modulate PrEP efficacy. Recent findings Studies using macaque or humanized mice models of mucosal simian immunodeficiency virus (Sly), HIV, or simian/human immunodeficiency virus (SHIV) transmission have provided efficacy data against rectal and vaginal infection. A multitude of oral and topical PrEP regimens including drugs such as tenofovir (TFV), tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) were tested against either wild-type or drug-resistant viruses. These models have also helped define prophylactic windows of protection of nondaily dosing and are being used increasingly to study pharmacokinetic and pharmacodynamic relationships. Summary As human data from PrEP trials validate animal models or help fine tune them, it is expected that these models will play increasingly important roles in PrEP development as the field extends into new drug classes and combinations, episodic dosing, and novel long-acting drug formulations. By providing both efficacy and pharmacologic information these models can define correlates and mechanisms of protection, inform dose selection, and advance the most promising PrEP candidates and dosing modalities. C1 [Garcia-Lerma, J. Gerardo; Heneine, Walid] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & Prevent, Atlanta, GA 30333 USA. RP Garcia-Lerma, JG (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & Prevent, Clifton Rd,Mailstop G45, Atlanta, GA 30333 USA. EM ggarcia-lerma@cdc.gov FU Centers for Disease Control and Prevention (CDC) [Y1-AI-0681-02]; National Institutes of Health [Y1-AI-0681-02] FX This work was partially supported by Interagency Agreement Y1-AI-0681-02 between the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of CDC. NR 60 TC 25 Z9 26 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1746-630X J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD NOV PY 2012 VL 7 IS 6 BP 505 EP 513 DI 10.1097/COH.0b013e328358e484 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 028IN UT WOS:000310416100003 PM 22964889 ER PT J AU Paxton, LA AF Paxton, Lynn A. TI Considerations regarding antiretroviral chemoprophylaxis and heterosexuals in generalized epidemic settings SO CURRENT OPINION IN HIV AND AIDS LA English DT Review DE Africa; antiretrovirals; heterosexuals; HIV prevention; pre-exposure prophylaxis ID FEMALE SEX WORKERS; SUB-SAHARAN AFRICA; PREEXPOSURE PROPHYLAXIS; HIV PREVENTION; MALE CIRCUMCISION; ANAL INTERCOURSE; DIFFERENT REGIONS; RISK-FACTORS; INFECTION; KENYA AB Purpose of review To discuss the factors pertinent to the use of pre-exposure prophylaxis (PrEP) by at-risk heterosexuals in countries with generalized HIV epidemics. Recent findings PrEP will have the greatest prevention effect if targeted to those at highest risk, but identifying and engaging such persons is challenging. Serodiscordant couples account for a high proportion of new infections and are an appropriate target for PrEP, but the proportion of people in such relationships is small and outside partnerships are common. Differences in adherence coupled to pharmacology of the drugs may account for differences in efficacy seen in the trials. Mathematical modeling indicates that the benefits of PrEP in highly endemic settings outweigh the risk of induced viral resistance. Behavioral risk compensation was not observed in the trials, but current open-label studies will better determine if disinhibition will be an important problem. Conclusions PrEP is a potentially useful HIV-prevention strategy for generalized heterosexual epidemics. Optimal implementation will require learning more about ways to improve acceptability and adherence and how best to deliver PrEP within the context of limited resource availability. C1 [Paxton, Lynn A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Paxton, LA (reprint author), 1600 Clifton Rd,Mailstop A06, Atlanta, GA 30333 USA. EM lap5@cdc.gov NR 75 TC 5 Z9 5 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1746-630X J9 CURR OPIN HIV AIDS JI Curr. Opin. HIV AIDS PD NOV PY 2012 VL 7 IS 6 BP 557 EP 562 DI 10.1097/COH.0b013e328359064a PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 028IN UT WOS:000310416100010 PM 23032738 ER PT J AU Jin, X Yu, L Wu, Y Zhang, S Shi, ZD Chen, XF Yang, Y Zhang, XL Jiang, C AF Jin, Xin Yu, Lei Wu, Yang Zhang, Shuang Shi, Zhenda Chen, Xianfeng Yang, Yang Zhang, Xiaoli Jiang, Chun TI S-Glutathionylation underscores the modulation of the heteromeric Kir4.1-Kir5.1 channel in oxidative stress SO JOURNAL OF PHYSIOLOGY-LONDON LA English DT Article ID RECTIFYING POTASSIUM CHANNELS; K+ CHANNEL; CRYSTAL-STRUCTURE; PH SENSITIVITY; I-TASSER; KIR4.1; KIR5.1; RECEPTORS; INHIBITION; ASTROCYTES AB The Kir4.1 channel is expressed in the brainstem, retina and kidney where it acts on K+ transportation and pH-dependent membrane potential regulation. Its heteromerization with Kir5.1 leads to K+ currents with distinct properties such as single-channel conductance, rectification, pH sensitivity and phosphorylation modulation. Here we show that Kir5.1 also enables S-glutathionylation to the heteromeric channel. Expressed in HEK cells, an exposure to the oxidant H2O2 or diamide produced concentration-dependent inhibitions of the whole-cell Kir4.1-Kir5.1 currents. In inside-out patches, currents were inhibited strongly by a combination of diamide/GSH or H2O2/GSH but not by either alone. The currents were also suppressed by GSSG and the thiol oxidants pyridine disulfides (PDSs), suggesting S-glutathionylation. In contrast, none of the exposures had significant effects on the homomeric Kir4.1 channel. Cys158 in the TM2 helix of Kir5.1 was critical for the S-glutathionylation, which was accessible to intracellular but not extracellular oxidants. Site-directed mutagenesis of this residue (C158A or C158T) abolished the Kir4.1-Kir5.1 current modulation by oxidants, and eliminated almost completely the biochemical interaction of Kir5.1 with GSH. In tandem Kir4.1-Kir5.1 constructs, the channel with a single Cys158 was inhibited to the same degree as the wild-type channel, suggesting that one glutathione moiety is sufficient to block the channel. Consistent with the location of Cys158, GSSG inhibited the channel only when the channel was open, indicating that the channel inhibition was state dependent. The finding that the heteromeric Kir4.1-Kir5.1 channel but not the homomeric Kir4.1 is subject to the S-glutathionylation thus suggests a novel Kir4.1-Kir5.1 channel modulation mechanism that is likely to occur in oxidative stress. C1 [Jin, Xin; Yu, Lei; Wu, Yang; Zhang, Shuang; Shi, Zhenda; Chen, Xianfeng; Yang, Yang; Zhang, Xiaoli; Jiang, Chun] Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA. [Chen, Xianfeng] Ctr Dis Control & Prevent, Pathogen Discovery GRVLB DVD NCIRD, Atlanta, GA 30329 USA. RP Jiang, C (reprint author), Georgia State Univ, Dept Biol, 100 Piedmont Ave, Atlanta, GA 30302 USA. EM cjiang@gsu.edu RI Yang, Yang/B-3440-2008; Jin, Xin/O-4506-2014; Jin, Xin/E-2746-2010; OI Yang, Yang/0000-0003-4275-0515; Yang, Yang/0000-0001-6417-3654 FU NIH [HD060959, NS073875]; International Rett Syndrome Research Foundation; Harbin Medical University; Georgia State University FX This work was supported by the NIH (HD060959, NS073875), and the International Rett Syndrome Research Foundation. L.Y. was partially supported by a scholarship of Harbin Medical University. S.Z. is an MBD fellow of Georgia State University, and Y.Y. was supported by a B&B fellowship of Georgia State University. NR 36 TC 7 Z9 7 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3751 J9 J PHYSIOL-LONDON JI J. Physiol.-London PD NOV PY 2012 VL 590 IS 21 BP 5335 EP 5348 DI 10.1113/jphysiol.2012.236885 PG 14 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA 027HV UT WOS:000310344000011 PM 22907060 ER PT J AU Sakthivel, SK Whitaker, B Lu, XY Oliveira, DBL Stockman, LJ Kamili, S Oberste, MS Erdman, DD AF Sakthivel, Senthilkumar K. Whitaker, Brett Lu, Xiaoyan Oliveira, Danielle B. L. Stockman, Lauren J. Kamili, Shifaq Oberste, M. Steven Erdman, Dean D. TI Comparison of fast-track diagnostics respiratory pathogens multiplex real-time RT-PCR assay with in-house singleplex assays for comprehensive detection of human respiratory viruses SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Respiratory virus; Real-time PCR; Multiplex ID SPECIMENS; PANEL; IDENTIFICATION; CORONAVIRUS; INFECTIONS AB Fast-track Diagnostics respiratory pathogens (FTDRP) multiplex real-time RT-PCR assay was compared with in-house singleplex real-time RT-PCR assays for detection of 16 common respiratory viruses. The FTDRP assay correctly identified 26 diverse respiratory virus strains, 35 of 41 (85%) external quality assessment samples spiked with cultured virus and 232 of 263 (88%) archived respiratory specimens that tested positive for respiratory viruses by in-house assays. Of 308 prospectively tested respiratory specimens selected from children hospitalized with acute respiratory illness, 270 (87.7%) and 265 (86%) were positive by FTDRP and in-house assays for one or more viruses, respectively, with combined test results showing good concordance (K=0.812, 95% CI = 0.786-0.838). Individual FTDRP assays for adenovirus, respiratory syncytial virus and rhinovirus showed the lowest comparative sensitivities with in-house assays, with most discrepancies occurring with specimens containing low virus loads and failed to detect some rhinovirus strains, even when abundant. The FTDRP enterovirus and human bocavirus assays appeared to be more sensitive than the in-house assays with some specimens. With the exceptions noted above, most FTDRP assays performed comparably with in-house assays for most viruses while offering enhanced throughput and easy integration by laboratories using conventional real-time PCR instrumentation. Published by Elsevier B.V. C1 [Erdman, Dean D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Sakthivel, Senthilkumar K.] Logist Hlth Inc, La Crosse, WI USA. [Whitaker, Brett; Kamili, Shifaq] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Oliveira, Danielle B. L.] Univ Sao Paulo, Inst Biomed Sci, Sao Paulo, Brazil. RP Erdman, DD (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM dde1@cdc.gov FU High Priority Pandemic and Seasonal Influenza Scientific proposal request initiative FX Funding for this project was awarded by the High Priority Pandemic and Seasonal Influenza Scientific proposal request initiative. NR 31 TC 24 Z9 24 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD NOV PY 2012 VL 185 IS 2 BP 259 EP 266 DI 10.1016/j.jviromet.2012.07.010 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 031RT UT WOS:000310660700014 PM 22796035 ER PT J AU Beral, V Bull, D Pirie, K Reeves, G Peto, R Skegg, D LaVecchia, C Magnusson, C Pike, MC Thomas, D Hamajima, N Hirose, K Tajima, K Rohan, T Friedenreich, CM Calle, EE Gapstur, SM Patel, AV Coates, RJ Liff, JM Talamini, R Chantarakul, N Koetsawang, S Rachawat, D Marcou, Y Kakouri, E Duffy, SW Morabia, A Schuman, L Stewart, W Szklo, M Coogan, PF Palmer, JR Rosenberg, L Band, P Coldman, AJ Gallagher, RP Hislop, TG Yang, P Cummings, SR Canfell, K Sitas, F Chao, P Lissowska, J Horn-Ross, PL John, EM Kolonel, LM Nomura, AMY Ghiasvand, R Hu, J Johnson, KC Mao, Y Callaghan, K Crossley, B Goodill, A Green, J Hermon, C Key, T Lindgard, I Liu, B Pirie, K Reeves, G Collins, R Doll, R Peto, R Bishop, T Fentiman, IS De Sanjose, S Gonzaler, CA Lee, N Marchbanks, P Ory, HW Peterson, HB Wingo, P Ebeling, K Kunde, D Nishan, P Hopper, JL Eliassen, H Gajalakshmi, V Martin, N Pardthaisong, T Silpisornkosol, S Theetranont, C Boosiri, B Chutivongse, S Jimakorn, P Virutamasen, P Wongsrichanalai, C Neugut, A Santella, R Baines, CJ Kreiger, N Miller, AB Wall, C Tjonneland, A Jorgensen, T Stahlberg, C Pedersen, AT Flesch-Janys, D Hakansson, N Cauley, J Heuch, I Adami, HO Persson, I Weiderpass, E Magnusson, C Chang-Claude, J Kaaks, R McCredie, M Paul, C Skegg, DCG Spears, GFS Iwasaki, M Tsugane, S Anderson, G Daling, JR Hampton, J Hutchinson, WB Li, CI Malone, K Mandelson, M Newcomb, P Noonan, EA Ray, RM Stanford, JL Tang, MTC Thomas, DB Weiss, NS White, E Izquierdo, A Viladiu, P Fourkala, EO Jacobs, I Menon, U Ryan, A Cuevas, HR Ontiveros, P Palet, A Salazar, SB Aristizabal, N Cuadros, A Tryggvadottir, L Tulinius, H Riboli, E Andrieu, N Bachelot, A Le, MG Bremond, A Gairard, B Lansac, J Piana, L Renaud, R Clavel-Chapelon, F Fournier, A Touillaud, M Mesrine, S Chabbert-Buffet, N Boutron-Ruault, MC Wolk, A Torres-Mejia, G Franceschi, S Romieu, I Boyle, P Lubin, F Modan, B Ron, E Wax, Y Friedman, GD Hiatt, RA Levi, F Kosmelj, K Primic-Zakelj, M Ravnihar, B Stare, J Ekbom, A Erlandsson, G Persson, I Beeson, WL Fraser, G Peto, J Hanson, RL Leske, MC Mahoney, MC Nasca, PC Varma, AO Weinstein, AL Hartman, ML Olsson, H Goldbohm, RA van den Brandt, PA Palli, D Teitelbaum, S Apelo, RA Baens, J de la Cruz, JR Javier, B Lacaya, LB Ngelangel, CA La Vecchia, C Negri, E Marubini, E Ferraroni, M Pike, MC Gerber, M Richardson, S Segala, C Gatei, D Kenya, P Kungu, A Mati, JG Brinton, LA Freedman, M Hoover, R Schairer, C Ziegler, R Banks, E Spirtas, R Lee, HP Rookus, MA van Leeuwen, FE Schoenberg, JA Graff-Iversen, S Selmer, R Jones, L McPherson, K Neil, A Vessey, M Yeates, D Mabuchi, K Preston, D Hannaford, P Kay, C McCann, SE Rosero-Bixby, L Gao, YT Jin, F Yuan, JM Wei, HY Yun, T Zhiheng, C Berry, G Booth, JC Jelihovsky, T MacLennan, R Shearman, R Hadjisavvas, A Kyriacou, K Loisidou, M Zhou, X Wang, QS Kawai, M Minami, Y Tsuji, I Lund, E Kumle, M Stalsberg, H Shu, XO Zheng, W Monninkhof, EM Onland-Moret, NC Peeters, PHM Katsouyanni, K Trichopoulou, A Trichopoulos, D Tzonou, A Baltzell, KA Dabancens, A Martinez, L Molina, R Salas, O Alexander, FE Anderson, K Folsom, AR Gammon, MD Hulka, BS Millikan, R Chilvers, CED Lumachi, F Bain, C Schofield, F Siskind, V Rebbeck, TR Bernstein, LR Enger, S Haile, RW Paganini-Hill, A Ross, RK Ursin, G Wu, AH Yu, MC Ewertz, DM Clarke, EA Bergkvist, L Anderson, GL Gass, M O'Sullivan, MJ Kalache, A Farley, TMM Holck, S Meirik, O Fukao, A AF Beral, V. Bull, D. Pirie, K. Reeves, G. Peto, R. Skegg, D. LaVecchia, C. Magnusson, C. Pike, M. C. Thomas, D. Hamajima, N. Hirose, K. Tajima, K. Rohan, T. Friedenreich, C. M. Calle, E. E. Gapstur, S. M. Patel, A. V. Coates, R. J. Liff, J. M. Talamini, R. Chantarakul, N. Koetsawang, S. Rachawat, D. Marcou, Y. Kakouri, E. Duffy, S. W. Morabia, A. Schuman, L. Stewart, W. Szklo, M. Coogan, P. F. Palmer, J. R. Rosenberg, L. Band, P. Coldman, A. J. Gallagher, R. P. Hislop, T. G. Yang, P. Cummings, S. R. Canfell, K. Sitas, F. Chao, P. Lissowska, J. Horn-Ross, P. L. John, E. M. Kolonel, L. M. Nomura, A. M. Y. Ghiasvand, R. Hu, J. Johnson, K. C. Mao, Y. Callaghan, K. Crossley, B. Goodill, A. Green, J. Hermon, C. Key, T. Lindgard, I. Liu, B. Pirie, K. Reeves, G. Collins, R. Doll, R. Peto, R. Bishop, T. Fentiman, I. S. De Sanjose, S. Gonzaler, C. A. Lee, N. Marchbanks, P. Ory, H. W. Peterson, H. B. Wingo, P. Ebeling, K. Kunde, D. Nishan, P. Hopper, J. L. Eliassen, H. Gajalakshmi, V. Martin, N. Pardthaisong, T. Silpisornkosol, S. Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. Wongsrichanalai, C. Neugut, A. Santella, R. Baines, C. J. Kreiger, N. Miller, A. B. Wall, C. Tjonneland, A. Jorgensen, T. Stahlberg, C. Pedersen, A. Tonnes Flesch-Janys, D. Hakansson, N. Cauley, J. Heuch, I. Adami, H. O. Persson, I. Weiderpass, E. Magnusson, C. Chang-Claude, J. Kaaks, R. McCredie, M. Paul, C. Skegg, D. C. G. Spears, G. F. S. Iwasaki, M. Tsugane, S. Anderson, G. Daling, J. R. Hampton, J. Hutchinson, W. B. Li, C. I. Malone, K. Mandelson, M. Newcomb, P. Noonan, E. A. Ray, R. M. Stanford, J. L. Tang, M. T. C. Thomas, D. B. Weiss, N. S. White, E. Izquierdo, A. Viladiu, P. Fourkala, E. O. Jacobs, I. Menon, U. Ryan, A. Cuevas, H. R. Ontiveros, P. Palet, A. Salazar, S. B. Aristizabal, N. Cuadros, A. Tryggvadottir, L. Tulinius, H. Riboli, E. Andrieu, N. Bachelot, A. Le, M. G. Bremond, A. Gairard, B. Lansac, J. Piana, L. Renaud, R. Clavel-Chapelon, F. Fournier, A. Touillaud, M. Mesrine, S. Chabbert-Buffet, N. Boutron-Ruault, M. C. Wolk, A. Torres-Mejia, G. Franceschi, S. Romieu, I. Boyle, P. Lubin, F. Modan, B. Ron, E. Wax, Y. Friedman, G. D. Hiatt, R. A. Levi, F. Kosmelj, K. Primic-Zakelj, M. Ravnihar, B. Stare, J. Ekbom, A. Erlandsson, G. Persson, I. Beeson, W. L. Fraser, G. Peto, J. Hanson, R. L. Leske, M. C. Mahoney, M. C. Nasca, P. C. Varma, A. O. Weinstein, A. L. Hartman, M. L. Olsson, H. Goldbohm, R. A. van den Brandt, P. A. Palli, D. Teitelbaum, S. Apelo, R. A. Baens, J. de la Cruz, J. R. Javier, B. Lacaya, L. B. Ngelangel, C. A. La Vecchia, C. Negri, E. Marubini, E. Ferraroni, M. Pike, M. C. Gerber, M. Richardson, S. Segala, C. Gatei, D. Kenya, P. Kungu, A. Mati, J. G. Brinton, L. A. Freedman, M. Hoover, R. Schairer, C. Ziegler, R. Banks, E. Spirtas, R. Lee, H. P. Rookus, M. A. van Leeuwen, F. E. Schoenberg, J. A. Graff-Iversen, S. Selmer, R. Jones, L. McPherson, K. Neil, A. Vessey, M. Yeates, D. Mabuchi, K. Preston, D. Hannaford, P. Kay, C. McCann, S. E. Rosero-Bixby, L. Gao, Y. T. Jin, F. Yuan, J-M Wei, H. Y. Yun, T. Zhiheng, C. Berry, G. Booth, J. Cooper Jelihovsky, T. MacLennan, R. Shearman, R. Hadjisavvas, A. Kyriacou, K. Loisidou, M. Zhou, X. Wang, Q-S Kawai, M. Minami, Y. Tsuji, I. Lund, E. Kumle, M. Stalsberg, H. Shu, X. O. Zheng, W. Monninkhof, E. M. Onland-Moret, N. C. Peeters, P. H. M. Katsouyanni, K. Trichopoulou, A. Trichopoulos, D. Tzonou, A. Baltzell, K. A. Dabancens, A. Martinez, L. Molina, R. Salas, O. Alexander, F. E. Anderson, K. Folsom, A. R. Gammon, M. D. Hulka, B. S. Millikan, R. Chilvers, C. E. D. Lumachi, F. Bain, C. Schofield, F. Siskind, V. Rebbeck, T. R. Bernstein, L. R. Enger, S. Haile, R. W. Paganini-Hill, A. Ross, R. K. Ursin, G. Wu, A. H. Yu, M. C. Ewertz, Denmark M. Clarke, E. A. Bergkvist, L. Anderson, G. L. Gass, M. O'Sullivan, M. J. Kalache, A. Farley, T. M. M. Holck, S. Meirik, O. Fukao, A. CA Collaborative Grp Hormonal Factors Collaborative Grp Hormonal Factors S Hankinson Nurses Hlth Study I II Res Grp TI Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies SO LANCET ONCOLOGY LA English DT Article ID REQUIRING PROLONGED OBSERVATION; COLLABORATIVE REANALYSIS; POSTMENOPAUSAL WOMEN; SEX-HORMONES; AGE; THERAPY; PATIENT; TRIALS; RECALL; REPRODUCIBILITY AB Background Menarche and menopause mark the onset and cessation, respectively, of ovarian activity associated with reproduction, and affect breast cancer risk. Our aim was to assess the strengths of their effects and determine whether they depend on characteristics of the tumours or the affected women. Methods Individual data from 117 epidemiological studies, including 118 964 women with invasive breast cancer and 306 091 without the disease, none of whom had used menopausal hormone therapy, were included in the analyses. We calculated adjusted relative risks (RRs) associated with menarche and menopause for breast cancer overall, and by tumour histology and by oestrogen receptor expression. Findings Breast cancer risk increased by a factor of 1.050 (95% CI 1.044-1.057; p < 0.0001) for every year younger at menarche, and independently by a smaller amount (1.029, 1.025-1.032; p < 0.0001), for every year older at menopause. Premenopausal women had a greater risk of breast cancer than postmenopausal women of an identical age (RR at age 45-54 years 1.43, 1.33-1.52, p < 0.001). All three of these associations were attenuated by increasing adiposity among postmenopausal women, but did not vary materially by women's year of birth, ethnic origin, childbearing history, smoking, alcohol consumption, or hormonal contraceptive use. All three associations were stronger for lobular than for ductal tumours (p < 0.006 for each comparison). The effect of menopause in women of an identical age and trends by age at menopause were stronger for oestrogen receptor-positive disease than for oestrogen receptor-negative disease (p < 0.01 for both comparisons). Interpretation The effects of menarche and menopause on breast cancer risk might not be acting merely by lengthening women's total number of reproductive years. Endogenous ovarian hormones are more relevant for oestrogen receptor-positive disease than for oestrogen receptor-negative disease and for lobular than for ductal tumours. Funding Cancer Research UK. C1 [Beral, V.; Bull, D.; Pirie, K.; Reeves, G.] Univ Oxford, Canc Epidemiol Unit, Oxford OX3 7LF, England. [Peto, R.] Univ Oxford, CRUK MRC BHF Clin Trial Serv Unit, Oxford OX3 7LF, England. [Peto, R.] Univ Oxford, Epidemiol Studies Unit, Oxford OX3 7LF, England. [Skegg, D.] Univ Otago, Dunedin, New Zealand. [LaVecchia, C.] Ist Mario Negri, Milan, Italy. [LaVecchia, C.] Univ Milan, Milan, Italy. [Magnusson, C.] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Pike, M. C.] Mem Sloan Kettering Canc Ctr, New York, NY USA. [Thomas, D.] Fred Hutchinson Canc Res Ctr, Seattle, WA USA. [Hamajima, N.; Hirose, K.; Tajima, K.] Aichi Canc Res Inst, Nagoya, Aichi, Japan. [Rohan, T.] Albert Einstein Coll Med, New York, NY USA. [Friedenreich, C. M.] Alberta Hlth Serv, Calgary, AB, Canada. [Calle, E. E.; Gapstur, S. M.; Patel, A. V.] Amer Canc Soc, Atlanta, GA USA. [Coates, R. J.; Liff, J. M.] Emory Univ, Atlanta, GA USA. [Talamini, R.] Aviano Canc Ctr, Pordenone, Italy. [Chantarakul, N.; Koetsawang, S.; Rachawat, D.] Mahidol Univ, Bangkok, Thailand. [Marcou, Y.; Kakouri, E.] Bank Cyprus Oncol Ctr, Nicosia, Cyprus. [Duffy, S. W.] Barts & London Queen Marys Sch Med & Dent, London, England. [Morabia, A.; Schuman, L.; Stewart, W.; Szklo, M.] Johns Hopkins Univ, Breast Tumor Collaborat Study, Baltimore, MD USA. [Coogan, P. F.; Palmer, J. R.; Rosenberg, L.] Boston Univ, Sloane Epidemiol Ctr, Boston, MA USA. [Band, P.; Coldman, A. J.; Gallagher, R. P.; Hislop, T. G.; Yang, P.] British Columbia Canc Agcy, Vancouver, BC, Canada. [Cummings, S. R.] Calif Pacific Med Ctr, San Francisco, CA USA. [Canfell, K.; Sitas, F.] Canc Council NSW, Sydney, NSW, Australia. [Chao, P.; Lissowska, J.] Canc Ctr & M Sklodowska Curie Inst Oncol, Warsaw, Poland. [Horn-Ross, P. L.; John, E. M.] Canc Prevent Inst Calif, Fremont, CA USA. [Kolonel, L. M.; Nomura, A. M. Y.] Univ Hawaii, Canc Res Ctr, Honolulu, HI USA. [Ghiasvand, R.] Univ Tehran, Inst Canc, Canc Res Ctr, Tehran, Iran. [Hu, J.; Johnson, K. C.; Mao, Y.] Canadian Canc Registries Epidemiol Res Grp, Ottawa, ON, Canada. [Beral, V.; Bull, D.; Callaghan, K.; Crossley, B.; Goodill, A.; Green, J.; Hermon, C.; Key, T.; Lindgard, I.; Liu, B.; Pirie, K.; Reeves, G.] Canc Res UK Epidemiol Unit, Oxford, England. [Collins, R.; Doll, R.; Peto, R.] Canc Res UK MRC BHF, Clin Trial Serv, Oxford, England. [Collins, R.; Doll, R.; Peto, R.] Canc Res UK MRC BHF, Epidemiol Studies Unit, Oxford, England. [Bishop, T.] Canc Res UK Genet Epidemiol Lab, Leeds, W Yorkshire, England. [Fentiman, I. S.] Canc Res UK, London, England. [De Sanjose, S.; Gonzaler, C. A.] Catalan Inst Oncol, Barcelona, Spain. [Lee, N.; Marchbanks, P.; Ory, H. W.; Peterson, H. B.; Wingo, P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ebeling, K.; Kunde, D.; Nishan, P.] Cent Inst Canc Res, Berlin, Germany. [Hopper, J. L.] Univ Melbourne, Ctr Genet Epidemiol, Melbourne, Vic, Australia. [Eliassen, H.; S Hankinson Nurses Hlth Study I II Res Grp] Harvard Med Sch, Brigham & Womens Hosp, Channing Lab, Boston, MA USA. [Gajalakshmi, V.] Chennai Canc Inst, Madras, Tamil Nadu, India. [Martin, N.; Pardthaisong, T.; Silpisornkosol, S.; Theetranont, C.] Chiang Mai Univ, Chiang Mai, Thailand. [Boosiri, B.; Chutivongse, S.; Jimakorn, P.; Virutamasen, P.; Wongsrichanalai, C.] Chulalongkorn Univ, Bangkok, Thailand. [Neugut, A.; Santella, R.] Columbia Univ, New York, NY 10027 USA. [Baines, C. J.; Kreiger, N.; Miller, A. B.; Wall, C.] Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Tjonneland, A.] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark. [Jorgensen, T.; Stahlberg, C.; Pedersen, A. Tonnes] Res Ctr Prevent & Hlth, Danish Nurse Cohort Study, Capital Reg, Denmark. [Flesch-Janys, D.] Univ Canc Ctr Hamburg, Dept Canc Epidemiol Clin Canc Registry, Hamburg, Germany. [Hakansson, N.] Karolinska Inst, Dept Environm Med, Stockholm, Sweden. [Cauley, J.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Heuch, I.] Univ Bergen, Dept Math, N-5007 Bergen, Norway. [Adami, H. O.; Persson, I.; Weiderpass, E.] Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden. [Magnusson, C.] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden. [Chang-Claude, J.; Kaaks, R.] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany. [McCredie, M.; Paul, C.; Skegg, D. C. G.; Spears, G. F. S.] Univ Otago, Dunedin, New Zealand. [Iwasaki, M.; Tsugane, S.] Natl Canc Ctr, Res Ctr Canc Prevent & Screening, Epidemiol & Prevent Div, Tokyo 104, Japan. [Anderson, G.; Daling, J. R.; Hampton, J.; Hutchinson, W. B.; Li, C. I.; Malone, K.; Mandelson, M.; Newcomb, P.; Noonan, E. A.; Ray, R. M.; Stanford, J. L.; Tang, M. T. C.; Thomas, D. B.; Weiss, N. S.; White, E.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Izquierdo, A.; Viladiu, P.] Girona Canc Registry, Girona, Spain. [Fourkala, E. O.; Jacobs, I.; Menon, U.; Ryan, A.] UCL, Dept Womens Canc, Inst Womens Hlth, Gynaecol Canc Res Ctr, London, England. [Cuevas, H. R.; Ontiveros, P.; Palet, A.; Salazar, S. B.] Hosp Gen Mexico City, Mexico City, DF, Mexico. [Aristizabal, N.; Cuadros, A.] Univ Hosp, Cali, Colombia. [Tryggvadottir, L.; Tulinius, H.] Iceland Canc Soc, Reykjavik, Iceland. [Riboli, E.] Univ London Imperial Coll Sci Technol & Med, London, England. [Andrieu, N.; Bachelot, A.; Le, M. G.; Bremond, A.; Gairard, B.; Lansac, J.; Piana, L.; Renaud, R.] Inst Gustave Roussy, Villejuif, France. [Clavel-Chapelon, F.; Fournier, A.; Touillaud, M.; Mesrine, S.; Chabbert-Buffet, N.; Boutron-Ruault, M. C.] Paris S Univ, INSERM, Inst Gustave Roussy, EPIC Grp E3N, Villejuif, France. [Wolk, A.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden. [Torres-Mejia, G.] Inst Nacl Salud Publ, Morelos, Mexico. [Franceschi, S.; Romieu, I.] Int Agcy Res Canc, F-69372 Lyon, France. [Boyle, P.] Int Prevent Res Inst, Lyon, France. [Lubin, F.; Modan, B.; Ron, E.; Wax, Y.] Israel Chaim Sheba Med Ctr, Tel Hashomer, Israel. [Friedman, G. D.; Hiatt, R. A.] Kaiser Permanente, Oakland, CA USA. [Levi, F.] Inst Univ Med Sociale & Prevent, Lausanne, Switzerland. [Kosmelj, K.; Primic-Zakelj, M.; Ravnihar, B.; Stare, J.] Inst Oncol, Ljubljana, Slovenia. [Ekbom, A.; Erlandsson, G.; Persson, I.] Karolinska Inst, Stockholm, Sweden. [Beeson, W. L.; Fraser, G.] Loma Linda Univ, Loma Linda, CA 92350 USA. [Peto, J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England. [Hanson, R. L.; Leske, M. C.; Mahoney, M. C.; Nasca, P. C.; Varma, A. O.; Weinstein, A. L.] Long Isl Breast Canc Study, Long Isl City, NY USA. [Hartman, M. L.; Olsson, H.] Univ Hosp, Lund, Sweden. [Goldbohm, R. A.; van den Brandt, P. A.] Maastricht Univ, Maastricht, Netherlands. [Palli, D.] ISPO, Mol & Nutrit Epidemiol Unit, Florence, Italy. [Teitelbaum, S.] Mt Sinai Sch Med, New York, NY 10029 USA. [Apelo, R. A.; Baens, J.; de la Cruz, J. R.; Javier, B.; Lacaya, L. B.; Ngelangel, C. A.] Univ Philippines, Manila, Philippines. [La Vecchia, C.; Negri, E.] Ist Mario Negri, Milan, Italy. [La Vecchia, C.; Negri, E.] Univ Milan, I-20122 Milan, Italy. [Marubini, E.] Ist Nazl Tumori, Div Stat Med & Biometria, Milan, Italy. [Ferraroni, M.] Ist Stat Med & Biometria, Milan, Italy. [Pike, M. C.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Gerber, M.; Richardson, S.; Segala, C.] Montpellier Canc Ctr, Montpellier, France. [Gerber, M.; Richardson, S.; Segala, C.] INSERM, Montpellier, France. [Gatei, D.; Kenya, P.; Kungu, A.; Mati, J. G.] Nairobi Ctr Res Reprod, Nairobi, Kenya. [Brinton, L. A.; Freedman, M.; Hoover, R.; Schairer, C.; Ziegler, R.] NCI, Bethesda, MD 20892 USA. [Banks, E.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia. [Spirtas, R.] NICHHD, Bethesda, MD 20892 USA. [Lee, H. P.] Natl Univ Singapore, Singapore 117548, Singapore. [Rookus, M. A.; van Leeuwen, F. E.] Netherlands Canc Inst, Amsterdam, Netherlands. [Schoenberg, J. A.] New Jersey State Dept Hlth, Trenton, NJ 08625 USA. [Graff-Iversen, S.; Selmer, R.] Norwegian Inst Publ Hlth, Oslo, Norway. [Jones, L.; McPherson, K.; Neil, A.; Vessey, M.; Yeates, D.] Dept Publ Hlth, Oxford, England. [Mabuchi, K.; Preston, D.] Radiat Effects Res Fdn, Hiroshima, Japan. [Hannaford, P.; Kay, C.] Royal Coll Gen Practitioners Oral Contracept Study, London, England. [McCann, S. E.] Roswell Pk Canc Inst, New York, NY USA. [Rosero-Bixby, L.] Univ Costa Rica, San Jose, Costa Rica. [Gao, Y. T.; Jin, F.; Yuan, J-M] Shanghai Canc Inst, Shanghai, Peoples R China. [Wei, H. Y.; Yun, T.; Zhiheng, C.] Shanghai Inst Planned Parenthood Res, Shanghai, Peoples R China. [Berry, G.; Booth, J. Cooper; Jelihovsky, T.; MacLennan, R.; Shearman, R.] Univ Sydney, Dept Publ Hlth, Sydney, NSW 2006, Australia. [Hadjisavvas, A.; Kyriacou, K.; Loisidou, M.] Cyprus Inst Neurol & Genet, Nicosia, Cyprus. [Zhou, X.] Wuhan Univ, Zhongman Hosp, Wuhan 430072, Peoples R China. [Wang, Q-S] Tianjin Canc Inst, Tianjin, Peoples R China. [Kawai, M.; Minami, Y.; Tsuji, I.] Tohoku Univ, Grad Sch Med, Sendai, Miyagi 980, Japan. [Lund, E.; Kumle, M.; Stalsberg, H.] Univ Tromso, Tromso, Norway. [Shu, X. O.; Zheng, W.] Vanderbilt Univ, Nashville, TN USA. [Monninkhof, E. M.; Onland-Moret, N. C.; Peeters, P. H. M.] Univ Med Ctr Utrecht, Utrecht, Netherlands. [Katsouyanni, K.; Trichopoulou, A.; Trichopoulos, D.; Tzonou, A.] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Baltzell, K. A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Dabancens, A.; Martinez, L.; Molina, R.; Salas, O.] Univ Chile, Santiago, Chile. [Alexander, F. E.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Anderson, K.; Folsom, A. R.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Gammon, M. D.; Hulka, B. S.; Millikan, R.] Univ N Carolina Chapel Hill, Sch Publ Hlth, Chapel Hill, NC USA. [Chilvers, C. E. D.] Univ Nottingham, Nottingham NG7 2RD, England. [Lumachi, F.] Univ Padua, Sch Med, Padua, Italy. [Bain, C.; Schofield, F.; Siskind, V.] Univ Queensland, Brisbane, Qld, Australia. [Rebbeck, T. R.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Bernstein, L. R.; Enger, S.; Haile, R. W.; Paganini-Hill, A.; Ross, R. K.; Ursin, G.; Wu, A. H.; Yu, M. C.] Univ So Calif, Los Angeles, CA USA. [Ewertz, Denmark M.] Univ So Denmark, Odense Univ Hosp, Dept Oncol, Odense, Denmark. [Clarke, E. A.] Univ Toronto, Toronto, ON, Canada. [Kalache, A.; Farley, T. M. M.; Holck, S.; Meirik, O.] World Hlth Org, World Bank Special Programme Res, UNDP, UNFPA, Geneva, Switzerland. [Fukao, A.] Yamagata Univ, Grad Sch Med, Yamagata 990, Japan. RP Beral, V (reprint author), Univ Oxford, Canc Epidemiol Unit, Richard Doll Bldg, Oxford OX3 7LF, England. RI Heuch, Ivar/A-4510-2008; Negri, Eva/B-7244-2013; KAWAI, MASAAKI/B-3461-2008; Jacobs, Ian/F-1743-2013; Boutron Ruault, Marie-Christine/G-3705-2013; Boutron, Marie-Christine/K-8168-2013; Loizidou, Maria/C-6607-2009; Hakansson, Niclas/L-7913-2013; Clavel-Chapelon, Francoise/G-6733-2014; ANDRIEU, Nadine/H-4255-2014; de Sanjose Llongueras, Silvia/H-6339-2014; Hartman, Mikael/B-4324-2011; Tsugane, Shocichiro/A-2424-2015; Boutron-Ruault, Marie-Christine/H-3936-2014; Brinton, Louise/G-7486-2015; Onland-Moret, N. Charlotte/G-9185-2011; Lumachi, Franco/K-9501-2015; Hamajima, Nobuyuki/I-7237-2014; IBIS, GENICA/O-1906-2015; Richardson, Sylvia/G-4691-2015; Weiderpass, Elisabete/M-4029-2016; Ferraroni, Monica/D-6548-2017; OI Lissowska, Jolanta/0000-0003-2695-5799; Sitas, Freddy/0000-0001-9679-1481; La Vecchia, Carlo/0000-0003-1441-897X; Yuan, Jian-Min/0000-0002-4620-3108; Bishop, Tim/0000-0002-8752-8785; PALLI, Domenico/0000-0002-5558-2437; Cauley, Jane A/0000-0003-0752-4408; Heuch, Ivar/0000-0003-3386-9688; Negri, Eva/0000-0001-9712-8526; KAWAI, MASAAKI/0000-0003-1383-0487; Jacobs, Ian/0000-0002-8112-4624; Hakansson, Niclas/0000-0001-7673-5554; Brinton, Louise/0000-0003-3853-8562; Lumachi, Franco/0000-0001-8349-631X; Richardson, Sylvia/0000-0003-1998-492X; Weiderpass, Elisabete/0000-0003-2237-0128; Ferraroni, Monica/0000-0002-4542-4996; Magnusson, Cecilia/0000-0002-8567-6725 FU Cancer Research UK FX Funding for this collaborative reanalysis of original data was provided by Cancer Research UK. Funding for the contributing studies is described in the publications of those studies. NR 25 TC 100 Z9 101 U1 2 U2 59 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD NOV PY 2012 VL 13 IS 11 BP 1141 EP 1151 DI 10.1016/S1470-2045(12)70425-4 PG 11 WC Oncology SC Oncology GA 030KZ UT WOS:000310570900045 ER PT J AU Lehman, EJ Hein, MJ Baron, SL Gersic, CM AF Lehman, Everett J. Hein, Misty J. Baron, Sherry L. Gersic, Christine M. TI Neurodegenerative causes of death among retired National Football League players SO NEUROLOGY LA English DT Article ID CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; TABLE ANALYSIS SYSTEM; PROFESSIONAL FOOTBALL; CONCUSSION; COLLEGIATE; MORTALITY; DISEASE; INJURY AB Objective: To analyze neurodegenerative causes of death, specifically Alzheimer disease (AD), Parkinson disease, and amyotrophic lateral sclerosis (ALS), among a cohort of professional football players. Methods: This was a cohort mortality study of 3,439 National Football League players with at least 5 pension-credited playing seasons from 1959 to 1988. Vital status was ascertained through 2007. For analysis purposes, players were placed into 2 strata based on characteristics of position played: nonspeed players (linemen) and speed players (all other positions except punter/kicker). External comparisons with the US population used standardized mortality ratios (SMRs); internal comparisons between speed and nonspeed player positions used standardized rate ratios (SRRs). Results: Overall player mortality compared with that of the US population was reduced (SMR 0.53, 95% confidence interval [CI] 0.48-0.59). Neurodegenerative mortality was increased using both underlying cause of death rate files (SMR 2.83, 95% CI 1.36-5.21) and multiple cause of death (MCOD) rate files (SMR 3.26, 95% CI 1.90-5.22). Of the neurodegenerative causes, results were elevated (using MCOD rates) for both ALS (SMR 4.31, 95% CI 1.73-8.87) and AD (SMR 3.86, 95% CI 1.55-7.95). In internal analysis (using MCOD rates), higher neurodegenerative mortality was observed among players in speed positions compared with players in nonspeed positions (SRR 3.29, 95% CI 0.92-11.7). Conclusions: The neurodegenerative mortality of this cohort is 3 times higher than that of the general US population; that for 2 of the major neurodegenerative subcategories, AD and ALS, is 4 times higher. These results are consistent with recent studies that suggest an increased risk of neurodegenerative disease among football players. Neurology (R) 2012;79:1970-1974 C1 [Lehman, Everett J.; Hein, Misty J.; Baron, Sherry L.; Gersic, Christine M.] NIOSH, Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. RP Lehman, EJ (reprint author), NIOSH, Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. EM elehman@cdc.gov FU National Institute for Occupational Safety and Health FX Supported by the Intramural Research Program of the National Institute for Occupational Safety and Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. The sponsor reviewed and approved final submission but did not have a role in design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation of the manuscript. NR 26 TC 138 Z9 139 U1 4 U2 49 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD NOV PY 2012 VL 79 IS 19 BP 1970 EP 1974 DI 10.1212/WNL.0b013e31826daf50 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 032US UT WOS:000310745200011 PM 22955124 ER PT J AU Eriksson, CO Graham, DA Uyeki, TM Randolph, AG AF Eriksson, Carl O. Graham, Dionne A. Uyeki, Timothy M. Randolph, Adrienne G. TI Risk factors for mechanical ventilation in US children hospitalized with seasonal influenza and 2009 pandemic influenza A SO PEDIATRIC CRITICAL CARE MEDICINE LA English DT Article DE child; human influenza; infant; mechanical ventilation; pediatric hospitals; pandemics; respiration ID UNITED-STATES; STAPHYLOCOCCUS-AUREUS; H1N1 INFLUENZA; RESPIRATORY-FAILURE; PNEUMONIA; INFECTION; OUTCOMES; A(H1N1); DISEASE; DEATHS AB Objective: We tested the hypothesis that the use of mechanical ventilator support in children hospitalized with influenza during the 2009 H1N1 influenza A (H1N1) pandemic was higher than would be expected in children hospitalized for seasonal influenza after adjusting for patient risk. Design: Retrospective cohort study. Setting: Forty-three U.S. pediatric hospitals. Patients: Children <18 yrs old with a discharge diagnosis of influenza admitted July 2006 through March 2009 (seasonal influenza) and June through December 2009 (2009 pandemic influenza A). Interventions: None. Measurements and Main Results: We included 10,173 children hospitalized with seasonal influenza and 9837 with presumed 2009 pandemic influenza A. The 2009 pandemic influenza A cohort was older (median 5.0 vs. 1.9 yrs), more likely to have asthma (30% vs. 18%), and less likely to receive mechanical ventilation (7.1% [n = 701] vs. 9.2% [n = 940]). Using logistic regression, we created a multivariable model of risk factors associated with endotracheal mechanical ventilator support in the seasonal influenza cohort and used this model to predict the number of expected mechanical ventilation cases in children with presumed 2009 pandemic influenza A. Adjusted for underlying health conditions, race, age, and a co-diagnosis of bacterial pneumonia, the observed/expected rate of mechanical ventilation in the presumed 2009 pandemic influenza A cohort was 0.74 (95% confidence interval 0.68-0.79). Early hospital treatment with influenza antiviral medications was associated with decreased initiation of mechanical ventilation on hospital day >= 3 in the seasonal influenza (odds ratio 0.66; 95% confidence interval 0.45-0.97) and 2009 pandemic influenza A (odds ratio 0.23; 95% confidence interval 0.16-0.34) periods; influenza antiviral use in the 2009 pandemic influenza A period was much higher (70% vs. 20%; p < .001). Conclusions: Although the number of children with a hospital discharge diagnosis of influenza almost tripled during the 2009 pandemic influenza A period, the risk-adjusted proportion of children receiving mechanical ventilation was lower than we would have predicted in a seasonal influenza cohort. Early hospital use of influenza antiviral medications was associated with a decrease in late-onset mechanical ventilation. (Pediatr Crit Care Med 2012; 13:625-631) C1 [Eriksson, Carl O.] Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Crit Care, Portland, OR 97201 USA. [Graham, Dionne A.] Harvard Univ, Sch Med, Harvard Pediat Hlth Serv Res Fellowship Program, Boston, MA USA. [Randolph, Adrienne G.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA. [Graham, Dionne A.] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA. [Randolph, Adrienne G.] Childrens Hosp, Div Crit Care, Dept Anesthesia Perioperat & Pain Med, Boston, MA 02115 USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Eriksson, CO (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Crit Care, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA. EM eriks-son@ohsu.edu OI Randolph, Adrienne/0000-0002-3084-3071 FU National Institute of Allergy and Infectious Diseases of the National Institutes of Health [NIH R01AI084011]; Children's Hospital Boston Anesthesia Foundation; Centers for Disease Control and Prevention FX Supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH R01AI084011, Dr. Randolph), the Children's Hospital Boston Anesthesia Foundation (Drs. Eriksson and Randolph) and the Centers for Disease Control and Prevention (Dr. Uyeki). This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Centers for Disease Control and Prevention. NR 40 TC 14 Z9 14 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1529-7535 J9 PEDIATR CRIT CARE ME JI Pediatr. Crit. Care Med. PD NOV PY 2012 VL 13 IS 6 BP 625 EP 631 DI 10.1097/PCC.0b013e318260114e PG 7 WC Critical Care Medicine; Pediatrics SC General & Internal Medicine; Pediatrics GA 033KP UT WOS:000310795100010 PM 22895006 ER PT J AU Anderson, C Law, JK Daniels, A Rice, C Mandell, DS Hagopian, L Law, PA AF Anderson, Connie Law, J. Kiely Daniels, Amy Rice, Catherine Mandell, David S. Hagopian, Louis Law, Paul A. TI Occurrence and Family Impact of Elopement in Children With Autism Spectrum Disorders SO PEDIATRICS LA English DT Article DE autism spectrum disorders; elopement; wandering ID CANCER CLINICAL-TRIALS; CHALLENGING BEHAVIORS; FUNCTIONAL-ANALYSIS; VALIDATION; QUESTIONNAIRE; PARTICIPATION; DEATH AB OBJECTIVES: Anecdotal reports suggest that elopement behavior in children with autism spectrum disorders (ASDs) increases risk of injury or death and places a major burden on families. This study assessed parent-reported elopement occurrence and associated factors among children with ASDs. METHODS: Information on elopement frequency, associated characteristics, and consequences was collected via an online questionnaire. The study sample included 1218 children with ASD and 1076 of their siblings without ASD. The association among family sociodemographic and child clinical characteristics and time to first elopement was estimated by using a Cox proportional hazards model. RESULTS: Forty-nine percent (n = 598) of survey respondents reported their child with an ASD had attempted to elope at least once after age 4 years; 26% (n = 316) were missing long enough to cause concern. Of those who went missing, 24% were in danger of drowning and 65% were in danger of traffic injury. Elopement risk was associated with autism severity, increasing, on average, 9% for every 10-point increase in Social Responsiveness Scale T score (relative risk 1.09, 95% confidence interval: 1.02, 1.16). Unaffected siblings had significantly lower rates of elopement across all ages compared with children with ASD. CONCLUSIONS: Nearly half of children with ASD were reported to engage in elopement behavior, with a substantial number at risk for bodily harm. These results highlight the urgent need to develop interventions to reduce the risk of elopement, to support families coping with this issue, and to train child care professionals, educators, and first responders who are often involved when elopements occur. Pediatrics 2012;130:870-877 C1 [Law, Paul A.] Kennedy Krieger Inst, Dept Med Informat, Baltimore, MD 21211 USA. [Law, J. Kiely; Hagopian, Louis; Law, Paul A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Daniels, Amy] Autism Speaks, New York, NY USA. [Rice, Catherine] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Mandell, David S.] Univ Penn, Perelman Sch Med, Ctr Mental Hlth Policy & Serv Res, Philadelphia, PA 19104 USA. RP Law, PA (reprint author), Kennedy Krieger Inst, Dept Med Informat, 3825 Greenspring Ave,Painter Bldg,1st Floor, Baltimore, MD 21211 USA. EM lawp@kennedykrieger.org RI Mandell, David/H-2730-2012; Rice, Catherine/D-6305-2016; OI Mandell, David/0000-0001-8240-820X; Daniels, Amy/0000-0003-0298-6267 FU Autism Research Institute; Autism Science Foundation, Autism Speaks; Global Autism Collaboration; National Autism Association; Autism Speaks FX Supported by the Autism Research Institute, the Autism Science Foundation, Autism Speaks, the Global Autism Collaboration, and the National Autism Association.; Dr Daniels was employed by Kennedy Krieger Institute through the submission of the manuscript. On February 26, she started a position with Autism Speaks. Autism Speaks is a financial supporter of the IAN Project, the study through which the elopement survey was implemented. The other authors have indicated they have no financial relationships relevant to this article to disclose. NR 34 TC 19 Z9 19 U1 2 U2 11 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD NOV PY 2012 VL 130 IS 5 BP 870 EP 877 DI 10.1542/peds.2012-0762 PG 8 WC Pediatrics SC Pediatrics GA 029OT UT WOS:000310505900056 PM 23045563 ER PT J AU McCormick, EV Durfee, J Vogt, TM Daley, MF Hambidge, SJ Shlay, J AF McCormick, Emily V. Durfee, Josh Vogt, Tara M. Daley, Matthew F. Hambidge, Simon J. Shlay, Judith TI Physician Attitudes Regarding School-Located Vaccinations SO PEDIATRICS LA English DT Article DE immunizations; adolescent; school-based program ID IMMUNIZATION PRACTICES ACIP; ADOLESCENT IMMUNIZATION; INFLUENZA VACCINATION; ADVISORY-COMMITTEE; CHILDREN; PEDIATRICIANS; DELIVERY; RECOMMENDATIONS; VACCINES; SETTINGS AB OBJECTIVE: To assess physician attitudes regarding school-located adolescent vaccination and influenza vaccination. METHODS: From July through September 2010, a 20-item survey was mailed to 1337 practicing Colorado family physicians and pediatricians. Standard statistical methods were used to examine unadjusted and adjusted odds ratios of factors associated with physician support for school-located vaccination programs. RESULTS: Overall, 943 physicians were survey-eligible, and 584 (62%) responded. More than half of physicians supported both school-located influenza and adolescent vaccination. However, fewer physicians supported school-located adolescent vaccination compared with influenza vaccination. More physicians supported school-located vaccination for their publicly insured patients compared with their privately insured patients. Some family physicians (32%) and pediatricians (39%) believed that school-located vaccination would make their patients less likely to attend well-child visits, and half of respondents believed that school-located vaccination would have a negative financial impact on their practice. In multivariate analyses, physicians concerned about the financial impact of school-located vaccination were less likely to support such programs. CONCLUSIONS: Although a majority of Colorado physicians supported influenza and adolescent vaccination at school, they expressed concerns regarding the implications on their practice. Lesser support for vaccination of their privately insured patients and concerns regarding attendance at well-child visits suggests the perceived financial impact from school-located vaccination is a barrier and merits additional examination. Pediatrics 2012;130:887-896 C1 [Shlay, Judith] Denver Hlth & Hosp Author, Denver Publ Hlth Dept, Denver, CO 80204 USA. [McCormick, Emily V.] Ctr Dis Control & Prevent, Publ Hlth Prevent Serv, Atlanta, GA USA. [Durfee, Josh] Denver Hlth & Hosp Author, Dept Hlth Serv Res, Denver, CO 80204 USA. [Hambidge, Simon J.] Denver Hlth & Hosp Author, Dept Community Hlth Serv, Denver, CO 80204 USA. [Vogt, Tara M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Daley, Matthew F.; Hambidge, Simon J.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Daley, Matthew F.; Hambidge, Simon J.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA. [Shlay, Judith] Univ Colorado, Sch Med, Dept Family Med, Aurora, CO USA. RP McCormick, EV (reprint author), Denver Hlth & Hosp Author, Denver Publ Hlth Dept, 605 Bannock,3rd Floor, Denver, CO 80204 USA. EM emily.mccormick@dhha.org FU Pfizer Inc; Centers for Disease Control and Prevention FX Dr Shlay has spoken on vaccination at a presentation sponsored by Pfizer Inc; the other authors have indicated they have no conflicts of interest relevant to this article to disclose.; This work was supported by the Centers for Disease Control and Prevention. NR 42 TC 7 Z9 7 U1 1 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD NOV PY 2012 VL 130 IS 5 BP 887 EP 896 DI 10.1542/peds.2011-2962 PG 10 WC Pediatrics SC Pediatrics GA 029OT UT WOS:000310505900058 PM 23027169 ER PT J AU Guilamo-Ramos, V Bouris, A Lee, J McCarthy, K Michael, SL Pitt-Barnes, S Dittus, P AF Guilamo-Ramos, Vincent Bouris, Alida Lee, Jane McCarthy, Katharine Michael, Shannon L. Pitt-Barnes, Seraphine Dittus, Patricia TI Paternal Influences on Adolescent Sexual Risk Behaviors: A Structured Literature Review SO PEDIATRICS LA English DT Review DE adolescents; fathers; paternal influences; sexual risk behavior ID 1ST SEX; PARENT; COMMUNICATION; PREDICTORS; YOUTH; INTERVENTIONS; ATTITUDES; FATHERS; HIV; PERCEPTIONS AB BACKGROUND AND OBJECTIVE: To date, most parent-based research has neglected the role of fathers in shaping adolescent sexual behavior and has focused on mothers. The objective of this study was to conduct a structured review to assess the role of paternal influence on adolescent sexual behavior and to assess the methodological quality of the paternal influence literature related to adolescent sexual behavior. METHODS: We searched electronic databases: PubMed, PsychINFO, Social Services Abstracts, Family Studies Abstracts, Sociological Abstracts, and the Cumulative Index to Nursing and Allied Health Literature. Studies published between 1980 and 2011 that targeted adolescents 11 to 18 years and focused on paternal parenting processes were included. Methodological quality was assessed by using an 11-item scoring system. RESULTS: Thirteen articles were identified and reviewed. Findings suggest paternal factors are independently associated with adolescent sexual behavior relative to maternal factors. The most commonly studied paternal influence was emotional qualities of the father-adolescent relationship. Paternal communication about sex was most consistently associated with adolescent sexual behavior, whereas paternal attitudes about sex was least associated. Methodological limitations include a tendency to rely on cross-sectional design, nonprobability sampling methods, and focus on sexual debut versus broader sexual behavior. CONCLUSIONS: Existing research preliminarily suggests fathers influence the sexual behavior of their adolescent children; however, more rigorous research examining diverse facets of paternal influence on adolescent sexual behavior is needed. We provide recommendations for primary care providers and public health practitioners to better incorporate fathers into interventions designed to reduce adolescent sexual risk behavior. Pediatrics 2012;130:e1313-e1325 C1 [Guilamo-Ramos, Vincent] NYU, Silver Sch Social Work, New York, NY 10003 USA. [Guilamo-Ramos, Vincent; Lee, Jane; McCarthy, Katharine] NYU, Ctr Latino Adolescent & Family Hlth, New York, NY 10003 USA. [Bouris, Alida] Univ Chicago, Sch Social Serv Adm, Chicago, IL 60637 USA. [Michael, Shannon L.; Pitt-Barnes, Seraphine; Dittus, Patricia] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Guilamo-Ramos, V (reprint author), NYU, Silver Sch Social Work, 1 Washington Sq N,Rm 320, New York, NY 10003 USA. EM vincent.ramos@nyu.edu FU Centers for Disease Control and Prevention Parenting Synthesis Project FX Supported by the Centers for Disease Control and Prevention Parenting Synthesis Project. NR 47 TC 17 Z9 17 U1 3 U2 34 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD NOV PY 2012 VL 130 IS 5 BP E1313 EP E1325 DI 10.1542/peds.2011-2066 PG 13 WC Pediatrics SC Pediatrics GA 029OT UT WOS:000310505900030 PM 23071205 ER PT J AU Barrios, LC Koonin, LM Kohl, KS Cetron, M AF Barrios, Lisa C. Koonin, Lisa M. Kohl, Katrin S. Cetron, Martin TI Selecting Nonpharmaceutical Strategies to Minimize Influenza Spread: The 2009 Influenza A (H1N1) Pandemic and Beyond SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; INTERVENTIONS AB Shortly after the influenza A (H1N1) 2009 pandemic began, the U.S. government provided guidance to state and local authorities to assist decision-making for the use of nonpharmaceutical strategies to minimize influenza spread. This. guidance included recommendations for flexible decision-making based on outbreak severity, and it allowed for uncertainty and course correction as the pandemic progressed. These recommendations build on a foundation of local, collaborative planning and posit a series of questions regarding epidemiology, the impact on the health-care system, and locally determined feasibility and acceptability of nonpharmaceutical strategies. This article describes recommendations and key questions for decision makers. C1 [Barrios, Lisa C.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Res Applicat & Evaluat Branch, Atlanta, GA 30033 USA. [Koonin, Lisa M.] Ctr Dis Control & Prevent, Off Infect Dis, Influenza Coordinat Unit, Atlanta, GA 30033 USA. [Kohl, Katrin S.; Cetron, Martin] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30033 USA. RP Barrios, LC (reprint author), Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Res Applicat & Evaluat Branch, 4770 Buford Hwy NE,MS K-12, Atlanta, GA 30033 USA. EM LBarrios@cdc.gov NR 22 TC 5 Z9 5 U1 1 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2012 VL 127 IS 6 BP 565 EP 571 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 033BZ UT WOS:000310769000006 PM 23115381 ER PT J AU Iqbal, K Klevens, RM Jiles, R AF Iqbal, Kashif Klevens, R. Monina Jiles, Ruth TI Comparison of Acute Viral Hepatitis Data Quality Using Two Methodologies, 2005-2007 SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; SURVEILLANCE AB Objective. We compared the quality of data reported to the Centers for Disease Control and Prevention (CDC) from sites that received funding for acute viral hepatitis surveillance through CDC's Emerging Infections Program (EIP) with sites that have electronic infrastructure to collect data but do not receive funding from CDC to support viral hepatitis surveillance. Methods. Descriptive analysis was conducted on acute hepatitis A, B, and C cases reported from EIP sites and National Electronic Disease Surveillance System (NEDSS)-based states (NBS) sites from 2005 to 2007. Data were compared for (1) completeness of demographic and risk behavior/exposure information; (2) adherence to CDC/Council of State and Territorial Epidemiologists (CSTE) case definition for confirmed cases of acute hepatitis A, B, and C; and (3) timeliness of reporting to the health department. Results. Data reported for sex and age were at least 98% complete for both EIP and NBS sites and race/ethnicity was more complete for EIP sites. For acute hepatitis A, B, and C, case reports from EIP sites were more likely than those from NBS sites to include a "yes" response to at least one risk behavior/exposure variable and were more likely to meet the CDC/CSTE case definition. EIP sites received case reports in a more timely fashion than did NBS sites. The case definition for acute hepatitis C proved problematic for both EIP and NBS sites. Conclusions. Data from the EIP sites were more complete and reported in a more timely way to health departments than data from the NBS sites. Funding for follow-up activities is essential to providing surveillance data of higher quality for decision-making and public health response. C1 [Iqbal, Kashif; Klevens, R. Monina; Jiles, Ruth] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Iqbal, K (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div Viral Hepatitis, 1600 Clifton Rd NE,MS G-37, Atlanta, GA 30333 USA. EM kai9@cdc.gov NR 13 TC 4 Z9 4 U1 0 U2 4 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD NOV-DEC PY 2012 VL 127 IS 6 BP 591 EP 597 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 033BZ UT WOS:000310769000009 PM 23115384 ER PT J AU Adjemian, J Weber, IB McQuiston, J Griffith, KS Mead, PS Nicholson, W Roche, A Schriefer, M Fischer, M Kosoy, O Laven, JJ Stoddard, RA Hoffmaster, AR Smith, T Bui, D Wilkins, PP Jones, JL Gupton, PN Quinn, CP Messonnier, N Higgins, C Wong, D AF Adjemian, Jennifer Weber, Ingrid B. McQuiston, Jennifer Griffith, Kevin S. Mead, Paul S. Nicholson, William Roche, Aubree Schriefer, Martin Fischer, Marc Kosoy, Olga Laven, Janeen J. Stoddard, Robyn A. Hoffmaster, Alex R. Smith, Theresa Bui, Duy Wilkins, Patricia P. Jones, Jeffery L. Gupton, Paige N. Quinn, Conrad P. Messonnier, Nancy Higgins, Charles Wong, David TI Zoonotic Infections Among Employees from Great Smoky Mountains and Rocky Mountain National Parks, 2008-2009 SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Incidence; National Park Service; Prevalence; Vector-borne; Zoonoses ID BORNE RELAPSING FEVER; WEST-NILE-VIRUS; TOXOPLASMA-GONDII INFECTION; LINKED-IMMUNOSORBENT-ASSAY; UNITED-STATES; SPOTTED-FEVER; IMMUNOGLOBULIN-G; INTERSTATE OUTBREAK; PROTECTIVE ANTIGEN; BACILLUS-ANTHRACIS AB U.S. National Park Service employees may have prolonged exposure to wildlife and arthropods, placing them at increased risk of infection with endemic zoonoses. To evaluate possible zoonotic risks present at both Great Smoky Mountains (GRSM) and Rocky Mountain (ROMO) National Parks, we assessed park employees for baseline seroprevalence to specific zoonotic pathogens, followed by evaluation of incident infections over a 1-year study period. Park personnel showed evidence of prior infection with a variety of zoonotic agents, including California serogroup bunyaviruses (31.9%), Bartonella henselae (26.7%), spotted fever group rickettsiae (22.2%), Toxoplasma gondii (11.1%), Anaplasma phagocytophilum (8.1%), Brucella spp. (8.9%), flaviviruses (2.2%), and Bacillus anthracis (1.5%). Over a 1-year study period, we detected incident infections with leptospirosis (5.7%), B. henselae (5.7%), spotted fever group rickettsiae (1.5%), T. gondii (1.5%), B. anthracis (1.5%), and La Crosse virus (1.5%) in staff members at GRSM, and with spotted fever group rickettsiae (8.5%) and B. henselae (4.3%) in staff at ROMO. The risk of any incident infection was greater for employees who worked as resource managers (OR 7.4; 95% CI 1.4,37.5; p = 0.02), and as law enforcement rangers/rescue crew (OR 6.5; 95% CI 1.1,36.5; p = 0.03), relative to those who worked primarily in administration or management. The results of this study increase our understanding of the pathogens circulating within both parks, and can be used to inform the development of effective guidelines and interventions to increase visitor and staff awareness and help prevent exposure to zoonotic agents. C1 [Adjemian, Jennifer; Weber, Ingrid B.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. [Adjemian, Jennifer; McQuiston, Jennifer; Nicholson, William; Roche, Aubree] CDC, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Atlanta, GA 30333 USA. [Weber, Ingrid B.; Griffith, Kevin S.; Mead, Paul S.; Schriefer, Martin] CDC, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. [Weber, Ingrid B.; Fischer, Marc; Kosoy, Olga; Laven, Janeen J.] CDC, Arboviral Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. [Stoddard, Robyn A.; Hoffmaster, Alex R.; Smith, Theresa; Bui, Duy] CDC, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Wilkins, Patricia P.; Jones, Jeffery L.; Gupton, Paige N.] CDC, Parasit Dis Branch, Div Parasit Dis, Atlanta, GA 30333 USA. [Quinn, Conrad P.; Messonnier, Nancy] CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Atlanta, GA 30333 USA. [Higgins, Charles; Wong, David] Natl Pk Serv, Off Publ Hlth, Washington, DC USA. [Higgins, Charles; Wong, David] Natl Pk Serv, Off Publ Hlth, Albuquerque, NM USA. RP Adjemian, J (reprint author), NIAID, Epidem Intelligence Serv, Lab Clin Infect Dis, Quarters 15 B-1,8 West Dr,MSC 2665, Bethesda, MD 20892 USA. EM Jennifer.adjemian@nih.gov NR 60 TC 10 Z9 11 U1 0 U2 13 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 EI 1557-7759 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD NOV PY 2012 VL 12 IS 11 BP 922 EP 931 DI 10.1089/vbz.2011.0917 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 033FW UT WOS:000310780600002 PM 22835153 ER PT J AU Boegler, KA Graham, CB Montenieri, JA MacMillan, K Holmes, JL Petersen, JM Gage, KL Eisen, RJ AF Boegler, Karen A. Graham, Christine B. Montenieri, John A. MacMillan, Katherine Holmes, Jennifer L. Petersen, Jeannine M. Gage, Kenneth L. Eisen, Rebecca J. TI Evaluation of the Infectiousness to Mice of Soil Contaminated with Yersinia pestis-Infected Blood SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Plague; Soil; Transmission; Yersinia pestis ID PLAGUE; PSEUDOTUBERCULOSIS; PERSISTENCE; FIELD AB Plague, an often-fatal zoonotic disease caused by Yersinia pestis, is characterized by epizootic and quiescent periods. How Y. pestis is maintained during inter-epizootic periods is poorly understood, but soil has been implicated as a potential reservoir. Although previous studies have suggested that Y. pestis is able to survive in soil for weeks or months, it is unclear whether or not it is infectious to susceptible hosts. Here we investigate the potential for Y. pestis to infect mice through close contact with contaminated soil under laboratory conditions. In an attempt to approximate the natural conditions under which animals would be exposed to Y. pestis-contaminated soil, mouse cages filled with soil from a plague-endemic region were held at temperature and humidity ranges observed in ground squirrel burrows. These laboratory "burrows" were contaminated with highly bacteremic blood (>10(8) cfu/mL) to simulate the introduction of infectious material from a dying animal during an epizootic. Outbred Swiss-Webster mice with scarified skin patches were held on contaminated soil for 10 days and monitored for signs of illness. Following exposure to contaminated soil, one animal of 104 became infected with Y. pestis. None of the remaining animals seroconverted following a 21-day holding period. Under our experimental conditions, which maximized the likelihood of contact between susceptible mice and contaminated soil, transmission efficiency from soil to mice was 0.96% (95% CI 0.17, 5.25%). This suggests that although transmission of Y. pestis from contaminated soils is possible, it is not likely a major transmission route under natural conditions. C1 [Boegler, Karen A.; Graham, Christine B.; Montenieri, John A.; MacMillan, Katherine; Holmes, Jennifer L.; Petersen, Jeannine M.; Gage, Kenneth L.; Eisen, Rebecca J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Boegler, KA (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Bacterial Dis Branch, 3150 Rampart Rd,MS P02, Ft Collins, CO 80521 USA. EM kje5@cdc.gov FU Emerging Infectious Diseases (EID) Fellowship Program; CDC FX We thank John Young, Ryan Pappert, and Laurel Respicio-Kingry, CDC National Center for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, for providing assistance with processing and evaluating diagnostic specimens; and the Fort Collins Natural Areas Program staff for their advice regarding soil collection. This research was supported in part by an appointment to the Emerging Infectious Diseases (EID) Fellowship Program administered by the Association of Public Health Laboratories (APHL) and funded by the CDC. NR 28 TC 5 Z9 5 U1 2 U2 19 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD NOV PY 2012 VL 12 IS 11 BP 948 EP 952 DI 10.1089/vbz.2012.1031 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 033FW UT WOS:000310780600006 PM 22925020 ER PT J AU Morassutti, AL Levert, K Perelygin, A da Silva, AJ Wilkins, P Graeff-Teixeira, C AF Morassutti, Alessandra L. Levert, Keith Perelygin, Andrey da Silva, Alexandre J. Wilkins, Patricia Graeff-Teixeira, Carlos TI The 31-kDa Antigen of Angiostrongylus cantonensis Comprises Distinct Antigenic Glycoproteins SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Abdominal angiostrongyliasis; Angiostrongylus; Eosinophilic meningitis; Immunodiagnosis31-kDa antigen ID EOSINOPHILIC MENINGITIS; 14-3-3 PROTEINS; 1ST REPORT; MENINGOENCEPHALITIS; METASTRONGYLIDAE; 14-3-3-PROTEIN; MEMBRANE; NEMATODA; COMPLEX; BRAZIL AB Human angiostrongyliasis results from accidental infection with Angiostrongylus, an intra-arterial nematode. Angiostrongylus cantonensis infections result in eosinophilic meningitis, and A. costaricensis infections cause eosinophilic enteritis. Immunological methodologies are critical to the diagnosis of both infections, since these parasites cannot be isolated from fecal matter and are rarely found in cerebrospinal fluid samples. A. costaricensis and A. cantonensis share common antigenic epitopes which elicit antibodies that recognize proteins present in either species. Detection of antibodies to a 31-kDa A. cantonensis protein present in crude adult worm extracts is a sensitive and specific method for immunodiagnosis of cerebral angiostrongyliasis. The objective of the present work was to isolate and characterize the 31-kDa proteins using soluble protein extracts derived from adult female worms using both one-(1DE) and two-dimensional (2DE) gel electrophoresis. Separated proteins were blotted onto nitrocellulose and probed using sera from infected and non-infected controls. The 31-kDa band present in 1DE gels and the 4 spots identified in 2DE gels were excised and analyzed by electrospray ionization mass spectrometry. Using the highest scores obtained following Mascot analysis, amino acid sequences were obtained that matched four unique proteins: tropomyosin, the 14-3-3 phosphoserine-binding protein, a protein containing a nascent polypeptide-associated complex domain, and the putative epsilon subunit of coatomer protein complex isoform 2. Oxidative cleavage of diols using sodium m-periodate demonstrated that carbohydrate moieties are essential for the antigenicity of all four spots of the 31-kDa antigen. In this article we describe the identification of the 31-kDa antigen, and provide DNA sequencing of the targets. In conclusion, these data suggest that reactivity to the 31-kDa proteins may represent antibody recognition of more than one protein, and recombinant protein-based assays for cerebral angiostrongyliasis diagnosis may require eukaryotic expression systems to maintain antigenicity. C1 [Morassutti, Alessandra L.; Graeff-Teixeira, Carlos] Pontificia Univ Rio Grande Sul PUCRS, Fac Biociencias, Lab Biol Parasitaria, BR-90690900 Porto Alegre, RS, Brazil. [Morassutti, Alessandra L.; Graeff-Teixeira, Carlos] Pontificia Univ Rio Grande Sul PUCRS, Mol Parasitol Lab, Inst Pesquisas Biomed, BR-90690900 Porto Alegre, RS, Brazil. [Levert, Keith] Georgia State Univ, Dept Biol, Atlanta, GA USA. [Levert, Keith; Perelygin, Andrey; da Silva, Alexandre J.; Wilkins, Patricia] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Morassutti, AL (reprint author), Pontificia Univ Rio Grande Sul PUCRS, Fac Biociencias, Lab Biol Parasitaria, Av Ipiranga 6690, BR-90690900 Porto Alegre, RS, Brazil. EM almorassutti@gmail.com RI Graeff-Teixeira, Carlos/A-5820-2012; Morassutti, Alessandra/E-1046-2015 OI Graeff-Teixeira, Carlos/0000-0003-2725-0061; Morassutti, Alessandra/0000-0002-8142-1055 FU CNPq; CAPES; FAPERGS; APHL-USA; CNPq PQ 1D fellowship; Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico do Brasil [300456/2007-7, 477260/2007-1] FX Financial support was provided by CNPq, CAPES, FAPERGS, and APHL-USA. is the recipient of a CNPq PQ 1D fellowship, and of grants 300456/2007-7 and 477260/2007-1 (Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico do Brasil). NR 29 TC 9 Z9 10 U1 1 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD NOV PY 2012 VL 12 IS 11 BP 961 EP 968 DI 10.1089/vbz.2011.0957 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 033FW UT WOS:000310780600008 PM 22925026 ER PT J AU Patton, TG Brandt, KS Gilmore, RD AF Patton, Toni G. Brandt, Kevin S. Gilmore, Robert D., Jr. TI Borrelia burgdorferi Visualized in Ixodes scapularis Tick Excrement by Immunofluorescence SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Borrelia burgdorferi; Immunofluorescence; Ixodes scapularis; Tick feces ID INFECTION AB The enzootic cycle of Borrelia burgdorferi, the etiologic agent of Lyme disease, involves Ixodes spp. ticks and vertebrates. Resident tick Borrelia, harbored inside the midgut, are eventually expelled with the tick's saliva into the vertebrate host when a tick consumes a blood meal. During this 4- to 5-day feeding period I. scapularis will defecate onto the host's skin. Previously we detected borrelial DNA in tick feces throughout engorgement. In this study we report the microscopic examination for B. burgdorferi in nymphal excrement. Using immunofluorescence assays, we observed Borrelia in all mouse skin and capsule fecal swabs tested, although we could not culture the spirochetes. These results update our previous analysis by revealing that spirochetes can also be visualized in tick excrement. Furthermore, the results emphasize that borrelial contamination by defecation is a possibility, and that caution should be exercised by researchers investigating pathogen/host/vector interactions. The biological significance of the presence of non-culturable Borrelia in tick feces during engorgement is unclear. C1 [Patton, Toni G.; Brandt, Kevin S.; Gilmore, Robert D., Jr.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. RP Patton, TG (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM hvp6@cdc.gov NR 10 TC 1 Z9 1 U1 1 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD NOV PY 2012 VL 12 IS 11 BP 1000 EP 1003 DI 10.1089/vbz.2011.0922 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 033FW UT WOS:000310780600013 PM 22651382 ER PT J AU Trotti, LM Rye, DB De Staercke, C Hooper, WC Quyyumi, A Bliwise, DL AF Trotti, Lynn Marie Rye, David B. De Staercke, Christine Hooper, W. Craig Quyyumi, Arshed Bliwise, Donald L. TI Elevated C-reactive protein is associated with severe periodic leg movements of sleep in patients with restless legs syndrome SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE C-reactive protein; Periodic leg movements of sleep; Restless legs syndrome; Interleukin-6; Tumor necrosis factor alpha; Cardiovascular disease ID CORONARY-HEART-DISEASE; CYTOKINE LEVELS; LIMB MOVEMENTS; BLOOD-PRESSURE; APNEA SYNDROME; RISK; INFLAMMATION; MARKERS; VARIABILITY; INTERLEUKIN-6 AB Background: Restless legs syndrome (RLS) is a common sleep disorder in which urges to move the legs are felt during rest, are felt at night, and are improved by leg movement. RLS has been implicated in the development of cardiovascular disease. Periodic leg movements (PLMs) may be a mediator of this relationship. We evaluated systemic inflammation and PLMs in RLS patients to further assess cardiovascular risk. Methods: 137 RLS patients had PLM measurements taken while unmedicated for RLS. Banked plasma was assayed for high sensitivity C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha). Results: Mean (SD) PLM index was 19.3 (22.0). PLMs were unrelated to TNF-a and IL-6, but were modestly correlated with logCRP (r(129)= 0.19, p = 0.03). Those patients with at least 45 PLMs/h had an odds ratio of 3.56 (95% Cl 1.26-10.03, p = 0.02, df = 1) for having elevated CRP compared to those with fewer than 45 PLMs/h. After adjustment for age, race, gender, diabetes, hypertension, hyperlipidemia, inflammatory disorders, CRP-lowering medications, and body mass index, the OR for those with >= 45 PLMs/h was 8.60 (95% Cl 1.23 to 60.17, p = 0.03, df = 10). Conclusions: PLMs are associated with increased inflammation, such that those RLS patients with at least 45 PLMs/h had more than triple the odds of elevated CRP than those with fewer PLMs. Further investigation into PLMs and inflammation is warranted. (C) 2012 Elsevier Inc. All rights reserved. C1 [Trotti, Lynn Marie; Rye, David B.; Bliwise, Donald L.] Emory Univ, Sch Med, Dept Neurol, Emory Program Sleep, Atlanta, GA 30322 USA. [De Staercke, Christine; Hooper, W. Craig] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [Quyyumi, Arshed] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA 30322 USA. RP Trotti, LM (reprint author), 1841 Clifton Rd NE, Atlanta, GA 30329 USA. EM Lbecke2@emory.edu FU PHS Grant from the Clinical and Translational Science Award program [KL2RR025009, 2P50AG025688, P30NS055077]; UCB Pharma FX Supported by PHS Grant KL2RR025009 from the Clinical and Translational Science Award program (LMT), 2P50AG025688, and P30NS055077.; Drs. Trotti and Rye have been consultants for UCB Pharma, and Dr. Rye has given CME lectures sponsored by UCB Pharma. Dr. Bliwise is a consultant for Ferring. The remaining authors declare that they have no conflicts of interest. NR 46 TC 16 Z9 17 U1 1 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD NOV PY 2012 VL 26 IS 8 BP 1239 EP 1243 DI 10.1016/j.bbi.2012.06.003 PG 5 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 025JV UT WOS:000310186000007 PM 22750520 ER PT J AU Louie, JK Yang, S Acosta, M Yen, C Samuel, MC Schechter, R Guevara, H Uyeki, TM AF Louie, Janice K. Yang, Samuel Acosta, Meileen Yen, Cynthia Samuel, Michael C. Schechter, Robert Guevara, Hugo Uyeki, Timothy M. TI Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1) pdm09 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID RESPIRATORY-TRACT COMPLICATIONS; VIRUS-INFECTION; OSELTAMIVIR TREATMENT; HOSPITALIZED-PATIENTS; UNITED-STATES; RISK-FACTORS; OUTCOMES; ILLNESS; ADULTS; CALIFORNIA AB Background. Neuraminidase inhibitor (NAI) antiviral drugs can shorten the duration of uncomplicated influenza when administered early (<48 hours after illness onset) to otherwise healthy outpatients, but the optimal timing of effective therapy for critically ill patients is not well established. Methods. We analyzed California surveillance data to characterize the outcomes of patients in intensive care units (ICUs) treated with NAIs for influenza A(H1N1) pdm09 (pH1N1). Demographic and clinical data were abstracted from medical records, using standardized case report forms. Results. From 3 April 2009 through 10 August 2010, 1950 pH1N1 cases hospitalized in ICUs were reported. Of 1859 (95%) with information available, 1676 (90%) received NAI treatment, and 183 (10%) did not. The median age was 37 years (range, 1 week-93 years), 1473 (79%) had >= 1 comorbidity, and 492 (26%) died. The median time from symptom onset to starting NAI treatment was 4 days (range, 0-52 days). NAI treatment was associated with survival: 107 of 183 untreated case patients (58%) survived, compared with 1260 of 1676 treated case patients (75%; P <= .0001). There was a trend toward improved survival for those treated earliest (P < .0001). Treatment initiated within 5 days after symptom onset was associated with improved survival compared to those never treated (P < .05). Conclusions. NAI treatment of critically ill pH1N1 patients improves survival. While earlier treatment conveyed the most benefit, patients who started treatment up to 5 days after symptom onset also were more likely to survive. Further research is needed about whether starting NAI treatment >5 days after symptom onset may also convey benefit. C1 [Louie, Janice K.; Yang, Samuel; Acosta, Meileen; Yen, Cynthia; Samuel, Michael C.; Schechter, Robert; Guevara, Hugo] Calif Dept Publ Hlth, Richmond, CA 94804 USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Louie, JK (reprint author), Calif Dept Publ Hlth, 850 Marina Bay Pkwy, Richmond, CA 94804 USA. EM Janice.louie@cdph.ca.gov NR 27 TC 77 Z9 79 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2012 VL 55 IS 9 BP 1198 EP 1204 DI 10.1093/cid/cis636 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 021IF UT WOS:000309877800009 PM 22843781 ER PT J AU Yoder, JS Straif-Bourgeois, S Roy, SL Moore, TA Visvesvara, GS Ratard, RC Hill, VR Wilson, JD Linscott, AJ Crager, R Kozak, NA Sriram, R Narayanan, J Mull, B Kahler, AM Schneeberger, C da Silva, AJ Poudel, M Baumgarten, KL Xiao, LH Beach, MJ AF Yoder, Jonathan S. Straif-Bourgeois, Susanne Roy, Sharon L. Moore, Thomas A. Visvesvara, Govinda S. Ratard, Raoult C. Hill, Vincent R. Wilson, Jon D. Linscott, Andrea J. Crager, Ron Kozak, Natalia A. Sriram, Rama Narayanan, Jothikumar Mull, Bonnie Kahler, Amy M. Schneeberger, Chandra da Silva, Alexandre J. Poudel, Mahendra Baumgarten, Katherine L. Xiao, Lihua Beach, Michael J. TI Primary Amebic Meningoencephalitis Deaths Associated With Sinus Irrigation Using Contaminated Tap Water SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID FREE-LIVING AMEBAS; NAEGLERIA-FOWLERI; PATHOGENIC NAEGLERIA; BALAMUTHIA-MANDRILLARIS; ACANTHAMOEBA SPP.; NESTED PCR; IDENTIFICATION; INFECTION; SAMPLES; USA AB Background. Naegleria fowleri is a climate-sensitive, thermophilic ameba found in the environment, including warm, freshwater lakes and rivers. Primary amebic meningoencephalitis (PAM), which is almost universally fatal, occurs when N. fowleri-containing water enters the nose, typically during swimming, and N. fowleri migrates to the brain via the olfactory nerve. In 2011, 2 adults died in Louisiana hospitals of infectious meningoencephalitis after brief illnesses. Methods. Clinical and environmental testing and case investigations were initiated to determine the cause of death and to identify the exposures. Results. Both patients had diagnoses of PAM. Their only reported water exposures were tap water used for household activities, including regular sinus irrigation with neti pots. Water samples, tap swab samples, and neti pots were collected from both households and tested; N. fowleri were identified in water samples from both homes. Conclusions. These are the first reported PAM cases in the United States associated with the presence of N. fowleri in household plumbing served by treated municipal water supplies and the first reports of PAM potentially associated with the use of a nasal irrigation device. These cases occurred in the context of an expanding geographic range for PAM beyond southern tier states with recent case reports from Minnesota, Kansas, and Virginia. These infections introduce an additional consideration for physicians recommending nasal irrigation and demonstrate the importance of using appropriate water (distilled, boiled, filtered) for nasal irrigation. Furthermore, the changing epidemiology of PAM highlights the importance of raising awareness about this disease among physicians treating persons showing meningitislike symptoms. C1 [Yoder, Jonathan S.; Roy, Sharon L.; Visvesvara, Govinda S.; Hill, Vincent R.; Sriram, Rama; Narayanan, Jothikumar; Mull, Bonnie; Kahler, Amy M.; Schneeberger, Chandra; Xiao, Lihua; Beach, Michael J.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. [Kozak, Natalia A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [da Silva, Alexandre J.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30329 USA. [Straif-Bourgeois, Susanne; Ratard, Raoult C.] Louisiana Dept Hlth & Hosp, New Orleans, LA USA. [Moore, Thomas A.; Linscott, Andrea J.; Poudel, Mahendra; Baumgarten, Katherine L.] Ochsner Hlth Syst, New Orleans, LA USA. [Wilson, Jon D.] Louisiana State Univ, Hlth Sci Ctr Shreveport, Dept Pathol, Mansfield, LA USA. [Crager, Ron] DeSoto Parish Coroner, Mansfield, LA USA. RP Yoder, JS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS C-09, Atlanta, GA 30329 USA. EM jey9@cdc.gov RI Hill, Vincent/G-1789-2012; Xiao, Lihua/B-1704-2013 OI Hill, Vincent/0000-0001-7069-7737; Xiao, Lihua/0000-0001-8532-2727 NR 34 TC 33 Z9 33 U1 3 U2 45 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD NOV 1 PY 2012 VL 55 IS 9 BP E79 EP E85 DI 10.1093/cid/cis626 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 021IF UT WOS:000309877800001 PM 22919000 ER PT J AU Ladd-Acosta, C Lee, BK Bonner, J Sheppard, B Gidaya, N Weiss, L Quinn, J Windham, G Reynolds, A Croen, L Schendel, D Newschaffer, C Fallin, D AF Ladd-Acosta, Christine Lee, Brian K. Bonner, Joseph Sheppard, Brooke Gidaya, Nicole Weiss, Lauren Quinn, Jeffrey Windham, Gayle Reynolds, Ann Croen, Lisa Schendel, Diana Newschaffer, Craig Fallin, Daniele TI Application of Genome-wide Gene-environment Interaction Methods: The SEED Autism Study SO GENETIC EPIDEMIOLOGY LA English DT Meeting Abstract CT Annual Meeting of the International-Genetic-Epidemiology-Society (IGES) CY OCT 18-20, 2012 CL Stevenson, WA SP Int Genet Epidemiol Soc (IGES) C1 [Ladd-Acosta, Christine; Sheppard, Brooke; Fallin, Daniele] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Lee, Brian K.; Gidaya, Nicole; Newschaffer, Craig] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA. [Bonner, Joseph] Michigan State Univ, Biomed Res Informat Core, E Lansing, MI 48824 USA. [Weiss, Lauren; Quinn, Jeffrey] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Windham, Gayle; Croen, Lisa] Kaiser Permanente No California, Div Res, Oakland, CA USA. [Reynolds, Ann] Univ Colorado, Denver Sch Med, Boulder, CO 80309 USA. [Schendel, Diana] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD NOV PY 2012 VL 36 IS 7 MA 131 BP 757 EP 757 PG 1 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA 021VJ UT WOS:000309913200136 ER PT J AU Napier, MD Poole, C Satten, GA Ashley-Koch, A Marrie, RA Williamson, DM AF Napier, Melanie D. Poole, Charles Satten, Glen A. Ashley-Koch, Allison Marrie, Ruth Ann Williamson, Dhelia M. TI Heavy Metals, Organic Solvents and Multiple Sclerosis: An Exploratory Analysis of Gene-environment Interactions SO GENETIC EPIDEMIOLOGY LA English DT Meeting Abstract CT Annual Meeting of the International-Genetic-Epidemiology-Society (IGES) CY OCT 18-20, 2012 CL Stevenson, WA SP Int Genet Epidemiol Soc (IGES) C1 [Napier, Melanie D.; Poole, Charles] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Satten, Glen A.; Williamson, Dhelia M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Ashley-Koch, Allison] Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC USA. [Marrie, Ruth Ann] Univ Manitoba, Dept Internal Med, Winnipeg, MB, Canada. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD NOV PY 2012 VL 36 IS 7 MA 133 BP 758 EP 758 PG 1 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA 021VJ UT WOS:000309913200138 ER PT J AU Satten, GA Ramachandran, D Mulle, JG Allen, AS Bean, LJH Maslen, C Sherman, SL Reeves, RH Zwick, ME AF Satten, Glen A. Ramachandran, Dhanya Mulle, Jennifer G. Allen, Andrew S. Bean, Lora J. H. Maslen, Cheryl Sherman, Stephanie L. Reeves, Roger H. Zwick, Michael E. TI Testing Copy Number Variant/Trait Associations Detected Using Manhattan Plots SO GENETIC EPIDEMIOLOGY LA English DT Meeting Abstract CT Annual Meeting of the International-Genetic-Epidemiology-Society (IGES) CY OCT 18-20, 2012 CL Stevenson, WA SP Int Genet Epidemiol Soc (IGES) C1 [Satten, Glen A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Ramachandran, Dhanya; Mulle, Jennifer G.; Bean, Lora J. H.; Sherman, Stephanie L.; Zwick, Michael E.] Emory Univ, Atlanta, GA 30322 USA. [Allen, Andrew S.] Duke Univ, Durham, NC 27706 USA. [Maslen, Cheryl] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Zwick, Michael E.] Johns Hopkins Univ, Baltimore, MD 21218 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0741-0395 J9 GENET EPIDEMIOL JI Genet. Epidemiol. PD NOV PY 2012 VL 36 IS 7 MA 164 BP 767 EP 767 PG 1 WC Genetics & Heredity; Mathematical & Computational Biology SC Genetics & Heredity; Mathematical & Computational Biology GA 021VJ UT WOS:000309913200169 ER PT J AU Bramley, AM Dasgupta, S Skarbinski, J Kamimoto, L Fry, AM Finelli, L Jain, S AF Bramley, Anna M. Dasgupta, Sharoda Skarbinski, Jacek Kamimoto, Laurie Fry, Alicia M. Finelli, Lyn Jain, Seema CA 2009 Pandemic Influenza A H1N1 TI Intensive care unit patients with 2009 pandemic influenza A (H1N1pdm09) virus infection - United States, 2009 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Epidemiology; influenza; intensive care; pandemic ID IMMUNIZATION PRACTICES ACIP; CRITICALLY-ILL PATIENTS; H1N1 VIRUS; ADVISORY-COMMITTEE; A(H1N1) INFECTION; VACCINES RECOMMENDATIONS; HOSPITALIZED-PATIENTS; SEASONAL INFLUENZA; RISK-FACTOR; CHILDREN AB Background The influenza A (H1N1pdm09) [pH1N1] virus resulted in intensive care unit (ICU) admissions, acute respiratory distress syndrome (ARDS), and death. Objectives To describe the characteristics of ICU patients with pH1N1 virus infection in the United States during the spring and fall of 2009 and to describe the factors associated with severe complications including ARDS and death. Patients/Methods Through two national case-series conducted during spring and fall of 2009, medical charts were reviewed on ICU patients with laboratory-confirmed pH1N1 infection by real-time reverse-transcriptase polymerase chain reaction. Results The majority (77%) of 154 patients hospitalized in an ICU were <50 years of age, and 65% had at least one underlying medical condition. One hundred and twenty-eight (83%) patients received influenza antiviral agents; 29% received treatment =2 days after illness onset. Forty-eight (38%) patients developed ARDS and 37 (24%) died. Patients with ARDS were more likely to be morbidly obese (36% versus 19%, P = 0.04) and patients who died were less likely to have asthma (11% versus 28%, P = 0.05). Compared with patients who received treatment =6 days after illness onset, patients treated =2 days after illness onset were less likely to develop ARDS (17% versus 37%, P < 0.01) or die (7% versus 35%, P < 0.01). Conclusions Among patients hospitalized in an ICU with pH1N1 virus infection, ARDS was a common complication, and one-quarter of patients died. Patients with asthma had less severe outcomes. Early treatment with influenza antiviral agents was likely beneficial, especially when initiated =2 days after illness onset. C1 [Bramley, Anna M.; Dasgupta, Sharoda; Skarbinski, Jacek; Kamimoto, Laurie; Fry, Alicia M.; Finelli, Lyn; Jain, Seema; 2009 Pandemic Influenza A H1N1] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Bramley, AM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS-A32, Atlanta, GA 30333 USA. EM abramley@cdc.gov FU Influenza Division at the Centers for Disease Control and Prevention FX Influenza Division at the Centers for Disease Control and Prevention. NR 39 TC 8 Z9 8 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2012 VL 6 IS 6 BP e134 EP e142 DI 10.1111/j.1750-2659.2012.00385.x PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 026IY UT WOS:000310270300013 PM 22672249 ER PT J AU DeVries, A Wotton, J Lees, C Boxrud, D Uyeki, T Lynfield, R AF DeVries, Aaron Wotton, Jason Lees, Christine Boxrud, David Uyeki, Timothy Lynfield, Ruth TI Neuraminidase H275Y and hemagglutinin D222G mutations in a fatal case of 2009 pandemic influenza A (H1N1) virus infection SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE 2009 H1N1; fatal; oseltamivir; pandemic influenza; pyrosequencing; resistance; severity ID RECEPTOR-BINDING AB Oseltamivir-resistant 2009 H1N1 influenza virus infections associated with neuraminidase (NA) H275Y have been identified sporadically. Strains possessing the hemagglutinin (HA) D222G mutation have been detected in small numbers of fatal 2009 H1N1 cases. We report the first clinical description of 2009 H1N1 virus infection with both NA-H275Y and HA-D222G mutations detected by pyrosequencing of bronchioalveolar lavage fluid obtained on symptom day 19. The 59-year-old immunosuppressed patient had multiple conditions conferring higher risk of prolonged viral replication and severe illness and died on symptom day 34. Further investigations are needed to determine the significance of infection with strains possessing NA-H275Y and HA-D222G. C1 [DeVries, Aaron; Lees, Christine; Lynfield, Ruth] Minnesota Dept Hlth, Infect Dis Epidemiol Prevent & Control Div, St Paul, MN 55164 USA. [Wotton, Jason; Boxrud, David] Minnesota Dept Hlth, Publ Hlth Lab, St Paul, MN 55164 USA. [Uyeki, Timothy] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP DeVries, A (reprint author), Minnesota Dept Hlth, Infect Dis Epidemiol Prevent & Control Div, 625 Robert St N,POB 64975, St Paul, MN 55164 USA. EM aaron.devries@state.mn.us NR 18 TC 5 Z9 5 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2012 VL 6 IS 6 BP e85 EP e88 DI 10.1111/j.1750-2659.2011.00329.x PG 4 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 026IY UT WOS:000310270300005 PM 22243670 ER PT J AU Greene, SK Shay, DK Yin, RH McCarthy, NL Baxter, R Jackson, ML Jacobsen, SJ Nordin, JD Irving, SA Naleway, AL Glanz, JM Lieu, TA AF Greene, Sharon K. Shay, David K. Yin, Ruihua McCarthy, Natalie L. Baxter, Roger Jackson, Michael L. Jacobsen, Steven J. Nordin, James D. Irving, Stephanie A. Naleway, Allison L. Glanz, Jason M. Lieu, Tracy A. TI Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE antiviral agents; human; influenza; oseltamivir; pandemics; physician's practice patterns ID UNITED-STATES; AMANTADINE; INFECTION; SURVEILLANCE; CALIFORNIA; CHILDREN; ILLNESS; DISEASE AB Background U.S. recommendations for using influenza antiviral medications changed in response to viral resistance (to reduce adamantane use) and during the 2009 H1N1 pandemic (to focus on protecting high-risk patients). Little information is available on clinician adherence to these recommendations. We characterized population-based outpatient antiviral medication usage, including diagnosis and testing practices, before and during the pandemic. Methods Eight medical care organizations in the Vaccine Safety Datalink Project provided data on influenza antiviral medication dispensings from January 2000 through June 2010. Dispensing rates were explored in relation to changes in recommendations and influenza diagnosis and laboratory testing frequencies. Factors associated with oseltamivir dispensings in pandemic versus pre-pandemic periods were identified using multivariable logistic regression. Results Antiviral use changed coincident with recommendations to avoid adamantanes in 2006, to use alternatives to oseltamivir in 2008, and to use oseltamivir during the pandemic. Of 38,019 oseltamivir dispensings during the pandemic, 31% were to patients not assigned an influenza diagnosis, and 97% were to patients not tested for influenza. Oseltamivir was more likely to be dispensed in pandemic versus pre-pandemic periods to patients <25 years old and to those with underlying conditions, including chronic pulmonary disease or pregnancy (P < 0.0001 for each factor in multivariable analysis). Conclusions Antiviral medication usage patterns suggest that clinicians followed recommendations to change antiviral prescribing based on resistance and to focus on high-risk patients during the pandemic. Medications were commonly dispensed to patients without influenza diagnoses and tests, suggesting that antiviral dispensings may offer useful supplemental data for monitoring influenza incidence. C1 [Greene, Sharon K.; Yin, Ruihua; Lieu, Tracy A.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA. [Greene, Sharon K.; Yin, Ruihua; Lieu, Tracy A.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA. [Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [McCarthy, Natalie L.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual & Promot, Atlanta, GA USA. [Baxter, Roger] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Jackson, Michael L.] Grp Hlth Res Inst, Seattle, WA USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Nordin, James D.] HealthPartners Res Fdn, Minneapolis, MN USA. [Irving, Stephanie A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Naleway, Allison L.] Kaiser Permanente, NW Ctr Hlth Res, Portland, OR USA. [Glanz, Jason M.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Lieu, Tracy A.] Childrens Hosp Boston, Div Gen Pediat, Boston, MA USA. RP Greene, SK (reprint author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA. EM sharon_greene@harvardpilgrim.org OI Irving, Stephanie/0000-0001-7437-6797; Naleway, Allison/0000-0001-5747-4643; Shay, David/0000-0001-9619-4820; Jacobsen, Steven/0000-0002-8174-8533 FU GlaxoSmithKline; Sanofi Pasteur; Novartis; MedImmune; Merck Research Labs; America's Health Insurance Plans from the Centers for Disease Control and Prevention [200-2002-00732] FX R. B. reports receiving research grants from GlaxoSmithKline, Sanofi Pasteur, Novartis, and MedImmune. S. J. J. reports receiving research funding from and serving as an unpaid consultant to Merck Research Labs. The remaining authors declare that they have no competing interests.; We thank Jeffry Mutuc (Centers for Disease Control and Prevention [CDC]) for providing National Respiratory and Enteric Virus Surveillance System data at local geographic resolution. For scientific, data management, and project management support, we also thank Jufu Chen, Paul Gargiullo, and Alicia Fry (CDC); Melisa Rett and Rich Fox (Harvard Medical School and Harvard Pilgrim Health Care Institute); Berwick Chan and Ajit DeSilva (Kaiser Permanente Vaccine Study Center); Lawrence Madziwa (Group Health Research Institute); Avalow Olsen (HealthPartners Research Foundation); Edward Belongia and Vidhu Choudhary (Marshfield Clinic Research Foundation); Brad Crane and Mark Schmidt (Kaiser Permanente Northwest Center for Health Research); and Timothy Johnson (Kaiser Permanente Colorado). This work was supported by a subcontract with America's Health Insurance Plans (contract 200-2002-00732) from the Centers for Disease Control and Prevention. NR 29 TC 9 Z9 9 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2012 VL 6 IS 6 BP e143 EP e151 DI 10.1111/j.1750-2659.2012.00390.x PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 026IY UT WOS:000310270300014 PM 22687171 ER PT J AU Regan, J Fowlkes, A Biggerstaff, M Jhung, MA Gindler, J Kennedy, E Fields, V Finelli, L AF Regan, Joanna Fowlkes, Ashley Biggerstaff, Matthew Jhung, Michael A. Gindler, Jacqueline Kennedy, Erin Fields, Victoria Finelli, Lyn CA 2009 Pandemic Influenza A H1N1 TI Epidemiology of influenza A (H1N1)pdm09-associated deaths in the United States, September-October 2009 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE H1N1pdm09 subtype; influenza A virus; influenza antiviral agents; influenza fatal cases ID RISK-FACTORS; H1N1; HOSPITALIZATION; A(H1N1); MORTALITY; OBESITY; VIRUS AB Background From April to July 2009, the United States experienced a wave of influenza A (H1N1)pdm09 virus (H1N1pdm09) infection. The majority of the deaths during that period occurred in persons <65 years of age with underlying medical conditions. Objective To describe the epidemiology of H1N1pdm09-associated deaths in the US during the fall of 2009. Methods We collected demographic, medical history, and cause of death information on a nationally representative, stratified random sample of 323 H1N1pdm09-associated deaths that occurred during September 1October 31, 2009. Results Data were available for 302/323 (93%) deaths. Most cases (74%) were 1864 years of age and had =1 underlying medical condition (72%). Among cases aged <18 years, 16/43 (37%) had a chronic lung disease, and 15/43 (35%) a neurological disorder; among cases aged =18 years, 94/254 (37%) had a chronic lung disease and 84/254 (33%) had a metabolic disorder. The median number of days between symptom onset and death was six among children (range, 148) and 12 among adults (range, 0109). Influenza antiviral agents were prescribed for 187/268 (70%) of cases, but only 48/153 (31%) received treatment within 2 days of illness onset. Conclusions The characteristics of H1N1pdm09 deaths identified during the fall of 2009 were similar to those occurring AprilJuly 2009. While most cases had conditions that were known to increase the risk for severe outcomes and were recommended to receive antiviral therapy, a minority of cases received antivirals early in the course of illness. C1 [Fowlkes, Ashley; Biggerstaff, Matthew; Jhung, Michael A.; Kennedy, Erin; Finelli, Lyn] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Regan, Joanna] Ctr Dis Control & Prevent, Natl Ctr Emerging Zoonot Infect Dis, Atlanta, GA 30333 USA. [Gindler, Jacqueline] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA 30333 USA. [Kennedy, Erin] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Biggerstaff, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30333 USA. EM zmo2@cdc.gov OI Regan, Joanna/0000-0002-9179-6694 NR 30 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD NOV PY 2012 VL 6 IS 6 BP e169 EP e177 DI 10.1111/j.1750-2659.2012.00408.x PG 9 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 026IY UT WOS:000310270300017 PM 22805001 ER PT J AU Iademarco, MF O'Grady, J Lonnroth, K AF Iademarco, Michael F. O'Grady, Justin Loennroth, Knut TI Chest radiography for tuberculosis screening is back on the agenda SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Editorial Material C1 [Iademarco, Michael F.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. [O'Grady, Justin] UCL, Ctr Clin Microbiol, London, England. [Loennroth, Knut] WHO, Stop TB Dept, CH-1211 Geneva, Switzerland. RP Iademarco, MF (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. EM miademarco@cdc.gov; j.ogrady@ucl.ac.uk; lonnrothk@who.int RI O'Grady, Justin/I-2982-2012; Lonnroth, Knut/L-2339-2014 OI O'Grady, Justin/0000-0001-5412-7152; Lonnroth, Knut/0000-0001-5054-8240 NR 8 TC 8 Z9 8 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD NOV PY 2012 VL 16 IS 11 BP 1421 EP 1422 DI 10.5588/ijtld.12.0774 PG 2 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 025GC UT WOS:000310173900001 PM 23044441 ER PT J AU He, GX Wang, LX Chai, SJ Klena, JD Cheng, SM Ren, YL Ren, LP Gao, F Li, YY He, GM Li, JB Wang, Y Rao, C Varma, JK AF He, G. X. Wang, L. X. Chai, S. J. Klena, J. D. Cheng, S. M. Ren, Y. L. Ren, L. P. Gao, F. Li, Y. Y. He, G. M. Li, J. B. Wang, Y. Rao, C. Varma, J. K. TI Risk factors associated with tuberculosis infection among health care workers in Inner Mongolia, China SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE QuantiFERON; tuberculin; infection control; prevalence ID ASSAY; PREVALENCE; DIAGNOSIS; DISEASE AB SETTING: Health care workers (HCWs) are at increased risk for tuberculosis (TB) infection. In China, surveys examining TB infection among HCWs have not studied general health care facilities, compared tuberculin tests conducted using local protocols against an internationally accepted test or characterised risk factors. OBJECTIVE: To measure the prevalence of and risk factors for TB infection among HCWs in Inner Mongolia, China. DESIGN: Between April and August 2010, we administered QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) tests, skin tests using Chinese tuberculin (TST) and surveys among HCWs at an infectious diseases hospital and a general medical hospital. We assessed whether demographic characteristics, personal exposure and work exposure were associated with QFT-GIT and TST positivity, and assessed agreement between test results. RESULTS: Of 999 HCWs, 683 (68%) were QFT-GIT-positive, which was associated with greater age, longer HCW career, TB disease in a co-worker and greater daily patient exposure using multivariable analysis. TST reactions >= 5 mm occurred in 69% of the HCWs; agreement between test results was low (kappa 0.22). CONCLUSIONS: The prevalence of TB infection among HCWs in Inner Mongolia is high; infection was associated with occupational exposure. Results from locally conducted TST are difficult to interpret. In China, TB infection control in health care facilities should be strengthened. C1 [He, G. X.; Wang, L. X.; Cheng, S. M.; Wang, Y.] Chinese Ctr Dis Control & Prevent, Beijing 102206, Peoples R China. [Chai, S. J.; Klena, J. D.; Rao, C.; Varma, J. K.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Klena, J. D.; Rao, C.; Varma, J. K.] China US Collaborat Program Emerging & Reemerging, Beijing, Peoples R China. [Ren, Y. L.; Ren, L. P.; Gao, F.; Li, Y. Y.] Inner Mongolia Ctr TB Control & Prevent, Hohhot, Peoples R China. [He, G. M.; Li, J. B.] Ulanqab Ctr TB Control & Prevent, Ulanqab, Peoples R China. RP Wang, Y (reprint author), Chinese Ctr Dis Control & Prevent, 155 Changbai Rd, Beijing 102206, Peoples R China. EM wangyu@chinacdc.cn FU China-US Collaborative Program on Emerging and Re-Emerging Infectious Diseases FX The authors thank X Nie, Jenny, H Guo, Y Li and N Ta for their help in project management. They thank J Rothel for his expertise and support in using QFT-GIT and interpreting its results. They also thank the staff at the following participating facilities in Inner Mongolia for project organisation and coordination, and conducting surveys and clinical tests: the Chinese Centers for Disease Control and Prevention (CDC), the infectious disease and tuberculosis hospitals, and the tuberculosis centres and dispensaries at the provincial, prefecture, county and district levels. This project was supported by the China-US Collaborative Program on Emerging and Re-Emerging Infectious Diseases. NR 27 TC 14 Z9 16 U1 0 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD NOV PY 2012 VL 16 IS 11 BP 1485 EP 1491 DI 10.5588/ijtld.12.0193 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 025GC UT WOS:000310173900012 PM 22964074 ER PT J AU Van Deun, A Cattamanchit, A Davis, JL Ridderhof, J AF Van Deun, Armand Cattamanchit, Adithya Davis, J. Lucian Ridderhof, John TI Can LED fluorescence microscopy replace Ziehl-Neelsen microscopy in tuberculosis detection? Reply SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Letter C1 [Van Deun, Armand] Int Union TB & Lung Dis, Paris, France. [Van Deun, Armand] Inst Trop Med, B-2000 Antwerp, Belgium. [Cattamanchit, Adithya; Davis, J. Lucian] UCSF, San Francisco, CA USA. [Cattamanchit, Adithya; Davis, J. Lucian] Makerere Univ, UCSF Res Collaborat, Kampala, Uganda. [Ridderhof, John] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Van Deun, A (reprint author), Int Union TB & Lung Dis, Paris, France. EM avandeun@theunion.org NR 3 TC 3 Z9 3 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD NOV PY 2012 VL 16 IS 11 BP 1558 EP 1559 DI 10.5588/ijtld.12.0407-2 PG 2 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 025GC UT WOS:000310173900025 PM 23044451 ER PT J AU Cox, CM D'Mello, T Perez, A Reingold, A Gershman, K Yousey-Hindes, K Arnold, KE Farley, MM Ryan, P Lynfield, R Morin, C Baumbach, J Hancock, EB Zansky, S Bennett, NM Thomas, A Schaffner, W Finelli, L AF Cox, Chad M. D'Mello, Tiffany Perez, Alejandro Reingold, Arthur Gershman, Ken Yousey-Hindes, Kimberly Arnold, Kathryn E. Farley, Monica M. Ryan, Patricia Lynfield, Ruth Morin, Craig Baumbach, Joan Hancock, Emily B. Zansky, Shelley Bennett, Nancy M. Thomas, Ann Schaffner, William Finelli, Lyn CA Emerging Infect Programs Network TI Increase in Rates of Hospitalization Due to Laboratory-Confirmed Influenza Among Children and Adults During the 2009-10 Influenza Pandemic SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID A H1N1 VIRUS; UNITED-STATES; HOUSEHOLD TRANSMISSION; ASTHMA EXACERBATIONS; INFECTION; A(H1N1); EPIDEMIOLOGY; SURVEILLANCE; HEMISPHERE; EXPERIENCE AB Background. The Emerging Infections Programs (EIP) network has conducted population-based surveillance for hospitalizations due to laboratory-confirmed influenza among children since 2003, with the network expanding in 2005 to include adults. Methods. From 15 April 2009 through 30 April 2010, the EIP conducted surveillance among 22.1 million people residing in 10 states. Incidence rates per 100 000 population were calculated using US Census Bureau data. Mean historic rates were calculated on the basis of previously published and unpublished EIP data. Results. During the 2009 pandemic of influenza A virus subtype H1N1 infection, rates of hospitalizations due to laboratory-confirmed influenza were 202, 88, 49, 31, 27, 36, 28, and 27 episodes per 100 000 among persons aged <6 months, 6-23 months, 2-4 years, 5-17 years, 18-49 years, 50-64 years, 65-74 years, and >= 75 years, respectively. Comparative mean rates from previous influenza seasons during which EIP conducted surveillance were 153, 53, 20, 6, 4, 8, 20, and 56 episodes per 100 000 among persons aged <6 months, 6-23 months, 2-4 years, 5-17 years, 18-49 years, 50-64 years, 65-74 years, and >= 75 years, respectively. Conclusions. During the pandemic, rates of hospitalization due to laboratory-confirmed influenza among individuals aged 5-17 years and 18-49 years increased 5-fold and 6-fold, respectively, compared with mean rates from previous influenza seasons. Hospitalization rates for other pediatric and adult age groups increased, compared with mean rates from previous influenza seasons, whereas the rate among individuals aged >= 75 years decreased. C1 [Cox, Chad M.; D'Mello, Tiffany; Perez, Alejandro; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Reingold, Arthur; Gershman, Ken; Yousey-Hindes, Kimberly; Arnold, Kathryn E.; Farley, Monica M.; Ryan, Patricia; Lynfield, Ruth; Morin, Craig; Baumbach, Joan; Hancock, Emily B.; Zansky, Shelley; Bennett, Nancy M.; Thomas, Ann; Schaffner, William] Ctr Dis Control & Prevent, Emerging Infect Program, Atlanta, GA 30333 USA. [D'Mello, Tiffany] Battelle Mem Inst, Atlanta, GA USA. [Arnold, Kathryn E.; Farley, Monica M.] Georgia Div Publ Hlth, Emerging Infect Program, Atlanta, GA USA. [Farley, Monica M.] Emory Univ, Atlanta, GA 30322 USA. [Farley, Monica M.] Atlanta VA Med Ctr, Atlanta, GA USA. [Reingold, Arthur] Calif Emerging Infect Program, Oakland, CA USA. [Gershman, Ken] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Yousey-Hindes, Kimberly] Yale Univ, Connecticut Emerging Infect Program, Sch Publ Hlth, New Haven, CT USA. [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Lynfield, Ruth; Morin, Craig] Minnesota Dept Hlth, St Paul, MN USA. [Baumbach, Joan; Hancock, Emily B.] New Mexico Dept Hlth, Santa Fe, NM USA. [Zansky, Shelley] New York State Dept Hlth, Emerging Infect Program, Albany, NY 12237 USA. [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA. [Thomas, Ann] Oregon Publ Hlth Div, Portland, OR USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. RP Finelli, L (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM lyf8@cdc.gov OI Yousey-Hindes, Kimberly/0000-0002-9418-575X FU CDC FX This work was supported by the CDC. NR 42 TC 17 Z9 17 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2012 VL 206 IS 9 BP 1350 EP 1358 DI 10.1093/infdis/jis517 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 022BT UT WOS:000309930700006 PM 23002448 ER PT J AU Lederman, ER Davidson, W Groff, HL Smith, SK Warkentien, T Li, Y Wilkins, KA Karem, KL Akondy, RS Ahmed, R Frace, M Shieh, WJ Zaki, S Hruby, DE Painter, WP Bergman, KL Cohen, JI Damon, IK AF Lederman, Edith R. Davidson, Whitni Groff, Harold L. Smith, Scott K. Warkentien, Tyler Li, Yu Wilkins, Kimberly A. Karem, Kevin L. Akondy, Rama S. Ahmed, Rafi Frace, Michael Shieh, Wun-Ju Zaki, Sherif Hruby, Dennis E. Painter, Wendy P. Bergman, Kimberly L. Cohen, Jeffrey I. Damon, Inger K. TI Progressive Vaccinia: Case Description and Laboratory-Guided Therapy With Vaccinia Immune Globulin, ST-246, and CMX001 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID T-CELL RESPONSES; SMALLPOX VACCINATION; MONKEYPOX; VIRUS; INFECTION; CHALLENGE; CONTACT; MICE AB Progressive vaccinia (PV) is a rare but potentially lethal complication that develops in smallpox vaccine recipients with severely impaired cellular immunity. We describe a patient with PV who required treatment with vaccinia immune globulin and who received 2 investigational agents, ST-246 and CMX001. We describe the various molecular, pharmacokinetic, and immunologic studies that provided guidance to escalate and then successfully discontinue therapy. Despite development of resistance to ST-246 during treatment, the patient had resolution of PV. This case demonstrates the need for continued development of novel anti-orthopoxvirus pharmaceuticals and the importance of both intensive and timely clinical and laboratory support in management of PV. C1 [Lederman, Edith R.; Davidson, Whitni; Smith, Scott K.; Li, Yu; Wilkins, Kimberly A.; Karem, Kevin L.; Frace, Michael; Shieh, Wun-Ju; Zaki, Sherif; Damon, Inger K.] Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA. [Warkentien, Tyler; Akondy, Rama S.; Ahmed, Rafi] Emory Univ, Sch Med, Vaccine Ctr, Atlanta, GA USA. [Lederman, Edith R.; Groff, Harold L.] USN, Div Infect Dis, San Diego Med Ctr, San Diego, CA USA. [Hruby, Dennis E.] Siga Technol, Corvallis, OR USA. [Painter, Wendy P.] Chimerix, Durham, NC USA. [Bergman, Kimberly L.] US FDA, Off Clin Pharmacol, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Cohen, Jeffrey I.] Natl Inst Allergy & Immunol, NIH, Bethesda, MD USA. RP Lederman, ER (reprint author), San Diego State Univ, Grad Sch Publ Hlth, Hardy Tower 119,5500 Campanile Dr, San Diego, CA 92182 USA. EM erlederman@yahoo.com OI Akondy, Rama/0000-0003-4737-5240 FU National Institute of Allergy and Infectious Diseases FX This work was supported by the intramural research program of the National Institute of Allergy and Infectious Diseases (to J. I. C.). NR 22 TC 18 Z9 18 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2012 VL 206 IS 9 BP 1372 EP 1385 DI 10.1093/infdis/jis510 PG 14 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 022BT UT WOS:000309930700009 PM 22904336 ER PT J AU Cooper, CP Gelb, CA Rim, SH Hawkins, NA Rodriguez, JL Polonec, L AF Cooper, Crystale Purvis Gelb, Cynthia A. Rim, Sun Hee Hawkins, Nikki A. Rodriguez, Juan L. Polonec, Lindsey TI Physicians who use social media and other internet-based communication technologies SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID HEALTH-CARE PROVIDERS; WOMEN; QUOTA AB The demographic and practice-related characteristics of physicians who use social networking websites, portable devices to access the internet, email to communicate with patients, podcasts, widgets, RSS feeds, and blogging were investigated. Logistic regression was used to analyze a survey of US primary care physicians, pediatricians, obstetrician/gynecologists, and dermatologists (N=1750). Reported technology use during the last 6 months ranged from 80.6% using a portable device to access the internet to 12.9% writing a blog. The most consistent predictors of use were being male, being younger, and having teaching hospital privileges. Physician specialty, practice setting, years in practice, average number of patients treated per week, and number of physicians in practice were found to be inconsistently associated or unassociated with use of the technologies examined. Demographic characteristics, rather than practice-related characteristics, were more consistent predictors of physician use of seven internet-based communication technologies with varying levels of uptake. C1 [Gelb, Cynthia A.; Rim, Sun Hee; Hawkins, Nikki A.; Rodriguez, Juan L.; Polonec, Lindsey] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Cooper, Crystale Purvis] Soltera Ctr Canc Prevent & Control, Tucson, AZ USA. RP Gelb, CA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, 4770 Buford Highway NE,MS K-64, Atlanta, GA 30341 USA. EM cgelb@cdc.gov FU Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control FX The Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control provided funding for this study. NR 23 TC 18 Z9 18 U1 1 U2 19 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD NOV PY 2012 VL 19 IS 6 BP 960 EP 964 DI 10.1136/amiajnl-2011-000628 PG 5 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 028FP UT WOS:000310408500007 PM 22634078 ER PT J AU Kass-Hout, TA Xu, ZH McMurray, P Park, S Buckeridge, DL Brownstein, JS Finelli, L Groseclose, SL AF Kass-Hout, Taha A. Xu, Zhiheng McMurray, Paul Park, Soyoun Buckeridge, David L. Brownstein, John S. Finelli, Lyn Groseclose, Samuel L. TI Application of change point analysis to daily influenza-like illness emergency department visits SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article ID PUBLIC-HEALTH SURVEILLANCE; SYNDROMIC SURVEILLANCE; DETECTION ALGORITHMS; BAYESIAN-ANALYSIS; PREPAREDNESS; OUTBREAK; MODELS AB Background The utility of healthcare utilization data from US emergency departments (EDs) for rapid monitoring of changes in influenza-like illness (ILI) activity was highlighted during the recent influenza A (H1N1) pandemic. Monitoring has tended to rely on detection algorithms, such as the Early Aberration Reporting System (EARS), which are limited in their ability to detect subtle changes and identify disease trends. Objective To evaluate a complementary approach, change point analysis (CPA), for detecting changes in the incidence of ED visits due to ILI. Methodology and principal findings Data collected through the Distribute project (isdsdistribute.org), which aggregates data on ED visits for ILI from over 50 syndromic surveillance systems operated by state or local public health departments were used. The performance was compared of the cumulative sum (CUSUM) CPA method in combination with EARS and the performance of three CPA methods (CUSUM, structural change model and Bayesian) in detecting change points in daily time-series data from four contiguous US states participating in the Distribute network. Simulation data were generated to assess the impact of autocorrelation inherent in these time-series data on CPA performance. The CUSUM CPA method was robust in detecting change points with respect to autocorrelation in time-series data (coverage rates at 90% when -0.2 <=rho <= 0.2 and 80% when -0.5 <=rho <= 0.5). During the 2008-9 season, 21 change points were detected and ILI trends increased significantly after 12 of these change points and decreased nine times. In the 2009-10 flu season, we detected 11 change points and ILI trends increased significantly after two of these change points and decreased nine times. Using CPA combined with EARS to analyze automatically daily ED-based ILI data, a significant increase was detected of 3% in ILI on April 27, 2009, followed by multiple anomalies in the ensuing days, suggesting the onset of the H1N1 pandemic in the four contiguous states. Conclusions and significance As a complementary approach to EARS and other aberration detection methods, the CPA method can be used as a tool to detect subtle changes in time-series data more effectively and determine the moving direction (ie, up, down, or stable) in ILI trends between change points. The combined use of EARS and CPA might greatly improve the accuracy of outbreak detection in syndromic surveillance systems. C1 [Kass-Hout, Taha A.; McMurray, Paul; Groseclose, Samuel L.] Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol, Atlanta, GA 30333 USA. [Kass-Hout, Taha A.; McMurray, Paul; Groseclose, Samuel L.] Ctr Dis Control & Prevent, Lab Serv, Atlanta, GA USA. [Xu, Zhiheng] US FDA, Silver Spring, MD USA. [Park, Soyoun] McKing Consulting Corp, Atlanta, GA USA. [Buckeridge, David L.; Brownstein, John S.] Int Soc Dis Surveillance, Boston, MA USA. [Buckeridge, David L.] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada. [Buckeridge, David L.] Agence Sante & Serv Sociaux Montreal, Direct Sante Publ, Montreal, PQ, Canada. [Brownstein, John S.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Finelli, Lyn] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Off Infect Dis, Atlanta, GA USA. RP Kass-Hout, TA (reprint author), Ctr Dis Control & Prevent, Publ Hlth Surveillance & Informat Program Off, Off Surveillance Epidemiol, Atlanta, GA 30333 USA. EM kasshout@gmail.com OI Kass-Hout, Taha/0000-0002-0123-5157 NR 22 TC 16 Z9 17 U1 1 U2 12 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1067-5027 EI 1527-974X J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD NOV PY 2012 VL 19 IS 6 BP 1075 EP 1081 DI 10.1136/amiajnl-2011-000793 PG 7 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics SC Computer Science; Health Care Sciences & Services; Information Science & Library Science; Medical Informatics GA 028FP UT WOS:000310408500023 PM 22759619 ER PT J AU Harper, MA Meyer, RE Berg, CJ AF Harper, Margaret A. Meyer, Robert E. Berg, Cynthia J. TI Peripartum Cardiomyopathy Population-Based Birth Prevalence and 7-Year Mortality SO OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 59th Annual Clinical Meeting of the American-College-of-Obstetricians-and-Gynecologists CY APR 30-MAY 04, 2011 CL Washington, DC SP Amer Coll Obstetricians & Gynecologists ID PREGNANCY; ECHOCARDIOGRAPHY; OUTCOMES; HEART AB OBJECTIVE: To estimate the birth prevalence and 7-year case-fatality rate of peripartum cardiomyopathy for a statewide population by applying the National Institutes of Health Workshop on Peripartum Cardiomyopathy definition, including echocardiographic criteria for left ventricular dysfunction. METHODS: This was an epidemiologic study of residents of North Carolina experiencing an obstetric delivery or a pregnancy-related death before delivery in 2002 through 2003 including 235,599 live births. Potential cases were identified from International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM), pregnancy and cardiovascular codes followed by medical record review, and from the state pregnancy-related mortality file. Only women meeting the established definition including echocardiographic criteria for left ventricular dysfunction and women with diagnoses at autopsy were included. The state death file and the U. S. Social Security Death Index were searched for the years 2002 through 2010 for all cases. RESULTS: A total of 740 potential cases from 70 hospitals were identified from discharge ICD-9-CM codes. The medical records for 698 (94.3%) were located and reviewed. Seventy-eight met inclusion criteria. An additional seven women had diagnoses only at autopsy. The birth prevalence was 1 case for every 2,772 live births or 3.61 cases per 10,000 live births (95% confidence interval 2.88-4.46). The 7-year case-fatality rate was 16.5% (95% confidence interval 10-25.9%). Black non-Hispanic women experienced an almost fourfold increased prevalence and fatality compared with white women. Women older than age 35 years had the highest prevalence. CONCLUSIONS: The racial disparity in both birth prevalence and case-fatality is striking; one in six women died within 7 years. (Obstet Gynecol 2012; 120: 1013-19) DOI: http://10.1097/AOG.0b013e31826e46a1 C1 [Harper, Margaret A.] Mt Area Hlth Educ Ctr, Dept Obstet & Gynecol, Asheville, NC 28803 USA. State Ctr Hlth Stat, N Carolina Div Publ Hlth, N Carolina Birth Defects Monitoring Program, Raleigh, NC USA. Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Harper, MA (reprint author), Mt Area Hlth Educ Ctr, Dept Obstet & Gynecol, 119 Hendersonville Rd, Asheville, NC 28803 USA. EM maggie.harper@mahec.net NR 23 TC 31 Z9 31 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD NOV PY 2012 VL 120 IS 5 BP 1013 EP 1019 DI 10.1097/AOG.0b013e31826e46a1 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 029RF UT WOS:000310512500006 PM 23090517 ER PT J AU Callaghan, WM Creanga, AA Kuklina, EV AF Callaghan, William M. Creanga, Andreea A. Kuklina, Elena V. TI Severe Maternal Morbidity Among Delivery and Postpartum Hospitalizations in the United States SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID SEVERE OBSTETRIC MORBIDITY; DISCHARGE DATA; PREGNANCY; DIAGNOSES; MORTALITY; ACCURACY; US AB OBJECTIVES: To propose a new standard for monitoring severe maternal morbidity, update previous estimates of severe maternal morbidity during both delivery and postpartum hospitalizations, and estimate trends in these events in the United States between 1998 and 2009. METHODS: Delivery and postpartum hospitalizations were identified in the Nationwide Inpatient Sample for the period 1998-2009. International Classification of Diseases, 9th Revision codes indicating severe complications were used to identify hospitalizations with severe maternal morbidity and related in-hospital mortality. Trends were reported using 2-year increments of data. RESULTS: Severe morbidity rates for delivery and postpartum hospitalizations for the 2008-2009 period were 129 and 29, respectively, for every 10,000 delivery hospitalizations. Compared with the 1998-1999 period, severe maternal morbidity increased by 75% and 114% for delivery and postpartum hospitalizations, respectively. We found increasing rates of blood transfusion, acute renal failure, shock, acute myocardial infarction, respiratory distress syndrome, aneurysms, and cardiac surgery during delivery hospitalizations. Moreover, during the study period, rates of postpartum hospitalization with 13 of the 25 severe complications examined more than doubled, and the overall mortality during postpartum hospitalizations increased by 66% (P<.05). CONCLUSIONS: Severe maternal morbidity currently affects approximately 52,000 women during their delivery hospitalizations and, based on current trends, this burden is expected to increase. Clinical review of identified cases of severe maternal morbidity can provide an opportunity to identify points of intervention for quality improvement in maternal care. (Obstet Gynecol 2012; 120: 1029-36) DOI: http://10.1097/AOG.0b013e31826d60c5 C1 [Callaghan, William M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Callaghan, WM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K-23, Atlanta, GA 30341 USA. EM WCallaghan@cdc.gov NR 26 TC 143 Z9 146 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD NOV PY 2012 VL 120 IS 5 BP 1029 EP 1036 DI 10.1097/AOG.0b013e31826d60c5 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 029RF UT WOS:000310512500008 PM 23090519 ER PT J AU Benard, VB Watson, M Castle, PE Saraiya, M AF Benard, Vicki B. Watson, Meg Castle, Philip E. Saraiya, Mona TI Cervical Carcinoma Rates Among Young Females in the United States SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS; CANCER INCIDENCE; RISK-FACTORS; GUIDELINES; WOMEN; METAANALYSIS; PREVENTION; OUTCOMES; PROGRAM AB OBJECTIVE: All national organizations now recommend that women be screened for cervical cancer beginning at age 21 years, regardless of age of sexual initiation; however, studies have shown that providers continue to screen much earlier than recommended. Two federal cancer surveillance systems were used to quantify the burden of invasive cervical carcinoma among women younger than 40 years of age. METHODS: We examined combined data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program covering 92% of the U. S. population. We calculated the age-adjusted incidence of cervical carcinoma among women younger than age 40 years by age, race, ethnicity, and histology for the time period of 1999-2008. RESULTS: For women younger than age 40 years, 78% of the cervical cancer cases were diagnosed in women aged 30-39, 21% were diagnosed in women 20-29 years of age, and 1% was diagnosed in women younger than age 20 years. There was an average of 3,063 cases of invasive cervical carcinomas annually from 1999 through 2008, with an average of 14 carcinomas per year (rate of 0.15 per 100,000 females) among those aged 15-19 years, and 125 carcinomas per year (rate of 1.4 per 100,000 females) among those aged 20-24 years. CONCLUSION: Cervical cancer is very rare in young women. Widespread implementation of Pap testing over the past four decades has detected very few cases of cervical cancer in women younger than 25 while potentially causing harm with unnecessary follow-up interventions. (Obstet Gynecol 2012; 120: 1117-23) DOI: http://10.1097/AOG.0b013e31826e4609 C1 [Benard, Vicki B.] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA 30341 USA. Amer Soc Clin Pathologists, Chicago, IL USA. RP Benard, VB (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, 4770 Buford Highway NE,Mailstop K-55, Atlanta, GA 30341 USA. EM vdb9@cdc.gov FU Intramural CDC HHS [CC999999] NR 33 TC 25 Z9 28 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD NOV PY 2012 VL 120 IS 5 BP 1117 EP 1123 DI 10.1097/AOG.0b013e31826e4609 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 029RF UT WOS:000310512500019 PM 23090530 ER PT J AU Castelo-, LA Nguyen, J Rubin, AI Paddock, CD Shah, KN AF Castelo-Soccio, Leslie A. Nguyen, Jennifer Rubin, Adam I. Paddock, Christopher D. Shah, Kara N. TI FEBRILE ILLNESS WITH PAPULAR AND VESICULAR EXANTHEM AND ULCERONECROTIC PLAQUES SO PEDIATRIC DERMATOLOGY LA English DT Article ID LYME BORRELIOSIS; LYMPHOCYTOMA; CUTIS C1 [Shah, Kara N.] Cincinnati Childrens Hosp, Div Dermatol, Cincinnati, OH 45243 USA. [Castelo-Soccio, Leslie A.] Childrens Hosp Philadelphia, Dermatol Sect, Div Gen Pediat, Philadelphia, PA 19104 USA. [Nguyen, Jennifer; Rubin, Adam I.] Hosp Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. RP Shah, KN (reprint author), Cincinnati Childrens Hosp, Div Dermatol, 3333 Burnet Ave,MLC 3004, Cincinnati, OH 45243 USA. EM kara.shah@cchmc.org NR 9 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-8046 J9 PEDIATR DERMATOL JI Pediatr. Dermatol. PD NOV-DEC PY 2012 VL 29 IS 6 BP 765 EP 766 DI 10.1111/j.1525-1470.2011.01704.x PG 2 WC Dermatology; Pediatrics SC Dermatology; Pediatrics GA 030IX UT WOS:000310565500013 PM 23106676 ER PT J AU Minniear, TD Zeh, C Polle, N Masaba, R Peters, PJ Oyaro, B Akoth, B Ndivo, R Angira, F Mills, LA Thomas, TK AF Minniear, Timothy D. Zeh, Clement Polle, Nicholas Masaba, Rose Peters, Philip J. Oyaro, Boaz Akoth, Benta Ndivo, Richard Angira, Frank Mills, Lisa A. Thomas, Timothy K. TI Rash, Hepatotoxicity and Hyperbilirubinemia Among Kenyan Infants Born to HIV-infected Women Receiving Triple-antiretroviral Drugs for the Prevention of Mother-to-child HIV Transmission SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE HIV; antiretroviral agents; toxicity; infant; newborn ID BREAST-MILK; NEVIRAPINE; NEWBORN AB We compared adverse events among breast-feeding neonates born to Kenyan mothers receiving triple-antiretroviral therapy, including either nevirapine or nelfinavir. Nevirapine-exposed infants had an absolute increase in the risk of rash but no significant risk differences for hepatotoxicity or high-risk hyperbilirubinemia compared with nelfinavir-exposed infants. From an infant-safety perspective, nevirapine-based regimens given during pregnancy and breast-feeding are viable options where alternatives to breast milk are not safe, affordable or feasible. C1 [Minniear, Timothy D.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Minniear, Timothy D.; Zeh, Clement; Peters, Philip J.; Mills, Lisa A.; Thomas, Timothy K.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Zeh, Clement; Masaba, Rose; Oyaro, Boaz; Akoth, Benta; Ndivo, Richard; Angira, Frank; Mills, Lisa A.; Thomas, Timothy K.] Kenya Med Res Inst CDC Res & Publ Hlth Collaborat, Kisumu, Kenya. [Polle, Nicholas] Minist Hlth Kenya, Nairobi, Kenya. RP Minniear, TD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS E-45, Atlanta, GA 30333 USA. EM iyo4@cdc.gov FU Kenya Medical Research Institute (KEMRI); US Centers for Disease Control and Prevention (US CDC) FX Funding for the study was provided by Kenya Medical Research Institute (KEMRI) through a cooperative agreement with the US Centers for Disease Control and Prevention (US CDC). Study drugs were provided by GlaxoSmithKline and Boehringer Ingelheim. The study design, data collection instruments, data collection, data analysis, decision to publish and preparation of the manuscript were led by CDC and KEMRI staff based in Atlanta and at the KEMRI/CDC Research and Public Health Collaboration in Kisumu, Kenya. This publication has been approved by the Director of the Kenya Medical Research Institute. TDM, CZ, PJP, LAM and TKT were employed by CDC during part or all of this study. The authors have no other conflicts of interest or funding to disclose. NR 11 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD NOV PY 2012 VL 31 IS 11 BP 1155 EP 1157 DI 10.1097/INF.0b013e318267ef6a PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 029XW UT WOS:000310532000018 PM 22772167 ER PT J AU Carroll, KN Griffin, MR Edwards, KM Ali, A Zhu, YW Iwane, MK Szilagyi, PG Staat, MA Stevens, TP Hall, CB Williams, JV Hartert, TV AF Carroll, Kecia N. Griffin, Marie R. Edwards, Kathryn M. Ali, Asad Zhu, Yuwei Iwane, Marika K. Szilagyi, Peter G. Staat, Mary A. Stevens, Timothy P. Hall, Caroline B. Williams, John V. Hartert, Tina V. TI ADHERENCE TO GUIDELINES FOR RESPIRATORY SYNCYTIAL VIRUS IMMUNOPROPHYLAXIS AMONG INFANTS WITH PREMATURITY OR CHRONIC LUNG DISEASE IN THREE UNITED STATES COUNTIES SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE respiratory syncytial virus; adherence; palivizumab ID YOUNG-CHILDREN; PALIVIZUMAB; INFECTION; HOSPITALIZATIONS; PREVENTION AB Among infants with prematurity and/or chronic lung disease for whom respiratory syncytial virus immunoprophylaxis is recommended, we examined adherence in infants enrolled during healthcare visits for acute respiratory illness in 3 US counties from 2001 to 2007. Immunoprophylaxis among infants who met national criteria for prophylaxis increased from 33% to 83% over the 6-year period; 17% (11/65) of infants who received immunoprophylaxis did not meet eligibility criteria. C1 [Carroll, Kecia N.] Vanderbilt Univ, Div Gen Pediat, Sch Med, Dept Pediat, Nashville, TN 37232 USA. [Griffin, Marie R.] Vanderbilt Univ, Dept Prevent Med, Sch Med, Nashville, TN 37232 USA. [Griffin, Marie R.; Hartert, Tina V.] Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA. [Zhu, Yuwei] Vanderbilt Univ, Dept Biostat, Sch Med, Nashville, TN 37232 USA. [Iwane, Marika K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Szilagyi, Peter G.; Stevens, Timothy P.; Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Staat, Mary A.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA. [Williams, John V.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Sch Med, Nashville, TN 37232 USA. RP Carroll, KN (reprint author), Vanderbilt Univ, Div Gen Pediat, Sch Med, Dept Pediat, 313 Oxford House, Nashville, TN 37232 USA. EM kecia.carroll@vanderbilt.edu RI Williams, John/F-6962-2010; OI Williams, John/0000-0001-8377-5175; Stevens, Timothy/0000-0002-2959-3925 FU US Centers for Disease Control and Prevention [U38/CCU217969, U01/IP000017, U38/CCU417958, U01/IP000022, U38/CCU522352, U01/IP000147]; MedImmune; GlaxoSmithKline FX This study was supported by the US Centers for Disease Control and Prevention [Cooperative agreement numbers U38/CCU217969, U01/IP000017, U38/CCU417958, U01/IP000022, U38/CCU522352, U01/IP000147]. AA received investigator-initiated research funding from MedImmune. MAS is a consultant for MedImmune, receives research funding from GlaxoSmithKline and is on the speaker's bureau for GlaxoSmithKline and Merck. CBH is a consultant for MedImmune and GlaxoSmithKline. JVW serves on the Scientific Advisory Board of Quidel. TVH has previously received grant funding from MedImmune. The authors have no other funding or conflicts of interest to disclose. NR 12 TC 6 Z9 6 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD NOV PY 2012 VL 31 IS 11 BP E229 EP E231 DI 10.1097/INF.0b013e318266bf89 PG 3 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 029XW UT WOS:000310532000007 PM 22760537 ER PT J AU Griffiths, UK Dieye, Y Fleming, J Hajjeh, R Edmond, K AF Griffiths, Ulla K. Dieye, Yakou Fleming, Jessica Hajjeh, Rana Edmond, Karen TI Costs of Meningitis Sequelae in Children in Dakar, Senegal SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE costs; Senegal; meningitis; sequelae; disability ID B CONJUGATE VACCINE; BACTERIAL-MENINGITIS; ECONOMIC-EVALUATION; MENTAL-RETARDATION; LIFE EXPECTANCY; METAANALYSIS; CHILDHOOD AB Background: Survivors of bacterial meningitis risk lifelong sequelae. In economic evaluations of vaccines protecting against meningitis, treatment and productivity costs due to meningitis sequelae are rarely included in studies from low-income countries, mainly due to lack of data. The aim of this study was to estimate the costs of meningitis sequelae in children in Senegal from the perspective of households. Methods: Children who had suffered from bacterial meningitis were identified from a database at Albert Royer Hospital in Dakar. Sixty-eight children were located at their home and caregivers interviewed about costs during the acute meningitis episode and due to meningitis sequelae, including productivity loss from caring for a disabled child. Lifetime costs were predicted by assuming a life expectancy of 30 years for disabled children. Results: Seventy-one percent of the children had either minor or major sequelae. Mean discounted lifetime sequelae costs amounted to US$ 34,895 995% confidence interval: US$ 67-96,755) per child. Discounted childcare costs amounted to US$ 3158 99%), treatment costs US$ 460 91%) and productivity costs US$ 31,276 990%). No children were receiving rehabilitation services by the time the study was conducted. Conclusion: The present study is the first to present data on household costs from families with disabled children in a low-income country setting. Caring for a disabled child is a considerable financial as well as emotional burden for the individual family. None of the families could afford the treatment they desired for their child. C1 [Griffiths, Ulla K.] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London WC1H 9SH, England. [Dieye, Yakou] Program Appropriate Technol Hlth, Dakar, Senegal. [Fleming, Jessica] Program Appropriate Technol Hlth, Seattle, WA USA. [Hajjeh, Rana] Ctr Dis Control & Prevent, Atlanta, GA USA. [Edmond, Karen] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1H 9SH, England. RP Griffiths, UK (reprint author), London Sch Hyg & Trop Med, Dept Global Hlth & Dev, 15-17 Tavistock Pl, London WC1H 9SH, England. EM ulla.griffiths@lshtm.ac.uk FU Hib Initiative, GAVI Alliance FX Supported by the Hib Initiative, a project funded by the GAVI Alliance. The authors have no other funding or conflicts of interest to disclose. NR 33 TC 13 Z9 13 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD NOV PY 2012 VL 31 IS 11 BP E189 EP E195 DI 10.1097/INF.0b013e3182615297 PG 7 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 029XW UT WOS:000310532000001 PM 22668806 ER PT J AU Terranella, A Beekmann, SE Polgreen, PM Cohn, A Wu, HM Clark, TA AF Terranella, Andrew Beekmann, Susan E. Polgreen, Philip M. Cohn, Amanda Wu, Henry M. Clark, Thomas A. TI Practice Patterns of Infectious Disease Physicians for Management of Meningococcal Disease SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE meningococcal disease; Neisseria meningitidis; antimicrobial resistance; meningitis ID COMPLEMENT DEFICIENCY; NEISSERIA-MENINGITIDIS; BACTERIAL-MENINGITIS; UNITED-STATES; PENICILLIN; CHILDREN; GUIDELINES; RESISTANCE AB Background: Although empiric treatment regimens for acute bacterial meningitis are well established, there are many uncertainties regarding management of meningococcal disease. A survey was conducted among infectious disease specialists to assess meningococcal disease practice patterns and availability of antimicrobial susceptibility testing for Neisseria menigitidis. Methods: An online survey was distributed to 1342 pediatric and adult infectious disease specialists to assess common practices and opinions regarding the diagnosis, treatment and prevention of meningococcal disease. Specialists were also asked about the availability of antimicrobial susceptibility testing for Neisseria meningitidis at their clinical microbiology laboratory. Results: Six hundred fifty members responded to the survey (48%). Pediatric infectious disease specialists were more likely than adult specialists to use penicillin as definitive therapy for meningococcal disease (56% versus 46%; P = 0.038). Most pediatric specialists who would narrow therapy report that they would only switch to penicillin upon confirmation of penicillin susceptibility (55%), although 44% would narrow therapy based on a N. meningitidis species confirmation alone. More than one third of respondents reported that susceptibility testing for N. meningitidis is not routinely performed. There was also wide variation in complement deficiency screening criteria and meningococcal disease chemoprophylaxis practices among respondents. Conclusions: Infectious disease specialists vary significantly in their practices regarding several aspects of meningococcal disease diagnosis, treatment and prevention. Antimicrobial susceptibility testing for N. meningitidis is not routinely performed in many practices. Consideration of these variations would be useful when developing treatment and prevention recommendations. C1 [Terranella, Andrew] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Off, Epidem Intelligence Serv, Atlanta, GA USA. [Terranella, Andrew; Cohn, Amanda; Wu, Henry M.; Clark, Thomas A.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Beekmann, Susan E.; Polgreen, Philip M.] Univ Iowa, Carver Coll Med, Emerging Infect Network, Iowa City, IA USA. RP Terranella, A (reprint author), Indian Hlth Serv, Pinon Hlth Ctr, Pinon, AZ 86510 USA. EM andrew.terranella@ihs.gov FU Centers for Disease Control and Prevention [U50 CI 00358] FX This publication was supported by Grant/Cooperative Agreement Number U50 CI 00358 from the Centers for Disease Control and Prevention. The authors have no other funding or conflicts of interest to disclose. NR 29 TC 5 Z9 5 U1 1 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD NOV PY 2012 VL 31 IS 11 BP E208 EP E212 DI 10.1097/INF.0b013e31826323a4 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 029XW UT WOS:000310532000004 PM 22705919 ER PT J AU Soge, OO Harger, D Schafer, S Toevs, K Raisler, KA Venator, K Holmes, KK Kirkcaldy, RD AF Soge, Olusegun O. Harger, Doug Schafer, Sean Toevs, Kim Raisler, Kathie A. Venator, Kathy Holmes, King K. Kirkcaldy, Robert D. TI Emergence of Increased Azithromycin Resistance During Unsuccessful Treatment of Neisseria gonorrhoeae Infection With Azithromycin (Portland, OR, 2011) SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HIGH-LEVEL; REDUCED SUSCEPTIBILITY; UNITED-STATES; MUTATION; IDENTIFICATION; PENICILLIN; CLUSTERS; SYSTEM AB We describe the emergence of an azithromycin-resistant Neisseria gonorrhoeae variant in a man from Portland, Oregon, during sole treatment with 2 g azithromycin. This report highlights the ease with which gonococcal macrolide resistance can emerge, the threat of multidrug resistant N. gonorrhoeae, and the need for adherence to Centers for Disease Control and Prevention treatment guidelines. C1 [Kirkcaldy, Robert D.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30329 USA. [Soge, Olusegun O.; Holmes, King K.] Univ Washington, Neisseria Reference Lab, Dept Global Hlth, Seattle, WA 98195 USA. [Soge, Olusegun O.; Holmes, King K.] Univ Washington, Ctr AIDS & STD, Seattle, WA 98195 USA. [Harger, Doug; Schafer, Sean] Oregon State Publ Hlth Div, Portland, OR USA. [Toevs, Kim; Raisler, Kathie A.; Venator, Kathy] Multnomah Cty Hlth Dept, Portland, OR USA. RP Kirkcaldy, RD (reprint author), Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30329 USA. EM hgl8@cdc.gov FU Centers for Disease Control and Prevention [PS001411-03] FX The University of Washington Neisseria Reference Laboratory is a Gonococcal Isolate Surveillance Project Regional Laboratory supported in part by the Centers for Disease Control and Prevention (PS001411-03). NR 30 TC 13 Z9 14 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2012 VL 39 IS 11 BP 877 EP 879 DI 10.1097/OLQ.0b013e3182685d2b PG 3 WC Infectious Diseases SC Infectious Diseases GA 022QB UT WOS:000309974300009 PM 23064537 ER PT J AU Lewis, DA Muller, E Steele, L Sternberg, M Radebe, F Lyall, M Ballard, RC Paz-Bailey, G AF Lewis, David A. Mueller, Etienne Steele, Lisa Sternberg, Maya Radebe, Frans Lyall, Michael Ballard, Ronald C. Paz-Bailey, Gabriela TI Prevalence and Associations of Genital Ulcer and Urethral Pathogens in Men Presenting With Genital Ulcer Syndrome to Primary Health Care Clinics in South Africa SO SEXUALLY TRANSMITTED DISEASES LA English DT Article; Proceedings Paper CT 17th International AIDS Conference CY AUG 03-08, 2008 CL Mexico City, MEXICO ID SEXUALLY-TRANSMITTED-DISEASES; HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION; HIV-INFECTION; CONTROLLED-TRIAL; MANAGEMENT; DIAGNOSIS; TRANSMISSION; ACCURACY; ETIOLOGY AB Background: This study aimed to determine the prevalence of genital ulcer and urethral pathogens, as well as their association with clinical features, in men with genital ulcer disease (GUD) enrolled in a clinical trial. Methods: Clinical data were collected by questionnaire. Ulcer swabs were tested for herpes simplex viruses (HSV-1/2), Treponema pallidum, Haemophilus ducreyi, and Chlamydia trachomatis L1-L3. First-pass urine was tested for urethral pathogens, namely Neisseria gonorrhoeae, C. trachomatis, Trichomonas vaginalis, and Mycoplasma genitalium. Pathogens were detected by real-time molecular assays. Blood was tested for HIV, HSV-2, and syphilis-associated antibodies. Pathogens and clinical associations were investigated using the chi(2) test. Results: A total of 615 men with GUD were recruited. Herpes simplex virus (HSV-1, 4.2%; HSV-2, 98.2%) and bacterial pathogens were detected in 451 (73.6%) and 48 (7.8%) of genital ulcers, respectively. Human immunodeficiency virus, HSV-2, and treponemal antibodies were detected in 387 (62.9%), 434 (70.6%), and 141 (23.0%) men, respectively, whereas 54 men (8.8%) were rapid plasmin reagin (RPR) seropositive. A total of 223 urethral infections were diagnosed in 188 men (30.6%), including 69 (11.2%) M. genitalium, 64 (10.4%) T. vaginalis, 60 (9.8%) C. trachomatis, and 30 (4.9%) N. gonorrhoeae infections. Dysuria was reported by 170 men (27.6%), and 69 men (11.5%) had urethral discharge on examination. Urethral pathogens were detected in 102/409 (24.9%) men without these clinical features. Conclusions: Herpes accounted for most GUD cases and urethral pathogen coinfections were common. Erythromycin, dispensed to treat infrequent chancroid and lymphogranuloma venereum cases, provided additional treatment of some asymptomatic urethral pathogens. Additional antibiotics would be required to treat asymptomatic trichomoniasis and gonorrhea. C1 [Lewis, David A.; Mueller, Etienne; Radebe, Frans] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr HIV & STIs, ZA-2131 Johannesburg, South Africa. [Lewis, David A.] Univ Witwatersrand, Fac Hlth Sci, Dept Internal Med, Johannesburg, South Africa. [Steele, Lisa; Ballard, Ronald C.; Paz-Bailey, Gabriela] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Sternberg, Maya] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. [Lyall, Michael] Johannesburg City Hlth Dept, Johannesburg, South Africa. [Paz-Bailey, Gabriela] Del Valle Univ Guatemala, Guatemala City, Guatemala. RP Lewis, DA (reprint author), Natl Hlth Lab Serv, Natl Inst Communicable Dis, Ctr HIV & STIs, Private Bag X4, ZA-2131 Johannesburg, South Africa. EM davidl@nicd.ac.za FU PHS HHS [U62/CCU022901] NR 30 TC 8 Z9 8 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2012 VL 39 IS 11 BP 880 EP 885 DI 10.1097/OLQ.0b013e318269cf90 PG 6 WC Infectious Diseases SC Infectious Diseases GA 022QB UT WOS:000309974300010 PM 23064538 ER PT J AU Bhattacharya, A Park, RM AF Bhattacharya, Anasua Park, Robert M. TI Excess healthcare costs associated with prior workers' compensation activity SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE workers compensation; health insurance; occupational disease; two-part models ID OCCUPATIONAL-DISEASE; WORKPLACE INJURIES; UNITED-STATES; MORAL HAZARD; CUMULATIVE TRAUMA; AUTO INDUSTRY; INSURANCE; ILLNESSES; SURVEILLANCE; MODELS AB Background Workers compensation (WC) does not fully compensate workplace injuries and illnesses. This work examines whether cost shifting occurs to group health insurance for work-related injuries and illnesses. Methods Thomson Reuters MarketScan databases of medical insurance claims were used. WC and other benefit system data, employee status and types of medical insurance coverage were also available. Medical cost was analyzed using two-part models: the first part modeled the monthly probability of a worker having any group health medical claims, and the second part modeled the total monthly cost of those medical claims. Models included an estimate of a worker's annual medical costs prior to a WC claim. The predicted monthly medical costs were derived by retransformation using Duan's smearing factor. Results Individuals with prior WC claims were more likely to file a group health medical claim compared to those with no prior WC claims (OR?=?1.25) and incurred a higher average monthly medical costs (among nonunion hourly men aged 1834 years with prior WC claims: $203.72 vs. $160.29 with no prior claim, an increase of $43). These increases were observed in all industrial sectors with the service sector having the highest monthly increase ($66). Discussion The results reveal that individuals with prior WC claims had higher probability of filing a group health medical claim and higher average monthly medical costs in all sectors. This suggests that a part of employer liability costs related to WC gets shifted to the group health medical insurance system. Am. J. Ind. Med. 55:10181027, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Bhattacharya, Anasua] NIOSH, Ctr Dis Control & Prevent, Educ & Informat Div, Cincinnati, OH 45226 USA. RP Bhattacharya, A (reprint author), NIOSH, Ctr Dis Control & Prevent, Educ & Informat Div, MSC 15,4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM fwa4@cdc.gov NR 45 TC 5 Z9 5 U1 6 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2012 VL 55 IS 11 BP 1018 EP 1027 DI 10.1002/ajim.22112 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 023VX UT WOS:000310066200007 PM 22968954 ER PT J AU Asfaw, A Pana-Cryan, R Bushnell, PT AF Asfaw, Abay Pana-Cryan, Regina Bushnell, P. Timothy TI Incidence and costs of family member hospitalization following injuries of workers' compensation claimants SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE occupational injury; family hospitalization; before-after analysis ID OCCUPATIONAL INJURY; UNITED-STATES; ECONOMIC CONSEQUENCES; SOCIAL-CONSEQUENCES; ILLNESSES; EARNINGS; IMPACT AB Background The consequences of occupational injuries for the health of family members have rarely been studied. We hypothesized that non-fatal occupational injury would increase the incidence and costs of hospitalization among workers' families, and that family members of severely injured workers would be likely to experience greater increases in hospitalizations than family members of non-severely injured workers. Data and Methods We used the MarketScan databases from Thomson Reuters for 2002-2005, which include workers' compensation and inpatient medical care claims data for injured workers' families. We used a beforeafter analysis to compare the odds and costs of family hospitalization 3 months before and after the index occupational injury among 18,411 families. Severe injuries were defined by receipt of indemnity payments and at least 7 days of lost work. Family hospitalizations were measured by the incidence of hospitalization of at least one family member. Results Among families of all injured workers, the odds of at least one family member being hospitalized were 31% higher [95% confidence intervals (CI)?=?1.111.55] in the 3 months following occupational injury than in the 3 months preceding injury. Among the families of severely injured workers, the odds of hospitalization were 56% higher [95% CI?=?1.052.34] in the 3 months following injury. Hospitalization costs were found to rise by approximately the same percentage as hospitalization incidence. Conclusion The impact of occupational injury may extend beyond the workplace and adversely affect the health and inpatient medical care use of family members. Am. J. Ind. Med. 55:10281036, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Asfaw, Abay; Pana-Cryan, Regina] NIOSH, Ctr Dis Control & Prevent CDC, Off Director, Washington, DC USA. [Bushnell, P. Timothy] NIOSH, Ctr Dis Control & Prevent CDC, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. RP Asfaw, A (reprint author), 395 E St, Washington, DC 20201 USA. EM hqp0@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 2 Z9 2 U1 6 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD NOV PY 2012 VL 55 IS 11 BP 1028 EP 1036 DI 10.1002/ajim.22110 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 023VX UT WOS:000310066200008 PM 22968927 ER PT J AU Liu, HM Roberts, JA Moore, D Anderson, B Pallansch, MA Pevear, DC Collett, MS Oberste, MS AF Liu, Hong-Mei Roberts, Jason A. Moore, Deborah Anderson, Barbara Pallansch, Mark A. Pevear, Daniel C. Collett, Marc S. Oberste, M. Steven TI Characterization of Poliovirus Variants Selected for Resistance to the Antiviral Compound V-073 SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID MOLECULAR-DYNAMICS; DRUG; MUTANTS; PLECONARIL; REGIONS; TYPE-3 AB V-073, a small-molecule capsid inhibitor originally developed for nonpolio enterovirus indications is considerably more potent against polioviruses. All poliovirus isolates tested to date (n = 45), including wild, vaccine, vaccine-derived, and laboratory strains, are susceptible to the antiviral capsid inhibitor V-073. We grew poliovirus in the presence of V-073 to allow for the identification of variants with reduced susceptibility to the drug. Sequence analysis of 160 independent resistant variants (80 isolates of poliovirus type 1, 40 isolates each of types 2 and 3) established that V-073 resistance involved a single amino acid change in either of two virus capsid proteins, VP1 (67 of 160 [42%]) or VP3 (93 of 160 [58%]). In resistant variants with a VP1 change, the majority (53 of 67 [79%]) exhibited a substitution of isoleucine at position 194 (equivalent position 192 in type 3) with either methionine or phenylalanine. Of those with a VP3 change, alanine at position 24 was replaced with valine in all variants (n = 93). The resistance phenotype was relatively stable upon passage of viruses in cell culture in the absence of drug. Single-step growth studies showed no substantial differences between drug-resistant variants and the virus stocks from which they were derived, while the resistant viruses were generally more thermally labile than the corresponding drug-susceptible parental viruses. These studies provide a foundation from which to build a greater understanding of resistance to antiviral compound V-073. C1 [Liu, Hong-Mei; Moore, Deborah; Anderson, Barbara; Pallansch, Mark A.; Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Roberts, Jason A.] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia. [Pevear, Daniel C.] VenatoRx Pharmaceut Inc, Malvern, PA USA. [Collett, Marc S.] ViroDefense Inc, Rockville, MD USA. RP Oberste, MS (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM soberste@cdc.gov OI Roberts, Jason/0000-0002-9734-9764 FU The Task Force for Global Health, Inc.; WHO; Rotary International FX ViroDefense, Inc., received financial support from The Task Force for Global Health, Inc., through grants from the WHO and Rotary International. NR 18 TC 15 Z9 15 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2012 VL 56 IS 11 BP 5568 EP 5574 DI 10.1128/AAC.00539-12 PG 7 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 023SN UT WOS:000310055800017 PM 22890765 ER PT J AU Espinel-Ingroff, A Aller, AI Canton, E Castanon-Olivares, LR Chowdhary, A Cordoba, S Cuenca-Estrella, M Fothergill, A Fuller, J Govender, N Hagen, F Illnait-Zaragozi, MT Johnson, E Kidd, S Lass-Florl, C Lockhart, SR Martins, MA Meis, JF Melhem, MSC Ostrosky-Zeichner, L Pelaez, T Pfaller, MA Schell, WA St-Germain, G Trilles, L Turnidge, J AF Espinel-Ingroff, A. Aller, A. I. Canton, E. Castanon-Olivares, L. R. Chowdhary, A. Cordoba, S. Cuenca-Estrella, M. Fothergill, A. Fuller, J. Govender, N. Hagen, F. Illnait-Zaragozi, M. T. Johnson, E. Kidd, S. Lass-Floerl, C. Lockhart, S. R. Martins, M. A. Meis, J. F. Melhem, M. S. C. Ostrosky-Zeichner, L. Pelaez, T. Pfaller, M. A. Schell, W. A. St-Germain, G. Trilles, L. Turnidge, J. TI Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID CLSI BROTH MICRODILUTION; IN-VITRO SUSCEPTIBILITY; METHOD M38-A2 DOCUMENT; ANTIFUNGAL DRUG SUSCEPTIBILITY; MIC DISTRIBUTIONS; AMPHOTERICIN-B; LANOSTEROL 14-ALPHA-DEMETHYLASE; ASPERGILLUS SPP.; CROSS-RESISTANCE; MOLECULAR TYPE AB Epidemiological cutoff values (ECVs) for the Cryptococcus neoformans-Cryptococcus gattii species complex versus fluconazole, itraconazole, posaconazole, and voriconazole are not available. We established ECVs for these species and agents based on wildtype (WT) MIC distributions. A total of 2,985 to 5,733 CLSI MICs for C. neoformans (including isolates of molecular type VNI [MICs for 759 to 1,137 isolates] and VNII, VNIII, and VNIV [MICs for 24 to 57 isolates]) and 705 to 975 MICs for C. gattii (including 42 to 260 for VGI, VGII, VGIII, and VGIV isolates) were gathered in 15 to 24 laboratories (Europe, United States, Argentina, Australia, Brazil, Canada, Cuba, India, Mexico, and South Africa) and were aggregated for analysis. Additionally, 220 to 359 MICs measured using CLSI yeast nitrogen base (YNB) medium instead of CLSI RPMI medium for C. neoformans were evaluated. CLSI RPMI medium ECVs for distributions originating from at least three laboratories, which included >= 95% of the modeled WT population, were as follows: fluconazole, 8 mu g/ml (VNI, C. gattii nontyped, VGI, VGIIa, and VGIII), 16 mu g/ml (C. neoformans nontyped, VNIII, and VGIV), and 32 mu g/ml (VGII); itraconazole, 0.25 mu g/ml (VNI), 0.5 mu g/ml (C. neoformans and C. gattii nontyped and VGI to VGIII), and 1 mu g/ml (VGIV); posaconazole, 0.25 mu g/ml (C. neoformans nontyped and VNI) and 0.5 mu g/ml (C. gattii nontyped and VGI); and voriconazole, 0.12 mu g/ml (VNIV), 0.25 mu g/ml (C. neoformans and C. gattii nontyped, VNI, VNIII, VGII, and VGIIa,), and 0.5 mu g/ml (VGI). The number of laboratories contributing data for other molecular types was too low to ascertain that the differences were due to factors other than assay variation. In the absence of clinical breakpoints, our ECVs may aid in the detection of isolates with acquired resistance mechanisms and should be listed in the revised CLSI M27-A3 and CLSI M27-S3 documents. C1 [Espinel-Ingroff, A.] VCU Med Ctr, Richmond, VA USA. [Aller, A. I.] Hosp Univ Valme, Seville, Spain. [Canton, E.] Hosp Univ La Fe, Unidad Microbiol Expt, Valencia, Spain. [Castanon-Olivares, L. R.] Univ Nacl Autonoma Mexico, Mexico City 04510, DF, Mexico. [Chowdhary, A.] Univ Delhi, Vallabhbhai Patel Chest Inst, Delhi 110007, India. [Cordoba, S.] ANLIS Dr Carlos G Malbran, Inst Nacl Enfermedades Infecciosas, Dept Micol, Buenos Aires, DF, Argentina. [Cuenca-Estrella, M.] Inst Salud Carlos III, Serv Micol, Ctr Nacl Microbiol, Madrid, Spain. [Fothergill, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Fuller, J.] Univ Alberta, Edmonton, AB, Canada. [Govender, N.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa. [Hagen, F.] Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands. [Illnait-Zaragozi, M. T.] Inst Trop Med Pedro Kouri, Havana, Cuba. [Johnson, E.] Kingsdown, HPA Mycol Reference Lab, Bristol, Avon, England. [Kidd, S.] Womens & Childrens Hosp, Adelaide, SA, Australia. [Lass-Floerl, C.] Innsbruck Med Univ, Innsbruck, Austria. [Lockhart, S. R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Martins, M. A.; Melhem, M. S. C.] Adolfo Lutz Inst Publ Hlth Reference Ctr, Sao Paulo, Brazil. [Martins, M. A.; Melhem, M. S. C.] Adolfo Lutz Inst Publ Hlth Reference Ctr, Rio Claro, Brazil. [Meis, J. F.] Radboud Univ Nijmegen, Dept Med Microbiol, Med Ctr, Canisius Wilhelmina Hosp, NL-6525 ED Nijmegen, Netherlands. [Ostrosky-Zeichner, L.] Univ Texas Hlth Sci Ctr, Houston, TX USA. [Pelaez, T.] Univ Complutense, Fac Med, Hosp Gen Univ Gregorio Maranon, E-28040 Madrid, Spain. [Pfaller, M. A.] Univ Iowa, Iowa City, IA USA. [Schell, W. A.] Duke Univ, Med Ctr, Durham, NC USA. [St-Germain, G.] Lab Sante Publ Quebec, Quebec City, PQ, Canada. [Trilles, L.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil. [Turnidge, J.] Univ Adelaide, Adelaide, SA, Australia. RP Espinel-Ingroff, A (reprint author), VCU Med Ctr, Richmond, VA USA. EM avingrof@vcu.edu RI Kidd, Sarah/A-1731-2009; Kidd, Sarah/N-1362-2013; Hagen, Ferry/B-9044-2009; MELHEM, MARCIA/D-4477-2012; OI Kidd, Sarah/0000-0002-5957-4178; Kidd, Sarah/0000-0002-5957-4178; Hagen, Ferry/0000-0002-5622-1916; MELHEM, MARCIA/0000-0002-1335-8808; Meis, Jacques/0000-0003-3253-6080; Chowdhary, Anuradha/0000-0002-2028-7462 NR 55 TC 67 Z9 68 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2012 VL 56 IS 11 BP 5898 EP 5906 DI 10.1128/AAC.01115-12 PG 9 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 023SN UT WOS:000310055800060 PM 22948877 ER PT J AU Moss, JA Malone, AM Smith, TJ Butkyavichene, I Cortez, C Gilman, J Kennedy, S Kopin, E Nguyen, C Sinha, P Hendry, RM Guenthner, P Holder, A Martin, A McNicholl, J Mitchell, J Pau, CP Srinivasan, P Smith, JM Baum, MM AF Moss, John A. Malone, Amanda M. Smith, Thomas J. Butkyavichene, Irina Cortez, Cassandra Gilman, Joshua Kennedy, Sean Kopin, Etana Cali Nguyen Sinha, Preetha Hendry, R. Michael Guenthner, Patricia Holder, Angela Martin, Amy McNicholl, Janet Mitchell, James Pau, Chou-Pong Srinivasan, Priya Smith, James M. Baum, Marc M. TI Safety and Pharmacokinetics of Intravaginal Rings Delivering Tenofovir in Pig-Tailed Macaques SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID HIV-INFECTION; DISOPROXIL FUMARATE; COHABITING COUPLES; VAGINAL DELIVERY; ANIMAL-MODELS; MICROBICIDES; NUCLEOSIDE; PREVENTION; ANTIRETROVIRALS; PROPHYLAXIS AB Antiretroviral-based microbicides applied topically to the vagina may play an important role in protecting women from HIV infection. Incorporation of the nucleoside reverse transcriptase inhibitor tenofovir (TFV) into intravaginal rings (IVRs) for sustained mucosal delivery may lead to increased microbicide product adherence and efficacy compared with those of conventional vaginal formulations. Formulations of a novel "pod IVR" platform spanning a range of IVR drug loadings and daily release rates of TFV were evaluated in a pig-tailed macaque model. The rings were safe and exhibited sustained release at controlled rates over 28 days. Vaginal secretion TFV levels were independent of IVR drug loading and were able to be varied over 1.5 log units by changing the ring configuration. Mean TFV levels in vaginal secretions were 72.4 +/- 109 mu g ml(-1) (slow releasing) and 1.84 +/- 1.97 mg ml(-1) (fast releasing). The mean TFV vaginal tissue concentration from the slow-releasing IVRs was 76.4 +/- 54.8 mu g g(-1) and remained at steady state 7 days after IVR removal, consistent with the long intracellular half-life of TFV. Intracellular tenofovir diphosphate (TFV-DP), the active moiety in defining efficacy, was measured in vaginal lymphocytes collected in the study using the fast-releasing IVR formulation. Mean intracellular TFV-DP levels of 446 +/- 150 fmol/10(6) cells fall within a range that may be protective of simian-human immunodeficiency virus strain SF162p3 (SHIVSF162p3) infection in nonhuman primates. These data suggest that TFV-releasing IVRs based on the pod design have potential for the prevention of transmission of human immunodeficiency virus type 1 (HIV-1) and merit further clinical investigation. C1 [Moss, John A.; Smith, Thomas J.; Cortez, Cassandra; Kennedy, Sean; Cali Nguyen; Sinha, Preetha; Baum, Marc M.] Oak Crest Inst Sci, Dept Chem, Pasadena, CA USA. [Malone, Amanda M.; Smith, Thomas J.; Butkyavichene, Irina; Cortez, Cassandra; Gilman, Joshua; Kopin, Etana; Cali Nguyen] Auritec Pharmaceut Inc, Santa Monica, CA USA. [Hendry, R. Michael; Guenthner, Patricia; Holder, Angela; Martin, Amy; McNicholl, Janet; Mitchell, James; Pau, Chou-Pong; Srinivasan, Priya; Smith, James M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Baum, MM (reprint author), Oak Crest Inst Sci, Dept Chem, Pasadena, CA USA. EM m.baum@oak-crest.org FU National Institutes of Health [5R21AI079791, 5R21AI076136]; federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [Y1-AI-0681-01] FX We thank the National Institutes of Health (grant numbers 5R21AI079791 and 5R21AI076136) for funding support. This project has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under interagency agreement no. Y1-AI-0681-01. NR 50 TC 24 Z9 25 U1 2 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD NOV PY 2012 VL 56 IS 11 BP 5952 EP 5960 DI 10.1128/AAC.01198-12 PG 9 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 023SN UT WOS:000310055800066 PM 22964245 ER PT J AU Carter, MW Bergdall, AR Henry-Moss, D Hatfield-Timajchy, K Hock-Long, L AF Carter, Marion W. Bergdall, Anna R. Henry-Moss, Dare Hatfield-Timajchy, Kendra Hock-Long, Linda TI A qualitative study of contraceptive understanding among young adults SO CONTRACEPTION LA English DT Article DE Contraception; Young adults; Knowledge; Attitudes; Qualitative ID REPRODUCTIVE HEALTH; DECISION-MAKING; HORMONAL CONTRACEPTIVES; CONSPIRACY BELIEFS; AFRICAN-AMERICANS; UNITED-STATES; BIRTH-CONTROL; WOMEN; BARRIERS; DISPARITIES AB Background: This study describes contraceptive understanding, sources of information and consequences of contraceptive misunderstandings among urban, young adults. Study Design: We used qualitative data from 16 focus groups and 53 interviews with Puerto Rican and African American men and women aged 18-25 years from Philadelphia and Hartford. We categorized and compared assertions made about all contraceptive methods' side effects, effectiveness and use using an iterative process. Results: Participants considered contraceptive use worthwhile but felt that it carried risks of problematic side effects and contraceptive failure, with variation among methods. Men knew most about condoms and withdrawal and trusted both more than women. Personal or second-hand experience was the dominant source of information on contraceptive understanding. Misunderstandings about contraception affected their relationships and risk of unintended pregnancy. Conclusion: Contraceptive understanding is a powerful determinant of contraceptive use and limits the options perceived by young adults to prevent pregnancy. Research is needed to strengthen contraceptive counseling and outreach in ways that better leverage peer influence. Published by Elsevier Inc. C1 [Carter, Marion W.; Hatfield-Timajchy, Kendra] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bergdall, Anna R.] Oak Ridge Inst Sci Educ, Oak Ridge, TN USA. [Henry-Moss, Dare; Hock-Long, Linda] Family Planning Council, Philadelphia, PA USA. RP Carter, MW (reprint author), Ctr Dis Control, 4770 Buford Highway,MS K-34, Atlanta, GA 30341 USA. EM Acq0@cdc.gov OI HENRY-MOSS, DARE/0000-0002-4088-0028 FU CDC FX There was no funding for this study. There was funding from CDC for the original data collection. NR 30 TC 9 Z9 9 U1 1 U2 26 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD NOV PY 2012 VL 86 IS 5 BP 543 EP 550 DI 10.1016/j.contraception.2012.02.017 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 022HL UT WOS:000309948500019 PM 22464411 ER PT J AU Dills, JE Rutt, CD Mumford, KG AF Dills, James E. Rutt, Candace D. Mumford, Karen G. TI Objectively Measuring Route-To-Park Walkability in Atlanta, Georgia SO ENVIRONMENT AND BEHAVIOR LA English DT Article DE walking; neighborhood environment; pedestrian; park use; physical activity ID PHYSICAL-ACTIVITY; URBAN FORM; WALKING; NEIGHBORHOOD; OBESITY; ADULTS; OVERWEIGHT; EXERCISE; ASSOCIATIONS; INSTRUMENTS AB Many people fail to achieve recommended levels of physical activity. Neighborhood parks serve as locations in which physical activity often occurs, and walking to parks provides added opportunity for leisure-time activity. The authors examine environmental characteristics of shortest pedestrian routes to parks to determine how route walkability affects park use. Using an objective environmental audit, the authors found that routes of park users were measurably more walkable than those of nonpark users and that each unit increase in total walkability score associated with a 20% increase in the likelihood of walking to the park, controlling for education and route length (odds ratio = 1.20; 95% confidence interval = [1.07, 1.34]). The most significant elements measured included route distance, traffic, neighborhood maintenance, street maintenance, safety, and aesthetics. Pedestrian scale environmental characteristics are associated with individuals' use of neighborhoods for physical activity. Understanding these relationships can contribute to evidence-based design interventions to increase physical activity. C1 [Rutt, Candace D.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Dills, James E.] Metropolitan Nashville Davidson Cty Publ Hlth Dep, Nashville, TN USA. [Mumford, Karen G.] Univ Minnesota, Div Sci & Math, Morris, MN 56267 USA. RP Rutt, CD (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE,MS K46, Atlanta, GA 30341 USA. EM CRutt@cdc.gov NR 38 TC 3 Z9 3 U1 0 U2 25 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0013-9165 J9 ENVIRON BEHAV JI Environ. Behav. PD NOV PY 2012 VL 44 IS 6 BP 841 EP 860 DI 10.1177/0013916511404409 PG 20 WC Environmental Studies; Psychology, Multidisciplinary SC Environmental Sciences & Ecology; Psychology GA 027CE UT WOS:000310328600006 ER PT J AU Thompson, WW Ridenhour, BL Barile, JP Shay, DK AF Thompson, William W. Ridenhour, Benjamin L. Barile, John P. Shay, David K. TI Time-Series Analyses of Count Data to Estimate the Burden of Seasonal Infectious Diseases SO EPIDEMIOLOGY LA English DT Editorial Material ID RESPIRATORY-SYNCYTIAL-VIRUS; INFLUENZA-ASSOCIATED MORTALITY; LONGITUDINAL DATA-ANALYSIS; GENERALIZED LINEAR-MODELS; UNITED-STATES; EXCESS MORTALITY; POISSON REGRESSION; YOUNG-CHILDREN; DEATHS; EPIDEMICS C1 [Thompson, William W.] Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Div Behav Surveillance, Atlanta, GA USA. [Ridenhour, Benjamin L.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA. [Ridenhour, Benjamin L.] Univ Hawaii Manoa, Manoa, HI USA. [Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Thompson, WW (reprint author), CDC, 1600 Clifton Rd,MS E-61, Atlanta, GA 30333 USA. EM wct2@cdc.gov RI Barile, John/F-9456-2015; OI Barile, John/0000-0003-4098-0640; Ridenhour, Benjamin/0000-0001-8271-4629; Shay, David/0000-0001-9619-4820 NR 61 TC 13 Z9 13 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD NOV PY 2012 VL 23 IS 6 BP 839 EP 842 DI 10.1097/EDE.0b013e31826cc1df PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 022NJ UT WOS:000309965800012 PM 23038110 ER PT J AU Park, RM AF Park, Robert M. TI Estimation with Vanishing Baseline Risk SO EPIDEMIOLOGY LA English DT Letter C1 NIOSH, Ctr Dis Control & Prevent, Educ & Informat Div, Cincinnati, OH 45226 USA. RP Park, RM (reprint author), NIOSH, Ctr Dis Control & Prevent, Educ & Informat Div, Cincinnati, OH 45226 USA. EM rhp9@cdc.gov FU Intramural CDC HHS [CC999999] NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD NOV PY 2012 VL 23 IS 6 BP 937 EP 938 DI 10.1097/EDE.0b013e31826d7968 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 022NJ UT WOS:000309965800036 PM 23038127 ER PT J AU FitzGerald, LZ Robbins, WA Kesner, JS Xun, L AF FitzGerald, Leah Z. Robbins, Wendie A. Kesner, James S. Xun, Lin TI Reproductive hormones and interleukin-6 in serious leisure male athletes SO EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE Estradiol; Testosterone; Reproductive hormones; Men; Serious leisure athletes; Cytokines; Interleukin ID UNCOMPENSABLE HEAT-STRESS; PHYSICAL-ACTIVITY; ENDURANCE EXERCISE; BODY-COMPOSITION; SKELETAL-MUSCLE; IMMUNE-SYSTEM; TESTOSTERONE; SERUM; RESPONSES; ESTROGEN AB Lifestyles associated with different types and intensities of exercise result in improved health including positive changes in chronic low-grade inflammatory biomarkers. Alternatively, some forms of exercise adversely affect reproductive health of men, including changes in circulating reproductive hormones. To explore the associations between exercise intensity and circulating levels of reproductive hormones, and inflammatory analytes in serious leisure athletes (triathletes and cyclists) and recreational athletes. Male athletes 18-60 years old, 16 triathletes, 46 cyclists and 45 recreational athletes, were recruited to provide plasma for the measurement of total testosterone, estradiol, follicular stimulating hormone, luteinizing hormone (LH), sex hormone-binding globulin (SHBG), cortisol, interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) levels, and calculation of free androgen index (FAI) and the estradiol:SHBG ratio (ESR). Plasma estradiol concentrations were more than two times higher in cyclists than in triathletes and recreational athletes (p < 0.01). Testosterone levels were also higher in cyclists than recreational athletes (p < 0.01), but not significantly different from triathletes. SHBG levels were higher in triathletes and cyclists than in recreational athletes (p < 0.01). LH levels were lower in cyclists than in recreational athletes (p < 0.05). IL-6 and IL-1 beta levels were each two times lower in triathletes than in cyclists (p < 0.05) and IL-6 levels were lower in cyclists than in recreational athletes (p < 0.01). IL-1 beta levels were two times lower in triathletes than in cyclists (p < 0.05). Circulating estradiol and testosterone levels were elevated in serious leisure male cyclists. This effect is discussed in light in the absence of a substantial concomitant change in gonadotropin levels and other variables. C1 [FitzGerald, Leah Z.; Robbins, Wendie A.; Xun, Lin] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90095 USA. [Robbins, Wendie A.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA. [Kesner, James S.] NIOSH, Div Appl Res & Technol, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP FitzGerald, LZ (reprint author), Univ Calif Los Angeles, Sch Nursing, 700 Tiverton Ave,Factor Bldg 5-137, Los Angeles, CA 90095 USA. EM lfitzger@sonnet.ucla.edu NR 61 TC 7 Z9 7 U1 2 U2 16 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1439-6319 J9 EUR J APPL PHYSIOL JI Eur. J. Appl. Physiol. PD NOV PY 2012 VL 112 IS 11 BP 3765 EP 3773 DI 10.1007/s00421-012-2356-2 PG 9 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 024DA UT WOS:000310086800007 PM 22382666 ER PT J AU Oloo, I Gust, DA Shinde, S Mc Lellan-Lemal, E Pals, SL Chege, W Gumbe, A Thomas, TK Mills, LA Chen, RT AF Oloo, Isaiah Gust, Deborah A. Shinde, Sanjyot Mc Lellan-Lemal, Eleanor Pals, Sherri L. Chege, Wairimu Gumbe, Anne Thomas, Timothy K. Mills, Lisa A. Chen, Robert T. TI Effect of Gender of the Recorded Voice on Responses to Sensitive Sexual Behavior Questions: Use of Audio Computer-Assisted Self-Interview (ACASI) in Kisumu, Kenya SO FIELD METHODS LA English DT Article DE ACASI; behavior; interview questionnaire; gender; Kenya; HIV; sexual risk ID ADOLESCENTS AB Audio computer-assisted self-interview (ACASI) has been shown to reduce interviewer and social desirability bias related to sensitive questions, which can be especially important for studies of sexual behavior and HIV risk. Baseline demographic and HIV risk data were collected using ACASI for 849 adults aged 18-34 (423 males and 426 females) of unknown or HIV-negative status as part of an HIV-incidence cohort study in Kisumu, Kenya. ACASI questionnaires and possible responses were recorded being read either by a male or female voice in the three most commonly used languages (English, Kiswahili, and Dholuo). Participants were randomly assigned to hear either male or female voice. Dependent variables, including 12 sexual behavior questions, were evaluated using logistic regression. No significant differences in responses to the 12 sensitive questions were found for gender of the recorded voice on ACASI or for the interaction between gender of recorded ACASI voice and respondent gender. C1 [Gust, Deborah A.; Shinde, Sanjyot; Mc Lellan-Lemal, Eleanor; Pals, Sherri L.; Chen, Robert T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Oloo, Isaiah; Gumbe, Anne] Kenya Govt Med Res Ctr, Kisumu, Kenya. [Shinde, Sanjyot] Northrup Grumman, Business Comp Applicat, Atlanta, GA USA. [Chege, Wairimu; Thomas, Timothy K.; Mills, Lisa A.] Ctr Dis Control & Prevent, Kisumu, Kenya. RP Gust, DA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM dgg6@cdc.gov NR 22 TC 4 Z9 4 U1 4 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1525-822X J9 FIELD METHOD JI Field Methods PD NOV PY 2012 VL 24 IS 4 BP 367 EP 381 DI 10.1177/1525822X11432087 PG 15 WC Anthropology; Social Sciences, Interdisciplinary SC Anthropology; Social Sciences - Other Topics GA 023FI UT WOS:000310017900001 ER PT J AU Semenya, AA Sullivan, JS Barnwell, JW Secor, WE AF Semenya, Amma A. Sullivan, JoAnn S. Barnwell, John W. Secor, W. Evan TI Schistosoma mansoni Infection Impairs Antimalaria Treatment and Immune Responses of Rhesus Macaques Infected with Mosquito-Borne Plasmodium coatneyi SO INFECTION AND IMMUNITY LA English DT Article ID POLY-PARASITISM; HAEMATOBIUM INFECTION; FALCIPARUM MALARIA; CHILDREN; EPIDEMIOLOGY; COINFECTION; IMPACT; MICE AB Malaria and schistosomiasis are the world's two most important parasitic infections in terms of distribution, morbidity, and mortality. In areas where Plasmodium and Schistosoma species are both endemic, coinfections are commonplace. Mouse models demonstrate that schistosomiasis worsens a malaria infection; however, just as mice and humans differ greatly, the murine-infecting Plasmodium species differ as much from those that infect humans. Research into human coinfections (Schistosoma haematobium-Plasmodium falciparum versus Schistosoma mansoni-P. falciparum) has produced conflicting results. The rhesus macaque model provides a helpful tool for understanding the role of S. mansoni on malaria parasitemia and antimalarial immune responses using Plasmodium coatneyi, a malaria species that closely resembles P. falciparum infection in humans. Eight rhesus macaques were exposed to S. mansoni cercariae. Eight weeks later, these animals plus 8 additional macaques were exposed to malaria either through bites of infected mosquitos or intravenous inoculation. When malaria infection was initiated from mosquito bites, coinfected animals displayed increased malaria parasitemia, decreased hematocrit levels, and suppressed malaria-specific antibody responses compared to those of malaria infection alone. However, macaques infected by intravenous inoculation with erythrocytic-stage parasites did not display these same differences in parasitemia, hematocrit, or antibody responses between the two groups. Use of the macaque model provides information that begins to unravel differences in pathological and immunological outcomes observed between humans with P. falciparum that are coinfected with S. mansoni or S. haematobium. Our results suggest that migration of malaria parasites through livers harboring schistosome eggs may alter host immune responses and infection outcomes. C1 [Semenya, Amma A.; Sullivan, JoAnn S.; Barnwell, John W.; Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Secor, WE (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM was4@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX This work was supported by an appointment to the Emerging Infectious Diseases Fellowship Program (A. A. S.) administered by the Association of Public Health Laboratories (APHL) and funded by the Centers for Disease Control and Prevention (CDC). NR 30 TC 9 Z9 10 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD NOV PY 2012 VL 80 IS 11 BP 3821 EP 3827 DI 10.1128/IAI.00590-12 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 022PK UT WOS:000309971600010 PM 22907811 ER PT J AU Pawar, D Tsay, R Nelson, DS Elumalai, MK Lessa, FC McDonald, LC Dumyati, G AF Pawar, Deepa Tsay, Rebecca Nelson, Deborah S. Elumalai, Meena Kumari Lessa, Fernanda C. McDonald, L. Clifford Dumyati, Ghinwa TI Burden of Clostridium difficile Infection in Long-Term Care Facilities in Monroe County, New York SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; NURSING-HOMES; RISK-FACTORS; SURVEILLANCE; EPIDEMIC; DIARRHEA; HOSPITALS; STRAIN; RATES AB BACKGROUND. Long-term care facility (LTCF) residents are at increased risk of Clostridium difficile infection (CDI). However, little is known about the incidence, recurrence, and severity of CDI in LTCFs or the extent to which acute care exposure contributes to CDI in LTCFs. We describe the epidemiology of CDI in a cohort of LTCF residents in Monroe County, New York, where recent estimates suggest a CDI incidence in hospitals of 9.2 cases per 10,000 patient-days. DESIGN. Population-based surveillance study. SETTING. Monroe County, New York. PATIENTS. LTCF residents with onset of CDI while in the LTCF or less than 4 calendar-days after hospital admission from the LTCF from January 1 through December 31, 2010. METHODS. We conducted surveillance for CDI in residents of 33 LTCFs. A CDI case was defined as a stool specimen positive for C. difficile obtained from a patient without a C. difficile-positive specimen in the previous 8 weeks; recurrence was defined as a stool specimen positive for C. difficile obtained between 2 and 8 weeks after the last C. difficile-positive stool specimen. RESULTS. There were 425 LTCF-onset cases and 184 recurrences, which yielded an incidence of 2.3 cases per 10,000 resident-days (interquartile range [IQR], 1.2-3.3) and a recurrence rate of 1.0 case per 10,000 resident-days (IQR, 0.3-1.4). The cases occurred in 394 LTCF residents, and 52% of these residents developed CDI within 4 weeks after hospital discharge. Hospitalization for CDI occurred in 70 cases (16%). Of those cases that involved hospitalization for CDI, 70% were severe CDI, and 23% ended in death within 30 days after hospital admission. CONCLUSION. CDI incidence in Monroe County LTCFs is one-fourth the incidence among hospitalized patients. Approximately 50% of LTCF-onset cases occurred more than 4 weeks after hospital discharge, which emphasizes that prevention of CDI transmission should go beyond acute care settings. C1 [Pawar, Deepa; Tsay, Rebecca; Nelson, Deborah S.; Elumalai, Meena Kumari; Dumyati, Ghinwa] Univ Rochester, Ctr Community Hlth, Rochester, NY USA. [Lessa, Fernanda C.; McDonald, L. Clifford] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Pawar, D (reprint author), Johns Hopkins Prevent Med Residency Program, 615 N Wolfe St,Room WB602, Baltimore, MD 21205 USA. EM dpawar@jhsph.edu FU Centers for Disease Control and Prevention, New York State Department of Health; University of Rochester FX This work was supported through a cooperative agreement between Centers for Disease Control and Prevention, New York State Department of Health, and University of Rochester. NR 29 TC 22 Z9 22 U1 1 U2 8 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV PY 2012 VL 33 IS 11 BP 1107 EP 1112 DI 10.1086/668031 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 018MU UT WOS:000309665800007 PM 23041808 ER PT J AU Lambert, LA Pratt, RH Armstrong, LR Haddad, MB AF Lambert, Lauren A. Pratt, Robert H. Armstrong, Lori R. Haddad, Maryam B. TI Tuberculosis among Healthcare Workers, United States, 1995-2007 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID FOREIGN-BORN PERSONS; MYCOBACTERIUM-TUBERCULOSIS; RISK; TRANSMISSION AB OBJECTIVE. We examined surveillance data to describe the epidemiology of tuberculosis (TB) among healthcare workers (HCWs) in the United States during the period 1995-2007. DESIGN. Cross-sectional descriptive analysis of existing surveillance data. SETTING AND PARTICIPANTS. TB cases reported to the Centers for Disease Control and Prevention from the 50 states and the District of Columbia from 1995 through 2007. RESULTS. Of the 200,744 reported TB cases in persons 18 years of age or older, 6,049 (3%) occurred in individuals who were classified as HCWs. HCWs with TB were more likely than other adults with TB to be women (unadjusted odds ratio [95% confidence interval], 4.1 [3.8-4.3]), be foreign born (1.3 [1.3-1.4]), have extrapulmonary TB (1.6 [1.5-1.7]), and complete TB treatment (2.5 [2.3-2.8]). CONCLUSIONS. Healthcare institutions may benefit from intensifying TB screening of HCWs upon hire, especially persons from countries with a high incidence of TB, and encouraging treatment for latent TB infection among HCWs to prevent progression to TB disease. C1 [Lambert, Lauren A.; Pratt, Robert H.; Armstrong, Lori R.; Haddad, Maryam B.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. RP Lambert, LA (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd,E-10, Atlanta, GA 30333 USA. EM lal0@cdc.gov FU Centers for Disease Control and Prevention FX The Centers for Disease Control and Prevention. NR 28 TC 6 Z9 6 U1 1 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV PY 2012 VL 33 IS 11 BP 1126 EP 1131 DI 10.1086/668016 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 018MU UT WOS:000309665800010 PM 23041811 ER PT J AU de Perio, MA AF de Perio, Marie A. TI Needlestick Injuries among Employees at a Nationwide Retail Pharmacy Chain, 2000-2011 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID HEALTH-CARE WORKERS; UNITED-STATES; VACCINATION; CAMPAIGN AB We reviewed a nationwide retail pharmacy chain's centralized needlestick injury reports. From 2000 to 2011, 33 needlestick injuries were reported by 31 different pharmacy locations and were likely preventable. The annual incidence of needlestick injuries ranged from 0 to 3.62 per 100,000 vaccinations and ranged from 0 to 5.65 per 1,000 immunizing pharmacists. C1 NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP de Perio, MA (reprint author), NIOSH, Ctr Dis Control & Prevent, 4676 Columbia Pkwy,R-10, Cincinnati, OH 45226 USA. EM mdeperio@cdc.gov FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD NOV PY 2012 VL 33 IS 11 BP 1156 EP 1158 DI 10.1086/668033 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 018MU UT WOS:000309665800015 PM 23041816 ER PT J AU Hamelin, EI Johnson, RC Osterloh, JD Howard, DJ Thomas, JD AF Hamelin, Elizabeth I. Johnson, Rudolph C. Osterloh, John D. Howard, David J. Thomas, Jerry D. TI Evaluation of Ricinine, a Ricin Biomarker, from a Non-Lethal Castor Bean Ingestion SO JOURNAL OF ANALYTICAL TOXICOLOGY LA English DT Article ID QUANTIFICATION; INTOXICATION; ELISA; RAT; OIL AB A case is presented of the attempted suicide of a 58-year-old man using castor beans. The patient came to the emergency room complaining of nausea, vomiting and diarrhea for nine hours following the ingestion of six castor beans. Urine samples were taken throughout the hospital stay and submitted to the Centers for Disease Control and Prevention for analysis of ricinine, a castor bean component. The samples were found to be positive for ricinine, with a maximum concentration of 674 g/g-creatinine excreted approximately 23 h post-exposure. Subsequent samples demonstrated lower ricinine concentrations, with the final sample taken at 62 h post-exposure at a concentration of 135 g/g-creatinine of ricinine. The estimated urinary excretion half-life was approximately 15 h and the recovery of ricinine in the urine over the three days was estimated to be less than 10. The patient fully recovered with supportive care and was discharged from the hospital six days after admission. C1 [Hamelin, Elizabeth I.; Johnson, Rudolph C.; Osterloh, John D.; Thomas, Jerry D.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA 30341 USA. [Howard, David J.] Cottage Hosp, Santa Barbara, CA 93101 USA. RP Thomas, JD (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, 4770 Buford Highway,Mailstop F44, Atlanta, GA 30341 USA. EM jthomas3@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 6 Z9 8 U1 1 U2 23 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0146-4760 J9 J ANAL TOXICOL JI J. Anal. Toxicol. PD NOV-DEC PY 2012 VL 36 IS 9 BP 660 EP 662 DI 10.1093/jat/bks077 PG 3 WC Chemistry, Analytical; Toxicology SC Chemistry; Toxicology GA 021ZI UT WOS:000309924300010 PM 23014889 ER PT J AU Lockhart, SR Iqbal, N Cleveland, AA Farley, MM Harrison, LH Bolden, CB Baughman, W Stein, B Hollick, R Park, BJ Chiller, T AF Lockhart, Shawn R. Iqbal, Naureen Cleveland, Angela A. Farley, Monica M. Harrison, Lee H. Bolden, Carol B. Baughman, Wendy Stein, Betsy Hollick, Rosemary Park, Benjamin J. Chiller, Tom TI Species Identification and Antifungal Susceptibility Testing of Candida Bloodstream Isolates from Population-Based Surveillance Studies in Two US Cities from 2008 to 2011 SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID IN-VITRO SUSCEPTIBILITIES; ACTIVE SURVEILLANCE; UNITED-STATES; NATIONAL SURVEILLANCE; CLINICAL BREAKPOINTS; SECULAR TREND; INFECTIONS; EPIDEMIOLOGY; PROGRAM; FLUCONAZOLE AB Between 2008 and 2011, population-based candidemia surveillance was conducted in Atlanta, GA, and Baltimore, MD. Surveillance had been previously performed in Atlanta in 1992 to 1993 and in Baltimore in 1998 to 2000, making this the first population-based candidemia surveillance conducted over multiple time points in the United States. From 2,675 identified cases of candidemia in the current surveillance, 2,329 Candida isolates were collected. Candida albicans no longer comprised the majority of isolates but remained the most frequently isolated species (38%), followed by Candida glabrata (29%), Candida parapsilosis (17%), and Candida tropicalis (10%). The species distribution has changed over time; in both Atlanta and Baltimore the proportion of C. albicans isolates decreased, and the proportion of C. glabrata isolates increased, while the proportion of C. parapsilosis isolates increased in Baltimore only. There were 98 multispecies episodes, with C. albicans and C. glabrata the most frequently encountered combination. The new species-specific CLSI Candida MIC breakpoints were applied to these data. With the exception of C. glabrata (11.9% resistant), resistance to fluconazole was very low (2.3% of isolates for C. albicans, 6.2% for C. tropicalis, and 4.1% for C. parapsilosis). There was no change in the proportion of fluconazole resistance between surveillance periods. Overall echinocandin resistance was low (1% of isolates) but was higher for C. glabrata isolates, ranging from 2.1% isolates resistant to caspofungin in Baltimore to 3.1% isolates resistant to anidulafungin in Atlanta. Given the increase at both sites and the higher echinocandin resistance, C. glabrata should be closely monitored in future surveillance. C1 [Lockhart, Shawn R.; Iqbal, Naureen; Cleveland, Angela A.; Bolden, Carol B.; Park, Benjamin J.; Chiller, Tom] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Farley, Monica M.; Baughman, Wendy] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Farley, Monica M.; Stein, Betsy] Emory Univ, Atlanta, GA 30322 USA. [Harrison, Lee H.; Hollick, Rosemary] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Lockhart, SR (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. EM gyi2@cdc.gov FU Office of Antimicrobial Resistance at the CDC FX This study received funding from the Office of Antimicrobial Resistance at the CDC. NR 38 TC 80 Z9 84 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2012 VL 50 IS 11 BP 3435 EP 3442 DI 10.1128/JCM.01283-12 PG 8 WC Microbiology SC Microbiology GA 022NU UT WOS:000309966900006 PM 22875889 ER PT J AU Waites, KB Duffy, LB Bebear, CM Matlow, A Talkington, DF Kenny, GE Totten, PA Bade, DJ Zheng, XT Davidson, MK Shortridge, VD Watts, JL Brown, SD AF Waites, Ken B. Duffy, Lynn B. Bebear, Cecile M. Matlow, Anne Talkington, Deborah F. Kenny, George E. Totten, Patricia A. Bade, Donald J. Zheng, Xiaotian Davidson, Maureen K. Shortridge, Virginia D. Watts, Jeffrey L. Brown, Steven D. TI Standardized Methods and Quality Control Limits for Agar and Broth Microdilution Susceptibility Testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article AB An international multilaboratory collaborative study was conducted to develop standard media and consensus methods for the performance and quality control of antimicrobial susceptibility testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum using broth microdilution and agar dilution techniques. A reference strain from the American Type Culture Collection was designated for each species, which was to be used for quality control purposes. Repeat testing of replicate samples of each reference strain by participating laboratories utilizing both methods and different lots of media enabled a 3-to4-dilution MIC range to be established for drugs in several different classes, including tetracyclines, macrolides, ketolides, lincosamides, and fluoroquinolones. This represents the first multilaboratory collaboration to standardize susceptibility testing methods and to designate quality control parameters to ensure accurate and reliable assay results for mycoplasmas and ureaplasmas that infect humans. C1 [Waites, Ken B.; Duffy, Lynn B.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Bebear, Cecile M.] Univ Bordeaux, Unite Contrat Mycoplasmal & Chlamydial Infect Hum, Bordeaux, France. [Matlow, Anne] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Talkington, Deborah F.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kenny, George E.; Totten, Patricia A.] Univ Washington, Sch Publ Hlth, Dept Med, Seattle, WA 98195 USA. [Bade, Donald J.] Microbial Res Inc, Ft Collins, CO USA. [Zheng, Xiaotian] Childrens Mem Hosp, Chicago, IL 60614 USA. [Davidson, Maureen K.] FDA Ctr Vet Med, Laurel, MD USA. [Shortridge, Virginia D.] BioMerieux Inc, Hazewood, MO USA. [Watts, Jeffrey L.] Pfizer Anim Hlth, Kalamazoo, MI USA. [Brown, Steven D.] Inst Clin Microbiol, Wilsonville, OR USA. RP Waites, KB (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. EM waiteskb@uab.edu OI Bebear, Cecile/0000-0001-6065-2332 FU Abbott Laboratories; AstraZeneca Pharmaceuticals; Bayer Pharmaceuticals; Bristol-Myers Squibb; Ortho-McNeil Pharmaceuticals; Pharmacia Upjohn; Pfizer Animal Health; Sanofi-Aventis Pharmaceuticals FX This work was performed by the Clinical and Laboratory Standards (CLSI) Subcommittee on Antimicrobial Susceptibility Testing of Human Mycoplasmas. Financial support was provided by Abbott Laboratories, AstraZeneca Pharmaceuticals, Bayer Pharmaceuticals, Bristol-Myers Squibb, Ortho-McNeil Pharmaceuticals, Pharmacia & Upjohn, Pfizer Animal Health, and Sanofi-Aventis Pharmaceuticals. Remel Laboratories provided commercially prepared SP4 and 10B broth media. NR 11 TC 20 Z9 27 U1 1 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2012 VL 50 IS 11 BP 3542 EP 3547 DI 10.1128/JCM.01439-12 PG 6 WC Microbiology SC Microbiology GA 022NU UT WOS:000309966900021 PM 22915608 ER PT J AU Shewmaker, PL Steigerwalt, AG Whitney, AM Morey, RE Graziano, JC Facklam, RR Musser, KA Merquior, VLC Teixeira, LM AF Shewmaker, Patricia Lynn Steigerwalt, Arnold G. Whitney, Anne M. Morey, Roger E. Graziano, James C. Facklam, Richard R. Musser, Kimberlee A. Merquior, Vania L. C. Teixeira, Lucia M. TI Evaluation of Methods for Identification and Determination of the Taxonomic Status of Strains Belonging to the Streptococcus porcinus-Streptococcus pseudoporcinus Complex Isolated from Animal, Human, and Dairy Sources SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID NEIGHBOR-JOINING METHOD; GROUP-B STREPTOCOCCI; SP-NOV.; PRESUMPTIVE IDENTIFICATION; PHYLOGENIES; DNA AB Ninety-seven animal, human, and dairy Streptococcus porcinus or Streptococcus pseudoporcinus isolates in the CDC Streptococcus strain collection were evaluated on the basis of DNA-DNA reassociation, 16S rRNA and rpoB gene sequencing, conventional biochemical and Rapid ID 32 Strep identification methods, and antimicrobial susceptibility testing to determine their taxonomic status, characteristics for species differentiation, antimicrobial susceptibility, and relevance of clinical source. Nineteen of the 97 isolates (1 human, 18 swine) were identified as S. porcinus. The remaining 72 human isolates and 6 dairy isolates were identified as S. pseudoporcinus. The use of 16S rRNA or rpoB gene sequencing was required to differentiate S. porcinus from S. pseudoporcinus. The human and dairy S. pseudoporcinus isolates were biochemically distinct from each other as well as distinct by 16S rRNA and rpoB gene sequencing. Therefore, we propose the subspecies denominations S. pseudoporcinus subsp. hominis subsp. nov. for the human isolates and S. pseudoporcinus subsp. lactis subsp. nov. for the dairy isolates. Most strains were susceptible to the antimicrobials tested, with the exception of tetracycline. Two strains of each species were also resistant to clindamycin and erythromycin and carried the erm(A) (S. pseudoporcinus) or the erm(B) (S. porcinus) gene. S. porcinus was identified from a single human isolate recovered from a wound in an abattoir worker. S. pseudoporcinus was primarily isolated from the genitourinary tract of women but was also associated with blood, placental, and wound infections. Isolates reacting with group B antiserum and demonstrating wide beta-hemolysis should be suspected of being S. pseudoporcinus and not S. agalactiae. C1 [Shewmaker, Patricia Lynn; Steigerwalt, Arnold G.; Whitney, Anne M.; Morey, Roger E.; Graziano, James C.; Facklam, Richard R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Musser, Kimberlee A.] NYS DOH, Wadsworth Ctr, Albany, NY USA. [Merquior, Vania L. C.] Univ Estado Rio de Janeiro, Fac Ciencias Med, Rio De Janeiro, RJ, Brazil. [Teixeira, Lucia M.] Univ Fed Rio de Janeiro, Inst Microbiol, Rio De Janeiro, RJ, Brazil. RP Shewmaker, PL (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM paw3@cdc.gov RI Merquior, Vania/D-6399-2013 FU Brazilian government agency (FAPERJ); Brazilian government agency (CNPq) FX L.M.T. and V.L.C.M. were supported in part by grants from Brazilian government agencies (FAPERJ and CNPq). NR 35 TC 3 Z9 3 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2012 VL 50 IS 11 BP 3591 EP 3597 DI 10.1128/JCM.01481-12 PG 7 WC Microbiology SC Microbiology GA 022NU UT WOS:000309966900029 PM 22933599 ER PT J AU Benitez, AJ Diaz, MH Wolff, BJ Pimentel, G Njenga, MK Estevez, A Winchell, JM AF Benitez, Alvaro J. Diaz, Maureen H. Wolff, Bernard J. Pimentel, Guillermo Njenga, M. Kariuki Estevez, Alejandra Winchell, Jonas M. TI Multilocus Variable-Number Tandem-Repeat Analysis of Mycoplasma pneumoniae Clinical Isolates from 1962 to the Present: a Retrospective Study SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID MACROLIDE RESISTANCE DETERMINATION; RESOLUTION MELT ANALYSIS; REAL-TIME PCR; INFECTIONS; SPECIMENS; STRAINS; FRENCH; TRACT AB In this study, we evaluated a recently developed multilocus variable-number tandem-repeat (VNTR) analysis (MLVA) method for the molecular typing of Mycoplasma pneumoniae. The method is based on GeneScan analysis of five VNTR loci throughout the genome which define a specific genotype based on the number of tandem repeats within each locus. A retrospective analysis of 154 M. pneumoniae clinical isolates collected over the last 50 years and a limited (n = 4) number of M. pneumoniae-positive primary specimens acquired by the CDC was performed using MLVA. Eighteen distinct VNTR types were identified, including two previously unidentified VNTR types. Isolates from several M. pneumoniae community outbreaks within the United States were also analyzed to examine clonality of a specific MLVA type. Observed in vitro variability of the Mpn1 VNTR locus prompted further analysis, which showed multiple insertions or deletions of tandem repeats within this locus for a number of specimens and isolates. To our knowledge, this is the first report showing variation within the Mpn1 locus, thus affecting precise and reliable classification using the current MLVA typing system. The superior discriminatory capability of MLVA provides a powerful tool for greater resolution of M. pneumoniae strains and could be useful during outbreaks and epidemiological investigations. C1 [Benitez, Alvaro J.; Diaz, Maureen H.; Wolff, Bernard J.; Winchell, Jonas M.] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Pimentel, Guillermo] USN, Med Res Ctr Frederick, Ft Detrick, MD USA. [Njenga, M. Kariuki] Ctr Dis Control & Prevent, GDD Kenya, Nairobi, Kenya. [Estevez, Alejandra] Univ Valle de Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jwinchell@cdc.gov OI Pimentel, Guillermo/0000-0003-2464-1526 NR 29 TC 22 Z9 24 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD NOV PY 2012 VL 50 IS 11 BP 3620 EP 3626 DI 10.1128/JCM.01755-12 PG 7 WC Microbiology SC Microbiology GA 022NU UT WOS:000309966900034 PM 22952264 ER PT J AU Cantey, PT Kurian, AK Jefferson, D Moerbe, MM Marshall, K Blankenship, WR Rothbarth, GR Hwang, J Hall, R Yoder, J Brunkard, J Johnston, S Xiao, LH Hill, VR Sarisky, J Zarate-Bermudez, MA Otto, C Hlavsa, MC AF Cantey, Paul T. Kurian, Anita K. Jefferson, David Moerbe, Micky M. Marshall, Karen Blankenship, William R. Rothbarth, Gary R. Hwang, Jimee Hall, Rebecca Yoder, Jonathan Brunkard, Joan Johnston, Stephanie Xiao, Lihua Hill, Vincent R. Sarisky, John Zarate-Bermudez, Max A. Otto, Charles Hlavsa, Michele C. TI Outbreak of Cryptosporidiosis Associated With a Man-Made Chlorinated Lake-Tarrant County, Texas, 2008 SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article ID RECREATIONAL WATER; UNITED-STATES; PARVUM; SURVEILLANCE; INACTIVATION; HOMINIS AB In July 2008, clusters of laboratory-confirmed cryptosporidiosis cases and reports of gastrointestinal illness in persons who visited a lake were reported to Tarrant County Public Health. In response, epidemiologic, laboratory, and environmental health investigations were initiated. A matched case-control study determined that swallowing the lake water was associated with illness (adjusted odds ratio = 16.3; 95% confidence interval: 2.5-infinity). The environmental health investigation narrowed down the potential sources of contamination. Laboratory testing detected Cryptosporidium hominis in case-patient stool specimens and Ctyptosporidium species in lake water. It was only through the joint effort that epidemiologic, laboratory, and environmental health investigators could determine that > 1 human diarrheal fecal incidents in the lake likely led to contamination of the water. This same collaborative effort will be needed to develop and maintain an effective national Model Aquatic Health Code. C1 [Cantey, Paul T.; Kurian, Anita K.; Jefferson, David; Moerbe, Micky M.; Marshall, Karen; Blankenship, William R.; Rothbarth, Gary R.; Hwang, Jimee; Hall, Rebecca; Yoder, Jonathan; Brunkard, Joan; Johnston, Stephanie; Xiao, Lihua; Hill, Vincent R.; Sarisky, John; Zarate-Bermudez, Max A.; Otto, Charles; Hlavsa, Michele C.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Cantey, PT (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RI Hill, Vincent/G-1789-2012; Hall, Rebecca/B-9381-2013; Xiao, Lihua/B-1704-2013 OI Hill, Vincent/0000-0001-7069-7737; Hall, Rebecca/0000-0002-7743-630X; Xiao, Lihua/0000-0001-8532-2727 NR 13 TC 7 Z9 7 U1 0 U2 5 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD NOV PY 2012 VL 75 IS 4 BP 14 EP 19 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 024RW UT WOS:000310127300003 PM 23210393 ER PT J AU Massoudi, CAPTM Blake, R Marcum, L AF Massoudi, C. A. P. T. Mehran Blake, Rob Marcum, Larry TI Enumerating the Environmental Public Health Workforce-Challenges and Opportunities SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 [Massoudi, C. A. P. T. Mehran] CDC, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Blake, Rob] CDC, EHSB, Atlanta, GA 30333 USA. RP Massoudi, CAPTM (reprint author), Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, 1600 Clifton Rd,Mailstop E-96, Atlanta, GA 30333 USA. EM MMassoudi@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD NOV PY 2012 VL 75 IS 4 BP 34 EP 36 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 024RW UT WOS:000310127300007 ER PT J AU Quiros-Alcala, L Bradman, A Smith, K Weerasekera, G Odetokun, M Barr, DB Nishioka, M Castorina, R Hubbard, AE Nicas, M Hammond, SK McKone, TE Eskenazi, B AF Quiros-Alcala, Lesliam Bradman, Asa Smith, Kimberly Weerasekera, Gayanga Odetokun, Martins Barr, Dana Boyd Nishioka, Marcia Castorina, Rosemary Hubbard, Alan E. Nicas, Mark Hammond, S. Katharine McKone, Thomas E. Eskenazi, Brenda TI Organophosphorous pesticide breakdown products in house dust and children's urine SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE biomarkers; dialkylphosphates; dust; metabolites; organophosphates; urine ID MEXICAN-AMERICAN CHILDREN; AGRICULTURAL COMMUNITY; RISK-ASSESSMENT; EXPOSURE; CHLORPYRIFOS; 3,5,6-TRICHLORO-2-PYRIDINOL; ASSESSMENTS; METABOLITES; CHAMACOS; COHORT AB Human exposure to preformed dialkylphosphates (DAPs) in food or the environment may affect the reliability of DAP urinary metabolites as biomarkers of organophosphate (OP) pesticide exposure. We conducted a study to investigate the presence of DAPs in indoor residential environments and their association with children's urinary DAP levels. We collected dust samples from homes in farmworker and urban communities (40 homes total, n = 79 samples) and up to two urine samples from resident children ages 3-6 years. We measured six DAPs in all samples and eight DAP-devolving OP pesticides in a subset of dust samples (n = 54). DAPs were detected in dust with diethylphosphate (DEP) being the most frequently detected (>= 60%); detection frequencies for other DAPs were <= 50%. DEP dust concentrations did not significantly differ between communities, nor were concentrations significantly correlated with concentrations of chlorpyrifos and diazinon, the most frequently detected diethyl-OP pesticides (Spearman rho = -0.41 to 0.38, P > 0.05). Detection of DEP, chlorpyrifos, or diazinon, was not associated with DEP and/or DEP + diethylthiophosphate detection in urine (Kappa coefficients = -0.33 to 0.16). Finally, estimated non-dietary ingestion intake from DEP in dust was found to be <= 5% of the dose calculated from DEP levels in urine, suggesting that ingestion of dust is not a significant source of DAPs in urine if they are excreted unchanged. C1 [Quiros-Alcala, Lesliam; Bradman, Asa; Castorina, Rosemary; McKone, Thomas E.; Eskenazi, Brenda] Univ Calif Berkeley, Ctr Environm Res & Childrens Hlth, Sch Publ Hlth, Berkeley, CA 94704 USA. [Quiros-Alcala, Lesliam] US EPA, EPA STAR, Washington, DC 20460 USA. [Smith, Kimberly; Weerasekera, Gayanga; Odetokun, Martins] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Barr, Dana Boyd] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Nishioka, Marcia] Battelle Mem Inst, Columbus, OH 43201 USA. [Hubbard, Alan E.] Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA. [Nicas, Mark; Hammond, S. Katharine] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA. [McKone, Thomas E.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Environm Energy Technol Div, Berkeley, CA 94720 USA. RP Bradman, A (reprint author), Univ Calif Berkeley, Ctr Environm Res & Childrens Hlth, Sch Publ Hlth, 1995 Univ Ave,Suite 265, Berkeley, CA 94704 USA. EM abradman@berkeley.edu RI Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013; Quiros-Alcala, Lesliam /Q-4928-2016 OI Quiros-Alcala, Lesliam /0000-0002-6600-7227 FU EPA [RD 83171001]; NIEHS [PO1 ES009605]; EPA STAR Doctoral Fellowship [F5D30812]; University of California Institute for Mexico; United States (UC MEXUS); Center for Latino Policy Research at the University of California at Berkeley FX This work was supported by EPA (RD 83171001) and NIEHS (PO1 ES009605). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the EPA, NIEHS, or other funders. Additional support was provided by an EPA STAR Doctoral Fellowship (F5D30812), the University of California Institute for Mexico and the United States (UC MEXUS), and the Center for Latino Policy Research at the University of California at Berkeley. We thank the CHAMACOS staff, community partners including Drs. John Pescetti and Claire Horton at Clinica de la Raze for their support in recruitment efforts, our study participants, Dr. Do-Gyun Kim and Carolina Fernandez from the Pesticide Toxicology Laboratory at the CDC for their assistance with urine sample analysis, and Dr. Rosana Weldon for editorial comments. NR 31 TC 13 Z9 13 U1 3 U2 37 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD NOV-DEC PY 2012 VL 22 IS 6 BP 559 EP 568 DI 10.1038/jes.2012.46 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 022US UT WOS:000309989900003 PM 22781438 ER PT J AU Schier, JG Sejvar, JJ Lutterloh, E Likaka, A Katsoudas, E Karaseva, YD Barr, BT Redwood, Y Monroe, S AF Schier, Joshua G. Sejvar, James J. Lutterloh, Emily Likaka, Andrew Katsoudas, Eugenia Karaseva, Yelena D. Barr, Beth Tippett Redwood, Yanique Monroe, Stephan TI Consumption of pesticide-treated wheat seed by a rural population in Malawi SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE pesticide; seed; exposure; environment; carboxin ID NEUROPSYCHIATRIC MANIFESTATIONS; BANGLADESH; EXPOSURE; OUTBREAK AB An outbreak of typhoid fever in rural Malawi triggered an investigation by the Malawi Ministry of Health and the Centers for Disease Control and Prevention in July 2009. During the investigation, villagers were directly consuming washed, donated, pesticide-treated wheat seed meant for planting. The objective of this study was to evaluate the potential for pesticide exposure and health risk in the outbreak community. A sample of unwashed (1430g) and washed (759g) wheat seed donated for planting, but which would have been directly consumed, was tested for 365 pesticides. Results were compared with each other (percentage change), the US Environmental Protection Agency's (EPA) health guidance values and estimated daily exposures were compared with their Reference dose (RfD). Unwashed and washed seed samples contained, respectively: carboxin, 244 and 57 p.p.m.; pirimiphos methyl, 8.18 and 8.56 p.p.m.; total permethrin, 3.62 and 3.27 p.p.m.; and carbaryl, 0.057 and 0.025 p.p.m.. Percentage change calculations (unwashed to washed) were as follows: carboxin, -76.6%; pirimiphos methyl, + 4.6%; total permethrin, -9.7%; and carbaryl -56.1%. Only carboxin and total permethrin concentration among washed seed samples exceeded US EPA health guidance values (285 x and seven times, respectively). Adult estimated exposure scenarios (1 kg seed) exceeded the RfD for carboxin (8 x) and pirimiphos methyl (12 x). Adult villagers weighing 70 kg would have to consume 0.123, 0.082, 1.06, and 280 kg of washed seed daily to exceed the RfD for carboxin, pirimiphos methyl, permethrins, and carbaryl, respectively. Carboxin, pirimiphos methyl, permethrins, and carbaryl were detected in both unwashed and washed samples of seed. Carboxin, total permethrin, and carbaryl concentration were partially reduced by washing. Health risks from chronic exposure to carboxin and pirimiphos methyl in these amounts are unclear. The extent of this practice among food insecure communities receiving relief seeds and resultant health impact needs further study. C1 [Schier, Joshua G.; Redwood, Yanique] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. [Sejvar, James J.; Monroe, Stephan] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Dis, Atlanta, GA USA. [Lutterloh, Emily] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Kentucky State Hlth Dept, Atlanta, GA 30333 USA. [Likaka, Andrew] Minist Hlth, Lilongwe, Malawi. [Katsoudas, Eugenia; Karaseva, Yelena D.] US FDA, NE Reg Lab, US Dept HHS, Jamaica, NY USA. [Barr, Beth Tippett] Ctr Dis Control & Prevent, Ctr Global Hlth, Global AIDS Program, Lilongwe, Malawi. RP Schier, JG (reprint author), CDC NCEH EHHE HSB, MS F-57,4770 Buford Hwy NE, Chamblee, GA 30341 USA. EM jschier@cdc.gov RI Schier, Joshua/F-9861-2013; OI Monroe, Stephan/0000-0002-5424-716X FU CDC FX This study was supported from the CDC. NR 26 TC 0 Z9 0 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD NOV-DEC PY 2012 VL 22 IS 6 BP 569 EP 573 DI 10.1038/jes.2012.47 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 022US UT WOS:000309989900004 PM 23047320 ER PT J AU Hoppin, JA Long, S Umbach, DM Lubin, JH Starks, SE Gerr, F Thomas, K Hines, CJ Weichenthal, S Kamel, F Koutros, S Alavanja, M Freeman, LEB Sandler, DP AF Hoppin, Jane A. Long, Stuart Umbach, David M. Lubin, Jay H. Starks, Sarah E. Gerr, Fred Thomas, Kent Hines, Cynthia J. Weichenthal, Scott Kamel, Freya Koutros, Stella Alavanja, Michael Freeman, Laura E. Beane Sandler, Dale P. TI Lifetime organophosphorous insecticide use among private pesticide applicators in the Agricultural Health Study SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE pesticide use; farming; organophosphorous insecticide AB Organophosphorous insecticides (OPs) are the most commonly used insecticides in US agriculture, but little information is available regarding specific OP use by individual farmers. We describe OP use for licensed private pesticide applicators from Iowa and North Carolina in the Agricultural Health Study (AHS) using lifetime pesticide use data from 701 randomly selected male participants collected at three time periods. Of 27 OPs studied, 20 were used by >1%. Overall, 95% had ever applied at least one OP. The median number of different OPs used was 4 (maximum = 13). Malathion was the most commonly used OP (74%) followed by chlorpyrifos (54%). OP use declined over time. At the first interview (1993-1997), 68% of participants had applied OPs in the past year; by the last interview (2005-2007), only 42% had. Similarly, median annual application days of OPs declined from 13.5 to 6 days. Although OP use was common, the specific OPs used varied by state, time period, and individual. Much of the variability in OP use was associated with the choice of OP, rather than the frequency or duration of application. Information on farmers' OP use enhances our ability to characterize and understand the potential health effects of multiple OP exposures. C1 [Hoppin, Jane A.; Kamel, Freya; Sandler, Dale P.] NIEHS, Epidemiol Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA. [Long, Stuart] WESTAT Corp, Durham, NC USA. [Umbach, David M.] NIEHS, Biost Branch, NIH, DHHS, Res Triangle Pk, NC 27709 USA. [Lubin, Jay H.] NCI, Biostat Branch, NIH, DHHS, Rockville, MD USA. [Starks, Sarah E.; Gerr, Fred] Univ IA, Coll Publ Hlth, Iowa City, IA USA. [Thomas, Kent] US EPA, Human Exposure & Atmosphere Sci Div, Res Triangle Pk, NC 27711 USA. [Hines, Cynthia J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Weichenthal, Scott] Hlth Canada, Ottawa, ON K1A 0L2, Canada. [Koutros, Stella; Alavanja, Michael; Freeman, Laura E. Beane] NCI, OEEB, DCEG, Rockville, MD USA. RP Hoppin, JA (reprint author), NIEHS, Epidemiol Branch, NIH, DHHS, MD A3-05,POB 12233, Res Triangle Pk, NC 27709 USA. EM hoppin1@niehs.nih.gov RI Beane Freeman, Laura/C-4468-2015; OI Beane Freeman, Laura/0000-0003-1294-4124; Kamel, Freya/0000-0001-5052-6615; Sandler, Dale/0000-0002-6776-0018 FU National Institutes of Health; National Institute of Environmental Health Sciences [Z01-ES049030]; National Cancer Institute [Z01-CP010119]; National Institute for Occupational Safety and Health FX We thank Dr. Joe Coble for his efforts to create the AHS pesticide use data base. This work was supported by the intramural research program of the National Institutes of Health, the National Institute of Environmental Health Sciences (Z01-ES049030), National Cancer Institute (Z01-CP010119), and the National Institute for Occupational Safety and Health. The United States Environmental Protection Agency through its Office of Research and Development collaborated in the research described here; it has been subjected to Agency review and approved for publication. NR 17 TC 5 Z9 5 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD NOV-DEC PY 2012 VL 22 IS 6 BP 584 EP 592 DI 10.1038/jes.2012.79 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 022US UT WOS:000309989900006 PM 22854518 ER PT J AU De Roos, AJ Ulrich, CM Sjodin, A McTiernan, A AF De Roos, Anneclaire J. Ulrich, Cornelia M. Sjodin, Andreas McTiernan, Anne TI Adiposity, body composition, and weight change in relation to organochlorine pollutant plasma concentrations SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE organochlorine; obesity; polychlorinated biphenyl; weight loss ID NON-HODGKINS-LYMPHOMA; POLYCHLORINATED-BIPHENYLS; POSTMENOPAUSAL WOMEN; OBESE INDIVIDUALS; TEMPORAL TRENDS; HUMAN SERUM; HEALTH; RISK; POPULATION; ASSOCIATION AB We investigated cross-sectional associations of body composition and weight change with polychlorinated biphenyls (PCB) and organochlorine pesticides/pesticide metabolites measured in blood collected at the baseline of the Physical Activity for Total Health study of postmenopausal, overweight women living in the Seattle, Washington metropolitan area. Indicators of greater adiposity were associated with lower plasma concentrations of most PCBs with six or more chlorine atoms. This pattern was observed for current weight, body mass index, fat mass percent, subcutaneous abdominal fat, intra-abdominal fat, waist circumference, hip circumference, waist-to-hip ratio, and maximum adult weight. Conversely, PCB 105, PCB 118, and p,p'-DDE were generally increased or showed no association with these variables. Weight gain since age 35 was associated with lower concentrations of almost every organochlorine we studied, and past weight loss episodes of at least 20 pounds (>= 9.1 kg) were associated with higher concentrations. Our results have implications for epidemiologic studies of organochlorines in terms of covariates that may be important to consider in statistical analyses, particularly as such considerations may differ importantly by specific analyte. Our finding of increased organochlorine concentrations with past weight loss episodes may have public health significance; however, this association requires confirmation in longitudinal studies. C1 [De Roos, Anneclaire J.; McTiernan, Anne] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98109 USA. [De Roos, Anneclaire J.; McTiernan, Anne] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Ulrich, Cornelia M.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98109 USA. [Ulrich, Cornelia M.] Natl Ctr Tumor Dis, Heidelberg, Germany. [Ulrich, Cornelia M.] German Canc Res Ctr, D-6900 Heidelberg, Germany. [Sjodin, Andreas] Ctr Dis Control & Prevent CDC, NCEH, DLS, Atlanta, GA USA. [McTiernan, Anne] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. RP De Roos, AJ (reprint author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, 1100 Fairview Ave N,M4-B874, Seattle, WA 98109 USA. EM aderoos@fhcrc.org RI Sjodin, Andreas/F-2464-2010 FU National Institute of Environmental Health Sciences of the National Institutes of Health [R03ES015787] FX This research was funded by a grant from the National Institute of Environmental Health Sciences of the National Institutes of Health (R03ES015787). NR 42 TC 15 Z9 15 U1 0 U2 13 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD NOV-DEC PY 2012 VL 22 IS 6 BP 617 EP 624 DI 10.1038/jes.2012.43 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 022US UT WOS:000309989900010 PM 22588213 ER PT J AU Kotchey, GP Hasan, SA Kapralov, AA Ha, SH Kim, K Shvedova, AA Kagan, VE Star, A AF Kotchey, Gregg P. Hasan, Saad A. Kapralov, Alexander A. Ha, Seung Han Kim, Kang Shvedova, Anna A. Kagan, Valerian E. Star, Alexander TI A Natural Vanishing Act: The Enzyme-Catalyzed Degradation of Carbon Nanomaterials SO ACCOUNTS OF CHEMICAL RESEARCH LA English DT Review ID PULMONARY INFLAMMATION; HUMAN MYELOPEROXIDASE; GRAPHENE NANORIBBONS; NANOTUBES; CELLS; EXPOSURE; BIODEGRADATION; HYPOCHLORITE; REDUCTION; RELEASE AB Over the past three decades, revolutionary research in nanotechnology by the scientific, medical, and engineering communities has yielded a treasure trove of discoveries with diverse applications that promise to benefit humanity. With their unique electronic and mechanical properties, carbon nanomaterials (CNMs) represent a prime example of the promise of nanotechnology with applications in areas that include electronics, fuel cells, composites, and nanomedicine. Because of toxicological issues associated with CNMs, however, their full commercial potential may not be achieved. The ex vitro, in vitro, and in vivo data presented in this Account provide fundamental insights into the biopersistence of CNMs, such as carbon nanotubes and graphene, and their oxidation/biodegradation processes as catalyzed by peroxidase enzymes. We also communicate our current understanding of the mechanism for the enzymatic oxidation and biodegradation. Finally, we outline potential future directions that could enhance our mechanistic understanding of the CNM oxidation and biodegradation and could yield benefits in terms of human health and environmental safety. The conclusions presented in this Account may catalyze a rational rethinking of CNM incorporation in diverse applications. For example, armed with an understanding of how and why CNMs undergo enzyme-catalyzed oxidation and biodegradation, researchers can tailor the structure of CNMs to either promote or inhibit these processes. In nanomedical applications such as drug delivery, the incorporation of carboxylate functional groups could facilitate biodegradation of the nanomaterial after delivery of the cargo. On the other hand, in the construction of aircraft, a CNM composite should be stable to oxidizing conditions in the environment. Therefore, pristine, inert CNMs would be ideal for this application. Finally, the incorporation of CNMs with defect sites in consumer goods could provide a facile mechanism that promotes the degradation of these materials once these products reach landfills. C1 [Kotchey, Gregg P.; Hasan, Saad A.; Star, Alexander] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA. [Kapralov, Alexander A.; Kagan, Valerian E.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA. [Ha, Seung Han; Kim, Kang] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Shvedova, Anna A.] CDC, Pathol & Physiol Res Branch, Hlth Effects Lab Div, NIOSH, Morgantown, WV USA. [Shvedova, Anna A.] W Virginia Univ, Sch Med, Dept Physiol & Pharmacol, Morgantown, WV 26506 USA. RP Star, A (reprint author), Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA. EM astar@pitt.du RI Star, Alexander/C-3399-2013; OI Kapralov, Oleksandr/0000-0002-3006-916X FU NIEHS [R01ES019304, HL70755, HL094488, U19AI068021]; NIOSH [OH008282]; NORA/NTRC NIOSH [1927ZHF]; EPA STAR Graduate Fellowship [FP-91713801] FX This work was supported by NIEHS R01ES019304, HL70755, HL094488, U19AI068021, NIOSH OH008282 and NORA/NTRC NIOSH 1927ZHF. G.P.K. acknowledges support from the EPA STAR Graduate Fellowship FP-91713801. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 42 TC 59 Z9 61 U1 9 U2 104 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0001-4842 EI 1520-4898 J9 ACCOUNTS CHEM RES JI Accounts Chem. Res. PD NOV PY 2012 VL 45 IS 10 SI SI BP 1770 EP 1781 DI 10.1021/ar300106h PG 12 WC Chemistry, Multidisciplinary SC Chemistry GA 020JL UT WOS:000309804700014 PM 22824066 ER PT J AU Thangarajh, M Yang, GY Fuchs, D Ponisio, MR McKinstry, RC Jaju, A Noetzel, MJ Casella, JF Barron-Casella, E Hooper, WC Boulet, SL Bean, CJ Pyle, ME Payne, AB Driggers, J Trau, HA Vendt, BA Rodeghier, M DeBaun, MR AF Thangarajh, Mathula Yang, Genyan Fuchs, Dana Ponisio, Maria R. McKinstry, Robert C. Jaju, Alok Noetzel, Michael J. Casella, James F. Barron-Casella, Emily Hooper, W. Craig Boulet, Sheree L. Bean, Christopher J. Pyle, Meredith E. Payne, Amanda B. Driggers, Jennifer Trau, Heidi A. Vendt, Bruce A. Rodeghier, Mark DeBaun, Michael R. TI Magnetic resonance angiography-defined intracranial vasculopathy is associated with silent cerebral infarcts and glucose-6-phosphate dehydrogenase mutation in children with sickle cell anaemia SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE sickle cell anaemia; a-thalassaemia; glucose-6-phosphate dehydrogenase; vasculopathy; silent cerebral infarcts ID NF-KAPPA-B; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY; ALPHA-THALASSEMIA DELETIONS; GLOBIN GENE TRIPLICATION; TRANSFUSION SIT TRIAL; OXIDATIVE STRESS; G6PD DEFICIENCY; MICROVASCULAR ABNORMALITIES; CEREBROVASCULAR-DISEASE; CYTOKINE PRODUCTION AB Silent cerebral infarct (SCI) is the most commonly recognized cause of neurological injury in sickle cell anaemia (SCA). We tested the hypothesis that magnetic resonance angiography (MRA)-defined vasculopathy is associated with SCI. Furthermore, we examined genetic variations in glucose-6-phosphate dehydrogenase (G6PD) and HBA (a-globin) genes to determine their association with intracranial vasculopathy in children with SCA. Magnetic resonance imaging (MRI) of the brain and MRA of the cerebral vasculature were available in 516 paediatric patients with SCA, enrolled in the Silent Infarct Transfusion (SIT) Trial. All patients were screened for G6PD mutations and HBA deletions. SCI were present in 41.5% (214 of 516) of SIT Trial children. The frequency of intracranial vasculopathy with and without SCI was 15.9% and 6.3%, respectively (P<0.001). Using a multivariable logistic regression model, only the presence of a SCI was associated with increased odds of vasculopathy (P=0.0007, odds ratio (OR) 2.84; 95% Confidence Interval (CI)=1.555.21). Among male children with SCA, G6PD status was associated with vasculopathy (P=0.04, OR 2.78; 95% CI=1.047.42), while no significant association was noted for HBA deletions. Intracranial vasculopathy was observed in a minority of children with SCA, and when present, was associated with G6PD status in males and SCI. C1 [DeBaun, Michael R.] Vanderbilt Univ, Dept Pediat, Vanderbilt Meharry Sickle Cell Dis Ctr Excellence, Nashville, TN 37232 USA. [Rodeghier, Mark] Stat Collaborator, Chicago, IL USA. [Vendt, Bruce A.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Elect Radiol Lab, St Louis, MO USA. [Casella, James F.; Barron-Casella, Emily] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Hematol, Baltimore, MD 21205 USA. [Fuchs, Dana; Ponisio, Maria R.; McKinstry, Robert C.; Jaju, Alok] Washington Univ, Sch Med, Pediat Radiol Sect, St Louis, MO USA. [Fuchs, Dana; Ponisio, Maria R.; McKinstry, Robert C.; Jaju, Alok] Washington Univ, Sch Med, Neuroradiol Sect, St Louis, MO USA. [Yang, Genyan; Hooper, W. Craig; Boulet, Sheree L.; Bean, Christopher J.; Pyle, Meredith E.; Payne, Amanda B.; Driggers, Jennifer; Trau, Heidi A.] Ctr Dis Control & Prevent, Clin & Mol Hemostasis Lab Branch, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Thangarajh, Mathula; Noetzel, Michael J.] Washington Univ, Sch Med, Dept Neurol & Pediat, St Louis, MO USA. RP DeBaun, MR (reprint author), Vanderbilt Univ, Sch Med, Vanderbilt Meharry Ctr Excellence, Nashville, TN 37232 USA. EM m.debaun@vanderbilt.edu FU National Institute of Neurological Disorders and Stroke (NINDS), Rockville, Maryland [U01 NS042804]; Burroughs Wellcome Foundation FX The SIT Trial is supported by the National Institute of Neurological Disorders and Stroke (NINDS), Rockville, Maryland (ClinicalTrials.gov identifier: U01 NS042804) and Burroughs Wellcome Foundation (MRD). Dr. Casella has received an honorarium and travel expenses in the past and presently receives salary support through Johns Hopkins for providing consultative advice to Adventrx Pharmaceuticals regarding a proposed clinical trial of an agent for treating vaso-occlusive crisis in sickle cell disease. NR 53 TC 17 Z9 18 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD NOV PY 2012 VL 159 IS 3 BP 352 EP 359 DI 10.1111/bjh.12034 PG 8 WC Hematology SC Hematology GA 019DO UT WOS:000309717500011 PM 22958163 ER PT J AU McClellan, AC Luthi, JC Lynch, JR Soucie, JM Kulkarni, R Guasch, A Huff, ED Gilbertson, D McClellan, WM DeBaun, MR AF McClellan, Ann C. Luthi, Jean-Christophe Lynch, Janet R. Soucie, J. Michael Kulkarni, Roshni Guasch, Antonio Huff, Edwin D. Gilbertson, David McClellan, William M. DeBaun, Michael R. TI High one year mortality in adults with sickle cell disease and end-stage renal disease SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE sickle cell disease; kidney disease; end-stage renal disease; mortality; disparities ID HEMODIALYSIS-PATIENTS; RISK-FACTORS; CHILDREN; DEATH; US AB Adequate pre-dialysis care reduces mortality among end-stage renal disease (ESRD) patients.We tested thehypothesis that individuals with ESRD due to sickle cell disease (SCDESRD) receiving pre-ESRD care have lower mortality compared to individuals without pre-ESRD care.We examined the association between mortality and pre-ESRD care in incident SCDESRD patients who started haemodialysis between 1 June, 2005 and 31 May, 2009using data provided by the Centers for Medicare and MedicaidServices (CMS).SCDESRD was reported for 410 (0.1%) of 442017 patients. One year after starting dialysis, 108 (26.3%) patients with incident ESRD attributed to SCD died; the hazard ratio (HR) for mortality among patients with SCDESRD compared to those without SCD as the primary cause of renal failure was 2.80 (95% confidence interval [CI] 2.313.38). Patients with SCDESRD receiving pre-dialysis nephrology care had a lower death rate than those with SCDESRD who did not receive pre-dialysis nephrology care (HR=0.67, 95% CI 0.450.99). The one-year mortality rate following an ESRD diagnosis was almost three times higher in individuals with SCD when compared to those without SCD but with ESRD and could be attenuated by pre-dialysis nephrology care. C1 [DeBaun, Michael R.] Vanderbilt Univ, Dept Pediat, Div Hematol Oncol, Nashville, TN 37232 USA. [Gilbertson, David] USRDS, Minneapolis, MN USA. [Huff, Edwin D.] Ctr Medicare Serv, Boston, MA USA. [Huff, Edwin D.] Ctr Medicaid Serv, Boston, MA USA. [Kulkarni, Roshni] Michigan State Univ, E Lansing, MI 48824 USA. [Lynch, Janet R.] Midatlantic Renal Coalit, Richmond, VA USA. [Luthi, Jean-Christophe] CHU Vaudois, Inst Social & Prevent Med IUMSP, Epalinges, Switzerland. [Luthi, Jean-Christophe] Univ Lausanne, CH-1066 Epalinges, Switzerland. [Luthi, Jean-Christophe; Guasch, Antonio; McClellan, William M.] Emory Univ, Atlanta, GA 30322 USA. [McClellan, Ann C.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [McClellan, Ann C.; Soucie, J. Michael; Kulkarni, Roshni] Ctr Dis Control & Prevent, Atlanta, GA USA. RP DeBaun, MR (reprint author), Vanderbilt Univ, Dept Pediat, Div Hematol Oncol, 2200 Childrens Way,DOT 11206, Nashville, TN 37232 USA. EM m.debaun@vanderbilt.edu FU Centers for Medicare and Medicaid Services (CMS), Department of Health and Human Services" [HHSM-500-2010-005C] FX The analyses upon which this publication is based were performed under Contract Number HHSM-500-2010-005C, entitled 'End Stage Renal Disease Networks Organization Number 5", sponsored by the Centers for Medicare and Medicaid Services (CMS), Department of Health and Human Services." This article is a direct result of the Health Care Quality Improvement Program initiated by CMS, which has encouraged identification of quality improvement projects derived from analysis of patterns of care, and therefore required no special funding on the part of this contractor. This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention, Division of Blood Disorders administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U. S. Department of Energy and the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. We thank Dr. Steven Embury and Mrs. Deborah Jones for reviewing and editing the manuscript. NR 13 TC 28 Z9 28 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD NOV PY 2012 VL 159 IS 3 BP 360 EP 367 DI 10.1111/bjh.12024 PG 8 WC Hematology SC Hematology GA 019DO UT WOS:000309717500012 PM 22967259 ER PT J AU Dubey, JP Tiao, N Gebreyes, WA Jones, JL AF Dubey, J. P. Tiao, N. Gebreyes, W. A. Jones, J. L. TI A review of toxoplasmosis in humans and animals in Ethiopia SO EPIDEMIOLOGY AND INFECTION LA English DT Review DE Epidemiology; Ethiopia; humans; Toxoplasma gondii ID ADDIS-ABABA; SEROLOGICAL SURVEY; GOATS; SHEEP; INFECTION; HIV/AIDS AB Toxoplasmosis caused by the protozoan parasite, Toxoplasma gondii, is a worldwide zoonosis. In this paper published information on toxoplasmosis in humans and other animals in Ethiopia is reviewed. Limited data indicate that the prevalence of T. gondii in humans in Ethiopia is very high, up to 41% of children aged 1-5 years were reported to be seropositive. There is little information on seroprevalence data in pregnant women and no data on congenital toxoplasmosis in children. About 1 million adults in Ethiopia are considered to be infected with HIV with less than one-third likely receive highly active antiviral therapy. Based on a conservative T. gondii seroprevalence of 50%, thousands might die of concurrent opportunistic infections, including toxoplasmosis. However, exact figures are not available, and most serological surveys are not current. Serological surveys indicate up to 79% of goats and sheep have T. gondii antibodies. However, there is no information on losses due to toxoplasmosis in livestock or the presence of viable T. gondii in any host in Ethiopia. C1 [Dubey, J. P.] USDA, ARS, Anim & Nat Resources Inst, Anim Parasit Dis Lab, Beltsville, MD 20705 USA. [Tiao, N.; Gebreyes, W. A.] Ohio State Univ, Coll Vet Med, Dept Vet Prevent Med, Columbus, OH 43210 USA. [Jones, J. L.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Dubey, JP (reprint author), USDA, APDL, ANRI, BARC, Bldg 1001, Beltsville, MD 20705 USA. EM jitender.dubey@ars.usda.gov NR 23 TC 16 Z9 16 U1 3 U2 27 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD NOV PY 2012 VL 140 IS 11 BP 1935 EP 1938 DI 10.1017/S0950268812001392 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 019GC UT WOS:000309724500002 PM 22874099 ER PT J AU Silk, BJ Moore, MR Bergtholdt, M Gorwitz, RJ Kozak, NA Tha, MM Brown, EW Winchester, JL Labus, BJ Rowley, P Middaugh, JP Fields, BS Hicks, LA AF Silk, B. J. Moore, M. R. Bergtholdt, M. Gorwitz, R. J. Kozak, N. A. Tha, M. M. Brown, E. W. Winchester, J. L. Labus, B. J. Rowley, P. Middaugh, J. P. Fields, B. S. Hicks, L. A. TI Eight years of Legionnaires' disease transmission in travellers to a condominium complex in Las Vegas, Nevada SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Bacterial infections; community-acquired pneumonia; Legionnaire's disease; respiratory infections; water-borne infections ID SEQUENCE-BASED SCHEME; LEGIONELLA-PNEUMOPHILA; WHIRLPOOL-SPA; UNITED-STATES; RISK-FACTORS; OUTBREAK; CONTAMINATION; SURVEILLANCE; PNEUMONIA; MORTALITY AB Travel is a risk factor for Legionnaires' disease. In 2008, two cases were reported in condominium guests where we investigated a 2001 outbreak. We reinvestigated to identify additional cases and determine whether ongoing transmission resulted from persistent colonization of potable water. Exposures were assessed by matched case-control analyses (2001) and case-series interviews (2008). We sampled potable water and other water sources. Isolates were compared using sequence-based typing. From 2001 to 2008, 35 cases were identified. Confirmed cases reported after the cluster in 2001-2002 were initially considered sporadic, but retrospective case-finding identified five additional cases. Cases were more likely than controls to stay in tower 2 of the condominium [matched odds ratio (mOR) 6.1, 95% confidence interval (CI) 1.6-22.9]; transmission was associated with showering duration (mOR 23.0, 95% CI 1.4-384). We characterized a clinical isolate as sequence type 35 (ST35) and detected ST35 in samples of tower 2's potable water in 2001, 2002, and 2008. This prolonged outbreak illustrates the importance of striving for permanent Legionella eradication from potable water. C1 [Silk, B. J.; Moore, M. R.; Gorwitz, R. J.; Kozak, N. A.; Brown, E. W.; Fields, B. S.; Hicks, L. A.] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Silk, B. J.; Gorwitz, R. J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Bergtholdt, M.; Tha, M. M.; Winchester, J. L.; Labus, B. J.; Rowley, P.; Middaugh, J. P.] So Nevada Hlth Dist, Las Vegas, NV USA. RP Silk, BJ (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30333 USA. EM bsilk@cdc.gov FU U.S. Centers for Disease Control and Prevention FX Financial support was received from the U.S. Centers for Disease Control and Prevention. NR 27 TC 11 Z9 11 U1 0 U2 12 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD NOV PY 2012 VL 140 IS 11 BP 1993 EP 2002 DI 10.1017/S0950268811002779 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 019GC UT WOS:000309724500010 PM 22214820 ER PT J AU Collier, SA Stockman, LJ Hicks, LA Garrison, LE Zhou, FJ Beach, MJ AF Collier, S. A. Stockman, L. J. Hicks, L. A. Garrison, L. E. Zhou, F. J. Beach, M. J. TI Direct healthcare costs of selected diseases primarily or partially transmitted by water SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Cryptosporidium; Giardia; Legionnaires' disease; mycobacteria; waterborne infections ID 5 FOODNET SITES; UNITED-STATES; RISK-FACTORS; DRINKING-WATER; PSEUDOMONAS-AERUGINOSA; OTITIS-EXTERNA; NONTUBERCULOUS MYCOBACTERIA; INFECTIONS; SURVEILLANCE; CALIFORNIA AB Despite US sanitation advancements, millions of waterborne disease cases occur annually, although the precise burden of disease is not well quantified. Estimating the direct healthcare cost of specific infections would be useful in prioritizing waterborne disease prevention activities. Hospitalization and outpatient visit costs per case and total US hospitalization costs for ten waterborne diseases were calculated using large healthcare claims and hospital discharge databases. The five primarily waterborne diseases in this analysis (giardiasis, cryptosporidiosis, Legionnaires' disease, otitis externa, and non-tuberculous mycobacterial infection) were responsible for over 40 000 hospitalizations at a cost of $970 million per year, including at least $430 million in hospitalization costs for Medicaid and Medicare patients. An additional 50 000 hospitalizations for campylobacteriosis, salmonellosis, shigellosis, haemolytic uraemic syndrome, and toxoplasmosis cost $860 million annually ($390 million in payments for Medicaid and Medicare patients), a portion of which can be assumed to be due to waterborne transmission. C1 [Collier, S. A.; Beach, M. J.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Collier, S. A.] Int Hlth Resources Consulting Inc, Atlanta, GA USA. [Stockman, L. J.; Hicks, L. A.; Garrison, L. E.; Zhou, F. J.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Collier, SA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Mailstop F-22,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM scollier@cdc.gov FU Intramural CDC HHS [CC999999] NR 38 TC 57 Z9 58 U1 2 U2 27 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD NOV PY 2012 VL 140 IS 11 BP 2003 EP 2013 DI 10.1017/S0950268811002858 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 019GC UT WOS:000309724500011 PM 22233584 ER PT J AU Behravesh, CB Blaney, D Medus, C Bidol, SA Phan, Q Soliva, S Daly, ER Smith, K Miller, B Taylor, T Nguyen, T Perry, C Hill, TA Fogg, N Kleiza, A Moorhead, D Al-Khaldi, S Braden, C Lynch, MF AF Behravesh, C. Barton Blaney, D. Medus, C. Bidol, S. A. Phan, Q. Soliva, S. Daly, E. R. Smith, K. Miller, B. Taylor, T., Jr. Nguyen, T. Perry, C. Hill, T. A. Fogg, N. Kleiza, A. Moorhead, D. Al-Khaldi, S. Braden, C. Lynch, M. F. TI Multistate outbreak of Salmonella serotype Typhimurium infections associated with consumption of restaurant tomatoes, USA, 2006: hypothesis generation through case exposures in multiple restaurant clusters SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Food safety; foodborne infections; outbreaks; public health; Salmonella Typhimurium ID UNITED-STATES; SURVEILLANCE; RODENTS; SEEDS AB Multiple salmonellosis outbreaks have been linked to contaminated tomatoes. We investigated a multistate outbreak of Salmonella Typhimurium infections among 190 cases. For hypothesis generation, review of patients' food histories from four restaurant-associated clusters in four states revealed that large tomatoes were the only common food consumed by patients. Two case-control studies were conducted to identify food exposures associated with infections. In a study conducted in nine states illness was significantly associated with eating raw, large, round tomatoes in a restaurant [matched odds ratio (mOR) 3.1, 95% confidence interval (CI) 1.3-7.3]. In a Minnesota study, illness was associated with tomatoes eaten at a restaurant (OR 6.3, mid-P 95% CI 1.05-50.4, P=0.046). State, local and federal regulatory officials traced the source of tomatoes to Ohio tomato fields, a growing area not previously identified in past tomato-associated outbreaks. Because tomatoes are commonly eaten raw, prevention of tomato contamination should include interventions on the farm, during packing, and at restaurants. C1 [Behravesh, C. Barton] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Outbreak Response & Prevent Branch, Atlanta, GA 30333 USA. [Behravesh, C. Barton; Blaney, D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Div Appl Sci, Atlanta, GA 30333 USA. [Blaney, D.; Daly, E. R.] New Hampshire Dept Hlth & Human Serv, Div Publ Hlth Serv, Concord, NH 03301 USA. [Medus, C.; Smith, K.] Minnesota Dept Hlth, St Paul, MN USA. [Bidol, S. A.] Michigan Dept Community Hlth, Lansing, MI USA. [Phan, Q.] Connecticut Dept Publ Hlth, Hartford, CT USA. [Soliva, S.] Massachusetts Dept Publ Hlth, Jamaica Plain, MA USA. [Miller, B.] Minnesota Dept Agr, St Paul, MN USA. [Taylor, T., Jr.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Hill, T. A.; Fogg, N.; Al-Khaldi, S.] US FDA, College Pk, MD USA. [Kleiza, A.; Moorhead, D.] US FDA, Cincinnati Dist Off, Cincinnati, OH USA. RP Behravesh, CB (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Outbreak Response & Prevent Branch, 1600 Clifton Rd NE,Mail Stop A-38, Atlanta, GA 30333 USA. EM CBartonBehravesh@cdc.gov OI Miller, Benjamin/0000-0003-1647-0122 NR 28 TC 10 Z9 10 U1 0 U2 6 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD NOV PY 2012 VL 140 IS 11 BP 2053 EP 2061 DI 10.1017/S0950268811002895 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 019GC UT WOS:000309724500017 PM 22261286 ER PT J AU Barskey, AE Schulte, C Rosen, JB Handschur, EF Rausch-Phung, E Doll, MK Cummings, KP Alleyne, EO High, P Lawler, J Apostolou, A Blog, D Zimmerman, CM Montana, B Harpaz, R Hickman, CJ Rota, PA Rota, JS Bellini, WJ Gallagher, KM AF Barskey, Albert E. Schulte, Cynthia Rosen, Jennifer B. Handschur, Elizabeth F. Rausch-Phung, Elizabeth Doll, Margaret K. Cummings, Kisha P. Alleyne, E. Oscar High, Patricia Lawler, Jacqueline Apostolou, Andria Blog, Debra Zimmerman, Christopher M. Montana, Barbara Harpaz, Rafael Hickman, Carole J. Rota, Paul A. Rota, Jennifer S. Bellini, William J. Gallagher, Kathleen M. TI Mumps Outbreak in Orthodox Jewish Communities in the United States SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID VACCINE EFFECTIVENESS; UNIVERSITY-STUDENTS; RECENT RESURGENCE; VIRUS; IMMUNITY; NETHERLANDS; ANTIBODIES; INFECTION AB Background By 2005, vaccination had reduced the annual incidence of mumps in the United States by more than 99%, with few outbreaks reported. However, in 2006, a large outbreak occurred among highly vaccinated populations in the United States, and similar outbreaks have been reported worldwide. The outbreak described in this report occurred among U. S. Orthodox Jewish communities during 2009 and 2010. Methods Cases of salivary-gland swelling and other symptoms clinically compatible with mumps were investigated, and demographic, clinical, laboratory, and vaccination data were evaluated. Results From June 28, 2009, through June 27, 2010, a total of 3502 outbreak-related cases of mumps were reported in New York City, two upstate New York counties, and one New Jersey county. Of the 1648 cases for which clinical specimens were available, 50% were laboratory-confirmed. Orthodox Jewish persons accounted for 97% of case patients. Adolescents 13 to 17 years of age (27% of all patients) and males (78% of patients in that age group) were disproportionately affected. Among case patients 13 to 17 years of age with documented vaccination status, 89% had previously received two doses of a mumps-containing vaccine, and 8% had received one dose. Transmission was focused within Jewish schools for boys, where students spend many hours daily in intense, face-to-face interaction. Orchitis was the most common complication (120 cases, 7% of male patients >= 12 years of age), with rates significantly higher among unvaccinated persons than among persons who had received two doses of vaccine. Conclusions The epidemiologic features of this outbreak suggest that intense exposures, particularly among boys in schools, facilitated transmission and overcame vaccine-induced protection in these patients. High rates of two-dose coverage reduced the severity of the disease and the transmission to persons in settings of less intense exposure. C1 [Barskey, Albert E.; Harpaz, Rafael; Hickman, Carole J.; Rota, Paul A.; Rota, Jennifer S.; Bellini, William J.; Gallagher, Kathleen M.] Ctr Res Dis Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Apostolou, Andria] Ctr Res Dis Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Schulte, Cynthia; Rausch-Phung, Elizabeth; Blog, Debra] New York State Dept Hlth, Albany, NY USA. [Rosen, Jennifer B.; Doll, Margaret K.; Cummings, Kisha P.; Zimmerman, Christopher M.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Alleyne, E. Oscar] Rockland Cty Dept Hlth, Pomona, NY USA. [Lawler, Jacqueline] Orange Cty Hlth Dept, Goshen, NY USA. [Handschur, Elizabeth F.; Montana, Barbara] New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA. [High, Patricia] Ocean Cty Hlth Dept, Toms River, NJ USA. RP Barskey, AE (reprint author), Ctr Res Dis Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop A-34, Atlanta, GA 30333 USA. EM abarskey@cdc.gov OI Doll, Margaret/0000-0002-2125-7820 NR 39 TC 50 Z9 50 U1 0 U2 14 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 1 PY 2012 VL 367 IS 18 BP 1704 EP 1713 DI 10.1056/NEJMoa1202865 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 028RS UT WOS:000310440800007 PM 23113481 ER PT J AU Neta, G Stewart, PA Rajaraman, P Hein, MJ Waters, MA Purdue, MP Samanic, C Coble, JB Linet, MS Inskip, PD AF Neta, Gila Stewart, Patricia A. Rajaraman, Preetha Hein, Misty J. Waters, Martha A. Purdue, Mark P. Samanic, Claudine Coble, Joseph B. Linet, Martha S. Inskip, Peter D. TI Occupational exposure to chlorinated solvents and risks of glioma and meningioma in adults SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CENTRAL-NERVOUS-SYSTEM; BRAIN-TUMORS; EPIDEMIOLOGIC EVIDENCE; CANCER; TRICHLOROETHYLENE; MORTALITY; STATES; WOMEN; MEN AB Objectives Chlorinated solvents are classified as probable or possible carcinogens. It is unknown whether exposure to these agents increases the risk of malignant or benign brain tumours. Our objective was to evaluate associations of brain tumour risk with occupational exposure to six chlorinated solvents (ie, dichloromethane, chloroform, carbon tetrachloride, 1,1,1-trichloroethane, trichloroethylene and perchloroethylene). Methods 489 glioma cases, 197 meningioma cases and 799 controls were enrolled in a hospital-based case-control study conducted at three USA hospitals in Arizona, Massachusetts and Pennsylvania. Information about occupational history was obtained through a detailed inperson interview that included job-specific modules of questions such that the interview was tailored to each individual's particular work history. An industrial hygienist assessed potential solvent exposure based on this information and an exhaustive review of the relevant industrial hygiene literature. Unconditional logistic regression models were used to calculate OR and 95% CI for each solvent for ever/never, duration, cumulative, average weekly and highest exposure. Results Overall, we found no consistent evidence of an increased risk of glioma or meningioma related to occupational exposure to the six chlorinated solvents evaluated. There was some suggestion of an association between carbon tetrachloride and glioma in analyses restricted to exposed subjects, with average weekly exposure above the median associated with increased risk compared with below the median exposure (OR = 7.1, 95% CI 1.1 to 45.2). Conclusions We found no consistent evidence for increased brain tumour risk related to chlorinated solvents. C1 [Neta, Gila; Stewart, Patricia A.; Rajaraman, Preetha; Purdue, Mark P.; Samanic, Claudine; Coble, Joseph B.; Linet, Martha S.; Inskip, Peter D.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Stewart, Patricia A.] Stewart Exposure Assessments LLC, Arlington, VA USA. [Hein, Misty J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Waters, Martha A.] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Neta, G (reprint author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,Dept Hlth & Human Serv,EPS, Room 7092,6120 Execut Blvd, Bethesda, MD 20852 USA. EM netagil@mail.nih.gov RI Purdue, Mark/C-9228-2016 OI Purdue, Mark/0000-0003-1177-3108 FU Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute at the National Institutes of Health FX This research was supported, in part, by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute at the National Institutes of Health. NR 38 TC 5 Z9 5 U1 2 U2 14 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1351-0711 J9 OCCUP ENVIRON MED JI Occup. Environ. Med. PD NOV PY 2012 VL 69 IS 11 BP 793 EP 801 DI 10.1136/oemed-2012-100742 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 020KF UT WOS:000309806700004 PM 22864249 ER PT J AU Bruce, FC Berg, CJ Joski, PJ Roblin, DW Callaghan, WM Bulkley, JE Bachman, DJ Hornbrook, MC AF Bruce, F. Carol Berg, Cynthia J. Joski, Peter J. Roblin, Douglas W. Callaghan, William M. Bulkley, Joanna E. Bachman, Donald J. Hornbrook, Mark C. TI Extent of Maternal Morbidity in a Managed Care Population in Georgia SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY LA English DT Article DE maternal morbidity; pregnancy-related complications; obstetric health care; surveillance ID SEVERE OBSTETRIC MORBIDITY; AREA SOCIOECONOMIC PATTERNS; PREGNANCY-RELATED MORTALITY; US CANCER MORTALITY; UNITED-STATES; DELIVERY; RATES; PREVALENCE; VALIDATION; DIAGNOSES AB Background: Although maternal deaths are among the most tragic events related to pregnancy, they are uncommon in the US and, therefore, inadequate indicators of a woman's pregnancy-related health. Maternal morbidity has become a more useful measure for surveillance and research. Traditional attempts to monitor maternal morbidity have used hospital discharge data, which include data only on complications that resulted in hospitalisation, underestimating the frequency and scope of complications. Methods: To obtain a more accurate assessment of morbidity, we applied a validated computerised algorithm to identify pregnancies and pregnancy-related complications in a defined population enrolled in a health maintenance organisation in the south-eastern US. We examined the most common morbidities by pregnancy outcome and maternal characteristics. Results: We identified 37 741 pregnancies; in half (50.7%), at least one complication occurred. The five most common were urinary tract infections, anaemia, mental health conditions, pelvic and perineal complications, and obstetrical infections. Complications were more likely in women with low socio-economic status (SES), and among non-Hispanic Black women compared with non-Hispanic White women. Multivariable models stratified by race/ethnicity indicated that in pregnancies among non-Hispanic White women, low SES had a modest effect on the odds of having preexisting medical conditions [adjusted odd ratio (AOR) 1.3 [95% confidence interval (CI) 1.2, 1.5]] or having any morbidity (AOR 1.3 [95% CI 1.2, 1.4]). Low SES had little effect on complications among non-Hispanic Black women. Conclusion: Our findings suggest that comprehensive health insurance coverage may lessen the unfavourable impact of socio-economic disadvantage on the risk of maternal morbidity. C1 [Bruce, F. Carol; Berg, Cynthia J.; Callaghan, William M.] Kaiser Permanente SE, Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Joski, Peter J.; Roblin, Douglas W.] Kaiser Permanente SE, Ctr Hlth Res, Atlanta, GA USA. [Bulkley, Joanna E.; Bachman, Donald J.; Hornbrook, Mark C.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. RP Bruce, FC (reprint author), Kaiser Permanente SE, Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,Mailstop K-23, Atlanta, GA 30341 USA. EM cbruce@cdc.gov OI Bulkley, Joanna/0000-0001-8293-2079 FU Centers for Disease Control and Prevention [200-2009-31663] FX The authors thank Lucinda England and Andrea Sharma for their very helpful comments on the manuscript. This study was funded by contract # 200-2009-31663, 'Extent of Maternal Morbidity in a Managed Care Setting' from the Centers for Disease Control and Prevention NR 39 TC 2 Z9 2 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-5022 EI 1365-3016 J9 PAEDIATR PERINAT EP JI Paediatr. Perinat. Epidemiol. PD NOV PY 2012 VL 26 IS 6 BP 497 EP 505 DI 10.1111/j.1365-3016.2012.01318.x PG 9 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics SC Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics GA 023KJ UT WOS:000310031000002 PM 23061685 ER PT J AU Soe, MM Swanson, ME Bolen, JC Thibadeau, JK Johnson, N AF Soe, Minn M. Swanson, Mark E. Bolen, Julie C. Thibadeau, Judy K. Johnson, Natalie TI Health risk behaviors among young adults with spina bifida SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY LA English DT Article ID PHYSICAL-DISABILITIES; UNITED-STATES; ADOLESCENTS; DEPRESSION; CHILDREN; FACILITATORS; SYMPTOMS; BARRIERS; CARE; SEX AB Aim Persons with spina bifida who adopt unhealthy lifestyles could be at increased risk of adverse health outcomes because the presence of spina bifida may magnify this risk. We estimated overall and age-specific prevalence of selected health risk behaviors (HRBs) in young people with spina bifida and examined the association between HRBs and depression. Method We performed analyses on data obtained from individuals with spina bifida (n=130; mean age 23y SD 4y 5mo; 64 males, 66 females; 64% lumbosacral lesion; 77% with shunt) who participated in a population-based survey conducted by the Arkansas Spinal Cord Commission in 2005. Results Compared with national estimates, young people with spina bifida tend to eat less healthy diets, do less exercise, and engage in more sedentary activities. Respondents were less likely to use substances (alcohol, tobacco, illegal drugs), which peaked among 25 to 31 year olds. About 90% saw a doctor in the previous year. Nearly one half reported mild or major depressive symptoms. In the logistic regression analysis after controlling for potential confounders (age, sex, ethnic group, education, employment, marital status, living arrangement, level of lesion, presence of shunt, mobility, self-rated health and healthcare utilization), major depressive symptoms were associated with current alcohol drinking (adjusted odds ratio: 4.74; 95% CI 1.1819.04). Interpretation Young adults with spina bifida exhibit unhealthy behaviors that continue into their late 20s. The findings highlight the need to increase awareness of their health risk profiles in the spina bifida community and show opportunities for mental health and health risk screening and counseling by healthcare providers. C1 [Soe, Minn M.; Swanson, Mark E.; Bolen, Julie C.; Thibadeau, Judy K.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA 30333 USA. [Johnson, Natalie] Univ Tennessee, Erlanger Baroness Hosp, Chattanooga, TN USA. RP Soe, MM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual Promot, Mailstop A24,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM msoe@cdc.gov FU Intramural CDC HHS [CC999999] NR 30 TC 5 Z9 5 U1 3 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0012-1622 J9 DEV MED CHILD NEUROL JI Dev. Med. Child Neurol. PD NOV PY 2012 VL 54 IS 11 BP 1057 EP 1064 DI 10.1111/j.1469-8749.2012.04402.x PG 8 WC Clinical Neurology; Pediatrics SC Neurosciences & Neurology; Pediatrics GA 017OB UT WOS:000309598500023 PM 22937873 ER PT J AU Chen, Z Roy, K Crawford, CAG AF Chen, Zhuo Roy, Kakoli Crawford, Carol A. Gotway TI EVALUATION OF VARIANCE ESTIMATORS FOR THE CONCENTRATION AND HEALTH ACHIEVEMENT INDICES: A MONTE CARLO SIMULATION SO HEALTH ECONOMICS LA English DT Article DE bootstrapping; concentration index; health achievement index; health inequalities; Monte Carlo simulation; statistical inference ID STATISTICAL-INFERENCE; INEQUALITIES AB Although the concentration index (CI) and the health achievement index (HAI) have been extensively used, previous studies have relied on bootstrapping to compute the variance of the HAI, whereas competing variance estimators exist for the CI. This paper provides methods of statistical inference for the HAI and compares the available variance estimators for both the CI and the HAI using Monte Carlo simulation. Results for both the CI and the HAI suggest that analytical methods and bootstrapping are well behaved. The convenient regression method gives standard errors close to the other methods, provided the CI is not too large (< 0.2), but otherwise tends to understate the standard errors. In our simulation setting, the improvement from the NeweyWest correction over the convenient regression method has mixed evidence when the CI?=?0.1 and is modest when the CI?>?0.1. Published 2011. This article is a US Government work and is in the public domain in the USA. C1 [Chen, Zhuo; Roy, Kakoli] US Ctr Dis Control & Prevent, Off Associate Director Policy, Atlanta, GA USA. [Crawford, Carol A. Gotway] US Ctr Dis Control & Prevent, Epidemiol & Anal Program Off, Atlanta, GA USA. RP Chen, Z (reprint author), 1600 Clifton Rd,NE,MS-D28, Atlanta, GA 30333 USA. EM zchen1@cdc.gov OI Chen, Zhuo/0000-0002-5351-3489 NR 9 TC 3 Z9 3 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9230 J9 HEALTH ECON JI Health Econ. PD NOV PY 2012 VL 21 IS 11 BP 1375 EP 1381 DI 10.1002/hec.1796 PG 7 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 015LN UT WOS:000309447600009 PM 21956946 ER PT J AU Luckhaupt, SE Deapen, D Cress, R Schumacher, P Shen, R Calvert, GM AF Luckhaupt, Sara E. Deapen, Dennis Cress, Rosemary Schumacher, Pam Shen, Rui Calvert, Geoffrey M. TI Leukemia among male construction workers in California, 1988-2007 SO LEUKEMIA & LYMPHOMA LA English DT Article DE Cancer; leukemia; surveillance; construction; occupational; floors and floor coverings ID ACUTE MYELOID-LEUKEMIA; CANCER-RISK; PROPORTIONATE MORTALITY; EPIDEMIOLOGIC EVIDENCE; RUBBER INDUSTRY; EXPOSURE; OCCUPATION; JOB; METAANALYSIS; REGISTRY AB A total of 18 708 male cases of leukemia from the California Cancer Registry, including 1703 cases usually employed in construction, were each matched with up to five controls from the same source who were diagnosed with cancers not thought to be related to exposures common in construction. Compared to other workers, construction workers were found to have a significantly elevated risk for all leukemia combined (morbidity odds ratio [MOR] = 1.14, 95% confidence interval [CI] = 1.08, 1.20), acute lymphocytic leukemia (ALL) (MOR = 1.30, 95% CI = 1.07, 1.58), acute myeloid leukemia (AML) (MOR = 1.15, 95% CI = 1.03, 1.27) and chronic myeloid leukemia (CML) (MOR = 1.25, 95% CI = 1.09, 1.44). Among the different construction occupations, the highest MOR for all leukemia was among carpet installers (MOR = 1.99, 95% CI = 1.16, 3.44), followed by plumbers (MOR = 1.28, 95% CI = 1.03, 1.59) and laborers (MOR = 1.26, 95% CI = 1.12, 1.42). Other associations were limited to specific construction occupations, leukemia subtypes and/or racial/ethnic groups. These associations should be further studied with more in-depth exposure assessment. C1 [Luckhaupt, Sara E.; Schumacher, Pam; Shen, Rui; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studi, Cincinnati, OH 45226 USA. [Deapen, Dennis] Univ So Calif, Los Angeles Canc Surveillance Program, Los Angeles, CA USA. [Cress, Rosemary] Calif Canc Registry, Inst Publ Hlth, Sacramento, CA USA. [Cress, Rosemary] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA. RP Luckhaupt, SE (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studi, 4676 Columbia Pkwy,MS R-17, Cincinnati, OH 45226 USA. EM sluckhaupt@cdc.gov FU California Department of Public Health as part of the statewide cancer reporting program [103885]; National Cancer Institute's Surveillance, Epidemiology and End Results Program [N01-PC-35136, N01-PC-35139, N01-PC-54404]; Centers for Disease Control and Prevention's National Program of Cancer Registries [1U58DP00807-01] FX The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California and contract N01-PC-54404 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement 1U58DP00807-01 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. NR 39 TC 3 Z9 3 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1042-8194 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD NOV PY 2012 VL 53 IS 11 BP 2228 EP 2236 DI 10.3109/10428194.2012.690873 PG 9 WC Oncology; Hematology SC Oncology; Hematology GA 015VX UT WOS:000309475600024 PM 22563817 ER PT J AU Stang, HL Astles, JR Breckenridge, K Willis, J Thompson, P Zavahir, Y Anderson, NL AF Stang, Heather L. Astles, J. Rex Breckenridge, Karen Willis, Jane Thompson, Pamela Zavahir, Yasmine Anderson, Nancy L. TI Proficiency Testing in the Clinical Laboratory: Challenges and Benefits Beyond Regulatory Requirements SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Meeting Abstract C1 [Stang, Heather L.; Astles, J. Rex; Zavahir, Yasmine; Anderson, Nancy L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Breckenridge, Karen] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Willis, Jane] Willis Consultants, Palos Verdes Estates, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9173 EI 1943-7722 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD NOV 1 PY 2012 VL 138 SU 2 MA 188 BP A188 EP A188 PG 1 WC Pathology SC Pathology GA V45XH UT WOS:000209848800148 ER PT J AU Aungkulanon, S McCarron, M Lertiendumrong, J Olsen, SJ Bundhamcharoen, K AF Aungkulanon, Suchunya McCarron, Margaret Lertiendumrong, Jongkol Olsen, Sonja J. Bundhamcharoen, Kanitta TI Infectious Disease Mortality Rates, Thailand, 1958-2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID DEATH; TUBERCULOSIS; PROGRAM; TRENDS; AIDS; COUNTRIES; BURDEN AB To better define infectious diseases of concern in Thailand, trends in the mortality rate during 1958-2009 were analyzed by using data from public health statistics reports. From 1958 to the mid-1990s, the rate of infectious disease associated deaths declined 5-fold (from 163.4 deaths/100,000 population in 1958 to 29.5/100,000 in 1997). This average annual reduction of 3.2 deaths/100,000 population was largely attributed to declines in deaths related to malaria, tuberculosis, pneumonia, and gastrointestinal infections. However, during 1998-2003, the mortality rate increased (peak of 70.0 deaths/100,000 population in 2003), coinciding with increases in mortality rate from AIDS, tuberculosis, and pneumonia. During 2004-2009, the rate declined to 41.0 deaths/100,000 population, coinciding with a decrease in AIDS-related deaths. The emergence of AIDS and the increase in tuberculosis- and pneumonia-related deaths in the late twentieth century emphasize the need to direct resources and efforts to the control of emerging and re-emerging infectious diseases. C1 [Aungkulanon, Suchunya; Lertiendumrong, Jongkol; Bundhamcharoen, Kanitta] IHPP, Nonthaburi, Thailand. [McCarron, Margaret; Olsen, Sonja J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Olsen, Sonja J.] Thailand Minist Publ Hlth US Ctr Dis Control & Pr, Nonthaburi, Thailand. RP Aungkulanon, S (reprint author), Minist Publ Hlth, Int Hlth Policy Program, Tiwanon Rd, Nonthaburi 11000, Thailand. EM suchunya@ihpp.thaigov.net NR 40 TC 8 Z9 10 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2012 VL 18 IS 11 BP 1794 EP 1801 DI 10.3201/eid1811.120637 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LQ UT WOS:000328172600011 PM 23092558 ER PT J AU Fleming-Dutra, K Mbaeyi, C Link-Gelles, R Alexander, N Guh, A Forbes, E Beall, B Winchell, JM Carvalho, MD Pimenta, F Kodani, M Vanner, C Stevens, H Brady, D Caulcrick-Grimes, M Bandy, U Moore, MR AF Fleming-Dutra, Katherine Mbaeyi, Chukwuma Link-Gelles, Ruth Alexander, Nicole Guh, Alice Forbes, Elizabeth Beall, Bernard Winchell, Jonas M. Carvalho, Maria da Gloria Pimenta, Fabiana Kodani, Maja Vanner, Cindy Stevens, Hilary Brady, Diane Caulcrick-Grimes, Mardea Bandy, Utpala Moore, Matthew R. TI Streptococcus pneumoniae Serotype 15A in Psychiatric Unit, Rhode Island, USA, 2010-2011 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID PNEUMOCOCCAL CONJUGATE VACCINE; DISEASE; RECOMMENDATIONS; PREVENTION; CHILDREN AB During a pneumococcal disease outbreak in a pediatric psychiatric unit in a hospital in Rhode Island, USA, 6 (30%) of 20 patients and staff were colonized with Streptococcus pneumoniae serotype 15A, which is not included in pneumococcal vaccines. The outbreak subsided after implementation of antimicrobial drug prophylaxis and enhanced infection control measures. C1 [Fleming-Dutra, Katherine; Mbaeyi, Chukwuma; Link-Gelles, Ruth; Guh, Alice; Beall, Bernard; Winchell, Jonas M.; Carvalho, Maria da Gloria; Pimenta, Fabiana; Kodani, Maja; Stevens, Hilary; Moore, Matthew R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Alexander, Nicole; Vanner, Cindy; Brady, Diane; Caulcrick-Grimes, Mardea; Bandy, Utpala] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Alexander, Nicole] Brown Univ Affiliated Hosp, Providence, RI USA. [Forbes, Elizabeth] Brown Univ, Providence, RI 02912 USA. RP Fleming-Dutra, K (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C25, Atlanta, GA 30333 USA. EM kflemingdutra@cdc.gov NR 14 TC 7 Z9 7 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2012 VL 18 IS 11 BP 1889 EP 1893 DI 10.3201/eid1811.120454 PG 5 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LQ UT WOS:000328172600027 PM 23092658 ER PT J AU Hajjeh, R Whitney, CG AF Hajjeh, Rana Whitney, Cynthia G. TI Call to Action on World Pneumonia Day SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 [Hajjeh, Rana; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Hajjeh, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30333 USA. EM rhajjeh@cdc.gov NR 12 TC 1 Z9 2 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2012 VL 18 IS 11 BP 1898 EP 1899 DI 10.3201/eid1811.121217 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LQ UT WOS:000328172600029 PM 23092708 ER PT J AU Ben Beard, C Nelson, CA Mead, PS Petersen, LR AF Ben Beard, C. Nelson, Christina A. Mead, Paul S. Petersen, Lyle R. TI Bartonella spp. Bacteremia and Rheumatic Symptoms in Patients from Lyme Disease-endemic Region SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID CAT-SCRATCH DISEASE C1 [Ben Beard, C.; Nelson, Christina A.; Mead, Paul S.; Petersen, Lyle R.] Ctr Dis Control & Prevent, Ft Collins, CO 80525 USA. RP Nelson, CA (reprint author), Ctr Dis Control & Prevent, 3150 Rampart Rd,Mailstop P02, Ft Collins, CO 80525 USA. EM wje1@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2012 VL 18 IS 11 BP 1918 EP 1919 DI 10.3201/eid1811.120675 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LQ UT WOS:000328172600040 PM 23092626 ER PT J AU Potter, P AF Potter, Polyxeni TI Science Avant-Garde SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM pmp1@cdc.gov NR 12 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD NOV PY 2012 VL 18 IS 11 BP 1922 EP 1923 DI 10.3201/eid1811.AC1811 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LQ UT WOS:000328172600043 PM 23092653 ER PT J AU Williams-Newkirk, AJ Rowe, LA Mixson-Hayden, TR Dasch, GA AF Williams-Newkirk, Amanda Jo Rowe, Lori A. Mixson-Hayden, Tonya R. Dasch, Gregory A. TI Presence, genetic variability, and potential significance of "Candidatus Midichloria mitochondrii" in the lone star tick Amblyomma americanum SO EXPERIMENTAL AND APPLIED ACAROLOGY LA English DT Article DE Midichloria mitochondrii; Amblyomma americanum; 16S rRNA; Metagenomics; Tick control; Pathogenic bacteria; Rickettsiales ID IXODES-RICINUS; RICKETTSIAL AGENTS; UNITED-STATES; NEW-YORK; IXODIDAE; ACARI; SYMBIONT; IDENTIFICATION; ENDOSYMBIONTS; PREVALENCE AB We used next generation sequencing to detect the bacterium "Candidatus Midichloria mitochondrii" for the first time in lone star ticks (Amblyomma americanum) from the eastern United States. 177 individuals and 11 tick pools from seven sites in four states were tested by pyrosequencing with barcoded 16S rRNA gene eubacterial primers targeting variable regions 5-3. Average infection prevalence was 0.15 across all surveyed populations (range 0-0.29) and only the site with the smallest sample size (n = 5) was negative. Three genotypes differing by 2.6-4.1 % in a 271 bp region of 16S rRNA gene were identified. Two variants co-occurred in sites in North Carolina and New York, but were not observed in the same tick at those sites. The third genotype was found only in Georgia. Phylogenetic analysis of this fragment indicated that the three variants are more closely related to "Candidatus Midichloria mitochondrii" genotypes from other tick species than to each other. This variation suggests that multiple independent introductions occurred in A. americanum which may provide insight into bacterial spread within its ecosystem and parasitism on this tick. Whether the presence of this bacterium affects acquisition or maintenance of other pathogens and symbionts in A. americanum or the survival, biology and evolution of the tick itself is unknown. C1 [Williams-Newkirk, Amanda Jo] Emory Univ, Grad Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA. [Williams-Newkirk, Amanda Jo; Rowe, Lori A.; Mixson-Hayden, Tonya R.; Dasch, Gregory A.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Williams-Newkirk, AJ (reprint author), Emory Univ, Grad Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA. EM igy7@cdc.gov OI Williams-Newkirk, Amanda/0000-0002-3466-2921; Dasch, Gregory/0000-0001-6090-1810 FU CDC FX This research was supported in part by an appointment of Williams-Newkirk to the Research Participation Program at the CDC administered by the Oak Ridge Institute for Science and Education. We thank A. Michael Frace for sequencing advice, Robert Newkirk for assistance with graphic preparation, and Scott Campbell, Howie Ginsberg, Terry Schlutz, and Michael Levin for providing the tick samples described in previous publications. Primer synthesis was kindly provided by the CDC Biotechnology Core Facility. NR 32 TC 11 Z9 11 U1 3 U2 18 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0168-8162 J9 EXP APPL ACAROL JI Exp. Appl. Acarol. PD NOV PY 2012 VL 58 IS 3 BP 291 EP 300 DI 10.1007/s10493-012-9582-5 PG 10 WC Entomology SC Entomology GA 008PA UT WOS:000308967800007 PM 22678102 ER PT J AU Markowitz, S Poe-Yamagata, E Andrews, T Deb, P Nesson, E Florence, C Barnett, SBL AF Markowitz, Sara Poe-Yamagata, Eileen Andrews, Tracy Deb, Partha Nesson, Erik Florence, Curtis Barnett, Sarah Beth L. TI Estimating the Relationship between Alcohol Policies and Criminal Violence and Victimization SO GERMAN ECONOMIC REVIEW LA English DT Article DE Alcohol; crime; public policy ID CRIME; AVAILABILITY; AREA; LAWS AB Violence is one of the leading social problems in both Europe and the United States. The development of appropriate public policies to curtail violence is confounded by the relationship between alcohol and violence. In this article, we estimate the propensity of alcohol control policies to reduce the perpetration and victimization of criminal violence. We measure violence with data on individual-level victimizations from the U.S. National Crime Victimization Survey. We examine the effects of a number of different alcohol control policies in reducing violent crime. These policies include the retail price of beer, drunk driving laws and penalties, keg laws and serving and selling laws. We find some evidence of a negative relationship between alcohol prices and the probability of alcohol- or drug-related assault victimizations. However, we find no strong evidence that other alcohol policies are effective in reducing violent crimes. C1 [Markowitz, Sara] Emory Univ, Dept Econ, Atlanta, GA 30322 USA. [Deb, Partha] CUNY, Grad Ctr, New York, NY USA. [Nesson, Erik] Ball State Univ, Muncie, IN 47306 USA. [Florence, Curtis; Barnett, Sarah Beth L.] Ctr Dis Control, Atlanta, GA 30333 USA. RP Markowitz, S (reprint author), Emory Univ, Dept Econ, Atlanta, GA 30322 USA. EM sara.markowitz@emory.edu NR 25 TC 5 Z9 5 U1 0 U2 23 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1465-6485 J9 GER ECON REV JI Ger. Econ. Rev. PD NOV PY 2012 VL 13 IS 4 SI SI BP 416 EP 435 DI 10.1111/j.1468-0475.2012.00574.x PG 20 WC Economics SC Business & Economics GA 011QJ UT WOS:000309179600004 ER PT J AU Lin, YS Caffrey, JL Hsu, PC Chang, MH Faramawi, MF Lin, JW AF Lin, Yu-Sheng Caffrey, James L. Hsu, Ping-Chi Chang, Man-Huei Faramawi, Mohammed F. Lin, Jou-Wei TI Environmental exposure to dioxin-like compounds and the mortality risk in the US population SO INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH LA English DT Article DE Polychlorinated dibenzo-p-dioxins (PCDDs); Polychlorinated dibenzofurans (PCDFs); Polychlorinated biphenyls (PCBs); NHANES; Mortality ID ARYL-HYDROCARBON RECEPTOR; POLYCHLORINATED-BIPHENYLS PCBS; TOXIC EQUIVALENCY FACTORS; DIBENZO-P-DIOXINS; CANCER-RISK; HEALTH; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; FURANS; ACTIVATION; NUTRITION AB Background: Little is known about the mortality risk associated with chronic dioxin exposure in the general U.S. populations. Objective: To explore the association between dioxin-like chemicals and mortality risk in a large population-based cohort study. Methods: The analysis included 2361 subjects aged 40 years or older from the 1999-2004 National Health and Nutrition Examination Survey (NHANES). Exposure to a mixture of dioxin-like chemicals, including dibenzo-p-dioxins, dibenzofurans, and polychlorinated biphenyls was estimated using toxic equivalency values (TEQs) calculated with 2005 World Health Organization toxic equivalency factors. All-cause and cause-specific mortalities were obtained from the NHANES-linked follow-up data through December 31, 2006. Cox proportional-hazards models were applied to assess the associations of interest. Results:A total of 242 deaths occurred during the follow-up period, including 75 from cardiovascular disease and 72 from cancer. There was an increased mortality risk associated with logarithmically expressed dioxin TEQs for all-cause deaths (hazard ratio = 1.19, 95% confidence interval = 1.02-1.39, p = 0.02). Similar graded dose-response trends were found for cardiovascular and cancer mortality which did not reach statistical significance. Conclusions: In general, higher dioxin exposure is associated with an increased mortality risk among subjects aged 40 and above. The cause-specific analyses and responsible mechanisms will require further investigation. (C) 2012 Elsevier GmbH. All rights reserved. C1 [Lin, Jou-Wei] Natl Taiwan Univ Hosp, Yun Lin Branch, Cardiovasc Ctr, Dou Liou City, Yun Lin, Taiwan. [Lin, Jou-Wei] Natl Taiwan Univ Hosp, Yun Lin Branch, Hlth Management Ctr, Dou Liou City, Yun Lin, Taiwan. [Lin, Yu-Sheng] Univ N Texas, Hlth Sci Ctr, Dept Environm & Occupat Hlth, Ft Worth, TX 76107 USA. [Caffrey, James L.] Univ N Texas, Hlth Sci Ctr, Dept Integrat Physiol, Ft Worth, TX 76107 USA. [Caffrey, James L.] Univ N Texas, Hlth Sci Ctr, Cardiovasc Res Inst, Ft Worth, TX 76107 USA. [Hsu, Ping-Chi] Natl Kaohsiung First Univ Sci & Technol, Dept Safety Hlth & Environm Engn, Kaohsiung, Taiwan. [Chang, Man-Huei] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Faramawi, Mohammed F.] Univ N Texas, Hlth Sci Ctr, Dept Epidemiol, Ft Worth, TX 76107 USA. RP Lin, JW (reprint author), Natl Taiwan Univ Hosp, Yun Lin Branch, Cardiovasc Ctr, Dou Liou City, Yun Lin, Taiwan. EM jouweilin@yahoo.com FU National Taiwan University Hospital Yun-Lin Branch [97.S005, 98.X002]; University of North Texas Health Science Center at Fort Worth [G62024] FX This work was in part supported by the grants from the National Taiwan University Hospital Yun-Lin Branch (97.S005 and 98.X002) and by the G62024 Interdisciplinary Research Grant from the University of North Texas Health Science Center at Fort Worth. NR 41 TC 14 Z9 14 U1 0 U2 13 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4639 J9 INT J HYG ENVIR HEAL JI Int. J. Hyg. Environ. Health. PD NOV PY 2012 VL 215 IS 6 BP 541 EP 546 DI 10.1016/j.ijheh.2012.02.006 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 013HW UT WOS:000309297500001 PM 22429684 ER PT J AU Reddy, V Ravi, V Desai, A Parida, M Powers, AM Johnson, BW AF Reddy, Vijayalakshmi Ravi, Vasanthapuram Desai, Anita Parida, Manmohan Powers, Ann M. Johnson, Barbara W. TI Utility of IgM ELISA, TaqMan real-time PCR, reverse transcription PCR, and RT-LAMP assay for the diagnosis of Chikungunya fever SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE Chikungunya; comparison of diagnostic methods; Chikungunya diagnosis; TaqMan real-time PCR for Chikungunya; IgM ELISA for Chikungunya ID VIRUS-INFECTION; DISEASE; INDIA; QUANTIFICATION; SEROPREVALENCE; AMPLIFICATION; OUTBREAKS; ISLAND; STEP AB Chikungunya fever a re-emerging infection with expanding geographical boundaries, can mimic symptoms of other infections like dengue, malaria which makes the definitive diagnosis of the infection important. The present study compares the utility of four laboratory diagnostic methods viz. IgM capture ELISA, an in house reverse transcription PCR for the diagnosis of Chikungunya fever, TaqMan real-time PCR, and a one step reverse transcription-loop mediated isothermal amplification assay (RT-LAMP). Out of the 70 serum samples tested, 29 (41%) were positive for Chikungunya IgM antibody by ELISA and 50 (71%) samples were positive by one of the three molecular assays. CHIKV specific nucleic acid was detected in 33/70 (47%) by reverse transcription PCR, 46/70 (66%) by TaqMan real-time PCR, and 43/70 (62%) by RT-LAMP assay. A majority of the samples (62/70; 89%) were positive by at least one of the four assays used in the study. The molecular assays were more sensitive for diagnosis in the early stages of illness (25 days post onset) when antibodies were not detectable. In the later stages of illness, the IgM ELISA is a more sensitive diagnostic test. In conclusion we recommend that the IgM ELISA be used as an initial screening test followed one of the molecular assays in samples that are collected in the early phase of illness and negative for CHIKV IgM antibodies. Such as approach would enable rapid confirmation of the diagnosis and implementation of public health measures especially during outbreaks. J. Med. Virol. 84:17711778, 2012. (c) 2012 Wiley Periodicals, Inc. C1 [Reddy, Vijayalakshmi; Ravi, Vasanthapuram; Desai, Anita] Natl Inst Mental Hlth & Neurosci, Dept Neurovirol, Bangalore 560029, Karnataka, India. [Parida, Manmohan] Def Res & Dev Estab DRDE, Div Virol, Gwalior, India. [Powers, Ann M.; Johnson, Barbara W.] Ctr Dis Control & Prevent CDC, Arbovirus Dis Branch, Div Vector Borne Infect Dis DVBID, Diagnost & Reference Lab, Ft Collins, CO USA. RP Ravi, V (reprint author), Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurovirol, Bangalore 560029, Karnataka, India. EM virusravi@gmail.com NR 32 TC 19 Z9 21 U1 1 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 J9 J MED VIROL JI J. Med. Virol. PD NOV PY 2012 VL 84 IS 11 BP 1771 EP 1778 DI 10.1002/jmv.23406 PG 8 WC Virology SC Virology GA 010AM UT WOS:000309066800010 PM 22997080 ER PT J AU Stein, CR Wolff, MS Calafat, AM Kato, K Engel, SM AF Stein, Cheryl R. Wolff, Mary S. Calafat, Antonia M. Kato, Kayoko Engel, Stephanie M. TI Comparison of polyfluoroalkyl compound concentrations in maternal serum and amniotic fluid: A pilot study SO REPRODUCTIVE TOXICOLOGY LA English DT Article DE Amniotic fluid; Fluorocarbons; Maternal serum; Perfluorooctanoate; Perfluorooctane sulfonate; Pregnancy ID PERFLUOROOCTANE SULFONATE PFOS; NATIONAL BIRTH COHORT; CORD BLOOD-SAMPLES; PERFLUORINATED COMPOUNDS; PERFLUOROALKYL ACIDS; NHANES 1999-2000; US POPULATION; FETAL-GROWTH; EXPOSURE; CHEMICALS AB The extent to which polyfluoroalkyl compounds (PFCs) are detectable in amniotic fluid is unknown. Using paired samples from 28 women, we compared the concentration of 8 PFCs measured in serum, the standard matrix for assessing human exposure, amniotic fluid from routine amniocentesis, and urine. Perfluorooctanoate (PFOA), perfluorononanoate (PFNA), perfluorooctane sulfonate (PFOS), and perfluorohexane sulfonate (PFHxS) were detected in all maternal serum samples. The number of amniotic fluid samples with detectable concentrations differed by PFC (PFOA n = 24; PFNA n = 10; PFOS n = 9; PFHxS n = 4). The correlation coefficient between maternal serum and amniotic PFC levels varied considerably by PFC (PFOA rho = 0.64, p < 0.001; PFNA rho = 0.05, p = 0.9; PFOS rho = 0.76, p = 0.01; PFHxS rho = 0.80, p = 0.2). Using linear regression, PFOA appeared to be commonly detected in amniotic fluid if the serum concentration exceeded approximately 1.5 ng/mL whereas PFOS was rarely detected in amniotic fluid until the serum concentration was about 5.5 ng/mL. No PFCs were detected in urine. (c) 2012 Elsevier Inc. All rights reserved. C1 [Stein, Cheryl R.; Wolff, Mary S.] Mt Sinai Sch Med, Dept Prevent Med, New York, NY 10029 USA. [Calafat, Antonia M.; Kato, Kayoko] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Engel, Stephanie M.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. RP Stein, CR (reprint author), Mt Sinai Sch Med, Dept Prevent Med, 1 Gustave L Levy Pl,Box 1057, New York, NY 10029 USA. EM cheryl.stein@mssm.edu; mary.wolff@mssm.edu; acalafat@cdc.gov; kkato1@cdc.gov; stephanie.engel@unc.edu FU National Institute of Environmental Health Sciences [R21ES014034, K01 ES019156]; Mount Sinai Children's Environmental Health Center FX This study was supported by the National Institute of Environmental Health Sciences (R21ES014034; K01 ES019156) and the Mount Sinai Children's Environmental Health Center. The authors thank Rebecca Bausell, Molly Meadows, Brian Basden, Carmen Dunbar, and Tao Jia for technical assistance. The findings and conclusions in this work are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 38 TC 25 Z9 26 U1 3 U2 27 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD NOV PY 2012 VL 34 IS 3 BP 312 EP 316 DI 10.1016/j.reprotox.2012.05.039 PG 5 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA 003NU UT WOS:000308619400004 PM 22613200 ER PT J AU Lisco, CG Parrott, DJ Tharp, AT AF Lisco, Claire G. Parrott, Dominic J. Tharp, Andra Teten TI The role of heavy episodic drinking and hostile sexism in men's sexual aggression toward female intimate partners SO ADDICTIVE BEHAVIORS LA English DT Article DE Heavy episodic drinking; Hostile sexism; Benevolent sexism; Sexual aggression ID GENDER-ROLE TRADITIONALITY; AMBIVALENT SEXISM; BENEVOLENT SEXISM; ALCOHOL-CONSUMPTION; BINGE DRINKING; DIFFERENTIATING HOSTILE; ASSAULT PERPETRATION; COGNITIVE FUNCTION; COLLEGE-STUDENTS; CONFLUENCE MODEL AB Research indicates that men's heavy episodic drinking is a significant risk factor for their perpetration of sexual aggression toward intimate partners. The aim of this investigation was to examine how hostile sexism (i.e., antipathy toward women) and benevolent sexism (i.e., subjectively positive, yet patriarchal, views of women) influence the relation between men's heavy episodic drinking and their perpetration of sexual aggression toward intimate partners. Method: Participants were 205 heterosexual drinking men who completed self-report measures of quantity of alcohol consumption during the past 12 months, hostile sexism, and sexual aggression toward an intimate partner during the past 12 months. Results: Men's heavy episodic drinking was positively associated with sexual aggression perpetration toward intimate partners amongst men who endorsed high, but not low, levels of hostile sexism. No such interactive effect emerged for men's endorsement of benevolent sexism. Conclusions: These results have important implications for understanding cumulative risk factors for the perpetration of sexual aggression toward intimates. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Lisco, Claire G.; Parrott, Dominic J.] Georgia State Univ, Dept Psychol, Atlanta, GA 30302 USA. [Tharp, Andra Teten] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. RP Parrott, DJ (reprint author), Georgia State Univ, Dept Psychol, 140 Decatur St SE,Suite 1151, Atlanta, GA 30303 USA. EM parrott@gsu.edu FU Centers for Disease Control and Prevention; Georgia State University FX Funding for this study was provided by a joint grant from the Centers for Disease Control and Prevention and Georgia State University awarded to Dominic J. Parrott and Andra Teten Tharp. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The study design, collection, analysis or interpretation of the data, writing the manuscript, and the decision to submit the paper for publication are also those of the authors and not necessarily represent decisions of the Centers for Disease Control and Prevention. NR 62 TC 8 Z9 8 U1 2 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD NOV PY 2012 VL 37 IS 11 BP 1264 EP 1270 DI 10.1016/j.addbeh.2012.06.010 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 994CL UT WOS:000307908400011 PM 22749405 ER PT J AU Arbyn, M de Sanjose, S Saraiya, M Sideri, M Palefsky, J Lacey, C Gillison, M Bruni, L Ronco, G Wentzensen, N Brotherton, J Qiao, YL Denny, L Bornstein, J Abramowitz, L Giuliano, A Tommasino, M Monsonego, J AF Arbyn, Marc de Sanjose, Silvia Saraiya, Mona Sideri, Mario Palefsky, Joel Lacey, Charles Gillison, Maura Bruni, Laia Ronco, Guglielmo Wentzensen, Nicolas Brotherton, Julia Qiao, You-Lin Denny, Lynnette Bornstein, Jacob Abramowitz, Laurent Giuliano, Anna Tommasino, Massimo Monsonego, Joseph TI EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease SO INTERNATIONAL JOURNAL OF CANCER LA English DT Review DE cervical cancer; vulvar cancer; anal cancer; penile cancer; head and neck cancer; genital warts; incidence; mortality; human papillomavirus; HPV; screening; vaccination ID VULVAR INTRAEPITHELIAL NEOPLASIA; SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL-CANCER PREVENTION; GENITAL WARTS; UNITED-STATES; ANAL CANCER; NECK-CANCER; BURDEN; LESIONS AB The EUROGIN 2011 roadmap reviews the current burden of human papillomavirus (HPV)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV infection. HPV infection causes similar to 600,000 cases of cancer of the cervix, vulva, vagina, anus and oropharynx annually, as well as benign diseases such as genital warts and recurrent respiratory papillomatosis. Whereas the incidence of cervical cancer has been decreasing over recent decades, the incidence of anal and oropharyngeal carcinoma, for which there are no effective screening programs, has been rising over the last couple of decades. Randomized trials have demonstrated improved efficacy of HPV-based compared to cytology-based cervical cancer screening. Defining the best algorithms to triage HPV-positive women, age ranges and screening intervals are priorities for pooled analyses and further research, whereas feasibility questions can be addressed through screening programs. HPV vaccination will reduce the burden of cervical precancer and probably also of invasive cervical and other HPV-related disease in women. Recent trials demonstrated that prophylactic vaccination also protects against anogenital HPV infection, anogenital intraepithelial lesions and warts associated with vaccine types, in males; and anal HPV infection and anal intraepithelial neoplasia in MSM. HPV-related oropharyngeal cancer could be treated less aggressively because of better survival compared to cancers of the oropharynx unrelated to HPV. Key findings in the field of cervical cancer prevention should now be translated in cost-effective strategies, following an organized approach integrating primary and secondary prevention, according to scientific evidence but adapted to the local situation with particular attention to regions with the highest burden of disease. C1 [Arbyn, Marc] Sci Inst Publ Hlth, Canc Epidemiol Unit, B-1050 Brussels, Belgium. [de Sanjose, Silvia; Bruni, Laia] CIBER Epidemiol & Salut Publ, Barcelona, Spain. [Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Sideri, Mario] European Inst Oncol, Gynecol Div, Prevent Gynecol Unit, Milan, Italy. [Palefsky, Joel] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Lacey, Charles] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England. [Gillison, Maura] Kimmel Canc Ctr, Div Viral Oncol, Baltimore, MD USA. [Ronco, Guglielmo] Ctr Prevenz Oncol, Canc Epidemiol Unit, Turin, Italy. [Wentzensen, Nicolas] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Bethesda, MD 20892 USA. [Brotherton, Julia] Victorian Cytol Serv, Victorian Cytol Serv Registries, Melbourne, Vic, Australia. [Qiao, You-Lin] Chinese Acad Med Sci, Inst Canc, Dept Canc Epidemiol, Beijing 100021, Peoples R China. [Denny, Lynnette] Univ Cape Town, Dept Obstet & Gynaecol, Cape Town, South Africa. [Denny, Lynnette] Groote Schuur Hosp, ZA-7925 Cape Town, South Africa. [Bornstein, Jacob] Bar Ilan Univ, Fac Med, IL-52100 Ramat Gan, Israel. [Bornstein, Jacob] Western Galilee Hosp, Dept Obstet & Gynecol, Nahariyya, Israel. [Abramowitz, Laurent] Hop Xavier Bichat, Dept Gastroenterol & Proctol, Paris, France. [Giuliano, Anna] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Canc Epidemiol, Tampa, FL 33682 USA. [Tommasino, Massimo] Int Agcy Res Canc, F-69372 Lyon, France. [Monsonego, Joseph] Inst Cervix, Paris, France. RP Arbyn, M (reprint author), Sci Inst Publ Hlth, Canc Epidemiol Unit, J Wytsmanst 14, B-1050 Brussels, Belgium. EM marc.arbyn@wiv-isp.be RI de Sanjose Llongueras, Silvia/H-6339-2014; Bruni, Laia/N-5816-2014; Qiao, You-Lin/B-4139-2012; OI Qiao, You-Lin/0000-0001-6380-0871; Bruni, Laia/0000-0003-3943-0326 FU Merck; GSK; MSD; Qiagen; SPMSD; Australian Research Council; Cooperative Research Centre for Aboriginal Health; CSL Limited; Directorate of SANCO of the European Commission, Luxembourg; Grand-Duchy of Luxembourg through the IARC, Lyon, France; Grand-Duchy of Luxembourg through the EUROCHIP-3 Network (Istituto Nazionale dei Tumori, Milan, Italy); Belgian Foundation Against Cancer (Brussels, Belgium); European Commission [242061]; HPV-AHEAD Project [FP7-HEALTH-2011-282562]; National Cancer Institute (Bethesda, USA) FX MA: Participation at Eurogin conference (Lisbon 2011) funded by organizers of the conference. SdS has an unrestricted grant from Merck and has had occasional grants for assistance to scientific meetings from GSK, MSD and Qiagen. MSi: consultancy with salary to IEO with the following companies: Qiagen, GSK, Sanofi Pasteur, MTM labs, Roche Diagnostics, Innogenetics. CL has acted as a consultant for SPMSD and received travel grants from SPMSD & GSK. MG: Merck (funding and consulting), GSK (consulting). JBr: investigator on an Australian Research Council Linkage Grant, for which CSL Biotherapies is a partner organization and was a chief investigator on a study of HPV prevalence in Australian women, which was funded by a grant from the Cooperative Research Centre for Aboriginal Health, as well as education grants in aid from GlaxoSmithKline and CSL Limited. LD has received honoraria from Merck and Glaxosmithkline for appearing on various speaker fora and has conducted research funded by both organizations. AG: Merck (Speaker Bureau, consult, grant funding), GSK (grant funding). JM has participated to Steering Committees at Merck and to the Advisory Board of Sanofi Pasteur MSD, Gen-Probe, Qiagen and Roche Diagnostics.; Grant sponsors: Directorate of SANCO of the European Commission, Luxembourg, Grand-Duchy of Luxembourg [through the ECCG project (European Cooperation on Development and Implementation of Cancer Screening and Prevention Guidelines), the IARC, Lyon, France and through the EUROCHIP-3 Network (Istituto Nazionale dei Tumori, Milan, Italy)]. The Belgian Foundation Against Cancer (Brussels, Belgium). The 7th Framework Programme of DG Research of the European Commission (PREHDICT Project, coordinated by the Vrije Universiteit Amsterdam, the Netherlands), Grant number: 242061; the HPV-AHEAD Project (coordinated by IARC), Grant number: FP7-HEALTH-2011-282562. The Intramural Research Program of the National Cancer Institute (Bethesda, USA). NR 98 TC 66 Z9 73 U1 0 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 EI 1097-0215 J9 INT J CANCER JI Int. J. Cancer PD NOV 1 PY 2012 VL 131 IS 9 BP 1969 EP 1982 DI 10.1002/ijc.27650 PG 14 WC Oncology SC Oncology GA 993XP UT WOS:000307893600003 PM 22623137 ER PT J AU Raphael, BH Lautenschlager, M Kalb, SR de Jong, LIT Frace, M Luquez, C Barr, JR Fernandez, RA Maslanka, SE AF Raphael, Brian H. Lautenschlager, Matthew Kalb, Suzanne R. de Jong, Laura I. T. Frace, Michael Luquez, Carolina Barr, John R. Fernandez, Rafael A. Maslanka, Susan E. TI Analysis of a unique Clostridium botulinum strain from the Southern hemisphere producing a novel type E botulinum neurotoxin subtype SO BMC MICROBIOLOGY LA English DT Article DE Botulism; Mass spectrometry; Genomics; Whole genome sequencing ID TOXIN; GENES; DIVERSITY; BUTYRICUM; INFANT AB Background: Clostridium botulinum strains that produce botulinum neurotoxin type E (BoNT/E) are most commonly isolated from botulism cases, marine environments, and animals in regions of high latitude in the Northern hemisphere. A strain of C. botulinum type E (CDC66177) was isolated from soil in Chubut, Argentina. Previous studies showed that the amino acid sequences of BoNT/E produced by various strains differ by < 6% and that the type E neurotoxin gene cluster inserts into the rarA operon. Results: Genetic and mass spectral analysis demonstrated that the BoNT/E produced by CDC66177 is a novel toxin subtype (E9). Toxin gene sequencing indicated that BoNT/E9 differed by nearly 11% at the amino acid level compared to BoNT/E1. Mass spectrometric analysis of BoNT/E9 revealed that its endopeptidase substrate cleavage site was identical to other BoNT/E subtypes. Further analysis of this strain demonstrated that its 16S rRNA sequence clustered with other Group II C. botulinum (producing BoNT types B, E, and F) strains. Genomic DNA isolated from strain CDC66177 hybridized with fewer probes using a Group II C. botulinum subtyping microarray compared to other type E strains examined. Whole genome shotgun sequencing of strain CDC66177 revealed that while the toxin gene cluster inserted into the rarA operon similar to other type E strains, its overall genome content shared greater similarity with a Group II C. botulinum type B strain (17B). Conclusions: These results expand our understanding of the global distribution of C. botulinum type E strains and suggest that the type E toxin gene cluster may be able to insert into C. botulinum strains with a more diverse genetic background than previously recognized. C1 [Raphael, Brian H.; Lautenschlager, Matthew; Kalb, Suzanne R.; Frace, Michael; Luquez, Carolina; Barr, John R.; Maslanka, Susan E.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [de Jong, Laura I. T.; Fernandez, Rafael A.] Univ Nacl Cuyo, Area Microbiol, RA-5500 Mendoza, Argentina. RP Raphael, BH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS G-29, Atlanta, GA 30329 USA. EM BRaphael@cdc.gov OI Kalb, Suzanne/0000-0002-8067-136X; Raphael, Brian/0000-0003-2778-2623 FU Centers for Disease Control and Prevention, Office of Public Health Preparedness and Response; Oak Ridge Institute for Science and Education fellowship FX Sanger sequencing was performed in the Genomics Unit within the Division of High Consequence Pathogens and Pathology at CDC. This publication was supported by funds made available from the Centers for Disease Control and Prevention, Office of Public Health Preparedness and Response. ML was supported by an Oak Ridge Institute for Science and Education fellowship. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 25 TC 19 Z9 19 U1 0 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2180 J9 BMC MICROBIOL JI BMC Microbiol. PD OCT 31 PY 2012 VL 12 AR 245 DI 10.1186/1471-2180-12-245 PG 10 WC Microbiology SC Microbiology GA 079EA UT WOS:000314151900001 PM 23113872 ER PT J AU Azziz-Baumgartner, E Cabrera, AM Chang, L Calli, R Kusznierz, G Baez, C Yedlin, P Zamora, AM Cuezzo, R Sarrouf, EB Uboldi, A Herrmann, J Zerbini, E Uez, O Cordeiro, POR Chavez, P Han, G Antman, J Coronado, F Bresee, J Kosacoff, M Widdowson, MA Echenique, H AF Azziz-Baumgartner, Eduardo Maria Cabrera, Ana Chang, Loretta Calli, Rogelio Kusznierz, Gabriela Baez, Clarisa Yedlin, Pablo Maria Zamora, Ana Cuezzo, Romina Beatriz Sarrouf, Elena Uboldi, Andrea Herrmann, Juan Zerbini, Elsa Uez, Osvaldo Rico Cordeiro, Pedro Osvaldo Chavez, Pollyanna Han, George Antman, Julian Coronado, Fatima Bresee, Joseph Kosacoff, Marina Widdowson, Marc-Alain Echenique, Horacio TI Mortality, Severe Acute Respiratory Infection, and Influenza-Like Illness Associated with Influenza A(H1N1)pdm09 in Argentina, 2009 SO PLOS ONE LA English DT Article ID A H1N1; VIRUS AB Introduction: While there is much information about the burden of influenza A(H1N1)pdm09 in North America, little data exist on its burden in South America. Methods: During April to December 2009, we actively searched for persons with severe acute respiratory infection and influenza-like illness (ILI) in three sentinel cities. A proportion of case-patients provided swabs for influenza testing. We estimated the number of case-patients that would have tested positive for influenza by multiplying the number of untested case-patients by the proportion who tested positive. We estimated rates by dividing the estimated number of case-patients by the census population after adjusting for the proportion of case-patients with missing illness onset information and ILI case-patients who visited physicians multiple times for one illness event. Results: We estimated that the influenza A(H1N1) pdm09 mortality rate per 100,000 person-years (py) ranged from 1.5 among persons aged 5-44 years to 5.6 among persons aged >= 65 years. A(H1N1)pdm09 hospitalization rates per 100,000 py ranged between 26.9 among children aged <5 years to 41.8 among persons aged >= 65 years. Influenza A(H1N1) pdm09 ILI rates per 100 py ranged between 1.6 among children aged <5 to 17.1 among persons aged 45-64 years. While 9 (53%) of 17 influenza A(H1N1)pdm09 decedents with available data had obesity and 7 (17%) of 40 had diabetes, less than 4% of surviving influenza A(H1N1)pdm09 case-patients had these pre-existing conditions (p <= 0.001). Conclusion: Influenza A(H1N1)pdm09 caused a similar burden of disease in Argentina as in other countries. Such disease burden suggests the potential value of timely influenza vaccinations. C1 [Azziz-Baumgartner, Eduardo; Chavez, Pollyanna; Coronado, Fatima; Bresee, Joseph; Widdowson, Marc-Alain] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Maria Cabrera, Ana; Antman, Julian; Kosacoff, Marina; Echenique, Horacio] Minist Salud Nacion, Direcc Epidemiol, Buenos Aires, DF, Argentina. [Chang, Loretta; Han, George] US Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Calli, Rogelio; Maria Zamora, Ana; Cuezzo, Romina; Beatriz Sarrouf, Elena] Minist Salud Publ Prov Tucuman, Direcc Epidemiol, San Miguel De Tucuman, Argentina. [Kusznierz, Gabriela; Zerbini, Elsa] Inst Nacl Enfermedades Resp, Santa Fe, Santa Fe, Argentina. [Baez, Clarisa] Minist Salud Prov Buenos Aires, Buenos Aires, DF, Argentina. [Uboldi, Andrea; Herrmann, Juan] Minist Salud Publ Santa Fe, Santa Fe, Santa Fe, Argentina. [Uez, Osvaldo] Inst Nacl Epidemiol Dr Juan H Jara, Serv Virol, Mar De Plata, Argentina. [Rico Cordeiro, Pedro Osvaldo] Org Panamer Salud, Buenos Aires, DF, Argentina. RP Azziz-Baumgartner, E (reprint author), US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM Eha9@cdc.gov OI Widdowson, Marc-Alain/0000-0002-0682-6933 NR 19 TC 6 Z9 6 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 31 PY 2012 VL 7 IS 10 AR e47540 DI 10.1371/journal.pone.0047540 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 030WJ UT WOS:000310600500022 PM 23118877 ER PT J AU Reed, C Katz, JM Hancock, K Balish, A Fry, AM AF Reed, Carrie Katz, Jacqueline M. Hancock, Kathy Balish, Amanda Fry, Alicia M. CA H1N1 Serosurvey Working Grp TI Prevalence of Seropositivity to Pandemic Influenza A/H1N1 Virus in the United States following the 2009 Pandemic SO PLOS ONE LA English DT Article ID A H1N1 VIRUS; HOUSEHOLD TRANSMISSION; INFECTION; VACCINE; CHALLENGE; ANTIBODY; DISEASE; ENGLAND; HUMANS; BURDEN AB Background: 2009 pandemic influenza A/H1N1 (A(H1N1)pdm09) was first detected in the United States in April 2009 and resulted in a global pandemic. We conducted a serologic survey to estimate the cumulative incidence of A(H1N1) pdm09 through the end of 2009 when pandemic activity had waned in the United States. Methods: We conducted a pair of cross sectional serologic surveys before and after the spring/fall waves of the pandemic for evidence of seropositivity (titer >= 40) using the hemagglutination inhibition (HI) assay. We tested a baseline sample of 1,142 serum specimens from the 2007-2008 National Health and Nutrition Examination Survey (NHANES), and 2,759 serum specimens submitted for routine screening to clinical diagnostic laboratories from ten representative sites. Results: The age-adjusted prevalence of seropositivity to A(H1N1) pdm09 by year-end 2009 was 36.9% (95%CI: 31.7-42.2%). After adjusting for baseline cross-reactive antibody, pandemic vaccination coverage and the sensitivity/specificity of the HI assay, we estimate that 20.2% (95%CI: 10.1-28.3%) of the population was infected with A(H1N1) pdm09 by December 2009, including 53.3% (95%CI: 39.0-67.1%) of children aged 5-17 years. Conclusions: By December 2009, approximately one-fifth of the US population, or 61.9 million persons, may have been infected with A(H1N1) pdm09, including around half of school-aged children. C1 [Reed, Carrie; Katz, Jacqueline M.; Hancock, Kathy; Balish, Amanda; Fry, Alicia M.; H1N1 Serosurvey Working Grp] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Reed, C (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM creed1@cdc.gov; agf1@cdc.gov NR 36 TC 14 Z9 14 U1 0 U2 41 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 31 PY 2012 VL 7 IS 10 AR e48187 DI 10.1371/journal.pone.0048187 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 030WJ UT WOS:000310600500078 PM 23118949 ER PT J AU Alwis, KU Blount, BC Britt, AS Patel, D Ashley, DL AF Alwis, K. Udeni Blount, Benjamin C. Britt, April S. Patel, Dhrusti Ashley, David L. TI Simultaneous analysis of 28 urinary VOC metabolites using ultra high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (UPLC-ESI/MSMS) SO ANALYTICA CHIMICA ACTA LA English DT Article DE VOC metabolites; Urinary biomarkers; Tobacco-related; UPLC-ESI/MSMS; Endogenous; Correlation ID VOLATILE ORGANIC-COMPOUNDS; S-PHENYLMERCAPTURIC ACID; MAJOR MERCAPTURIC ACIDS; BENZENE EXPOSURE; STYRENE; BLOOD; RAT; QUANTIFICATION; 1,3-BUTADIENE; POPULATION AB Volatile organic compounds (VOCs) are ubiquitous in the environment, originating from many different natural and anthropogenic sources, including tobacco smoke. Long-term exposure to certain VOCs may increase the risk for cancer, birth defects, and neurocognitive impairment. Therefore. VOC exposure is an area of significant public health concern. Urinary VOC metabolites are useful biomarkers for assessing VOC exposure because of non-invasiveness of sampling and longer physiological half-lives of urinary metabolites compared with VOCs in blood and breath. We developed a method using reversed-phase ultra high performance liquid chromatography (UPLC) coupled with electrospray ionization tandem mass spectrometry (ESI/MSMS) to simultaneously quantify 28 urinary VOC metabolites as biomarkers of exposure. We describe a method that monitors metabolites of acrolein, acrylamide, acrylonitrile, benzene, 1-bromopropane, 1,3-butadiene, carbon-disulfide, crotonaldehyde, cyanide, N,N-dimethylformamide, ethylbenzene, ethylene oxide, propylene oxide, styrene, tetrachloroethylene, toluene, trichloroethylene, vinyl chloride and xylene. The method is accurate (mean accuracy for spiked matrix ranged from 84 to104%), sensitive (limit of detection ranged from 0.5 to 20 ng mL(-1)) and precise (the relative standard deviations ranged from 2.5 to 11%). We applied this method to urine samples collected from 1203 non-smokers and 347 smokers and demonstrated that smokers have significantly elevated levels of tobacco-related biomarkers compared to non-smokers. We found significant (p < 0.0001) correlations between serum cotinine and most of the tobacco-related biomarkers measured. These findings confirm that this method can effectively quantify urinary VOC metabolites in a population exposed to volatile organics. Published by Elsevier B.V. C1 [Alwis, K. Udeni; Blount, Benjamin C.; Britt, April S.; Patel, Dhrusti; Ashley, David L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. RP Alwis, KU (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. EM UAlwis@cdc.gov NR 46 TC 36 Z9 40 U1 3 U2 81 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0003-2670 EI 1873-4324 J9 ANAL CHIM ACTA JI Anal. Chim. Acta PD OCT 31 PY 2012 VL 750 SI SI BP 152 EP 160 DI 10.1016/j.aca.2012.04.009 PG 9 WC Chemistry, Analytical SC Chemistry GA 028GD UT WOS:000310409900013 PM 23062436 ER PT J AU Knopp, S Mohammed, KA Ali, SM Khamis, IS Ame, SM Albonico, M Gouvras, A Fenwick, A Savioli, L Colley, DG Utzinger, J Person, B Rollinson, D AF Knopp, Stefanie Mohammed, Khalfan A. Ali, Said M. Khamis, I. Simba Ame, Shaali M. Albonico, Marco Gouvras, Anouk Fenwick, Alan Savioli, Lorenzo Colley, Daniel G. Utzinger, Juerg Person, Bobbie Rollinson, David TI Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approach SO BMC PUBLIC HEALTH LA English DT Article DE Urogenital schistosomiasis; Schistosoma haematobium; Preventive chemotherapy; Snail control intervention; Bulinus globosus; Behaviour change intervention; Morbidity control; Transmission control; Elimination; Zanzibar; Tanzania ID URINARY SCHISTOSOMIASIS; SCHOOL-CHILDREN; RISK-FACTORS; SCHOOLCHILDREN; PRAZIQUANTEL; HAEMATOBIUM; MORBIDITY; PROGRAM; INFECTIONS; HEMATOBIUM AB Background: Schistosomiasis is a parasitic infection that continues to be a major public health problem in many developing countries being responsible for an estimated burden of at least 1.4 million disability-adjusted life years (DALYs) in Africa alone. Importantly, morbidity due to schistosomiasis has been greatly reduced in some parts of the world, including Zanzibar. The Zanzibar government is now committed to eliminate urogenital schistosomiasis. Over the next 3-5 years, the whole at-risk population will be administered praziquantel (40 mg/kg) biannually. Additionally, snail control and behaviour change interventions will be implemented in selected communities and the outcomes and impact measured in a randomized intervention trial. Methods/Design: In this 5-year research study, on both Unguja and Pemba islands, urogenital schistosomiasis will be assessed in 45 communities with urine filtration and reagent strips in 4,500 schoolchildren aged 9-12 years annually, and in 4,500 first-year schoolchildren and 2,250 adults in years 1 and 5. Additionally, from first-year schoolchildren, a finger-prick blood sample will be collected and examined for Schistosoma haematobium infection biomarkers. Changes in prevalence and infection intensity will be assessed annually. Among the 45 communities, 15 were randomized for biannual snail control with niclosamide, in concordance with preventive chemotherapy campaigns. The reduction of Bulinus globosus snail populations and S. haematobium-infected snails will be investigated. In 15 other communities, interventions triggering behaviour change have been designed and will be implemented in collaboration with the community. A change in knowledge, attitudes and practices will be assessed annually through focus group discussions and in-depth interviews with schoolchildren, teachers, parents and community leaders. In all 45 communities, changes in the health system, water and sanitation infrastructure will be annually tracked by standardized questionnaire-interviews with community leaders. Additional issues potentially impacting on study outcomes and all incurring costs will be recordedand monitored longitudinally. Discussion: Elimination of schistosomiasis has become a priority on the agenda of the Zanzibar government and the international community. Our study will contribute to identifying what, in addition to preventive chemotherapy, needs to be done to prevent, control, and ultimately eliminate schistosomiasis, and to draw lessons for current and future schistosomiasis elimination programmes in Africa and elsewhere. C1 [Knopp, Stefanie; Utzinger, Juerg] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland. [Knopp, Stefanie; Utzinger, Juerg] Univ Basel, CH-4003 Basel, Switzerland. [Knopp, Stefanie; Gouvras, Anouk; Rollinson, David] Nat Hist Museum, Dept Life Sci, Wolfson Wellcome Biomed Labs, London SW7 5BD, England. [Mohammed, Khalfan A.; Khamis, I. Simba] Minist Hlth, Helminth Control Lab Unguja, Zanzibar, Tanzania. [Ali, Said M.; Ame, Shaali M.] Minist Hlth, Publ Hlth Lab Ivo de Carneri, Chake Chake Pemba, Tanzania. [Albonico, Marco] Ivo de Carneri Fdn, I-20127 Milan, Italy. [Fenwick, Alan] Fac Med, Dept Infect Dis Epidemiol, Schistosomiasis Control Initiat, London, England. [Savioli, Lorenzo] WHO, Dept Control Neglected Trop Dis, CH-1211 Geneva 27, Switzerland. [Colley, Daniel G.] Univ Georgia, Dept Microbiol, Athens, GA 30602 USA. [Colley, Daniel G.] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA. [Person, Bobbie] Ctr Dis Control & Prevent, Natl Ctr Preparedness Detect & Control Infect Dis, Atlanta, GA 30333 USA. RP Rollinson, D (reprint author), Nat Hist Museum, Dept Life Sci, Wolfson Wellcome Biomed Labs, Cromwell Rd, London SW7 5BD, England. EM d.rollinson@nhm.ac.uk RI Rollinson, David/C-7406-2009; OI ALBONICO, Marco/0000-0002-7805-2391 FU University of Georgia Research Foundation [RR374-053/4893206, RR374-053/4787996]; Bill & Melinda Gates Foundation [50816] FX All researchers are grateful for the sub-award (no. RR374-053/4893206 and no. RR374-053/4787996) from the University of Georgia Research Foundation, which is awarded by the Bill & Melinda Gates Foundation (prime award no. 50816). Moreover they are particularly indebted to all members of the SCORE secretariat for valuable advise and input, the ZEST partners (Zanzibar MoH, including the Zanzibar NTD Programme, the PHL-IdC Pemba, Zanzibar government agencies, WHO, SCI, NHM, Swiss TPH, LSHTM and University of New Mexico) for support in the design and implementation of the study. The Zanzibar NTD Programme acknowledges the WHO for the donation of praziquantel to cover biannual preventive chemotherapy of the population for the next 5 years, SCI for covering the treatment implementation costs and Bayer S. A. S. for the donation of 3 MT niclosamide for snail control. Thanks also to colleagues who have participated in various ways to help establish this programme and study including Fiona Allen, Aidan Emery, Muriel Rabone and Linzy Elton at NHM, Michael French at SCI, Tracy Glass, Christian Burri and the study secretariat team at Swiss TPH, Seleman Ally at Zanzibar HMIS and the intervention and survey teams on Unguja and Pemba. NR 78 TC 34 Z9 34 U1 0 U2 20 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD OCT 30 PY 2012 VL 12 AR 930 DI 10.1186/1471-2458-12-930 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 064VT UT WOS:000313104200001 PM 23110494 ER PT J AU Eziefula, AC Gosling, R Hwang, J Hsiang, MS Bousema, T von Seidlein, L Drakeley, C AF Eziefula, Alice C. Gosling, Roly Hwang, Jimee Hsiang, Michelle S. Bousema, Teun von Seidlein, Lorenz Drakeley, Chris CA Primaquine Africa Discussion Grp TI Rationale for short course primaquine in Africa to interrupt malaria transmission SO MALARIA JOURNAL LA English DT Article DE Plasmodium falciparum; Malaria; Primaquine; 8-aminoquinoline; Transmission; Gametocyte; Glucose-6-phosphate dehydrogenase deficiency; G6PD; Africa ID PLASMODIUM-FALCIPARUM GAMETOCYTES; CONTROLLED-TRIAL; BURKINA-FASO; COMBINATION; PYRIMETHAMINE; ARTEMISININ; EPIDEMIOLOGY; INDIVIDUALS; PROPHYLAXIS; INFECTIVITY AB Following the recent successes of malaria control in sub-Saharan Africa, the gametocytocidal drug primaquine needs evaluation as a tool to further reduce the transmission of Plasmodium falciparum malaria. The drug has scarcely been used in Africa because of concerns about its safety in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency. The evidence base for the use of primaquine as a transmission blocker is limited by a lack of comparable clinical and parasitological endpoints between trials. In March 2012, a group of experts met in London to discuss the existing evidence on the ability of primaquine to block malaria transmission, to define the roadblocks to the use of primaquine in Africa and to develop a roadmap to enable its rapid, safe and effective deployment. The output of this meeting is a strategic plan to optimize trial design to reach desired goals efficiently. The roadmap includes suggestions for a series of phase 1, 2, 3 and 4 studies to address specific hurdles to primaquine's deployment. These include ex-vivo studies on efficacy, primaquine pharmacokinetics and pharmacodynamics and dose escalation studies for safety in high-risk groups. Phase 3 community trials are proposed, along with Phase 4 studies to evaluate safety, particularly in pregnancy, through pharmacovigilance in areas where primaquine is already deployed. In parallel, efforts need to be made to address issues in drug supply and regulation, to map G6PD deficiency and to support the evaluation of alternative gametocytocidal compounds. C1 [Eziefula, Alice C.; Bousema, Teun; Drakeley, Chris] Univ London London Sch Hyg & Trop Med, Malaria Ctr, London WC1E 7HT, England. [Gosling, Roly; Hwang, Jimee; Hsiang, Michelle S.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94105 USA. [Hwang, Jimee] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA 30333 USA. [Hsiang, Michelle S.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [von Seidlein, Lorenz] Menzies Sch Hlth Res, Casuarina, NT 0811, Australia. RP Drakeley, C (reprint author), Univ London London Sch Hyg & Trop Med, Malaria Ctr, Keppel St, London WC1E 7HT, England. EM chris.drakeley@lshtm.ac.uk RI D'Alessandro, Umberto/D-3457-2015; Bousema, Teun/N-3574-2014 OI D'Alessandro, Umberto/0000-0001-6341-5009; FU Bill and Melinda Gates Foundation; Global Health Group at the University of San Francisco in California; Malaria Centre at the London School of Hygiene and Tropical Medicine; Wellcome Trust of Great Britain [090558/Z/09/Z] FX The authors would like to thank Dalia Iskander (London School of Hygiene and Tropical Medicine, UK) for logistical support and the Bill and Melinda Gates Foundation, The Global Health Group at the University of San Francisco in California and the Malaria Centre at the London School of Hygiene and Tropical Medicine for financial support. Alice C. Eziefula is funded by a Clinical Fellowship from the Wellcome Trust of Great Britain (#090558/Z/09/Z). NR 45 TC 26 Z9 26 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD OCT 30 PY 2012 VL 11 AR 360 DI 10.1186/1475-2875-11-360 PG 15 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 044EO UT WOS:000311602400001 PM 23130957 ER PT J AU Bagamian, KH Towner, JS Kuenzi, AJ Douglass, RJ Rollin, PE Waller, LA Mills, JN AF Bagamian, Karoun H. Towner, Jonathan S. Kuenzi, Amy J. Douglass, Richard J. Rollin, Pierre E. Waller, Lance A. Mills, James N. TI Transmission Ecology of Sin Nombre Hantavirus in Naturally Infected North American Deermouse Populations in Outdoor Enclosures SO PLOS ONE LA English DT Article ID MOUSE PEROMYSCUS-MANICULATUS; MALE NORWAY RATS; SOUTHWESTERN UNITED-STATES; CREEK CANAL VIRUS; DEER MICE; SEOUL-VIRUS; GENETIC IDENTIFICATION; PUUMALA HANTAVIRUS; PULMONARY SYNDROME; HEMORRHAGIC-FEVER AB Sin Nombre hantavirus (SNV), hosted by the North American deermouse (Peromyscus maniculatus), causes hantavirus pulmonary syndrome (HPS) in North America. Most transmission studies in the host were conducted under artificial conditions, or extrapolated information from mark-recapture data. Previous studies using experimentally infected deermice were unable to demonstrate SNV transmission. We explored SNV transmission in outdoor enclosures using naturally infected deermice. Deermice acquiring SNV in enclosures had detectable viral RNA in blood throughout the acute phase of infection and acquired significantly more new wounds (indicating aggressive encounters) than uninfected deermice. Naturally-infected wild deermice had a highly variable antibody response to infection, and levels of viral RNA sustained in blood varied as much as 100-fold, even in individuals infected with identical strains of virus. Deermice that infected other susceptible individuals tended to have a higher viral RNA load than those that did not infect other deermice. Our study is a first step in exploring the transmission ecology of SNV infection in deermice and provides new knowledge about the factors contributing to the increase of the prevalence of a zoonotic pathogen in its reservoir host and to changes in the risk of HPS to human populations. The techniques pioneered in this study have implications for a wide range of zoonotic disease studies. C1 [Bagamian, Karoun H.; Mills, James N.] Emory Univ, Populat Biol Ecol & Evolut Program, Atlanta, GA 30322 USA. [Bagamian, Karoun H.; Towner, Jonathan S.; Rollin, Pierre E.; Mills, James N.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Bagamian, Karoun H.; Kuenzi, Amy J.; Douglass, Richard J.] Univ Montana, Dept Biol, Butte, MT USA. [Waller, Lance A.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA. RP Bagamian, KH (reprint author), Emory Univ, Populat Biol Ecol & Evolut Program, Atlanta, GA 30322 USA. EM karoun11@gmail.com FU Oak Ridge Institute for Science and Education (ORISE); National Institutes of Health-Centers for Disease Control and Prevention (NIH-CDC) Public Health Dissertation Research [R-36]; NIH from the IDeA Network of Biomedical Research Excellence-Biomedical Research Infrastructure Network (INBRE-BRIN) program of the National Center for Research Resources [P20 RR16455-06, P20 RR16455-07]; CDC Viral Special Pathogens Branch; Montana Tech, University of Montana FX This project was funded by the Oak Ridge Institute for Science and Education (ORISE) Research Fellowship, National Institutes of Health-Centers for Disease Control and Prevention (NIH-CDC) Public Health Dissertation Research Grant R-36, NIH Grant P20 RR16455-06,07 from the IDeA Network of Biomedical Research Excellence-Biomedical Research Infrastructure Network (INBRE-BRIN) program of the National Center for Research Resources, CDC Viral Special Pathogens Branch, and Montana Tech, University of Montana. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 5 Z9 5 U1 1 U2 30 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 26 PY 2012 VL 7 IS 10 AR e47731 DI 10.1371/journal.pone.0047731 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 026GL UT WOS:000310262500019 PM 23110096 ER PT J AU Nguyen, T Rivailler, P Davis, CT Hoa, DT Balish, A Dang, NH Jones, J Vui, DT Simpson, N Huong, NT Shu, B Loughlin, R Ferdinand, K Lindstrom, SE York, IA Klimov, A Donis, RO AF Tung Nguyen Rivailler, Pierre Davis, C. Todd Do Thi Hoa Balish, Amanda Nguyen Hoang Dang Jones, Joyce Dam Thi Vui Simpson, Natosha Ngo Thu Huong Shu, Bo Loughlin, Rosette Ferdinand, Karen Lindstrom, Stephen E. York, Ian A. Klimov, Alexander Donis, Ruben O. TI Evolution of highly pathogenic avian influenza (H5N1) virus populations in Vietnam between 2007 and 2010 SO VIROLOGY LA English DT Article DE Orthomyxovirus; Highly pathogenic avian influenza virus; Phylogenetics; Geographic distribution; H5N1; Evolution; Reassortment ID NEURAMINIDASE INHIBITORS; GENETIC DIVERSITY; SOUTHERN CHINA; POULTRY; SEQUENCE; HEMAGGLUTININ; OUTBREAKS; ALIGNMENT; PROTEIN; PORTS AB We report on the genetic analysis of 213 highly pathogenic avian influenza (HPAI) H5N1 viruses isolated from poultry in Vietnam between 2007 and 2010. Phylogenetic analyses of the viral genomes revealed 38 distinct viral genotypes, 29 were novel and 9 were reported in Vietnam or neighboring countries in recent years. Viruses from only six genotypes persisted beyond one season or year. Thus, most reassortant viruses were transient, suggesting that such genotypes lacked significant fitness advantages. Viruses with clade 2.3.2.1 HA were re-introduced into Vietnam in 2009 and their prevalence rose steeply towards the end of 2010. Clade 2.3.4-like viruses (genotype V) were predominant in northern Vietnam and caused the majority of zoonotic infections, whereas clade 1.1 (genotype Z) viruses were only detected in the Mekong delta region, in southern Vietnam. Antigenic analysis of representative viruses from the four clades indicated substantial drift. Published by Elsevier Inc. C1 [Rivailler, Pierre; Davis, C. Todd; Balish, Amanda; Jones, Joyce; Simpson, Natosha; Shu, Bo; Loughlin, Rosette; Ferdinand, Karen; Lindstrom, Stephen E.; York, Ian A.; Klimov, Alexander; Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Tung Nguyen] Hanoi Univ Agr, Grad Sch, Hanoi, Vietnam. [Tung Nguyen; Do Thi Hoa; Nguyen Hoang Dang; Dam Thi Vui; Ngo Thu Huong] Natl Ctr Vet Diagnost, Dept Anim Hlth, Hanoi, Vietnam. RP Donis, RO (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM rvd6@cdc.gov OI York, Ian/0000-0002-3478-3344 FU Vietnam Avian and Human Influenza Control and Preparedness Project; World Bank; USAID; FAO FX We are grateful to the Vietnam Department of Animal Health (DAH) and DAH Regional Animal Health offices for submission of swab material, tissue homogenates and surveillance data to NCVD. Collection and testing of diagnostic material in Vietnam were financed by the Vietnam Avian and Human Influenza Control and Preparedness Project, the World Bank, USAID and FAO. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry. NR 42 TC 31 Z9 32 U1 0 U2 12 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT 25 PY 2012 VL 432 IS 2 BP 405 EP 416 DI 10.1016/j.virol.2012.06.021 PG 12 WC Virology SC Virology GA 996UZ UT WOS:000308121600019 PM 22818871 ER PT J AU Ferrante, J O'Brien, C Osterhout, C Gilchrist, J AF Ferrante, Jacqueline O'Brien, Craig Osterhout, Cheryl Gilchrist, Julie TI Injuries From Batteries Among Children Aged Less Than 13 Years-United States, 1995-2010 (Reprint from MMWR, vol 34, pg 661-666, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Ferrante, Jacqueline; Osterhout, Cheryl] CDC, Div Hlth Sci, Natl Ctr Injury Prevent & Control, Consumer Prod Safety Commiss, Atlanta, GA 30333 USA. [O'Brien, Craig] CDC, Div Hazard Anal, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Gilchrist, Julie] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. RP Ferrante, J (reprint author), CDC, Div Hlth Sci, Natl Ctr Injury Prevent & Control, Consumer Prod Safety Commiss, Atlanta, GA 30333 USA. EM jferrante@cpsc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 24 PY 2012 VL 308 IS 16 BP 1622 EP 1624 DI 10.1001/jama.2012.12804 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 028PI UT WOS:000310434100007 ER PT J AU Lazarte, RA Litman-Mazo, F Crewalk, JA Keim, DE Baram, M Klassen-Fischer, MK Massif, D Zabielski, ML Sockwell, D Kurkjian, K Moore, A Qvarnstrom, Y Steurer, F AF Lazarte, Raul A. Litman-Mazo, Fern Crewalk, Julie-Ann Keim, Daniel E. Baram, Mujahida Klassen-Fischer, Mary K. Massif, Douglas Zabielski, Marion L. Sockwell, Denise Kurkjian, Katie Moore, Anne Qvarnstrom, Yvonne Steurer, Frank TI Congenital Transmission of Chagas Disease-Virginia, 2010 (Reprint from MMWR, vol 26, pg 477-479, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID UNITED-STATES; NEWBORNS C1 [Moore, Anne; Qvarnstrom, Yvonne; Steurer, Frank] CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Moore, A (reprint author), CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. EM aym2@cdc.gov NR 11 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 24 PY 2012 VL 308 IS 16 BP 1624 EP 1626 DI 10.1001/jama.2012.9296 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 028PI UT WOS:000310434100008 ER PT J AU Trivedi, TK DeSalvo, T Lee, L Palumbo, A Moll, M Curns, A Hall, AJ Patel, M Parashar, UD Lopman, BA AF Trivedi, Tarak K. DeSalvo, Traci Lee, Lore Palumbo, Aimee Moll, Maria Curns, Aaron Hall, Aron J. Patel, Manish Parashar, Umesh D. Lopman, Benjamin A. TI Hospitalizations and Mortality Associated With Norovirus Outbreaks in Nursing Homes, 2009-2010 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID TERM-CARE FACILITIES; MINIMUM DATA SET; UNITED-STATES; GASTROENTERITIS OUTBREAKS; RESIDENT ASSESSMENT; NORWALK VIRUS; ENGLAND; SURVEILLANCE; OUTCOMES; VARIANT AB Context Norovirus outbreaks are common among vulnerable, elderly populations in US nursing homes. Objectives To assess whether all-cause hospitalization and mortality rates are increased during norovirus outbreak vs nonoutbreak periods in nursing homes, and to identify factors associated with increased risk. Design, Setting, and Participants A retrospective cohort study of Medicare-certified nursing homes in Oregon, Wisconsin, and Pennsylvania that reported at least 1 confirmed or suspected norovirus outbreak to the Centers for Disease Control and Prevention's National Outbreak Reporting System (NORS), January 2009 to December 2010. Deaths and hospitalizations occurring among residents of these nursing homes were identified through the Medicare Minimum Data Set (MDS). Main Outcome Measures Rates of all-cause hospitalization and mortality during outbreak compared with nonoutbreak periods were estimated using a random-effects Poisson regression model controlling for background seasonality in both outcomes. Results The cohort consisted of 308 nursing homes that reported 407 norovirus outbreaks to NORS. Per MDS, 67 730 hospitalizations and 26 055 deaths occurred in these homes during the 2-year study. Hospitalization rates were 124.0 (95% CI, 119.4-129.1) vs 109.5 (95% CI, 108.6-110.3) hospitalizations per nursing home-year during outbreak vs nonoutbreak periods, yielding a seasonally adjusted rate ratio (RR) of 1.09 (95% CI, 1.05-1.14). Similarly, mortality rates were 53.7 (95% CI, 50.6-57.0) vs 41.9 (95% CI, 41.4-42.4) deaths per nursing home-year in outbreak vs nonoutbreak periods (seasonally adjusted RR, 1.11; 95% CI, 1.05-1.18). The increases in hospitalizations and mortality were concentrated in the first 2 weeks (week 0 and 1) and the initial week (week 0) of the outbreak, respectively. Homes with lower daily registered nurse (RN) hours per resident (<0.75) had increased mortality rates during norovirus outbreaks compared with baseline (RR, 1.26; 95% CI, 1.14-1.40), while no increased risk (RR, 1.03; 95% CI, 0.96-1.12) was observed in homes with higher daily RN hours per resident (P=.007 by likelihood ratio test); the increase in hospitalization rates did not show a similar pattern. Conclusion Norovirus outbreaks were associated with significant concurrent increases in all-cause hospitalization and mortality in nursing homes. JAMA. 2012;308(16):1668-1675 Published online October 18, 2012. doi:10.1001/jama.2012.14023 www.jama.com C1 [Trivedi, Tarak K.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA 30333 USA. [Curns, Aaron; Hall, Aron J.; Patel, Manish; Parashar, Umesh D.; Lopman, Benjamin A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [DeSalvo, Traci] Wisconsin Dept Hlth Serv, Div Publ Hlth, Madison, WI USA. [Lee, Lore] Oregon Publ Hlth Div, Portland, OR USA. [Palumbo, Aimee; Moll, Maria] Div Infect Dis Epidemiol, Harrisburg, PA USA. [Palumbo, Aimee; Moll, Maria] Penn Dept Hlth, Harrisburg, PA 17108 USA. RP Trivedi, TK (reprint author), Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, 1600 Clifton Rd NE,MS A34, Atlanta, GA 30333 USA. EM ttrivedi@uchicago.edu FU Centers for Disease Control and Prevention (CDC); Pfizer Inc.; CDC FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Mr Trivedi reports being a fellow of The CDC Experience, a 1-year fellowship for medical students in applied epidemiology at the Centers for Disease Control and Prevention (CDC) and made possible by a public/private partnership supported by a grant to the CDC Foundation from external medical affairs, Pfizer Inc. Ms DeSalvo reports receipt of a grant to the institution and travel support to the institution from the CDC; and travel/accommodations/meeting expenses unrelated to activities listed from the Association of Public Health Laboratories and the Council of State and Territorial Epidemiologists. The other authors report no disclosures. NR 32 TC 36 Z9 36 U1 0 U2 18 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 24 PY 2012 VL 308 IS 16 BP 1668 EP 1675 DI 10.1001/jama.2012.14023 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 028PI UT WOS:000310434100021 PM 23079758 ER PT J AU Gu, QP Burt, VL Dillon, CF Yoon, S AF Gu, Qiuping Burt, Vicki L. Dillon, Charles F. Yoon, Sarah TI Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults With Hypertension The National Health and Nutrition Examination Survey, 2001 to 2010 SO CIRCULATION LA English DT Article DE hypertension; population; treatment; trends; NHANES ID LIPID-LOWERING TREATMENT; HEART-ATTACK TRIAL; OFFICE-BASED PHYSICIANS; RANDOMIZED-TRIALS; DRUG-THERAPY; 7TH REPORT; LONG-TERM; PREVENTION; GUIDELINES; COMMITTEE AB Background-The monitoring of national trends in hypertension treatment and control can provide important insight into the effectiveness of primary prevention efforts for cardiovascular disease. The objective of this study was to examine recent trends in antihypertensive medication use and its impact on blood pressure control among US adults with hypertension. Methods and Results-A total of 9320 hypertensive people aged >= 18 years from the National Health and Nutrition Examination Survey 2001 to 2010 were included in this study. The prevalence of antihypertensive medication use increased from 63.5% in 2001 to 2002 to 77.3% in 2009 to 2010 (P-trend <0.01). Most notably, there was a large increase in the use of multiple antihypertensive agents (from 36.8% to 47.7%, P-trend <0.01). Overall, the use of thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers increased by 23%, 57%, 31%, and 100%, respectively. In comparison with monotherapy, single-pill combinations and multiple-pill combinations were associated with 55% and 26% increased likelihoods of blood pressure control, respectively. By the 2009 to 2010 time period, 47% of all hypertensive people and 60% of treated hypertensive people had blood pressure controlled. However, higher treated but uncontrolled hypertension rates continued to persist among older Americans, non-Hispanic blacks, diabetic people, and those with chronic kidney disease. Also, Mexican Americans with hypertension were still less likely to take antihypertensive medication than non-Hispanic whites with hypertension. Conclusions-Antihypertensive medication use and blood pressure control among US adults with hypertension significantly increased over the past 10 years. Combination therapy regimens can facilitate achievement of blood pressure goals. (Circulation. 2012;126:2105-2114.) C1 [Gu, Qiuping] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Gu, QP (reprint author), Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Room 4333,3311 Toledo Rd, Hyattsville, MD 20782 USA. EM qag3@cdc.gov FU National Center for Health Statistics; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute, National Institutes of Health FX This study was funded by the National Center for Health Statistics, Centers for Disease Control and Prevention and the National Heart, Lung, and Blood Institute, National Institutes of Health. NR 33 TC 151 Z9 165 U1 7 U2 27 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD OCT 23 PY 2012 VL 126 IS 17 BP 2105 EP + DI 10.1161/CIRCULATIONAHA.112.096156 PG 12 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 027PO UT WOS:000310365500020 PM 23091084 ER PT J AU Cavanaugh, JS Shah, NS Cain, KP Winston, CA AF Cavanaugh, J. Sean Shah, N. Sarita Cain, Kevin P. Winston, Carla A. TI Survival among Patients with HIV Infection and Smear-Negative Pulmonary Tuberculosis - United States, 1993-2006 SO PLOS ONE LA English DT Article ID ACID-FAST BACILLI; DIAGNOSIS; MALAWI; SEROPREVALENCE; PREVALENCE; MORTALITY; COUNTRIES; PROGRAM; AFRICA; PEOPLE AB Background: In patients with HIV and tuberculosis (TB) in resource-constrained settings, smear-negative disease has been associated with higher mortality than smear-positive disease. Higher reported mortality may be due to misdiagnosis, diagnostic delays, or because smear-negative disease indicates more advanced immune suppression. Methods: We analyzed culture-confirmed, pulmonary TB among patients with TB and HIV in the United States from 1993-2008 to calculate prevalence ratios (PRs) for smear-negative disease by demographic and clinical characteristics. Allowing two years for treatment outcome to be reported, we determined hazard ratios (HRs) for survival by smear status, adjusted for significant covariates on patients before 2006. Results: Among 16,710 cases with sputum smear results, 6,739 (39%) were sputum smear-negative and 9,971 (58%) were sputum smear-positive. The prevalence of smear-negative disease was lower in male patients (PR: 0.89, 95% confidence interval [CI]: 0.86-0.93) and in those who were homeless (PR: 0.92, CI: 0.87-0.97) or used alcohol excessively (PR: 0.91, CI: 0.87-0.95), and higher in persons diagnosed while incarcerated (PR: 1.20, CI: 1.13-1.27). Patients with smear-negative disease had better survival compared to patients with smear-positive disease, both before (HR: 0.82, CI: 0.75-0.90) and after (HR: 0.81, CI: 0.71-0.92) the introduction of combination anti-retroviral therapy. Conclusions: In the United States, smear-negative pulmonary TB in patients with HIV was not associated with higher mortality, in contrast to what has been documented in high TB burden settings. Smear-negative TB can be routinely and definitively diagnosed in the United States, whereas high-burden countries often rely solely on AFB-smear microscopy. This difference could contribute to diagnostic and treatment delays in high-burden countries, possibly resulting in higher mortality. C1 [Cavanaugh, J. Sean; Shah, N. Sarita; Cain, Kevin P.; Winston, Carla A.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Shah, N. Sarita] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. RP Cavanaugh, JS (reprint author), US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. EM hgi7@cdc.gov; saritashah2@gmail.com FU Division of TB Elimination, Centers for Disease Control and Prevention FX This study was funded through the Division of TB Elimination, Centers for Disease Control and Prevention, no specific grants were used. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 43 TC 5 Z9 5 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 23 PY 2012 VL 7 IS 10 AR e47855 DI 10.1371/journal.pone.0047855 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 025MO UT WOS:000310193600032 PM 23110113 ER PT J AU Mody, RK Luna-Gierke, RE Jones, TF Comstock, N Hurd, S Scheftel, J Lathrop, S Smith, G Palmer, A Strockbine, N Talkington, D Mahon, BE Hoekstra, RM Griffin, PM AF Mody, Rajal K. Luna-Gierke, Ruth E. Jones, Timothy F. Comstock, Nicole Hurd, Sharon Scheftel, Joni Lathrop, Sarah Smith, Glenda Palmer, Amanda Strockbine, Nancy Talkington, Deborah Mahon, Barbara E. Hoekstra, Robert M. Griffin, Patricia M. TI Infections in Pediatric Postdiarrheal Hemolytic Uremic Syndrome Factors Associated With Identifying Shiga Toxin-Producing Escherichia coli SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID UNITED-STATES; O157; SURVEILLANCE; GERMANY; STREPTOCOCCUS; EPIDEMIOLOGY; WASHINGTON; PATHOGENS; CHILDREN; DISEASES AB Objective: To describe pathogens identified through routine clinical practice and factors associated with identifying Shiga toxin-producing Escherichia coli (STEC) infection in patients with postdiarrheal hemolytic uremic syndrome (D+HUS). Design: Population-based active surveillance. Setting: Hospitals in the FoodNet surveillance areas from 2000 through 2010. Participants: Children younger than 18 years with D+HUS. Main Exposures: Testing for STEC and demographic and clinical characteristics. Main Outcome Measures: Percentage of patients with evidence of infection with likely HUS-causing agents and associations between exposures and evidence of STEC infection. Results: Of 617 patients, 436 (70.7%) had evidence of infection with likely HUS-causing agents: STEC O157 (401 patients), non-O157 STEC (21 patients), O157 and non-O157 STEC (1 patient), Streptococcus pneumoniae (11 patients), and other pathogens (2 patients). Among patients without microbiological evidence of STEC, 76.9% of those tested had serologic evidence of STEC infection. Children more likely to have evidence of STEC infections included those patients tested for STEC less than 4 days after diarrhea onset, 12 months or older (71.6% vs 27.8% if <12 months of age), with infections as part of an outbreak (94.3% vs 67.3%), with bloody diarrhea (77.2% vs 40.4%), with onset during June through September (76.9% vs 60.1%), with a leukocyte count greater than 18000/mu L (to convert to x 10(9)/L, multiply by 0.001) (75.7% vs 65.3%), or with only moderate anemia (hemoglobin >7.0 g/dL [to convert to grams per liter, multiply by 10] or hematocrit greater than 20% [to convert to a proportion of 1, multiply by 0.01]) (75.1% vs 66.3%). However, many of these associations were weaker among children with thorough STEC testing. Conclusions: Early stool collection for E coli O157 culture and Shiga toxin testing of all children with possible bacterial enteric infection will increase detection of STEC strains causing HUS. In the absence of microbiological evidence of STEC, serologic testing should be performed. Arch Pediatr Adolesc Med. 2012;166(10):902-909. Published online August 6, 2012. doi: 10.1001/archpediatrics.2012.471 C1 [Mody, Rajal K.; Luna-Gierke, Ruth E.; Strockbine, Nancy; Talkington, Deborah; Mahon, Barbara E.; Hoekstra, Robert M.; Griffin, Patricia M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN USA. [Comstock, Nicole] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Hurd, Sharon] Connecticut Emerging Infect Program, New Haven, CT USA. [Scheftel, Joni] Minnesota Dept Hlth, St Paul, MN USA. [Lathrop, Sarah] New Mexico Emerging Infect Program, Albuquerque, NM USA. [Smith, Glenda] New York State Emerging Infect Program, Albany, NY USA. [Palmer, Amanda] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. RP Mody, RK (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Mailstop C-09,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM rmody@cdc.gov FU CDC's Emerging Infections Program FX This study was funded by the CDC's Emerging Infections Program. NR 48 TC 8 Z9 8 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD OCT 23 PY 2012 VL 166 IS 10 BP 902 EP 909 DI 10.1001/archpediatrics.2012.471 PG 8 WC Pediatrics SC Pediatrics GA 014ZL UT WOS:000309414400004 PM 22869280 ER PT J AU Kendall, EA Zaman, RU Naved, RT Rahman, MW Kadir, MA Arman, S Azziz-Baumgartner, E Gurley, ES AF Kendall, Emily A. Zaman, Rashid Uz Naved, Ruchira Tabassum Rahman, Muhammad Waliur Kadir, Mohammad Abdul Arman, Shaila Azziz-Baumgartner, Eduardo Gurley, Emily S. TI Medically unexplained illness and the diagnosis of hysterical conversion reaction (HCR) in women's medicine wards of Bangladeshi hospitals: a record review and qualitative study SO BMC WOMENS HEALTH LA English DT Review DE Women's health services; Mental health; Somatoform disorders; Conversion disorder; Diagnosis; Physician's practice patterns; Health services needs and demand; Bangladesh ID PRIMARY-CARE; PSYCHIATRIC-DISORDERS; SOMATOFORM DISORDERS; INCOME COUNTRIES; SPOUSAL VIOLENCE; SOMATIC SYMPTOMS; FOLLOW-UP; SOMATIZATION; PREVALENCE; DISTRESS AB Background: Frequent reporting of cases of hysterical conversion reaction (HCR) among hospitalized female medical patients in Bangladesh's public hospital system led us to explore the prevalence of "HCR" diagnoses within hospitals and the manner in which physicians identify, manage, and perceive patients whom they diagnose with HCR. Methods: We reviewed admission records from women's general medicine wards in two public hospitals to determine how often and at what point during hospitalization patients received diagnoses of HCR. We also interviewed 13 physicians about their practices and perceptions related to HCR. Results: Of 2520 women admitted to the selected wards in 2008, 6% received diagnoses of HCR. HCR patients had wide-ranging symptoms including respiratory distress, headaches, chest pain, convulsions, and abdominal complaints. Most doctors diagnosed HCR in patients who had any medically-unexplained physical symptom. According to physician reports, women admitted to medical wards for HCR received brief diagnostic evaluations and initial treatment with short-acting tranquilizers or placebo agents. Some were referred to outpatient psychiatric treatment. Physicians reported that repeated admissions for HCR were common. Physicians noted various social factors associated with HCR, and they described failures of the current system to meet psychosocial needs of HCR patients. Conclusions: In these hospital settings, physicians assign HCR diagnoses frequently and based on vague criteria. We recommend providing education to increase general physicians' awareness, skill, and comfort level when encountering somatization and other common psychiatric issues. Given limited diagnostic capacity for all patients, we raise concern that when HCR is used as a "wastebasket" diagnosis for unexplained symptoms, patients with treatable medical conditions may go unrecognized. We also advocate introducing non-physician hospital personnel to address psychosocial needs of HCR patients, assist with triage in a system where both medical inpatient beds and psychiatric services are scarce commodities, and help ensure appropriate follow up. C1 [Kendall, Emily A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Zaman, Rashid Uz] Oxford Policy Management, Oxford OX1 1BN, England. [Naved, Ruchira Tabassum] Icddr B, Ctr Equ & Hlth Syst, Dhaka 1000, Bangladesh. [Rahman, Muhammad Waliur; Arman, Shaila; Gurley, Emily S.] Icddr B, Ctr Communicable Dis, Dhaka 1000, Bangladesh. [Kadir, Mohammad Abdul] Univ Queensland, Hlth Communities Res Ctr, Ipswich, Qld 4305, Australia. [Azziz-Baumgartner, Eduardo] US Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Atlanta, GA 30075 USA. RP Kendall, EA (reprint author), Massachusetts Gen Hosp, Dept Med, Bigelow 740,55 Fruit St, Boston, MA 02114 USA. EM ekendall1@partners.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Kendall, Emily/0000-0002-0083-422X FU Centers for Disease Control and Prevention (CDC), United States of America [U01/CI000298]; National Institutes of Health (NIH), Fogarty International Center [R24 TW007988] FX This study was funded by the Centers for Disease Control and Prevention (CDC), United States of America, under cooperative agreement U01/CI000298, and by the National Institutes of Health (NIH), Fogarty International Center grant R24 TW007988. icddr,b acknowledges with gratitude the commitment of the CDC and NIH to its research efforts. NR 36 TC 0 Z9 0 U1 4 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6874 J9 BMC WOMENS HEALTH JI BMC Womens Health PD OCT 22 PY 2012 VL 12 AR 38 DI 10.1186/1472-6874-12-38 PG 10 WC Public, Environmental & Occupational Health; Obstetrics & Gynecology SC Public, Environmental & Occupational Health; Obstetrics & Gynecology GA 070LR UT WOS:000313508100001 PM 23088583 ER PT J AU Fairlie, T Shapiro, DJ Hersh, AL Hicks, LA AF Fairlie, Tarayn Shapiro, Daniel J. Hersh, Adam L. Hicks, Lauri A. TI National Trends in Visit Rates and Antibiotic Prescribing for Adults With Acute Sinusitis SO ARCHIVES OF INTERNAL MEDICINE LA English DT Letter ID CLINICAL-PRACTICE GUIDELINE; ACUTE RHINOSINUSITIS C1 [Fairlie, Tarayn; Hicks, Lauri A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Resp Dis Branch, Atlanta, GA 30333 USA. [Shapiro, Daniel J.] Univ Calif San Francisco, Div Gen Pediat, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA. [Hersh, Adam L.] Univ Utah, Div Pediat Infect Dis, Salt Lake City, UT USA. RP Fairlie, T (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Resp Dis Branch, 1600 Clifton Rd NE,MS C-25, Atlanta, GA 30333 USA. EM iyl9@cdc.gov NR 9 TC 21 Z9 21 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD OCT 22 PY 2012 VL 172 IS 19 BP 1513 EP 1514 DI 10.1001/archinternmed.2012.4089 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 023XG UT WOS:000310070200019 PM 23007315 ER PT J AU Dalton, T Cegielski, P Akksilp, S Asencios, L Caoili, JC Cho, SN Erokhin, VV Ershova, J Gler, MT Kazennyy, BY Kim, HJ Kliiman, K Kurbatova, E Kvasnovsky, C Leimane, V van der Walt, M Via, LE Volchenkov, GV Yagui, MA Kang, H AF Dalton, Tracy Cegielski, Peter Akksilp, Somsak Asencios, Luis Campos Caoili, Janice Cho, Sang-Nae Erokhin, Vladislav V. Ershova, Julia Tarcela Gler, Ma Kazennyy, Boris Y. Kim, Hee Jin Kliiman, Kai Kurbatova, Ekaterina Kvasnovsky, Charlotte Leimane, Vaira van der Walt, Martie Via, Laura E. Volchenkov, Grigory V. Yagui, Martin A. Kang, Hyungseok CA Global PETTS Investigators TI Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study SO LANCET LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; INDIA; TB AB Background The prevalence of extensively drug-resistant (XDR) tuberculosis is increasing due to the expanded use of second-line drugs in people with multidrug-resistant (MDR) disease. We prospectively assessed resistance to second-line antituberculosis drugs in eight countries. Methods From Jan 1, 2005, to Dec 31, 2008, we enrolled consecutive adults with locally confirmed pulmonary MDR tuberculosis at the start of second-line treatment in Estonia, Latvia, Peru, Philippines, Russia, South Africa, South Korea, and Thailand. Drug-susceptibility testing for study purposes was done centrally at the Centers for Disease Control and Prevention for 11 first-line and second-line drugs. We compared the results with clinical and epidemiological data to identify risk factors for resistance to second-line drugs and XDR tuberculosis. Findings Among 1278 patients, 43.7% showed resistance to at least one second-line drug, 20.0% to at least one second-line injectable drug, and 12.9% to at least one fluoroquinolone. 6.7% of patients had XDR tuberculosis (range across study sites 0.8-15.2%). Previous treatment with second-line drugs was consistently the strongest risk factor for resistance to these drugs, which increased the risk of XDR tuberculosis by more than four times. Fluoroquinolone resistance and XDR tuberculosis were more frequent in women than in men. Unemployment, alcohol abuse, and smoking were associated with resistance to second-line injectable drugs across countries. Other risk factors differed between drugs and countries. Interpretation Previous treatment with second-line drugs is a strong, consistent risk factor for resistance to these drugs, including XDR tuberculosis. Representative drug-susceptibility results could guide in-country policies for laboratory capacity and diagnostic strategies. C1 [Dalton, Tracy; Cegielski, Peter; Ershova, Julia; Kurbatova, Ekaterina; Kvasnovsky, Charlotte] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Akksilp, Somsak] Off Dis Prevent & Control Reg 7, Ubon Ratchathani, Thailand. [Asencios, Luis] Natl TB Reference Lab, Lima, Peru. [Campos Caoili, Janice; Tarcela Gler, Ma] Trop Dis Fdn, Manila, Philippines. [Cho, Sang-Nae] Int TB Res Ctr, Masan, South Korea. [Cho, Sang-Nae] Yonsei Univ, Coll Med, Seoul, South Korea. [Erokhin, Vladislav V.] Russian Acad Med Sci, Cent TB Res Inst, Moscow, Russia. [Kazennyy, Boris Y.] Orel Oblast TB Dispensary, Oryol, Russia. [Kim, Hee Jin] Korean Inst TB, Seoul, South Korea. [Kliiman, Kai] Tartu Univ Hosp, Tartu, Estonia. [Leimane, Vaira] State Agcy, Infectol Ctr Latvia, TB & Lung Dis Clin, Riga, Latvia. [van der Walt, Martie] MRC, Pretoria, South Africa. [Via, Laura E.] NIAID, NIH, Bethesda, MD 20892 USA. [Volchenkov, Grigory V.] Vladimir Oblast TB Dispensary, Vladimir, Russia. [Yagui, Martin A.] Natl Inst Hlth, Lima, Peru. [Kang, Hyungseok] Natl Masan TB Hosp, Masan, South Korea. RP Dalton, T (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd NE,Mailstop F08, Atlanta, GA 30333 USA. EM tldalton@cdc.gov RI Barry, III, Clifton/H-3839-2012; Kuznetsova, Tatiana/I-6882-2013; OI Kuznetsova, Tatiana/0000-0003-3564-7405; Via, Laura/0000-0001-6074-9521 FU US Agency for International Development; Centers for Disease Control and Prevention; National Institutes of Health/National Institute of Allergy and Infectious Diseases; Korean Ministry of Health and Welfare; Centers for Disease Control and Prevention Division of Tuberculosis Elimination; National Institute of Allergy and Infectious Diseases; North Estonia Regional Hospital; Tartu University Hospital, Estonia National Tuberculosis Registry; Estonia National Institute for Health Development; State Agency Infectology Centre of Latvia; Riga Tuberculosis and Lung Disease Clinic; Lima Ciudad and Lima Este Health Districts and reference laboratories; Philippines Tropical Disease Foundation; Orel and Vladimir Oblast Tuberculosis Dispensaries; Central Tuberculosis Research Institute of the Russian Academy of Medical Sciences; South Africa Medical Research Council; KwaZulu-Natal King George V Hospital; Klerksdorp Hospital; Witbank Specialised Tuberculosis Hospital; Jose Pearson Hospital; Korean Institute of Tuberculosis; National Masan Tuberculosis Hospital; Thai Office of Disease Prevention and Control; WHO in Switzerland, Denmark, Peru, and Russia FX US Agency for International Development, Centers for Disease Control and Prevention, National Institutes of Health/National Institute of Allergy and Infectious Diseases, and Korean Ministry of Health and Welfare.; The findings and conclusions in this Article are those of the authors and do not necessarily represent the views of the US CDC. We thank the patients who gave their time and energy to contribute to this study and the doctors, nurses, and microbiologists at each of the enrolment sites for their contributions to this work. We thank the people in the following countries and organisations for support and contributions: Centers for Disease Control and Prevention Division of Tuberculosis Elimination, US Agency for International Development, National Institute of Allergy and Infectious Diseases, North Estonia Regional Hospital, Tartu University Hospital, Estonia National Tuberculosis Registry, Estonia National Institute for Health Development, State Agency Infectology Centre of Latvia, Riga Tuberculosis and Lung Disease Clinic, Lima Ciudad and Lima Este Health Districts and reference laboratories, Philippines Tropical Disease Foundation, Orel and Vladimir Oblast Tuberculosis Dispensaries, Central Tuberculosis Research Institute of the Russian Academy of Medical Sciences, South Africa Medical Research Council, KwaZulu-Natal King George V Hospital, Klerksdorp Hospital, Witbank Specialised Tuberculosis Hospital, Jose Pearson Hospital, Korean Institute of Tuberculosis, National Masan Tuberculosis Hospital, Thai Office of Disease Prevention and Control, and WHO in Switzerland, Denmark, Peru, and Russia. We also thank medical and nursing staff in the Ubon Ratchathani, Srisaket, Sakon Nakon, Yasothon Provinces, Thailand. NR 23 TC 98 Z9 101 U1 3 U2 41 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD OCT 20 PY 2012 VL 380 IS 9851 BP 1406 EP 1417 DI 10.1016/S0140-6736(12)60734-X PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 025NM UT WOS:000310196500030 PM 22938757 ER PT J AU Kothera, L Godsey, MS Doyle, MS Savage, HM AF Kothera, Linda Godsey, Marvin S., Jr. Doyle, Michael S. Savage, Harry M. TI Characterization of Culex pipiens Complex (Diptera: Culicidae) Populations in Colorado, USA Using Microsatellites SO PLOS ONE LA English DT Article ID WEST-NILE-VIRUS; EASTERN UNITED-STATES; CHAIN-REACTION ASSAY; VECTOR COMPETENCE; NORTH-AMERICA; F-STATISTICS; FRONT RANGE; MOSQUITOS; SOFTWARE; QUINQUEFASCIATUS AB Mosquitoes such as those in the Culex pipiens complex are important vectors of disease. This study was conducted to genetically characterize Cx. pipiens complex populations in the state of Colorado, USA, and to determine the number of genetic clusters represented by the data. Thirteen populations located among four major river basins were sampled (n = 597 individuals) using a panel of 14 microsatellites. The lowest-elevation sites had the highest Expected Heterozygosity (H-E) values (range 0.54-0.65). AMOVA results indicated the presence of statistically significant amounts of variation within each level when populations were analyzed as one group or when they were grouped either by river basin or by their position on the east or west side of the Rocky Mountains. Most pairwise F-ST values were significant via permutation test (range 0-0.10), with the highest values from comparisons with Lamar, in southeast CO. A neighbor joining tree based on Cavalli-Sforza and Edwards's chord distances was consistent with the geographic locations of populations, as well as with the AMOVA results. There was a significant isolation by distance effect, and the cluster analysis resolved five groups. Individuals were also assayed with an additional microsatellite marker, Cxpq78, proposed to be monomorphic in Cx. pipiens but polymorphic in the closely related but biologically distinct species Cx. quinquefasciatus. Low frequencies (<= 3%) of Cx. quinquefasciatus alleles for this marker were noted, and mostly confined to populations along the Interstate 25 corridor. Pueblo was distinct in that it had 10% Cx. quinquefasciatus alleles, mostly of one allele size. The degree of population genetic structure observed in this study is in contrast with that of Cx. tarsalis, the other major vector of WNV in the western U.S., and likely reflects the two species' different dispersal strategies. C1 [Kothera, Linda; Godsey, Marvin S., Jr.; Doyle, Michael S.; Savage, Harry M.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Kothera, L (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. EM lkothera@cdc.gov NR 49 TC 4 Z9 4 U1 0 U2 17 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 19 PY 2012 VL 7 IS 10 AR e47602 DI 10.1371/journal.pone.0047602 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 023QT UT WOS:000310050200035 PM 23094068 ER PT J AU Lo, MK Peeples, ME Bellini, WJ Nichol, ST Rota, PA Spiropoulou, CF AF Lo, Michael K. Peeples, Mark E. Bellini, William J. Nichol, Stuart T. Rota, Paul A. Spiropoulou, Christina F. TI Distinct and Overlapping Roles of Nipah Virus P Gene Products in Modulating the Human Endothelial Cell Antiviral Response SO PLOS ONE LA English DT Article ID DEPENDENT INTERFERON INDUCTION; PARAMYXOVIRUS V PROTEINS; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; SENDAI-VIRUS; MESSENGER-RNA; MEASLES-VIRUS; C-PROTEIN; W-PROTEIN; RIG-I AB Nipah virus (NiV) is a highly pathogenic zoonotic paramyxovirus that causes fatal encephalitis in up to 75% of infected humans. Like other paramyxoviruses, NiV employs co-transcriptional mRNA editing during transcription of the phosphoprotein (P) gene to generate additional mRNAs encoding the V and W proteins. The C protein is translated from the P mRNA, but in an alternative reading frame. There is evidence from both in vitro and in vivo studies to show that the P gene products play a role in NiV pathogenesis. We have developed a reverse genetic system to dissect the individual roles of the NiV P gene products in limiting the antiviral response in primary human microvascular lung endothelial cells, which represent important targets in human NiV infection. By characterizing growth curves and early antiviral responses against a number of recombinant NiVs with genetic modifications altering expression of the proteins encoded by the P gene, we observed that multiple elements encoded by the P gene have both distinct and overlapping roles in modulating virus replication as well as in limiting expression of antiviral mediators such as IFN-beta, CXCL10, and CCL5. Our findings corroborate observations from in vivo hamster infection studies, and provide molecular insights into the attenuation and the histopathology observed in hamsters infected with C, V, and W-deficient NiVs. The results of this study also provide an opportunity to verify the results of earlier artificial plasmid expression studies in the context of authentic viral infection. C1 [Lo, Michael K.; Nichol, Stuart T.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30329 USA. [Lo, Michael K.; Bellini, William J.; Rota, Paul A.] Ctr Dis Control & Prevent, Measles Mumps Rubella & Herpes Virus Branch, Atlanta, GA USA. [Peeples, Mark E.] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA. [Peeples, Mark E.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA. RP Lo, MK (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30329 USA. EM mko2@cdc.gov OI Lo, Michael/0000-0002-0409-7896 FU Centers for Disease Control and Prevention; National Institutes of Health [AI069014]; ASM/CCID Postdoctoral Fellowship FX This work was supported by core funding from the Centers for Disease Control and Prevention, and by National Institutes of Health AI069014 to MEP. MKL was supported in part by an ASM/CCID Postdoctoral Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 96 TC 17 Z9 17 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 19 PY 2012 VL 7 IS 10 AR e47790 DI 10.1371/journal.pone.0047790 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 023QT UT WOS:000310050200046 PM 23094089 ER PT J AU Smith, DK Thigpen, MC Nesheim, SR Lampe, MA Paxton, LA Samandari, T Lansky, A Mermin, J Fenton, K AF Smith, D. K. Thigpen, Michael C. Nesheim, Steven R. Lampe, Margaret A. Paxton, Lynn A. Samandari, Taraz Lansky, Amy Mermin, Jonathan Fenton, Kevin TI Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults (Reprinted from MMWR, vol 61, pg 586-589, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Smith, D. K.; Thigpen, Michael C.; Nesheim, Steven R.; Lampe, Margaret A.; Paxton, Lynn A.; Samandari, Taraz; Lansky, Amy; Mermin, Jonathan; Fenton, Kevin] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Smith, DK (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM dsmith1@cdc.gov RI Mermin, Jonathan/J-9847-2012 NR 1 TC 0 Z9 0 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 17 PY 2012 VL 308 IS 15 BP 1516 EP 1519 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 021AQ UT WOS:000309858100008 ER PT J AU Barrera-Badillo, G Ramirez-Gonzalez, E Aparicio-Antonio, R Nunez-Garcia, T Arellano-Suarez, D Alcantara-Perez, P Rodriguez-Maldonado, A Rodriguez-Reyes, B Wong-Arambula, C Gonzalez-Duran, E Ortiz-Alcantara, J Diaz-Quinonez, A Lopez-Martinez, I Reyes-Teran, G Vazquez-Perez, J Avila-Rios, S Castaneda-Lopez, G Robles-Cruz, A Montoya-Fuentes, H Borja-Aburto, V Ruiz-Matus, C Gonzalez-Roldan, JF Kuri-Morales, P Davis, T Villanueva, J Veguilla, V Widdowson, MA Bresee, J Azziz-Baumgartner, E Tokars, J Uyeki, T Klimov, A Lindstrom, S Shu, B Cox, N AF Barrera-Badillo, Gisela Ramirez-Gonzalez, Ernesto Aparicio-Antonio, Rodrigo Nunez-Garcia, Tatiana Arellano-Suarez, Dayanira Alcantara-Perez, Patricia Rodriguez-Maldonado, Abril Rodriguez-Reyes, Brisia Wong-Arambula, Claudia Gonzalez-Duran, Elizabeth Ortiz-Alcantara, Joanna Diaz-Quinonez, Alberto Lopez-Martinez, Irma Reyes-Teran, Gustavo Vazquez-Perez, Joel Avila-Rios, Santiago Castaneda-Lopez, Guadalupe Robles-Cruz, Armando Montoya-Fuentes, Hector Borja-Aburto, Victor Ruiz-Matus, Cuitlahuac Felipe Gonzalez-Roldan, Jesus Kuri-Morales, Pablo Davis, Todd Villanueva, Julie Veguilla, Vic Widdowson, Marc-Alain Bresee, Joseph Azziz-Baumgartner, Eduardo Tokars, Jerome Uyeki, Timothy Klimov, Alexander Lindstrom, Stephen Shu, Bo Cox, Nancy TI Notes from the Field: Highly Pathogenic Avian Influenza A (H7N3) Virus Infection in Two Poultry Workers - Jalisco, Mexico, July 2012 (Reprinted from MMWR, vol 61, pg 726-727, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Barrera-Badillo, Gisela; Ramirez-Gonzalez, Ernesto; Aparicio-Antonio, Rodrigo; Nunez-Garcia, Tatiana; Arellano-Suarez, Dayanira; Alcantara-Perez, Patricia; Rodriguez-Maldonado, Abril; Rodriguez-Reyes, Brisia; Wong-Arambula, Claudia; Gonzalez-Duran, Elizabeth; Ortiz-Alcantara, Joanna; Diaz-Quinonez, Alberto; Lopez-Martinez, Irma] Inst Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico. [Davis, Todd; Villanueva, Julie; Veguilla, Vic; Widdowson, Marc-Alain; Bresee, Joseph; Azziz-Baumgartner, Eduardo; Tokars, Jerome; Uyeki, Timothy; Klimov, Alexander; Lindstrom, Stephen; Shu, Bo; Cox, Nancy] CDC, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. RP Diaz-Quinonez, A (reprint author), Inst Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico. EM alberto.diaz@salud.gob.mx NR 10 TC 0 Z9 0 U1 1 U2 15 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 17 PY 2012 VL 308 IS 15 BP 1519 EP 1520 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 021AQ UT WOS:000309858100009 ER PT J AU Carroll, MD Kit, BK Lacher, DA Shero, ST Mussolino, ME AF Carroll, Margaret D. Kit, Brian K. Lacher, David A. Shero, Susan T. Mussolino, Michael E. TI Trends in Lipids and Lipoproteins in US Adults, 1988-2010 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID CORONARY-HEART-DISEASE; NUTRITION-EXAMINATION-SURVEYS; UNITED-STATES ADULTS; SERUM-CHOLESTEROL; RISK-FACTOR; NATIONAL-HEALTH; PREVALENCE; PLASMA; REDUCTION; OBESITY AB Context Serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) contribute to atherosclerosis and its clinical consequences. Between the periods 1988-1994 and 1999-2002, mean TC and mean LDL-C declined in adults. During this time, there was an increase in the percentage of adults receiving lipid-lowering medications. Geometric mean triglyceride levels increased but mean high-density lipoprotein cholesterol (HDL-C) remained unchanged. Objective To examine trends in serum lipids in adults between 1988 and 2010. Design, Setting, and Participants Three distinct US cross-sectional National Health and Nutrition Examination Surveys, 1988-1994 (n=16 573), 1999-2002 (n=9471), and 2007-2010 (n=11 766). Main Outcome Measures Mean TC, LDL-C, HDL-C, non-HDL-C, and geometric mean triglyceride levels and the prevalence of lipid-lowering medication use. Results Mean TC declined from 206 (95% CI, 205-207) mg/dL in 1988-1994 to 196 (95% CI, 195-198) mg/dL in 2007-2010 (P<.001 for linear trend); mean LDL-C declined from 129 (95% CI, 127-130) mg/dL to 116 (95% CI, 114-117) mg/dL (P<.001 for linear trend). Mean non-HDL-C declined from 155 (95% CI, 153-157) mg/dL in 1988-1994 to 144 (95% CI, 143-145) mg/dL in 2007-2010 (P<.001 for linear trend). Mean HDL-C increased from 50.7 (95% CI, 50.0-51.0) mg/dL during 1988-1994 to 52.5 (95% CI, 51.8-53.2) mg/dL in 2007-2010 (P=.001 for linear trend). Geometric mean serum triglyceride levels increased from 118 (95% CI, 114-121) mg/dL in 1988-1994 to 123 (95% CI, 119-127) mg/dL in 1999-2002 and decreased to 110 (95% CI, 107-113) mg/dL in 2007-2010 (P<.001 for quadratic trend). The prevalence of lipid-lowering medication use increased from 3.4% (95% CI, 2.9%-3.9%) in 1988-1994 to 15.5% (95% CI, 14.7%-16.3%) in 2007-2010 (P<.001 for linear trend). Among adults not receiving lipid-lowering medications, trends in lipids were similar to those reported for adults overall. Among obese adults, mean TC, non-HDL-C, LDL-C, and geometric mean triglycerides declined between 1988 and 2010. Conclusion Between 1988 and 2010, favorable trends in lipid levels have occurred among adults in the United States. JAMA. 2012;308(15):1545-1554 www.jama.com C1 [Carroll, Margaret D.; Kit, Brian K.; Lacher, David A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth & Nutr Examinat Surveys, Hyattsville, MD 20782 USA. [Shero, Susan T.] NHLBI, Div Applicat Res Discoveries, NIH, Bethesda, MD USA. [Mussolino, Michael E.] NHLBI, Div Cardiovasc Sci, NIH, Bethesda, MD USA. RP Carroll, MD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Hlth & Nutr Examinat Surveys, 3311 Toledo Rd,Room 4311, Hyattsville, MD 20782 USA. EM mdc3@cdc.gov FU National Heart, Lung, and Blood Institute, National Institutes of Health [Y1-HC-8039] FX The laboratory analysis of lipids was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health (intra-agency agreement Y1-HC-8039). NR 38 TC 83 Z9 87 U1 0 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 17 PY 2012 VL 308 IS 15 BP 1545 EP 1554 DI 10.1001/jama.2012.13260 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 021AQ UT WOS:000309858100021 PM 23073951 ER PT J AU Williams, PRD Dotson, GS Maier, A AF Williams, Pamela R. D. Dotson, G. Scott Maier, Andrew TI Cumulative Risk Assessment (CRA): Transforming the Way We Assess Health Risks SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID NONCHEMICAL STRESSORS; IPCS FRAMEWORK; RELEVANCE; EXPOSURE; HUMANS; MODE AB Human health risk assessments continue to evolve and now focus on the need for cumulative risk assessment (CRA). CRA involves assessing the combined risk from coexposure to multiple chemical and nonchemical stressors for varying health effects. CRAs are broader in scope than traditional chemical risk assessments because they allow for a more comprehensive evaluation of the interaction between different stressors and their combined impact on human health. Future directions of CRA include greater emphasis on local-level community-based assessments; integrating environmental, occupational, community, and individual risk factors; and identifying and implementing common frameworks and risk metrics for incorporating multiple stressors. C1 [Williams, Pamela R. D.] E Risk Sci LLP, Boulder, CO USA. [Dotson, G. Scott; Maier, Andrew] CDC, NIOSH, Cincinnati, OH USA. [Maier, Andrew] Toxicol Excellence Risk Assessment, Cincinnati, OH USA. RP Williams, PRD (reprint author), E Risk Sci LLP, Boulder, CO USA. EM pwilliams@erisksciences.com FU Intramural CDC HHS [CC999999] NR 47 TC 4 Z9 5 U1 0 U2 50 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD OCT 16 PY 2012 VL 46 IS 20 BP 10868 EP 10874 DI 10.1021/es3025353 PG 7 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 020JO UT WOS:000309805000002 PM 22938698 ER PT J AU Wong, K Mukherjee, B Kahler, AM Zepp, R Molina, M AF Wong, Kelvin Mukherjee, Biplab Kahler, Amy M. Zepp, Richard Molina, Marirosa TI Influence of Inorganic Ions on Aggregation and Adsorption Behaviors of Human Adenovirus SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID ATOMIC-FORCE MICROSCOPY; NATURAL ORGANIC-MATTER; ENTERIC VIRUSES; POROUS-MEDIA; SAND COLUMNS; HYDROPHOBIC INTERACTIONS; DEPOSITION KINETICS; NESTED-PCR; TRANSPORT; WATERS AB In this study, we investigated the influence of inorganic ions on the aggregation and deposition (adsorption) behavior of human adenovirus (HAdV). Experiments were conducted to determine the surface charge and size of HAdV and viral adsorption capacity of sand in different salt conditions. The interfacial potential energy was calculated using extended Derjaguin and Landau, Verwey and Overbeek (XDLVO) and steric hindrance theories to interpret the experimental results. Results showed that different compositions of inorganic ions have minimal effect on varying the iso-electric point pH (pH(lep)) of HAdV (ranging from 3.5 to 4.0). Divalent cations neutralized/shielded virus surface charge much more effectively than monovalent cations at pH above pH(lep). Consequently, at neutral pH the presence of divalent cations enhanced the aggregation of HAdV as well as its adsorption to sand. Aggregation and adsorption behaviors generally agreed with XDLVO theory; however, in the case of minimal electrostatic repulsion, steric force by virus' fibers can increase the energy barrier and distance of secondary minimum, resulting in limited aggregation and deposition. Overall, our results indicated that subsurface water with low hardness residing in sandy soils may have a higher potential of being contaminated by HAdV. C1 [Wong, Kelvin; Zepp, Richard; Molina, Marirosa] US EPA, Ecosyst Res Div, Athens, GA 30605 USA. [Mukherjee, Biplab] Dow Chem Co USA, Midland, MI 48667 USA. [Kahler, Amy M.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Waterborne Dis Prevent Branch, Atlanta, GA 30329 USA. RP Wong, K (reprint author), US EPA, Ecosyst Res Div, 960 Coll Stn Rd, Athens, GA 30605 USA. EM wong.kelvin@epa.gov NR 64 TC 23 Z9 23 U1 7 U2 49 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD OCT 16 PY 2012 VL 46 IS 20 BP 11145 EP 11153 DI 10.1021/es3028764 PG 9 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 020JO UT WOS:000309805000039 PM 22950445 ER PT J AU Balakrishnan, S Vijayan, S Nair, S Subramoniapillai, J Mrithyunjayan, S Wilson, N Satyanarayana, S Dewan, PK Kumar, AMV Karthickeyan, D Willis, M Harries, AD Nair, SA AF Balakrishnan, Shibu Vijayan, Shibu Nair, Sanjeev Subramoniapillai, Jayasankar Mrithyunjayan, Sunilkumar Wilson, Nevin Satyanarayana, Srinath Dewan, Puneet K. Kumar, Ajay M. V. Karthickeyan, Durai Willis, Matthew Harries, Anthony D. Nair, Sreenivas Achuthan TI High Diabetes Prevalence among Tuberculosis Cases in Kerala, India SO PLOS ONE LA English DT Article ID IMPACT AB Background: While diabetes mellitus (DM) is a known risk factor for tuberculosis, the prevalence among TB patients in India is unknown. Routine screening of TB patients for DM may be an opportunity for its early diagnosis and improved management and might improve TB treatment outcomes. We conducted a cross-sectional survey of TB patients registered from June-July 2011 in the state of Kerala, India, to determine the prevalence of DM. Methodology/Principal Findings: A state-wide representative sample of TB patients in Kerala was interviewed and screened for DM using glycosylated hemoglobin (HbA1c); patients self-reporting a history of DM or those with HbA1c >= 6.5% were defined as diabetic. Among 552 TB patients screened, 243(44%) had DM - 128(23%) had previously known DM and 115(21%) were newly diagnosed - with higher prevalence among males and those aged >50years. The number needed to screen(NNS) to find one newly diagnosed case of DM was just four. Of 128 TB patients with previously known DM, 107(84%) had HbA1c >= 7% indicating poor glycemic control. Conclusions/Significance: Nearly half of TB patients in Kerala have DM, and approximately half of these patients were newly-diagnosed during this survey. Routine screening of TB patients for DM using HbA1c yielded a large number of DM cases and offered earlier management opportunities which may improve TB and DM outcomes. However, the most cost-effective ways of DM screening need to be established by futher operational research. C1 [Balakrishnan, Shibu; Dewan, Puneet K.; Kumar, Ajay M. V.; Karthickeyan, Durai; Nair, Sreenivas Achuthan] Off WHO Representat India, Dept TB, New Delhi, India. [Vijayan, Shibu; Wilson, Nevin; Satyanarayana, Srinath] SE Asia Reg Off, Int Union TB & Lung Dis, New Delhi, India. [Nair, Sanjeev] Govt Med Coll, Dept Resp Med, Thiruvananthapuram, Kerala, India. [Subramoniapillai, Jayasankar; Mrithyunjayan, Sunilkumar] Directorate Hlth Serv, Thiruvananthapuram, Kerala, India. [Willis, Matthew] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div TB Eliminat, Atlanta, GA USA. [Harries, Anthony D.] Int Union TB & Lung Dis, Paris, France. [Harries, Anthony D.] London Sch Hyg & Trop Med, London WC1, England. RP Balakrishnan, S (reprint author), Off WHO Representat India, Dept TB, New Delhi, India. EM balakrishnans@rntcp.org FU Central TB Division, Government of India FX Funding support of Indian Rupees 180000/- was provided only by the Central TB Division, Government of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 32 TC 32 Z9 32 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 15 PY 2012 VL 7 IS 10 AR e46502 DI 10.1371/journal.pone.0046502 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 022WO UT WOS:000309995100033 PM 23077512 ER PT J AU Hansen, C Desai, S Bredfeldt, C Cheetham, C Gallagher, M Li, DK Raebel, MA Riedlinger, K Shay, DK Thompson, M Davis, RL AF Hansen, Craig Desai, Sheila Bredfeldt, Christine Cheetham, Craig Gallagher, Mia Li, De-Kun Raebel, Marsha A. Riedlinger, Karen Shay, David K. Thompson, Mark Davis, Robert L. TI A Large, Population-Based Study of 2009 Pandemic Influenza A Virus Subtype H1N1 Infection Diagnosis During Pregnancy and Outcomes for Mothers and Neonates SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID A(H1N1) VIRUS; UNITED-STATES; WOMEN; OSELTAMIVIR; DEATH AB Background. Pregnant women were at increased risk for serious outcomes of 2009 pandemic influenza A virus subtype H1N1 (influenza A[H1N1]pdm09) infection, but little is known about the overall impact of the pandemic on neonatal and maternal outcomes. Methods. We identified live births that occurred from 1 July 2008 through 31 May 2010 in 5 Kaiser Permanente regions. Pregnant women were considered to have influenza if they had a positive result of a laboratory test for influenza virus or if they received a diagnosis of influenza during a period in which seasonal influenza virus or A(H1N1)pdm09 was the predominant circulating virus. Results. There were 111 158 births from 109 015 pregnancies involving 107 889 mothers; 368 pregnant women (0.3%) received a diagnosis of influenza due to seasonal virus, and 959 (0.9%) received a diagnosis of influenza due to A(H1N1)pdm09; 107 688 did not receive an influenza diagnosis. Pregnant women with influenza due to A(H1N1)pdm09 were more likely than women with seasonal influenza infection to be hospitalized within 30 days of the diagnosis (27% vs 12%; odds ratio [OR], 2.84 [95% confidence interval {CI}, 2.01-4.02]). Pregnant women with A(H1N1)pdm09 who started antiviral treatment >= 2 days after the diagnosis were significantly more likely to be hospitalized than those who started antiviral treatment < 2 days after diagnosis (OR, 3.43 [95% CI, 1.55-7.56]). Mothers with seasonal influenza virus infection had an increased risk for having a small-for-gestational-age infant (OR, 1.59 [95% CI, 1.15-2.20]). Conclusions. In this large, geographically diverse population, A(H1N1)pdm09 infection increased the risk for hospitalization during pregnancy. Late initiation of antiviral treatment was also associated with an increased risk for hospitalization. C1 [Hansen, Craig] Kaiser Permanente, Ctr Hlth Res, Eleven Piedmont Ctr, Atlanta, GA 30305 USA. [Shay, David K.; Thompson, Mark] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Bredfeldt, Christine] Kaiser Permanente Midatlantic States, Midatlantic Permanente Res Inst, Rockville, MD USA. [Cheetham, Craig] Kaiser Permanente So Calif, Downey, CA USA. [Li, De-Kun] Kaiser Permanente No Calif, Oakland, CA USA. [Raebel, Marsha A.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA. [Riedlinger, Karen] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. RP Hansen, C (reprint author), Kaiser Permanente, Ctr Hlth Res, Eleven Piedmont Ctr, 3495 Piedmont Rd NE,Ste 110, Atlanta, GA 30305 USA. EM Craig.A.Hansen@kp.org RI Hansen, Craig /C-7543-2014; OI Hansen, Craig /0000-0002-5227-0155; Shay, David/0000-0001-9619-4820 FU KP Center for Effectiveness and Safety Research FX This work was supported by the KP Center for Effectiveness and Safety Research. NR 18 TC 13 Z9 14 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2012 VL 206 IS 8 BP 1260 EP 1268 DI 10.1093/infdis/jis488 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 015RH UT WOS:000309463200014 PM 22859826 ER PT J AU Boom, JA Sahni, LC Payne, DC Gautam, R Lyde, F Mijatovic-Rustempasic, S Bowen, MD Tate, JE Rench, MA Gentsch, JR Parashar, UD Baker, CJ AF Boom, Julie A. Sahni, Leila C. Payne, Daniel C. Gautam, Rashi Lyde, Freda Mijatovic-Rustempasic, Slavica Bowen, Michael D. Tate, Jacqueline E. Rench, Marcia A. Gentsch, Jon R. Parashar, Umesh D. Baker, Carol J. TI Symptomatic Infection and Detection of Vaccine and Vaccine-Reassortant Rotavirus Strains in 5 Children: A Case Series SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID REAL-TIME PCR; CLINICAL SPECIMENS; TRANSMISSION AB Vaccine or vaccine-reassortant rotavirus strains were detected in fecal specimens from 5 of 106 (4.7%) immunocompetent children who required treatment for rotavirus gastroenteritis at a large pediatric hospital in Texas in 2009-2010. Four strains were related to pentavalent rotavirus vaccine, whereas one was related to monovalent rotavirus vaccine. The contribution of these strains to each patient's illness was unclear given that 2 patients had prominent respiratory symptoms and 2 were concurrently infected with another pathogen (group F adenovirus and norovirus). Continued monitoring is necessary to assess the role of vaccine strains and vaccine-reassortant strains in pediatric rotavirus infections. C1 [Boom, Julie A.; Sahni, Leila C.; Rench, Marcia A.; Baker, Carol J.] Texas Childrens Hosp, Ctr Vaccine Awareness & Res, Houston, TX 77030 USA. [Boom, Julie A.; Sahni, Leila C.] Texas Childrens Hosp, Immunizat Project, Houston, TX 77030 USA. [Boom, Julie A.; Rench, Marcia A.; Baker, Carol J.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Baker, Carol J.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Payne, Daniel C.; Gautam, Rashi; Lyde, Freda; Mijatovic-Rustempasic, Slavica; Bowen, Michael D.; Tate, Jacqueline E.; Gentsch, Jon R.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Boom, JA (reprint author), Texas Childrens Hosp, Ctr Vaccine Awareness & Res, 1102 Bates St,Ste 1550, Houston, TX 77030 USA. EM jboom@bcm.edu FU Texas Department of State Health Services; Texas Children's Hospital; Centers for Disease Control and Prevention [CDC-RFA-CI07-70405ARRA09] FX This work was funded by a contract between the Texas Department of State Health Services and Texas Children's Hospital. Texas Department of State Health Services received funding from the Centers for Disease Control and Prevention (funding opportunity number CDC-RFA-CI07-70405ARRA09: Strengthening the Evidence Base: Epidemiology and Laboratory Capacity for Infectious Diseases [ELC] Rotavirus Vaccine Effectiveness) and subsequently contracted with Texas Children's Hospital. Drs Boom and Baker and Ms Sahni report having received institutional support for aspects of the work contained in this manuscript. NR 14 TC 20 Z9 20 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 15 PY 2012 VL 206 IS 8 BP 1275 EP 1279 DI 10.1093/infdis/jis490 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 015RH UT WOS:000309463200016 PM 22872730 ER PT J AU Ruecker, NJ Matsune, JC Wilkes, G Lapen, DR Topp, E Edge, TA Sensen, CW Xiao, LH Neumann, NF AF Ruecker, Norma J. Matsune, Joanne C. Wilkes, Graham Lapen, David R. Topp, Edward Edge, Thomas A. Sensen, Christoph W. Xiao, Lihua Neumann, Norman F. TI Molecular and phylogenetic approaches for assessing sources of Cryptosporidium contamination in water SO WATER RESEARCH LA English DT Article DE Cryptosporidium; Molecular epidemiology; Bioinformatics; Source tracking; Contamination; Health risk ID RIBOSOMAL-RNA GENE; SOURCE TRACKING; PUBLIC-HEALTH; DAIRY-CATTLE; RAW WATER; NEW-YORK; GENOTYPES; SEQUENCE; PARASITES; PARVUM AB The high sequence diversity and heterogeneity observed within species or genotypes of Cryptosporidium requires phylogenetic approaches for the identification of novel sequences obtained from the environment. A long-term study on Cryptosporidium in the agriculturally-intensive South Nation River watershed in Ontario, Canada was undertaken, in which 60 sequence types were detected. Of these sequence types 33 were considered novel with no identical matches in GenBank. Detailed phylogenetic analysis identified that most sequences belonged to 17 previously described species: Cryptosporidium andersoni, Cryptosporidium baileyi, Cryptosporidium hominis, Cryptosporidium paruum, Cryptosporidium ubiquitum, Cryptosporidium meleagridis, muskrat I, muskrat II, deer mouse II, fox, vole, skunk, shrew, W12, W18, W19 and W25 genotypes. In addition, two new genotypes were identified, W27 and W28. C. andersoni and the muskrat II genotype were most frequently detected in the water samples. Species associated with livestock made up 39% of the total molecular detections, while wildlife associated species and genotypes accounted for 55% of the Cryptosporidium identified. The human pathogenic species C. hominis and C. parvum had an overall prevalence of 1.6% in the environment, indicating a small risk to humans from the Cryptosporidium present in the watershed. Phylogenetic analysis and knowledge of host parasite relationships are fundamental in using Cryptosporidium as a source-tracking or human health risk assessment tool. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Neumann, Norman F.] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 2G7, Canada. [Ruecker, Norma J.] Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB, Canada. [Ruecker, Norma J.; Matsune, Joanne C.; Sensen, Christoph W.; Neumann, Norman F.] Alberta Prov Lab Publ Hlth, Calgary, AB, Canada. [Wilkes, Graham; Lapen, David R.] Agr & Agri Food Canada, Ottawa, ON, Canada. [Topp, Edward] Agr & Agri Food Canada, London, ON, Canada. [Edge, Thomas A.] Environm Canada, Natl Water Res Inst, Burlington, ON L7R 4A6, Canada. [Xiao, Lihua] Ctr Dis Control, Atlanta, GA 30333 USA. RP Neumann, NF (reprint author), Univ Alberta, Sch Publ Hlth, Room 357,Civil Elect Engn Bldg CEB, Edmonton, AB T6G 2G7, Canada. EM norman.neumann@albertahealthservices.ca RI Xiao, Lihua/B-1704-2013; Sensen, Christoph/C-1798-2013; Neumann, Norman/J-8310-2015; OI Xiao, Lihua/0000-0001-8532-2727; Sensen, Christoph/0000-0001-9604-8962; Topp, Ed/0000-0002-8273-9372 FU Agriculture and Agri-Food Canada (Government of Canada) through the National Water Quality Research Initiative; Environment Canada (Government of Canada) through the National Agri-Environmental Standards Initiative [NAESI]; Alberta Water Research Institute [AWRI]; Natural Sciences and Engineering Research Council FX This study was funded by Agriculture and Agri-Food Canada (Government of Canada) through the National Water Quality Research Initiative and by Environment Canada (Government of Canada) through the National Agri-Environmental Standards Initiative [NAESI]. Funding support was also obtained through the Alberta Water Research Institute [AWRI]. NJR was supported by a scholarship from the Natural Sciences and Engineering Research Council. NR 60 TC 24 Z9 26 U1 2 U2 32 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0043-1354 J9 WATER RES JI Water Res. PD OCT 15 PY 2012 VL 46 IS 16 BP 5135 EP 5150 DI 10.1016/j.watres.2012.06.045 PG 16 WC Engineering, Environmental; Environmental Sciences; Water Resources SC Engineering; Environmental Sciences & Ecology; Water Resources GA 010LL UT WOS:000309095800023 PM 22841595 ER PT J AU Spradling, PR Rupp, L Moorman, AC Lu, M Teshale, EH Gordon, SC Nakasato, C Boscarino, JA Henkle, EM Nerenz, DR Denniston, MM Holmberg, SD AF Spradling, Philip R. Rupp, Loralee Moorman, Anne C. Lu, Mei Teshale, Eyasu H. Gordon, Stuart C. Nakasato, Cynthia Boscarino, Joseph A. Henkle, Emily M. Nerenz, David R. Denniston, Maxine M. Holmberg, Scott D. CA Chronic Hepatitis Cohort Study TI Hepatitis B and C Virus Infection Among 1.2 Million Persons With Access to Care: Factors Associated With Testing and Infection Prevalence SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID CHRONIC VIRAL-HEPATITIS; UNITED-STATES; DIAGNOSIS; COHORT; RISK AB Background. Little is known about viral hepatitis testing and infection prevalence among persons in private healthcare organizations (HCOs) in the United States. Methods. To determine the frequency of and characteristics associated with viral hepatitis testing and infection prevalence among adults with access to care, we conducted an observational cohort study among 1.25 million adults from 4 US HCOs and included persons with >= 1 clinical encounter during 2006-2008 and >= 12 months of continuous follow-up before 2009. We compared the number of infections identified with the number expected based on adjusted data from the National Health and Nutrition Examination Survey (NHANES). Results. Of 866 886 persons without a previous hepatitis B virus (HBV) diagnosis, 18.8% were tested for HBV infection, of whom 1.4% tested positive; among 865 659 without a previous hepatitis C virus (HCV) diagnosis, 12.7% were tested, of whom 5.5% tested positive. Less than half of those with >= 2 abnormal alanine aminotransferase (ALT) levels were subsequently tested for HBV or HCV. When tested, Asians (adjusted odds ratio [aOR] 6.33 relative to whites) were most likely HBV infected, whereas those aged 50-59 years were most likely HCV infected (aOR 6.04, relative to age <30 years). Based on estimates from NHANES, nearly one-half of HCV and one-fifth of HBV infections in this population were not identified. Conclusions. Even in this population with access to care and lengthy follow-up, only a fraction of expected viral hepatitis infections were identified. Abnormal ALT levels often but not consistently triggered testing. These findings have implications for the identification and care of 4-5 million US residents with HBV and HCV infection. C1 [Spradling, Philip R.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Rupp, Loralee; Lu, Mei; Gordon, Stuart C.; Nerenz, David R.] Henry Ford Hlth Syst, Detroit, MI USA. [Nakasato, Cynthia] Kaiser Permanente, Honolulu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. [Henkle, Emily M.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA. RP Spradling, PR (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div Viral Hepatitis, Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pspradling@cdc.gov FU CDC Foundation; Abbott Laboratories; Genentech; Janssen Pharmaceutical Companies of Johnson Johnson; Vertex Pharmaceuticals; Abbott Pharmaceuticals; Anadys Pharmaceuticals; Bristol-Myers Squibb; Conatus; Eiger Biopharmaceuticals, Inc; Exalenz BioScience; Gilead Pharmaceuticals; GlaxoSmithKline; GlobeImmune; Intercept Pharmaceuticals; Merck; Roche Pharmaceuticals; Tibotec; Zymogenetics; Henry Ford Health System; NIH FX CHeCS was funded by the CDC Foundation, which received grants from Abbott Laboratories; Genentech, A Member of the Roche Group; Janssen Pharmaceutical Companies of Johnson & Johnson; and Vertex Pharmaceuticals.; S. C. G. receives grant/research support from Abbott Pharmaceuticals, Anadys Pharmaceuticals, Bristol-Myers Squibb, Conatus, Eiger Biopharmaceuticals, Inc, Exalenz BioScience, Gilead Pharmaceuticals, GlaxoSmithKline, GlobeImmune, Intercept Pharmaceuticals, Merck, Roche Pharmaceuticals, Tibotec, Vertex Pharmaceuticals, and Zymogenetics; serves as a consultant for Achillion, Bristol-Myers Squibb, CVS Caremark, Gilead Pharmaceuticals, Merck, Salix Pharmaceuticals, Johnson and Johnson, and Vertex; serves on the Data Monitoring Board for Tibotec; and serves as a speaker for Bayer, Gilead, Roche, Merck, and Vertex. M. L. receives grant support to institution from Henry Ford Health System. J. A. B. has consulted for Pfizer and Janssen, and receives grant support from NIH. All other authors report no potential conflicts. NR 24 TC 78 Z9 79 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2012 VL 55 IS 8 BP 1047 EP 1055 DI 10.1093/cid/cis616 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 010BX UT WOS:000309070500008 PM 22875876 ER PT J AU Gutman, J AF Gutman, Julie TI Intermittent Preventive Treatment in Pregnancy With Sulfadoxine-Pyrimethamine: The Controversy Continues SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID CONTROLLED-TRIAL; MALARIA; RESISTANCE; WOMEN C1 Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30322 USA. RP Gutman, J (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, 1600 Clifton Rd NE,Mailstop A06, Atlanta, GA 30322 USA. EM jgutman@cdc.gov FU Intramural CDC HHS [CC999999] NR 15 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2012 VL 55 IS 8 BP 1103 EP 1105 DI 10.1093/cid/cis604 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 010BX UT WOS:000309070500015 PM 22767650 ER PT J AU Gardner, LI Marks, G Craw, JA Wilson, TE Drainoni, ML Moore, RD Mugavero, MJ Rodriguez, AE Bradley-Springer, LA Holman, S Keruly, JC Sullivan, M Skolnik, PR Malitz, F Metsch, LR Raper, JL Giordano, TP AF Gardner, Lytt I. Marks, Gary Craw, Jason A. Wilson, Tracey E. Drainoni, Mari-Lynn Moore, Richard D. Mugavero, Michael J. Rodriguez, Allan E. Bradley-Springer, Lucy A. Holman, Susan Keruly, Jeanne C. Sullivan, Meg Skolnik, Paul R. Malitz, Faye Metsch, Lisa R. Raper, James L. Giordano, Thomas P. CA Retention Care Study Grp TI A Low-Effort, Clinic-Wide Intervention Improves Attendance for HIV Primary Care SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID MEDICAL-CARE; RETENTION; ENGAGEMENT; PREVENTION; INFECTION AB Background. Retention in care for human immunodeficiency virus (HIV)-infected patients is a National HIV/AIDS Strategy priority. We hypothesized that retention could be improved with coordinated messages to encourage patients' clinic attendance. We report here the results of the first phase of the Centers for Disease Control and Prevention/Health Resources and Services Administration Retention in Care project. Methods. Six HIV-specialty clinics participated in a cross-sectionally sampled pretest-posttest evaluation of brochures, posters, and messages that conveyed the importance of regular clinic attendance. 10 018 patients in 20082009 (preintervention period) and 11 039 patients in 2009-2010 (intervention period) were followed up for clinic attendance. Outcome variables were the percentage of patients who kept 2 consecutive primary care visits and the mean proportion of all primary care visits kept. Stratification variables were: new, reengaging, and active patients, HIV RNA viral load, CD4 cell count, age, sex, race or ethnicity, risk group, number of scheduled visits, and clinic site. Data were analyzed by multivariable log-binomial and linear models using generalized estimation equation methods. Results. Clinic attendance for primary care was significantly higher in the intervention versus preintervention year. Overall relative improvement was 7.0% for keeping 2 consecutive visits and 3.0% for the mean proportion of all visits kept (P < .0001). Larger relative improvement for both outcomes was observed for new or reengaging patients, young patients and patients with elevated viral loads. Improved attendance among the new or reengaging patients was consistent across the 6 clinics, and less consistent across clinics for active patients. Conclusion. Targeted messages on staying in care, which were delivered at minimal effort and cost, improved clinic attendance, especially for new or reengaging patients, young patients, and those with elevated viral loads. C1 [Gardner, Lytt I.; Marks, Gary; Craw, Jason A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Craw, Jason A.] ICF Int, Atlanta, GA USA. [Wilson, Tracey E.] Suny Downstate Med Ctr, Dept Community Hlth Sci, Brooklyn, NY 11203 USA. [Holman, Susan] Suny Downstate Med Ctr, Coll Med, Brooklyn, NY 11203 USA. [Holman, Susan] Suny Downstate Med Ctr, Coll Nursing, Brooklyn, NY 11203 USA. [Drainoni, Mari-Lynn] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Drainoni, Mari-Lynn] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA. [Drainoni, Mari-Lynn; Sullivan, Meg] Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA. [Moore, Richard D.; Keruly, Jeanne C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Malitz, Faye] Hlth Resources & Serv Adm, Div Sci & Policy, Rockville, MD USA. [Moore, Richard D.; Raper, James L.] Univ Alabama Birmingham, HIV AIDS Clin 1917, Birmingham, AL USA. [Mugavero, Michael J.; Raper, James L.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Div Infect Dis, Coral Gables, FL 33124 USA. [Metsch, Lisa R.] Univ Miami, Dept Epidemiol & Publ Hlth, Coral Gables, FL 33124 USA. [Bradley-Springer, Lucy A.] Univ Colorado Denver, Sch Med, Denver, CO USA. [Skolnik, Paul R.] Univ Connecticut, Sch Med, Dept Med, Farmington, CT USA. [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Giordano, Thomas P.] DeBakey VA Med Ctr, Houston, TX USA. RP Gardner, LI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Mailstop E-45, Atlanta, GA 30333 USA. EM lig0@cdc.gov FU CDC; HRSA (CDC) [200-2007-23685, 200-2007-23690, 200-2007-23689, 200-2007-23687]; SUNY Downstate Medical Center [200-2007-23684]; [200-2007-23692] FX This work was supported by the CDC and the HRSA (CDC contracts 200-2007-23685 to Baylor College of Medicine, 200-2007-23690 to Boston Medical Center, 200-2007-23689 to Johns Hopkins University School of Medicine, 200-2007-23687 to Research Foundation of the State University of New York, SUNY Downstate Medical Center, 200-2007-23684 to University of Alabama at Birmingham, and 200-2007-23692 to University of Miami Miller School of Medicine). NR 26 TC 33 Z9 33 U1 2 U2 18 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2012 VL 55 IS 8 BP 1124 EP 1134 DI 10.1093/cid/cis623 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 010BX UT WOS:000309070500020 PM 22828593 ER PT J AU Desai, R Hall, AJ Lopman, BA Shimshoni, Y Rennick, M Efron, N Matias, Y Patel, MM Parashar, UD AF Desai, Rishi Hall, Aron J. Lopman, Benjamin A. Shimshoni, Yair Rennick, Marcus Efron, Niv Matias, Yossi Patel, Manish M. Parashar, Umesh D. TI Norovirus Disease Surveillance Using Google Internet Query Share Data SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; GASTROENTERITIS; IMPACT AB Google Internet query share (IQS) data for gastroenteritis-related search terms correlated strongly with contemporaneous national (R-2 = 0.70) and regional (R-2 = 0.74) norovirus surveillance data in the United States. IQS data may facilitate rapid identification of norovirus season onset, elevated peak activity, and potential emergence of novel strains. C1 [Desai, Rishi; Hall, Aron J.; Lopman, Benjamin A.; Patel, Manish M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Shimshoni, Yair; Efron, Niv; Matias, Yossi] Google Labs, Tel Aviv, Israel. [Rennick, Marcus] Boston Publ Hlth Commiss, Boston, MA USA. RP Desai, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS-A34, Atlanta, GA 30333 USA. EM rdesai1@cdc.gov NR 10 TC 17 Z9 17 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 15 PY 2012 VL 55 IS 8 BP E75 EP E78 DI 10.1093/cid/cis579 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 010BX UT WOS:000309070500006 PM 22715172 ER PT J AU Benhafid, M Rguig, A Trivedi, T Elqazoui, M Teleb, N Mouane, N Maltouf, AF Parashar, U Patel, M El Aouad, R AF Benhafid, Mohammed Rguig, Ahmed Trivedi, Tarak Elqazoui, Maria Teleb, Nadia Mouane, Nezha Maltouf, Abdelkarim Filali Parashar, Umesh Patel, Manish El Aouad, Rajae TI Monitoring of rotavirus vaccination in Morocco: Establishing the baseline burden of rotavirus disease SO VACCINE LA English DT Article DE Rotavirus; Diarrheal deaths; Diarrheal hospitalizations; Rotavirus vaccine; Morocco ID MOLECULAR EPIDEMIOLOGY; CHILDHOOD DIARRHEA; SAUDI-ARABIA; CHILDREN; GASTROENTERITIS; SURVEILLANCE; PROGRAMS; EFFICACY; STRAINS; SAFETY AB Background: Rotavirus is a leading cause of childhood morbidity and mortality worldwide. Clinical trials for two rotavirus vaccines recommended by the WHO for global use since 2009 have successfully demonstrated the safety and efficacy of these vaccines in a wide range of countries. To control the burden of severe and fatal diarrheal disease, the Ministry of Health of Morocco introduced the single strain rotavirus vaccine into their national immunization program in 2010. Methods: We employed a standard WHO case definition to identify children under 5 hospitalized with AGE at four hospitals from June 2006 to May 2010 to establish baseline burden of rotavirus disease before introduction of vaccine. Stool samples were collected and tested for rotavirus using a standard enzyme immunoassay. Results: Overall, 40% (741 of 1841) of the children hospitalized with AGE tested positive for rotavirus, making it the single most common cause of severe gastroenteritis among children in Morocco. Applying this prevalence to the estimates of diarrheal hospitalizations and deaths in Morocco, we estimate that rotavirus annually causes 19,646 hospitalizations and 1604 deaths in children under 5 years of age. Discussion: On the basis of these surveillance data, we estimate that 1 in 389 Moroccan children died and 1 in 32 was hospitalized due to rotavirus before their fifth birthday. A considerable proportion of these deaths and hospitalizations should be preventable through vaccination, and the 4 years of stable prevaccine surveillance in Morocco will be a tremendously useful platform for assessing potential changes in the epidemiology of rotavirus disease and measuring impact of the new rotavirus vaccine program in Morocco. Published by Elsevier Ltd. C1 [Trivedi, Tarak; Parashar, Umesh; Patel, Manish] Ctr Dis Control & Prevent, Viral Gastroenteritis Div, Atlanta, GA 30333 USA. [Benhafid, Mohammed; Elqazoui, Maria; El Aouad, Rajae] Minist Hlth, Natl Inst Hyg, Rabat, Morocco. [Rguig, Ahmed] Minist Hlth, Epidemiol & Dis Control Dept, Rabat, Morocco. [Teleb, Nadia] WHO, Reg Off Eastern Mediterranean, Cairo, Egypt. [Mouane, Nezha] Children Hosp, Pediat Unit 3, Nutr Unit, Rabat, Morocco. [Benhafid, Mohammed; Maltouf, Abdelkarim Filali] Mohamed V Univ, Fac Sci Agdal, Rabat, Morocco. RP Trivedi, T (reprint author), Ctr Dis Control & Prevent, Viral Gastroenteritis Div, Atlanta, GA 30333 USA. EM benhafidm@yahoo.fr; rguigahmed@hotmail.com; Ttrivedi@cdc.gov; elqazouimaria@yahoo.fr; telebn@emro.who.int; nezhamouane@hotmail.com; filalilmbm@yahoo.fr; uap2@cdc.gov; aul3@cdc.gov; rajaeelaouad@yahoo.fr OI Trivedi, Tarak/0000-0003-3357-9525; FILALI-MALTOUF, Abdelkarim/0000-0002-2727-3389 FU EMRO WHO FX This surveillance program was supported by funding from EMRO WHO. NR 37 TC 7 Z9 7 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD OCT 12 PY 2012 VL 30 IS 46 BP 6515 EP 6520 DI 10.1016/j.vaccine.2012.08.058 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 028JX UT WOS:000310419700002 PM 22959990 ER PT J AU Hansudewechakul, R Naiwatanakul, T Katana, A Faikratok, W Lolekha, R Thainuea, V McConnell, MS AF Hansudewechakul, Rawiwan Naiwatanakul, Thananda Katana, Abraham Faikratok, Worawan Lolekha, Rangsima Thainuea, Vorapathu McConnell, Michelle S. TI Successful clinical outcomes following decentralization of tertiary paediatric HIV care to a community-based paediatric antiretroviral treatment network, Chiangrai, Thailand, 2002 to 2008 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Article DE Paediatric HIV; HIV care network; paediatric HIV treatment outcomes; task shifting; decentralized HIV care; Thailand ID IMMUNODEFICIENCY-VIRUS-INFECTION; RESOURCE-LIMITED SETTINGS; PROGRAM SCALE-UP; HIV-1-INFECTED CHILDREN; COMBINATION THERAPY; PATIENT OUTCOMES; NATIONAL PROGRAM; UNITED-STATES; MORTALITY; ADHERENCE AB Introduction: Most paediatric antiretroviral treatments (ARTs) in Thailand are limited to tertiary care hospitals. To decentralize paediatric HIV treatment and care, Chiangrai Prachanukroh Hospital (CRH) strengthened a provincial paediatric HIV care network by training community hospital (CH) care teams to receive referrals of children for community follow-up. In this study, we assessed factors associated with death and clinical outcomes of HIV-infected children who received care at CRH and CHs after implementation of a community-based paediatric HIV care network. Methods: Clinical records were abstracted for all children who initiated ART at CRH. Paired Wilcoxon signed rank tests were used to assess CD4% and virological change among all children. Cox proportional hazard models were used to assess factors associated with death. Treatment outcomes (CD4%, viral load (VL) and weight-for-age Z-score (WAZ)) were compared between CRH and CH children who met the criteria for analysis. Results: Between February 2002 and April 2008, 423 HIV-infected children initiated ART and 410 included in the cohort analysis. Median follow-up for the cohort was 28 months (interquartile range (IQR) = 12 to 42); 169 (41%) children were referred for follow- up at CH. As of 31 March 2008, 42 (10%) children had died. Baseline WAZ (< -2 (p = 0.001)) and baseline CD4% (<5% (p = .015)) were independently associated with death. At 48 months, 86% of ART-naive children in follow- up had VL <400 copies/ml. For sub-group analysis, 133 children at CRH and 154 at CHs were included for comparison. Median baseline WAZ was lower in CH children than in CRH children (p = 0.001); in both groups, WAZ, CD4% and VL improved after ART with no difference in rate of WAZ and CD4% gain (p = 0.421 and 0.207, respectively). Conclusions: Children at CHs had more severe immunological suppression and low WAZ at baseline. Community- and tertiary care-based paediatric ART follow-ups result in equally beneficial outcomes with the strengthening of a provincial referral network between tertiary and community care. Nutrition interventions may benefit children in community-based HIV treatment and care. C1 [Naiwatanakul, Thananda; Faikratok, Worawan; Lolekha, Rangsima; Thainuea, Vorapathu; McConnell, Michelle S.] Thailand MOPH US CDC Collaborat, GAP Thailand Asia Reg Program, Nonthaburi 11000, Thailand. [Naiwatanakul, Thananda; Faikratok, Worawan; Lolekha, Rangsima; Thainuea, Vorapathu; McConnell, Michelle S.] CDC SE Asia Reg Off, Nonthaburi 11000, Thailand. [Hansudewechakul, Rawiwan] Chiangrai Prachanukroh Hosp, Minist Publ Hlth, Chiangrai, Thailand. [Katana, Abraham] Univ Oxford, Oxford, England. [McConnell, Michelle S.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Naiwatanakul, T (reprint author), Thailand MOPH US CDC Collaborat, GAP Thailand Asia Reg Program, DDC7 Bldg,Dept Dis Control Tivanon Rd, Nonthaburi 11000, Thailand. EM tdm6@th.cdc.gov FU President's Emergency Plan for AIDS Relief (PEPFAR) through CDC/DGHA; Thai Ministry of Public Health [1U2G GH000616] FX This research has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through CDC/DGHA under the terms of Cooperative Agreement with the Thai Ministry of Public Health #1U2G GH000616. NR 36 TC 11 Z9 11 U1 0 U2 5 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT 11 PY 2012 VL 15 AR 17358 DI 10.7448/IAS.15.2.17358 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 025PC UT WOS:000310202400001 PM 23078768 ER PT J AU Lee, GM Kleinman, K Soumerai, SB Tse, A Cole, D Fridkin, SK Horan, T Platt, R Gay, C Kassler, W Goldmann, DA Jernigan, J Jha, AK AF Lee, Grace M. Kleinman, Ken Soumerai, Stephen B. Tse, Alison Cole, David Fridkin, Scott K. Horan, Teresa Platt, Richard Gay, Charlene Kassler, William Goldmann, Donald A. Jernigan, John Jha, Ashish K. TI Effect of Nonpayment for Preventable Infections in US Hospitals SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CARE-ASSOCIATED INFECTIONS; PAY-FOR-PERFORMANCE; URINARY-TRACT-INFECTIONS; QUALITY-OF-CARE; SAFETY-NET HOSPITALS; HEALTH-CARE; MEDICARE POLICY; PAYMENT POLICY; UNINTENDED CONSEQUENCES; ACQUIRED CONDITIONS AB Background In October 2008, the Centers for Medicare and Medicaid Services (CMS) discontinued additional payments for certain hospital-acquired conditions that were deemed preventable. The effect of this policy on rates of health care-associated infections is unknown. Methods Using a quasi-experimental design with interrupted time series with comparison series, we examined changes in trends of two health care-associated infections that were targeted by the CMS policy (central catheter-associated bloodstream infections and catheter-associated urinary tract infections) as compared with an outcome that was not targeted by the policy (ventilator-associated pneumonia). Hospitals participating in the National Healthcare Safety Network and reporting data on at least one health care-associated infection before the onset of the policy were eligible to participate. Data from January 2006 through March 2011 were included. We used regression models to measure the effect of the policy on changes in infection rates, adjusting for base-line trends. Results A total of 398 hospitals or health systems contributed 14,817 to 28,339 hospital unit-months, depending on the type of infection. We observed decreasing secular trends for both targeted and nontargeted infections long before the policy was implemented. There were no significant changes in quarterly rates of central catheter-associated bloodstream infections (incidence-rate ratio in the postimplementation vs. preimplementation period, 1.00; P = 0.97), catheter-associated urinary tract infections (incidence-rate ratio, 1.03; P = 0.08), or ventilator-associated pneumonia (incidence-rate ratio, 0.99; P = 0.52) after the policy implementation. Our findings did not differ for hospitals in states without mandatory reporting, nor did it differ according to the quartile of percentage of Medicare admissions or hospital size, type of ownership, or teaching status. Conclusions We found no evidence that the 2008 CMS policy to reduce payments for central catheter-associated bloodstream infections and catheter-associated urinary tract infections had any measurable effect on infection rates in U.S. hospitals. (Funded by the Agency for Healthcare Research and Quality.) C1 [Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Ctr Child Hlth Care Studies, Boston, MA 02215 USA. [Lee, Grace M.] Harvard Univ, Sch Med, Div Infect Dis, Boston, MA USA. [Lee, Grace M.] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA. [Kassler, William] Harvard Univ, Sch Publ Hlth, Ctr Medicare Serv, Boston, MA 02115 USA. [Kassler, William] Harvard Univ, Sch Publ Hlth, Ctr Medicaid Serv, Boston, MA 02115 USA. [Goldmann, Donald A.] Harvard Univ, Sch Publ Hlth, Inst Healthcare Improvement, Boston, MA 02115 USA. [Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Fridkin, Scott K.; Horan, Teresa; Jernigan, John] Ctr Dis Control & Prevent, Div Healthcare Qual & Promot, Atlanta, GA USA. RP Lee, GM (reprint author), Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Ctr Child Hlth Care Studies, 133 Brookline Ave,6th Fl, Boston, MA 02215 USA. EM grace.lee@childrens.harvard.edu FU Agency for Healthcare Research and Quality [5R01HS018414-03] FX Supported by a grant from the Agency for Healthcare Research and Quality (5R01HS018414-03, to Dr. Lee). NR 53 TC 94 Z9 98 U1 3 U2 18 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 11 PY 2012 VL 367 IS 15 BP 1428 EP 1437 DI 10.1056/NEJMsa1202419 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 018ID UT WOS:000309652700009 PM 23050526 ER PT J AU Liu, X Chan, CB Qi, Q Xiao, G Luo, HR He, XL Ye, KQ AF Liu, Xia Chan, Chi-Bun Qi, Qi Xiao, Ge Luo, Hongbo R. He, Xiaolin Ye, Keqiang TI Optimization of a Small Tropomyosin-Related Kinase B (TrkB) Agonist 7,8-Dihydroxyflavone Active in Mouse Models of Depression SO JOURNAL OF MEDICINAL CHEMISTRY LA English DT Article ID ASSESSING ANTIDEPRESSANT ACTIVITY; ADULT HIPPOCAMPAL NEUROGENESIS; NEUROTROPHIC FACTORS; DNA-DAMAGE; BRAIN; DISEASE; RECEPTORS; SAFETY; DRUGS; CELLS AB Structure-activity relationship study shows that the catechol group in 7,8-dihdyroxyflavone, a selective small TrkB receptor agonist, is critical for agonistic activity. To improve the poor pharmacolcinetic profiles intrinsic to catechol-containing molecules and to elevate the agonistic effect of the lead compound, we initiated the lead optimization campaign by synthesizing various bioisosteric derivatives. Here we show that the optimized 2-methyl-8-(4'-(pyrrolidin-l-yl)phenyl)chromeno[7,8-d]imidazol-6(1H)-one derivative possesses enhanced TrkB stimulatory activity. Chronic oral administration of this compound significantly reduces the immobility in forced swim test and tail suspension test, two classical antidepressant behavioral animal models, which is accompanied by robust TrkB activation in hippocampus of mouse brain. Further, in vitro ADMET studies demonstrate that this compound possesses the improved features compared to the previous lead compound. Hence, this optimized compound may act as a promising lead candidate for in-depth drug development for treating various neurological disorders including depression. C1 [Liu, Xia; Chan, Chi-Bun; Qi, Qi; Ye, Keqiang] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Xiao, Ge] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Luo, Hongbo R.] Harvard Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02115 USA. [Luo, Hongbo R.] Childrens Hosp, Boston, MA 02115 USA. [He, Xiaolin] Northwestern Univ, Feinberg Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA. RP Ye, KQ (reprint author), Emory Univ, Sch Med, Dept Pathol & Lab Med, 615 Michael St, Atlanta, GA 30322 USA. EM kye@emory.edu RI Qi, Qi/J-3508-2013 OI Qi, Qi/0000-0003-4460-0713 FU NIDCD, National Institutes of Health [RO1 DC010204] FX This work is supported by grant from NIDCD, National Institutes of Health (Grant RO1 DC010204), to K.Y. The authors thank Andrei Halavaty for the help in molecular modeling. The authors are thankful to Dr. Obianyo at the Ye laboratory for proofreading of the manuscript. NR 31 TC 32 Z9 33 U1 4 U2 9 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0022-2623 J9 J MED CHEM JI J. Med. Chem. PD OCT 11 PY 2012 VL 55 IS 19 BP 8524 EP 8537 DI 10.1021/jm301099x PG 14 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA 018ES UT WOS:000309643500029 PM 22984948 ER PT J AU Tynan, MA McAfee, T Promoff, G Pechacek, T AF Tynan, Michael A. McAfee, Tim Promoff, Gabbi Pechacek, Terry TI Consumption of Cigarettes and Combustible Tobacco-United States, 2000-2011 (Reprinted from MMWR, vol 30, pg 565-569, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Tynan, Michael A.; McAfee, Tim; Promoff, Gabbi; Pechacek, Terry] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Tynan, MA (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM mtynan@cdc.gov NR 11 TC 1 Z9 1 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 10 PY 2012 VL 308 IS 14 BP 1422 EP 1424 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 017GY UT WOS:000309579300008 ER PT J AU Bedard, B Kennedy, B Escuyer, V Mitchell, K Duchin, JS Pottinger, P Hurst, S Sharp, K Wickham, T Jackson, S Bamberg, W LeBlanc, P Katz, LM MacCannell, T Noble-Wang, J O'Connell, H Kallen, A Jensen, B Nguyen, DB Kinzer, MH AF Bedard, Brenden Kennedy, Byron Escuyer, Vincent Mitchell, Kara Duchin, Jeffrey S. Pottinger, Paul Hurst, Stanley Sharp, Ken Wickham, Timothy Jackson, Sarah Bamberg, Wendy LeBlanc, Pamela Katz, Linda M. MacCannell, Taranisia Noble-Wang, Judith O'Connell, Heather Kallen, Alexander Jensen, Bette Nguyen, Duc B. Kinzer, Michael H. TI Tattoo-Associated Nontuberculous Mycobacterial Skin Infections-Multiple States, 2011-2012 (Reprinted from MMWR, vol 61, pg 653-656, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Nguyen, Duc B.; Kinzer, Michael H.] CDC, Atlanta, GA 30333 USA. [Escuyer, Vincent; Mitchell, Kara] New York State Dept Hlth, Mycobacteriol Lab, Wadsworth Ctr, Albany, NY 12237 USA. [Duchin, Jeffrey S.] Publ Hlth Seattle & King Cty, Washington, DC USA. [Pottinger, Paul; Hurst, Stanley] Univ Washington, Seattle, WA 98195 USA. [Sharp, Ken; Wickham, Timothy] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA. [Katz, Linda M.] US FDA, Off Colors & Cosmet, Ctr Food Safety & Appl Nutr, Rockville, MD 20857 USA. RP Nguyen, DB (reprint author), CDC, Atlanta, GA 30333 USA. EM vif8@cdc.gov; michael.kinzer@kingcounty.gov NR 1 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 10 PY 2012 VL 308 IS 14 BP 1424 EP 1426 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 017GY UT WOS:000309579300009 ER PT J AU Pal, R Galmin, L Pereira, LE Li, B Zhang, JN Li, D Francis, J McNicholl, JM Weiss, DE Smith, JM AF Pal, Ranajit Galmin, Lindsey Pereira, Lara E. Li, Bin Zhang, Jining Li, Daniel Francis, Jesse McNicholl, Janet M. Weiss, Deborah E. Smith, James M. TI Virological and molecular characterization of a simian human immunodeficiency virus (SHIV) encoding the envelope and reverse transcriptase genes from HIV-1 SO VIROLOGY LA English DT Article DE HIV-1; RT Env SHIV; Rhesus macaques; Microbicide; Entry inhibitor; RT inhibitor ID RHESUS MACAQUES; VAGINAL TRANSMISSION; NONHUMAN-PRIMATES; PRECLINICAL INTERVENTIONS; INTERMITTENT PROPHYLAXIS; TYPE-1; INHIBITORS; INFECTION; MICROBICIDES; PREVENTION AB Simian-human immunodeficiency virus encoding both reverse transcriptase (RT) and envelope genes of HIV-1 (RT Env SHIV) is important for evaluating biomedical prevention modalities for HIV/AIDS. We describe virological characterization of a clade B RT Env SHIV following infection of macaques via multiple routes. In vivo passage of the RT Env SHIV through Indian rhesus macaque enhanced infectivity. Expanded virus had minimal envelope heterogeneity and was inhibited by NNRTIs and CCR5 antagonists. Infection of macaques with RT Env SHIV via mucosal or intravenous routes resulted in stable infection accompanied by peak plasma viremia of approximately 5 x 10(6) copies/ml that was controlled beyond set point. Molecular homogeneity of the virus was maintained following in vivo passage. Inhibition of RT Env SHIV by RT and entry inhibitors and ease of in vivo transmission make it a useful model for testing the efficacy of combinations of entry and RT inhibitors in nonhuman primates. (C) 2012 Elsevier Inc. All rights reserved. C1 [Pal, Ranajit; Galmin, Lindsey; Francis, Jesse; Weiss, Deborah E.] Adv BioSci Labs Inc, Rockville, MD 20850 USA. [Pereira, Lara E.; Li, Bin; Zhang, Jining; Li, Daniel; McNicholl, Janet M.; Smith, James M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Pal, R (reprint author), Adv BioSci Labs Inc, 9800 Med Ctr Dr,Bldg D, Rockville, MD 20850 USA. EM Ranajit.pal@ablinc.com FU NIAID [HHSN272200800020C]; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [Y1-AI-0681-01] FX We would like to thank Dr. Frosso Voulgaropoulou, Dr. Michael Hendry, and Priya Srinivasan for valuable discussions, Jim Treece and Sharon Orndorff for coordinating the animal studies and Dr. Anthony Cristillo for assisting in synergy analysis. Maraviroc was obtained from the AIDS Reagent program whereas CMPD167 and dapivirine were provided by the International Partnership for Microbicides. Work performed at ABL was supported by contract HHSN272200800020C with NIAID and in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Interagency Agreement no. Y1-AI-0681-01. NR 62 TC 6 Z9 6 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD OCT 10 PY 2012 VL 432 IS 1 BP 173 EP 183 DI 10.1016/j.virol.2012.05.034 PG 11 WC Virology SC Virology GA 982FB UT WOS:000307027100020 PM 22769870 ER PT J AU Mei, ZG Pfeiffer, CM Looker, AC Flores-Ayala, RC Lacher, DA Mirel, LB Grummer-Strawn, LM AF Mei, Zuguo Pfeiffer, Christine M. Looker, Anne C. Flores-Ayala, Rafael C. Lacher, David A. Mirel, Lisa B. Grummer-Strawn, Laurence M. TI Serum soluble transferrin receptor concentrations in US preschool children and non-pregnant women of childbearing age from the National Health and Nutrition Examination Survey 2003-2010 SO CLINICA CHIMICA ACTA LA English DT Article DE Serum soluble transferrin receptor; Iron deficiency; Cutoff value; NHANES ID IRON-DEFICIENCY; REFERENCE RANGES; ERYTHROPOIESIS; HITACHI; ASSAY AB Background: Serum soluble transferrin receptor (sTfR) is recommended as a sensitive and accurate measure of iron deficiency (ID) in populations when only a single indicator can be used. The lack of assay standardization and of representative data on the distribution of sTfR in at-risk populations currently limits its utility. Methods: Using data from NHANES 2003-2010, we examined the distribution of sTfR and developed assay-specific cutoff values for defining elevated sTfR in 2 US populations groups: children aged 1-5 y (n=2820) and non-pregnant women aged 15-49 y (n=6575). Results: On average, children had higher geometric mean sTfR concentrations (4.09 mg/l; 95% CI: 4.04-4.14) than non-pregnant women (3.31 mg/l; 95% CI: 3.26-3.35) (p<0.001). Among children, those aged 1-2y (compared to those aged 3-5 y), boys (compared to girls), and non-Hispanic black (NHB) children (compared to non-Hispanic white (NHW) and Mexican-American (MA) children) had higher sTfR concentrations. Among non-pregnant women, adolescents (15-19 y) had higher sTfR concentrations than adults aged 20-34 y but not compared to adults aged 35-49 y; NHB women (compared to NHW and MA women) and multiparous women (compared to nulliparous women) had higher sTfR concentrations. The derived cutoff values (97.5th percentile in a defined healthy reference population) for defining elevated sTfR in the US were 6.00 mg/l for children 1-5 y and 5.33 mg/l for non-pregnant women 15-49 y. Conclusions: A different sTfR cutoff value may be needed in children and non-pregnant women to define ID. Published by Elsevier B.V. C1 [Mei, Zuguo; Flores-Ayala, Rafael C.; Grummer-Strawn, Laurence M.] Ctr Dis Control & Prevent CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Pfeiffer, Christine M.] CDC, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Looker, Anne C.; Lacher, David A.; Mirel, Lisa B.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Mei, ZG (reprint author), Ctr Dis Control & Prevent, Mailstop K-25,4770 Buford Highway, Atlanta, GA 30341 USA. EM zmei@cdc.gov NR 30 TC 9 Z9 9 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD OCT 9 PY 2012 VL 413 IS 19-20 BP 1479 EP 1484 DI 10.1016/j.cca.2012.05.022 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 994IL UT WOS:000307924000010 PM 22705806 ER PT J AU Rowe, AK Onikpo, F Lama, M Deming, MS AF Rowe, Alexander K. Onikpo, Faustin Lama, Marcel Deming, Michael S. TI Evaluating health worker performance in Benin using the simulated client method with real children SO IMPLEMENTATION SCIENCE LA English DT Article DE Benin; Child health; Developing country; Methods; Health services research; Integrated management of childhood illness; Simulated clients ID CHILDHOOD ILLNESS; INTEGRATED MANAGEMENT; QUALITY; CONSULTATIONS; PREVENTION; COUNTRIES; EDUCATION AB Background: The simulated client (SC) method for evaluating health worker performance utilizes surveyors who pose as patients to make surreptitious observations during consultations. Compared to conspicuous observation (CO) by surveyors, which is commonly done in developing countries, SC data better reflect usual health worker practices. This information is important because CO can cause performance to be better than usual. Despite this advantage of SCs, the method's full potential has not been realized for evaluating performance for pediatric illnesses because real children have not been utilized as SCs. Previous SC studies used scenarios of ill children that were not actually brought to health workers. During a trial that evaluated a quality improvement intervention in Benin (the Integrated Management of Childhood Illness [IMCI] strategy), we conducted an SC survey with adult caretakers as surveyors and real children to evaluate the feasibility of this approach and used the results to assess the validity of CO. Methods: We conducted an SC survey and a CO survey (one right after the other) of health workers in the same 55 health facilities. A detailed description of the SC survey process was produced. Results of the two surveys were compared for 27 performance indicators using logistic regression modeling. Results: SC and CO surveyors observed 54 and 185 consultations, respectively. No serious problems occurred during the SC survey. Performance levels measured by CO were moderately higher than those measured by SCs (median CO - SC difference = 16.4 percentage-points). Survey differences were sometimes much greater for IMCI-trained health workers (median difference = 29.7 percentage-points) than for workers without IMCI training (median difference = 3.1 percentage-points). Conclusion: SC surveys can be done safely with real children if appropriate precautions are taken. CO can introduce moderately large positive biases, and these biases might be greater for health workers exposed to quality improvement interventions. C1 [Rowe, Alexander K.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Onikpo, Faustin] Minist Publ Hlth, Direct Dept Sante Publ Oueme & Plateau, Porto Novo, Benin. [Lama, Marcel] Africare Benin, Porto Novo, Benin. [Deming, Michael S.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Rowe, AK (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Mailstop A06,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM axr9@cdc.gov FU United States Agency for International Development's Africa Integrated Malaria Initiative [936-3100] FX This work was supported by the United States Agency for International Development's Africa Integrated Malaria Initiative (project number 936-3100). The funding agency did not influence any aspect of the study or the decision to submit it for publication. NR 29 TC 9 Z9 9 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD OCT 8 PY 2012 VL 7 AR 95 DI 10.1186/1748-5908-7-95 PG 11 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 104AR UT WOS:000315961900001 PM 23043671 ER PT J AU Yoshioka, M Couret, J Kim, F McMillan, J Burkot, TR Dotson, EM Kitron, U Vazquez-Prokopec, GM AF Yoshioka, Miho Couret, Jannelle Kim, Frances McMillan, Joseph Burkot, Thomas R. Dotson, Ellen M. Kitron, Uriel Vazquez-Prokopec, Gonzalo M. TI Diet and density dependent competition affect larval performance and oviposition site selection in the mosquito species Aedes albopictus (Diptera: Culicidae) SO PARASITES & VECTORS LA English DT Article DE Habitat selection; Oviposition; Diet; Conspecific density; Mosquito ID PLAGIORCHIS ELEGANS TREMATODA; AEGYPTI L DIPTERA; OFFSPRING PERFORMANCE; FEEDING-BEHAVIOR; GROWTH-RETARDANT; FECUNDITY; FIELD; DENGUE; POPULATIONS; STARVATION AB Background: Oviposition-site choice is an essential component of the life history of all mosquito species. According to the oviposition-preference offspring-performance (P-P) hypothesis, if optimizing offspring performance and fitness ensures high overall reproductive fitness for a given species, the female should accurately assess details of the heterogeneous environment and lay her eggs preferentially in sites with conditions more suitable to offspring. Methods: We empirically tested the P-P hypothesis using the mosquito species Aedes albopictus by artificially manipulating two habitat conditions: diet (measured as mg of food added to a container) and conspecific density (CD; number of pre-existing larvae of the same species). Immature development (larval mortality, development time to pupation and time to emergence) and fitness (measured as wing length) were monitored from first instar through adult emergence using a factorial experimental design over two ascending gradients of diet (2.0, 3.6, 7.2 and 20 mg food/300 ml water) and CD (0, 20, 40 and 80 larvae/300 ml water). Treatments that exerted the most contrasting values of larval performance were recreated in a second experiment consisting of single-female oviposition site selection assay. Results: Development time decreased as food concentration increased, except from 7.2 mg to 20.0 mg (Two-Way CR ANOVA Post-Hoc test, P > 0.1). Development time decreased also as conspecific density increased from zero to 80 larvae (Two-Way CR ANOVA Post-Hoc test, P < 0.5). Combined, these results support the role of density-dependent competition for resources as a limiting factor for mosquito larval performance. Oviposition assays indicated that female mosquitoes select for larval habitats with conspecifics and that larval density was more important than diet in driving selection for oviposition sites. Conclusions: This study supports predictions of the P-P hypothesis and provides a mechanistic understanding of the underlying factors driving mosquito oviposition site selection. C1 [Vazquez-Prokopec, Gonzalo M.] Emory Univ, Dept Environm Studies, Atlanta, GA 30322 USA. [Kitron, Uriel; Vazquez-Prokopec, Gonzalo M.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Burkot, Thomas R.; Dotson, Ellen M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Burkot, Thomas R.] James Cook Univ, Cairns, Australia. RP Vazquez-Prokopec, GM (reprint author), Emory Univ, Dept Environm Studies, Atlanta, GA 30322 USA. EM gmvazqu@emory.edu RI Burkot, Thomas/C-6838-2013 FU Emory University (Department of Environmental Studies James G. Lester Research Grant); Scholarly Inquiry and Research at Emory (SIRE) program; Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate, U.S. Department of Homeland Security; Fogarty International Center, National Institutes of Health FX We gratefully thank Paul Howell for helping with mosquito bloodfeeding and colony maintenance. This study was supported by funds from Emory University (Department of Environmental Studies James G. Lester Research Grant) and the Scholarly Inquiry and Research at Emory (SIRE) program through a student fellowship to M.Y. Development of the ideas presented here was assisted by support from Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate, U.S. Department of Homeland Security, and the Fogarty International Center, National Institutes of Health. NR 50 TC 21 Z9 22 U1 3 U2 54 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD OCT 8 PY 2012 VL 5 AR 225 DI 10.1186/1756-3305-5-225 PG 11 WC Parasitology SC Parasitology GA 028YE UT WOS:000310461000003 PM 23044004 ER PT J AU Hyde, TB Dentz, H Wang, SA Burchett, HE Mounier-Jack, S Mantel, CF AF Hyde, Terri B. Dentz, Holly Wang, Susan A. Burchett, Helen E. Mounier-Jack, Sandra Mantel, Carsten F. CA New Vaccine Intro Impact Published TI The impact of new vaccine introduction on immunization and health systems: A review of the published literature SO VACCINE LA English DT Review DE New vaccines; Under-utilized vaccines; Introduction; Immunization program; Health system ID INFLUENZAE TYPE-B; PNEUMOCOCCAL CONJUGATE VACCINE; PENTAVALENT ROTAVIRUS VACCINE; HUMAN-PAPILLOMAVIRUS VACCINATION; TECHNICAL ADVISORY GROUPS; C MENINGOCOCCAL DISEASE; ACUTE OTITIS-MEDIA; UNITED-STATES; CHILDHOOD VACCINATION; MASS IMMUNIZATION AB We conducted a systematic review of the published literature to examine the impact of new vaccine introduction on countries' immunization and broader health systems. Six publication databases were searched using 104 vaccine and health system-related search terms. The search yielded 15,795 unique articles dating from December 31, 1911 to September 29, 2010. Based on review of the title and abstract, 654 (4%) of these articles were found to be potentially relevant and were referred for full review. After full review, 130 articles were found to be relevant and included in the analysis. These articles represented vaccines introduced to protect against 10 different diseases (hepatitis A, hepatitis B, Haemophilus influenzae type b disease, human papilloma virus infection, influenza, Japanese encephalitis, meningococcal meningitis, Streptococcus pneumoniae disease, rotavirus diarrhea and typhoid), in various formulations and combinations. Most reviewed articles (97 [75%]) reported experiences in high-income countries. New vaccine introduction was most efficient when the vaccine was introduced into an existing delivery platform and when introduced in combination with a vaccine already in the routine childhood immunization schedule (i.e., as a combination vaccine). New vaccine introduction did not impact coverage of vaccines already included in the routine childhood immunization schedule. The need for increased cold chain capacity was frequently reported. New vaccines facilitated the introduction and widespread use of auto-disable syringes into the immunization and the broader health systems. The importance of training and education for health care workers and social mobilization was frequently noted. There was evidence in high-income countries that new vaccine introduction was associated with reduced healthcare costs. Future evaluations of new vaccine introductions should include the systematic and objective assessment of the impacts on a country's immunization system and broader health system, especially in lower-income countries. Published by Elsevier Ltd. C1 [Hyde, Terri B.; Dentz, Holly] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Wang, Susan A.; Mantel, Carsten F.] World Hlth Org, CH-1204 Geneva, Switzerland. [Burchett, Helen E.; Mounier-Jack, Sandra] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England. RP Hyde, TB (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd NE,MS-A04, Atlanta, GA 30333 USA. EM thyde@cdc.gov; hollydentz@gmail.com; wangsu@who.int; Helen.Burchett@lshtm.ac.uk; Sandra.Mounier-Jack@lshtm.ac.uk; mantelc@who.int RI Chiang, Vincent, Ming-Hsien/D-4312-2016 OI Chiang, Vincent, Ming-Hsien/0000-0002-2029-7863 FU Intramural CDC HHS [CC999999] NR 143 TC 26 Z9 26 U1 1 U2 17 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD OCT 5 PY 2012 VL 30 IS 45 BP 6347 EP 6358 DI 10.1016/j.vaccine.2012.08.029 PG 12 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 024NZ UT WOS:000310117200002 PM 22940378 ER PT J AU Mahamud, A Fiebelkorn, AP Nelson, G Aguon, A McKenna, J Villarruel, G Gallagher, K Ortega-Sanchez, IR AF Mahamud, Abdirahman Fiebelkorn, A. Parker Nelson, George Aguon, Annette McKenna, John Villarruel, Gissela Gallagher, Kathleen Ortega-Sanchez, Ismael R. TI Economic impact of the 2009-2010 Guam mumps outbreak on the public health sector and affected families SO VACCINE LA English DT Article DE Mumps; Economic impact; Outbreak ID UNITED-STATES; MEASLES OUTBREAK; VACCINATION AB Background: The United States Territory of Guam reported a large mumps outbreak of 505 cases during 2009-2010. We assessed the economic impact of the outbreak from the perspectives of the local public health sector and affected families. Methods: Using standard cost analysis methods, we retrospectively identified all public health personnel involved in the outbreak response and surveyed them about their outbreak-related activities. We then estimated the costs of outbreak-related personnel hours and materials. We also assessed out-of-pocket costs and costs incurred for work-time missed for persons with mumps and their families. We defined the analysis period as February 25-October 22, 2010. Results: Seventy-six public health personnel were involved in outbreak response activities. Overall, the response required approximately 8264 person-hours, 2380 miles driven, and 3000 doses of measles-mumps-rubella vaccine ordered. The cost to the public health sector was 256,785 U.S. dollars (USD). Families of 102 persons with mumps were interviewed. An estimated 761 USD per person with mumps was spent by families; 88% of this cost was due to missed days of work. The estimated total cost to families of the 470 persons with mumps during the analysis period was 357,670 USD. Total outbreak-related costs were 614,455 USD. Conclusions: The costs reported underscore the impact of mumps outbreaks in highly vaccinated populations and the need for effective mumps prevention and control strategies. Published by Elsevier Ltd. C1 [Mahamud, Abdirahman; Fiebelkorn, A. Parker; Nelson, George; McKenna, John; Villarruel, Gissela; Gallagher, Kathleen; Ortega-Sanchez, Ismael R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, CDC, Atlanta, GA 30333 USA. [Mahamud, Abdirahman; Nelson, George] CDC, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Gallagher, Kathleen] CDC, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Mahamud, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, CDC, 1600 Clifton Rd NE,Mailstop A-34, Atlanta, GA 30333 USA. EM AMahamud@cdc.gov NR 23 TC 4 Z9 4 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD OCT 5 PY 2012 VL 30 IS 45 BP 6444 EP 6448 DI 10.1016/j.vaccine.2012.08.001 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 024NZ UT WOS:000310117200015 PM 22902678 ER PT J AU Hirve, S Bavdekar, A Pandit, A Juvekar, S Patil, M Preziosi, MP Tang, YX Marchetti, E Martellet, L Findlow, H Elie, C Parulekar, V Plikaytis, B Borrow, R Carlone, G Kulkarni, PS Goel, A Suresh, K Beri, S Kapre, S Jadhav, S Preaud, JM Viviani, S LaForce, FM AF Hirve, Siddhivinayak Bavdekar, Ashish Pandit, Anand Juvekar, Sanjay Patil, Malini Preziosi, Marie-Pierre Tang, Yuxiao Marchetti, Elisa Martellet, Lionel Findlow, Helen Elie, Cheryl Parulekar, Varsha Plikaytis, Brian Borrow, Ray Carlone, George Kulkarni, Prasad S. Goel, Akshay Suresh, Karupothula Beri, Suresh Kapre, Subhash Jadhav, Suresh Preaud, Jean-Marie Viviani, Simonetta LaForce, F. Marc TI Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: A Phase II/III double-blind randomized controlled trial SO VACCINE LA English DT Article ID AFRICAN MENINGITIS BELT; NEISSERIA-MENINGITIDIS; EPIDEMIOLOGY; ANTIBODY; DISEASE AB This study compares the immunogenicity and safety of a single dose of a new meningococcal A conjugate vaccine (PsA-TT, MenAfriVac (TM), Serum Institute of India Ltd., Pune) against the meningococcal group A component of a licensed quadrivalent meningococcal polysaccharide vaccine (PsACWY, Mencevax ACWY (R), GSK, Belgium) 28 days after vaccination in Indian children. This double-blind, randomized, controlled study included 340 Indian children aged 2-10 years enrolled from August to October 2007; 169 children received a dose of PsA-TT while 171 children received a dose of PsACWY. Intention-to-treat analysis showed that 95.2% of children in PsA-TT group had a >= 4-fold response in serum bactericidal titers (rSBA) 28 days post vaccination as compared to 78.2% in the PsACWY group. A significantly higher rSBA GMT (11,209, 95%Cl 9708-12,942) was noted in the PsA-TT group when compared to PsACWY group (2838, 95%Cl 2368-3401). Almost all children in both vaccine groups had a >= 4-fold response in group A-specific IgG concentration but the IgG GMC was significantly greater in the PsA-TT group (89.1 mu g/ml, 95%Cl 75.5-105.0) when compared to the PsACWY group (15.3 mu g/ml, 95%Cl 12.3-19.2). Local and systemic reactions during the 4 days after immunization were similar for both vaccine groups except for tenderness (30.2% in PsA-TT group vs 12.3% in PsACWY group). None of the adverse events or serious adverse events was related to the study vaccines. We conclude that MenAfriVac (TM) is well tolerated and significantly more immunogenic when compared to a licensed polysaccharide vaccine, in 2-to-10-year-old Indian children. (c) 2012 Elsevier Ltd. All rights reserved. C1 [Tang, Yuxiao; Marchetti, Elisa; Martellet, Lionel; Preaud, Jean-Marie; Viviani, Simonetta; LaForce, F. Marc] PATH, Meningitis Vaccine Project, Ferney Voltaire, France. [Hirve, Siddhivinayak; Bavdekar, Ashish; Pandit, Anand; Juvekar, Sanjay; Patil, Malini] King Edward Mem Hosp Res Ctr, Pune, Maharashtra, India. [Preziosi, Marie-Pierre] WHO, Meningitis Vaccine Project, Initiat Vaccine Res, CH-1211 Geneva, Switzerland. [Findlow, Helen; Borrow, Ray] Hlth Protect Agcy, Vaccine Evaluat Unit, Manchester, Lancs, England. [Elie, Cheryl; Plikaytis, Brian; Carlone, George] Ctr Dis Control & Prevent, Atlanta, GA USA. [Parulekar, Varsha] DiagnoSearch LifeSci Pvt Ltd, Bombay, Maharashtra, India. [Kulkarni, Prasad S.; Goel, Akshay; Suresh, Karupothula; Beri, Suresh; Kapre, Subhash; Jadhav, Suresh] Serum Inst India Ltd, Pune, Maharashtra, India. RP LaForce, FM (reprint author), PATH, 455 Massachusetts Ave NW, Washington, DC 20001 USA. EM fmarclaforce@gmail.com FU Meningitis Vaccine Project; Serum Institute of India, Ltd; Health and Demographic Surveillance System; Vadu community FX The authors gratefully acknowledge financial support from the Meningitis Vaccine Project; the Serum Institute of India, Ltd. for vaccines, and technical support; DiagnoSearch for their help with pharmacovigilance, data management, and logistics; and the laboratories at CDC, Atlanta, GA, USA (Julie Chatt-Soroka and Jeffrey Martin), and the Health Protection Agency, Manchester, UK for ELISA and rSBA testing, respectively. The authors gratefully acknowledge the assistance of Nicole Basta who helped draft the initial manuscript. The study received support from the Health and Demographic Surveillance System, Vadu which is a member of the INDEPTH Network. Lastly, the authors express their gratitude to the children and their parents and the Vadu community as a whole for their support and participation in the study. NR 16 TC 15 Z9 15 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD OCT 5 PY 2012 VL 30 IS 45 BP 6456 EP 6460 DI 10.1016/j.vaccine.2012.08.004 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 024NZ UT WOS:000310117200017 PM 22898557 ER PT J AU Klimov, AI Garten, R Russell, C Barr, IG Besselaar, TG Daniels, R Engelhardt, OG Grohmann, G Itamura, S Kelso, A McCauley, J Odagiri, T Smith, D Tashiro, M Xu, XY Webby, R Wang, DY Ye, ZP Shu, YL Zhang, WQ Cox, N AF Klimov, Alexander I. Garten, Rebecca Russell, Colin Barr, Ian G. Besselaar, Terry G. Daniels, Rod Engelhardt, Othmar G. Grohmann, Gary Itamura, Shigeyuki Kelso, Anne McCauley, John Odagiri, Takato Smith, Derek Tashiro, Masato Xu, Xiyan Webby, Richard Wang, Dayan Ye, Zhiping Shu Yuelong Zhang, Wenqing Cox, Nancy CA Writing Committee World Hlth Org C TI WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011 SO VACCINE LA English DT Article DE Influenza; Vaccine; Human; Seasonal ID SUBSTITUTION AB In February and September each year the World Health Organisation (WHO) recommends influenza viruses to be included in influenza vaccines for the forthcoming winters in the Northern and Southern Hemispheres respectively. These recommendations are based on data collected by National Influenza Centres (NIC) through the Global Influenza Surveillance and Response System (GISRS) and a more detailed analysis of representative and potential antigenically variant influenza viruses from the WHO Collaborating Centres for Influenza (WHO CCs) and Essential Regulatory Laboratories (ERLs). This article provides a detailed summary of the antigenic and genetic properties of viruses and additional background data used by WHO experts during development of the recommendations for the 2012 Southern Hemisphere influenza vaccine composition. Published by Elsevier Ltd. C1 [Klimov, Alexander I.] Ctr Dis Control & Prevent, WHO Collaborating Ctr Surveillance Epidemiol & Co, Influenza Div, Atlanta, GA 30333 USA. [Barr, Ian G.; Kelso, Anne] WHO Collaborating Ctr Reference & Res Influenza, VIDRL, Melbourne, Australia. [Daniels, Rod; McCauley, John] Natl Inst Med Res, WHO Collaborating Ctr Reference & Res Influenza, London, England. [Itamura, Shigeyuki; Odagiri, Takato; Tashiro, Masato] NIID, WHO Collaborating Ctr Reference & Res Influenza, Tokyo, Japan. [Webby, Richard] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Wang, Dayan; Shu Yuelong] CNIC, WHO Collaborating Ctr Reference & Res Influenza, Beijing, Peoples R China. [Besselaar, Terry G.; Zhang, Wenqing] WHO Global Influenza Programme GIP, Geneva, Switzerland. [Engelhardt, Othmar G.] HPA, NIBSC, Potters Bar, Herts, England. [Ye, Zhiping] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA. [Grohmann, Gary] TGA, Canberra, ACT, Australia. [Russell, Colin; Smith, Derek] Univ Cambridge, Cambridge CB2 1TN, England. [Russell, Colin; Smith, Derek] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. RP Klimov, AI (reprint author), Ctr Dis Control & Prevent, WHO Collaborating Ctr Surveillance Epidemiol & Co, Influenza Div, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM AKlimov@cdc.gov OI Russell, Colin/0000-0002-2113-162X FU Medical Research Council [MC_U117512708, MC_U117512723, MC_U117585868] NR 13 TC 33 Z9 34 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD OCT 5 PY 2012 VL 30 IS 45 BP 6461 EP 6471 DI 10.1016/j.vaccine.2012.07.089 PG 11 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 024NZ UT WOS:000310117200018 PM 22917957 ER PT J AU Petersen, LR Fischer, M AF Petersen, Lyle R. Fischer, Marc TI Unpredictable and Difficult to Control - The Adolescence of West Nile Virus SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Petersen, Lyle R.; Fischer, Marc] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Petersen, LR (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. NR 5 TC 28 Z9 28 U1 0 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 4 PY 2012 VL 367 IS 14 BP 1281 EP 1284 DI 10.1056/NEJMp1210537 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 014WJ UT WOS:000309406100003 PM 23013055 ER PT J AU Kaptoge, S Di Angelantonio, E Pennells, L Wood, AM White, IR Gao, P Walker, M Thompson, A Sarwar, N Caslake, M Butterworth, AS Amouyel, P Assmann, G Bakker, SJL Barr, ELM Barrett-Connor, E Benjamin, EJ Bjorkelund, C Brenner, H Brunner, E Clarke, R Cooper, JA Cremer, P Cushman, M Dagenais, GR D'Agostino, RB Dankner, R Davey-Smith, G Deeg, D Dekker, JM Engstrom, G Folsom, AR Fowkes, FGR Gallacher, J Gaziano, JM Giampaoli, S Gillum, RF Hofman, A Howard, BV Ingelsson, E Iso, H Jorgensen, T Kiechl, S Kitamura, A Kiyohara, Y Koenig, W Kromhout, D Kuller, LH Lawlor, DA Meade, TW Nissinen, A Nordestgaard, BG Onat, A Panagiotakos, DB Psaty, BM Rodriguez, B Rosengren, A Salomaa, V Kauhanen, J Salonen, JT Shaffer, JA Shea, S Ford, I Stehouwer, CDA Strandberg, TE Tipping, RW Tosetto, A Wassertheil-Smoller, S Wennberg, P Westendorp, RG Whincup, PH Wilhelmsen, L Woodward, M Lowe, GDO Wareham, NJ Khaw, KT Sattar, N Packard, CJ Gudnason, V Ridker, PM Pepys, MB Thompson, SG Danesh, J AF Kaptoge, Stephen Di Angelantonio, Emanuele Pennells, Lisa Wood, Angela M. White, Ian R. Gao, Pei Walker, Matthew Thompson, Alexander Sarwar, Nadeem Caslake, Muriel Butterworth, Adam S. Amouyel, Philippe Assmann, Gerd Bakker, Stephan J. L. Barr, Elizabeth L. M. Barrett-Connor, Elizabeth Benjamin, Emelia J. Bjorkelund, Cecilia Brenner, Hermann Brunner, Eric Clarke, Robert Cooper, Jackie A. Cremer, Peter Cushman, Mary Dagenais, Gilles R. D'Agostino, Ralph B., Sr. Dankner, Rachel Davey-Smith, George Deeg, Dorly Dekker, Jacqueline M. Engstrom, Gunnar Folsom, Aaron R. Fowkes, F. Gerry R. Gallacher, John Gaziano, J. Michael Giampaoli, Simona Gillum, Richard F. Hofman, Albert Howard, Barbara V. Ingelsson, Erik Iso, Hiroyasu Jorgensen, Torben Kiechl, Stefan Kitamura, Akihiko Kiyohara, Yutaka Koenig, Wolfgang Kromhout, Daan Kuller, Lewis H. Lawlor, Debbie A. Meade, Tom W. Nissinen, Aulikki Nordestgaard, Borge G. Onat, Altan Panagiotakos, Demosthenes B. Psaty, Bruce M. Rodriguez, Beatriz Rosengren, Annika Salomaa, Veikko Kauhanen, Jussi Salonen, Jukka T. Shaffer, Jonathan A. Shea, Steven Ford, Ian Stehouwer, Coen D. A. Strandberg, Timo E. Tipping, Robert W. Tosetto, Alberto Wassertheil-Smoller, Sylvia Wennberg, Patrik Westendorp, Rudi G. Whincup, Peter H. Wilhelmsen, Lars Woodward, Mark Lowe, Gordon D. O. Wareham, Nicholas J. Khaw, Kay-Tee Sattar, Naveed Packard, Chris J. Gudnason, Vilmundur Ridker, Paul M. Pepys, Mark B. Thompson, Simon G. Danesh, John CA Emerging Risk Factors TI C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID CORONARY-HEART-DISEASE; NONVASCULAR MORTALITY; PRACTICE GUIDELINES; PRIMARY PREVENTION; COST-EFFECTIVENESS; STATIN THERAPY; RISK PROFILE; ASSOCIATION; INFLAMMATION; METAANALYSIS AB Background There is debate about the value of assessing levels of C-reactive protein (CRP) and other biomarkers of inflammation for the prediction of first cardiovascular events. Methods We analyzed data from 52 prospective studies that included 246,669 participants without a history of cardiovascular disease to investigate the value of adding CRP or fibrinogen levels to conventional risk factors for the prediction of cardiovascular risk. We calculated measures of discrimination and reclassification during follow-up and modeled the clinical implications of initiation of statin therapy after the assessment of CRP or fibrinogen. Results The addition of information on high-density lipoprotein cholesterol to a prognostic model for cardiovascular disease that included age, sex, smoking status, blood pressure, history of diabetes, and total cholesterol level increased the C-index, a measure of risk discrimination, by 0.0050. The further addition to this model of information on CRP or fibrinogen increased the C-index by 0.0039 and 0.0027, respectively (P < 0.001), and yielded a net reclassification improvement of 1.52% and 0.83%, respectively, for the predicted 10-year risk categories of "low" (< 10%), " intermediate" (10% to < 20%), and "high" (>= 20%) (P < 0.02 for both comparisons). We estimated that among 100,000 adults 40 years of age or older, 15,025 persons would initially be classified as being at intermediate risk for a cardiovascular event if conventional risk factors alone were used to calculate risk. Assuming that statin therapy would be initiated in accordance with Adult Treatment Panel III guidelines (i.e., for persons with a predicted risk of >= 20% and for those with certain other risk factors, such as diabetes, irrespective of their 10-year predicted risk), additional targeted assessment of CRP or fibrinogen levels in the 13,199 remaining participants at intermediate risk could help prevent approximately 30 additional cardiovascular events over the course of 10 years. Conclusions In a study of people without known cardiovascular disease, we estimated that under current treatment guidelines, assessment of the CRP or fibrinogen level in people at intermediate risk for a cardiovascular event could help prevent one additional event over a period of 10 years for every 400 to 500 people screened. (Funded by the British Heart Foundation and others.) C1 [Kaptoge, Stephen] Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Emerging Risk Factors Collaborat Coordinating Ctr, Cambridge CB1 8RN, England. [White, Ian R.] MRC, Biostat Unit, Cambridge CB2 2BW, England. [Caslake, Muriel; Ford, Ian; Lowe, Gordon D. O.; Sattar, Naveed; Packard, Chris J.] Univ Glasgow, Glasgow, Lanark, Scotland. [Amouyel, Philippe] Inst Pasteur, Lille, France. [Bakker, Stephan J. L.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [Bakker, Stephan J. L.] Univ Groningen, Groningen, Netherlands. [Barrett-Connor, Elizabeth] Univ Calif San Diego, San Diego, CA 92103 USA. [Benjamin, Emelia J.; D'Agostino, Ralph B., Sr.] Boston Univ, Boston, MA 02215 USA. [Bjorkelund, Cecilia; Wilhelmsen, Lars] Univ Gothenburg, Gothenburg, Sweden. [Brenner, Hermann] German Canc Res Ctr, D-6900 Heidelberg, Germany. [Brunner, Eric; Cooper, Jackie A.; Pepys, Mark B.] UCL, London, England. [Clarke, Robert] Univ Oxford, Oxford, England. [Cremer, Peter] Klinikum Univ Munchen LMU, Munich, Germany. [Cushman, Mary] Univ Vermont, Burlington, ON, Canada. [Dagenais, Gilles R.] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada. [Dankner, Rachel] Gertner Inst Epidemiol & Hlth Policy Res, Ramat Gan, Israel. [Davey-Smith, George; Lawlor, Debbie A.] Univ Bristol, Bristol, Avon, England. [Deeg, Dorly; Dekker, Jacqueline M.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands. [Engstrom, Gunnar] Lund Univ, Lund, Sweden. [Folsom, Aaron R.] Univ Minnesota, Minneapolis, MN USA. [Fowkes, F. Gerry R.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Gallacher, John] Cardiff Univ, Cardiff, S Glam, Wales. [Gaziano, J. Michael] Harvard Univ, Sch Med, Boston, MA USA. [Giampaoli, Simona] Ist Super Sanita, I-00161 Rome, Italy. [Gillum, Richard F.] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Hofman, Albert] Erasmus MC, Rotterdam, Netherlands. [Howard, Barbara V.] Medstar Hlth Res Inst, Hyattsville, MD USA. [Ingelsson, Erik] Karolinska Inst, Stockholm, Sweden. [Iso, Hiroyasu] Osaka Univ, Osaka, Japan. [Jorgensen, Torben] Glostrup Univ Hosp, Glostrup, Denmark. [Jorgensen, Torben; Nordestgaard, Borge G.] Univ Copenhagen, Copenhagen, Denmark. [Kiechl, Stefan] Med Univ Innsbruck, Innsbruck, Austria. [Kitamura, Akihiko] Osaka Med Ctr Hlth Sci & Promot, Osaka, Japan. [Kiyohara, Yutaka] Kyushu Univ, Fukuoka 812, Japan. [Koenig, Wolfgang] Univ Ulm, Med Ctr, Ulm, Germany. [Kromhout, Daan] Wageningen Univ, Wageningen, Netherlands. [Kuller, Lewis H.] Univ Pittsburgh, Pittsburgh, PA USA. [Meade, Tom W.] London Sch Hyg & Trop Med, London WC1, England. [Nissinen, Aulikki] Natl Inst Hlth & Welf, Helsinki, Finland. [Onat, Altan] Istanbul Univ, Istanbul, Turkey. [Panagiotakos, Demosthenes B.] Harokopio Univ, Athens, Greece. [Psaty, Bruce M.] Univ Washington, Seattle, WA 98195 USA. [Rodriguez, Beatriz] Univ Hawaii, Honolulu, HI 96822 USA. [Rosengren, Annika] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden. [Kauhanen, Jussi] Univ Eastern Finland, Kuopio, Finland. [Salomaa, Veikko] Natl Inst Hlth & Welf, Helsinki, Finland. [Salonen, Jukka T.] Metab Analyt Serv, Helsinki, Finland. [Shaffer, Jonathan A.; Shea, Steven] Columbia Univ, Med Ctr, New York, NY USA. [Stehouwer, Coen D. A.] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Strandberg, Timo E.] Univ Helsinki, Oulu, Finland. [Strandberg, Timo E.] Univ Oulu, Oulu, Finland. [Tipping, Robert W.] Merck Res Labs, Philadelphia, PA USA. [Tosetto, Alberto] San Bortolo Hosp, Vicenza, Italy. [Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, New York, NY USA. [Wennberg, Patrik] Umea Univ, Umea, Sweden. [Westendorp, Rudi G.] Leiden Univ, Med Ctr, Leiden, Netherlands. [Whincup, Peter H.] St Georges Univ London, London, England. [Woodward, Mark] Univ Sydney, Sydney, NSW 2006, Australia. [Wareham, Nicholas J.] MRC Epidemiol Unit, Cambridge, England. [Gudnason, Vilmundur] Iceland Heart Assoc, Kopavogur, Iceland. [Gudnason, Vilmundur] Univ Iceland, Kopavogur, Iceland. [Ridker, Paul M.] Brigham & Womens Hosp, Boston, MA 02115 USA. RP Kaptoge, S (reprint author), Univ Cambridge, Dept Publ Hlth & Primary Care, Strangeways Res Lab, Emerging Risk Factors Collaborat Coordinating Ctr, Worts Causeway, Cambridge CB1 8RN, England. EM erfc@phpc.cam.ac.uk RI Shaffer, Jonathan/B-2783-2013; Panagiotakos, Demosthenes/C-9776-2013; Kromhout, Daan/A-8566-2014; Schottker, Ben/F-8183-2014; Woodward, Mark/D-8492-2015; Bakker, Stephan/J-4023-2015; Gudnason, Vilmundur/K-6885-2015; Brenner, Hermann/B-4627-2017; Davey Smith, George/A-7407-2013; OI Benn, Marianne/0000-0002-1701-595X; Kivimaki, Mika/0000-0002-4699-5627; Whincup, Peter/0000-0002-5589-4107; Engstrom, Gunnar/0000-0002-8618-9152; Benjamin, Emelia/0000-0003-4076-2336; Jorgensen, Torben/0000-0001-9453-2830; Marmot, Michael/0000-0002-2431-6419; strandberg, timo/0000-0001-6299-925X; Lawlor, Debbie A/0000-0002-6793-2262; Schottker, Ben/0000-0002-1217-4521; Bakker, Stephan/0000-0003-3356-6791; Gudnason, Vilmundur/0000-0001-5696-0084; Brenner, Hermann/0000-0002-6129-1572; Davey Smith, George/0000-0002-1407-8314; Alexander, Myriam/0000-0002-6848-9370; Di Angelantonio, Emanuele/0000-0001-8776-6719 FU British Heart Foundation FX Funded by the British Heart Foundation and others. NR 30 TC 312 Z9 319 U1 9 U2 71 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD OCT 4 PY 2012 VL 367 IS 14 BP 1310 EP 1320 DI 10.1056/NEJMoa1107477 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 014WJ UT WOS:000309406100007 ER PT J AU Getahun, H Raviglione, M Varma, JK Cain, K Samandari, T Popovic, T Frieden, T AF Getahun, Haileyesus Raviglione, Mario Varma, Jay K. Cain, Kevin Samandari, Taraz Popovic, Tanja Frieden, Thomas TI CDC Grand Rounds: the TB/HIV Syndemic (Reprinted from MMWR vol 26, pg 484, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID HIV-ASSOCIATED TUBERCULOSIS; INFECTION; SETTINGS C1 [Cain, Kevin] CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Getahun, Haileyesus; Raviglione, Mario] WHO, CH-1211 Geneva, Switzerland. [Varma, Jay K.] CDC, Global Dis Detect Br, Ctr Global Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Popovic, Tanja; Frieden, Thomas] CDC, Off Director, Atlanta, GA 30333 USA. RP Cain, K (reprint author), CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM kcain@cdc.gov NR 22 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 3 PY 2012 VL 308 IS 13 BP 1311 EP + PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 014IV UT WOS:000309369300009 ER PT J AU Weltman, A Smee, A Moll, M Deasy, M Pringle, J Williams, I Behravesh, CB Wright, J Routh, J Longenberger, A AF Weltman, Andre Smee, Aaron Moll, Maria Deasy, Marshall Pringle, Jeshua Williams, Ian Behravesh, Casey Barton Wright, Jennifer Routh, Janell Longenberger, Allison TI Notes From the Field: Outbreak of Salmonellosis Associated With Pet Turtle Exposures-United States, 2011 (Reprinted from MMWR vol 61, pg 79, 2012) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Routh, Janell; Longenberger, Allison] CDC, EIS, Atlanta, GA 30333 USA. [Pringle, Jeshua; Williams, Ian; Behravesh, Casey Barton; Wright, Jennifer] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Routh, J (reprint author), CDC, EIS, Atlanta, GA 30333 USA. EM jrouth@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD OCT 3 PY 2012 VL 308 IS 13 BP 1317 EP 1317 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 014IV UT WOS:000309369300010 ER PT J AU Hirshfield, S Chiasson, MA Joseph, H Scheinmann, R Johnson, WD Remien, RH Shaw, FS Emmons, R Yu, G Margolis, AD AF Hirshfield, Sabina Chiasson, Mary Ann Joseph, Heather Scheinmann, Roberta Johnson, Wayne D. Remien, Robert H. Shaw, Francine Shuchat Emmons, Reed Yu, Gary Margolis, Andrew D. TI An Online Randomized Controlled Trial Evaluating HIV Prevention Digital Media Interventions for Men Who Have Sex with Men SO PLOS ONE LA English DT Article ID FACE-TO-FACE; RISK BEHAVIOR; DISEASE PREVENTION; NONRESPONSE RATES; DATA-COLLECTION; BISEXUAL MEN; SEEK SEX; STUDY-II; INTERNET; SURVEILLANCE AB Background: As HIV infection continues unabated, there is a need for effective interventions targeting at-risk men who have sex with men (MSM). Engaging MSM online where they meet sexual partners is critical for HIV prevention efforts. Methods: A randomized controlled trial (RCT) conducted online among U. S. MSM recruited from several gay sexual networking websites assessed the impact of 2 HIV prevention videos and an HIV prevention webpage compared to a control condition for the study outcomes HIV testing, serostatus disclosure, and unprotected anal intercourse (UAI) at 60-day follow-up. Video conditions were pooled due to reduced power from low retention (53%, n = 1,631). No participant incentives were provided. Principal Findings: Follow-up was completed by 1,631 (53%) of 3,092 eligible men. In the 60 days after the intervention, men in the pooled video condition were significantly more likely than men in the control to report full serostatus disclosure ('asked and told') with their last sexual partner (OR 1.32, 95% CI 1.01-1.74). Comparing baseline to follow-up, HIV-negative men in the pooled video (OR 0.70, 95% CI 0.54-0.91) and webpage condition (OR 0.43, 95% CI 0.25-0.72) significantly reduced UAI at follow-up. HIV-positive men in the pooled video condition significantly reduced UAI (OR 0.38, 95% CI 0.20-0.67) and serodiscordant UAI (OR 0.53, 95% CI 0.28-0.96) at follow-up. Conclusions/Significance: Findings from this online RCT of MSM recruited from sexual networking websites suggest that a low cost, brief digital media intervention designed to engage critical thinking can increase HIV disclosure to sexual partners and decrease sexual risk. Effective, brief HIV prevention interventions featuring digital media that are made widely available may serve as a complementary part of an overall behavioral and biomedical strategy for reducing sexual risk by addressing the specific needs and circumstances of the target population, and by changing individual knowledge, motivations, and community norms. C1 [Hirshfield, Sabina; Chiasson, Mary Ann; Scheinmann, Roberta; Emmons, Reed] Publ Hlth Solut, New York, NY USA. [Joseph, Heather; Johnson, Wayne D.; Margolis, Andrew D.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Remien, Robert H.] Columbia Univ, HIV Ctr Clin & Behav Studies, New York State Psychiat Inst, New York, NY USA. [Shaw, Francine Shuchat] NYU, Steinhardt Sch Culture Educ & Human Dev, New York, NY USA. [Yu, Gary] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. RP Hirshfield, S (reprint author), Publ Hlth Solut, New York, NY USA. EM shirshfield@healthsolutions.org FU Centers for Disease Control and Prevention (CDC) [UR6-PS000415] FX Funding is from the Centers for Disease Control and Prevention (CDC) cooperative agreement UR6-PS000415 (to Public Health Solutions). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 76 TC 31 Z9 32 U1 1 U2 18 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD OCT 2 PY 2012 VL 7 IS 10 AR e46252 DI 10.1371/journal.pone.0046252 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 015NG UT WOS:000309452600030 PM 23071551 ER PT J AU Shen, CH Tie, YF Yu, XX Wang, YF Kovalevsky, AY Harrison, RW Weber, IT AF Shen, Chen-Hsiang Tie, Yunfeng Yu, Xiaxia Wang, Yuan-Fang Kovalevsky, Andrey Y. Harrison, Robert W. Weber, Irene T. TI Capturing the Reaction Pathway in Near-Atomic-Resolution Crystal Structures of HIV-1 Protease SO BIOCHEMISTRY LA English DT Article ID DRUG-RESISTANT MUTANTS; X-RAY-DIFFRACTION; KINETIC CHARACTERIZATION; COMPLEXES; SUBSTRATE; CRYSTALLOGRAPHY; INTERMEDIATE; MECHANISM; NEUTRON; ENZYME AB Snapshots of three consecutive steps in the proteolytic reaction of HIV-1 protease (PR) were obtained in crystal structures at resolutions of 1.2-1.4 angstrom. Structures of wild-type protease and two mutants (PRV32I and PRI47V) with V32I and I47V substitutions, which are common in drug resistance, reveal the gem-diol tetrahedral intermediate, the separating N- and C-terminal products, and the C-terminal product of an autoproteolytic peptide. These structures represent three stages in the reaction pathway and shed light on the reaction mechanism. The near-atomic-resolution geometric details include a short hydrogen bond between the intermediate and the outer carboxylate oxygen of one catalytic Asp25 that is conserved in all three structures. The two products in the complex with mutant PRI47V have a 2.2 angstrom separation of the amide and carboxyl carbon of the adjacent ends, suggesting partial cleavage prior to product release. The complex of mutant PRV32I with a single C-terminal product shows density for water molecules in the other half of the binding site, including a partial occupancy water molecule interacting with the product carboxylate end and the carbonyl oxygen of one conformation of Gly27, which suggests a potential role of Gly27 in recycling from the product complex to the ligand-free enzyme. These structural details at near-atomic resolution enhance our understanding of the reaction pathway and will assist in the design of mechanism-based inhibitors as antiviral agents. C1 [Shen, Chen-Hsiang; Tie, Yunfeng; Yu, Xiaxia; Wang, Yuan-Fang; Kovalevsky, Andrey Y.; Harrison, Robert W.; Weber, Irene T.] Georgia State Univ, Dept Biol, Mol Basis Dis Program, Atlanta, GA 30303 USA. [Tie, Yunfeng] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Yu, Xiaxia; Harrison, Robert W.] Georgia State Univ, Dept Comp Sci, Mol Basis Dis Program, Atlanta, GA 30303 USA. [Kovalevsky, Andrey Y.] Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA. [Weber, Irene T.] Georgia State Univ, Dept Chem, Mol Basis Dis Program, Atlanta, GA 30303 USA. RP Weber, IT (reprint author), Georgia State Univ, Dept Biol, POB 4010, Atlanta, GA 30302 USA. EM iweber@gsu.edu RI Lujan Center, LANL/G-4896-2012; shen, chen-hsiang/D-7309-2016; OI Kovalevsky, Andrey/0000-0003-4459-9142 FU Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH); Intramural AIDS-Targeted Antiviral Program of the Office of the Director, NIH; NIH [GM062920]; Georgia State University Research Program Enhancement award in Bioinformatics; Georgia State University Molecular Basis of Disease Fellowships FX This research was supported, in whole or in part, by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), Intramural AIDS-Targeted Antiviral Program of the Office of the Director, NIH, and Grant GM062920 from the NIH. C.-H.S. and X.Y. were supported in part by the Georgia State University Research Program Enhancement award in Bioinformatics and by Georgia State University Molecular Basis of Disease Fellowships. NR 32 TC 5 Z9 5 U1 0 U2 11 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0006-2960 J9 BIOCHEMISTRY-US JI Biochemistry PD OCT 2 PY 2012 VL 51 IS 39 BP 7726 EP 7732 DI 10.1021/bi3008092 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 013QQ UT WOS:000309320300008 PM 22963370 ER PT J AU Madsen, A Thihalolipavan, S Maduro, G Zimmerman, R Koppaka, R Li, WH Foster, V Begier, E AF Madsen, Ann Thihalolipavan, Sayone Maduro, Gil Zimmerman, Regina Koppaka, Ram Li, Wenhui Foster, Victoria Begier, Elizabeth TI An Intervention to Improve Cause-of-Death Reporting in New York City Hospitals, 2009-2010 SO PREVENTING CHRONIC DISEASE LA English DT Article ID CORONARY-HEART-DISEASE; CERTIFICATE COMPLETION; PROPER COMPLETION; ACCURACY AB Introduction Poor-quality cause-of-death reporting reduces reliability of mortality statistics used to direct public health efforts. Overreporting of heart disease has been documented in New York City (NYC) and nationwide. Our objective was to evaluate the immediate and longer-term effects of a cause-of-death (COD) educational program that NYC's health department conducted at 8 hospitals on heart disease reporting and on average conditions per certificate, which are indicators of the quality of COD reporting. Methods From June 2009 through January 2010, we intervened at 8 hospitals that overreported heart disease deaths in 2008. We shared hospital-specific data on COD reporting, held conference calls with key hospital staff, and conducted inservice training. For deaths reported from January 2009 through June 2011, we compared the proportion of heart disease deaths and average number of conditions per death certificate before and after the intervention at both intervention and nonintervention hospitals. Results At intervention hospitals, the proportion of death certificates that reported heart disease as the cause of death decreased from 68.8% preintervention to 32.4% postintervention (P < .001). Individual hospital proportions ranged from 58.9% to 79.5% preintervention and 25.9% to 45.0% postintervention. At intervention hospitals the average number of conditions per death certificate increased from 2.4 conditions preintervention to 3.4 conditions postintervention (P < .001) and remained at 3.4 conditions a year later. At nonintervention hospitals, these measures remained relatively consistent across the intervention and postintervention period. Conclusion This NYC health department's hospital-level intervention led to durable changes in COD reporting. C1 [Madsen, Ann; Thihalolipavan, Sayone; Maduro, Gil; Zimmerman, Regina; Koppaka, Ram; Li, Wenhui; Foster, Victoria; Begier, Elizabeth] New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA. [Koppaka, Ram] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Madsen, A (reprint author), New York City Dept Hlth & Mental Hyg, 125 Worth St,Rm 204,CN 7, New York, NY 10013 USA. EM amadsenstraight@health.nyc.gov NR 33 TC 1 Z9 1 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD OCT PY 2012 VL 9 AR UNSP 120071 DI 10.5888/pcd9.120071 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 173AR UT WOS:000321050800006 ER PT J AU Murphy, LB Yelin, E AF Murphy, Louise B. Yelin, Edward TI Introduction to special issue of best practices in rheumatology: Health economics of musculoskeletal diseases SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY LA English DT Editorial Material C1 [Murphy, Louise B.] Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA 30333 USA. [Yelin, Edward] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Yelin, Edward] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA USA. RP Murphy, LB (reprint author), Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA 30333 USA. EM alx2@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-6942 J9 BEST PRACT RES CL RH JI Best Pract. Res. Clin. Rheumatol. PD OCT PY 2012 VL 26 IS 5 BP 559 EP 560 DI 10.1016/j.berh.2012.08.009 PG 2 WC Rheumatology SC Rheumatology GA 063CI UT WOS:000312973300001 PM 23218422 ER PT J AU Brady, TJ AF Brady, Teresa J. TI Cost implications of self-management education intervention programmes in arthritis SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY LA English DT Article DE Cost-effectiveness analyses; Self-management education; Self-management support; Arthritis Self-Management Program; Chronic Disease Self-Management Program ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC DISEASE; RHEUMATOID-ARTHRITIS; PRIMARY-CARE; PUBLIC-HEALTH; KNEE OSTEOARTHRITIS; CHRONIC ILLNESS; RECOMMENDATIONS; EFFICACY; OUTCOMES AB The purpose of this review is to examine cost implications, including cost-effectiveness analyses, cost-savings calculated from health-care utilisation and intervention delivery costs of arthritis-related self-management education (SME) interventions. Methods: Literature searches, covering 1980-March 2012, using arthritis, self-management and cost-related terms, identified 487 articles; abstracts were reviewed to identify those with cost information. Results: Three formal cost-effectiveness analyses emerged; results were equivocal but analyses done from the societal perspective, including out-of-pocket and other indirect costs, were more promising. Eight studies of individual, group and telephone-delivered SME calculated cost-savings based on health-care utilisation changes. These studies had variable results but the costs-savings extrapolation methods are questionable. Meta-analyses of health-care utilisation changes in two specific SME interventions demonstrated only one significant result at 6 months, which did not persist at 12 months. Eleven studies reported intervention delivery costs ranging from $35 to $740 per participant; the variability is likely due to costing methods and differences in delivery mode. Conclusions: Economic analysis in arthritis-related SME is in its infancy; more robust economic evaluations are required to reach sound conclusions. The most common form of analysis used changes in health-care utilisation as a proxy for cost-savings: the results are less than compelling. However, other value metrics, including the value of SME as part of health systems' self-management support efforts, to population health (from improved self-efficacy, psychological well-being and physical activity), and to igniting patient activation, are all important to consider. Published by Elsevier Ltd. C1 Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA 30341 USA. RP Brady, TJ (reprint author), Ctr Dis Control & Prevent, Arthrit Program, 4770 Buford Hwy NE,MS K-51, Atlanta, GA 30341 USA. EM tob9@cdc.gov NR 56 TC 3 Z9 3 U1 4 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-6942 J9 BEST PRACT RES CL RH JI Best Pract. Res. Clin. Rheumatol. PD OCT PY 2012 VL 26 IS 5 BP 611 EP 625 DI 10.1016/j.berh.2012.09.001 PG 15 WC Rheumatology SC Rheumatology GA 063CI UT WOS:000312973300005 PM 23218426 ER PT J AU Murphy, LB Yelin, E Theis, KA AF Murphy, Louise B. Yelin, Edward Theis, Kristina A. TI Compromised access to prescriptions and medical care because of cost among US adults with arthritis SO BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY LA English DT Article DE Arthritis; Access to health care; Health insurance; Population-based; Socio-economic factors ID RANDOMIZED CONTROLLED-TRIAL; RHEUMATOID-ARTHRITIS; MUSCULOSKELETAL CONDITIONS; WORK DISABILITY; DISEASES; POPULATION; PREVALENCE; EMPLOYMENT; HEALTH AB Introduction: Study objectives were to: 1) determine the magnitude of three outcomes (prescription unaffordable, care delayed and needed. care not obtained) related to cost-attributable compromised medical care access among US adults >= 18 years with and without arthritis and 2) identify US adults with arthritis with the highest levels of these outcomes. Materials and methods: We analysed 2009-2011 US National Health Interview Survey data and estimated prevalence of outcomes by arthritis status and, among people with arthritis, by socio-demographic, medical care access and health status characteristics. Unadjusted and multivariable (MV) adjusted (prevalence ratios) PRs quantified associations between each outcome and arthritis status, and, among people with arthritis, selected characteristics. Number and proportion of adults with arthritis without health insurance coverage were estimated. Results: Outcomes were more prevalent (statistically-significant) among those with arthritis than those without: prescription unaffordable = 14% (9%), care delayed = 14% (11%) and needed care not obtained = 11% (8%). Outcomes were marginally more likely (statistically significant) among adults with arthritis than those without (range MV PRs = 1.2-1.3). Among those with arthritis, the uninsured had the highest prevalence of, and were most likely to have, each outcome (MV PRs: prescription unaffordable = 3.6(95% confidence interval [CI] = 3.6-4.4), delayed care = 4.7 (95% CI = 3.9-5.7) and needed care not obtained = 5.9 (95% CI = 4.7-7.5) (referent: those with both public and private coverage)). An estimated 4.5 million adults with arthritis were uninsured. Conclusions: Cost-attributable compromised access is common among US adults with arthritis; they are also slightly more likely than those without arthritis to have compromised care. Compromised access is highest among the uninsured. For those with limited access, convenient, inexpensive and proven community-based strategies that improve physical and psychosocial health may be especially practical. Published by Elsevier Ltd. C1 [Murphy, Louise B.; Theis, Kristina A.] Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30333 USA. [Yelin, Edward] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Murphy, LB (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Atlanta, GA 30333 USA. EM lmurphy1@cdc.gov NR 50 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1521-6942 J9 BEST PRACT RES CL RH JI Best Pract. Res. Clin. Rheumatol. PD OCT PY 2012 VL 26 IS 5 BP 677 EP 694 DI 10.1016/j.berh.2012.10.007 PG 18 WC Rheumatology SC Rheumatology GA 063CI UT WOS:000312973300010 PM 23218431 ER PT J AU Levings, J Cogswell, M Curtis, CJ Gunn, J Neiman, A Angell, SY AF Levings, Jessica Cogswell, Mary Curtis, Christine J. Gunn, Janelle Neiman, Andrea Angell, Sonia Y. TI Progress toward sodium reduction in the United States SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article DE Sodium; world health; United States ID SELF-REPORTED HYPERTENSION; ADULTS; HEALTH; DISEASE; CONSUMPTION; NUTRITION; MORTALITY AB The average adult in the United States of America consumes well above the recommended daily limit of sodium. Average sodium intake is about 3 463 mg/day, as compared to the 2010 dietary guidelines for Americans recommendation of < 2 300 mg/day. A further reduction to 1 500 mg/day is advised for people 51 years or older; African Americans; and people with high blood pressure, diabetes, or chronic kidney disease. In the United States of America, the problem of excess sodium intake is related to the food supply. Most sodium consumed comes from packaged, processed, and restaurant foods and therefore is in the product at the time of purchase. This paper describes sodium reduction policies and programs in the United States at the federal, state, and local levels; efforts to monitor the health impact of sodium reduction; ways to assess consumer knowledge, attitudes, and behavior; and how these activities depend on and inform global efforts to reduce sodium intake. Reducing excess sodium intake is a public health opportunity that can save lives and health care dollars in the United States and globally. Future efforts, including sharing successes achieved and barriers identified in the United States and globally, may quicken and enhance progress. C1 [Levings, Jessica; Cogswell, Mary; Gunn, Janelle; Neiman, Andrea; Angell, Sonia Y.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Curtis, Christine J.] New York City Dept Hlth & Mental Hyg, New York, NY USA. RP Levings, J (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM isb4@cdc.gov NR 37 TC 11 Z9 11 U1 0 U2 9 PU PAN AMER HEALTH ORGANIZATION PI WASHINGTON PA 525 23RD ST NW, WASHINGTON, DC 20037 USA SN 1020-4989 J9 REV PANAM SALUD PUBL JI Rev. Panam. Salud Publica PD OCT PY 2012 VL 32 IS 4 BP 301 EP 306 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 068DF UT WOS:000313344000009 PM 23299292 ER PT J AU Beaucham, CC Lentz, TJ Rice, FL AF Beaucham, Catherine C. Lentz, Thomas J. Rice, Faye L. TI Expanding control banding for workplace silica exposures throughout the Americas SO INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Control banding; Silica; Silcosis; International collaboration AB Background: Silicosis, a lung disease caused by inhaling respirable crystalline silica dust, is an occupational illness affecting millions of workers worldwide. The National Institute for Occupational Safety and Health (NIOSH) has partnered with the World Health Organization, the International Labour Organization, and multiple agencies in the Americas to implement the program "The Elimination of Silicosis in the Americas". Objectives: One component of this program is control banding, a qualitative risk assessment and management strategy that allows non-experts to use task-based hazard data and potential exposure information to determine appropriate controls. Results: From 2005 to the present, NIOSH occupational health researchers have worked with experts in Chile, Peru, Colombia, and Brazil to assess, implement, and provide tools to evaluate the use of control banding methodology. C1 [Beaucham, Catherine C.; Lentz, Thomas J.; Rice, Faye L.] CDC, NIOSH, Cincinnati, OH USA. RP Beaucham, CC (reprint author), CDC, NIOSH, Cincinnati, OH USA. EM htn9@cdc.gov FU Chilean Institute of Public Health; Venezuelan Occupational Hygiene Association; Corporation of Occupational and Environmental Health (Medellin, Colombia); Brazilian Occupational Hygiene Association FX We would like to offer appreciation to all of our international partners for their devotion to the elimination of silicosis. We would also like to thank John Lechliter for editing this document and Maria Lioce, Marilyn Fingerhut, Donna Heidel, Anne Bracker, Wendy MacDonald, and Deborah Nelson for reviewing this manuscript. Support for this research was provided by the Chilean Institute of Public Health, the Venezuelan Occupational Hygiene Association, the Corporation of Occupational and Environmental Health (Medellin, Colombia), and the Brazilian Occupational Hygiene Association. NR 6 TC 1 Z9 1 U1 0 U2 12 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1077-3525 J9 INT J OCCUP ENV HEAL JI Int. J. Occup. Environ. Health PD OCT-DEC PY 2012 VL 18 IS 4 BP 344 EP 347 DI 10.1179/2049396712Y.0000000001 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 061CH UT WOS:000312824200011 PM 23433296 ER PT J AU Gordon, SC Lamerato, L Rupp, LB Holmberg, SD Moorman, AC Spradling, PR Teshale, EH Nakasato, C Boscarino, JA Henkle, E Nerenz, DR Oja-Tebbe, N Lu, M AF Gordon, Stuart C. Lamerato, Lois Rupp, Loralee B. Holmberg, Scott D. Moorman, Anne C. Spradling, Philip R. Teshale, Eyasu H. Nakasato, Cynthia Boscarino, Joseph A. Henkle, Emily Nerenz, David R. Oja-Tebbe, Nancy Lu, Mei TI Hepatitis B therapy and incidence of hepatocellular carcinoma in a US population SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Gordon, Stuart C.] Henry Ford Hlth Syst, Div Gastroenterol & Hepatol, Detroit, MI USA. [Lamerato, Lois; Oja-Tebbe, Nancy; Lu, Mei] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA. [Rupp, Loralee B.; Nerenz, David R.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA. [Holmberg, Scott D.; Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu H.] Ctr Dis Control, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Nakasato, Cynthia] Kaiser Permanente, Ctr Hlth Res Hawaii, Honolulu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Geisinger Ctr Hlth Res, Danville, PA USA. [Henkle, Emily] Kaiser Permanente, Ctr Hlth Res NW, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 318 BP 347A EP 348A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955601317 ER PT J AU Lu, M Lamerato, L Rupp, LB Holmberg, SD Moorman, AC Spradling, PR Teshale, EH Nakasato, C Boscarino, JA Henkle, E Nerenz, DR Gordon, SC AF Lu, Mei Lamerato, Lois Rupp, Loralee B. Holmberg, Scott D. Moorman, Anne C. Spradling, Philip R. Teshale, Eyasu H. Nakasato, Cynthia Boscarino, Joseph A. Henkle, Emily Nerenz, David R. Gordon, Stuart C. TI Noninvasive serum markers to stage fibrosis in patients with chronic hepatitis B infection SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Lu, Mei; Lamerato, Lois] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA. [Gordon, Stuart C.] Henry Ford Hlth Syst, Div Gastroenterol Hepatol, Detroit, MI USA. [Nerenz, David R.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA. [Holmberg, Scott D.; Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu H.] Ctr Dis Control, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Nakasato, Cynthia] Kaiser Permanente, Ctr Hlth Res Hawaii, Honolulu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Geisinger Ctr Hlth Res, Danville, PA USA. [Henkle, Emily] Kaiser Permanente, Ctr Hlth Res NW, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 346 BP 360A EP 361A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955601345 ER PT J AU Mixson-Hayden, T Martin, A Kodani, M Drobeniuc, J Kamili, S AF Mixson-Hayden, Tonya Martin, Alyssa Kodani, Maja Drobeniuc, Jan Kamili, Saleem TI High detection rate of HDV RNA in HBsAg/HDVAb-positive sera from diverse geographical regions including the United States SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Mixson-Hayden, Tonya; Martin, Alyssa; Kodani, Maja; Drobeniuc, Jan; Kamili, Saleem] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 495 BP 434A EP 434A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955601494 ER PT J AU Teshale, EH Williams, R Xing, J Dulski, T Mahamud, A Drobeniuc, J Masunu-Falaefaga, Y Spradling, PR AF Teshale, Eyasu H. Williams, Roxanne Xing, Jian Dulski, Theresa Mahamud, Abdirahman Drobeniuc, Jan Masunu-Falaefaga, Yolanda Spradling, Philip R. TI Low anamnestic response to a challenge dose of hepatitis B vaccine among American Samoan college students vaccinated during infancy SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Teshale, Eyasu H.; Williams, Roxanne; Xing, Jian; Dulski, Theresa; Mahamud, Abdirahman; Drobeniuc, Jan; Spradling, Philip R.] CDC, Atlanta, GA 30333 USA. [Masunu-Falaefaga, Yolanda] Amer Samoa Dept Hlth, Pago Pago, AS USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 922 BP 639A EP 639A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955602301 ER PT J AU Vijayadeva, V Nakasato, C Gordon, SC Rupp, LB Lu, M Henkle, E Boscarino, JA Moorman, AC Teshale, EH Holmberg, SD Spradling, PR AF Vijayadeva, Vinutha Nakasato, Cynthia Gordon, Stuart C. Rupp, Loralee B. Lu, Mei Henkle, Emily Boscarino, Joseph A. Moorman, Anne C. Teshale, Eyasu H. Holmberg, Scott D. Spradling, Philip R. TI Hepatitis B Virus Testing among US-Born and Foreign-Born Persons of Asian and Pacific Island Descent in a Health Maintenance Organization, Hawai'i SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Vijayadeva, Vinutha; Nakasato, Cynthia] Kaiser Permanente Hawaii, Kaiser Permanente Ctr Hlth Res, Honolulu, HI USA. [Moorman, Anne C.; Teshale, Eyasu H.; Holmberg, Scott D.; Spradling, Philip R.] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Gordon, Stuart C.; Rupp, Loralee B.; Lu, Mei] Henry Ford Hlth Syst, Detroit, MI USA. [Henkle, Emily] Kaiser Permanente NW, Kaiser Permanente Ctr Hlth Res, Portland, OR USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Danville, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 932 BP 644A EP 644A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955602311 ER PT J AU Morgan, R Baack, B Smith, BD Pitasi, M Falck-Ytter, Y AF Morgan, Rebecca Baack, Brittney Smith, Bryce D. Pitasi, Marc Falck-Ytter, Yngve TI Response to Treatment as a Predictor of Hepatocellular Carcinoma (HCC) Development among Persons Chronically Infected with Hepatitis C Virus (HCV) Infection: A Meta-Analysis SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Morgan, Rebecca; Smith, Bryce D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Baack, Brittney] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Pitasi, Marc] Rollins Sch Publ Hlth, Atlanta, GA USA. [Falck-Ytter, Yngve] Case Western Reserve Univ, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 942 BP 648A EP 649A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955602321 ER PT J AU Mahajan, R Liu, SJ Klevens, M Holmberg, SD AF Mahajan, Reena Liu, Stephen J. Klevens, Monina Holmberg, Scott D. TI Indications for Screening among Reported Cases of Hepatitis C Virus Infection from Enhanced Hepatitis Surveillance Sites-United States, 2004-2010 SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Mahajan, Reena; Liu, Stephen J.; Klevens, Monina; Holmberg, Scott D.] Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 944 BP 649A EP 650A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955602323 ER PT J AU Drobeniuc, J Hayden, TM Ganova-Raeva, L Teshale, EH Kamili, S Teo, CG AF Drobeniuc, Jan Hayden, Tonya M. Ganova-Raeva, Lilia Teshale, Eyasu H. Kamili, Saleem Teo, Chong-Gee TI Hepatitis E in the United States, 2005-2012: demographic, clinical, virologic and travel-history characteristics of cases SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Drobeniuc, Jan; Hayden, Tonya M.; Ganova-Raeva, Lilia; Teshale, Eyasu H.; Kamili, Saleem; Teo, Chong-Gee] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 971 BP 663A EP 663A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955602350 ER PT J AU Lu, M Lamerato, L Rupp, LB Holmberg, SD Moorman, AC Spradling, PR Teshale, EH Nakasato, C Boscarino, JA Henkle, E Nerenz, DR Gordon, SC AF Lu, Mei Lamerato, Lois Rupp, Loralee B. Holmberg, Scott D. Moorman, Anne C. Spradling, Philip R. Teshale, Eyasu H. Nakasato, Cynthia Boscarino, Joseph A. Henkle, Emily Nerenz, David R. Gordon, Stuart C. TI Optimal noninvasive markers for fibrosis stage in chronic hepatitis C SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Lu, Mei; Lamerato, Lois] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA. [Gordon, Stuart C.] Henry Ford Hlth Syst, Div Gastroenterol Hepatol, Detroit, MI USA. [Rupp, Loralee B.; Nerenz, David R.] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA. [Holmberg, Scott D.; Moorman, Anne C.; Spradling, Philip R.; Teshale, Eyasu H.] Ctr Dis Control, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Nakasato, Cynthia] Kaiser Permanente, Ctr Hlth Res Hawaii, Honolulu, HI USA. [Boscarino, Joseph A.] Geisinger Hlth Syst, Geisinger Ctr Hlth Res, Danville, PA USA. [Henkle, Emily] Kaiser Permanente, Ctr Hlth Res NW, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 1015 BP 683A EP 683A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955602393 ER PT J AU Campo, DS Skums, P Vaughan, G Zoya, D Teo, CG Yury, K Lau, D AF Campo, David S. Skums, Pavel Vaughan, Gilberto Zoya, Dimitrova Teo, Chong Gee Yury, Khudyakov Lau, Daryl TI Changes in the extent of IFN-resistance of HCV quasi-species variants during the first 48 hours of IFN therapy are associated with outcome of treatment at week 12 SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Campo, David S.; Skums, Pavel; Vaughan, Gilberto; Zoya, Dimitrova; Teo, Chong Gee; Yury, Khudyakov] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Lau, Daryl] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 1742 BP 1003A EP 1004A PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955603338 ER PT J AU Rein, DB Wagner, LD Brown, KA Fallon, MB Krauskopf, K Massoud, OI Smith, BD AF Rein, David B. Wagner, Laura D. Brown, Kimberly Ann Fallon, Michael B. Krauskopf, Katherine Massoud, Omar I. Smith, Bryce D. TI Current Practices of Hepatitis C Antibody Testing and Follow-up Evaluation in Primary Care Settings: A Retrospective Study of Four Large, Primary Care Service Centers SO HEPATOLOGY LA English DT Meeting Abstract CT 63rd Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) CY NOV 09-13, 2012 CL Boston, MA SP Amer Assoc Study Liver Dis C1 [Rein, David B.] Univ Chicago, NORC, Atlanta, GA USA. [Wagner, Laura D.] RTI Int, Atlanta, GA USA. [Brown, Kimberly Ann] Henry Ford Hosp, Detroit, MI 48202 USA. [Fallon, Michael B.] Univ Texas Houston, Houton, TX USA. [Krauskopf, Katherine] Mt Sinai Sch Med, New York, NY USA. [Massoud, Omar I.] Univ Alabama Birmingham, Birmingham, AL USA. [Smith, Bryce D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD OCT PY 2012 VL 56 SU 1 MA 1938 BP 1094A EP 1094A PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035OD UT WOS:000310955603531 ER PT J AU Fluke, JD Goldman, PS Shriberg, J Hillis, SD Yun, K Allison, S Light, E AF Fluke, John D. Goldman, Philip S. Shriberg, Janet Hillis, Susan D. Yun, Katherine Allison, Susannah Light, Enid TI Systems, strategies, and interventions for sustainable long-term care and protection of children with a history of living outside of family care SO CHILD ABUSE & NEGLECT LA English DT Article DE Child protection system; Trafficked children; Street children; Institutionalized children; Conflict; Disaster; Family care; Children outside of family care ID MENTAL-HEALTH; FOSTER-CARE; INSTITUTIONAL CARE; ORPHANAGES; ATTACHMENT; SOLDIERS; RECOVERY; ADOPTION; OUTCOMES; PROJECT AB Objectives: This article reviews the available evidence regarding the efficacy, effectiveness, ethics, and sustainability of approaches to strengthen systems to care for and protect children living outside family care in low- and middle-income countries. Method: For trafficked children, children of and on the street, children of conflict/disaster, and institutionalized children, a systems framework approach was used to organize the topic of sustainable approaches in low- and middle-income countries and addresses the following: legislation, policies, and regulations; system structures and functions (formal and informal); and continuum of care and services. The article draws on the findings of a focal group convened by the U.S. Government Evidence Summit: Protecting Children Outside of Family Care (December 12-13,2011, Washington, DC), tasked with reviewing the literature on systems, strategies, and interventions for sustainable long-term care and protection of children with a history of living outside of family care in low- and middle-income country contexts. The specific methodology for the review is described in the commentary paper (Higgs, Zlidar, & Balster, 2012) that accompanies these papers. Results: For the most part, the evidence base in support of sustainable long-term care for the populations of interest is relatively weak, with some stronger but unreplicated studies. Some populations have been studied more thoroughly than others, and there are many gaps. Most of the existing studies identify population characteristics, needs, and consequences of a lack of systemic services to promote family-like care. There is some evidence of the effectiveness of laws and policies, as well as some evidence of service effectiveness, in improving outcomes for children outside of family care. Conclusions: Despite the weaknesses and gaps of the existing research, there is a foundation of research for going forward, which should focus on developing and implementing systems for these most vulnerable children. The evidence reviewed indicates that child protection systems should aim for appropriate, permanent family care (including reunification, adoption, kinship care, or kafalah) for children in order to secure the best environment for a child's developmental prospects. Evidence also suggests that the quality and duration of care, including both permanent family care and alternative care, are important regardless of setting. The diversity of political, socioeconomic, historical, regional, community, and cultural contexts in which child protection systems operate need to be taken into account during programming and research design. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Goldman, Philip S.] Maestral Int, Minneapolis, MN USA. [Shriberg, Janet] USAID, Off HIV AIDS, Washington, DC USA. [Hillis, Susan D.] Ctr Dis Control & Prevent, US Publ Hlth Serv, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Yun, Katherine] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Allison, Susannah] NIMH, Infant Child & Adolescent Res Program, Div AIDS Res, NIH, Bethesda, MD 20892 USA. [Light, Enid] NIMH, Div Int Training & Res, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Fluke, John D.] Univ Colorado, Sch Med, Dept Pediat, Kempe Ctr Prevent & Treatment Child Abuse & Negle, Aurora, CO 80045 USA. RP Fluke, JD (reprint author), Univ Colorado, Sch Med,Dept Pediat, Colorado Sch Med,Gary Pavil Childrens Hosp Colora, Kempe Ctr Prevent & Treatment Child Abuse & Negle, Anschutz Med Campus,13123 E 16th Ave,B390, Aurora, CO 80045 USA. NR 86 TC 9 Z9 9 U1 2 U2 42 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2134 J9 CHILD ABUSE NEGLECT JI Child Abuse Negl. PD OCT PY 2012 VL 36 IS 10 SI SI BP 722 EP 731 DI 10.1016/j.chiabu.2012.09.005 PG 10 WC Family Studies; Psychology, Social; Social Work SC Family Studies; Psychology; Social Work GA 039TP UT WOS:000311269700005 PM 23102720 ER PT J AU Grummer-Strawn, LM AF Grummer-Strawn, Laurence M. TI Surgeon General's Call to Action to Support Breastfeeding: Significant Actions in the First Year SO BREASTFEEDING MEDICINE LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Nutr Branch, Atlanta, GA 30341 USA. RP Grummer-Strawn, LM (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Nutr Branch, 4770 Buford Highway,MS K25, Atlanta, GA 30341 USA. EM lxg8@cdc.gov NR 2 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1556-8253 J9 BREASTFEED MED JI Breastfeed. Med. PD OCT PY 2012 VL 7 IS 5 BP 332 EP 333 DI 10.1089/bfm.2012.0103 PG 2 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 017AB UT WOS:000309559900006 PM 22950527 ER PT J AU Hutchinson, A Sansom, S Farnham, P AF Hutchinson, A. Sansom, S. Farnham, P. TI Cost-effectiveness of more frequent HIV screening of men who have sex with men in the United States SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Hutchinson, A.; Sansom, S.; Farnham, P.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM ash2@cdc.gov NR 0 TC 1 Z9 1 U1 0 U2 4 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 36 EP 36 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200083 ER PT J AU Ouma, K Basavaraju, S Okonji, J Williamson, J Mills, L Zeh, C AF Ouma, K. Basavaraju, S. Okonji, J. Williamson, J. Mills, L. Zeh, C. TI A field evaluation of HIV-1 RNA viral load in plasma and dried blood spots using the COBAS Amplicor Analyzer and the Nucleic Acid Extraction COBAS Ampliprep/Taqman in Kisumu, Kenya SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Okonji, J.] KEMRI CDC Res & Publ Hlth Collaborat, HIV Res Lab, Kisumu, Kenya. [Basavaraju, S.] Ctr Dis Control & Prevent, HIV Prevent Branch, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Williamson, J.; Mills, L.; Zeh, C.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Kisumu, Kenya. EM kouma@kemricdc.org NR 0 TC 0 Z9 0 U1 0 U2 3 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 37 EP 38 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200085 ER PT J AU Sterling, T Benson, C Shang, N Miro, J Grinsztejn, B Chaisson, R Lucchetti, A Sanchez, J Scott, N Villarino, E AF Sterling, T. Benson, C. Shang, N. Miro, J. Grinsztejn, B. Chaisson, R. Lucchetti, A. Sanchez, J. Scott, N. Villarino, E. CA AIDS Clinical Trials Grp TB Trials Consortium TI Tolerability among HIV-positive persons of three months of once-weekly rifapentine plus INH (3HP) versus 9 months of daily INH (9H) for treatment of latent tuberculosis infection: the PREVENT TB Study (TBTC Study 26/ACTG 5259) SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Sterling, T.] Vanderbilt Univ, Nashville, TN USA. [Benson, C.] Univ Calif San Diego, San Diego, CA 92103 USA. [Shang, N.; Scott, N.; Villarino, E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Miro, J.] Agencia Salut Publ, Barcelona, Spain. [Grinsztejn, B.] Fundaao Oswaldo Cruz, IPEC Evandro Chagas, Rio De Janeiro, Brazil. [Chaisson, R.] Johns Hopkins Univ, Baltimore, MD USA. [Lucchetti, A.] Inmensa, Lima, Peru. [Sanchez, J.] Impacta, Lima, Peru. EM timothy.sterling@vanderbilt.edu NR 0 TC 0 Z9 0 U1 1 U2 3 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 42 EP 42 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200093 ER PT J AU Beer, L Oster, A Mattson, C Skarbinski, J AF Beer, L. Oster, A. Mattson, C. Skarbinski, J. TI Racial disparities in antiretroviral therapy use and viral suppression among sexually active HIV-positive men who have sex with men receiving medical care: United States, Medical Monitoring Project, 2009 data collection cycle SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Beer, L.; Oster, A.; Mattson, C.; Skarbinski, J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. EM lbeer@cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 3 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 82 EP 83 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200162 ER PT J AU Phillips, S Curtis, K Polis, C AF Phillips, S. Curtis, K. Polis, C. TI Hormonal contraception and HIV disease progression: a systematic review of the epidemiological evidence SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Phillips, S.] World Hlth Org, Reprod Hlth & Res, Geneva, Switzerland. [Curtis, K.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Polis, C.] US Agcy Int Dev, Off Populat & Reprod Hlth, Washington, DC 20523 USA. EM phillipss@who.int NR 0 TC 0 Z9 0 U1 0 U2 2 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 82 EP 82 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200161 ER PT J AU Polis, C Curtis, K AF Polis, C. Curtis, K. TI Hormonal contraception and HIV acquisition in women: a systematic review of the epidemiological evidence SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Polis, C.] USAID, Off Populat & Reprod Hlth, Washington, DC USA. [Curtis, K.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. EM cpolis@usaid.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 82 EP 82 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200160 ER PT J AU Hall, HI Frazier, EL Rhodes, P Holtgrave, DR Furlow-Parmley, C Tang, T Gray, KM Cohen, SM Skarbinski, J AF Hall, H. I. Frazier, E. L. Rhodes, P. Holtgrave, D. R. Furlow-Parmley, C. Tang, T. Gray, K. M. Cohen, S. M. Skarbinski, J. TI Continuum of HIV care: differences in care and treatment by sex and race/ethnicity in the United States SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Hall, H. I.; Frazier, E. L.; Rhodes, P.; Furlow-Parmley, C.; Gray, K. M.; Cohen, S. M.; Skarbinski, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Holtgrave, D. R.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Tang, T.] ICF Int, Atlanta, GA USA. EM ixh1@cdc.gov NR 0 TC 1 Z9 1 U1 0 U2 6 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 86 EP 86 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200168 ER PT J AU Oster, A Russell, K Wiegand, R Le, B Valverde, E Forrest, D Cribbin, M Paz-Bailey, G AF Oster, A. Russell, K. Wiegand, R. Le, B. Valverde, E. Forrest, D. Cribbin, M. Paz-Bailey, G. CA NHBS Study Grp TI Foreign location of birth and time since immigration are associated with HIV status among Latino MSM in the United States SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Oster, A.; Russell, K.; Wiegand, R.; Le, B.; Valverde, E.; Cribbin, M.; Paz-Bailey, G.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Forrest, D.] Univ Miami, Miami, FL USA. EM aoster@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 92 EP 93 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200179 ER PT J AU Oster, A Johnson, C Le, B Finlayson, T Balaji, A Lansky, A Mermin, J Valleroy, L MacKellar, D Behel, S Paz-Bailey, G AF Oster, A. Johnson, C. Le, B. Finlayson, T. Balaji, A. Lansky, A. Mermin, J. Valleroy, L. MacKellar, D. Behel, S. Paz-Bailey, G. TI Trends in HIV prevalence and HIV testing among young MSM: five United States cities, 1994-2008 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Oster, A.; Johnson, C.; Le, B.; Finlayson, T.; Balaji, A.; Lansky, A.; Mermin, J.; Valleroy, L.; MacKellar, D.; Behel, S.; Paz-Bailey, G.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM aoster@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 3 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 93 EP 94 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200180 ER PT J AU Taylor, M Schillinger, J Pathela, P Skinner, J Newman, D Braunstein, S Shepard, C Brewer, T Ahmed, T Griffin, A Furness, B AF Taylor, M. Schillinger, J. Pathela, P. Skinner, J. Newman, D. Braunstein, S. Shepard, C. Brewer, T. Ahmed, T. Griffin, A. Furness, B. TI Gonorrhea infections diagnosed among persons living with HIV: cross matching surveillance registries to identify potential opportunities for integrated partner services-New York City, Washington DC, Miami/Dade County and Arizona SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Taylor, M.; Schillinger, J.; Newman, D.; Brewer, T.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Taylor, M.; Skinner, J.] Arizona Dept Hlth Serv, STD Program, Phoenix, AZ 85007 USA. [Schillinger, J.; Pathela, P.; Braunstein, S.; Shepard, C.] Dept Hlth & Mental Hyg, New York, NY USA. [Brewer, T.] Miami Dade Cty Dept Hlth, Miami, FL USA. [Ahmed, T.; Griffin, A.; Furness, B.] Dept Hlth, HIV AIDS Hepatitis STD & TB Adm, Washington, DC USA. EM mdt7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 99 EP 100 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200192 ER PT J AU Reed, JB Justman, J Bicego, G Donnell, D Bock, N Ginindza, H Koler, A Philip, N Makhanya, M Mlambo, C Parekh, BS Duong, YT Ellenberger, DL Sexton, C Nkambule, R AF Reed, J. B. Justman, J. Bicego, G. Donnell, D. Bock, N. Ginindza, H. Koler, A. Philip, N. Makhanya, M. Mlambo, C. Parekh, B. S. Duong, Y. T. Ellenberger, D. L. Sexton, C. Nkambule, R. TI Estimating national HIV incidence from directly observed seroconversions in the Swaziland HIV Incidence Measurement Survey (SHIMS) longitudinal cohort SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Reed, J. B.; Bock, N.; Parekh, B. S.; Duong, Y. T.; Ellenberger, D. L.; Sexton, C.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. [Justman, J.; Koler, A.; Philip, N.] Columbia Univ, ICAP, Mailman Sch Publ Hlth, New York, NY USA. [Bicego, G.; Makhanya, M.] US Ctr Dis Control & Prevent, Swaziland, Mbabane, Swaziland. [Donnell, D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Ginindza, H.; Nkambule, R.] Minist Hlth Swaziland, Mbabane, Swaziland. [Mlambo, C.] Columbia Univ, ICAP, Swaziland, Mbabane, Swaziland. EM eso7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 3 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 112 EP 112 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200216 ER PT J AU Bennett, DE Jordan, MR Bertagnolio, S Hong, SY Ravasi, G McMahon, JH Kelley, KF AF Bennett, D. E. Jordan, M. R. Bertagnolio, S. Hong, S. Y. Ravasi, G. McMahon, J. H. Kelley, K. F. TI The World Health Organization's HIV drug resistance early warning indicators: results from 50 countries 2004-2009 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Bennett, D. E.] US Ctr Dis Control & Prevent, CGH DGHA, Atlanta, GA USA. [Jordan, M. R.; Bertagnolio, S.] World Hlth Org, Dept HIV AIDS, Geneva, Switzerland. [Jordan, M. R.; Hong, S. Y.; McMahon, J. H.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Ravasi, G.] Pan Amer Hlth Org, Brasilia, DF, Brazil. [McMahon, J. H.] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia. [Kelley, K. F.] US Presidents Emergency Plan AIDS Relief, New Delhi, India. EM dib1@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 121 EP 121 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200225 ER PT J AU Koole, O Tsui, S Wabwire-Mangen, F Kwesigabo, G Menten, J Mulenga, M Auld, A Agolory, S Mukadi, YD Colebunders, R Bangsberg, DR Van Praag, E Torpey, K Williams, S Kaplan, J Zee, A Denison, J AF Koole, O. Tsui, S. Wabwire-Mangen, F. Kwesigabo, G. Menten, J. Mulenga, M. Auld, A. Agolory, S. Mukadi, Y. D. Colebunders, R. Bangsberg, D. R. Van Praag, E. Torpey, K. Williams, S. Kaplan, J. Zee, A. Denison, J. TI Retention and risk factors for attrition among adults in antiretroviral treatment (ART) programs in Tanzania, Uganda and Zambia SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Koole, O.; Menten, J.; Colebunders, R.] Inst Trop Med, B-2000 Antwerp, Belgium. [Tsui, S.] FHI 360, Durham, NC USA. [Wabwire-Mangen, F.] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda. [Kwesigabo, G.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania. [Mulenga, M.] Trop Dis Res Ctr, Ndola, Zambia. [Auld, A.; Agolory, S.; Williams, S.; Kaplan, J.; Zee, A.] Ctr Dis Control & Prevent, Div Global AIDS, Atlanta, GA USA. [Mukadi, Y. D.; Denison, J.] FHI 360, Washington, DC USA. [Bangsberg, D. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Torpey, K.] FHI 360, Lagos, Nigeria. EM okoole@itg.be NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 123 EP 124 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200228 ER PT J AU Althoff, KN Buchacz, K Hall, I Zhang, J Hanna, DB Rebeiro, P Gange, SJ Moore, RD Kitahata, M Gebo, KA Martin, J Justice, AC Horberg, M Hogg, RS Sterling, TR Cescon, A Klein, MB Thorne, J Crane, H Mugavero, MJ Napravnik, S Kirk, GD Jacobson, LP Rodriguez, B Brooks, JT AF Althoff, K. N. Buchacz, K. Hall, I. Zhang, J. Hanna, D. B. Rebeiro, P. Gange, S. J. Moore, R. D. Kitahata, M. Gebo, K. A. Martin, J. Justice, A. C. Horberg, M. Hogg, R. S. Sterling, T. R. Cescon, A. Klein, M. B. Thorne, J. Crane, H. Mugavero, M. J. Napravnik, S. Kirk, G. D. Jacobson, L. P. Rodriguez, B. Brooks, J. T. CA N Amer AIDS Cohort Collaboration TI Trends in antiretroviral therapy use, HIV RNA plasma viral load and CD4 T-lymphocyte counts at death among HIV-positive persons in care in the United States, 2000-2008 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Althoff, K. N.; Zhang, J.; Hanna, D. B.; Rebeiro, P.; Gange, S. J.; Moore, R. D.; Gebo, K. A.; Thorne, J.; Kirk, G. D.; Jacobson, L. P.] Johns Hopkins Univ, Baltimore, MD USA. [Buchacz, K.; Hall, I.; Brooks, J. T.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Kitahata, M.; Crane, H.] Univ Washington, Seattle, WA 98195 USA. [Martin, J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Justice, A. C.] Yale Univ, New Haven, CT USA. [Justice, A. C.] VA Connecticut Healthcare Syst, New Haven, CT USA. [Horberg, M.] Midatlantic Permanente Res Inst, Rockville, MD USA. [Hogg, R. S.; Cescon, A.] Simon Fraser Univ, Vancouver, BC, Canada. [Hogg, R. S.; Cescon, A.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Sterling, T. R.] Vanderbilt Univ, Nashville, TN USA. [Klein, M. B.] McGill Univ, Montreal, PQ, Canada. [Mugavero, M. J.] Univ Alabama Birmingham, Birmingham, AL USA. [Napravnik, S.] Univ N Carolina, Chapel Hill, NC USA. [Rodriguez, B.] Case Western Reserve Univ, Cleveland, OH 44106 USA. EM kalthoff@jhsph.edu NR 0 TC 0 Z9 0 U1 0 U2 4 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 128 EP 129 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200235 ER PT J AU Singh, S Lampe, MA Babu, AS Rao, S Borkowf, CB Nesheim, SR AF Singh, S. Lampe, M. A. Babu, A. Surendera Rao, S. Borkowf, C. B. Nesheim, S. R. TI HIV seroconversion during pregnancy and mother-to-child HIV transmission: data from the Enhanced Perinatal Surveillance Project, United States, 2005-2010 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Singh, S.; Lampe, M. A.; Rao, S.; Borkowf, C. B.; Nesheim, S. R.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Babu, A. Surendera] ICF Int, Atlanta, GA USA. EM fyv7@cdc.gov NR 0 TC 1 Z9 1 U1 0 U2 3 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 130 EP 131 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200240 ER PT J AU Mwandi, Z Ochieng, A Grund, J Mwalili, S Kimanga, D Otieno, G Ohaga, S Oyaro, P Mwangi, C Knight, N Chesang, K Bock, N AF Mwandi, Z. Ochieng, A. Grund, J. Mwalili, S. Kimanga, D. Otieno, G. Ohaga, S. Oyaro, P. Mwangi, C. Knight, N. Chesang, K. Bock, N. TI Service delivery trends in Kenya's voluntary medical male circumcision scale-up from 2008-2011 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Mwandi, Z.; Mwalili, S.; Knight, N.; Chesang, K.] CDC Kenya, Nairobi, Kenya. [Ochieng, A.; Kimanga, D.] Minist Hlth, Natl AIDS & STD Control Program, Nairobi, Kenya. [Grund, J.; Bock, N.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Otieno, G.] Nyanza Reprod Hlth Soc, Kisumu, Kenya. [Ohaga, S.] Impact Res & Dev Org, Kisumu, Kenya. [Oyaro, P.] Kenya Govt Med Res Ctr, FACES Program, Nairobi, Kenya. [Mwangi, C.] Eastern Deanery AIDS Relief Program, Kisumu, Kenya. EM zmwandi@ke.cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 136 EP 137 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200251 ER PT J AU Reed, JB Mirira, M Grund, J Nqeketo, A Ginindza, H Donnell, D Nkambule, R Bicego, G Ryan, C Justman, J AF Reed, J. B. Mirira, M. Grund, J. Nqeketo, A. Ginindza, H. Donnell, D. Nkambule, R. Bicego, G. Ryan, C. Justman, J. TI Male circumcision in Swaziland: demographics, behaviours and HIV prevalence SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Mirira, M.] USAID Swaziland, Mbabane, Swaziland. [Nqeketo, A.; Ginindza, H.; Nkambule, R.] Minist Hlth Swaziland, Mbabane, Swaziland. [Donnell, D.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Bicego, G.] US Ctr Dis Control & Prevent Swaziland, Mbabane, Swaziland. [Ryan, C.] Off Global AIDS, Washington, DC USA. [Justman, J.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY USA. [Reed, J. B.; Grund, J.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div HIV AIDS, Atlanta, GA USA. EM eso7@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 137 EP 137 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200252 ER PT J AU Valverde, E Dinenno, E Oster, A Chavez, P Thomas, P Schulden, J Heffelfinger, J AF Valverde, E. Dinenno, E. Oster, A. Chavez, P. Thomas, P. Schulden, J. Heffelfinger, J. TI Sexually transmitted disease diagnoses associated with exchange sex among Hispanic migrant men who have sex with men in the United States SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Valverde, E.; Dinenno, E.; Oster, A.; Chavez, P.; Thomas, P.; Heffelfinger, J.] Ctr Dis Control & Prevent, Div HIV AIDS, Atlanta, GA USA. [Schulden, J.] NIDA, NIH, Bethesda, MD 20892 USA. EM eid8@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 138 EP 138 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200255 ER PT J AU Massud, I Aung, W Martin, A Bachman, S Mitchell, J Deyounks, F Kersh, E Pau, CP Heneine, W Garcia-Lerma, JG AF Massud, I. Aung, W. Martin, A. Bachman, S. Mitchell, J. Deyounks, F. Kersh, E. Pau, C. -P. Heneine, W. Garcia-Lerma, J. G. TI High maraviroc concentrations in rectal secretions after oral dosing do not prevent rectal SHIV transmission in macaques SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Massud, I.; Aung, W.; Martin, A.; Bachman, S.; Mitchell, J.; Deyounks, F.; Kersh, E.; Pau, C. -P.; Heneine, W.; Garcia-Lerma, J. G.] Ctr Dis Control & Prevent, Atlanta, GA USA. EM jng5@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 144 EP 144 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200267 ER PT J AU Njenga, F Kiima, D Siminyu, M Munyi, E Abdool, R Muthui, M Lambdin, B Mbwambo, J Mwamburi, E McCurdy, S Pick, B Anderson, G Mital, S Needle, R AF Njenga, F. Kiima, D. Siminyu, M. Munyi, E. Abdool, R. Muthui, M. Lambdin, B. Mbwambo, J. Mwamburi, E. McCurdy, S. Pick, B. Anderson, G. Mital, S. Needle, R. TI Heroin scarcity in coastal Kenya: consequences for persons who inject drugs (PWID) and national and provincial response to the crisis SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Njenga, F.] Natl Campaign Drug Abuse Author, Nairobi, Kenya. [Kiima, D.] Minist Med Serv, Div Mental Hlth Serv, Nairobi, Kenya. [Abdool, R.] UN Off Drugs & Crime, Nairobi, Kenya. [Muthui, M.] US Ctr Dis Control & Prevent Kenya, Nairobi, Kenya. [Lambdin, B.] Pangaea Global AIDS Fdn, Oakland, CA USA. [Mbwambo, J.] Muhimbili Univ Hlth & Allied Sci MUHAS, Dar Es Salaam, Tanzania. [Mwamburi, E.] US Agcy Int Dev Kenya, Nairobi, Kenya. [McCurdy, S.] Univ Texas Austin, Sch Publ Hlth, Austin, TX 78712 USA. [Anderson, G.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Atlanta, GA USA. [Pick, B.] USAID, Washington, DC USA. [Needle, R.] US Off Global AIDS Coordinator, Washington, DC USA. EM fnjenga@africaonline.co.ke NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 152 EP 153 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200283 ER PT J AU Habarta, N Wang, G Mulatu, M AF Habarta, N. Wang, G. Mulatu, M. TI HIV testing among transgender persons funded by the Centers for Disease Control and Prevention in the United States, Puerto Rico and US Virgin Islands, 2008-2009 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Habarta, N.; Wang, G.; Mulatu, M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM nhabarta@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 2 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 154 EP 154 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200286 ER PT J AU Carr, M Lehman, JS Purcell, DW AF Carr, M. Lehman, J. S. Purcell, D. W. TI Applying public health law research methods to address legal barriers and facilitators to effective HIV prevention programs SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Carr, M.; Lehman, J. S.; Purcell, D. W.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM dpurcell@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 6 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 208 EP 209 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200400 ER PT J AU Gupta, SS Granich, R Suthar, AB Smyth, C Baggaley, R Sculier, D Date, A Desai, MA Lule, F Raizes, E Blanc, L McClure, C Hirnschall, G AF Gupta, S. S. Granich, R. Suthar, A. B. Smyth, C. Baggaley, R. Sculier, D. Date, A. Desai, M. A. Lule, F. Raizes, E. Blanc, L. McClure, C. Hirnschall, G. TI Three I's for HIV/TB and early ART to prevent HIV and TB: policy review of HIV and TB guidelines for high HIV/TB-burden African countries SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Gupta, S. S.; Granich, R.; Suthar, A. B.; Smyth, C.; Baggaley, R.; Sculier, D.; Blanc, L.; McClure, C.; Hirnschall, G.] WHO, CH-1211 Geneva, Switzerland. [Date, A.; Desai, M. A.; Raizes, E.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Lule, F.] WHO, WR Country Off, Brazzaville, Congo. EM somyagupta17@gmail.com NR 0 TC 3 Z9 3 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 213 EP 213 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200412 ER PT J AU Revill, P Sculpher, M Walker, S Chasela, CS Kayira, D Hosseinipour, MC Merry, C Barry, M King, CK Jamieson, DJ Gibb, DM van der Horst, C Ryan, M AF Revill, P. Sculpher, M. Walker, S. Chasela, C. S. Kayira, D. Hosseinipour, M. C. Merry, C. Barry, M. King, C. K. Jamieson, D. J. Gibb, D. M. van der Horst, C. Ryan, M. TI The cost-effectiveness of maternal and infant antiretroviral regimens to prevent vertical HIV transmission in Malawi SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Revill, P.; Sculpher, M.; Walker, S.] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England. [Chasela, C. S.; Kayira, D.; Hosseinipour, M. C.] Univ N Carolina Project, Lilongwe, Malawi. [Hosseinipour, M. C.; van der Horst, C.] Univ N Carolina, Div Infect Dis, Ctr AIDS Res, Chapel Hill, NC USA. [Merry, C.; Barry, M.; Ryan, M.] Trinity Coll Dublin, Sch Med, Dept Pharmacol & Therapeut, Dublin, Ireland. [King, C. K.; Jamieson, D. J.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Gibb, D. M.] MRC, Clin Trials Unit, London, England. EM paul.revill@york.ac.uk NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 258 EP 258 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200502 ER PT J AU Muttai, H Wanjiku, L Gichangi, A Miruka, F Ayuaya, T Soti, D Zeh, C Ackers, M AF Muttai, H. Wanjiku, L. Gichangi, A. Miruka, F. Ayuaya, T. Soti, D. Zeh, C. Ackers, M. TI Use of viral load testing in resource-limited settings to confirm treatment failure in children: experience from Nyanza Province, western Kenya SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Muttai, H.; Miruka, F.; Zeh, C.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Kisumu, Kenya. [Wanjiku, L.; Gichangi, A.] Ctr Dis Control & Prevent CDC, Div Global HIV AIDS, Nairobi, Kenya. [Ayuaya, T.] KEMRI CDC Res & Publ Hlth Collaborat, HISS, Kisumu, Kenya. [Soti, D.] Minist Hlth, Kisumu, Kenya. [Ackers, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. EM hmuttai@ke.cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 281 EP 281 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200540 ER PT J AU Nganga, L Muttai, H Anthony, G Miruka, F Soti, D Okonji, J Ackers, M AF Nganga, L. Muttai, H. Anthony, G. Miruka, F. Soti, D. Okonji, J. Ackers, M. TI Routine viral load testing among pregnant HIV-positive women on antiretroviral therapy: implications for prevention, Nyanza province, Kenya, 2011 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Nganga, L.; Muttai, H.; Anthony, G.; Miruka, F.] Ctr Dis Control & Prevent, Nairobi, Kenya. [Soti, D.] Kenya Minist Publ Hlth & Sanitat, Nairobi, Kenya. [Okonji, J.] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Ackers, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. EM lnganga@ke.cdc.gov NR 0 TC 0 Z9 0 U1 1 U2 1 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD OCT PY 2012 VL 15 SU 3 BP 281 EP 282 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 030RQ UT WOS:000310588200541 ER PT J AU Amman, BR Carroll, SA Reed, ZD Sealy, TK Balinandi, S Swanepoel, R Kemp, A Erickson, BR Comer, JA Campbell, S Cannon, DL Khristova, ML Atimnedi, P Paddock, CD Crockett, RJK Flietstra, TD Warfield, KL Unfer, R Katongole-Mbidde, E Downing, R Tappero, JW Zaki, SR Rollin, PE Ksiazek, TG Nichol, ST Towner, JS AF Amman, Brian R. Carroll, Serena A. Reed, Zachary D. Sealy, Tara K. Balinandi, Stephen Swanepoel, Robert Kemp, Alan Erickson, Bobbie Rae Comer, James A. Campbell, Shelley Cannon, Deborah L. Khristova, Marina L. Atimnedi, Patrick Paddock, Christopher D. Crockett, Rebekah J. Kent Flietstra, Timothy D. Warfield, Kelly L. Unfer, Robert Katongole-Mbidde, Edward Downing, Robert Tappero, Jordan W. Zaki, Sherif R. Rollin, Pierre E. Ksiazek, Thomas G. Nichol, Stuart T. Towner, Jonathan S. TI Seasonal Pulses of Marburg Virus Circulation in Juvenile Rousettus aegyptiacus Bats Coincide with Periods of Increased Risk of Human Infection SO PLOS PATHOGENS LA English DT Article ID EBOLA HEMORRHAGIC-FEVER; SEQUENCE ALIGNMENT; OUTBREAK; DISEASE; KIKWIT; KENYA; CONGO AB Marburg virus (family Filoviridae) causes sporadic outbreaks of severe hemorrhagic disease in sub-Saharan Africa. Bats have been implicated as likely natural reservoir hosts based most recently on an investigation of cases among miners infected in 2007 at the Kitaka mine, Uganda, which contained a large population of Marburg virus-infected Rousettus aegyptiacus fruit bats. Described here is an ecologic investigation of Python Cave, Uganda, where an American and a Dutch tourist acquired Marburg virus infection in December 2007 and July 2008. More than 40,000 R. aegyptiacus were found in the cave and were the sole bat species present. Between August 2008 and November 2009, 1,622 bats were captured and tested for Marburg virus. Q-RT-PCR analysis of bat liver/spleen tissues indicated similar to 2.5% of the bats were actively infected, seven of which yielded Marburg virus isolates. Moreover, Q-RT-PCR-positive lung, kidney, colon and reproductive tissues were found, consistent with potential for oral, urine, fecal or sexual transmission. The combined data for R. aegyptiacus tested from Python Cave and Kitaka mine indicate low level horizontal transmission throughout the year. However, Q-RT-PCR data show distinct pulses of virus infection in older juvenile bats (similar to six months of age) that temporarily coincide with the peak twice-yearly birthing seasons. Retrospective analysis of historical human infections suspected to have been the result of discrete spillover events directly from nature found 83% (54/65) events occurred during these seasonal pulses in virus circulation, perhaps demonstrating periods of increased risk of human infection. The discovery of two tags at Python Cave from bats marked at Kitaka mine, together with the close genetic linkages evident between viruses detected in geographically distant locations, are consistent with R. aegyptiacus bats existing as a large meta-population with associated virus circulation over broad geographic ranges. These findings provide a basis for developing Marburg hemorrhagic fever risk reduction strategies. C1 [Amman, Brian R.; Carroll, Serena A.; Reed, Zachary D.; Sealy, Tara K.; Balinandi, Stephen; Erickson, Bobbie Rae; Comer, James A.; Campbell, Shelley; Cannon, Deborah L.; Flietstra, Timothy D.; Rollin, Pierre E.; Ksiazek, Thomas G.; Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. [Swanepoel, Robert; Kemp, Alan] Natl Inst Communicable Dis, Special Pathogens Unit, Johannesburg, South Africa. [Khristova, Marina L.] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Atlanta, GA USA. [Atimnedi, Patrick] Uganda Wildlife Author, Kampala, Uganda. [Paddock, Christopher D.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. [Crockett, Rebekah J. Kent] Ctr Dis Control & Prevent, Div Vector borne Dis, Arbovirus Dis Branch, Atlanta, GA USA. [Warfield, Kelly L.; Unfer, Robert] Integrated BioTherapeut, Gaithersburg, MD USA. [Katongole-Mbidde, Edward] Uganda Virus Res Inst, Entebbe, Uganda. [Downing, Robert; Tappero, Jordan W.] Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA. RP Amman, BR (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. EM jit8@cdc.gov RI Kading, Rebekah/E-5633-2017 OI Kading, Rebekah/0000-0002-4996-915X FU Department of Health and Human Services FX Funding was received from the Department of Health and Human Services. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript NR 33 TC 77 Z9 77 U1 4 U2 83 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD OCT PY 2012 VL 8 IS 10 AR e1002877 DI 10.1371/journal.ppat.1002877 PG 11 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 029XH UT WOS:000310530300002 PM 23055920 ER PT J AU Patel, MM Clark, AD Sanderson, CFB Tate, J Parashar, UD AF Patel, Manish M. Clark, Andrew D. Sanderson, Colin F. B. Tate, Jacqueline Parashar, Umesh D. TI Removing the Age Restrictions for Rotavirus Vaccination: A Benefit-Risk Modeling Analysis SO PLOS MEDICINE LA English DT Article ID RETROSPECTIVE SURVEILLANCE; CHILDHOOD INTUSSUSCEPTION; US INFANTS; CHILDREN; VACCINES; DIARRHEA; SAFETY; EFFICACY; HOSPITALIZATIONS; GASTROENTERITIS AB Background: To minimize potential risk of intussusception, the World Health Organization (WHO) recommended in 2009 that rotavirus immunization should be initiated by age 15 weeks and completed before 32 weeks. These restrictions could adversely impact vaccination coverage and thereby its health impact, particularly in developing countries where delays in vaccination often occur. Methods and Findings: We conducted a modeling study to estimate the number of rotavirus deaths prevented and the number of intussusception deaths caused by vaccination when administered on the restricted schedule versus an unrestricted schedule whereby rotavirus vaccine would be administered with DTP vaccine up to age 3 years. Countries were grouped on the basis of child mortality rates, using WHO data. Inputs were estimates of WHO rotavirus mortality by week of age from a recent study, intussusception mortality based on a literature review, predicted vaccination rates by week of age from USAID Demographic and Health Surveys, the United Nations Children's Fund (UNICEF) Multiple Indicator Cluster Surveys (MICS), and WHO-UNICEF 2010 country-specific coverage estimates, and published estimates of vaccine efficacy and vaccine-associated intussusception risk. On the basis of the error estimates and distributions for model inputs, we conducted 2,000 simulations to obtain median estimates of deaths averted and caused as well as the uncertainty ranges, defined as the 5th-95th percentile, to provide an indication of the uncertainty in the estimates. We estimated that in low and low-middle income countries a restricted schedule would prevent 155,800 rotavirus deaths (5th-95th centiles, 83,300-217,700) while causing potentially 253 intussusception deaths (76-689). In contrast, vaccination without age restrictions would prevent 203,000 rotavirus deaths (102,000-281,500) while potentially causing 547 intussusception deaths (237-1,160). Thus, removing the age restrictions would avert an additional 47,200 rotavirus deaths (18,700-63,700) and cause an additional 294 (161-471) intussusception deaths, for an incremental benefit-risk ratio of 154 deaths averted for every death caused by vaccine. These extra deaths prevented under an unrestricted schedule reflect vaccination of an additional 21%-25% children, beyond the 63%-73% of the children who would be vaccinated under the restricted schedule. Importantly, these estimates err on the side of safety in that they assume high vaccine-associated risk of intussusception and do not account for potential herd immunity or non-fatal outcomes. Conclusions: Our analysis suggests that in low- and middle-income countries the additional lives saved by removing age restrictions for rotavirus vaccination would far outnumber the potential excess vaccine-associated intussusception deaths. C1 [Patel, Manish M.; Tate, Jacqueline; Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Clark, Andrew D.; Sanderson, Colin F. B.] London Sch Hyg & Trop Med, London WC1, England. RP Patel, MM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. EM Aul3@CDC.GOV OI Sanderson, Colin/0000-0002-4838-6112 FU PanAmerican Health Organization's ProVac Initiative FX CS has received salary support from WHO's Initiative for Vaccine Research for collecting some of the data (vaccine timeliness and age distribution of rotavirus deaths) used in the model. AC was funded by PanAmerican Health Organization's ProVac Initiative. MMP, UDP, and JT were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this paper). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention (CDC). NR 64 TC 29 Z9 29 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD OCT PY 2012 VL 9 IS 10 AR e1001330 DI 10.1371/journal.pmed.1001330 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 030OC UT WOS:000310579000012 PM 23109915 ER PT J AU Chai, M Birch, ME Deye, G AF Chai, Ming Birch, M. Eileen Deye, Greg TI Organic and Elemental Carbon Filter Sets: Preparation Method and Interlaboratory Results SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE black carbon; carbonaceous aerosol; elemental carbon; organic carbon; particulate matter; ultrafine ID PARTICULATE AIR-POLLUTION; DIESEL EXHAUST; PARTICLES; ASSOCIATION; REFLECTANCE; MORTALITY; SAMPLES; CITIES AB Carbonaceous aerosols play an important role in climate, visibility, air quality, and human health effects, and they have been routinely monitored in workplace and environmental settings. Different thermal analysis methods have been applied to determine the carbon content of carbonaceous aerosols. Good agreement between results for total carbon (TC) generally has been found, but the organic and elemental carbon (OC and EC) fractions determined by different methods often disagree. Measurement uncertainty is mainly due to pyrolysis and charring of OC sample components. Lack of reference materials has impeded progress on method standardization and understanding method biases. A relatively simple method for generating matched filter sets having known OC-EC contents is reported. After generation and analysis of each set to confirm agreement between filters, the filter sets were distributed to six laboratories for an interlaboratory comparison. Analytical results indicate a uniform carbon distribution for the filter sets and good agreement between the participating laboratories. Relative standard deviations (RSDs) for mean TC (OC + EC), OC, and EC results for seven laboratories were < 10, 11, and 12% (respectively). Except for one EC result (RSD = 16%), RSDs reported by individual laboratories for TC, OC, and EC were < 12%. The method of filter generation is generally applicable and reproducible. Depending on the application, different filter loadings and types of OC materials can be employed. Matched filter sets prepared by the described approach can be used for determining the accuracy of OC-EC methods and thereby contribute to method standardization. C1 [Birch, M. Eileen; Deye, Greg] NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Chai, Ming] Univ Cincinnati, Dept Civil & Environm Engn, Cincinnati, OH 45221 USA. RP Birch, ME (reprint author), NIOSH, Div Appl Res & Technol, 4676 Columbia Pkwy,MS-R7, Cincinnati, OH 45226 USA. EM mib2@cdc.gov FU National Institute for Occupational Safety and Health Nanotechnology Research Center FX National Institute for Occupational Safety and Health Nanotechnology Research Center. NR 25 TC 2 Z9 2 U1 1 U2 15 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD OCT PY 2012 VL 56 IS 8 BP 959 EP 967 DI 10.1093/annhyg/mes029 PG 9 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 025AL UT WOS:000310154600009 PM 22459320 ER PT J AU Barbour, KE Lui, LY Barnes, DE Ensrud, KE Newman, AB Yaffe, K Cummings, SR Cauley, JA AF Barbour, Kamil E. Lui, Li-Yung Barnes, Deborah E. Ensrud, Kristine E. Newman, Anne B. Yaffe, Kristine Cummings, Steven R. Cauley, Jane A. TI Trajectories of Change in Physical Function: Effects On Fractures and Mortality. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Barbour, Kamil E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lui, Li-Yung] Calif Pacific Med Ctr, San Francisco, CA USA. [Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ensrud, Kristine E.] Univ Minnesota, Minneapolis, MN USA. [Ensrud, Kristine E.] Minneapolis VAHS, Minneapolis, MN USA. [Newman, Anne B.; Cauley, Jane A.] Univ Pittsburgh, Pittsburgh, PA USA. [Cummings, Steven R.] San Francisco Coordinating Ctr, CPMC Res Inst, San Francisco, CA USA. RI Newman, Anne/C-6408-2013 OI Newman, Anne/0000-0002-0106-1150 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 819 BP S356 EP S357 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748301356 ER PT J AU Brady, TJ Mills, S Sargious, P Ziabakhsh, S AF Brady, Teresa J. Mills, Sue Sargious, Peter Ziabakhsh, Shabnam TI An International Framework for Chronic Condition Self Management Support: Results from an International Electronic Consultation Process. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Brady, Teresa J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mills, Sue] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Sargious, Peter] Alberta Hlth Serv, Calgary, AB, Canada. [Ziabakhsh, Shabnam] BC Womens Hosp & Hlth Ctr, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2401 BP S1011 EP S1012 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748305321 ER PT J AU Drenkard, C Dunlop-Thomas, CM Easley, K Bao, GB Lim, SS Brady, TJ AF Drenkard, Cristina Dunlop-Thomas, Charmayne M. Easley, Kirk Bao, Gaobin Lim, S. Sam Brady, Teresa J. TI Benefits of the Chronic Disease Self-Management Program in Low-Income African American Women with Systemic Lupus Erythematosus: Results of a Pilot Test SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Drenkard, Cristina; Dunlop-Thomas, Charmayne M.; Easley, Kirk; Bao, Gaobin; Lim, S. Sam] Emory Univ, Atlanta, GA 30322 USA. [Brady, Teresa J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2695 BP S1142 EP S1143 PG 2 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748306204 ER PT J AU Nelson, AE Shi, XYA Schwartz, TA Renner, JB Caldwell, KL Helmick, CG Jordan, JM AF Nelson, Amanda E. Shi, Xiaoyan A. Schwartz, Todd A. Renner, Jordan B. Caldwell, Kathleen L. Helmick, Charles G. Jordan, Joanne M. TI Whole Blood Lead Is Associated with Symptoms, but Not Radiographic Osteoarthritis, in Multiple Joint Sites: The Johnston County Osteoarthritis Project. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Nelson, Amanda E.; Jordan, Joanne M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC USA. [Shi, Xiaoyan A.] SAS Inst Inc, Cary, NC USA. [Schwartz, Todd A.] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Renner, Jordan B.] Univ N Carolina, Sch Med, Dept Radiol, Chapel Hill, NC 27514 USA. [Caldwell, Kathleen L.; Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 1099 BP S472 EP S472 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748302174 ER PT J AU Theis, KA Brady, TJ Helmick, CG Murphy, L Barbour, KE AF Theis, Kristina A. Brady, Teresa J. Helmick, Charles G. Murphy, Louise Barbour, Kamil E. TI Arthritis-Attributable Interference in Routine Life Activities. SO ARTHRITIS AND RHEUMATISM LA English DT Meeting Abstract CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) CY NOV 09-14, 2012 CL Washington, DC SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP) C1 [Theis, Kristina A.; Brady, Teresa J.; Helmick, Charles G.; Barbour, Kamil E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Murphy, Louise] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD OCT PY 2012 VL 64 IS 10 SU S MA 2416 BP S1018 EP S1018 PG 1 WC Rheumatology SC Rheumatology GA 019OD UT WOS:000309748305336 ER PT J AU Plikaytis, BD Stella, M Boccadifuoco, G DeTora, LM Agnusdei, M Santini, L Brunelli, B Orlandi, L Simmini, I Giuliani, M Ledroit, M Hong, E Taha, MK Ellie, K Rajam, G Carlone, GM Claus, H Vogel, U Borrow, R Findlow, J Gilchrist, S Stefanelli, P Fazio, C Carannante, A Oksnes, J Fritzsonn, E Klem, AM Caugant, DA Abad, R Vazquez, JA Rappuoli, R Pizza, M Donnelly, JJ Medini, D AF Plikaytis, Brian D. Stella, Maria Boccadifuoco, Giuseppe DeTora, Lisa M. Agnusdei, Mauro Santini, Laura Brunelli, Brunella Orlandi, Luca Simmini, Isabella Giuliani, Marzia Ledroit, Morgan Hong, Eva Taha, Muhamed-Kheir Ellie, Kim Rajam, Gowrisankar Carlone, George M. Claus, Heike Vogel, Ulrich Borrow, Ray Findlow, Jamie Gilchrist, Stefanie Stefanelli, Paola Fazio, Cecilia Carannante, Anna Oksnes, Jan Fritzsonn, Elisabeth Klem, Anne-Marie Caugant, Dominique A. Abad, Raquel Vazquez, Julio A. Rappuoli, Rino Pizza, Mariagrazia Donnelly, John J. Medini, Duccio TI Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID MEMBRANE VESICLE VACCINE; SEROGROUP-B MENINGOCOCCUS; NEISSERIA-MENINGITIDIS; SEQUENCE VARIATION; PROTEIN; RECOMBINATION; SURVEILLANCE; POPULATIONS; ANTIGENS; EVALUATE AB The meningococcal antigen typing system (MATS) sandwich enzyme-linked immunosorbent assay (ELISA) was designed to measure the immunologic cross-reactivity and quantity of antigens in target strains of a pathogen. It was first used to measure the factor H-binding protein (fHbp), neisserial adhesin A (NadA), and neisserial heparin-binding antigen (NHBA) content of serogroup B meningococcal (MenB) isolates relative to a reference strain, or "relative potency" (RP). With the PorA genotype, the RPs were then used to assess strain coverage by 4CMenB, a multicomponent MenB vaccine. In preliminary studies, MATS accurately predicted killing in the serum bactericidal assay using human complement, an accepted correlate of protection for meningococcal vaccines. A study across seven laboratories assessed the reproducibility of RPs for fHbp, NadA, and NHBA and established qualification parameters for new laboratories. RPs were determined in replicate for 17 MenB reference strains at laboratories A to G. The reproducibility of RPs among laboratories and against consensus values across laboratories was evaluated using a mixed-model analysis of variance. Interlaboratory agreement was very good; the Pearson correlation coefficients, coefficients of accuracy, and concordance correlation coefficients exceeded 99%. The summary measures of reproducibility, expressed as between-laboratory coefficients of variation, were 7.85% (fHbp), 16.51% (NadA), and 12.60% (NHBA). The overall within-laboratory measures of variation adjusted for strain and laboratory were 19.8% (fHbp), 28.8% (NHBA), and 38.3% (NadA). The MATS ELISA was successfully transferred to six laboratories, and a further laboratory was successfully qualified. C1 [Stella, Maria; Boccadifuoco, Giuseppe; DeTora, Lisa M.; Agnusdei, Mauro; Santini, Laura; Brunelli, Brunella; Orlandi, Luca; Simmini, Isabella; Giuliani, Marzia; Rappuoli, Rino; Pizza, Mariagrazia; Donnelly, John J.; Medini, Duccio] Novartis Vaccines & Diagnost, Siena, Italy. [Plikaytis, Brian D.; Ellie, Kim; Rajam, Gowrisankar; Carlone, George M.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Ledroit, Morgan; Hong, Eva; Taha, Muhamed-Kheir] Inst Pasteur, Invas Bacterial Infect Unit, Paris, France. [Ledroit, Morgan; Hong, Eva; Taha, Muhamed-Kheir] Natl Reference Ctr Meningococci, Paris, France. [Claus, Heike; Vogel, Ulrich] Univ Wurzburg, Inst Hyg & Microbiol, Natl Reference Lab Meningococci, Wurzburg, Germany. [Borrow, Ray; Findlow, Jamie; Gilchrist, Stefanie] Manchester Royal Infirm, Hlth Protect Agcy, Manchester M13 9WL, Lancs, England. [Stefanelli, Paola; Fazio, Cecilia; Carannante, Anna] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy. [Oksnes, Jan; Fritzsonn, Elisabeth; Klem, Anne-Marie; Caugant, Dominique A.] Norwegian Inst Publ Hlth, Dept Bacteriol & Immunol, Oslo, Norway. [Abad, Raquel; Vazquez, Julio A.] Inst Hlth Carlos III, Madrid, Spain. RP Medini, D (reprint author), Novartis Vaccines & Diagnost, Siena, Italy. EM duccio.medini@novartis.com RI Abad, Raquel/L-7595-2015; STEFANELLI, PAOLA/B-8729-2016; Medini, Duccio/Q-9556-2016 OI Abad, Raquel/0000-0002-8339-0950; STEFANELLI, PAOLA/0000-0003-1620-4385; Medini, Duccio/0000-0001-6041-2603 NR 27 TC 30 Z9 31 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD OCT PY 2012 VL 19 IS 10 BP 1609 EP 1617 DI 10.1128/CVI.00202-12 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 016TE UT WOS:000309541600008 PM 22875603 ER PT J AU Watanabe, E Zehnbauer, BA Oda, S Sato, Y Hirasawa, H Buchman, TG AF Watanabe, Eizo Zehnbauer, Barbara A. Oda, Shigeto Sato, Yasunori Hirasawa, Hiroyuki Buchman, Timothy G. TI Tumor necrosis factor-308 polymorphism (rs1800629) is associated with mortality and ventilator duration in 1057 Caucasian patients SO CYTOKINE LA English DT Article DE Genetic Predisposition to Disease; Genetic testing; Sepsis; Cytokines; Ventilators, mechanical ID INTERLEUKIN-6 BLOOD-LEVELS; CRITICALLY-ILL PATIENTS; ORGAN FAILURE; SEVERE SEPSIS; GENOTYPIC DIFFERENCES; INNOVATIVE THERAPIES; SEPTIC COMPLICATIONS; ALPHA PROMOTER; CARE; SUSCEPTIBILITY AB Purpose: Management of sepsis in critically ill patients remains difficult and requires prolonged intensive care. Genetic testing has been proposed as a strategy to identify patients at risk for adverse outcome of critical illnesses. Therefore, we wished to determine the influence of heredity on predisposition to poor outcome and on duration of ventilator support of intensive care unit (ICU) patients. Methods: A study was conducted from July 2001 to December 2005 in heterogeneous population of patients from 12 US ICUs represented by the Genetic Predisposition to Severe Sepsis (GenPSS) archive. In 1057 Caucasian critically ill patients with SAPS II probability of survival of >0.2 in the US, six functional single nucleotide polymorphisms in relation to inflammatory cytokines and innate immunity (rs1800629, rs16944, rs1800795, rs1800871, rs2569190, and rs909253) were evaluated in terms of mortality and ventilator free days. Results: The AA homozygote of TNR-308) (rs1800629) was most over-represented in the deceased patient group (P.= 0.015 with recessive model). The carriage of the TNF(-308)*AA genotype showed significantly higher odds ratio of 2.67(1.29-5.55) (P = 0.008) after adjustment with the covariates. However, the presence of 1, 2, or 3 acute organ dysfunctions was larger prognostic factors for the adverse outcome (OR(95%CI) = 2.98(2.00-4.45), 4.01(2.07-7.77), or 19.95(4.99-79.72), P<0.001 for all). Kaplan-Mayer plot on ventilator duration of TNF(-308)*AA patient significantly diverged from that of TNF(-308)*(GG + GA) ((AA v GG + GA), Adjusted HR(95%C1) - 2.53(1.11-5.79) with Cox regression, P = 0.028). Conclusions: TNF(-308)*AA is significantly associated with susceptibility to adverse outcome and to longer ventilator duration. Therefore, heredity likely affects both predisposition to ICU prognosis as well as the resource utilization. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Watanabe, Eizo] Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chuo Ku, Chiba 2608670, Japan. [Watanabe, Eizo; Buchman, Timothy G.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA. [Sato, Yasunori] Chiba Univ, Sch Med, Clin Lab, Chiba 2608670, Japan. [Zehnbauer, Barbara A.] Ctr Dis Control & Prevent, Lab Sci, Policy & Practice Program Off, Atlanta, GA USA. [Buchman, Timothy G.] Emory Univ, Emory Ctr Crit Care ECCC, Atlanta, GA 30322 USA. [Buchman, Timothy G.] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA. RP Watanabe, E (reprint author), Chiba Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan. EM watanabee@faculty.chiba-u.jp OI Buchman, Timothy/0000-0001-7350-5921 FU NIH/GM [062809]; Pfizer by Japanese Association for Acute Medicine FX This research was supported by NIH/GM (062809) and the Pfizer Travel Fellowship 2006 by Japanese Association for Acute Medicine. The funding sources had no role in study design, collection, analysis, and interpretation of data. NR 41 TC 4 Z9 6 U1 0 U2 3 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD OCT PY 2012 VL 60 IS 1 BP 249 EP 256 DI 10.1016/j.cyto.2012.06.016 PG 8 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 024FL UT WOS:000310095000038 PM 22749237 ER PT J AU Iademarco, MF Koh, WJ AF Iademarco, M. F. Koh, W. J. TI 2011: The year in review. Part II: Tuberculosis and lung disease SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Review ID MULTIDRUG-RESISTANT TUBERCULOSIS; OBSTRUCTIVE PULMONARY-DISEASE; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; ISONIAZID PREVENTIVE THERAPY; MYCOBACTERIUM-TUBERCULOSIS; LATENT TUBERCULOSIS; NONTUBERCULOUS MYCOBACTERIA; QUANTIFERON(R)-TB GOLD; TREATMENT ADHERENCE C1 [Iademarco, M. F.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. [Koh, W. J.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Pulm & Crit Care Med,Dept Med, Seoul, South Korea. RP Iademarco, MF (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. EM mai9@cdc.gov RI Koh, Won Jung/C-9595-2011 NR 87 TC 0 Z9 0 U1 0 U2 6 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD OCT PY 2012 VL 16 IS 10 BP 1291 EP 1299 DI 10.5588/ijtld.12.0566 PG 9 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 028HJ UT WOS:000310413100004 PM 23107631 ER PT J AU Althomsons, SP Cegielski, JP AF Althomsons, S. P. Cegielski, J. P. TI Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE drug-resistant TB; treatment outcomes; second-line resistance ID SURVEILLANCE AB SETTING: The worldwide emergence of extensively drug-resistant tuberculosis (TB) has focused attention on treatment with second-line drugs (SLDs). OBJECTIVE: To determine the impact on outcomes of resistance to individual SLDs, we analyzed successful treatment completion and death among drug-resistant TB cases in the US national TB surveillance system, 1993-2007 (N = 195518). DESIGN: We defined four combinations of first-line drug (FLD) resistance based on isoniazid (INH) and rifamycin, and three patterns of SLD resistance: fluoroquinolones, injectable SLDs and other oral SLDs. We compared treatment outcomes of cases by FLD resistance, with and without each pattern of SLD resistance. RESULTS: In all but one instance, cases with FLD resistance but no SLD resistance had better outcomes than cases with SLD resistance. Rifamycin resistance, alone or with INH, resulted in a greater decline in treatment completion and greater increase in deaths than resistance to SLDs. Among patients with multidrug-resistant TB, additional resistance to injectable SLDs was statistically significant. Outcomes were better for human immunodeficiency virus (HIV) negative than HIV-positive cases for all resistance patterns, but improved among HIV-infected cases after 1998, when highly active antiretroviral treatment became widely available. CONCLUSION: These results suggest that the effect of rifamycin resistance may outweigh the more modest effects of resistance to specific SLDs. C1 [Althomsons, S. P.; Cegielski, J. P.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Althomsons, SP (reprint author), Ctr Dis Control & Prevent, Outbreak Invest Branch, Div TB Eliminat, Mailstop E-10,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM SAlthomsons@cdc.gov FU Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA FX The authors thank V Robison for helpful discussions on methodological approach to data analysis, and S Smith for assistance in table arrangement. The study was funded by the Division of Tuberculosis Elimination, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. NR 12 TC 5 Z9 6 U1 0 U2 6 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD OCT PY 2012 VL 16 IS 10 BP 1331 EP 1334 DI 10.5588/ijtld.11.0812 PG 4 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 028HJ UT WOS:000310413100010 PM 22863311 ER PT J AU Kurbatova, EV Gammino, VM Bayona, J Becerra, MC Danilovitz, M Falzon, D Gelmanova, I Keshavjee, S Leimane, V Mitnick, CD Quelapio, MI Riekstina, V Taylor, A Viiklepp, P Zignol, M Cegielski, JP AF Kurbatova, E. V. Gammino, V. M. Bayona, J. Becerra, M. C. Danilovitz, M. Falzon, D. Gelmanova, I. Keshavjee, S. Leimane, V. Mitnick, C. D. Quelapio, M. I. Riekstina, V. Taylor, A. Viiklepp, P. Zignol, M. Cegielski, J. P. TI Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE MDR-TB; time to culture conversion; predictive values ID PULMONARY TUBERCULOSIS; TB PATIENTS; TIME; SMEAR; BIOMARKERS; DEFAULT AB OBJECTIVE: To identify predictors of initial sputum culture conversion, estimate the usefulness of persistent positive cultures at different time points in predicting treatment failure, and evaluate different definitions of culture conversion for predicting failure among patients with multidrug-resistant tuberculosis (MDR-TB) in five countries, 2000-2004. METHODS: Predictors of time to conversion were identified using multivariate Cox proportional hazards regression modeling. Receiver operating characteristic curves were plotted to visualize the effect of using different definitions of 'culture conversion' on the balance between sensitivity and specificity. RESULTS: Overall, 1209/1416 (85%) of patients with baseline positive cultures converted in a median of 3.0 months (interquartile range 2.0-5.0). Independent predictors of less likely conversion included baseline positive smear (hazard ratio [HR] 0.60, 95%CI 0.53-0.68), resistance to pyrazinamide (HR 0.82, 95%CI 0.70-0.96), fluoroquinolones (FQs; HR 0.65, 95%CI 0.51-0.83) or thioamide (HR 0.83, 95%CI 0.71-0.96), previous use of FQs (HR 0.71, 95%CI 0.60-0.83), poor outcome of previous anti-tuberculosis treatment (HR 0.69, 95%CI 0.54-0.88) and alcoholism (HR 0.74, 95%CI 0.63-0.87). The maximum combined sensitivity (84%) and specificity (94%) in predicting treatment failure was based on lack of culture conversion at month 9 of treatment, assuming conversion is defined as five consecutive negative cultures. CONCLUSION: Patients with identified risk factors were less likely to achieve sputum culture conversion during MDR-TB treatment. C1 [Kurbatova, E. V.; Gammino, V. M.; Taylor, A.; Cegielski, J. P.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Bayona, J.; Becerra, M. C.; Gelmanova, I.; Keshavjee, S.; Mitnick, C. D.] Partners Hlth, Lima, Peru. [Bayona, J.; Becerra, M. C.; Gelmanova, I.; Keshavjee, S.; Mitnick, C. D.] Partners Hlth, Tomsk, Russia. [Bayona, J.; Becerra, M. C.; Gelmanova, I.; Keshavjee, S.; Mitnick, C. D.] Partners Hlth, Boston, MA USA. [Bayona, J.; Becerra, M. C.; Keshavjee, S.; Mitnick, C. D.] Harvard Univ, Sch Med, Boston, MA USA. [Danilovitz, M.] Univ Tartu, Lung Hosp, EE-50090 Tartu, Estonia. [Falzon, D.; Zignol, M.] WHO, CH-1211 Geneva, Switzerland. [Leimane, V.; Riekstina, V.] Infectol Ctr Latvia, TB & Lung Dis Clin, Riga, Latvia. [Quelapio, M. I.] Trop Dis Fdn, Manila, Philippines. [Viiklepp, P.] Natl Inst Hlth Dev, Tallinn, Estonia. RP Kurbatova, EV (reprint author), Ctr Dis Control & Prevent, Int Res & Programs Branch, Div TB Eliminat, Mailstop E-10 NE,1600 Clifton Rd, Atlanta, GA 30333 USA. EM ekurbatova@cdc.gov FU United States Agency for International Development (USAID); US Centers for Disease Control and Prevention (CDC) FX The authors thank J Becerra for helpful discussions on the methodological approach to data analysis, S Kammerer for SAS programming expertise, M Chen for statistical advice and W R Mac Kenzie for the critical review of the manuscript. This study was funded by the United States Agency for International Development (USAID) and the US Centers for Disease Control and Prevention (CDC). NR 32 TC 26 Z9 26 U1 0 U2 7 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD OCT PY 2012 VL 16 IS 10 BP 1335 EP 1343 DI 10.5588/ijtld.11.0811 PG 9 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 028HJ UT WOS:000310413100011 PM 23107633 ER PT J AU Venezia, J Cassiday, PK Marini, RP Shen, ZL Buckley, EM Peters, Y Taylor, N Dewhirst, FE Tondella, ML Fox, JG AF Venezia, Jaime Cassiday, Pamela K. Marini, Robert P. Shen, Zeli Buckley, Ellen M. Peters, Yaicha Taylor, Nancy Dewhirst, Floyd E. Tondella, Maria L. Fox, James G. TI Characterization of Corynebacterium species in macaques SO JOURNAL OF MEDICAL MICROBIOLOGY LA English DT Article ID CUTANEOUS DIPHTHERIA; SEQUENCE-ANALYSIS; URINARY CALCULUS; ULCERANS STRAINS; UNITED-KINGDOM; IDENTIFICATION; PSEUDOTUBERCULOSIS; MICROBIOLOGY; INFECTION; RATS AB Bacteria of the genus Corynebacterium are important primary and opportunistic pathogens. Many are zoonotic agents. In this report, phenotypic (API Coryne analysis), genetic (rpoB and 16S rRNA gene sequencing), and physical methods (MS) were used to distinguish the closely related diphtheroid species Corynebacterium ulcerans and Corynebacterium pseudotuberculosis, and to definitively diagnose Corynebacterium renale from cephalic implants of rhesus (Macaca mulatta) and cynomolgus (Macaca fascicularis) macaques used in cognitive neuroscience research. Throat and cephalic implant cultures yielded 85 isolates from 43 macaques. Identification by API Coryne yielded C. ulcerans (n=74), Corynebacterium pseudotuberculosis (n=2), C. renale or most closely related to C. renale (n=3), and commensals and opportunists (n=6). The two isolates identified as C. pseudo tuberculosis by API Coryne required genetic and MS analysis for accurate characterization as C. ulcerans. Of three isolates identified as C. renale by 16S rRNA gene sequencing, only one could be confirmed as such by API Coryne, rpoB gene sequencing and MS. This study emphasizes the importance of adjunct methods in identification of coryneforms and is the first isolation of C. renale from cephalic implants in macaques. C1 [Venezia, Jaime; Marini, Robert P.; Shen, Zeli; Buckley, Ellen M.; Peters, Yaicha; Taylor, Nancy; Fox, James G.] MIT, Div Comparat Med, Cambridge, MA 02139 USA. [Cassiday, Pamela K.; Tondella, Maria L.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30333 USA. [Dewhirst, Floyd E.] Forsyth Inst, Dept Mol Genet, Cambridge, MA 02142 USA. [Dewhirst, Floyd E.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. RP Fox, JG (reprint author), MIT, Div Comparat Med, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM jgfox@mit.edu FU NIH [DE106937, T32-RR032307] FX This study was funded by NIH grant(s): DE106937 (F. E. D.); T32-RR032307 (J. G. F.). NR 34 TC 6 Z9 9 U1 0 U2 8 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 0022-2615 J9 J MED MICROBIOL JI J. Med. Microbiol. PD OCT PY 2012 VL 61 IS 10 BP 1401 EP 1408 DI 10.1099/jmm.0.045377-0 PG 8 WC Microbiology SC Microbiology GA 028HX UT WOS:000310414500008 PM 22723254 ER PT J AU Joesoef, RM Harpaz, R Leung, J Bialek, SR AF Joesoef, Riduan M. Harpaz, Rafael Leung, Jessica Bialek, Stephanie R. TI Chronic Medical Conditions as Risk Factors for Herpes Zoster SO MAYO CLINIC PROCEEDINGS LA English DT Article ID POSTHERPETIC NEURALGIA; RHEUMATOID-ARTHRITIS; VARICELLA-ZOSTER; UNITED-STATES; PREDICTIVE-VALUE; OLDER-ADULTS; VACCINATION; INFECTION; VIRUS; RATES AB Objective: To determine the degree to which chronic conditions might contribute to the unexplained burden of herpes zoster. Methods: We conducted a case-control study using Market Scan data from January 1, 2007, through December 31, 2007, to investigate chronic conditions as risk factors for herpes zoster among persons 20 to 64 years old. Cases were enrollees with a herpes zoster diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification codes 053.xx), and controls were those without a herpes zoster diagnosis, matched by age groups and insurance plan. We selected 10 chronic conditions based on their prevalence in the general population. We calculated the attributable fraction and created a comorbidity composite score by summing the significant coefficient of regression of chronic conditions. We used logistic regression to evaluate the associations between herpes zoster and chronic conditions. Results: We identified a total of 59,173 cases and 616,177 controls for the analysis. Risk of herpes zoster was significant for 8 of the 10 study conditions (odds ratios, 1.06-1.52). Herpes zoster risk also increased as a function of comorbidity composite score. The attributable fractions for these 8 significant conditions ranged from 0.24% to 2.89%. Conclusion: The risk of herpes zoster may be increased in people with chronic conditions. However, this risk may not contribute substantially to the burden of herpes zoster in the population. The causes for most cases of herpes zoster remain unknown. (C) 2012 Mayo Foundation for Medical Education and Research square Mayo Clin Proc. 2012:87(10)961-967 C1 [Joesoef, Riduan M.; Harpaz, Rafael; Leung, Jessica; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Harpaz, R (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA. EM Rharpaz@cdc.gov NR 32 TC 20 Z9 20 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD OCT PY 2012 VL 87 IS 10 BP 961 EP 967 DI 10.1016/j.mayocp.2012.05.021 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 024QE UT WOS:000310122900006 PM 23036671 ER PT J AU Zhu, TT Cheng, R Lee, SA Rajaraman, E Eiteman, MA Querec, TD Unger, ER Mao, LD AF Zhu, Taotao Cheng, Rui Lee, Sarah A. Rajaraman, Eashwar Eiteman, Mark A. Querec, Troy D. Unger, Elizabeth R. Mao, Leidong TI Continuous-flow ferrohydrodynamic sorting of particles and cells in microfluidic devices SO MICROFLUIDICS AND NANOFLUIDICS LA English DT Article DE Cell sorting; Ferrohydrodynamics; Continuous-flow; Ferrofluid; Microfluidics ID POLYMERASE-CHAIN-REACTION; CIRCULATING TUMOR-CELLS; ON-A-CHIP; MAGNETIC MICROBEADS; SEPARATION; MANIPULATION; FERROFLUIDS; MICROCHIP; FORCE; SYSTEMS AB A new sorting scheme based on ferrofluid hydrodynamics (ferrohydrodynamics) was used to separate mixtures of particles and live cells simultaneously. Two species of cells, including Escherichia coli and Saccharomyces cerevisiae, as well as fluorescent polystyrene microparticles were studied for their sorting throughput and efficiency. Ferrofluids are stable magnetic nanoparticles suspensions. Under external magnetic field gradients, magnetic buoyancy forces exerted on particles and cells lead to size-dependent deflections from their laminar flow paths and result in spatial separation. We report the design, modeling, fabrication and characterization of the sorting device. This scheme is simple, low-cost and label-free compared to other existing techniques. C1 [Cheng, Rui; Mao, Leidong] Univ Georgia, Fac Engn, Nanoscale Sci & Engn Ctr, Athens, GA 30602 USA. [Zhu, Taotao] Univ Georgia, Dept Chem, Nanoscale Sci & Engn Ctr, Athens, GA 30602 USA. [Lee, Sarah A.; Rajaraman, Eashwar; Eiteman, Mark A.] Univ Georgia, Dept Biol & Agr Engn, Ctr Mol BioEngn, Athens, GA 30602 USA. [Querec, Troy D.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis Pathol, Atlanta, GA 30333 USA. RP Mao, LD (reprint author), Univ Georgia, Fac Engn, Nanoscale Sci & Engn Ctr, Athens, GA 30602 USA. EM mao@uga.edu RI Cheng, Rui/M-2238-2016; OI Cheng, Rui/0000-0001-7784-1658; Zhu, Taotao/0000-0001-5152-163X; Unger, Elizabeth/0000-0002-2925-5635 FU National Science Foundation, American Society for Microbiology/Centers for Disease Control and Prevention Postdoctoral Research Fellowship; Centers for Disease Control and Prevention; University of Georgia Seed Award Program FX This work is in part supported by the National Science Foundation, American Society for Microbiology/Centers for Disease Control and Prevention Postdoctoral Research Fellowship, Centers for Disease Control and Prevention and University of Georgia Seed Award Program. NR 67 TC 38 Z9 39 U1 2 U2 57 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1613-4982 J9 MICROFLUID NANOFLUID JI Microfluid. Nanofluid. PD OCT PY 2012 VL 13 IS 4 SI SI BP 645 EP 654 DI 10.1007/s10404-012-1004-9 PG 10 WC Nanoscience & Nanotechnology; Instruments & Instrumentation; Physics, Fluids & Plasmas SC Science & Technology - Other Topics; Instruments & Instrumentation; Physics GA 028AE UT WOS:000310394400012 PM 26430394 ER PT J AU Drexler, N Washington, CH Lovegrove, M Grady, C Milord, MD Streit, T Lammie, P AF Drexler, Naomi Washington, Charles H. Lovegrove, Maribeth Grady, Caroline Milord, Marie Denise Streit, Thomas Lammie, Patrick TI Secondary Mapping of Lymphatic Filariasis in Haiti-Definition of Transmission Foci in Low-Prevalence Settings SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID LEOGANE AB To eliminate Lymphatic filariasis (LF) as a public health problem, the World Health Organization (WHO) recommends that any area with infection prevalence greater than or equal to 1% (denoted by presence of microfilaremia or antigenemia) should receive mass drug administration (MDA) of antifilarial drugs for at least five consecutive rounds. Areas of low-antigen prevalence (, 1%) are thought to pose little risk for continued transmission of LF. Five low-antigen prevalence communes in Haiti, characterized as part of a national survey, were further assessed for transmission in this study. An initial evaluation of schoolchildren was performed in each commune to identify antigen-positive children who served as index cases for subsequent community surveys conducted among households neighboring the index cases. Global positioning system (GPS) coordinates and immunochromatographic tests (ICT) for filarial antigenemia were collected on approximately 1,600 persons of all ages in the five communes. The relationship between antigen-positive cases in the community and distance from index cases was evaluated using multivariate regression techniques and analyses of spatial clustering. Community surveys demonstrated higher antigen prevalence in three of the five communes than was observed in the original mapping survey; autochthonous cases were found in the same three communes. Regression techniques identified a significantly increased likelihood of being antigen-positive when living within 20 meters of index cases when controlling for age, gender, and commune. Spatial clustering of antigen-positive cases was observed in some, but not all communes. Our results suggest that localized transmission was present even in low-prevalence settings and suggest that better surveillance methods may be needed to detect microfoci of LF transmission. C1 [Drexler, Naomi] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Drexler, Naomi; Lovegrove, Maribeth; Grady, Caroline; Lammie, Patrick] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Washington, Charles H.; Milord, Marie Denise; Streit, Thomas] Univ Notre Dame, Ctr Trop Res Dis & Training, Notre Dame, IN 46556 USA. [Milord, Marie Denise] Minist Hlth & Populat, Port Au Prince, Haiti. RP Drexler, N (reprint author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. EM isj3@cdc.gov FU Bill & Melinda Gates Foundation; Centers for Disease Control and Prevention; Emerging Infectious Disease Fellowship Program FX This study was supported by the Bill & Melinda Gates Foundation and the Centers for Disease Control and Prevention. Stipend support for ML and CG was provided through the Emerging Infectious Disease Fellowship Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 3 Z9 3 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2012 VL 6 IS 10 AR e1807 DI 10.1371/journal.pntd.0001807 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 029WH UT WOS:000310527200005 PM 23071849 ER PT J AU Montgomery, JM Blair, PJ Carroll, DS Mills, JN Gianella, A Iihoshi, N Briggiler, AM Felices, V Salazar, M Olson, JG Glabman, RA Bausch, DG AF Montgomery, Joel M. Blair, Patrick J. Carroll, Darin S. Mills, James N. Gianella, Alberto Iihoshi, Naomi Briggiler, Ana M. Felices, Vidal Salazar, Milagros Olson, James G. Glabman, Raisa A. Bausch, Daniel G. TI Hantavirus Pulmonary Syndrome in Santa Cruz, Bolivia: Outbreak Investigation and Antibody Prevalence Study SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID SOUTHWESTERN UNITED-STATES; RIO-MAMORE VIRUS; PYGMY RICE RAT; GENETIC-CHARACTERIZATION; OLIGORYZOMYS-MICROTIS; NORTHWESTERN ARGENTINA; POPULATION-DYNAMICS; WESTERN PARAGUAY; LATIN-AMERICA; ANDES-VIRUS AB We report the results of an investigation of a small outbreak of hantavirus pulmonary syndrome in 2002 in the Department of Santa Cruz, Bolivia, where the disease had not previously been reported. Two cases were initially reported. The first case was a physician infected with Laguna Negra virus during a weekend visit to his ranch. Four other persons living on the ranch were IgM antibody-positive, two of whom were symptomatic for mild hantavirus pulmonary syndrome. The second case was a migrant sugarcane worker. Although no sample remained to determine the specific infecting hantavirus, a virus 90% homologous with Rio Mamore virus was previously found in small-eared pygmy rice rats (Oligoryzomys microtis) trapped in the area. An antibody prevalence study conducted in the region as part of the outbreak investigation showed 45 (9.1%) of 494 persons to be IgG positive, illustrating that hantavirus infection is common in Santa Cruz Department. Precipitation in the months preceding the outbreak was particularly heavy in comparison to other years, suggesting a possible climatic or ecological influence on rodent populations and risk of hantavirus transmission to humans. Hantavirus infection appears to be common in the Santa Cruz Department, but more comprehensive surveillance and field studies are needed to fully understand the epidemiology and risk to humans. C1 [Montgomery, Joel M.; Carroll, Darin S.; Mills, James N.; Bausch, Daniel G.] Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA USA. [Blair, Patrick J.; Felices, Vidal; Salazar, Milagros; Olson, James G.] US Naval Med Res Unit 6, Lima, Peru. [Gianella, Alberto; Iihoshi, Naomi] Bolivian Natl Ctr Trop Dis, Santa Cruz, Bolivia. [Briggiler, Ana M.] Argentine Natl Inst Viral Dis Dr Julio I Maiztegu, Pergamino, Argentina. [Glabman, Raisa A.; Bausch, Daniel G.] Tulane Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA USA. RP Montgomery, JM (reprint author), Ctr Dis Control & Prevent, Global Dis Detect Div, Nairobi, Kenya. EM dbausch@tulane.edu RI Valle, Ruben/A-7512-2013 FU Centers for Disease Control and Prevention, Atlanta, GA; U.S. Naval Medical Research Unit 6, Lima, Peru; Bolivian National Center for Tropical Diseases, Santa Cruz, Bolivia FX Funding for this work was provided by the Centers for Disease Control and Prevention, Atlanta, GA; U.S. Naval Medical Research Unit 6, Lima, Peru; and Bolivian National Center for Tropical Diseases, Santa Cruz, Bolivia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 3 Z9 4 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD OCT PY 2012 VL 6 IS 10 AR e1840 DI 10.1371/journal.pntd.0001840 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 029WH UT WOS:000310527200010 PM 23094116 ER PT J AU Agopian, AJ Lupo, PJ Herdt-Losavio, ML Langlois, PH Rocheleau, CM Mitchell, LE AF Agopian, A. J. Lupo, Philip J. Herdt-Losavio, Michele L. Langlois, Peter H. Rocheleau, Carissa M. Mitchell, Laura E. CA Natl Birth Defects Prevention TI Differences in folic acid use, prenatal care, smoking, and drinking in early pregnancy by occupation SO PREVENTIVE MEDICINE LA English DT Article DE Folic acid; Prenatal care; Smoking; Alcohol drinking; Occupations; Pregnancy; Epidemiology ID BIRTH-DEFECTS; CIGARETTE-SMOKING; WORK ORGANIZATION; BEHAVIOR; RISK AB Objective: To describe differences in four high risk periconceptional behaviors (lack of folic acid supplementation, lack of early prenatal care, smoking, and drinking) by maternal occupation. Methods: Analyses were conducted among women in the National Birth Defects Prevention Study who delivered liveborn infants without birth defects. Periconceptional occupational data were collected using a computer-assisted telephone interview and occupational coding was performed using the 2000 Standard Occupational Classification System. Logistic regression analyses were conducted to determine whether prevalence of behaviors differed between occupational groups. Results: Subjects included 5153 women employed during early pregnancy from 1997 to 2007. Compared to women in management, business, science, and arts occupations, women in other occupations (e.g., service occupations) were significantly more likely to engage in all four high risk behaviors. Specifically, women in food preparation/serving-related occupations were significantly more likely to engage in all four behaviors compared to women in all other occupational groups (odds ratios: 1.8-3.0), while women in education/training/library occupations were significantly less likely to do so (odds ratios: 02-0.5). Conclusion: We identified several occupational groups with an increased prevalence of high-risk maternal behaviors during pregnancy. Our findings could aid in developing interventions targeted towards women in these occupational groups. (C) 2012 Elsevier Inc. All rights reserved. C1 [Agopian, A. J.; Lupo, Philip J.; Mitchell, Laura E.] Univ Texas Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Ctr Human Genet, Houston, TX 77030 USA. [Herdt-Losavio, Michele L.] New York State Dept Health, Ctr Environm Hlth, Troy, NY 12180 USA. [Langlois, Peter H.] Texas Dept State Hlth Services, Birth Defects Epidemiol & Surveillance Branch, Austin, TX 78714 USA. [Rocheleau, Carissa M.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Health, Cincinnati, OH 45226 USA. RP Mitchell, LE (reprint author), Univ Texas Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Ctr Human Genet, 1200 Herman Pressler Dr, Houston, TX 77030 USA. EM laura.e.mitchell@uth.tmc.edu OI Lupo, Philip/0000-0003-0978-5863 FU Texas Center for Birth Defects Research and Prevention from the Centers for Disease Control and Prevention [U01DD000494]; Texas Department of State Health Services FX This project was partially supported by the Texas Center for Birth Defects Research and Prevention, under cooperative agreement U01DD000494 from the Centers for Disease Control and Prevention with the Texas Department of State Health Services. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 23 TC 3 Z9 3 U1 0 U2 11 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD OCT PY 2012 VL 55 IS 4 BP 341 EP 345 DI 10.1016/j.ypmed.2012.07.015 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 028CM UT WOS:000310400400014 PM 22846503 ER PT J AU Frye, V Bonner, S Williams, K Henny, K Bond, K Lucy, D Cupid, M Smith, S Koblin, BA AF Frye, Victoria Bonner, Sebastian Williams, Kim Henny, Kirk Bond, Keosha Lucy, Debbie Cupid, Malik Smith, Stephen Koblin, Beryl A. CA Straight Talk Study Team TI STRAIGHT TALK: HIV PREVENTION FOR AFRICAN-AMERICAN HETEROSEXUAL MEN: THEORETICAL BASES AND INTERVENTION DESIGN SO AIDS EDUCATION AND PREVENTION LA English DT Article ID RISK-REDUCTION INTERVENTION; SEXUALLY-TRANSMITTED-DISEASES; BEHAVIORAL INTERVENTIONS; UNITED-STATES; PLANNED SHRINKAGE; CLINIC PATIENTS; PUBLIC-HEALTH; TRANSMISSION; RATES; METAANALYSIS AB In the United States, racial disparities in HIV/AIDS are stark. Although African Americans comprise an estimated 14% of the U.S. population, they made up 52% of new HIV cases among adults and adolescents diagnosed in 2009. Heterosexual transmission is now the second leading cause of HIV in the United States. African Americans made up a full two-thirds of all heterosexually acquired HIV/AIDS cases between 2005 and 2008. Few demonstrated efficacious HIV prevention interventions designed specifically for adult, African-American heterosexual men exist. Here, we describe the process used to design a theory-based HIV prevention intervention to increase condom use, reduce concurrent partnering, and increase HIV testing among heterosexually active African-American men living in high HIV prevalence areas of New York City. The intervention integrated empowerment, social identity, and rational choices theories and focused on four major content areas: HIV/AIDS testing and education; condom skills training; key relational and behavioral turning points; and masculinity and fatherhood. C1 [Frye, Victoria] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Social & Behav Sci, New York, NY 10065 USA. [Frye, Victoria] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY USA. [Bonner, Sebastian; Bond, Keosha; Cupid, Malik] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA. [Williams, Kim; Henny, Kirk] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Lucy, Debbie; Koblin, Beryl A.] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Infect Dis Prevent, New York, NY 10065 USA. [Smith, Stephen] CUNY, John Jay Coll, Dept Psychol, New York, NY USA. RP Frye, V (reprint author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Social & Behav Sci, 310 E 67th St, New York, NY 10065 USA. EM vfrye@nybloodcenter.org OI Henny, Kirk/0000-0002-0886-8651 FU Intramural CDC HHS [CC999999]; NCHHSTP CDC HHS [1-UR6/PS-000667-01, UR6 PS000667]; NIDA NIH HHS [K01 DA-020774, K01 DA020774] NR 73 TC 1 Z9 2 U1 2 U2 3 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD OCT PY 2012 VL 24 IS 5 BP 389 EP 407 PG 19 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 020GT UT WOS:000309797700001 PM 23016501 ER PT J AU Smith, DK Toledo, L Smith, DJ Adams, MA Rothenberg, R AF Smith, Dawn K. Toledo, Lauren Smith, Donna Jo Adams, Mary Anne Rothenberg, Richard TI ATTITUDES AND PROGRAM PREFERENCES OF AFRICAN-AMERICAN URBAN YOUNG ADULTS ABOUT PRE-EXPOSURE PROPHYLAXIS (PrEP) SO AIDS EDUCATION AND PREVENTION LA English DT Article ID GAY PRIDE EVENTS; HIV PREVENTION; LIMITED KNOWLEDGE; BISEXUAL MEN; ATTENDEES; RISK; SEX; POSTEXPOSURE; INFECTION; AWARENESS AB We elicited attitudes about, and service access preferences for, daily oral antiretroviral pre-exposure prophylaxis (PrEP) from urban, African-American young men and women, ages 18-24 years, at risk for HIV transmission through their sexual and drug-related behaviors participating in eight mixed-gender and two MSM-only focus groups in Atlanta, Georgia. Participants reported substantial interest in PrEP associated with its perceived cost, effectiveness, and ease of accessing services and medication near to their homes or by public transportation. Frequent HIV testing was a perceived benefit. Participants differed about whether risk-reduction behaviors would change, and in which direction; and whether PrEP use would be associated with HIV stigma or would enhance the reputation for PrEP users. This provides the first information about the interests, concerns, and preferences of young adult African Americans that can be used to inform the introduction of PrEP services into HIV prevention efforts for this critical population group. C1 [Smith, Dawn K.; Toledo, Lauren] Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Toledo, Lauren] IDF Int, Atlanta, GA USA. [Smith, Donna Jo; Adams, Mary Anne; Rothenberg, Richard] Georgia State Univ, Inst Publ Hlth, Atlanta, GA 30303 USA. RP Smith, DK (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop E-45, Atlanta, GA 30333 USA. EM dsmith1@cdc.gov NR 21 TC 38 Z9 39 U1 1 U2 11 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD OCT PY 2012 VL 24 IS 5 BP 408 EP 421 PG 14 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 020GT UT WOS:000309797700002 PM 23016502 ER PT J AU Patel, SS Burns, TL Botto, LD Riehle-Colarusso, TJ Lin, AE Shaw, GM The, PAR AF Patel, Sonali S. Burns, Trudy L. Botto, Lorenzo D. Riehle-Colarusso, Tiffany J. Lin, Angela E. Shaw, Gary M. The, Paul A. Romitti CA Natl Birth Defects Prevention Stud TI Analysis of Selected Maternal Exposures and Non-Syndromic Atrioventricular Septal Defects in the National Birth Defects Prevention Study, 1997-2005 SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE atrioventricular septal defect; defect; endocardial cushion; atrioventricular canal defect; heart defects; congenital; risk factors; cigarette smoking; secondhand smoke exposure ID CONGENITAL HEART-DEFECTS; CARDIOVASCULAR MALFORMATIONS; MEDICATION USE; RISK-FACTORS; TOBACCO-SMOKE; UNITED-STATES; PREGNANCY; DISEASE; PREVALENCE; POLYMORPHISMS AB Although the descriptive epidemiology of atrioventricular septal defects (AVSDs), a group of serious congenital heart defects (CHDs), has been recently reported, non-genetic risk factors have not been consistently identified. Using data (1997-2005) from the National Birth Defects Prevention Study, an ongoing multisite population-based case-control study, the association between selected non-genetic factors and non-syndromic AVSDs was examined. Data on periconceptional exposures to such factors were collected by telephone interview from 187 mothers of AVSD case infants and 6,703 mothers of unaffected infants. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated from logistic regression models. Mothers who reported cigarette smoking during the periconceptional period were more likely to have infants with AVSDs compared with non-smokers, independent of maternal age, periconceptional alcohol consumption, infant gestational age, family history of CHDs, and study site (aOR 1.5, 95% CI 1.1-2.4). The association was strongest in mothers who smoked more than 25 cigarettes/day. In addition, mothers with periconceptional passive smoke exposure were more likely to have infants with AVSDs than unexposed mothers, independent of maternal age, active periconceptional smoking, infant gestational age, and family history of CHDs (aOR 1.4, 95% CI 1.0-2.0). No associations were observed between AVSDs and maternal history of a urinary tract infection or pelvic inflammatory disease, maternal use of a wide variety of medications, maternal occupational exposure, parental drug use, or maternal alcohol consumption. If the results of this preliminary study can be replicated, minimizing maternal active and passive smoke exposure may decrease the incidence of AVSDs. (C) 2012 Wiley Periodicals, Inc. C1 [Patel, Sonali S.; Burns, Trudy L.] Univ Iowa, Carver Coll Med, Dept Pediat, Iowa City, IA 52242 USA. [Burns, Trudy L.; The, Paul A. Romitti] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA. [Botto, Lorenzo D.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA. [Riehle-Colarusso, Tiffany J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Lin, Angela E.] Massachusetts Ctr Birth Defects Res & Prevent, Massachusetts Dept Publ Hlth, Boston, MA USA. [Lin, Angela E.] MassGen Hosp Children, Genet Unit, Boston, MA USA. [Shaw, Gary M.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA. RP Patel, SS (reprint author), Univ Iowa, Childrens Hosp, Dept Pediat, Div Pediat Cardiol, 200 Hawkins Dr, Iowa City, IA 52242 USA. EM sonali-patel@uiowa.edu FU Centers for Disease Control and Prevention [U01/DD000492]; Slone Epidemiology Center of Boston University FX Grant sponsor: Centers for Disease Control and Prevention; Grant number: U01/DD000492; Grant sponsor: Slone Epidemiology Center of Boston University. NR 46 TC 18 Z9 19 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4825 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD OCT PY 2012 VL 158A IS 10 BP 2447 EP 2455 DI 10.1002/ajmg.a.35555 PG 9 WC Genetics & Heredity SC Genetics & Heredity GA 023XK UT WOS:000310070700012 PM 22903798 ER PT J AU Byams, VR Anderson, BL Grant, AM Atrash, H Schulkin, J AF Byams, Vanessa R. Anderson, Britta L. Grant, Althea M. Atrash, Hani Schulkin, Jay TI Evaluation of bleeding disorders in women with menorrhagia: a survey of obstetrician-gynecologists SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE bleeding disorder; menorrhagia; physician survey; practice patterns; von Willebrand disease ID VON-WILLEBRAND-DISEASE; HEMOPHILIA TREATMENT CENTERS; AMBULATORY RESEARCH NETWORK; OUTPATIENT OBSTETRICS; UNITED-STATES; MANAGEMENT; PREVALENCE; GUIDELINES; TRENDS; LUNG AB OBJECTIVE: To better understand the current evaluation of unexplained menorrhagia by obstetrician-gynecologists and the extent to which a bleeding disorder diagnosis is being considered in this population. STUDY DESIGN: A total of 1200 Fellows and Junior Fellows of the American College of Obstetricians and Gynecologists were invited to participate in a survey on blood disorders. Respondents completed a questionnaire regarding their patient population and their evaluation of patients with unexplained menorrhagia. RESULTS: The overall response rate was 42.4%. Eighty-two percent of respondents reported having seen patients with menorrhagia caused by a bleeding disorder. Seventy-seven percent of physicians reported they would be likely or very likely to consider a bleeding disorder as causing menorrhagia in adolescent patients; however, only 38.8% would consider bleeding disorders in reproductive age women. CONCLUSION: The current data demonstrate that obstetrician-gynecologists seem to have a relatively high awareness of bleeding disorders as a potential underlying cause of menorrhagia. C1 [Byams, Vanessa R.; Grant, Althea M.; Atrash, Hani] Ctr Dis Control & Prevent, Div Blood Disorders, NCBDDD, Atlanta, GA 30333 USA. [Anderson, Britta L.; Schulkin, Jay] Amer Coll Obstetricians & Gynecologists, Washington, DC 20024 USA. RP Byams, VR (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, NCBDDD, Atlanta, GA 30333 USA. FU Centers for Disease Control and Prevention; U.S. Department of Health and Human Services, Health Resources and Services Administration [UA6MC19010] FX This study was funded by the Centers for Disease Control and Prevention and by grant, UA6MC19010, through the U.S. Department of Health and Human Services, Health Resources and Services Administration, Maternal and Child Health Research Programs. NR 24 TC 1 Z9 1 U1 0 U2 6 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2012 VL 207 IS 4 AR 269.e1 DI 10.1016/j.ajog.2012.07.010 PG 5 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 025SA UT WOS:000310212000014 PM 22901979 ER PT J AU Okoroh, EM Hooper, WC Atrash, HK Yusuf, HR Boulet, SL AF Okoroh, Ekwutosi M. Hooper, W. Craig Atrash, Hani K. Yusuf, Hussain R. Boulet, Sheree L. TI Prevalence of polycystic ovary syndrome among the privately insured, United States, 2003-2008 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE phenotype; polycystic ovary syndrome; prevalence ID CRITERIA; WOMEN; ASSOCIATION; DATABASE; PROFILE AB OBJECTIVE: The purpose of this study was to estimate the prevalence of polycystic ovary syndrome (PCOS) and its phenotypes as defined by the National Institutes of Health, Rotterdam criteria, and Androgen Society. STUDY DESIGN: Thomson Reuters MarketScan Commercial databases (Thomson Reuters Healthcare Inc, New York, NY) for 2003-2008 were used to calculate the prevalence of PCOS and to assess differences in demographic characteristics and comorbid conditions among women who were 18-45 years old with and without PCOS. RESULTS: The prevalence of PCOS was 1585.1 per 100,000; women with phenotype A or classic PCOS were most prevalent at 1031.5 per 100,000. Women with PCOS were more likely than those without PCOS to be 25-34 years old, be from the South, be infertile, have metabolic syndrome, have been seen by an endocrinologist, and have taken oral contraceptives. CONCLUSION: This is the first study to use all available criteria to estimate the prevalence of PCOS. Providers should evaluate women with menstrual dysfunction for the presence of PCOS. C1 [Okoroh, Ekwutosi M.; Hooper, W. Craig; Atrash, Hani K.; Yusuf, Hussain R.; Boulet, Sheree L.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Okoroh, EM (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E64, Atlanta, GA 30333 USA. EM Eokoroh@cdc.gov NR 14 TC 0 Z9 1 U1 0 U2 4 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2012 VL 207 IS 4 AR 299.e1 DI 10.1016/j.ajog.2012.07.023 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 025SA UT WOS:000310212000027 PM 22921097 ER PT J AU Rasmussen, SA Power, ML Jamieson, DJ Williams, J Schulkin, J Kahn, EB Zhang, YJ MacFarlane, K Kissin, DM AF Rasmussen, Sonja A. Power, Michael L. Jamieson, Denise J. Williams, Jennifer Schulkin, Jay Kahn, Emily B. Zhang, Yujia MacFarlane, Kitty Kissin, Dmitry M. TI Practices of obstetrician-gynecologists regarding nonvaccine-related public health recommendations during the 2009 H1N1 influenza pandemic SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE infection control; influenza; nonpharmaceutical interventions; pandemic; pregnancy; treatment; 2009 H1N1 ID PREGNANT-WOMEN; UNITED-STATES; A H1N1; INFANTS; VIRUS; IMMUNIZATION; VACCINATION; INFECTION; ATTITUDES; TESTS AB OBJECTIVE: We examined practices of obstetrician-gynecologists regarding nonvaccine-related public health recommendations during the 2009 H1N1 influenza pandemic. STUDY DESIGN: From February to May 2010, a survey was sent to a random sample of members of the American College of Obstetricians and Gynecologists involved in obstetric care. RESULTS: Obstetrician-gynecologists varied in their adherence to 2009 H1N1 influenza public health recommendations. Nearly all reported prescribing antiviral medications to pregnant women with suspected influenza. Most obstetrician-gynecologists reported using preventive practices in the outpatient setting to reduce exposure of well patients to ill ones. A wide range of responses was provided regarding postpartum infection control practices, suggesting lack of awareness of, disagreement with, or difficulty adhering to these recommendations. CONCLUSION: Obstetrician-gynecologists reported that they adhered to some recommendations related to 2009 H1N1 influenza, but not to others. These data provide insight into strategies for development and dissemination of recommendations in a future pandemic. C1 [Rasmussen, Sonja A.; Jamieson, Denise J.; Williams, Jennifer; Kahn, Emily B.; Zhang, Yujia; MacFarlane, Kitty; Kissin, Dmitry M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Power, Michael L.; Schulkin, Jay] Amer Coll Obstetricians & Gynecologists, Washington, DC 20024 USA. RP Rasmussen, SA (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. OI Kahn, Emily/0000-0001-7812-7958; Power, Michael/0000-0002-6120-3528 FU Centers for Disease Control and Prevention [U65PS000813-03]; Maternal and Child Health Bureau, Health Resources and Services Administration [UA6MC19010] FX Funding was provided by the cooperative agreement U65PS000813-03 from the Centers for Disease Control and Prevention and by the cooperative agreement number UA6MC19010 from the Maternal and Child Health Bureau, Health Resources and Services Administration. NR 26 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2012 VL 207 IS 4 AR 294.e1 DI 10.1016/j.ajog.2012.07.009 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 025SA UT WOS:000310212000025 PM 22921096 ER PT J AU Vesco, KK Dietz, PM Bulkley, J Bruce, FC Callaghan, WM England, L Kimes, T Bachman, DJ Hartinger, KJ Hornbrook, MC AF Vesco, Kimberly K. Dietz, Patricia M. Bulkley, Joanna Bruce, F. Carol Callaghan, William M. England, Lucinda Kimes, Terry Bachman, Donald J. Hartinger, Karen J. Hornbrook, Mark C. TI A system-based intervention to improve postpartum diabetes screening among women with gestational diabetes SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the Diabetes-in-Pregnancy-Study-Group-West CY MAY 18-19, 2012 CL Pasadena, CA SP Diabet Pregnancy Study Grp W DE gestational diabetes; postpartum; reminders; screening ID MELLITUS AB OBJECTIVE: We sought to determine whether our process improvement program led to increased postpartum diabetes screening rates among women with gestational diabetes mellitus (GDM). STUDY DESIGN: In early 2009, we conducted obstetrics department staff education sessions, revised GDM patient care protocols, and developed an electronic system to trigger reminder calls to patients who had not completed diabetes mellitus screening by 3 months postpartum. We then evaluated the rates of postpartum glucose test order entry and completion for women with GDM delivering from July 2009 through June 2010 (n = 179) and July 2007 through June 2008 (n = 200). RESULTS: After the program's implementation, the proportion of women receiving an order for a postpartum glucose test within 3 months of delivery increased from 77.5-88.8% (P = .004), and test completion increased from 59.5-71.5% (hazard ratio, 1.37; 95% confidence interval, 1.07-1.75). CONCLUSION: Rates of postpartum diabetes testing can be improved with system changes and reminders. C1 [Vesco, Kimberly K.; Bulkley, Joanna; Kimes, Terry; Bachman, Donald J.; Hartinger, Karen J.; Hornbrook, Mark C.] Kaiser Permanente NW, Ctr Hlth Res, NW Hawaii SE, Portland, OR 97227 USA. [Dietz, Patricia M.; Bruce, F. Carol; Callaghan, William M.; England, Lucinda] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Vesco, KK (reprint author), Kaiser Permanente NW, Ctr Hlth Res, NW Hawaii SE, 3800 N Interstate Ave, Portland, OR 97227 USA. EM Kimberly.k.vesco@kpchr.org OI Bulkley, Joanna/0000-0001-8293-2079 NR 8 TC 2 Z9 3 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2012 VL 207 IS 4 AR 283.e1 DI 10.1016/j.ajog.2012.08.017 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 025SA UT WOS:000310212000020 PM 23021689 ER PT J AU Patel, MK Harris, JR Juliao, P Nygren, B Were, V Kola, S Sadumah, I Faith, SH Otieno, R Obure, A Hoekstra, RM Quick, R AF Patel, Minal K. Harris, Julie R. Juliao, Patricia Nygren, Benjamin Were, Vincent Kola, Steve Sadumah, Ibrahim Faith, Sitnah Hamidah Otieno, Ronald Obure, Alfredo Hoekstra, Robert M. Quick, Robert TI Impact of a Hygiene Curriculum and the Installation of Simple Handwashing and Drinking Water Stations in Rural Kenyan Primary Schools on Student Health and Hygiene Practices SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID WESTERN KENYA; NYANZA PROVINCE; SAFE WATER; INTERVENTION; CHILDREN; PROGRAM; DIFFICULTIES; PREVENTION; GUATEMALA; PROMOTION AB School-based hygiene and water treatment programs increase student knowledge, improve hygiene, and decrease absenteeism, however health impact studies of these programs are lacking. We collected baseline information from students in 42 schools in Kenya. We then instituted a curriculum on safe water and hand hygiene and installed water stations in half ("intervention schools"). One year later, we implemented the intervention in remaining schools. Through biweekly student household visits and two annual surveys, we compared the effect of the intervention on hygiene practices and reported student illness. We saw improvement in proper handwashing techniques after the school program was introduced. We observed a decrease in the median percentage of students with acute respiratory illness among those exposed to the program; no decrease in acute diarrhea was seen. Students in this school program exhibited sustained improvement in hygiene knowledge and a decreased risk of respiratory infections after the intervention. C1 [Patel, Minal K.; Harris, Julie R.; Juliao, Patricia; Nygren, Benjamin; Hoekstra, Robert M.; Quick, Robert] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Patel, Minal K.; Harris, Julie R.; Juliao, Patricia; Nygren, Benjamin; Obure, Alfredo; Hoekstra, Robert M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Were, Vincent] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Kola, Steve; Sadumah, Ibrahim; Faith, Sitnah Hamidah; Otieno, Ronald] NICHE Project, Kisumu, Kenya. RP Patel, MK (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS A04, Atlanta, GA 30333 USA. EM hgo9@cdc.gov; ggt5@cdc.gov; patricia.d.juliao@gsk.com; ghz8@cdc.gov; vincentwere@yahoo.com; stvkola@yahoo.co.uk; sitnahfaith@yahoo.com; ronotieno@yahoo.com; rth6@cdc.gov; rxq1@cdc.gov FU Centers for Disease Control and Prevention; USAID's Global Health Bureau FX Funding was provided by the Centers for Disease Control and Prevention and USAID's Global Health Bureau. NR 26 TC 8 Z9 8 U1 2 U2 17 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2012 VL 87 IS 4 BP 594 EP 601 DI 10.4269/ajtmh.2012.11-0494 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 020FS UT WOS:000309795000003 PM 22869631 ER PT J AU Webster, D Umar, I Kolyvas, G Bilbao, J Guiot, MC Duplisea, K Qvarnstrom, Y Visvesvara, GS AF Webster, Duncan Umar, Imram Kolyvas, George Bilbao, Juan Guiot, Marie-Christine Duplisea, Kevin Qvarnstrom, Yvonne Visvesvara, Govinda S. TI Case Report: Treatment of Granulomatous Amoebic Encephalitis with Voriconazole and Miltefosine in an Immunocompetent Soldier SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID FREE-LIVING AMEBAS; BALAMUTHIA-MANDRILLARIS; ACANTHAMOEBA INFECTION; NAEGLERIA-FOWLERI; PATIENT; MENINGITIS; COMBINATION; SPP. AB A 38-year-old male immunocompetent soldier developed generalized seizures. He underwent surgical debulking and a progressive demyelinating pseudotumor was identified. Serology and molecular testing confirmed a diagnosis of granulomatous amoebic encephalitis caused by Acanthamoeba sp. in this immunocompetent male. The patient was treated with oral voriconazole and miltefosine with Acanthamoeba titers returning to control levels and serial imaging demonstrating resolution of the residual lesion. C1 [Webster, Duncan] St Johns Hosp, Dept Internal Med, St John, NB E2L 4L2, Canada. [Umar, Imram] St Johns Hosp, Dept Lab Med, St John, NB E2L 4L2, Canada. [Kolyvas, George] St Johns Hosp, Dept Neurosurg, St John, NB E2L 4L2, Canada. [Bilbao, Juan] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Anat Pathol, Toronto, ON M4N 3M5, Canada. McGill Univ, Montreal Neurol Inst, Ctr Hlth, Montreal, PQ, Canada. [Duplisea, Kevin] Toronto Western Hosp, Dept Pharm, Toronto, ON M5T 2S8, Canada. [Qvarnstrom, Yvonne] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA. [Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. Toronto Western Hosp, Univ Hlth Network, Toronto, ON M5T 2S8, Canada. RP Webster, D (reprint author), St Johns Hosp, Dept Internal Med, 400 Univ Ave, St John, NB E2L 4L2, Canada. EM Duncan.Webster@HorizonNB.ca; Imran.UmarDr@HorizonNB.ca; George.Kolyvas@HorizonNB.ca; Juan.Bilbao@sunnybrook.ca; marie.christine.guiot@mcgill.ca; Kevin.Duplisea@uhn.on.ca; bvp2@cdc.gov; gsv1@cdc.gov NR 27 TC 16 Z9 16 U1 0 U2 9 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD OCT PY 2012 VL 87 IS 4 BP 715 EP 718 DI 10.4269/ajtmh.2012.12-0100 PG 4 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 020FS UT WOS:000309795000022 PM 22869634 ER PT J AU Tinker, SC Hamner, HC Berry, RJ Bailey, LB Pfeiffer, CM AF Tinker, Sarah C. Hamner, Heather C. Berry, Robert J. Bailey, Lynn B. Pfeiffer, Christine M. TI Does obesity modify the association of supplemental folic acid with folate status among nonpregnant women of childbearing age in the United States? SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article; Proceedings Paper CT 7th International Conference on Neural Tube Defects CY NOV 06-09, 2011 CL Austin, TX DE folic acid; folate status; obesity; NHANES ID NEURAL-TUBE DEFECTS; SERUM FOLATE; BLOOD FOLATE; HOMOCYSTEINE; PREVENTION; PREVALENCE; METAANALYSIS; DEFICIENCY; OVERWEIGHT; HEALTH AB BACKGROUND Obesity is associated with an increased risk of having a pregnancy affected by a neural tube defect (NTD). It is not clear whether the amount of folic acid required by obese women to protect against NTDs is the same as that for nonobese women. METHODS We analyzed data from the National Health and Nutrition Examination Survey, representative of the noninstitutionalized civilian U.S. population, to assess whether body mass index (BMI; normal weight, overweight, and obese categories) modified the association between supplemental folic acid intake and folate status. We estimated the geometric mean concentration among nonpregnant women of childbearing age (15-44 years) during the postfortification period of: serum folate (2003-2008); red blood cell (RBC) folate (2007-2008); and plasma total homocysteine (tHcy; 2003-2006), adjusted for age, race and ethnicity, and total dietary folate expressed as dietary folate equivalents for strata of supplement use and BMI. RESULTS BMI was inversely associated with serum folate among women who did not use supplements containing folic acid; no differences between women in different BMI categories were observed among supplement users. Regardless of supplement use, obese women had the highest RBC folate concentrations. There were no differences in tHcy by BMI, regardless of supplement use. CONCLUSIONS These results do not support a straightforward modification of the relationship between supplemental folic acid intake and folate status by BMI. In this population, BMI may affect the body distribution of folate, as reflected by lower serum and higher RBC folate levels in obese women who do not use supplements. Birth Defects Research (Part A) 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Tinker, Sarah C.; Hamner, Heather C.; Berry, Robert J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Bailey, Lynn B.] Univ Georgia, Dept Foods & Nutr, Coll Family & Consumer Sci, Athens, GA 30602 USA. [Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Tinker, SC (reprint author), 1600 Clifton Rd NE,Mail Stop E86, Atlanta, GA 30333 USA. EM Zzu9@cdc.gov OI Berry, Robert/0000-0002-7162-5046 NR 31 TC 22 Z9 23 U1 0 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2012 VL 94 IS 10 SI SI BP 749 EP 755 DI 10.1002/bdra.23024 PG 7 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 023WS UT WOS:000310068400002 PM 22641603 ER PT J AU Yazdy, MM Tinker, SC Mitchell, AA Demmer, LA Werler, MM AF Yazdy, Mahsa M. Tinker, Sarah C. Mitchell, Allen A. Demmer, Laurie A. Werler, Martha M. TI Maternal tea consumption during early pregnancy and the risk of spina bifida SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article; Proceedings Paper CT 7th International Conference on Neural Tube Defects CY NOV 06-09, 2011 CL Austin, TX DE spina bifida; tea consumption; catechins; folic acid; birth defects ID NEURAL-TUBE DEFECTS; SERUM FOLATE LEVELS; BIRTH-DEFECTS; FOLIC-ACID; BLACK TEA; GREEN; WOMEN; FLAVONOIDS; PREVENTION; DRINKING AB Studies have demonstrated that catechin, an antioxidant found in tea, can reduce the bioavailability of folate. Because periconceptional folic acid intake has been demonstrated to reduce the risk of spina bifida, tea consumption may put pregnant women at risk because of its possible antifolate properties. Using data collected in the Slone Epidemiology Center Birth Defects Study, we examined whether tea consumption during early pregnancy was associated with an increased risk of spina bifida. Mothers of 518 spina bifida cases and 6424 controls were interviewed within 6 months after delivery about pregnancy events and exposures. Data on tea intake were collected during three periods (1976-1988, 1998-2005 and 2009-2010). Logistic regression models were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for study center. Intake of both periconceptional food folate and diet and supplemental folic acid were examined as a potential effect modifier. For 1976 to 1988, ORs were not elevated for daily tea intake. For 1998 and onward, ORs were also close to 1.0, but there was a modest increase for those who drank more than 3 cups/day (OR, 1.92; 95% CI, 0.84-4.38). Among women with total folic acid intake greater than 400 mu g, consumption of 3 cups or more of tea per day was associated with an increased risk of spina bifida in 1976 to 1988 (OR, 2.04; 95% CI, 0.697.66) and in the later periods (OR, 3.13; 95% CI, 0.8711.33). Our data do not support an overall association between tea consumption and spina bifida, but there is a suggestion of a possible interaction between higher levels of folic acid intake and tea consumption. Birth Defects Research (Part A) 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Yazdy, Mahsa M.; Mitchell, Allen A.; Werler, Martha M.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Tinker, Sarah C.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Demmer, Laurie A.] Tufts Univ, Sch Med, Boston, MA 02111 USA. RP Yazdy, MM (reprint author), 1010 Commonwealth Ave,4th Floor, Boston, MA 02215 USA. EM mahsa@bu.edu OI Mitchell, Allen/0000-0003-0950-6799; Werler, Martha/0000-0003-3392-6814; Yazdy, Mahsa/0000-0002-7415-5350 FU Centers for Disease Control and Prevention [DD000697] FX Supported by the Centers for Disease Control and Prevention (DD000697). NR 38 TC 10 Z9 10 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD OCT PY 2012 VL 94 IS 10 SI SI BP 756 EP 761 DI 10.1002/bdra.23025 PG 6 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 023WS UT WOS:000310068400003 PM 22641606 ER PT J AU Morris, SK Awasthi, S Khera, A Bassani, DG Kang, G Parashar, UD Kumar, R Shet, A Glass, RI Jha, P AF Morris, Shaun K. Awasthi, Shally Khera, Ajay Bassani, Diego G. Kang, Gagandeep Parashar, Umesh D. Kumar, Rajesh Shet, Anita Glass, Roger I. Jha, Prabhat CA Million Death Study Collaborators TI Rotavirus mortality in India: estimates based on a nationally representative survey of diarrhoeal deaths SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID CHILD-MORTALITY; VACCINE; DISEASE; EFFICACY; SAFETY; GASTROENTERITIS; IMMUNIZATION; INEQUITY; INFANTS AB Objective To estimate the number of rotavirus-associated deaths among Indian children younger than five years. Methods We surveyed more than 23 000 child deaths from a nationally representative survey of 1.1 million Indian households during 2001-2003. Diarrhoeal deaths were characterized by region, age and sex and were combined with the proportion of deaths attributable to rotavirus, as determined by hospital microbiologic data collected by the Indian Rotavirus Strain Surveillance Network from December 2005 to November 2007. Rotavirus vaccine efficacy data from clinical trials in developing countries were used to estimate the number of deaths preventable by a national vaccination programme. Data were analysed using Stata SE version 10. Findings Rotavirus caused an estimated 113 000 deaths (99% confidence interval, CI: 86 000-155 000); 50% (54 700) and 75% (85 400) occurred before one and two years of age, respectively. One child in 242 died from rotavirus infection before five years of age. Rotavirus-associated mortality rates overall, among girls and among boys were 4.14 (99% CI: 3.14-5.68), 4.89 (99% CI: 3.75-6.79) and 3.45 (99% CI: 2.58-4.66) deaths per 1000 live births, respectively. Rates were highest in Bihar, Uttar Pradesh and Madhya Pradesh, which together accounted for >50% of deaths (64 400) nationally. Rotavirus vaccine could prevent 41 000-48 000 deaths among children aged 3-59 months. Conclusion The burden of rotavirus-associated mortality is high among Indian children, highlighting the potential benefits of rotavirus vaccination. C1 [Morris, Shaun K.] Univ Toronto, Hosp Sick Children, Div Infect Dis, Toronto, ON M5G 1X8, Canada. [Awasthi, Shally] King Georges Med Univ, Dept Paediat, Lucknow, Uttar Pradesh, India. [Khera, Ajay] Govt India, Minist Hlth & Family Welf, New Delhi, India. [Bassani, Diego G.] Univ Toronto, Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada. [Kang, Gagandeep] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Parashar, Umesh D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Kumar, Rajesh] Post Grad Inst Med Educ, Sch Publ Hlth, Chandigarh, India. [Shet, Anita] St Johns Natl Acad Hlth Sci, Dept Paediat, Bangalore, Karnataka, India. [Glass, Roger I.] Fogarty Int Ctr, Bethesda, MD USA. [Jha, Prabhat] Univ Toronto, St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Global Hlth Res, Toronto, ON M5G 1X8, Canada. RP Morris, SK (reprint author), Univ Toronto, Hosp Sick Children, Div Infect Dis, 555 Univ Ave, Toronto, ON M5G 1X8, Canada. EM shaun.morris@mail.utoronto.ca OI Shet, Anita/0000-0002-7204-8164; Kang, Gagandeep/0000-0002-3656-564X FU Fogarty International Centre of the United States National Institutes of Health [R01 TW05991-01]; Canadian Institute of Health Research [IEG-53506]; International Development Research Centre [102172]; Li Ka Shing Knowledge Institute; Keenan Research Centre at St Michael's Hospital, University of Toronto; United States Fund from the Bill & Melinda Gates Foundation [50140]; Canada Research Chair programme; Paediatric Scientist Development Program; Sick Kids Foundation; Paediatric Chairs of Canada; March of Dimes FX This work was supported by the Fogarty International Centre of the United States National Institutes of Health (grant R01 TW05991-01), the Canadian Institute of Health Research, (grant IEG-53506), the International Development Research Centre (grant 102172), the Li Ka Shing Knowledge Institute and Keenan Research Centre at St Michael's Hospital, University of Toronto, and the United States Fund for the United Nations Children's Fund (subgrant 50140, via a grant from the Bill & Melinda Gates Foundation for the Child Health Epidemiology Reference Group). Authors received support from the Canada Research Chair programme (PJ) and from the Paediatric Scientist Development Program, the Sick Kids Foundation, the Paediatric Chairs of Canada and the March of Dimes (SKM). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 28 TC 20 Z9 20 U1 0 U2 9 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD OCT PY 2012 VL 90 IS 10 BP 720 EP 727 DI 10.2471/BLT.12.101873 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 021NY UT WOS:000309893500005 PM 23109739 ER PT J AU Clara, W Armero, J Rodriguez, D de Lozano, C Bonilla, L Minaya, P Chacon, R Jara, J Blanco, N Widdowson, MA Bresee, J Xu, XY Klimov, A Azziz-Baumgartner, E Linares-Perez, N AF Clara, Wilfrido Armero, Julio Rodriguez, David de Lozano, Celina Bonilla, Luis Minaya, Percy Chacon, Rafael Jara, Jorge Blanco, Natalia Widdowson, Marc-Alain Bresee, Joseph Xu, Xiyan Klimov, Alexander Azziz-Baumgartner, Eduardo Linares-Perez, Nivaldo TI Estimated incidence of influenza-virus-associated severe pneumonia in children in El Salvador, 2008-2010 SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID SEASONAL INFLUENZA; RESPIRATORY-INFECTIONS; UNITED-STATES; BURDEN; BANGLADESH; THAILAND; ILLNESS AB Objective To estimate the incidence of influenza-virus-associated severe pneumonia among Salvadorian children aged <5 years. Methods Data on children aged <5 years admitted with severe pneumonia to a sentinel hospital in the western region were collected weekly. Nasal and oropharyngeal swab specimens were collected from a convenience sample of case patients for respiratory virus testing. A health-care utilization survey was conducted in the hospital catchment area to determine the proportion of residents who sought care at the hospital. The incidence of influenza-virus-associated severe pneumonia among all Salvadorian children aged <5 years was estimated from surveillance and census data, with adjustment for health-care utilization. Influenza virus strains were characterized by the United States Centers for Disease Control and Prevention to determine their correspondence with northern and southern hemisphere influenza vaccine formulations. Findings Physicians identified 2554 cases of severe pneumonia. Samples from 608 cases were tested for respiratory viruses and 37 (6%) were positive for influenza virus. The estimated incidence of influenza-virus-associated severe pneumonia was 3.2 cases per 1000 person-years (95% confidence interval, CI: 2.8-3.7) overall; 1.5 cases per 1000 person-years.(95% CI: 1.0-2.0) during 2008, 7.6 cases per 1000 person-years (95% CI: 6.5-8.9) during 2009 and 0.6 cases per 1000 person-years (95% CI: 0.3-1.0) during 2010. Northern and southern hemisphere vaccine formulations matched influenza virus strains isolated during 2008 and 2010. Conclusion Influenza-virus-associated severe pneumonia occurred frequently among young Salvadorian children during 2008-2010. Antigens in northern and southern hemisphere influenza vaccine formulations corresponded to circulating strains. C1 [Clara, Wilfrido] Cent Amer Reg CDC CAR, Ctr Dis Control & Prevent, Antiguo Cuscatlan, La Libertad, El Salvador. [Armero, Julio; Rodriguez, David; de Lozano, Celina] Minist Hlth, San Salvador, El Salvador. [Bonilla, Luis; Jara, Jorge; Blanco, Natalia] Univ Valle Guatemala, Guatemala City, Guatemala. [Minaya, Percy] Training Epidemiol & Publ Hlth Intervent Network, Atlanta, GA USA. [Chacon, Rafael] Council Minist Hlth Cent Amer & Dominican Republ, San Salvador, El Salvador. [Widdowson, Marc-Alain; Bresee, Joseph; Xu, Xiyan; Klimov, Alexander; Azziz-Baumgartner, Eduardo; Linares-Perez, Nivaldo] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Clara, W (reprint author), Cent Amer Reg CDC CAR, Ctr Dis Control & Prevent, Anal Blvd Santa Elena, Antiguo Cuscatlan, La Libertad, El Salvador. EM aclara@gt.cdc.gov OI Widdowson, Marc-Alain/0000-0002-0682-6933 NR 34 TC 14 Z9 14 U1 0 U2 1 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD OCT PY 2012 VL 90 IS 10 BP 756 EP 763 DI 10.2471/BLT.11.098202 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 021NY UT WOS:000309893500009 PM 23109743 ER PT J AU Ford, ES Caspersen, CJ AF Ford, Earl S. Caspersen, Carl J. TI Sedentary behaviour and cardiovascular disease: a review of prospective studies SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Cardiovascular diseases; prospective studies; sedentary lifestyle; television ID CORONARY-HEART-DISEASE; TELEVISION VIEWING TIME; RANDOMIZED CONTROLLED-TRIAL; DEEP-VEIN THROMBOSIS; ALL-CAUSE MORTALITY; URBAN BUS-DRIVERS; PHYSICAL-ACTIVITY; LEISURE-TIME; UNITED-STATES; BED REST AB Background Current estimates from objective accelerometer data suggest that American adults are sedentary for similar to 7.7h/day. Historically, sedentary behaviour was conceptualized as one end of the physical activity spectrum but is increasingly being viewed as a behaviour distinct from physical activity. Methods Prospective studies examining the associations between screen time (watching television, watching videos and using a computer) and sitting time and fatal and non-fatal cardiovascular disease (CVD) were identified. These prospective studies relied on self-reported sedentary behaviour. Results The majority of prospective studies of screen time and sitting time has shown that greater sedentary time is associated with an increased risk of fatal and non-fatal CVD. Compared with the lowest levels of sedentary time, risk estimates ranged up to 1.68 for the highest level of sitting time and 2.25 for the highest level of screen time after adjustment for a series of covariates, including measures of physical activity. For six studies of screen time and CVD, the summary hazard ratio per 2-h increase was 1.17 (95% CI: 1.13-1.20). For two studies of sitting time, the summary hazard ratio per 2-h increase was 1.05 (95% CI: 1.01-1.09). Conclusions Future prospective studies using more objective measures of sedentary behaviour might prove helpful in quantifying better the risk between sedentary behaviour and CVD morbidity and mortality. This budding science may better shape future guideline development as well as clinical and public health interventions to reduce the amount of sedentary behaviour in modern societies. C1 [Ford, Earl S.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K67, Atlanta, GA 30341 USA. EM eford@cdc.gov RI Caspersen, Carl/B-2494-2009 FU Intramural CDC HHS [CC999999] NR 79 TC 128 Z9 132 U1 6 U2 66 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD OCT PY 2012 VL 41 IS 5 BP 1338 EP 1353 DI 10.1093/ije/dys078 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 021YU UT WOS:000309922700019 PM 22634869 ER PT J AU Wormser, D Di Angelantonio, E Kaptoge, S Wood, AM Gao, P Sun, Q Walldius, G Selmer, R Verschuren, WMM Bueno-de-Mesquita, HB Engstrom, G Ridker, PM Njolstad, I Iso, H Holme, I Giampaoli, S Tunstall-Pedoe, H Gaziano, JM Brunner, E Kee, F Tosetto, A Meisinger, C Brenner, H Ducimetiere, P Whincup, PH Tipping, RW Ford, I Cremer, P Hofman, A Wilhelmsen, L Clarke, R de Boer, IH Jukema, JW Ibanez, AM Lawlor, DA D'Agostino, RB Rodriguez, B Casiglia, E Stehouwer, CDA Simons, LA Nietert, PJ Barrett-Connor, E Panagiotakos, DB Bjorkelund, C Strandberg, TE Wassertheil-Smoller, S Blazer, DG Meade, TW Welin, L Svardsudd, K Woodward, M Nissinen, A Kromhout, D Jorgensen, T Tilvis, RS Guralnik, JM Rosengren, A Taylor, JO Kiechl, S Dagenais, GR Fowkes, FGR Wallace, RB Khaw, KT Shaffer, JA Visser, M Kauhanen, J Salonen, JT Gallacher, J Ben-Shlomo, Y Kitamura, A Sundstrom, J Wennberg, P Kiyohara, Y Daimon, M de la Camara, AG Cooper, JA Onat, A Devereux, R Mukamal, KJ Dankner, R Knuiman, MW Crespo, CJ Gansevoort, RT Goldbourt, U Nordestgaard, BG Shaw, JE Mussolino, M Nakagawa, H Fletcher, A Kuller, LH Gillum, RF Gudnason, V Assmann, G Wald, N Jousilahti, PR Greenland, P Trevisan, M Ulmer, H Butterworth, AS Folsom, AR Davey-Smith, G Hu, FB Danesh, J AF Wormser, David Di Angelantonio, Emanuele Kaptoge, Stephen Wood, Angela M. Gao, Pei Sun, Qi Walldius, Goeran Selmer, Randi Verschuren, W. M. Monique Bueno-de-Mesquita, H. Bas Engstrom, Gunnar Ridker, Paul M. Njolstad, Inger Iso, Hiroyasu Holme, Ingar Giampaoli, Simona Tunstall-Pedoe, Hugh Gaziano, J. Michael Brunner, Eric Kee, Frank Tosetto, Alberto Meisinger, Christa Brenner, Hermann Ducimetiere, Pierre Whincup, Peter H. Tipping, Robert W. Ford, Ian Cremer, Peter Hofman, Albert Wilhelmsen, Lars Clarke, Robert de Boer, Ian H. Jukema, J. Wouter Ibanez, Alejandro Marin Lawlor, Debbie A. D'Agostino, Ralph B., Sr. Rodriguez, Beatriz Casiglia, Edoardo Stehouwer, Coen D. A. Simons, Leon A. Nietert, Paul J. Barrett-Connor, Elizabeth Panagiotakos, Demosthenes B. Bjorkelund, Cecilia Strandberg, Timo E. Wassertheil-Smoller, Sylvia Blazer, Dan G. Meade, Tom W. Welin, Lennart Svardsudd, Kurt Woodward, Mark Nissinen, Aulikki Kromhout, Daan Jorgensen, Torben Tilvis, Reijo S. Guralnik, Jack M. Rosengren, Annika Taylor, James O. Kiechl, Stefan Dagenais, Gilles R. Fowkes, F. Gerry R. Wallace, Robert B. Khaw, Kay-Tee Shaffer, Jonathan A. Visser, Marjolein Kauhanen, Jussi Salonen, Jukka T. Gallacher, John Ben-Shlomo, Yoav Kitamura, Akihiko Sundstrom, Johan Wennberg, Patrik Kiyohara, Yutaka Daimon, Makoto Gomez de la Camara, Agustin Cooper, Jackie A. Onat, Altan Devereux, Richard Mukamal, Kenneth J. Dankner, Rachel Knuiman, Matthew W. Crespo, Carlos J. Gansevoort, Ron T. Goldbourt, Uri Nordestgaard, Borge G. Shaw, Jonathan E. Mussolino, Michael Nakagawa, Hidaeki Fletcher, Astrid Kuller, Lewis H. Gillum, Richard F. Gudnason, Vilmundur Assmann, Gerd Wald, Nicholas Jousilahti, Pekka R. Greenland, Philip Trevisan, Maurizio Ulmer, Hanno Butterworth, Adam S. Folsom, Aaron R. Davey-Smith, George Hu, Frank B. Danesh, John CA Emerging Risk Factors Collaboratio TI Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Height; cardiovascular disease; cancer; cause-specific mortality; epidemiological study; meta-analysis ID CAUSE-SPECIFIC MORTALITY; CORONARY-HEART-DISEASE; CHILDHOOD SOCIOECONOMIC CIRCUMSTANCES; BODY-MASS INDEX; CANCER-RISK; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; MEN; WOMEN; ASSOCIATIONS AB Background The extent to which adult height, a biomarker of the interplay of genetic endowment and early-life experiences, is related to risk of chronic diseases in adulthood is uncertain. Methods We calculated hazard ratios (HRs) for height, assessed in increments of 6.5 cm, using individual-participant data on 174 374 deaths or major non-fatal vascular outcomes recorded among 1 085 949 people in 121 prospective studies. Results For people born between 1900 and 1960, mean adult height increased 0.5-1 cm with each successive decade of birth. After adjustment for age, sex, smoking and year of birth, HRs per 6.5 cm greater height were 0.97 (95% confidence interval: 0.96-0.99) for death from any cause, 0.94 (0.93-0.96) for death from vascular causes, 1.04 (1.03-1.06) for death from cancer and 0.92 (0.90-0.94) for death from other causes. Height was negatively associated with death from coronary disease, stroke subtypes, heart failure, stomach and oral cancers, chronic obstructive pulmonary disease, mental disorders, liver disease and external causes. In contrast, height was positively associated with death from ruptured aortic aneurysm, pulmonary embolism, melanoma and cancers of the pancreas, endocrine and nervous systems, ovary, breast, prostate, colorectum, blood and lung. HRs per 6.5 cm greater height ranged from 1.26 (1.12-1.42) for risk of melanoma death to 0.84 (0.80-0.89) for risk of death from chronic obstructive pulmonary disease. HRs were not appreciably altered after further adjustment for adiposity, blood pressure, lipids, inflammation biomarkers, diabetes mellitus, alcohol consumption or socio-economic indicators. Conclusion Adult height has directionally opposing relationships with risk of death from several different major causes of chronic diseases. C1 [Wormser, David] Univ Cambridge, Dept Publ Hlth & Primary Care, Emerging Risk Factors Collaborat Coordinating Ctr, Strangeways Res Lab, Cambridge CB1 8RN, England. [Sun, Qi; Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Walldius, Goeran] Karolinska Inst, S-10401 Stockholm, Sweden. [Selmer, Randi] Norwegian Inst Publ Hlth, Oslo, Norway. [Engstrom, Gunnar] Lund Univ, S-22100 Lund, Sweden. [Ridker, Paul M.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Njolstad, Inger] Univ Tromso, N-9001 Tromso, Norway. [Iso, Hiroyasu] Osaka Univ, Suita, Osaka 565, Japan. [Holme, Ingar] Oslo Univ Hosp, Oslo, Norway. [Giampaoli, Simona] Ist Super Sanita, Rome, Italy. [Tunstall-Pedoe, Hugh] Univ Dundee, Dundee DD1 4HN, Scotland. [Gaziano, J. Michael; Mukamal, Kenneth J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Brunner, Eric] UCL, London WC1E 6BT, England. [Kee, Frank] Queens Univ Belfast, Belfast BT7 1NN, Antrim, North Ireland. [Tosetto, Alberto] San Bortolo Hosp, Vicenza, Italy. [Meisinger, Christa] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Munich, Germany. [Brenner, Hermann] German Canc Res Ctr, D-6900 Heidelberg, Germany. [Ducimetiere, Pierre] INSERM, F-75654 Paris 13, France. [Whincup, Peter H.] Univ London, London, England. [Ford, Ian] Univ Glasgow, Glasgow G12 8QQ, Lanark, Scotland. [Cremer, Peter] LMU, Klinikum Univ Munchen, Munich, Germany. [Hofman, Albert] Erasmus MC, Rotterdam, Netherlands. [Rosengren, Annika] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden. [Clarke, Robert] Univ Oxford, Oxford OX1 2JD, England. [de Boer, Ian H.] Univ Washington, Seattle, WA 98195 USA. [Jukema, J. Wouter] Leiden Univ, Med Ctr, Leiden, Netherlands. [Jukema, J. Wouter] InterUniv Cardiol Inst Netherlands, Utrecht, Netherlands. [Lawlor, Debbie A.] Univ Bristol, Bristol BS8 1TH, Avon, England. [D'Agostino, Ralph B., Sr.] Boston Univ, Boston, MA 02215 USA. [Rodriguez, Beatriz] Univ Hawaii, Honolulu, HI 96822 USA. [Casiglia, Edoardo] Univ Padua, I-35100 Padua, Italy. [Stehouwer, Coen D. A.] Maastricht Univ, Med Ctr, Maastricht, Netherlands. [Simons, Leon A.] Univ NSW, Sydney, NSW, Australia. [Nietert, Paul J.] Med Univ S Carolina, Charleston, SC USA. [Barrett-Connor, Elizabeth] Univ Calif San Diego, San Diego, CA 92103 USA. [Panagiotakos, Demosthenes B.] Harokopio Univ Athens, Athens, Greece. [Strandberg, Timo E.] Univ Oulu, Oulu, Finland. [Strandberg, Timo E.] Oulu Univ Hosp, Oslo, Norway. [Wassertheil-Smoller, Sylvia] Albert Einstein Coll Med, New York, NY USA. [Blazer, Dan G.] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Meade, Tom W.; Fletcher, Astrid] London Sch Hyg & Trop Med, London WC1, England. [Welin, Lennart] Lidkoping Hosp, Lidkoping, Sweden. [Svardsudd, Kurt] Uppsala Univ, Uppsala, Sweden. [Woodward, Mark] Univ Sydney, Sydney, NSW 2006, Australia. [Kromhout, Daan] Wageningen Univ, Wageningen, Netherlands. [Jorgensen, Torben] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark. [Jorgensen, Torben] Univ Copenhagen, DK-1168 Copenhagen, Denmark. [Tilvis, Reijo S.] Helsinki Univ Hosp, Helsinki, Finland. [Tilvis, Reijo S.] Univ Helsinki, FIN-00014 Helsinki, Finland. [Guralnik, Jack M.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Taylor, James O.] E Boston Neighborhood Hlth Ctr, E Boston, MA USA. [Kiechl, Stefan] Med Univ Innsbruck, Innsbruck, Austria. [Dagenais, Gilles R.] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada. [Fowkes, F. Gerry R.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Wallace, Robert B.] Univ Iowa, Iowa City, IA USA. [Shaffer, Jonathan A.] Columbia Univ, Med Ctr, New York, NY USA. [Visser, Marjolein] Vrije Univ Amsterdam, Amsterdam, Netherlands. [Kauhanen, Jussi] Univ Eastern Finland, Helsinki, Finland. [Gallacher, John] Cardiff Univ, Cardiff, S Glam, Wales. [Ben-Shlomo, Yoav; Davey-Smith, George] Univ Bristol, Bristol BS8 1TH, Avon, England. [Kitamura, Akihiko] Osaka Med Ctr Hlth Sci & Promot, Osaka, Japan. [Sundstrom, Johan] Uppsala Univ, Uppsala, Sweden. [Wennberg, Patrik] Umea Univ, S-90187 Umea, Sweden. [Kiyohara, Yutaka] Kyushu Univ, Fukuoka 812, Japan. [Daimon, Makoto] Yamagata Univ, Yamagata 990, Japan. [Gomez de la Camara, Agustin] Hosp 12 Octubre, Madrid, Spain. [Cooper, Jackie A.] UCL, London, England. [Onat, Altan] Istanbul Univ, Istanbul, Turkey. [Devereux, Richard] Weill Cornell Med Coll, New York, NY USA. [Knuiman, Matthew W.] Univ Western Australia, Nedlands, WA 6009, Australia. [Crespo, Carlos J.] Portland State Univ, Portland, OR 97207 USA. [Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Goldbourt, Uri] Chaim Sheba Med Ctr, Tel Hashomer, Israel. [Nordestgaard, Borge G.] Univ Copenhagen, Copenhagen Univ Hosp, DK-1168 Copenhagen, Denmark. [Nakagawa, Hidaeki] Kanazawa Med Univ, Kanazawa, Ishikawa, Japan. [Kuller, Lewis H.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Gillum, Richard F.] Ctr Dis Control & Prevent, New York, NY USA. [Gudnason, Vilmundur] Iceland Heart Assoc, Reykjavik, Iceland. [Gudnason, Vilmundur] Univ Iceland, Reykjavik, Iceland. [Wald, Nicholas] Wolfson Inst Prevent Med, London, England. [Greenland, Philip] Northwestern Univ, Chicago, IL 60611 USA. [Ulmer, Hanno] Innsbruck Med Univ, Innsbruck, Austria. [Folsom, Aaron R.] Univ Minnesota, Minneapolis, MN 55455 USA. RP Wormser, D (reprint author), Univ Cambridge, Dept Publ Hlth & Primary Care, Emerging Risk Factors Collaborat Coordinating Ctr, Strangeways Res Lab, Cambridge CB1 8RN, England. RI Panico, Salvatore/K-6506-2016; Panagiotakos, Demosthenes/C-9776-2013; Knuiman, Matthew/I-5549-2013; Kromhout, Daan/A-8566-2014; Sundstrom, Johan/A-6286-2009; Meisinger, Christine/B-5358-2014; Schottker, Ben/F-8183-2014; vhmpp, aks/F-9756-2012; Shaffer, Jonathan/B-2783-2013; Woodward, Mark/D-8492-2015; Gudnason, Vilmundur/K-6885-2015; Brenner, Hermann/B-4627-2017; Davey Smith, George/A-7407-2013; Ulmer, Hanno/C-3488-2011; OI Shay, Christina/0000-0002-8310-7043; Feskens, Edith/0000-0001-5819-2488; Tikhonoff, Valerie/0000-0001-7846-0101; Di Angelantonio, Emanuele/0000-0001-8776-6719; Wannamethee, Sasiwarang/0000-0001-9484-9977; Nietert, Paul/0000-0002-3933-4986; Kivimaki, Mika/0000-0002-4699-5627; Panico, Salvatore/0000-0002-5498-8312; Whincup, Peter/0000-0002-5589-4107; Engstrom, Gunnar/0000-0002-8618-9152; Ikram, Mohammad Arfan/0000-0003-0372-8585; Sundstrom, Johan/0000-0003-2247-8454; Schottker, Ben/0000-0002-1217-4521; Gudnason, Vilmundur/0000-0001-5696-0084; Brenner, Hermann/0000-0002-6129-1572; Davey Smith, George/0000-0002-1407-8314; Ulmer, Hanno/0000-0001-5911-1002; Ramachandran, Vasan/0000-0001-7357-5970; Tiemeier, Henning/0000-0002-4395-1397; Meisinger, Christa/0000-0002-9026-6544; Jorgensen, Torben/0000-0001-9453-2830; Lawlor, Debbie A/0000-0002-6793-2262; Marmot, Michael/0000-0002-2431-6419; strandberg, timo/0000-0001-6299-925X; Morris, Richard/0000-0001-7240-4563 FU British Heart Foundation [RG/08/014]; UK Medical Research Council; National Institute of Health, Cambridge Biomedical Research Centre FX The ERFC Coordinating Centre is underpinned by a programme grant from the British Heart Foundation (RG/08/014) and grants from the UK Medical Research Council and the National Institute of Health, Cambridge Biomedical Research Centre. A variety of sources have supported recruitment, follow-up and laboratory measurements in the cohorts contributing to the ERFC. Investigators of several of these studies have contributed to a list naming some of these funding sources, which can be found at http://www.phpc.cam.ac.uk/ceu/research/erfc/studies/. NR 49 TC 40 Z9 41 U1 1 U2 32 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD OCT PY 2012 VL 41 IS 5 BP 1419 EP 1433 DI 10.1093/ije/dys086 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 021YU UT WOS:000309922700028 ER PT J AU Hinkle, SN Schieve, LA Stein, AD Swan, DW Ramakrishnan, U Sharma, AJ AF Hinkle, S. N. Schieve, L. A. Stein, A. D. Swan, D. W. Ramakrishnan, U. Sharma, A. J. TI Associations between maternal prepregnancy body mass index and child neurodevelopment at 2 years of age SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE pregnancy; neurodevelopment; mental; psychomotor; underweight; body mass index ID GESTATIONAL WEIGHT-GAIN; LOW-BIRTH-WEIGHT; DEVELOPING BRAIN; UNITED-STATES; PREGNANCY; OBESITY; PREVALENCE; OUTCOMES; RISK; INFLAMMATION AB OBJECTIVE: Both underweight and obese mothers have an increased risk for adverse offspring outcomes. Few studies have examined the association between prepregnancy body mass index (BMI) and children's neurodevelopment. SUBJECTS: We used data from the nationally representative Early Childhood Longitudinal Study-Birth Cohort (ECLS-B; n = 6850). Children were classified according to their mother's prepregnancy BMI (kg m(-2)) status: underweight (BMI <18.5), normal weight (BMI 18.5-24.9), overweight (BMI 25.0-29.9), obese class I (BMI 30.0-34.9), and obese class II and III (BMI >= 35.0). Children's age-adjusted mental development index (MDI) and psychomotor development index (PDI) T-scores (mean 50, s.d. 10) were obtained using a validated shortened version of the Bayley Scales of Infant Development-II at approximately 2 years of age. While adjusting for sociodemographics, we estimated the average MDI and PDI scores or the risk of delayed (< -1 s.d. vs >1 s.d.) mental or motor development, relative to children of normal weight mothers. RESULTS: Compared with children of normal weight mothers, MDI scores were lower among children of mothers of all other prepregnancy BMI categories, with the greatest adjusted difference among children of class II and III obese mothers (-2.13 (95% CI -3.32, -0.93)). The adjusted risk of delayed mental development was increased among children of underweight (risk ratio (RR) 1.36 (95% CI 1.04, 1.78)) and class II and III obese (RR 1.38 (95% CI 1.03, 1.84)) mothers. Children's PDI scores or motor delay did not differ by maternal prepregnancy BMI. CONCLUSION: In this nationally representative sample of 2-year-old US children, low and very-high maternal prepregnancy BMI were associated with increased risk of delayed mental development but not motor development. C1 [Sharma, A. J.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. [Hinkle, S. N.; Stein, A. D.; Ramakrishnan, U.; Sharma, A. J.] Emory Univ, Div Biol & Biomed Sci, Atlanta, GA 30322 USA. [Hinkle, S. N.; Sharma, A. J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Schieve, L. A.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. [Swan, D. W.] Inst Museum & Lib Serv, Off Planning Res & Evaluat, Washington, DC USA. [Stein, A. D.; Swan, D. W.; Ramakrishnan, U.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Sharma, AJ (reprint author), US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. EM AJSharma@cdc.gov RI Hinkle, Stefanie/F-8253-2013; Ramakrishnan, Usha/L-8921-2016; OI Hinkle, Stefanie/0000-0003-4312-708X; Stein, Aryeh/0000-0003-1138-6458; Sharma, Andrea/0000-0003-0385-0011 FU US Department of Energy [DE-AC05-06OR23100]; Oak Ridge Associated Universities [DE-AC05-06OR23100] FX This research was performed under an appointment to the Centers for Disease Control and Prevention, administered by the Oak Ridge Institute for Science and Education under contract number DE-AC05-06OR23100 between the US Department of Energy and Oak Ridge Associated Universities. NR 53 TC 36 Z9 38 U1 4 U2 22 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD OCT PY 2012 VL 36 IS 10 BP 1312 EP 1319 DI 10.1038/ijo.2012.143 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 018GX UT WOS:000309649400009 PM 22964791 ER PT J AU McCollum, JT Williams, NJ Beam, SW Cosgrove, S Ettestad, PJ Ghosh, TS Kimura, AC Nguyen, L Stroika, SG Vogt, RL Watkins, AK Weiss, JR Williams, IT Cronquist, AB AF McCollum, J. T. Williams, N. J. Beam, S. W. Cosgrove, S. Ettestad, P. J. Ghosh, T. S. Kimura, A. C. Nguyen, L. Stroika, S. G. Vogt, R. L. Watkins, A. K. Weiss, J. R. Williams, I. T. Cronquist, A. B. TI Multistate Outbreak of Escherichia coli O157:H7 Infections Associated with In-Store Sampling of an Aged Raw-Milk Gouda Cheese, 2010 SO JOURNAL OF FOOD PROTECTION LA English DT Article ID HEMOLYTIC-UREMIC SYNDROME; FOODBORNE DISEASE OUTBREAKS; UNITED-STATES; COLI O157-H7; SURVEILLANCE; MANUFACTURE; CONSUMPTION; SALMONELLA; SURVIVAL; PULSENET AB In 2010, 41 patients ill with Escherichia coli O157:H7 isolates determined to be indistinguishable by pulsed-field gel electrophoresis were identified among residents of five Southwestern U.S. states. A majority of patients reported consuming complimentary samples of aged raw-milk Gouda cheese at national warehouse chain store locations; sampling Gouda cheese was significantly associated with illness (odds ratio, 9.0; 95% confidence interval, 1.7 to 47). Several Gouda samples yielded the O157:H7 outbreak strain, confirming the food vehicle and source of infections. Implicated retail food-sampling operations were inconsistently regulated among affected states, and sanitation deficiencies were common among sampling venues. Inspection of the cheese manufacturer indicated deficient sanitation practices and insufficient cheese curing times. Policymakers should continue to reexamine the adequacy and enforcement of existing rules intended to ensure the safety of raw-milk cheeses and retail food sampling. Additional research is necessary to clarify the food safety hazards posed to patrons who consume free food samples while shopping. C1 [McCollum, J. T.; Williams, N. J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Stroika, S. G.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Williams, I. T.] Ctr Dis Control & Prevent, Outbreak Response & Prevent Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [McCollum, J. T.; Cosgrove, S.; Watkins, A. K.; Cronquist, A. B.] Colorado Dept Publ Hlth & Environm, Dis Control & Environm Epidemiol Div, Denver, CO 80246 USA. [Williams, N. J.; Ghosh, T. S.; Vogt, R. L.; Watkins, A. K.] Tri County Hlth Dept, Greenwood Village, CO 80111 USA. [Beam, S. W.] Calif Dept Food & Agr, Sacramento, CA 95814 USA. [Ettestad, P. J.] New Mexico Dept Hlth, Santa Fe, NM 87502 USA. [Kimura, A. C.] Calif Dept Publ Hlth, Gardena, CA 90248 USA. [Nguyen, L.] So Nevada Hlth District, Las Vegas, NV 89127 USA. [Weiss, J. R.] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. RP McCollum, JT (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM jeffrey.mccollum@us.army.mil NR 25 TC 13 Z9 14 U1 1 U2 9 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD OCT PY 2012 VL 75 IS 10 BP 1759 EP 1765 DI 10.4315/0362-028X.JFP-12-136 PG 7 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 020WD UT WOS:000309846400005 PM 23043823 ER PT J AU Cleveland, JL Foster, M Barker, L Brown, GG Lenfestey, N Lux, L Corley, TJ Bonito, AJ AF Cleveland, Jennifer L. Foster, Misty Barker, Laurie Brown, G. Gordon Lenfestey, Nancy Lux, Linda Corley, Tammy J. Bonito, Arthur J. TI Advancing infection control in dental care settings Factors associated with dentists' implementation of guidelines from the Centers for Disease Control and Prevention SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article DE Dentistry; infection control; guidelines ID TRANSMISSION; PREDICTORS; ADHERENCE; VIRUS AB Background and Overview. The authors set out to identify factors associated with implementation by U.S. dentists of four practices first recommended in the Centers for Disease Control and Prevention's Guidelines for Infection Control in Dental Health-Care Settings-2003. Methods. In 2008, the authors surveyed a stratified random sample of 6,825 U.S. dentists. The response rate was 49 percent. The authors gathered data regarding dentists' demographic and practice characteristics, attitudes toward infection control, sources of instruction regarding the guidelines and knowledge about the need to use sterile water for surgical procedures. Then they assessed the impact of those factors on the implementation of four recommendations: having an infection control coordinator, maintaining dental unit water quality, documenting percutaneous injuries and using safer medical devices, such as safer syringes and scalpels. The authors conducted bivariate analyses and proportional odds modeling. Results. Responding dentists in 34 percent of practices had implemented none or one of the four recommendations, 40 percent had implemented two of the recommendations and 26 percent had implemented three or four of the recommendations. The likelihood of implementation was higher among dentists who acknowledged the importance of infection control, had practiced dentistry for less than 30 years, had received more continuing dental education credits in infection control, correctly identified more surgical procedures that require the use of sterile water, worked in larger practices and had at least three sources of instruction regarding the guidelines. Dentists with practices in the South Atlantic, Middle Atlantic or East South Central U.S. Census divisions were less likely to have complied. Conclusions. Implementation of the four recommendations varied among U.S. dentists. Strategies targeted at raising awareness of the importance of infection control, increasing continuing education requirements and developing multiple modes of instruction may increase implementation of current and future Centers for Disease Control and Prevention guidelines. C1 [Cleveland, Jennifer L.; Brown, G. Gordon; Lenfestey, Nancy; Lux, Linda; Bonito, Arthur J.] RTI Int, Res Triangle Pk, NC USA. [Cleveland, Jennifer L.; Barker, Laurie; Corley, Tammy J.] Ctr Dis Control & Prevent, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Cleveland, JL (reprint author), RTI Int, Res Triangle Pk, NC USA. EM JLCleveland@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 7 Z9 8 U1 1 U2 5 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD OCT PY 2012 VL 143 IS 10 BP 1127 EP 1138 PG 12 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 023NS UT WOS:000310042300019 PM 23024311 ER PT J AU Mcleland, S Duncan, C Spraker, T Wheeler, E Lockhart, SR Gulland, F AF Mcleland, Shannon Duncan, Colleen Spraker, Terry Wheeler, Elizabeth Lockhart, Shawn R. Gulland, Frances TI Cryptococcus albidus Infection in a California Sea Lion (Zalophus californianus) SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE California sea lion; Cryptococcus albidus; fungal infection; pinniped ID MARINE MAMMALS; GATTII; NEOFORMANS; OUTBREAK AB Sporadic cases of cryptococcosis have been reported in marine mammals, typically due to Cryptococeus neoformans and, more recently, to Cryptococcus gattii in cetaceans. Cryptococcus (libidos, a ubiquitous fungal species not typically considered to be pathogenic, was recovered from a juvenile California sea lion (Zalophus californianus) rescued near San Francisco Bay, California. Yeast morphologically consistent with a Cryptococcus sp. was identified histologically in a lymph node and C. (libidos was identified by an rDNA sequence from the lung. Infection with C. albidus was thought to have contributed to mortality in this sea lion, along with concurrent bacterial pneumonia. Cryptococcos albidus. should be considered as a potential pathogen with a role in marine mammal morbidity and mortality. C1 [Mcleland, Shannon; Duncan, Colleen; Spraker, Terry] Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA. [Lockhart, Shawn R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. [Wheeler, Elizabeth; Gulland, Frances] Marine Mammal Ctr, Sausalito, CA 94965 USA. RP Mcleland, S (reprint author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA. EM Shannon.Mcleland@colostate.edu NR 24 TC 3 Z9 3 U1 0 U2 10 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD OCT PY 2012 VL 48 IS 4 BP 1030 EP 1034 DI 10.7589/2011-08-226 PG 5 WC Veterinary Sciences SC Veterinary Sciences GA 020VV UT WOS:000309845600019 PM 23060504 ER PT J AU Mutebi, JP Swope, BN Saxton-Shaw, KD Graham, AC Turmel, JP Berl, E AF Mutebi, John-Paul Swope, Bethany N. Saxton-Shaw, Kali D. Graham, Alan C. Turmel, Jon P. Berl, Erica TI Eastern Equine Encephalitis in Moose (Alces americanus) in Northeastern Vermont SO JOURNAL OF WILDLIFE DISEASES LA English DT Article ID WHITE-TAILED DEER; HOME-RANGE; MAINE AB During fall 2010, 21 moose (Alces americanus) sera collected in northeastern Vermont were screened for eastern equine encephalitis virus (EEEV) antibodies using plaque reduction neutralization tests. Six (29%) were antibody positive. This is the first evidence of EEEV activity in Vermont, and the second report of EEEV antibodies in moose. C1 [Mutebi, John-Paul; Saxton-Shaw, Kali D.] Ctr Dis Control & Prevent CDC, DVBD, Ft Collins, CO 80521 USA. [Swope, Bethany N.] Inviragen Inc, Ft Collins, CO 80525 USA. [Graham, Alan C.; Turmel, Jon P.] Agcy Agr Food & Markets, Plant Ind Sect, Waterbury, VT 05671 USA. [Berl, Erica] Vermont Dept Hlth, Burlington, VT 05401 USA. RP Mutebi, JP (reprint author), Ctr Dis Control & Prevent CDC, DVBD, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM jmutebi@cdc.gov FU Vermont Agency of Agriculture; Vermont Department of Health; CDC FX We thank wildlife biologists from the Vermont Department of Fish and Wildlife for help in collecting serum samples on youth weekend. We thank the many volunteers that helped to collect serum samples. Also, we thank students from the University of Vermont, Green Mountain College, and Paul Smiths College and staff from the Vermont Department of Health; the Vermont Agency of Agriculture, Food and Markets; the Vermont Department of Forest, Parks and Recreation; the Vermont Center for Ecostudies; and the United States Department of Agriculture, Animal, and Plant Health Inspection Service. This study was funded in part by the Vermont Agency of Agriculture, the Vermont Department of Health, and the CDC. NR 15 TC 4 Z9 4 U1 1 U2 9 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD OCT PY 2012 VL 48 IS 4 BP 1109 EP 1112 DI 10.7589/2012-03-076 PG 4 WC Veterinary Sciences SC Veterinary Sciences GA 020VV UT WOS:000309845600035 PM 23060520 ER PT J AU Bouris, A Guilamo-Ramos, V Cherry, K Dittus, P Michael, S Gloppen, K AF Bouris, Alida Guilamo-Ramos, Vincent Cherry, Kevin Dittus, Patricia Michael, Shannon Gloppen, Kari TI Preventing Rapid Repeat Births Among Latina Adolescents: The Role of Parents SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID CONTRACEPTIVE USE; INTERGENERATIONAL CYCLE; TEENAGE CHILDBEARING; YOUNGER SIBLINGS; RISK BEHAVIORS; PREGNANCY RISK; HEALTH FACTORS; SEXUAL RISK; MOTHERS; FAMILY AB Latina adolescent parents are at increased risk for rapid repeat births (second birth 24 months after the first), sexually transmitted infections, and negative educational and social outcomes. Although several effective parent-based interventions have been developed to prevent Latino youths' sexual risk taking, little research has explored the development of interventions to prevent repeat births that involve the parents of these adolescents. Existing preventative interventions involving parents suffer from important methodological limitations. Additional research is needed to advance theories of behavior, identify the causal pathways of parental influence, and specify appropriate behavioral targets. Future parent-based interventions to prevent repeat births should target pregnancy intentions, age of partners, contraceptive use, integrated prevention of pregnancies and sexually transmitted infections, educational attainment, and future orientations. (Am J Public Health. 2012;102:1842-1847. doi:10.2105/AJPH.2011.300578) C1 [Bouris, Alida; Cherry, Kevin] Univ Chicago, Sch Social Serv Adm, Chicago, IL 60637 USA. [Guilamo-Ramos, Vincent] NYU, Silver Sch Social Work, Ctr Latino Adolescent & Family Hlth, New York, NY USA. [Dittus, Patricia; Michael, Shannon] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gloppen, Kari] Univ Washington, Sch Social Work, Seattle, WA 98195 USA. RP Bouris, A (reprint author), Univ Chicago, Sch Social Serv Adm, 969 E 60th St, Chicago, IL 60637 USA. EM abouris@uchicago.edu FU Centers for Disease Control and Prevention as part of the Parenting Synthesis Project FX This research was funded by the Centers for Disease Control and Prevention as part of the Parenting Synthesis Project (principal investigator, V.G.-R.). NR 71 TC 3 Z9 3 U1 2 U2 14 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2012 VL 102 IS 10 BP 1842 EP 1847 DI 10.2105/AJPH.2011.300578 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 015GU UT WOS:000309435200007 PM 22897524 ER PT J AU Lorch, SA Kroelinger, CD Ahlberg, C Barfield, WD AF Lorch, Scott A. Kroelinger, Charlan D. Ahlberg, Corinne Barfield, Wanda D. TI Factors That Mediate Racial/Ethnic Disparities in US Fetal Death Rates SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NEONATAL INTENSIVE-CARE; INFANTS AFTER-DISCHARGE; UNITED-STATES; PERINATAL-MORTALITY; HEALTH-CARE; CESAREAN DELIVERY; CHILDHOOD ASTHMA; RACIAL DISPARITY; HIGH-RISK; PREGNANCY AB Objectives. We sought to determine the importance of socioeconomic factors, maternal comorbid conditions, antepartum and intrapartum complications of pregnancy, and fetal factors in mediating racial disparities in fetal deaths. Methods. We undertook a mediation analysis on a retrospective cohort study of hospital-based deliveries with a gestational age between 23 and 44 weeks in California, Missouri, and Pennsylvania from 1993 to 2005 (n = 7 104 674). Results. Among non-Hispanic Black women and Hispanic women, the fetal death rate was higher than among non-Hispanic White women (5.9 and 3.6 per 1000 deliveries, respectively, vs 2.6 per 1000 deliveries; P<.01). For Black women, fetal factors mediated the largest percentage (49.6%; 95% confidence interval [Cl] = 42.7, 54.7) of the disparity in fetal deaths, whereas antepartum and intrapartum factors mediated some of the difference in fetal deaths for both Black and Asian women. Among Hispanic women, socioeconomic factors mediated 35.8% of the disparity in fetal deaths (95% CI=25.8%, 46.2%). Conclusions. The factors that mediate racial/ethnic disparities in fetal death differ depending on the racial/ethnic group. Interventions targeting mediating factors specific to racial/ethnic groups, such as improved access to care, may help reduce US fetal death disparities. (Am J Public Health. 2012;102:1902-1910. doi:10.2105/AJPH.2012.300852) C1 [Lorch, Scott A.; Ahlberg, Corinne] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA. [Lorch, Scott A.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Kroelinger, Charlan D.; Barfield, Wanda D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Lorch, Scott A.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA. RP Lorch, SA (reprint author), Childrens Hosp Philadelphia, Ctr Outcomes Res, 3535 Market St,Suite 1029, Philadelphia, PA 19104 USA. EM lorch@e-mail.chop.edu FU Maternal and Child Health Bureau [1 R40 MC05474-01-00]; Agency for Healthcare Research and Quality [R01 HS 015696] FX This work was supported by the Maternal and Child Health Bureau (grant 1 R40 MC05474-01-00) and the Agency for Healthcare Research and Quality (grant R01 HS 015696). NR 47 TC 9 Z9 9 U1 1 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2012 VL 102 IS 10 BP 1902 EP 1910 DI 10.2105/AJPH.2012.300852 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 015GU UT WOS:000309435200018 PM 22897542 ER PT J AU Iqbal, S Clower, JH Hernandez, SA Damon, SA Yip, FY AF Iqbal, Shahed Clower, Jacquelyn H. Hernandez, Sandra A. Damon, Scott A. Yip, Fuyuen Y. TI A Review of Disaster-Related Carbon Monoxide Poisoning: Surveillance, Epidemiology, and Opportunities for Prevention SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Review ID ICE STORM; UNITED-STATES; HURRICANE SEASON; NORTH-CAROLINA; EXPOSURES; FLORIDA; OUTBREAK; DEATHS; RITA AB Objectives. We conducted a systematic literature review to better understand aspects of disaster-related carbon monoxide (CO) poisoning surveillance and determine potentially effective prevention strategies. Methods. This review included information from 28 journal articles on disaster-related CO poisoning cases occurring between 1991 and 2009 in the United States. Results. We identified 362 incidents and 1888 disaster-related CO poisoning cases, including 75 fatalities. Fatalities occurred primarily among persons who were aged 18 years or older (88%) and male (79%). Hispanics and Asians accounted for 20% and 14% of fatal cases and 21% and 7% of nonfatal cases, respectively. Generators were the primary exposure source for 83% of fatal and 54% of nonfatal cases; 67% of these fatal cases were caused by indoor generator placement. Charcoal grills were a major source of exposure during winter storms. Most fatalities (94%) occurred at home. Nearly 89% of fatal and 53% of nonfatal cases occurred within 3 days of disaster onset. Conclusions. Public health prevention efforts could benefit from emphasizing predisaster risk communication and tailoring interventions for racial, ethnic, and linguistic minorities. These findings highlight the need for surveillance and CO-related information as components of disaster preparedness, response, and prevention. (Am J Public Health. 2012;102:1957-1963. doi:10.2105/AJPH.2012.300674) C1 [Iqbal, Shahed; Clower, Jacquelyn H.; Damon, Scott A.; Yip, Fuyuen Y.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Iqbal, S (reprint author), 1600 Clifton Rd NE,MS D26, Atlanta, GA 30333 USA. EM siqbal@cdc.gov NR 63 TC 15 Z9 16 U1 1 U2 8 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2012 VL 102 IS 10 BP 1957 EP 1963 DI 10.2105/AJPH.2012.300674 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 015GU UT WOS:000309435200025 PM 22897556 ER PT J AU Rossen, LM Schoendorf, KC AF Rossen, Lauren M. Schoendorf, Kenneth C. TI Measuring health disparities: trends in racial-ethnic and socioeconomic disparities in obesity among 2- to 18-year old youth in the United States, 2001-2010 SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Inequities; Inequalities; Children; Adolescents; Weight; Socioeconomic status; Measurement; Ethnic differences ID INFANT-DEATH-SYNDROME; BODY-MASS INDEX; US CHILDREN; CHILDHOOD OVERWEIGHT; SOCIAL INEQUALITIES; ADOLESCENTS; PREVALENCE; ASSOCIATION; POSITION; GENDER AB Purpose: Although eliminating health disparities by race, ethnicity, and socioeconomic status (SES) is a top public health priority internationally and in the United States, weight-related racial/ethnic and SES disparities persist among adults and children in the United States. Few studies have examined how these disparities have changed over time; these studies are limited by the reliance on rate differences or ratios to measure disparities. We sought to advance existing research by using a set of disparity metrics on both the absolute and relative scales to examine trends in childhood obesity disparities over time. Methods: Data from 7066 children, ages 2 to 18 years, in the National Health and Nutrition Examination Surveys were used to explore trends in racial/ethnic and SES disparities in pediatric obesity from 2001 to 2010 using a set of different disparity metrics. Results: Racial/ethnic and SES-related disparities in pediatric obesity did not change significantly from 2001 to 2010 and remain significant. Conclusions: Disparities in obesity have not improved during the past decade. The use of different disparity metrics may lead to different conclusions with respect to how disparities have changed over time, highlighting the need to evaluate disparities using a variety of metrics. Published by Elsevier Inc. C1 [Rossen, Lauren M.; Schoendorf, Kenneth C.] Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Rossen, LM (reprint author), Ctr Dis Control & Prevent, Infant Child & Womens Hlth Stat Branch, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM lrossen@cdc.gov FU Intramural CDC HHS [CC999999] NR 50 TC 41 Z9 42 U1 0 U2 44 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD OCT PY 2012 VL 22 IS 10 BP 698 EP 704 DI 10.1016/j.annepidem.2012.07.005 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 017DO UT WOS:000309570500003 PM 22884768 ER PT J AU Otterstatter, MC Brierley, JD De, P Ellison, LF MacIntyre, M Marrett, LD Semenciw, R Weir, HK AF Otterstatter, Michael C. Brierley, James D. De, Prithwish Ellison, Larry F. MacIntyre, Maureen Marrett, Loraine D. Semenciw, Robert Weir, Hannah K. CA Canadian Canc Stat Steering Comm TI Esophageal cancer in Canada: Trends according to morphology and anatomical location SO CANADIAN JOURNAL OF GASTROENTEROLOGY LA English DT Review DE Adenocarcinoma; Esophageal cancer; Incidence; Mortality; Squamous cell carcinoma; Survival ID GASTROESOPHAGEAL-REFLUX DISEASE; GASTRIC CARDIA; UNITED-STATES; RISK-FACTORS; TIME TRENDS; ADENOCARCINOMA; EPIDEMIOLOGY; COUNTRIES; PREVALENCE; CARCINOMA AB BACKGROUND: Esophageal adenocarcinoma has one of the fastest rising incidence rates and one of the lowest survival rates of any cancer type in the Western world. However, in many countries, trends in esophageal cancer differ according to tumour morphology and anatomical location. In Canada, incidence and survival trends for esophageal cancer subtypes are poorly known. METHODS: Cancer incidence and mortality rates were obtained from the Canadian Cancer Registry, the National Cancer Incidence Reporting System and the Canadian Vital Statistics Death databases for the period from 1986 to 2006. Observed trends (annual per cent change) and five-year relative survival ratios were estimated separately for esophageal adenocarcinoma and squamous cell carcinoma, and according to location (upper, middle, or lower one-third of the esophagus). Incidence rates were projected up to the year 2026. RESULTS: Annual age-standardized incidence rates for esophageal cancer in 2004 to 2006 were 6.1 and 1.7 per 100,000 for males and females, respectively. Esophageal adenocarcinoma incidence rose by 3.9% (males) and 3.6% (females) per year for the period 1986 to 2006, with the steepest increase in the lower one-third of the esophagus (4.8% and 5.0% per year among males and females, respectively). In contrast, squamous cell carcinoma incidence declined by 3.3% (males) and 3.2% (females) per year since the early 1990s. The five-year relative survival ratio for esophageal cancer was 13% between 2004 and 2006, approximately a 3% increase since the period from 1992 to 1994. Projected incidence rates showed increases of 40% to 50% for esophageal adenocarcinoma and decreases of 30% for squamous cell carcinoma by 2026. DISCUSSION: Although esophageal cancer is rare in Canada, the incidence of esophageal adenocarcinoma has doubled in the past 20 years, which may reflect the increasing prevalence of obesity and gastroesophageal reflux disease. Declines in squamous cell carcinoma may be the result of the decreases in the prevalence of smoking in Canada. Given the low survival rates and the potential for further increases in incidence, esophageal adenocarcinoma warrants close attention. C1 [Otterstatter, Michael C.; Semenciw, Robert] Publ Hlth Agcy Canada, Ctr Chron Dis Prevent & Control, Ottawa, ON, Canada. [Brierley, James D.] Univ Toronto, Dept Radiat Oncol, Univ Hlth Network, Toronto, ON, Canada. [De, Prithwish] Canadian Canc Soc, Toronto, ON, Canada. [Ellison, Larry F.] STAT Canada, Hlth Stat Div, Ottawa, ON, Canada. [MacIntyre, Maureen] Canc Care Nova Scotia, Surveillance & Epidemiol Unit, Halifax, NS, Canada. [Marrett, Loraine D.] Canc Care Ontario, Surveillance & Populat Studies, Toronto, ON, Canada. [Weir, Hannah K.] US Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Otterstatter, MC (reprint author), BC Ctr Dis Control, CDPACS, 655 W 12th Ave, Vancouver, BC V5Z 4R4, Canada. EM michael.otterstatter@bccdc.ca NR 53 TC 14 Z9 15 U1 0 U2 2 PU PULSUS GROUP INC PI OAKVILLE PA 2902 S SHERIDAN WAY, OAKVILLE, ONTARIO L6J 7L6, CANADA SN 0835-7900 J9 CAN J GASTROENTEROL JI Can. J. Gastroenterol. PD OCT PY 2012 VL 26 IS 10 BP 723 EP 727 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 019TV UT WOS:000309763200012 PM 23061066 ER PT J AU Levy, SS Macera, CA Hootman, JM Coleman, KJ Lopez, R Nichols, JF Marshall, SJ Ainsworth, BA Ji, M AF Levy, Susan S. Macera, Caroline A. Hootman, Jennifer M. Coleman, Karen J. Lopez, Ruby Nichols, Jeanne F. Marshall, Simon J. Ainsworth, Barbara A. Ji, Ming TI Evaluation of a multi-component group exercise program for adults with arthritis: Fitness and Exercise for People with Arthritis (FEPA) SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Community programs; Intervention effects; Physical activity; Physical function ID RESIDING OLDER-ADULTS; RHEUMATOID-ARTHRITIS; PHYSICAL-ACTIVITY; FUNCTIONAL FITNESS; KNEE OSTEOARTHRITIS; UNITED-STATES; HEALTH; PREVALENCE; STRENGTH; TRIAL AB Background: Research supports the favorable effects of exercise on physical and psychosocial outcomes in those with arthritis. Few easily disseminated, multi-component, arthritis-specific programs have been evaluated using both physical function and psychosocial measures. Fitness and Exercise for People with Arthritis (FEPA) is a new community-based, 3-month, instructor supervised multicomponent exercise program for individuals with arthritis designed to increase strength, flexibility, balance, and aerobic conditioning, while emphasizing joint-protection and proper biomechanics. Purpose: To conduct a preliminary evaluation of the effects of the FEPA program on physical function and arthritis-related outcomes in individuals with arthritis. Method: Middle-aged (n = 31, M-age = 54.8 +/- 7.2) and older (n = 79, M-age = 76.0 +/- 6.6) adults with arthritis completed the instructor led FEPA program in community senior centers, churches, and adult education settings. Changes in physical function, measured using the arm curl, back-scratch test, 8-foot up-and-go, and 6 min walk and self-reported arthritis-related pain, perceived physical function, affect, and self-efficacy for symptom management were assessed using RM ANOVA. Results: Significant improvements (ps < .05) in all physical function measures were found in the older group. In the middle-aged group, significant improvements (ps < .05) were found in the 8-foot up-and-go and 6 min walk. Self-reported physical function, pain perceptions, and self-efficacy for pain management significantly improved (ps < .05) in middle-aged participants, while only self-reported pain perceptions significantly improved in the older group. Conclusions: FEPA shows promise for improving health-related outcomes in those with arthritis, and has potential for sustainability in community settings. (C) 2012 Elsevier Inc. All rights reserved. C1 [Levy, Susan S.; Nichols, Jeanne F.] San Diego State Univ, Sch Exercise & Nutr Sci, San Diego, CA 92182 USA. [Macera, Caroline A.; Lopez, Ruby; Ji, Ming] San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA. [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA USA. [Coleman, Karen J.] Kaiser Permanente, Dept Res & Evaluat, Pasadena, CA USA. [Marshall, Simon J.] Univ Calif San Diego, San Diego, CA 92103 USA. [Ainsworth, Barbara A.] Arizona State Univ, Coll Nursing & Hlth Innovat, Mesa, AZ USA. RP Levy, SS (reprint author), San Diego State Univ, Sch Exercise & Nutr Sci, 5500 Campanile Dr, San Diego, CA 92182 USA. EM slevy@mail.sdsu.edu FU Centers for Disease Control and Prevention (CDC) through the Association of Schools of Public Health (ASPH) [U36/CCU300430-23] FX "This project was supported under a cooperative agreement from the Centers for Disease Control and Prevention (CDC) through the Association of Schools of Public Health (ASPH) (gs1) Grant Number U36/CCU300430-23. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of CDC or ASPH.'' NR 35 TC 11 Z9 11 U1 1 U2 28 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD OCT PY 2012 VL 5 IS 4 BP 305 EP 311 DI 10.1016/j.dhjo.2012.07.003 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 016VQ UT WOS:000309548300014 PM 23021743 ER PT J AU Choudhary, E Chen, TH Martin, C Vagi, S Roth, J Keim, M Noe, R Ponausuia, SE Lemusu, S Bayleyegn, T Wolkin, A AF Choudhary, Ekta Chen, Tai-Ho Martin, Colleen Vagi, Sara Roth, Joseph, Jr. Keim, Mark Noe, Rebecca Ponausuia, Seiuli Elisapeta Lemusu, Siitia Bayleyegn, Tesfaye Wolkin, Amy TI Public Health Needs Assessments of Tutuila Island, American Samoa, After the 2009 Tsunami SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE community assessment; disaster; tsunami response; public health assessment; rapid needs assessment ID SAMPLING METHOD AB Objective: An 8.3 magnitude earthquake followed by tsunami waves devastated American Samoa on September 29, 2009, resulting in widespread loss of property and public services. An initial and a follow-up Community Needs Assessment for Public Health Emergency Response (CASPER) objectively quantified disaster-affected population needs. Methods: Using a 2-stage cluster sampling method of CASPER, a household questionnaire eliciting information about medical and basic needs, illnesses, and injuries was administered. To assess response efforts, percent changes in basic and medical needs, illnesses, and injuries between the initial and follow-up CASPER were calculated. Results: During the initial CASPER (N=212 households), 47.6% and 51.6% of households reported needing a tarpaulin and having no electricity, respectively. The self-reported greatest needs were water (27.8%) and financial help with cleanup (25.5%). The follow-up CASPER (N=207 households) identified increased vector problems compared to pre-tsunami, and food (26%) was identified as the self-reported greatest need. As compared to the initial CASPER, the follow-up CASPER observed decreases in electricity(-78.3%), drinking water(-44.4%), and clothing(-26.6%). Conclusion: This study highlights the use of CASPER during the response and recovery phases following a disaster. The initial CASPER identified basic needs immediately after the earthquake, whereas the follow-up CASPER assessed effectiveness of relief efforts and identified ongoing community needs. (Disaster Med Public Health Preparedness. 2012;6:209-216) C1 [Choudhary, Ekta; Martin, Colleen; Vagi, Sara; Noe, Rebecca; Bayleyegn, Tesfaye; Wolkin, Amy] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Atlanta, GA USA. [Keim, Mark] Ctr Dis Control & Prevent, Off Director, Natl Ctr Environm Hlth, Atlanta, GA USA. [Chen, Tai-Ho; Roth, Joseph, Jr.] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Ponausuia, Seiuli Elisapeta; Lemusu, Siitia] Amer Samoa Dept Hlth, Pago Pago, AS USA. RP Choudhary, E (reprint author), CDC NCEH HSB, 4770 Buford Hwy NE,MS F-57, Atlanta, GA 30341 USA. EM Echoudhary@CDC.gov FU Intramural CDC HHS [CC999999] NR 21 TC 3 Z9 3 U1 1 U2 11 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD OCT PY 2012 VL 6 IS 3 BP 209 EP 216 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 019GM UT WOS:000309725500004 PM 23077263 ER PT J AU Wray, RJ Harris, JK Jupka, K Vijaykumar, S Mitchell, EW Pollard, W Zielinski-Gutierrez, E Reissman, D Lubell, K AF Wray, Ricardo J. Harris, Jenine K. Jupka, Keri Vijaykumar, Santosh Mitchell, Elizabeth W. Pollard, William Zielinski-Gutierrez, Emily Reissman, Dori Lubell, Keri TI Individual and Community Influences on Adherence to Directives in the Event of a Plague Attack: Survey Results SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE social determinants; public health directive adherence; infectious disease outbreak; multilevel modeling ID HEALTH-CARE WORKERS; SELF-RATED HEALTH; NEIGHBORHOOD DEPRIVATION; PRETERM BIRTH; UNITED-STATES; RACIAL DISPARITIES; METROPOLITAN-AREAS; MULTILEVEL; BLACK; DETERMINANTS AB Objectives: During a public health emergency, public health officials issue directives with actions people need to take to protect themselves. Past research has shown that adherence to these directives depends on individual beliefs and circumstances. This report presents new research about the effects of community factors on adherence. Methods: A random digit-dial survey of 936 residents in the St Louis, Missouri, area was conducted in 2008 to assess barriers to and facilitators of adherence to directives issued in response to a hypothetical scenario involving the intentional release of the bacterium that causes plague. Community factors were assessed using characteristics of census tracts for individual respondents. Multilevel modeling was used to understand how individual and community factors contributed to the likelihood of adherence. Results: The majority of participants indicated that they would adhere to 3 distinct directives. Community poverty and ethnic homogeneity as well as individual-level barriers were negatively associated with adherence to a 6-day quarantine. Having children younger than 18 years and being away from home when the directive was called were negatively associated with adherence to a 10-hour quarantine. Logistical concerns were negatively associated with visiting a point of dispensing for prophylactic antibiotics. Conclusions: Our findings establish an empirical basis for the influence of community factors on adherence to public health directives. The influence of community and individual factors on adherence varies across directives. Consequently, communication strategies to disseminate directives and organizational strategies to support them must vary according to the nature of the directives. (Disaster Med Public Health Preparedness. 2012;6:253-262) C1 [Wray, Ricardo J.; Jupka, Keri] St Louis Univ, St Louis, MO 63103 USA. [Harris, Jenine K.] Washington Univ, St Louis, MO USA. [Vijaykumar, Santosh] Nanyang Technol Univ, Singapore, Singapore. [Mitchell, Elizabeth W.; Pollard, William; Zielinski-Gutierrez, Emily; Reissman, Dori; Lubell, Keri] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Wray, RJ (reprint author), 3545 Lafayette, St Louis, MO 63104 USA. EM wray@slu.edu FU Centers for Disease Control and Prevention FX This research was funded by the Centers for Disease Control and Prevention. NR 56 TC 0 Z9 0 U1 2 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD OCT PY 2012 VL 6 IS 3 BP 253 EP 262 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 019GM UT WOS:000309725500009 PM 23077268 ER PT J AU Wilson, T Chang, A Berro, A Still, A Brown, C Demma, A Nemhauser, J Martin, C Salame-Alfie, A Fisher-Tyler, F Smith, L Grady-Erickson, O Alvarado-Ramy, F Brunette, G Ansari, A McAdam, D Marano, N AF Wilson, Todd Chang, Arthur Berro, Andre Still, Aaron Brown, Clive Demma, Andrew Nemhauser, Jeffrey Martin, Colleen Salame-Alfie, Adela Fisher-Tyler, Frieda Smith, Lee Grady-Erickson, Onalee Alvarado-Ramy, Francisco Brunette, Gary Ansari, Armin McAdam, David Marano, Nina TI US Screening of International Travelers for Radioactive Contamination After the Japanese Nuclear Plant Disaster in March 2011 SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS LA English DT Article DE radiological disaster; traveler screening; preparedness; response; partnerships ID PREPAREDNESS AB On March 11, 2011, a magnitude 9.0 earthquake and subsequent tsunami damaged nuclear reactors at the Fukushima Daiichi complex in Japan, resulting in radionuclide release. In response, US officials augmented existing radio-logical screening at it sports of entry (POEs) to detect and decontaminate travelers contaminated with radioactive materials. During March 12 to 16, radiation screening protocols detected 3 travelers from Japan with external radioactive material contamination at 2 air POEs. Beginning March 23, federal officials collaborated with state and local public health and radiation control authorities to enhance screening and decontamination protocols at POEs. Approximately 543 000 (99%) travelers arriving directly from Japan at 25 US airports were screened for radiation contamination from March 17 to April 30, and no traveler was detected with contamination sufficient to require a large-scale public health response. The response highlighted synergistic collaboration across government levels and leveraged screening methods already in place at POEs, leading to rapid protocol implementation. Policy development, planning, training, and exercising response protocols and the establishment of federal authority to compel decontamination of travelers are needed for future radiological responses. Comparison of resource-intensive screening costs with the public health yield should guide policy decisions, given the historically low frequency of contaminated travelers arriving during radiological disasters. (Disaster Med Public Health Preparedness. 2012;6:291-296) C1 [Wilson, Todd; Chang, Arthur; Berro, Andre; Brown, Clive; Demma, Andrew; Nemhauser, Jeffrey; Martin, Colleen; Smith, Lee; Grady-Erickson, Onalee; Alvarado-Ramy, Francisco; Brunette, Gary; Ansari, Armin; McAdam, David; Marano, Nina] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Still, Aaron] US Customs & Border Protect, Washington, DC USA. [Salame-Alfie, Adela] New York State Dept Hlth, Albany, NY USA. [Fisher-Tyler, Frieda] Delaware Div Publ Hlth, Dover, DE USA. RP Wilson, T (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E04, Atlanta, GA 30329 USA. EM twilson@cdc.gov NR 20 TC 2 Z9 2 U1 0 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 1935-7893 J9 DISASTER MED PUBLIC JI Dis. Med. Public Health Prep. PD OCT PY 2012 VL 6 IS 3 BP 291 EP 296 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 019GM UT WOS:000309725500013 PM 23077272 ER PT J AU Maisonet, M Terrell, ML McGeehin, MA Christensen, KY Holmes, A Calafat, AM Marcus, M AF Maisonet, Mildred Terrell, Metrecia L. McGeehin, Michael A. Christensen, Krista Yorita Holmes, Adrianne Calafat, Antonia M. Marcus, Michele TI Maternal Concentrations of Polyfluoroalkyl Compounds during Pregnancy and Fetal and Postnatal Growth in British Girls SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE ALSPAC; birth weight; early childhood growth; perfluorohexane sulfonate; perfluorooctanoate; perfluorooctane sulfonate; polyfluoroalkyl compounds; postnatal growth ID NATIONAL BIRTH COHORT; PERFLUOROOCTANOIC ACID; PERFLUORINATED CHEMICALS; DEVELOPMENTAL TOXICITY; CROSS-FOSTER; EXPOSURE; MOUSE; SERUM; AGE; SULFONATE AB BACKGROUND: Prenatal exposures to polyfluoroalkyl compounds (PFCs) may be associated with adverse changes in fetal and postnatal growth. OBJECTIVE: We explored associations of prenatal serum concentrations of perfluorooctane sulfonate (PFOS), perfluorooctanoate (PFOA), and perfluorohexane sulfonate (PFHxS) with fetal and postnatal growth in girls. METHODS: We studied a sample of 447 singleton girls and their mothers participating in the Avon Longitudinal Study of Parents and Children (ALSPAC). Data on weight and length were obtained at birth and at 2, 9, and 20 months. Serum samples were obtained in 1991-1992, from mothers during pregnancy. We explored associations between prenatal PFC concentrations and weight at birth as well as longitudinal changes in weight-for-age SD scores between birth and 20 months. RESULTS: PFOS (median, 19.6 ng/mL), PFOA (median, 3.7 ng/mL), and PFHxS (median, 1.6 ng/mL) were detected in 100% of samples. On average, girls born to mothers with prenatal concentrations of PFOS in the upper tertile weighed 140 g less [95% confidence interval (CI): 238, 421 at birth than girls born to mothers with concentrations in the lower tertile in adjusted models. Similar patterns were seen for PFOA (-133 g; 95% Cl: 237, 30) and PFHxS (-108 g; 95% CI: 206, 10). At 20 months, however, girls born to mothers with prenatal concentrations of PFOS in the upper tertile weighed 580 g more (95% CI: 301, 858) when compared with those in the lower tertile. No differences in weight were found for PFOA and PFHxS. CONCLUSIONS: Girls with higher prenatal exposure to each of the PFCs examined were smaller at birth than those with lower exposure. In addition, those with higher exposure to PFOS were larger at 20 months. C1 [Maisonet, Mildred; Terrell, Metrecia L.; Christensen, Krista Yorita; Marcus, Michele] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Maisonet, Mildred; McGeehin, Michael A.; Holmes, Adrianne; Calafat, Antonia M.; Marcus, Michele] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Marcus, Michele] Kaiser Permanente Ctr Hlth Res, Atlanta, GA USA. RP Marcus, M (reprint author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, 1518 Clifton Rd NE,Claudia N Rollins Bldg 4045, Atlanta, GA 30322 USA. EM mmarcus@emory.edu RI Marcus, Michele/J-2746-2015; OI Terrell, Metrecia/0000-0001-9406-2226; Maisonet, Mildred/0000-0003-3561-2632 FU Centers for Disease Control and Prevention FX The UK Medical Research Council, the Wellcome Trust and the University of Bristol provide core support for ALSPAC. This research was specifically funded by Centers for Disease Control and Prevention. NR 31 TC 46 Z9 48 U1 3 U2 41 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2012 VL 120 IS 10 BP 1432 EP 1437 DI 10.1289/ehp.1003096 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 018US UT WOS:000309692600026 PM 22935244 ER PT J AU Hoffman, K Adgent, M Goldman, BD Sjodin, A Daniels, JL AF Hoffman, Kate Adgent, Margaret Goldman, Barbara Davis Sjoedin, Andreas Daniels, Julie L. TI Lactational Exposure to Polybrominated Diphenyl Ethers and Its Relation to Social and Emotional Development among Toddlers SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE neurodevelopment; polybrominated diphenyl ethers (PBDEs); social and emotional development ID POLYCHLORINATED-BIPHENYLS; POSTNATAL EXPOSURE; FLAME RETARDANTS; BREAST-MILK; HOUSE-DUST; PBDE-99; SAMPLES; BLOOD; MICE AB BACKGROUND: Polybrominated diphenyl ethers (PBDEs) have been widely used as flame retardants and are ubiquitous environmental contaminants. PBDEs have been linked to adverse neurodevelopment in animals and humans. OBJECTIVES: We investigated the association between breast milk PBDE levels and social and emotional development in toddlers. METHODS: The Pregnancy Infection and Nutrition (PIN) and PIN Babies studies followed a cohort of North Carolina pregnant women and their children through 36 months of age. Breast milk samples obtained at 3 months postpartum were analyzed for PBDEs. The Infant Toddler Social and Emotional Assessment (ITSEA) was completed by mothers when children were approximately 30 months of age (n = 222). We assessed the relationship between breast milk concentrations of five PBDE congeners-BDEs 28, 47, 99, 100, and 153-and children's social and emotional development, adjusting for other factors. RESULTS: A small, imprecise, yet consistent positive association was apparent between BDEs 47, 99, and 100 and increased externalizing behaviors, specifically activity/impulsivity behaviors. Externalizing domain T-scores ranged from 30 to 87 with a mean of 47.8. Compared with those with BDE-47 concentrations below the median, adjusted externalizing behavior domain scores were 1.6 [95% confidence interval (CI): -1.2, 4.4] and 2.8 (95% CI -0.1, 5.7) points higher for children born to women with breast milk concentrations in the 3rd and 4th quartiles, respectively. PBDEs were not associated with other social and emotional developmental domains. CONCLUSIONS: Our results, although imprecise, suggest a subtle association between early-life PBDE exposure and increased activity/impulsivity behaviors in early childhood. Confirmation of these results is needed in other longitudinal studies. C1 [Daniels, Julie L.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Adgent, Margaret] NIEHS, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA. [Goldman, Barbara Davis] Univ N Carolina, Frank Porter Graham Child Dev Inst, Chapel Hill, NC 27599 USA. [Goldman, Barbara Davis] Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA. [Sjoedin, Andreas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. RP Daniels, JL (reprint author), Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA. EM juliedaniels@unc.edu RI Sjodin, Andreas/F-2464-2010 FU U.S. Environmental Protection Agency [RD832736]; National Institute of Environmental Health Sciences (NIEHS) [P30ES10126]; NIEHS Environmental Biostatistics Training Program [T32ES007018]; Intramural Research Program of the National Institutes of Health, NIEHS FX This research was supported by grants from the U.S. Environmental Protection Agency (RD832736) and the National Institute of Environmental Health Sciences (NIEHS; P30ES10126). The work of K.H. was supported by the NIEHS Environmental Biostatistics Training Program (T32ES007018). The work of M.A. on this project was supported [in part] by the Intramural Research Program of the National Institutes of Health, NIEHS. NR 29 TC 39 Z9 40 U1 3 U2 30 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2012 VL 120 IS 10 BP 1438 EP 1442 DI 10.1289/ehp.1205100 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 018US UT WOS:000309692600027 PM 22814209 ER PT J AU Lo, YC Dooyema, CA Neri, A Durant, J Jefferies, T Medina-Marino, A de Ravello, L Thoroughman, D Davis, L Dankoli, RS Samson, MY Ibrahim, LM Okechukwu, O Umar-Tsafe, NT Dama, AH Brown, MJ AF Lo, Yi-Chun Dooyema, Carrie A. Neri, Antonio Durant, James Jefferies, Taran Medina-Marino, Andrew de Ravello, Lori Thoroughman, Douglas Davis, Lora Dankoli, Raymond S. Samson, Matthias Y. Ibrahim, Luka M. Okechukwu, Ossai Umar-Tsafe, Nasir T. Dama, Alhassan H. Brown, Mary Jean TI Childhood Lead Poisoning Associated with Gold Ore Processing: a Village-Level Investigation-Zamfara State, Nigeria, October-November 2010 SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE environmental health; lead poisoning ID OUTBREAK; CHILDREN AB BACKGROUND: During May June 2010, a childhood lead poisoning outbreak related to gold ore processing was confirmed in two villages in Zamfara State, Nigeria. During June September of that year, villages with suspected or confirmed childhood lead poisoning continued to be identified in Zamfara State. OBJECTIVES: We investigated the extent of childhood lead poisoning [>= 1 child with a blood lead level (BLL) >= 10 mu g/dL] and lead contamination (>= 1 soil/dust sample with a lead level > 400 parts per million) among villages in Zamfara State and identified villages that should be prioritized for urgent interventions. METHODS: We used chain-referral sampling to identify villages of interest, defined as villages suspected of participation in gold ore processing during the previous 12 months. We interviewed villagers, determined BLLs among children < 5 years of age, and analyzed soil/dust from public areas and homes for lead. RESULTS: We identified 131 villages of interest and visited 74 (56%) villages in three local government areas. Fifty-four (77%) of 70 villages that completed the survey reported gold ore processing. Ore-processing villages were more likely to have a >= 1 child < 5 years of age with lead poisoning (68% vs. 50%, p = 0.17) or death following convulsions (74% vs. 44%, p = 0.02). Soil/dust contamination and BLL >= 45 mu g/dL were identified in ore-processing villages only [50% (p < 0.001) and 15% (p = 0.22), respectively]. The odds of childhood lead poisoning or lead contamination was 3.5 times. as high in ore-processing villages than the other villages (95% confidence interval: 1.1, 11.3). CONCLUSION: Childhood lead poisoning and lead contamination were widespread in surveyed areas, particularly among villages that had processed ore recently. Urgent interventions are required to reduce lead exposure, morbidity, and mortality in affected communities. C1 [Neri, Antonio; Jefferies, Taran; Brown, Mary Jean] Ctr Dis Control & Prevent, Hlth Homes & Lead Poisoning Prevent Branch, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA USA. [Lo, Yi-Chun; Dooyema, Carrie A.; Medina-Marino, Andrew] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [de Ravello, Lori] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Durant, James] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [Thoroughman, Douglas] Ctr Dis Control & Prevent, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. [Davis, Lora] Ctr Dis Control & Prevent, Hlth Off 1, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Dankoli, Raymond S.; Samson, Matthias Y.; Ibrahim, Luka M.; Okechukwu, Ossai] Nigeria Field Epidemiol & Lab Training Program, Abuja, Nigeria. [Umar-Tsafe, Nasir T.] Minist Hlth, Blood Lead & Inorgan Met Lab, Gusau, Zamfara State, Nigeria. [Umar-Tsafe, Nasir T.; Dama, Alhassan H.] Minist Hlth, Zamfara State Rapid Response Team Lead Poisoning, Gusau, Zamfara State, Nigeria. RP Brown, MJ (reprint author), Ctr Dis Control & Prevent, Hlth Homes & Lead Poisoning Prevent Branch, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Highway,MS F-60, Chamblee, GA 30341 USA. EM mjb5@cdc.gov FU United States Agency for International Development's Office of Foreign Disaster Assistance FX Financial support was provided by the United States Agency for International Development's Office of Foreign Disaster Assistance. NR 22 TC 25 Z9 25 U1 3 U2 15 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2012 VL 120 IS 10 BP 1450 EP 1455 DI 10.1289/ehp.1104793 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 018US UT WOS:000309692600029 PM 22766030 ER PT J AU Just, AC Whyatt, RM Perzanowski, MS Calafat, AM Perera, FP Goldstein, IF Chen, QX Rundle, AG Miller, RL AF Just, Allan C. Whyatt, Robin M. Perzanowski, Matthew S. Calafat, Antonia M. Perera, Frederica P. Goldstein, Inge F. Chen, Qixuan Rundle, Andrew G. Miller, Rachel L. TI Prenatal Exposure to Butylbenzyl Phthalate and Early Eczema in an Urban Cohort SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE butylbenzyl phthalate; eczema; plasticizers ID ATOPIC-DERMATITIS; US POPULATION; ASSOCIATION; CHILDREN; DUST; METABOLITES; PREVALENCE; CHILDHOOD; HEALTH; ASTHMA AB BACKGROUND: Recent cross-sectional studies suggest a link between butylbenzyl phthalate (BBzP) in house dust and childhood eczema. OBJECTIVES: We aimed to evaluate whether concentrations of monobenzyl phthalate (MBzP), the main BBzP metabolite in urine, during pregnancy are associated prospectively with eczema in young children, and whether this association varies by the child's sensitization to indoor allergens or serological evidence of any allergies. METHoDs: MBzP was measured in spot urine samples during the third trimester of pregnancy from 407 African-American and Dominican women residing in New York City in 1999-2006. Repeated questionnaires asked mothers whether their doctor ever said their child had eczema. Child blood samples at 24, 36, and 60 months of age were analyzed for total, anti-cockroach, dust mite, and mouse IgE. Relative risks (RR) were estimated with multivariable modified Poisson regression. Analyses included a multinomial logistic regression model for early- and late-onset eczema versus no eczema through 60 months of age. RESULTS: MBzP was detected in > 99% of samples (geometric mean = 13.6; interquartile range: 5.7-31.1 ng/mL). By 24 months, 30% of children developed eczema, with the proportion higher among African Americans (48%) than among Dominicans (21%) (p < 0.001). An interquartile range increase in log MBzP concentration was associated positively with early-onset eczema (RR = 1.52 for eczema by 24 months; 95% confidence interval: 1.21, 1.91, p = 0.0003, n = 113 reporting eczema/376 total sample), adjusting for urine specific gravity, sex, and race/ethnicity. MBzP was not associated with allergic sensitization, nor did seroatopy modify consistently the MBzP and eczema association. CONCLUSIONS: Prenatal exposure to BBzP may influence the risk of developing eczema in early childhood. C1 [Just, Allan C.; Whyatt, Robin M.; Perzanowski, Matthew S.; Perera, Frederica P.; Goldstein, Inge F.; Rundle, Andrew G.; Miller, Rachel L.] Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Goldstein, Inge F.; Rundle, Andrew G.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA. [Chen, Qixuan] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA. [Miller, Rachel L.] Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm, New York, NY 10032 USA. RP Just, AC (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, Dept Environm Hlth Sci, 722 W 168th St,12th Floor, New York, NY 10032 USA. EM acj2109@columbia.edu RI Rundle, Andrew/A-5282-2009; OI Rundle, Andrew/0000-0003-0211-7707; Just, Allan/0000-0003-4312-5957 FU National Institute of Environmental Health Sciences [R01 ES014393, R01 ES013163, P01 ES09600, R01 ES008977, P30 ES009089]; U.S. Environmental Protection Agency (EPA) [R827027, RD832141, RD834509]; EPA STAR graduate fellowship [FP-91712001]; John and Wendy Neu Family Foundation; Blanchette Hooker Rockefeller Fund; New York Community Trust; Educational Foundation of America; Millstream Fund FX This work was supported by the National Institute of Environmental Health Sciences (grants R01 ES014393, R01 ES013163, P01 ES09600, R01 ES008977, and P30 ES009089), the U.S. Environmental Protection Agency (EPA; grants R827027, RD832141, and RD834509, and EPA STAR graduate fellowship FP-91712001 for A.C.J.), the John and Wendy Neu Family Foundation, Blanchette Hooker Rockefeller Fund, New York Community Trust, Educational Foundation of America, and Millstream Fund. NR 36 TC 33 Z9 35 U1 2 U2 27 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD OCT PY 2012 VL 120 IS 10 BP 1475 EP 1480 DI 10.1289/ehp.1104544 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 018US UT WOS:000309692600033 PM 22732598 ER PT J AU Riediker, M Schubauer-Berigan, MK Brouwer, DH Nelissen, I Koppen, G Frijns, E Clark, KA Hoeck, J Liou, SH Ho, SF Bergamaschi, E Gibson, R AF Riediker, Michael Schubauer-Berigan, Mary K. Brouwer, Derk H. Nelissen, Inge Koppen, Gudrun Frijns, Evelien Clark, Katherine A. Hoeck, Juergen Liou, Saou-Hsing Ho, Sweet Far Bergamaschi, Enrico Gibson, Rosemary TI A Road Map Toward a Globally Harmonized Approach for Occupational Health Surveillance and Epidemiology in Nanomaterial Workers SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID CARBON NANOTUBE; ENGINEERED NANOPARTICLES; EXHALED BREATH; AIR-POLLUTION; MANUFACTURED NANOPARTICLES; MEDICAL-SURVEILLANCE; ULTRAFINE PARTICLES; INHALATION EXPOSURE; RISK; TRANSLOCATION AB Objective: Few epidemiological studies have addressed the health of workers exposed to novel manufactured nanomaterials. The small current workforce will necessitate pooling international cohorts. Method: A road map was defined for a globally harmonized framework for the careful choice of materials, exposure characterization, identification of study populations, definition of health endpoints, evaluation of appropriateness of study designs, data collection and analysis, and interpretation of the results. Results: We propose a road map to reach global consensus on these issues. The proposed strategy should ensure that the costs of action are not disproportionate to the potential benefits and that the approach is pragmatic and practical. Conclusions: We should aim to go beyond the collection of health complaints, illness statistics, or even counts of deaths; the manifestation of such clear endpoints would indicate a failure of preventive measures. C1 [Riediker, Michael; Clark, Katherine A.] Univ Lausanne Geneve, IST Inst Univ Romand Sante Travail, Inst Work & Hlth, CH-1011 Lausanne, Switzerland. [Schubauer-Berigan, Mary K.] NIOSH, Cincinnati, OH 45226 USA. [Brouwer, Derk H.] TNO, Res Grp Qual & Safety, NL-3700 AJ Zeist, Netherlands. [Nelissen, Inge; Koppen, Gudrun; Frijns, Evelien] VITO NV Flemish Inst Technol Res, Mol, Belgium. [Hoeck, Juergen] TEMAS AG, Arbon, Switzerland. [Liou, Saou-Hsing] Natl Hlth Res Inst, Zhunan Town, Miaoli County, Taiwan. [Ho, Sweet Far] Minist Manpower, Occupat Safety & Hlth Div, Singapore, Singapore. [Bergamaschi, Enrico] Univ Parma, Sch Med, Lab Ind Toxicol, I-43100 Parma, Italy. [Gibson, Rosemary] Hlth & Safety Lab, Buxton, England. RP Riediker, M (reprint author), Univ Lausanne Geneve, IST Inst Univ Romand Sante Travail, Inst Work & Hlth, Bugnon 21, CH-1011 Lausanne, Switzerland. EM michael.riediker@hospvd.ch RI Schubauer-Berigan, Mary/B-3149-2009; Liou, Saou-Hsing /B-2667-2010; Brouwer, Derk/A-1594-2016; OI Schubauer-Berigan, Mary/0000-0002-5175-924X; Riediker, Michael/0000-0002-5268-864X FU European Commission [NMP4-CA-2008-218539] FX This work was funded by grant NMP4-CA-2008-218539 from the European Commission to NanoImpactNet-the European network on the health and environmental impact of nanomaterials, and the contributing authors' institutions. NR 76 TC 14 Z9 14 U1 1 U2 24 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-2752 EI 1536-5948 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD OCT PY 2012 VL 54 IS 10 BP 1214 EP 1223 DI 10.1097/JOM.0b013e31826e27f1 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 020FK UT WOS:000309794200009 PM 22995812 ER PT J AU Yaroch, AL Tooze, J Thompson, FE Blanck, HM Thompson, OM Colon-Ramos, U Shaikh, AR McNutt, S Nebeling, LC AF Yaroch, Amy L. Tooze, Janet Thompson, Frances E. Blanck, Heidi M. Thompson, Olivia M. Colon-Ramos, Uriyoan Shaikh, Abdul R. McNutt, Susanne Nebeling, Linda C. TI Evaluation of Three Short Dietary Instruments to Assess Fruit and Vegetable Intake: The National Cancer Institute's Food Attitudes and Behaviors Survey SO JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS LA English DT Article DE Fruits and vegetables; Screener; Validity; Reliability ID FREQUENCY QUESTIONNAIRE; SERUM CAROTENOIDS; BIOMARKERS; PERFORMANCE; CONSUMPTION; ENERGY; ADULTS AB Background Fruit and vegetable (F/V) intake assessment tools that are valid, reliable, brief, and easy to administer and code are vital to the field of public health nutrition. Objective To evaluate three short F/V intake screeners (ie, a 2-item serving tool, a 2-item cup tool, and a 16-item F/V intake screener) among adults using multiple 24-hour dietary recalls (24-hour recalls) as the reference instrument and evaluate test-retest reliability of the screeners across a 2- to 3-week time period. Design Validity and reliability study. Participants/setting Two hundred forty-four adults for the validity study and 335 adults for test-retest reliability. Statistical analyses performed Median values for F/V intakes were calculated for the screeners and 24-hour recalls. The Wilcoxon signed rank test was used to compare screeners with the 24-hour recalls. Deattenuated Pearson correlations were reported for validity and intraclass correlation coefficient used for reliability. Results The estimated median daily servings/cups of F/V for the 2-item serving screener was lower, for the 2-item cup screener was equivalent for then but higher for women, and for the 16-item F/V intake screener were about the same when compared with 24-hour recall values. The deattenuated correlations comparing the 24-hour recalls with the screeners were positive but weak for the 2-item serving screener, and were positive and moderate in strength for the 2-item cup and 16-item F/V intake screeners. The test-retest intraclass correlation coefficients were all positive and fairly strong for all of the screeners. Conclusions Although dietary screeners offer a more cost-effective, less burdensome way to obtain gross estimates to rank individuals with regard to F/V intake, these methods are not recommended for assessing precise intake levels. J Acad Nutr Diet. 2012;112:1570-1577. C1 [Yaroch, Amy L.] Gretchen Swanson Ctr Nutr, Omaha, NE 68105 USA. [Tooze, Janet] Wake Forest Univ, Dept Biostat Studies, Winston Salem, NC 27109 USA. [Thompson, Frances E.; Shaikh, Abdul R.; Nebeling, Linda C.] NCI, Rockville, MD USA. [Blanck, Heidi M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Thompson, Olivia M.] Coll Charleston, Dept Hlth & Human Performance, Charleston, SC 29401 USA. [Colon-Ramos, Uriyoan] George Washington Univ, Dept Global Hlth, Sch Publ Hlth & Hlth Serv, Washington, DC USA. [McNutt, Susanne] Westat Corp, Rockville, MD USA. RP Yaroch, AL (reprint author), Gretchen Swanson Ctr Nutr, 505 Durham Res Plaza, Omaha, NE 68105 USA. EM ayaroch@centerfornutrition.org FU Division of Cancer Control and Population Sciences at the National Cancer Institute FX This project was supported through the Division of Cancer Control and Population Sciences at the National Cancer Institute. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the National Cancer Institute or the Centers for Disease Control and Prevention. NR 25 TC 25 Z9 25 U1 3 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-2672 J9 J ACAD NUTR DIET JI J. Acad. Nutr. Diet. PD OCT PY 2012 VL 112 IS 10 BP 1570 EP 1577 DI 10.1016/j.jand.2012.06.002 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 017CB UT WOS:000309566600009 PM 23017567 ER PT J AU Tong, VT Dietz, PM England, LJ AF Tong, Van T. Dietz, Patricia M. England, Lucinda J. TI "Smoking Cessation for Pregnancy and Beyond: A Virtual Clinic,'' an Innovative Web-Based Training for Healthcare Professionals SO JOURNAL OF WOMENS HEALTH LA English DT Article ID INTERVENTIONS; WOMEN AB This article provides an overview of an interactive online training designed for healthcare professionals to hone their skills in assisting pregnant women to quit smoking and to remain quit postpartum. The curriculum teaches a best practice approach for smoking cessation, the 5A's, and is based on current clinical recommendations. The program offers five interactive case simulations and comprehensive discussions of patient visits, short lectures on relevant topics from leading experts, interviews with real patients who have quit, and a dedicated website of pertinent links and office resources. The training is accredited for up to 4.5 hours of continuing education credits. To access the training, please visit www.smokingcessationandpregnancy.org. C1 [Tong, Van T.; Dietz, Patricia M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [England, Lucinda J.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS-K22, Atlanta, GA 30341 USA. EM vtong@cdc.gov OI Tong, Van/0000-0002-3970-1440 FU CDC cooperative agreement [1U48DP001935-01]; Dartmouth Prevention Research Center; IML; Robert Wood Johnson Foundation FX The current, updated version of the training program was developed by the Interactive Media Laboratory, Dartmouth Medical School (IML) in collaboration with ACOG and was supported by the CDC cooperative agreement 1U48DP001935-01 with the Dartmouth Prevention Research Center. The original version of this program was developed by the IML, with support from the Robert Wood Johnson Foundation. The original and updated versions of this program were designed, written, directed, and produced by Joseph Henderson, M.D., Professor of Community and Family Medicine, Dartmouth Medical School. NR 13 TC 6 Z9 6 U1 0 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD OCT PY 2012 VL 21 IS 10 BP 1014 EP 1017 DI 10.1089/jwh.2012.3871 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 018JF UT WOS:000309655600081 PM 22934934 ER PT J AU Schaffzin, JK Southwick, KL Clement, EJ Konings, F Ganova-Raeva, L Xia, GL Khudyakov, Y Johnson, GS AF Schaffzin, Joshua K. Southwick, Karen L. Clement, Ernest J. Konings, Franciscus Ganova-Raeva, Lilia Xia, Guoliang Khudyakov, Yury Johnson, Geraldine S. TI Transmission of hepatitis B virus associated with assisted monitoring of blood glucose at an assisted living facility in New York State SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Cross-infection; Diabetes mellitus; Humans; Infection control; Long-term care AB Background: Hepatitis B virus (HBV) transmission has been reported after patient-to-patient blood exposure during assisted monitoring of blood glucose (AMBG). Three assisted-living facility (ALF) residents who underwent AMBG developed acute HBV infection (HBVI) within 10 days. We investigated HBV transmission and implemented preventive measures. Methods: A retrospective cohort study was conducted. Infection control practices were assessed. HBVI screening was conducted for all staff and epidemiologically linked residents. Viral DNA sequences were compared for a subset of isolates. Results: Lancing devices and glucometers were shared among residents without proper sanitization. Serologic testing of all 34 residents with diabetes and 12 epidemiologically linked residents present during the exposure period detected 6 residents with diabetes with current HBVI and 4 residents with diabetes and 1 epidemiologically linked resident with previous HBVI. A cohort study of 32 individuals with diabetes identified AMBG as a significant risk factor for HBVI (relative risk, 6.7; 95% confidence interval, 1.7-26.3). Viral DNA sequences for 5 AMBG-exposed residents' isolates were identical, suggesting a common source. Conclusions: AMBG was significantly associated with HBVI in ALF residents with diabetes. Despite clear preventive recommendations, bloodborne pathogen transmission continues to occur in the setting of AMBG. Strengthening direct care provider, infection preventionist, and health department partnerships with ALFs is crucial to ensure safe AMBG practices and prevent HBV transmission. Copyright (C) 2012 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Schaffzin, Joshua K.; Southwick, Karen L.; Clement, Ernest J.; Konings, Franciscus; Johnson, Geraldine S.] New York State Dept Hlth, Bur Communicable Dis Control, Albany, NY USA. [Ganova-Raeva, Lilia; Xia, Guoliang; Khudyakov, Yury] Ctr Dis Control & Prevent, Mol Epidemiol & Bioinformat Lab, Div Viral Hepatitis, Atlanta, GA USA. RP Schaffzin, JK (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Gen & Community Pediat, MLC 2011,3333 Burnet Ave, Cincinnati, OH 45229 USA. EM Joshua.schaffzin@cchmc.org NR 16 TC 8 Z9 9 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT PY 2012 VL 40 IS 8 BP 726 EP 731 DI 10.1016/j.ajic.2011.11.002 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 017LV UT WOS:000309592300013 PM 22284938 ER PT J AU Williams, NJ Ghosh, TS Vogt, RL AF Williams, Nancy J. Ghosh, Tista S. Vogt, Richard L. TI Needlestick injury surveillance during mass vaccination clinics: Lessons learned and why more is needed-Tri-County (Denver Metropolitan) region, Colorado, 2009 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Sharps injuries; Surveys; Bloodborne pathogen; Influenza vaccination; Public health nursing; Accident prevention ID PERCUTANEOUS INJURY AB Tri-County Health Department studied needlestick injury (NSI) risks in pandemic influenza A (H1N1) mass vaccination clinics through incident reports and an Internet-based vaccinator survey. The mass vaccination clinic NSI rate was 4.9 times the mean rate observed during Tri-County Health Department's 2003 to 2009 routine vaccination clinics. There was also a trend of increased risk for NSI with vaccination inexperience. These findings can be used to improve future mass vaccination clinic safety. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Williams, Nancy J.; Ghosh, Tista S.; Vogt, Richard L.] Tricty Hlth Dept, Greenwood Village, CO USA. [Williams, Nancy J.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. RP Williams, NJ (reprint author), So Nevada Hlth Dist, POB 3902, Las Vegas, NV 89127 USA. EM williams@snhdmail.org NR 10 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT PY 2012 VL 40 IS 8 BP 768 EP 770 DI 10.1016/j.ajic.2011.09.014 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 017LV UT WOS:000309592300021 PM 22305115 ER PT J AU Tai, E Buchanan, N Townsend, J Fairley, T Moore, A Richardson, LC AF Tai, Eric Buchanan, Natasha Townsend, Julie Fairley, Temeika Moore, Angela Richardson, Lisa C. TI Health status of adolescent and young adult cancer survivors SO CANCER LA English DT Article DE cancer; neoplasm; survivorship; adolescent cancer ID QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; CHILDHOOD-CANCER; RISK-FACTORS; 5-YEAR SURVIVORS; LATE MORTALITY; BREAST-CANCER; UNITED-STATES; SMOKING; DIAGNOSIS AB BACKGROUND: Adolescents and young adults (AYA) ages 15 to 29 years who are diagnosed with cancer are at risk for long-term morbidity and mortality associated with treatment of their cancer and the cancer itself. In this article, the authors describe the self-reported health status of AYA cancer survivors. METHODS: The authors examined 2009 data from the Behavioral Risk Factor Surveillance System, including demographic characteristics, risk behaviors, chronic conditions, health status, and health care access, among AYA cancer survivors compared with respondents who had no history of cancer. RESULTS: The authors identified 4054 AYA cancer survivors and 345,592 respondents who had no history of cancer. AYA cancer survivors, compared with respondents who had no history of cancer, reported a significantly higher prevalence of current smoking (26% vs 18%); obesity (31% vs 27%); chronic conditions, including cardiovascular disease (14% vs 7%), hypertension (35% vs 29%), asthma (15% vs 8%), disability (36% vs 18%), and poor mental health (20% vs 10%) and physical health (24% vs 10%); and not receiving medical care because of cost (24% vs 15%). CONCLUSIONS: AYA cancer survivors commonly reported adverse behavioral, medical, and health care access characteristics that may lead to poor long-term medical and psychosocial outcomes. Increased adherence to established follow-up guidelines may lead to improved health among AYA cancer survivors. Cancer 2012. (c) 2012 American Cancer Society. C1 [Tai, Eric; Buchanan, Natasha; Townsend, Julie; Fairley, Temeika; Moore, Angela; Richardson, Lisa C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. RP Tai, E (reprint author), 4770 Buford Highway,NE,MS K57, Atlanta, GA 30341 USA. EM cvn5@cdc.gov FU Centers for Disease Control and Prevention FX All funding for this project and analysis was provided by the Centers for Disease Control and Prevention. NR 58 TC 60 Z9 60 U1 3 U2 25 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X J9 CANCER-AM CANCER SOC JI Cancer PD OCT 1 PY 2012 VL 118 IS 19 BP 4884 EP 4891 DI 10.1002/cncr.27445 PG 8 WC Oncology SC Oncology GA 008BK UT WOS:000308931900031 PM 22688896 ER PT J AU Kolor, K Duquette, D Zlot, A Foland, J Anderson, B Giles, R Wrathall, J Khoury, MJ AF Kolor, Katherine Duquette, Debra Zlot, Amy Foland, Joan Anderson, Beth Giles, Rebecca Wrathall, Jennifer Khoury, Muin J. TI Public awareness and use of direct-to-consumer personal genomic tests from four state population-based surveys, and implications for clinical and public health practice SO GENETICS IN MEDICINE LA English DT Article DE awareness and use; direct-to-consumer; personal genomic tests; population-based; practice implications ID GENETIC TESTS; RISK ASSESSMENTS; PERCEPTIONS; RECOMMENDATIONS AB Purpose: Direct-to-consumer personal genomic tests are widely available, but population-based data are limited on awareness and use of these tests among the general public in the United States. Methods: We assessed awareness and use of direct-to-consumer personal genomic tests in Connecticut, Michigan, Oregon, and Utah using the 2009 Behavioral Risk Factor Surveillance System and compared the state results to the 2008 national HealthStyles survey results. Results: Awareness was the highest in Oregon (29.1%) and the lowest in Michigan (15.8%). Factors associated with awareness across all states and nationally were higher education, higher income, and increasing age, except among those 75 years or older. Less than 1% of respondents had used the tests, with about one-half to three-quarters of those sharing the results with a health-care provider. Conclusions: Awareness of direct-to-consumer genetic tests is greater in this study as compared with a related study conducted in 2006, whereas use is similarly low in both studies. The few respondents who reported using the tests often reported sharing their results with their health-care provider, indicating an important opportunity for health-care providers to offer patient education regarding these tests. Public health agencies have important roles in surveillance, education, and policy development on direct-to-consumer genomic tests. C1 [Kolor, Katherine; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30329 USA. [Duquette, Debra; Anderson, Beth] Michigan Dept Community Hlth, Lansing, MI USA. [Zlot, Amy] Oregon Hlth Author, Oregon Genet Program, Publ Hlth Div, Portland, OR USA. [Foland, Joan] Connecticut Dept Publ Hlth & Addict Serv, Genom Off, Hartford, CT 06106 USA. [Giles, Rebecca; Wrathall, Jennifer] Utah Dept Hlth, Salt Lake City, UT 84116 USA. RP Kolor, K (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30329 USA. EM kkolor@cdc.gov FU Centers for Disease Control and Prevention [5U38GD000054]; Oregon Department of Human Services [1U38GD000061]; Connecticut Department of Public Health [3U58/DP00200601W1] FX This work was supported in part by the Centers for Disease Control and Prevention through cooperative agreements awarded to the Michigan Department of Community Health (5U38GD000054), the Oregon Department of Human Services (1U38GD000061), and the Connecticut Department of Public Health (3U58/DP00200601W1). The authors appreciate the assistance and support of Chris Fussman, Jennifer McLosky, John Gehring, Kerry Silvey, Robert Nystrom, Nanette Newell, and Katherine Bradley. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agencies. NR 37 TC 18 Z9 19 U1 2 U2 14 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD OCT PY 2012 VL 14 IS 10 BP 860 EP 867 DI 10.1038/gim.2012.67 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 018FQ UT WOS:000309645900005 PM 22814860 ER PT J AU Rishishwar, L Katz, LS Sharma, NV Rowe, L Frace, M Thomas, JD Harcourt, BH Mayer, LW Jordan, IK AF Rishishwar, Lavanya Katz, Lee S. Sharma, Nitya V. Rowe, Lori Frace, Michael Thomas, Jennifer Dolan Harcourt, Brian H. Mayer, Leonard W. Jordan, I. King TI Genomic Basis of a Polyagglutinating Isolate of Neisseria meningitidis SO JOURNAL OF BACTERIOLOGY LA English DT Article ID POPULATION-STRUCTURE; ESCHERICHIA-COLI; GROUP-B; SEROGROUP; CAPSULE; DISEASE; IDENTIFICATION; RECOMBINATION; EXPRESSION; SOFTWARE AB Containment strategies for outbreaks of invasive Neisseria meningitidis disease are informed by serogroup assays that characterize the polysaccharide capsule. We sought to uncover the genomic basis of conflicting serogroup assay results for an isolate (M16917) from a patient with acute meningococcal disease. To this end, we characterized the complete genome sequence of the M16917 isolate and performed a variety of comparative sequence analyses against N. meningitidis reference genome sequences of known serogroups. Multilocus sequence typing and whole-genome sequence comparison revealed that M16917 is a member of the ST-11 sequence group, which is most often associated with serogroup C. However, sequence similarity comparisons and phylogenetic analysis showed that the serogroup diagnostic capsule polymerase gene (synD) of M16917 belongs to serogroup B. These results suggest that a capsule-switching event occurred based on homologous recombination at or around the capsule locus of M16917. Detailed analysis of this locus uncovered the locations of recombination breakpoints in the M16917 genome sequence, which led to the introduction of an similar to 2-kb serogroup B sequence cassette into the serogroup C genomic background. Since there is no currently available vaccine for serogroup B strains of N. meningitidis, this kind capsule-switching event could have public health relevance as a vaccine escape mutant. C1 [Rishishwar, Lavanya; Katz, Lee S.; Sharma, Nitya V.; Jordan, I. King] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. [Rowe, Lori; Frace, Michael] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Atlanta, GA USA. [Katz, Lee S.; Thomas, Jennifer Dolan; Harcourt, Brian H.; Mayer, Leonard W.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA USA. RP Jordan, IK (reprint author), Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA. EM king.jordan@biology.gatech.edu FU Alfred P. Sloan Research Fellowship in Computational and Evolutionary Molecular Biology [BR-4839]; Georgia Research Alliance [GRA.VAC09.O]; Bioinformatics Program, Georgia Institute of Technology FX This work was supported by the Alfred P. Sloan Research Fellowship in Computational and Evolutionary Molecular Biology (BR-4839 to I.K.J.), the Georgia Research Alliance (GRA.VAC09.O to I.K.J., B.H.H., J.D.T., L.W.M., and L.S.K.), and the Bioinformatics Program, Georgia Institute of Technology (to N.V.S.). NR 35 TC 2 Z9 2 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD OCT PY 2012 VL 194 IS 20 BP 5649 EP 5656 DI 10.1128/JB.06604-11 PG 8 WC Microbiology SC Microbiology GA 016AV UT WOS:000309490600017 PM 22904290 ER PT J AU Novak, RT Kambou, JL Diomande, FVK Tarbangdo, TF Ouedraogo-Traore, R Sangare, L Lingani, C Martin, SW Hatcher, C Mayer, LW LaForce, FM Avokey, F Djingarey, MH Messonnier, NE Tiendrebeogo, SR Clark, TA AF Novak, Ryan T. Kambou, Jean Ludovic Diomande, Fabien V. K. Tarbangdo, Tiga F. Ouedraogo-Traore, Rasmata Sangare, Lassana Lingani, Clement Martin, Stacey W. Hatcher, Cynthia Mayer, Leonard W. LaForce, F. Marc Avokey, Fenella Djingarey, Mamoudou H. Messonnier, Nancy E. Tiendrebeogo, Sylvestre R. Clark, Thomas A. TI Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data SO LANCET INFECTIOUS DISEASES LA English DT Article ID MENINGITIS EPIDEMICS; NEISSERIA-MENINGITIDIS; HERD-IMMUNITY; PNEUMOCOCCAL MENINGITIS; B DISEASE; AFRICA; VACCINES; IMPACT; IMMUNOGENICITY; IMPLEMENTATION AB Background An affordable, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA-TT) was licensed for use in sub-Saharan Africa in 2009. In 2010, Burkina Faso became the first country to implement a national prevention campaign, vaccinating 11.4 million people aged 1-29 years. We analysed national surveillance data around PsA-TT introduction to investigate the early effect of the vaccine on meningitis incidence and epidemics. Methods We examined national population-based meningitis surveillance data from Burkina Faso using two sources, one with cases and deaths aggregated at the district level from 1997 to 2011, and the other enhanced with results of cerebrospinal fluid examination and laboratory testing from 2007 to 2011. We compared mortality rates and incidence of suspected meningitis, probable meningococcal meningitis by age, and serogroup-specific meningococcal disease before and during the first year after PsA-TT implementation. We assessed the risk of meningitis disease and death between years. Findings During the 14 year period before PsA-TT introduction, Burkina Faso had 148603 cases of suspected meningitis with 17965 deaths, and 174 district-level epidemics. After vaccine introduction, there was a 71% decline in risk of meningitis (hazard ratio 0.29, 95% CI 0.28-0.30, p<0.0001) and a 64% decline in risk of fatal meningitis (0.36, 0.33-0.40, p<0.0001). We identified a statistically significant decline in risk of probable meningococcal meningitis across the age group targeted for vaccination (62%, cumulative incidence ratio [CIR] 0.38, 95% CI 0.31-0.45, p<0.0001), and among children aged less than 1 year (54%, 0.46, 0.24-0.86, p=0.02) and people aged 30 years and older (55%, 0.45, 0-22-0.91, p=0.003) who were ineligible for vaccination. No cases of serogroup A meningococcal meningitis occurred among vaccinated individuals, and epidemics were eliminated. The incidence of laboratory-confirmed serogroup A N meningitidis dropped significantly to 0.01 per 100000 individuals per year, representing a 99.8% reduction in the risk of meningococcal A meningitis (CIR 0.002, 95% CI 0.0004-0.02, p<0.0001). Interpretation Early evidence suggests the conjugate vaccine has substantially reduced the rate of meningitis in people in the target age group, and in the general population because of high coverage and herd immunity. These data suggest that fully implementing the PsA-TT vaccine could end epidemic meningitis of serogroup A in sub-Saharan Africa. C1 [Novak, Ryan T.; Diomande, Fabien V. K.; Martin, Stacey W.; Hatcher, Cynthia; Mayer, Leonard W.; Messonnier, Nancy E.; Clark, Thomas A.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Kambou, Jean Ludovic; Tarbangdo, Tiga F.; Tiendrebeogo, Sylvestre R.] Minist Sante, Direct Lutte Malad, Ouagadougou, Burkina Faso. [Ouedraogo-Traore, Rasmata] Ctr Hosp Univ Pediat Charles de Gaulle, Ouagadougou, Burkina Faso. [Sangare, Lassana] Ctr Hosp Univ Yalgado, Ouagadougou, Burkina Faso. [Diomande, Fabien V. K.; Lingani, Clement; Avokey, Fenella; Djingarey, Mamoudou H.] WHO Intercountry Support Team W Africa, Ouagadougou, Burkina Faso. [LaForce, F. Marc] Meningitis Vaccine Project PATH, Ferney, France. RP Novak, RT (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM bnk4@cdc.gov FU Intramural CDC HHS [CC999999] NR 39 TC 63 Z9 67 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1473-3099 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD OCT PY 2012 VL 12 IS 10 BP 757 EP 764 DI 10.1016/S1473-3099(12)70168-8 PG 8 WC Infectious Diseases SC Infectious Diseases GA 018AB UT WOS:000309631200023 PM 22818241 ER PT J AU Ma, Q He, XQ AF Ma, Qiang He, Xiaoqing TI Molecular Basis of Electrophilic and Oxidative Defense: Promises and Perils of Nrf2 SO PHARMACOLOGICAL REVIEWS LA English DT Review ID TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT RESPONSE ELEMENT; GLUTATHIONE-S-TRANSFERASE; YA-SUBUNIT GENE; PROTEIN-KINASE-C; ARYL-HYDROCARBON RECEPTOR; HEME OXYGENASE-1 GENE; CONTROLLING INDUCIBLE EXPRESSION; URINARY-BLADDER CARCINOGENESIS; UBIQUITIN-PROTEASOME PATHWAY AB Induction of drug-metabolizing enzymes through the antioxidant response element (ARE)-dependent transcription was initially implicated in chemoprevention against cancer by antioxidants. Recent progress in understanding the biology and mechanism of induction revealed a critical role of induction in cellular defense against electrophilic and oxidative stress. Induction is mediated through a novel signaling pathway via two regulatory proteins, the nuclear factor erythroid 2-related factor 2 (Nrf2) and the Kelch-like erythroid cell-derived protein with CNC homology-associated protein 1 (Keap1). Nrf2 binds to Keap1 at a two site-binding interface and is ubiquitinated by the Keap1/cullin 3/ring box protein-1-ubiquitin ligase, resulting in a rapid turnover of Nrf2 protein. Electrophiles and oxidants modify critical cysteine thiols of Keap1 and Nrf2 to inhibit Nrf2 ubiquitination, leading to Nrf2 activation and induction. Induction increases stress resistance critical for cell survival, because knockout of Nrf2 in mice increased susceptibility to a variety of toxicity and disease processes. Collateral to diverse functions of Nrf2, genome-wide search has led to the identification of a plethora of ARE-dependent genes regulated by Nrf2 in an inducer-, tissue-, and disease-dependent manner to control drug metabolism, antioxidant defense, stress response, proteasomal degradation, and cell proliferation. The protective nature of Nrf2 could also be hijacked in a number of pathological conditions by means of somatic mutation, epigenetic alteration, and accumulation of disruptor proteins, promoting drug resistance in cancer and pathologic liver features in autophagy deficiency. The repertoire of ARE inducers has expanded enormously; the therapeutic potential of the inducers has been examined beyond cancer prevention. Developing potent and specific ARE inducers and Nrf2 inhibitors holds certain new promise for the prevention and therapy against cancer, chronic disease, and toxicity. C1 [Ma, Qiang; He, Xiaoqing] NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Morgantown, WV USA. RP Ma, Q (reprint author), Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM qam1@cdc.gov FU Intramural CDC HHS [CC999999] NR 237 TC 81 Z9 87 U1 2 U2 32 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0031-6997 EI 1521-0081 J9 PHARMACOL REV JI Pharmacol. Rev. PD OCT PY 2012 VL 64 IS 4 BP 1055 EP 1081 DI 10.1124/pr.110.004333 PG 27 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 016WW UT WOS:000309551500009 PM 22966037 ER PT J AU Pratt, LA AF Pratt, Laura Ann TI Characteristics of Adults With Serious Mental Illness in the United States Household Population in 2007 SO PSYCHIATRIC SERVICES LA English DT Article ID DISORDERS; SCHIZOPHRENIA; PREVALENCE; DISABILITY; WORLD AB Objective: This study described the epidemiology of serious mental illness in the adult household population. Methods: Data from the 2007 National Health Interview Survey of 23,393 adult respondents were used. Serious mental illness was defined when respondents reported that a health professional had told them that they had schizophrenia, bipolar disorder, mania, or psychosis. Sociodemographic and health characteristics, health care utilization, and participation in government assistance programs among adults with and without serious mental illness were compared. Results: Over 2% of adults reported having received a diagnosis of serious mental illness. Thirty-five percent of adults with serious mental illness had a history of homelessness or of having been in jail. Fewer than two-thirds of adults with serious mental illness had seen a mental health professional in the past year. Conclusions: Adults with serious mental illness were socially disadvantaged and had worse health compared with adults without serious mental illness. (Psychiatric Services 63: 1042-1046, 2012; doi: 10.1176/appi.ps.201100442) C1 Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Pratt, LA (reprint author), Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM lpratt@cdc.gov NR 12 TC 6 Z9 6 U1 3 U2 13 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD OCT PY 2012 VL 63 IS 10 BP 1042 EP 1046 DI 10.1176/appi.ps.201100442 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA 015ZX UT WOS:000309488100015 PM 23032677 ER PT J AU Hood, JE MacKellar, D Spaulding, A Nelson, R Mosiakgabo, B Sikwa, B Puso, I Raats, J Loeto, P Alwano, MG Monyatsi, B AF Hood, Julia E. MacKellar, Duncan Spaulding, Anne Nelson, Rob Mosiakgabo, Boingotlo Sikwa, Bangwato Puso, Innocentia Raats, Jan Loeto, Peter Alwano, Mary Grace Monyatsi, Blessed TI Client Characteristics and Gender-Specific Correlates of Testing HIV Positive: A Comparison of Standalone Center Versus Mobile Outreach HIV Testing and Counseling in Botswana SO AIDS AND BEHAVIOR LA English DT Article DE HIV testing; Botswana; Voluntary counseling and testing; Evaluation ID SUB-SAHARAN AFRICA; COMMUNITY-BASED INTERVENTION; PROJECT ACCEPT; HPTN 043; SERVICES; RISK; PREVENTION; STRATEGIES; INFECTION; TANZANIA AB Using data from Botswana's largest HIV testing and counseling (HTC) provider, Tebelopele, we evaluate populations served and gender-specific correlates of testing HIV-positive among clients of two programs: standalone centers and outreach testing. Client records from January to June 2007 (n = 47,890) were evaluated by HTC program and gender. Bivariate and multivariate analyses were performed to identify demographic, testing, and risk-behavior variables associated with testing HIV-positive. Compared to outreach testing, standalone centers served proportionally more clients who were young, well-educated, unmarried, and HIV-infected; outreach testing reached an older, less-educated population. Age, educational attainment, marital status, couples testing, testing because of illness or discordant relationship, and nonuse of condoms (among young clients only) were consistently associated with testing HIV-positive, by HTC program and gender. Our evaluation suggests that Tebelopele standalone and outreach HTC programs serve different populations, and identifies strategies to reduce HIV infection risk and to improve uptake of HTC by HIV-infected, undiagnosed Batswana. C1 [Hood, Julia E.; Nelson, Rob] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [MacKellar, Duncan] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Spaulding, Anne] Emory Univ, Atlanta, GA 30322 USA. [Mosiakgabo, Boingotlo; Sikwa, Bangwato; Puso, Innocentia; Monyatsi, Blessed] Tebelopele VCT, Gaborone, Botswana. [Raats, Jan] Family Hlth Int, Dar Es Salaam, Tanzania. [Loeto, Peter; Alwano, Mary Grace] Botswana USA BOTUSA, Gaborone, Botswana. RP Hood, JE (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM juliaehood@gmail.com NR 21 TC 6 Z9 6 U1 1 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2012 VL 16 IS 7 BP 1902 EP 1916 DI 10.1007/s10461-012-0253-7 PG 15 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 012GC UT WOS:000309223000023 PM 22814569 ER PT J AU Reback, CJ Grant, DL Fletcher, JB Branson, CM Shoptaw, S Bowers, JR Charania, M Mansergh, G AF Reback, Cathy J. Grant, Deborah Ling Fletcher, Jesse B. Branson, Catherine M. Shoptaw, Steven Bowers, Jane Rohde Charania, Mahnaz Mansergh, Gordon TI Text Messaging Reduces HIV Risk Behaviors Among Methamphetamine-Using Men Who Have Sex with Men SO AIDS AND BEHAVIOR LA English DT Article DE MSM; Methamphetamine; HIV; Text messaging; Mobile communication technology ID RANDOMIZED CONTROLLED-TRIAL; BISEXUAL MEN; STIMULANT USE; YOUNG-PEOPLE; POSITIVE MSM; SERVICE SMS; URBAN GAY; INTERVENTION; PHONE; INTERNET AB Text-messaging interventions present a novel approach for targeting high-risk men who have sex with men (MSM) who may not respond to or may be difficult to reach for face-to-face or site-based interventions. Project Tech Support (N = 52) was an open label pilot study testing the feasibility and utility of a text-messaging intervention to reduce methamphetamine use and high-risk sexual behaviors among out-of-treatment MSM. Participants in the two-week intervention received social support and health education text messages transmitted in real-time. At follow-up, there were significant decreases in frequency of methamphetamine use and unprotected sex while on methamphetamine (both p < 0.01), and a significant increase in self-reported abstinence from methamphetamine use (13.3 % vs. 48.9 %; p < 0.001). Additionally, participants reported reductions of unprotected anal intercourse with HIV-positive partners (p < 0.01); with HIV-negative partners, participants reported fewer insertive and receptive episodes (both p < 0.05). Findings demonstrate that text messaging is a promising intervention for reaching and potentially changing HIV high-risk behaviors among out-of-treatment, methamphetamine-using MSM. C1 [Reback, Cathy J.; Grant, Deborah Ling; Fletcher, Jesse B.] Friends Res Inst Inc, Los Angeles, CA 90028 USA. [Reback, Cathy J.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Integrated Subst Abuse Programs, Los Angeles, CA USA. [Branson, Catherine M.] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Shoptaw, Steven] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA. [Bowers, Jane Rohde] Off AIDS Programs & Policy, Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Charania, Mahnaz; Mansergh, Gordon] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Reback, CJ (reprint author), Friends Res Inst Inc, 1419 N La Brea Ave, Los Angeles, CA 90028 USA. EM reback@friendsresearch.org FU NCHHSTP CDC HHS [UR6 PS000312, UR6PS000312]; NIMH NIH HHS [P30 MH58107, P30 MH058107] NR 56 TC 27 Z9 28 U1 3 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2012 VL 16 IS 7 BP 1993 EP 2002 DI 10.1007/s10461-012-0200-7 PG 10 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 012GC UT WOS:000309223000033 PM 22610370 ER PT J AU Malebranche, DJ Gvetadze, R Millett, GA Sutton, MY AF Malebranche, David J. Gvetadze, Roman Millett, Gregorio A. Sutton, Madeline Y. TI The Relationship Between Gender Role Conflict and Condom Use Among Black MSM SO AIDS AND BEHAVIOR LA English DT Article DE HIV/AIDS; Black MSM; Gender role conflict; Masculinity; Condom use ID AFRICAN-AMERICAN MEN; SEXUAL RISK BEHAVIORS; UNITED-STATES; HIV RISK; COLLEGE-STUDENTS; PUBLIC-HEALTH; YOUNG MEN; IDENTITY; EPIDEMIC; GAY AB Gender role conflict may influence condom use among black MSM. We examined relationships between the Gender Role Conflict Scale (GRCS), social/demographic variables and condom use among 456 black MSM. Higher total GRCS scores did not predict unprotected insertive anal intercourse (UIAI) or unprotected receptive anal intercourse (URAI) with men, but were associated with unprotected vaginal or anal intercourse (UVI/UAI) with women among bisexually active participants (n = 69). Higher perceived HIV risk reduced the likelihood of both UIAI and URAI with men. Internet recruitment venues, sexual discrimination experiences, higher numbers of sex partners and UVI/UAI with women all increased the likelihood of UIAI with men, while education (college/technical school or college degree) was associated with URAI with men. Future sexual health interventions for black MSM should emphasize broader social/demographic and alternative gender role variables with male sexual partners, while traditional GRCS variables may prove useful among those with female sexual partners. C1 [Malebranche, David J.] Emory Univ, Div Gen Med, Atlanta, GA 30303 USA. [Gvetadze, Roman; Millett, Gregorio A.; Sutton, Madeline Y.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Malebranche, DJ (reprint author), Emory Univ, Div Gen Med, 49 Jesse Hill Jr Dr,Suite 413, Atlanta, GA 30303 USA. EM dmalebr@emory.edu NR 67 TC 9 Z9 9 U1 4 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS Behav. PD OCT PY 2012 VL 16 IS 7 BP 2051 EP 2061 DI 10.1007/s10461-011-0055-3 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 012GC UT WOS:000309223000038 PM 21983695 ER PT J AU Spear, GT Kersh, E Guenthner, P Vishwanathan, SA Gilbert, D Zariffard, MR Mirmonsef, P Landay, A Zheng, LY Gillevet, P AF Spear, Gregory T. Kersh, Ellen Guenthner, Patricia Vishwanathan, Sundaram Ajay Gilbert, Douglas Zariffard, M. Reza Mirmonsef, Paria Landay, Alan Zheng, Luyang Gillevet, Patrick TI Longitudinal Assessment of Pigtailed Macaque Lower Genital Tract Microbiota by Pyrosequencing Reveals Dissimilarity to the Genital Microbiota of Healthy Humans SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID SIMPLEX-VIRUS TYPE-2; BACTERIAL VAGINOSIS; LACTOBACILLUS-INERS; WOMEN; HIV; IDENTIFICATION; INFECTION; ACQUISITION; MODEL; DIVERSITY AB Vaginal bacterial communities play an important role in human health and have been shown to influence HIV infection. Pigtailed macaques (Macaca nemestrina) are used as an animal model of HIV vaginal infection of women. Since the bacterial microbiota could influence retrovirus infection of pigtailed macaques, the genital microbiota in 10 cycling macaques was determined by pyrosequencing. The microbiota of all macaques was polymicrobial with a median of 13 distinct genera. Strikingly, the genera Sneathia and Fusobacterium, both in the phylum Fusobacteria, accounted for 18.9% and 13.3% of sequences while the next most frequent were Prevotella (5.6%), Porphyromonas (4.1%), Atopobium (3.6%), and Parvimonas (2.6%). Sequences corresponding to Lactobacillus comprised only 2.2% of sequences on average and were essentially all L. amylovorus. Longitudinal sampling of the 10 macaques over an 8-week period, which spanned at least one full ovulatory cycle, showed a generally stable presence of the major types of bacteria with some exceptions. These studies show that the microbiota of the pigtailed macaques is substantially dissimilar to that found in most healthy humans, where the genital microbiota is usually dominated by Lactobacillus sp. The polymicrobial makeup of the macaque bacterial populations, the paucity of lactobacilli, and the specific types of bacteria present suggest that the pigtailed macaque microbiota could influence vaginal retrovirus infection. C1 [Spear, Gregory T.; Gilbert, Douglas; Zariffard, M. Reza; Mirmonsef, Paria; Landay, Alan; Zheng, Luyang] Rush Univ, Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA. [Kersh, Ellen; Guenthner, Patricia; Vishwanathan, Sundaram Ajay] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA USA. [Gillevet, Patrick] George Mason Univ, Microbiome Anal Ctr, Dept Environm Sci & Policy, Manassas, VA USA. RP Spear, GT (reprint author), Rush Univ, Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA. EM gspear@rush.edu FU NIH [U19 AI076981, P30 A1082151]; James B. Pendleton Charitable Trust [Y1-AI-0681-02] FX We thank Drs. Ron Otten and Nat Promadej-Lanier for macaque samples. This work was supported by NIH Grants U19 AI076981 and P30 A1082151, by the James B. Pendleton Charitable Trust, and by the Interagency Agreement Y1-AI-0681-02 between CDC and NTH. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 29 TC 9 Z9 11 U1 1 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD OCT PY 2012 VL 28 IS 10 BP 1244 EP 1249 DI 10.1089/aid.2011.0382 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 013TV UT WOS:000309329700011 PM 22264029 ER PT J AU Humann, MJ Sanderson, WT Gerr, F Kelly, KM Merchant, JA AF Humann, Michael J. Sanderson, Wayne T. Gerr, Fred Kelly, Kevin M. Merchant, James A. TI Effects of common agricultural tasks on measures of hearing loss SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE hearing loss; occupational health; agricultural health; risk factors; noise ID COUNTY RURAL HEALTH; YORK DAIRY FARMERS; COHORT; CONSERVATION; PREVALENCE AB Background Among agricultural populations, hearing loss caused by excessive noise exposure is common. However, examinations of associations between exposure to agricultural tasks and hearing loss are limited. Methods Audiometry and lifetime exposure to 11 agricultural tasks were analyzed among 1,568 participants. Gender stratified multivariable linear regression was used to estimate associations between exposure duration and three hearing loss metrics. Results Among men, significant associations were observed between hearing loss and hunting or target shooting, all-terrain vehicle (ATV) or motorcycle riding, chain saw use, electric or pneumatic tool use, living on a farm, and all agricultural tasks combined. When all significant exposure metrics were included in a single model, associations remained for hunting or target shooting, electric or pneumatic tool use and living on a farm. Significant associations were sparse among women, and in all cases paradoxical. Conclusions Despite imprecise estimation of noise exposure, specific agricultural tasks were associated with hearing loss. Am. J. Ind. Med. 55:904916, 2012. (C) 2012 Wiley Periodicals, Inc. C1 [Humann, Michael J.; Gerr, Fred; Kelly, Kevin M.; Merchant, James A.] Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, Iowa City, IA USA. [Sanderson, Wayne T.] Univ Kentucky, Coll Publ Hlth, Dept Epidemiol, Lexington, KY USA. RP Humann, MJ (reprint author), NIOSH, Field Studies Branch, Div Resp Dis Studies, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS H2800, Morgantown, WV 26505 USA. EM humann.michael@gmail.com RI Kelly, Kevin/E-2716-2013 OI Kelly, Kevin/0000-0002-9177-1454 FU NIOSH Heartland Center for Occupational Health and Safety [T42OH008491]; NIOSH Great Plains Center for Agricultural Health [U54OH007548] FX Contract grant sponsor: NIOSH Heartland Center for Occupational Health and Safety; Contract grant number: T42OH008491;; Contract grant sponsor: NIOSH Great Plains Center for Agricultural Health; Contract grant number: U54OH007548. NR 27 TC 4 Z9 5 U1 1 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD OCT PY 2012 VL 55 IS 10 BP 904 EP 916 DI 10.1002/ajim.22077 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 003SP UT WOS:000308631900006 PM 22674632 ER PT J AU Lindsey, NP Lehman, JA Campbell, GL Staples, JE Fischer, M Yendell, SJ AF Lindsey, Nicole P. Lehman, Jennifer A. Campbell, Grant L. Staples, J. Erin Fischer, Marc Yendell, Stephanie J. TI West Nile Virus Disease and Other Arboviral Diseases-United States, 2011 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID INFECTION C1 [Yendell, Stephanie J.] CDC, Atlanta, GA 30333 USA. RP Yendell, SJ (reprint author), CDC, Atlanta, GA 30333 USA. EM syendell@cdc.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD OCT PY 2012 VL 12 IS 10 BP 2849 EP 2854 DI 10.1111/j.1600-6143.2012.04298.x PG 6 WC Surgery; Transplantation SC Surgery; Transplantation GA 011QN UT WOS:000309180000032 ER PT J AU Yu, LL Jarrett, JM Davis, WC Kilpatrick, EL Oflaz, R Turk, GC Leber, DD Valentin, L Morel-Espinosa, M Blount, BC AF Yu, Lee L. Jarrett, Jeffery M. Davis, W. Clay Kilpatrick, Eric L. Oflaz, Rabia Turk, Gregory C. Leber, Dennis D. Valentin, Liza Morel-Espinosa, Maria Blount, Benjamin C. TI Characterization of perchlorate in a new frozen human urine standard reference material SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Perchlorate; Urine; Standard reference material; Certified reference material ID WEIGHTED MEANS STATISTICS; MASS-SPECTROMETRY; UNITED-STATES; INHIBITION; NITRATE AB Perchlorate, an inorganic anion, has recently been recognized as an environmental contaminant by the US Environmental Protection Agency. Urine is the preferred matrix for assessment of human exposure to perchlorate. Although the measurement technique for perchlorate in urine was developed in 2005, the calibration and quality assurance aspects of the metrology infrastructure for perchlorate are still lacking in that there is no certified reference material (CRM) traceable to the International System of Units. To meet the quality assurance needs in biomonitoring measurements of perchlorate and the related anions that affect thyroid health, the National Institute of Standards and Technology (NIST), in collaboration with the Centers for Disease Control and Prevention (CDC), developed Standard Reference Material (SRM) 3668 Mercury, Perchlorate, and Iodide in Frozen Human Urine. SRM 3668 consists of perchlorate, nitrate, thiocyanate, iodine, and mercury in urine at two levels that represent the 50th and 95th percentiles, respectively, of the concentrations (with some adjustments) in the US population. It is the first CRM being certified for perchlorate. Measurements leading to the certification of perchlorate were made collaboratively at NIST and CDC using three methods based on liquid or ion chromatography tandem mass spectrometry. Potential sources of bias were analyzed, and results were compared for the three methods. Perchlorate in SRM 3668 Level I urine was certified to be 2.70 +/- 0.21 mu g L-1, and for SRM 3668 Level II urine, the certified value is 13.47 +/- 0.96 mu g L-1. C1 [Yu, Lee L.; Davis, W. Clay; Kilpatrick, Eric L.; Oflaz, Rabia; Turk, Gregory C.] Natl Inst Stand & Technol, Div Analyt Chem, Gaithersburg, MD 20899 USA. [Jarrett, Jeffery M.] Ctr Dis Control & Prevent, Inorgan & Radiat Analyt Toxicol Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Leber, Dennis D.] Natl Inst Stand & Technol, Stat Engn Div, Gaithersburg, MD 20899 USA. [Valentin, Liza; Morel-Espinosa, Maria; Blount, Benjamin C.] Ctr Dis Control & Prevent, Emergency Response & Air Toxicants Branch, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Yu, LL (reprint author), Natl Inst Stand & Technol, Div Analyt Chem, Gaithersburg, MD 20899 USA. EM lee.yu@nist.gov RI Yu, Lee/N-7263-2015; OI Yu, Lee/0000-0002-8043-6853; Jarrett, Jeffery/0000-0001-5755-3552 FU Intramural CDC HHS [CC999999] NR 23 TC 1 Z9 1 U1 0 U2 15 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD OCT PY 2012 VL 404 IS 6-7 BP 1877 EP 1886 DI 10.1007/s00216-012-6263-5 PG 10 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 014AW UT WOS:000309348400026 PM 22850897 ER PT J AU Hernandez, SM Keel, K Sanchez, S Trees, E Gerner-Smidt, P Adams, JK Cheng, Y Ray, A Martin, G Presotto, A Ruder, MG Brown, J Blehert, DS Cottrell, W Maurer, JJ AF Hernandez, Sonia M. Keel, Kevin Sanchez, Susan Trees, Eija Gerner-Smidt, Peter Adams, Jennifer K. Cheng, Ying Ray, Al, III Martin, Gordon Presotto, Andrea Ruder, Mark G. Brown, Justin Blehert, David S. Cottrell, Walter Maurer, John J. TI Epidemiology of a Salmonella enterica subsp enterica Serovar Typhimurium Strain Associated with a Songbird Outbreak SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID FIELD GEL-ELECTROPHORESIS; WILD BIRDS; AVIAN WILDLIFE; SEROTYPE TYPHIMURIUM; UNITED-STATES; NEW-ZEALAND; INFECTIONS; PULSENET; NORWAY; GASTROENTERITIS AB Salmonella enterica subsp. enterica serovar Typhimurium is responsible for the majority of salmonellosis cases worldwide. This Salmonella serovar is also responsible for die-offs in songbird populations. In 2009, there was an S. Typhimurium epizootic reported in pine siskins in the eastern United States. At the time, there was also a human outbreak with this serovar that was associated with contaminated peanuts. As peanuts are also used in wild-bird food, it was hypothesized that the pine siskin epizootic was related to this human outbreak. A comparison of songbird and human S. Typhimurium pulsed-field gel electrophoresis (PFGE) patterns revealed that the epizootic was attributed not to the peanut-associated strain but, rather, to a songbird strain first characterized from an American goldfinch in 1998. This same S. Typhimurium strain (PFGE type A3) was also identified in the PulseNet USA database, accounting for 137 of 77,941 total S. Typhimurium PFGE entries. A second molecular typing method, multiple-locus variable-number tandem-repeat analysis (MLVA), confirmed that the same strain was responsible for the pine siskin epizootic in the eastern United States but was distinct from a genetically related strain isolated from pine siskins in Minnesota. The pine siskin A3 strain was first encountered in May 2008 in an American goldfinch and later in a northern cardinal at the start of the pine siskin epizootic. MLVA also confirmed the clonal nature of S. Typhimurium in songbirds and established that the pine siskin epizootic strain was unique to the finch family. For 2009, the distribution of PFGE type A3 in passerines and humans mirrored the highest population density of pine siskins for the East Coast. C1 [Hernandez, Sonia M.; Keel, Kevin; Cheng, Ying; Ray, Al, III; Ruder, Mark G.; Brown, Justin; Maurer, John J.] Univ Georgia, Dept Populat Hlth, Athens, GA 30602 USA. [Sanchez, Susan] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA. [Martin, Gordon] Univ Georgia, Dept Environm Hlth Sci, Athens, GA 30602 USA. [Presotto, Andrea] Univ Georgia, Dept Geog, Athens, GA 30602 USA. [Trees, Eija; Gerner-Smidt, Peter] Ctr Dis Control & Prevent, Atlanta, GA USA. [Adams, Jennifer K.] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Blehert, David S.] US Geol Survey, Natl Wildlife Hlth Ctr, Madison, WI USA. [Cottrell, Walter] Penn Game Commiss, University Pk, PA USA. RP Maurer, JJ (reprint author), Univ Georgia, Dept Populat Hlth, Athens, GA 30602 USA. EM jmaurer@uga.edu FU NIH [1R15A1089565-01]; USDA NRICGP [2005-01378, 2001-96130032-CA]; Veterinary Services; APHIS; USDA [01ERAG0013]; United States Geological Survey; USDOI; SCWDS by the fish and wildlife agency of Alabama; SCWDS by the fish and wildlife agency of Arkansas; SCWDS by the fish and wildlife agency of Florida; SCWDS by the fish and wildlife agency of Georgia; SCWDS by the fish and wildlife agency of Kentucky; SCWDS by the fish and wildlife agency of Kansas; SCWDS by the fish and wildlife agency of Louisiana; SCWDS by the fish and wildlife agency of Maryland; SCWDS by the fish and wildlife agency of Mississippi; SCWDS by the fish and wildlife agency of Missouri; SCWDS by the fish and wildlife agency of North Carolina; SCWDS by the fish and wildlife agency of Ohio; SCWDS by the fish and wildlife agency of Puerto Rico; SCWDS by the fish and wildlife agency of South Carolina; SCWDS by the fish and wildlife agency of Tennessee; SCWDS by the fish and wildlife agency of Virginia; SCWDS by the fish and wildlife agency of West Virginia; Federal Aid to Wildlife Restoration Act [50 Stat. 917] FX This work was supported by NIH grant 1R15A1089565-01, USDA NRICGP 2005-01378, cooperative agreement no. 2001-96130032-CA, Veterinary Services, APHIS, USDA, cooperative agreement no. 01ERAG0013, United States Geological Survey, USDOI, and sponsorship of the SCWDS by the fish and wildlife agencies of Alabama, Arkansas, Florida, Georgia, Kentucky, Kansas, Louisiana, Maryland, Mississippi, Missouri, North Carolina, Ohio, Puerto Rico, South Carolina, Tennessee, Virginia, and West Virginia. Support from the states to the SCWDS was provided in part by the Federal Aid to Wildlife Restoration Act (50 Stat. 917). NR 40 TC 18 Z9 20 U1 1 U2 23 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD OCT PY 2012 VL 78 IS 20 BP 7290 EP 7298 DI 10.1128/AEM.01408-12 PG 9 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 013TL UT WOS:000309328700014 PM 22885752 ER PT J AU Warren, CW Erguder, T Lee, J Lea, V Sauer, AG Jones, NR Bilir, N AF Warren, Charles W. Erguder, Toker Lee, Juliette Lea, Veronica Sauer, Ann Goding Jones, Nathan R. Bilir, Nazmi TI Effect of policy changes on cigarette sales: the case of Turkey SO EUROPEAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SMOKING; ECONOMICS AB Background: In 1996, Turkey made tobacco control a health priority. The tobacco control effort was extended in July 2009 with the expansion of the smoke-free law to include all enclosed workplaces and public places and, in January 2010, with a 20% increase in the Special Consumption Tax on Tobacco. Methods: Sales data were averaged, by month, for the period January 2005 through June 2009 to establish an 'expected' monthly sales pattern. This was the period when no new tobacco control measures were implemented. The overall monthly average was then calculated for the same period. The expected monthly sales pattern was then graphed against the overall monthly sales average to delineate a seasonal sales pattern that was used to evaluate the divergence of actual monthly sales from the 'expected' pattern. Results: A distinct seasonal pattern was found with sales above average from May through August. Comparison of actual cigarette sales to the 'expected' monthly sales pattern following the implementation of the expanded smoke-free law in July resulted in a 5.2% decrease. Cigarettes sales decreased by 13.6% following the January 2010 Special Consumption Tax. Since the implementation of the expanded smoke-free law in July 2009 and the tax increase in January 2010, cigarette sales in Turkey decreased by 10.7%. Conclusion: The effect of recent Turkish tobacco control policies could contribute to a reduction in the number of premature deaths related to tobacco use. Evidence has shown that periodic tax increases and strong enforcement of all tobacco control policies are essential to further decrease tobacco consumption. C1 [Warren, Charles W.; Lee, Juliette; Lea, Veronica; Sauer, Ann Goding] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Jones, Nathan R.] Univ Wisconsin, Survey Res Ctr, Paul P Carbone Comprehens Canc Ctr, Madison, WI 53706 USA. [Bilir, Nazmi] Hacettepe Univ, Dept Publ Hlth, TR-06100 Ankara, Turkey. RP Warren, CW (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,NE, Atlanta, GA 30341 USA. EM wwarren@cdc.gov NR 19 TC 7 Z9 7 U1 2 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1101-1262 J9 EUR J PUBLIC HEALTH JI Eur. J. Public Health PD OCT PY 2012 VL 22 IS 5 BP 712 EP 716 DI 10.1093/eurpub/ckr157 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 015SC UT WOS:000309465400026 PM 22467758 ER PT J AU Ward, JW Rein, DB Smith, BD AF Ward, John W. Rein, David B. Smith, Bryce D. TI Data to Guide the "Test and Treat Era" of Hepatitis C SO GASTROENTEROLOGY LA English DT Editorial Material ID COST-EFFECTIVENESS; UNITED-STATES; MORTALITY; VIRUS; INFECTION C1 [Ward, John W.; Smith, Bryce D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Rein, David B.] Univ Chicago, NORC, Chicago, IL 60637 USA. RP Ward, JW (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM jww4@cdc.gov NR 18 TC 6 Z9 6 U1 1 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2012 VL 143 IS 4 BP 887 EP 889 DI 10.1053/j.gastro.2012.08.027 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 014FY UT WOS:000309361800016 PM 22922026 ER PT J AU Byrd, TL Wilson, KM Smith, JL Heckert, A Orians, CE Vernon, SW Fernandez-Esquer, ME Fernandez, ME AF Byrd, Theresa L. Wilson, Katherine M. Smith, Judith Lee Heckert, Andrea Orians, Carlyn E. Vernon, Sally W. Fernandez-Esquer, Maria E. Fernandez, Maria E. TI Using Intervention Mapping as a Participatory Strategy: Development of a Cervical Cancer Screening Intervention for Hispanic Women SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE cancer prevention and screening; community-based participatory research; community health promotion; health disparities; lay health workers ID BREAST AB Cervical cancer is preventable with treatment of precancerous lesions and treatable at early stages. Hispanics have higher rates of cervical cancer and lower rates of screening. Ayndando a las Mujeres con Informaccion, Guia, y Amor para su Salud (AMIGAS) is an intervention to increase cervical cancer screening in U.S. women of Mexican origin. AMIGAS was developed with the participation of the community using intervention mapping (IM). Following the IM process, the authors completed a needs assessment, development of program objectives, selection of intervention methods and strategies, and program design. A benefit of IM is its linkage with community-based participatory research as it includes engagement of community members to identify and refine priority areas. The success of this strategy suggests it a useful tool for other populations. The resulting intervention program is currently being tested for efficacy and cost-effectiveness in three sites: El Paso, Texas; Houston, Texas; and Yakima, Washington. C1 [Byrd, Theresa L.] Texas Tech Paul L Foster Sch Med, El Paso, TX 79905 USA. [Wilson, Katherine M.; Smith, Judith Lee] Ctr Dis Control & Prevent, Atlanta, GA USA. [Heckert, Andrea] Univ N Carolina, Chapel Hill, NC USA. [Orians, Carlyn E.] Battelle Ctr Publ Hlth Res & Evaluat, Seattle, WA USA. [Vernon, Sally W.; Fernandez-Esquer, Maria E.; Fernandez, Maria E.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. RP Byrd, TL (reprint author), Texas Tech Paul L Foster Sch Med, El Paso, TX 79905 USA. EM Theresa.Byrd@ttuhsc.edu NR 24 TC 16 Z9 16 U1 1 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD OCT PY 2012 VL 39 IS 5 BP 603 EP 611 DI 10.1177/1090198111426452 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 014DB UT WOS:000309354200013 PM 22388451 ER PT J AU Chen, BT Schwegler-Berry, D McKinney, W Stone, S Cumpston, JL Friend, S Porter, DW Castranova, V Frazer, DG AF Chen, Bean T. Schwegler-Berry, Diane McKinney, Walter Stone, Samuel Cumpston, Jared L. Friend, Sherri Porter, Dale W. Castranova, Vincent Frazer, David G. TI Multi-walled carbon nanotubes: sampling criteria and aerosol characterization SO INHALATION TOXICOLOGY LA English DT Article DE Multi-walled carbon nanotubes; engineered nanoparticles; characterization; inhalation studies; exposure assessment method ID INHALATION EXPOSURE; IN-VITRO; PULMONARY; TOXICITY; FIBERS; RATS; SIZE; DEPOSITION; DISPERSION; IMPACTOR AB This study intends to develop protocols for sampling and characterizing multi-walled carbon nanotube (MWCNT) aerosols in workplaces or during inhalation studies. Manufactured dry powder containing MWCNT's, combined with soot and metal catalysts, form complex morphologies and diverse shapes. The aerosols, examined in this study, were produced using an acoustical generator. Representative samples were collected from an exposure chamber using filters and a cascade impactor for microscopic and gravimetric analyses. Results from filters showed that a density of 0.008-0.10 particles per mu m(2) filter surface provided adequate samples for particle counting and sizing. Microscopic counting indicated that MWCNT's, resuspended at a concentration of 10 mg/m(3), contained 2.7 x 10(4) particles/cm(3). Each particle structure contained an average of 18 nanotubes, resulting in a total of 4.9 x 10(5) nanotubes/cm(3). In addition, fibrous particles within the aerosol had a count median length of 3.04 mu m and a width of 100.3 nm, while the isometric particles had a count median diameter of 0.90 mu m. A combination of impactor and microscopic measurements established that the mass median aerodynamic diameter of the mixture was 1.5 mu m. It was also determined that the mean effective density of well-defined isometric particles was between 0.71 and 0.88 g/cm(3), and the mean shape factor of individual nanotubes was between 1.94 and 2.71. The information obtained from this study can be used for designing animal inhalation exposure studies and adopted as guidance for sampling and characterizing MWCNT aerosols in workplaces. The measurement scheme should be relevant for any carbon nanotube aerosol. C1 [Chen, Bean T.] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, CDC, Morgantown, WV 26505 USA. RP Chen, BT (reprint author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, CDC, Mailstop L2015,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM bdc4@cdc.gov FU Intramural CDC HHS [CC999999] NR 44 TC 22 Z9 22 U1 1 U2 22 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0895-8378 J9 INHAL TOXICOL JI Inhal. Toxicol. PD OCT PY 2012 VL 24 IS 12 BP 798 EP 820 DI 10.3109/08958378.2012.720741 PG 23 WC Toxicology SC Toxicology GA 015XD UT WOS:000309478800003 PM 23033994 ER PT J AU Eke, PI Dye, BA Wei, L Thornton-Evans, GO Genco, RJ AF Eke, P. I. Dye, B. A. Wei, L. Thornton-Evans, G. O. Genco, R. J. CA CDC Periodontal Dis Surveillance TI Prevalence of Periodontitis in Adults in the United States: 2009 and 2010 SO JOURNAL OF DENTAL RESEARCH LA English DT Article DE NHANES; periodontal disease; periodontitis; epidemiology; surveillance; adults ID PARTIAL RECORDING PROTOCOLS; DISEASE; SURVEILLANCE; DEFINITIONS; SEVERITY; OLDER; HALF AB This study estimated the prevalence, severity, and extent of periodontitis in the adult U.S. population, with data from the 2009 and 2010 National Health and Nutrition Examination Survey (NHANES) cycle. Estimates were derived from a sample of 3,742 adults aged 30 years and older, of the civilian non-institutionalized population, having 1 or more natural teeth. Attachment loss (AL) and probing depth (PD) were measured at 6 sites per tooth on all teeth (except the third molars). Over 47% of the sample, representing 64.7 million adults, had periodontitis, distributed as 8.7%, 30.0%, and 8.5% with mild, moderate, and severe periodontitis, respectively. For adults aged 65 years and older, 64% had either moderate or severe periodontitis. Eighty-six and 40.9% had 1 or more teeth with AL >= 3 mm and PD >= 4 mm, respectively. With respect to extent of disease, 56% and 18% of the adult population had 5% or more periodontal sites with >= 3 mm AL and >= 4 mm PD, respectively. Periodontitis was highest in men, Mexican Americans, adults with less than a high school education, adults below 100% Federal Poverty Levels (FPL), and current smokers. This survey has provided direct evidence for a high burden of periodontitis in the adult U.S. population. C1 [Eke, P. I.] Ctr Dis Control & Prevent CDC, Div Populat Hlth, Natl Ctr Chron Dis & Hlth Promot, Atlanta, GA 30341 USA. [Wei, L.; Thornton-Evans, G. O.] Ctr Dis Control & Prevent CDC, Div Oral Hlth, Atlanta, GA 30341 USA. [Genco, R. J.] SUNY Buffalo, Buffalo, NY 14260 USA. RP Eke, PI (reprint author), Ctr Dis Control & Prevent CDC, Div Populat Hlth, Natl Ctr Chron Dis & Hlth Promot, Atlanta, GA 30341 USA. EM peke@cdc.gov FU CDC FX The authors provided the following disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors acknowledge the contributions from the CDC Periodontal Disease Surveillance Workgroup (Eke and Genco, 2007). This workgroup was supported by CDC as part of an internal project and was not supported by any external funding or institution. The authors declare no potential conflicts of interest with respect to the authorship and/or publication of this article. NR 20 TC 447 Z9 455 U1 9 U2 85 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0022-0345 J9 J DENT RES JI J. Dent. Res. PD OCT PY 2012 VL 91 IS 10 BP 914 EP 920 DI 10.1177/0022034512457373 PG 7 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 007HH UT WOS:000308878900004 PM 22935673 ER PT J AU Carlson, VP Lehman, EJ Armstrong, M AF Carlson, Valeria P. Lehman, Everett J. Armstrong, Myrna TI Tattooing Regulations in U.S. States, 2011 SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article ID MEDICAL COMPLICATIONS; PERMANENT COSMETICS; MALIGNANT-MELANOMA; UNITED-STATES; BODY ART; SKIN; PREVALENCE; INFECTION; PIGMENTS; BEHAVIOR AB Tattooing's popularity has led to regulatory concerns because medical complications linked to unsanitary practices can have a lasting health impact. The authors' study sought to determine whether existing state tattooing laws and regulations (rules) effectively protect public health. A 10-item checklist was created for each of three types of rules (sanitation, training, and infection control) identified as having the greatest public health impact. State rules were classified as effective if the state scored >= 7 on all three categories, moderate if >= 4 in all three categories, minimal if <4 in one or more categories, and ineffective if <= 2 in all three categories. Forty-one states have at least one state statute regulating tattooing practice. On the basis of the authors' study criteria, 36 states regulate sanitation effectively; 15 states regulate training effectively; and 26 states regulate infection control effectively. Fourteen states meet the criteria for regulating all three categories effectively. Specific rules vary substantially by state. Public health agencies should encourage states to adopt and enforce effective, evidence-based tattooing rules. C1 [Carlson, Valeria P.] Ctr Dis Control & Prevent, Off State Tribal Local & Terr Support, Div Publ Hlth Performance Improvement, Hlth Dept Syst Dev Branch, Atlanta, GA 30341 USA. [Armstrong, Myrna] Texas Tech Univ, Hlth Sci Ctr, Sch Nursing, Lubbock, TX 79409 USA. RP Carlson, VP (reprint author), Ctr Dis Control & Prevent, Off State Tribal Local & Terr Support, Div Publ Hlth Performance Improvement, Hlth Dept Syst Dev Branch, 4770 Buford Highway,MS E-70, Atlanta, GA 30341 USA. EM guz6@cdc.gov NR 49 TC 4 Z9 4 U1 1 U2 2 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD OCT PY 2012 VL 75 IS 3 BP 30 EP 37 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 013PF UT WOS:000309316600005 PM 23091968 ER PT J AU Nielsen, JA AF Nielsen, Jay A. CA Natl Conversation Public Hlth Chem TI From Conversation to Action: Implementation of the National Conversation on Public Health and Chemical Exposures SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 [Nielsen, Jay A.] CDC, ORISE, NCEH ATSDR, Atlanta, GA 30341 USA. RP Nielsen, JA (reprint author), CDC, ORISE, NCEH ATSDR, 4770 Buford Highway,Mailstop F-61, Atlanta, GA 30341 USA. EM jnielsen@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD OCT PY 2012 VL 75 IS 3 BP 38 EP 39 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 013PF UT WOS:000309316600006 PM 23091969 ER PT J AU Gelting, RJ Baloch, MA AF Gelting, Richard J. Baloch, Mansoor A. TI The Food-Water Nexus: Irrigation Water Quality, Risks to Food Safety, and the Need for a Systems-Based Preventive Approach SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Editorial Material C1 [Baloch, Mansoor A.] CDC, ORISE, Environm Hlth Serv Branch, Div Emergency & Environm Hlth Serv,Natl Ctr Envir, Atlanta, GA 30341 USA. RP Baloch, MA (reprint author), CDC, ORISE, Environm Hlth Serv Branch, Div Emergency & Environm Hlth Serv,Natl Ctr Envir, 4770 Buford Highway NE,MS F-60, Atlanta, GA 30341 USA. EM mbaloch@cdc.gov OI Baloch, Mansoor/0000-0002-1502-086X NR 5 TC 0 Z9 0 U1 0 U2 14 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD OCT PY 2012 VL 75 IS 3 BP 40 EP 41 PG 2 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 013PF UT WOS:000309316600007 PM 23091970 ER PT J AU Gargano, JW Wilkinson, EJ Unger, ER Steinau, M Watson, M Huang, YJ Copeland, G Cozen, W Goodman, MT Hopenhayn, C Lynch, CF Hernandez, BY Peters, ES Saber, MS Lyu, CW Sands, LA Saraiya, M AF Gargano, Julia W. Wilkinson, Edward J. Unger, Elizabeth R. Steinau, Martin Watson, Meg Huang, Youjie Copeland, Glenn Cozen, Wendy Goodman, Marc T. Hopenhayn, Claudia Lynch, Charles F. Hernandez, Brenda Y. Peters, Edward S. Saber, Maria Sibug Lyu, Christopher W. Sands, Lauren A. Saraiya, Mona TI Prevalence of Human Papillomavirus Types in Invasive Vulvar Cancers and Vulvar Intraepithelial Neoplasia 3 in the United States Before Vaccine Introduction SO JOURNAL OF LOWER GENITAL TRACT DISEASE LA English DT Article DE vulvar cancers; vulvar intraepithelial neoplasia; human papillomavirus; cancer registry; vaccine ID SQUAMOUS-CELL CARCINOMA; PARTICLE VACCINE; HPV; PRECURSORS; INFECTION; EFFICACY; TISSUES; UPDATE; DNA AB Objective. The study aimed to determine the baseline prevalence of human papillomavirus (HPV) types in invasive vulvar cancer (IVC) and vulvar intraepithelial neoplasia 3 WIN 3) cases using data from 7 US cancer registries. Materials and Methods. Registries identified eligible cases diagnosed in 1994 to 2005 and requested pathology laboratories to prepare 1 representative block for HPV testing on those selected. Hematoxylin-eosin stained sections preceding and following those used for extraction were reviewed to confirm representation. Human papillomavirus was detected using L1 consensus polymerase chain reaction (PCR) with PGMY9/11 primers and type-specific hybridization, with retesting of samples with negative and inadequate results with SPF10 primers. For IVC, the confirmatory hematoxylin-eosin slides were re-evaluated to determine histological type. Descriptive analyses were performed to examine distributions of HPV by histology and other factors. Results. Human papillomavirus was detected in 121/176 (68.8%) cases of IVC and 66/68 (97.1%) cases of VIN 3 (p < .0001). Patients with IVC and VIN 3 differed by median age (70 vs 55 y, p = .003). Human papillomavirus 16 was present in 48.6% of IVC cases and 80.9% of VIN 3 cases; other high-risk HPV was present in 19.2% of IVC cases and 13.2% of VIN 3 cases. Prevalence of HPV differed by squamous cell carcinoma histological subtype (p < .0001) as follows: keratinizing, 49.1% (n = 55); nonkeratinizing, 85.7% (n = 14), basaloid, 92.3% (n = 14), warty 78.2% (n = 55), and mixed warty/basaloid, 100% (n = 7). Conclusions. Nearly all cases of VIN 3 and two thirds of IVC cases were positive for high-risk HPV. Prevalence of HPV ranged from 49.1% to 100% across squamous cell carcinoma histological subtypes. Given the high prevalence of HPV in IVC and VIN 3 cases, prophylactic vaccines have the potential to decrease the incidence of vulvar neoplasia. C1 [Gargano, Julia W.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Gargano, Julia W.; Unger, Elizabeth R.; Steinau, Martin; Sands, Lauren A.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Wilkinson, Edward J.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA. [Watson, Meg] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Huang, Youjie; Saraiya, Mona] Florida Dept Hlth, Bur Epidemiol, Tallahassee, FL USA. [Copeland, Glenn] Michigan Dept Community Hlth, Lansing, MI USA. [Cozen, Wendy; Saber, Maria Sibug] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. [Cozen, Wendy; Saber, Maria Sibug] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA. [Goodman, Marc T.; Hernandez, Brenda Y.] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA. [Hopenhayn, Claudia] Univ Kentucky, Coll Publ Hlth, Dept Epidemiol, Lexington, KY USA. [Hopenhayn, Claudia] Univ Kentucky, Markey Canc Control Program, Lexington, KY USA. [Lynch, Charles F.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Peters, Edward S.] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol, New Orleans, LA USA. [Lyu, Christopher W.] Battelle Mem Inst, Durham, NC USA. RP Gargano, JW (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Natl Ctr Emerging & Zoonot Infect Dis, MS C09,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM igc5@cdc.gov OI /0000-0003-4928-6532; Unger, Elizabeth/0000-0002-2925-5635 FU Centers for Disease Control and Prevention (Kentucky) [5U58DP000810-5]; Centers for Disease Control and Prevention (Florida) [5U58DP000844-5]; Centers for Disease Control and Prevention (Michigan) [5U58DP000812-5]; Centers for Disease Control and Prevention (Louisiana) [5U58DP000769-5]; National Cancer Institute Surveillance Epidemiology; End Results population based registry program, National Institutes of Health; Department of Health and Human Services (Los Angeles) [N01-PC-35139]; Department of Health and Human Services (Iowa) [N01-PC-35143]; Department of Health and Human Services (Hawaii) [N01-PC-35137] FX The support for the collection of original specimens fromnonrepositories (Kentucky, Florida, Michigan, and Lousiana), the coordination of genotyping data from both registries of Surveillance. Epidemiology, and End Results and National Program of Cancer Registries, and the genotyping was largely supported by Centers for Disease Control and Prevention intramural funds and Vaccine for Children funds. This project has been supported in part with federal funds by the Centers for Disease Control and Prevention under grant number no. 5U58DP000810-5 (Kentucky), 5U58DP000844-5 (Florida), 5U58DP000812-5 (Michigan), and 5U58DP000769-5 (Louisiana) and with federal funds for residual tissue repositories from the National Cancer Institute Surveillance Epidemiology and End Results population based registry program, National Institutes of Health. Department of Health and Human Services, under contract no. N01-PC-35139 (Los Angeles), N01-PC-35143 (Iowa), and N01-PC-35137 (Hawaii). NR 28 TC 31 Z9 32 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1089-2591 J9 J LOW GENIT TRACT DI JI J. Low. Genit. Tract. Dis. PD OCT PY 2012 VL 16 IS 4 BP 471 EP 479 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 013SM UT WOS:000309326200025 PM 22652576 ER PT J AU Farooqi, J Jabeen, K Saeed, N Zafar, A Brandt, ME Hasan, R AF Farooqi, Joveria Jabeen, Kauser Saeed, Noureen Zafar, Afia Brandt, Mary Eleanor Hasan, Rumina TI Species identification of invasive yeasts including Candida in Pakistan: limitations of phenotypic methods SO JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION LA English DT Article DE Invasive yeasts; Candida; Rhodotorula; Cryptococcus; Luminex MAP ID RAPID IDENTIFICATION; EPIDEMIOLOGY AB Objective: To compare phenotypic and genotypic methods of yeast identification. Methods: The in-vitro cross-sectional study was conducted from January 2006 to May 2009. Invasive yeasts isolated at the clinical microbiology laboratory at the Aga Khan University (AKU), Karachi, Pakistan, were identified. Speciation by phenotypic and molecular methods was compared. All yeasts isolated during the study period from blood and other invasive sites were identified using standard methods. Isolates were shipped to Mycotic Diseases Branch, Centres for Disease Control and Prevention, Atlanta, Georgia, USA, for identification by Luminex flow cytometric multianalyte profiling (xMAP) system. Ribosomal ITS2 DNA sequencing was performed on isolates not identified by Luminex. Result: Of the 214 invasive yeasts evaluated, Candida species were 209 (97.7%) while the frequency of non-Candida species was 5 (2.3%). Overall agreement between phenotypic and molecular identification was 81.3%, 90.3% amongst the more common Candida species, and only 38.8% amongst the uncommon yeasts. Conclusion: Phenotypic methods of identification proved adequate for common Candida species, but were deficient in recognising rare Candida and non-Candida yeasts, highlighting the importance of molecular methods for identification. C1 [Farooqi, Joveria; Jabeen, Kauser; Saeed, Noureen; Zafar, Afia; Hasan, Rumina] Aga Khan Hosp Karachi, Dept Pathol & Microbiol, Karachi, Pakistan. [Brandt, Mary Eleanor] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Farooqi, J (reprint author), Aga Khan Hosp Karachi, Dept Pathol & Microbiol, Karachi, Pakistan. EM joveria.farooqi@aku.edu FU Joint Pakistan-US Academic and Research Programme HEC/MoST/USAID FX The study was financially supported by the Joint Pakistan-US Academic and Research Programme HEC/MoST/USAID. We would like to acknowledge the technical expertise and support of Eszter Deak, Joyce Petersen and Lalitha Gade at the Mycotic Diseases Branch, Centres for Disease Control and Prevention, Atlanta Georgia, USA. We are grateful to Syed Iqbal Azam, Assistant Professor, Community Health Sciences, Aga Khan University, Karachi, for his guidance in statistical analysis. NR 25 TC 2 Z9 2 U1 1 U2 6 PU PAKISTAN MEDICAL ASSOC PI KARACHI PA PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN SN 0030-9982 J9 J PAK MED ASSOC JI J. Pak. Med. Assoc. PD OCT PY 2012 VL 62 IS 10 BP 995 EP 998 PG 4 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 010ND UT WOS:000309100200002 PM 23866432 ER PT J AU Yang, QH Zhang, ZF Kuklina, EV Fang, J Ayala, C Hong, YL Loustalot, F Dai, SF Gunn, JP Tian, N Cogswell, ME Merritt, R AF Yang, Quanhe Zhang, Zefeng Kuklina, Elena V. Fang, Jing Ayala, Carma Hong, Yuling Loustalot, Fleetwood Dai, Shifan Gunn, Janelle P. Tian, Niu Cogswell, Mary E. Merritt, Robert TI Sodium Intake and Blood Pressure Among US Children and Adolescents SO PEDIATRICS LA English DT Article DE sodium intake; overweight; blood pressure; hypertension; cardiovascular risk factor ID CARDIOVASCULAR RISK-FACTORS; EPISODICALLY CONSUMED FOODS; HEART-ASSOCIATION COUNCIL; YOUNG FINNS; HYPERTENSION PREVENTION; SCIENTIFIC STATEMENT; PHYSICAL-ACTIVITY; WEIGHT-LOSS; CHILDHOOD; ADULTHOOD AB OBJECTIVE: To assess the association between usual dietary sodium intake and blood pressure among US children and adolescents, overall and by weight status. METHODS: Children and adolescents aged 8 to 18 years (n = 6235) who participated in NHANES 2003-2008 comprised the sample. Subjects' usual sodium intake was estimated by using multiple 24-hour dietary recalls. Linear or logistic regression was used to examine association between sodium intake and blood pressure or risk for pre-high blood pressure and high blood pressure (pre-HBP/HPB). RESULTS: Study subjects consumed an average of 3387 mg/day of sodium, and 37% were overweight/obese. Each 1000 mg per day sodium intake was associated with an increased SD score of 0.097 (95% confidence interval [CI] 0.006-0.188, similar to 1.0 mm Hg) in systolic blood pressure (SBP) among all subjects and 0.141 (95% CI: -0.010 to 0.298, similar to 1.5 mm Hg) increase among overweight/obese subjects. Mean adjusted SBP increased progressively with sodium intake quartile, from 106.2 mm Hg (95% CI: 105.1-107.3) to 108.8 mm Hg (95% CI: 107.5-110.1) overall (P=.010) and from 109.0 mm Hg (95% CI: 107.2-110.8) to 112.8 mm Hg (95% CI: 110.7-114.9; P=.037) among those overweight/obese. Adjusted odds ratios comparing risk for pre-HBP/HPB among subjects in the highest versus lowest sodium intake quartile were 2.0 (95% CI: 0.95-4.1, P=.062) overall and 3.5 (95% CI: 1.3-9.2, P=.013) among those overweight/obese. Sodium intake and weight status appeared to have synergistic effects on risk for pre-HBP/HPB (relative excess risk for interaction = 0.29 (95% CI: 0.01-0.90, P<.05). CONCLUSIONS: Sodium intake is positively associated with SBP and risk for pre-HBP/HPB among US children and adolescents, and this association may be stronger among those who are overweight/obese. Pediatrics 2012; 130: 611-619 C1 [Yang, Quanhe; Zhang, Zefeng; Kuklina, Elena V.; Fang, Jing; Ayala, Carma; Hong, Yuling; Loustalot, Fleetwood; Dai, Shifan; Gunn, Janelle P.; Tian, Niu; Cogswell, Mary E.; Merritt, Robert] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. RP Yang, QH (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Highway,MailStop F-72, Atlanta, GA 30341 USA. EM qay0@cdc.gov NR 60 TC 71 Z9 71 U1 0 U2 16 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD OCT PY 2012 VL 130 IS 4 BP 611 EP 619 DI 10.1542/peds.2011-3870 PG 9 WC Pediatrics SC Pediatrics GA 014YO UT WOS:000309412100044 PM 22987869 ER PT J AU Nesheim, S Taylor, A Lampe, MA Kilmarx, PH Harris, LF Whitmore, S Griffith, J Thomas-Proctor, M Fenton, K Mermin, J AF Nesheim, Steven Taylor, Allan Lampe, Margaret A. Kilmarx, Peter H. Harris, Lauren Fitz Whitmore, Suzanne Griffith, Judy Thomas-Proctor, Melissa Fenton, Kevin Mermin, Jonathan TI A Framework for Elimination of Perinatal Transmission of HIV in the United States SO PEDIATRICS LA English DT Article DE elimination; HIV; mother-to-child; perinatal; transmission ID TO-CHILD TRANSMISSION; HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH-CARE SETTINGS; FOR-DISEASE-CONTROL; ANTIRETROVIRAL THERAPY; TESTING RECOMMENDATIONS; INFECTED INFANTS; DRUG-RESISTANCE; PREVENTION; COHORT AB The availability of effective interventions to prevent mother-to-child HIV transmission and the significant reduction in the number of HIV-infected infants in the United States have led to the concept that elimination of mother-to-child HIV transmission (EMCT) is possible. Goals for elimination are presented. We also present a framework by which elimination efforts can be coordinated, beginning with comprehensive reproductive health care (including HIV testing) and real-time case-finding of pregnancies in HIV-infected women, and conducted through the following: facilitation of comprehensive clinical care and social services for women and infants; case review and community action; allowing continuous quality research in prevention and long-term follow-up of HIV-exposed infants; and thorough data reporting for HIV surveillance and EMCT evaluation. It is emphasized that EMCT will not be a one-time accomplishment but, rather, will require sustained effort as long as there are new HIV infections in women of childbearing age. Pediatrics 2012;130:738-744 C1 [Nesheim, Steven] Ctr Dis Control & Prevent, DHAP NCHHSTP, Natl Ctr Viral Hepatitis HIV AIDS Sexually Transm, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Harris, Lauren Fitz] Assoc Sch Publ Hlth, Washington, DC USA. RP Nesheim, S (reprint author), Ctr Dis Control & Prevent, DHAP NCHHSTP, Natl Ctr Viral Hepatitis HIV AIDS Sexually Transm, Div HIV AIDS Prevent, MS E-45,1600 Clifton Rd, Atlanta, GA 30333 USA. EM sxn9@cdc.gov RI Mermin, Jonathan/J-9847-2012; OI Kilmarx, Peter/0000-0001-6464-3345 NR 36 TC 24 Z9 25 U1 0 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD OCT PY 2012 VL 130 IS 4 BP 738 EP 744 DI 10.1542/peds.2012-0194 PG 7 WC Pediatrics SC Pediatrics GA 014YO UT WOS:000309412100060 PM 22945404 ER PT J AU Boulet, SL Grosse, SD Thornburg, CD Yusuf, H Tsai, J Hooper, WC AF Boulet, Sheree L. Grosse, Scott D. Thornburg, Courtney D. Yusuf, Hussain Tsai, James Hooper, W. Craig TI Trends in Venous Thromboembolism-Related Hospitalizations, 1994-2009 SO PEDIATRICS LA English DT Article DE venous thromboembolism; venous thrombosis; pulmonary embolism; central venous catheterization; infant; child; adolescent ID UNITED-STATES; RISK-FACTORS; CHILDREN; THROMBOSIS; POPULATION; REGISTRY; CHILDHOOD; CODES AB OBJECTIVE: Information on trends in venous thromboembolism (VTE) in US children is scant and inconsistent. We assessed national trends in VTE-associated pediatric hospitalizations. METHODS: All nonroutine newborn hospitalizations for children 0 to 17 years of age in the 1994-2009 Nationwide Inpatient Samples were included; routine newborn discharges were excluded. VTE diagnoses were identified by using the International Classification of Diseases, Ninth Revision, Clinical Modification codes. Variance weighted least square regression was used to assess trends in patient characteristics and rates of hospitalization per 100 000 population <18 years of age. Multivariable logistic regression models were used to estimate the probability of VTE diagnosis over the study period. RESULTS: The rate of VTE-associated hospitalization increased for all age subgroups (<1, 1-5, 6-11, and 12-17 years), with the largest increase noted among children <1 year of age (from 18.1 per 100 000 during 1994 to 49.6 per 100 000 during 2009). Compared with 1994-1997, the adjusted odds of hospitalization with a VTE diagnosis were 88% higher during 2006-2009 (adjusted odds ratio: 1.88 [95% confidence interval: 1.64-2.17]). Venous catheter use, mechanical ventilation, malignancy, hospitalization >= 5 days, and VTE-related medical conditions were associated with increased likelihood of VTE diagnosis. CONCLUSIONS: The rate of VTE-associated hospitalization among US children increased from 1994 through 2009. Increases in venous catheter procedures were associated with and may have contributed to the observed trends. The degree to which increased awareness of VTE influenced the temporal differences could not be determined. Pediatrics 2012; 130: e812-e820 C1 [Boulet, Sheree L.; Grosse, Scott D.; Yusuf, Hussain; Tsai, James; Hooper, W. Craig] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. [Thornburg, Courtney D.] Duke Univ, Med Ctr, Durham, NC USA. RP Boulet, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS D02, Atlanta, GA 30329 USA. EM sboulet@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 12 Z9 12 U1 1 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD OCT PY 2012 VL 130 IS 4 BP E812 EP E820 DI 10.1542/peds.2012-0267 PG 9 WC Pediatrics SC Pediatrics GA 014YO UT WOS:000309412100004 PM 22987875 ER PT J AU Williams, DJ Edwards, KM Payne, DC Manning, J Parashar, UD Lopman, BA AF Williams, Derek J. Edwards, Kathryn M. Payne, Daniel C. Manning, Judith Parashar, Umesh D. Lopman, Benjamin A. TI Decline in Gastroenteritis-Related Triage Calls After Rotavirus Vaccine Licensure SO PEDIATRICS LA English DT Article DE gastroenteritis; rotavirus; rotavirus vaccines; norovirus ID 1ST 2 YEARS; UNITED-STATES; DOUBLE-BLIND; EFFICACY; SAFETY; INFANTS; SURVEILLANCE; POPULATION; NOROVIRUS; CHILDREN AB OBJECTIVE: We sought to determine the impact of rotavirus vaccine implementation on gastroenteritis (GE)-related calls to a large telephone triage service in Tennessee. METHODS: Total and GE-related calls received by the Vanderbilt Telephone Triage Program for children <5 years of age were examined from May 1, 2004 to April 30, 2010. Time series adapted Poisson regression models were used to compare weekly GE-related call proportions between the prevaccine (May 2004 to April 2007) and postlicensure (May 2007 to April 2010) periods. Separate models compared GE-related call proportions in the historical rotavirus (February to April) and nonrotavirus (May to January) seasons. Associations between call data and laboratory-confirmed rotavirus detections and regionally reported norovirus activity were also assessed. RESULTS: There were 156 362 total calls and 19 731 GE-related calls. Annual GE-related call proportions declined by 8% (95% confidence interval, 3%-12%) in the postlicensure period; declines ranging from 23% to 31% occurred during the historical rotavirus season in all 3 postlicensure years. No declines occurred in the nonrotavirus season. After vaccine licensure, reductions in laboratory-confirmed rotavirus activity were associated with declines in GE-related call proportions. Peak GE-related call proportions in the postlicensure period occurred earlier than in prevaccine years and were not strongly associated with laboratory-confirmed rotavirus but instead showed good correlation with norovirus outbreaks. CONCLUSIONS: A decline in GE-related call proportions among young children after rotavirus vaccine licensure was documented by using a novel surveillance platform that captures mild GE not detected in other surveillance systems. Since rotavirus vaccine licensure, peak call proportions correlate with regional norovirus activity, highlighting the role of that pathogen in community GE. Pediatrics 2012;130:e872-e878 C1 [Williams, Derek J.] Vanderbilt Univ, Sch Med, Div Hosp Med, Dept Pediat,Vanderbilt Vaccine Res Program, Nashville, TN 37212 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Pediat,Vanderbilt Vaccine Res Program, Nashville, TN 37212 USA. [Manning, Judith] Jr Childrens Hosp Vanderbilt, Vanderbilt Tel Triage Program, Nashville, TN USA. [Payne, Daniel C.; Parashar, Umesh D.; Lopman, Benjamin A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Williams, DJ (reprint author), 1161 21st Ave S,CCC 5311 Med Ctr N, Nashville, TN 37232 USA. EM derek.williams@vanderbilt.edu FU Centers for Disease Control and Prevention; New Vaccine Surveillance Network [5 U01 IP000022-05] FX This work was supported by the Centers for Disease Control and Prevention and the New Vaccine Surveillance Network (5 U01 IP000022-05). NR 24 TC 6 Z9 6 U1 0 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD OCT PY 2012 VL 130 IS 4 BP E872 EP E878 DI 10.1542/peds.2012-0330 PG 7 WC Pediatrics SC Pediatrics GA 014YO UT WOS:000309412100011 PM 22966021 ER PT J AU Mbaeyi, C Panlilio, AL Hobbs, C Patel, PR Kuhar, DT AF Mbaeyi, Chukwuma Panlilio, Adelisa L. Hobbs, Cynthia Patel, Priti R. Kuhar, David T. TI Assessment of Management Policies and Practices for Occupational Exposure to Bloodborne Pathogens in Dialysis Facilities SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Occupational; bloodborne pathogen; exposure; dialysis; survey; health care personnel ID HEALTH-CARE WORKERS; HUMAN-IMMUNODEFICIENCY-VIRUS; POSTEXPOSURE PROPHYLAXIS; HIV-INFECTION; RISK; SURVEILLANCE; KNOWLEDGE; ATTITUDES AB Background: Occupational exposure management is an important element in preventing the transmission of bloodborne pathogens in health care settings. In 2008, the US Centers for Disease Control and Prevention conducted a survey to assess procedures for managing occupational bloodborne pathogen exposures in outpatient dialysis facilities in the United States. Study Design: A cross-sectional survey of randomly selected outpatient dialysis facilities. Setting & Participants: 339 outpatient dialysis facilities drawn from the 2006 US end-stage renal disease database. Predictors: Hospital affiliation (free-standing vs hospital-based facilities), profit status (for-profit vs not-for-profit facilities), and number of health care personnel (>= 100 vs <100 health care personnel). Outcomes: Exposures to hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV); provision of HBV and HIV postexposure prophylaxis. Measurements: We calculated the proportion of facilities reporting occupational bloodborne pathogen exposures and offering occupational exposure management services. We analyzed bloodborne pathogen exposures and provision of postexposure prophylaxis by facility type. Results: Nearly all respondents (99.7%) had written policies and 95% provided occupational exposure management services to health care personnel during the daytime on weekdays, but services were provided infrequently during other periods of the week. Approximately 10%-15% of facilities reported having HIV, HBV, or HCV exposures in health care personnel in the 12 months prior to the survey, but inconsistencies were noted in procedures for managing such exposures. Despite 86% of facilities providing HIV prophylaxis for exposed health care personnel, only 37% designated a primary HIV postexposure prophylaxis regimen. For-profit and free-standing facilities reported fewer exposures, but did not as reliably offer HBV prophylaxis or have a primary HIV postexposure prophylaxis regimen relative to not-for-profit and hospital-based facilities. Limitations: The survey response rate was low (37%) and familiarity of individuals completing the survey with facility policies or national guidelines could not be ascertained. Conclusions: Significant improvements are required in the implementation of guidelines for managing occupational exposures to bloodborne pathogens in outpatient dialysis facilities. Am J Kidney Dis. 60(4):617-625. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is a US Government Work. There are no restrictions on its use. C1 [Mbaeyi, Chukwuma; Panlilio, Adelisa L.; Patel, Priti R.; Kuhar, David T.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Mbaeyi, Chukwuma] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Hobbs, Cynthia] Natl Res Corp NRC Picker, Lincoln, NE USA. RP Mbaeyi, C (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd,Mail Stop A31, Atlanta, GA 30333 USA. EM cmbaeyi@cdc.gov FU CDC (Atlanta, GA) FX The survey of occupational exposure management policies and practices in US dialysis facilities, conducted in 2008, was supported and funded by the CDC (Atlanta, GA). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 25 TC 2 Z9 2 U1 0 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD OCT PY 2012 VL 60 IS 4 BP 617 EP 625 DI 10.1053/j.ajkd.2012.05.013 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 010QO UT WOS:000309109400020 PM 22742864 ER PT J AU Ambalavanan, N Carlo, WA McDonald, SA Das, A Schendel, DE Thorsen, P Hougaard, DM Skogstrand, K Higgins, RD AF Ambalavanan, Namasivayam Carlo, Waldemar A. McDonald, Scott A. Das, Abhik Schendel, Diana E. Thorsen, Poul Hougaard, David M. Skogstrand, Kristin Higgins, Rosemary D. CA Eunice Kennedy Shriver Natl Inst TI Cytokines and Posthemorrhagic Ventricular Dilation in Premature Infants SO AMERICAN JOURNAL OF PERINATOLOGY LA English DT Article DE infant; premature; cytokines; hydrocephalus; intraventricular hemorrhage; intracranial hemorrhage ID NECROSIS-FACTOR-ALPHA; BIRTH-WEIGHT INFANTS; GROWTH-FACTOR-BETA; INTERFERON-GAMMA EXPRESSION; WHITE-MATTER INJURY; PERIVENTRICULAR LEUKOMALACIA; CEREBROSPINAL-FLUID; PRETERM INFANTS; CEREBRAL-PALSY; TRANSFORMING GROWTH-FACTOR-BETA-1 AB Objective To determine in extremely low-birth-weight infants if elevated blood interferon-gamma (IFN-gamma), interleukin (IL)-1 beta, IL-18, tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor-beta are associated with need for shunt following severe intraventricular hemorrhage (IVH) or with ventricular dilation following milder grades/no IVH. Study Design Whole blood cytokines were measured on postnatal days 1,3,7, 14, and 21. Maximum IVH grade in the first 28 days, and shunt surgery or ventricular dilation on subsequent ultrasound (28 days' to 36 weeks' postmenstrual age) were determined. Results Of 902 infants in the National Institute of Child Health and Human Development Neonatal Research Network Cytokine study who survived to 36 weeks or discharge, 3.1% had shunts. Of the 12% of infants with severe (grade III to IV) IVH, 26% had a shunt associated with elevated TNF-alpha. None of the infants without IVH (69%) or with grade I(12%) or II (7%) IVH received shunts, but 8.4% developed ventricular dilation, associated with lower IFN-gamma and higher IL-18. Conclusion Statistically significant but clinically nondiscriminatory alterations in blood cytokines were noted in infants with severe IVH who received shunts and in those without severe IVH who developed ventricular dilation. Blood cytokines are likely associated with brain injury but may not be clinically useful as biomarkers for white matter damage. C1 [Ambalavanan, Namasivayam; Carlo, Waldemar A.] Univ Alabama Birmingham, Div Neonatol, Dept Pediat, Birmingham, AL 35249 USA. [McDonald, Scott A.; Das, Abhik] RTI Int, Res Triangle Pk, NC USA. [Schendel, Diana E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Thorsen, Poul] Lillebaelt Hosp, Dept Obstet & Gynecol, Kolding, Denmark. [Hougaard, David M.; Skogstrand, Kristin] Statens Serum Inst, DK-2300 Copenhagen, Denmark. [Higgins, Rosemary D.] NICHD Neonatal Res Network, Bethesda, MD USA. RP Ambalavanan, N (reprint author), Univ Alabama Birmingham, Div Neonatol, Dept Pediat, 176F Suite,9380 Women & Infants Ctr,619 S 19th St, Birmingham, AL 35249 USA. EM ambal@uab.edu OI Skogstrand, Kristin/0000-0002-0026-3711; Ambalavanan, Namasivayam/0000-0003-0731-9092 FU National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Centers for Disease Control and Prevention FX The National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the Centers for Disease Control and Prevention provided grant support for recruitment for 1999 to 2001 and data analysis for the Neonatal Research Network's Cytokines Study. NR 36 TC 2 Z9 3 U1 1 U2 5 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 0735-1631 J9 AM J PERINAT JI Am. J. Perinatol. PD OCT PY 2012 VL 29 IS 9 BP 731 EP 740 DI 10.1055/s-0032-1316443 PG 10 WC Obstetrics & Gynecology; Pediatrics SC Obstetrics & Gynecology; Pediatrics GA 006UY UT WOS:000308845900011 PM 22773292 ER PT J AU Kim, M Chang, SI Seong, JC Holt, JB Park, TH Ko, JH Croft, JB AF Kim, Minho Chang, Seo I. Seong, Jeong C. Holt, James B. Park, Tae H. Ko, Joon H. Croft, Janet B. TI Road Traffic Noise Annoyance, Sleep Disturbance, and Public Health Implications SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID EXPOSURE; HYPERTENSION; COMMUNITY; CITY AB Background: The WHO has recognized environmental noise as harmful pollution that causes adverse psychosocial and physiologic effects (i.e., annoyance and sleep disturbance) on human health. In Europe, noise-related health studies have been actively conducted, but the U.S. has lagged behind in this research field. Purpose: This research predicted ambient levels of road traffic noise for a highly urbanized area: Fulton County GA. Assessment was made of noise impacts on the population, focusing on annoyance and sleep disturbance. Methods: All the data sets were collected during 2009-2011, and data analysis was performed in 2010-2011. The study used a sound-propagation model for noise-level prediction and derived noise-impact indicators for annoyance and sleep disturbance from exposure-response models. Then, annoyed and sleep-disturbed populations were predicted with the use of each noise-impact indicator. Results: It was predicted that 109,967 people would be at risk of being highly annoyed, with 19,621 people at risk for high sleep disturbance for Fulton County GA. Noise-impact indicators such as the percentage of those who were highly annoyed and who had high levels of sleep disturbance were expected to be valuable metrics to compare noise equity among urban communities. Conclusions: Many residents of the greater Atlanta area may be exposed to noise levels that put them at risk of being highly annoyed or having high levels of sleep disturbance. These results, if generalized to other urban areas with high levels of road traffic, indicate that it may be important for the public's health to update existing noise-related policies or develop new ones to control and abate noise concerns in urban communities. (Am J Prev Med 2012;43(4):353-360) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Kim, Minho] Sangmyung Univ, Dept Geog, Seoul 110743, South Korea. [Chang, Seo I.; Park, Tae H.; Ko, Joon H.] Univ Seoul, Dept Environm Engn, Seoul, South Korea. [Holt, James B.; Croft, Janet B.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Epidemiol & Surveillance Branch, Div Populat Hlth, Atlanta, GA 30333 USA. [Seong, Jeong C.] Univ W Georgia, Dept Geosci, Carrollton, GA USA. RP Kim, M (reprint author), Sangmyung Univ, Dept Geog, 7 Hongji Dong, Seoul 110743, South Korea. EM mhkim73@gmail.com FU University of Seoul, Republic of Korea FX The authors thank Fulton County, the Georgia Department of Transportation, and the Atlanta Regional Commission for providing relevant data sets to be used in creating noise maps. The authors also thank Marie Urban at the Geographic Information and Science Technology Department of Oak Ridge National Laboratory for providing valuable comments on the LandScan U.S. population data set. SIC, THP, and JHK were supported by the 2011 Research Fund of the University of Seoul, Republic of Korea. This document has been reviewed in accordance with U.S. CDC policy and approved for publication. NR 33 TC 23 Z9 24 U1 1 U2 44 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2012 VL 43 IS 4 BP 353 EP 360 DI 10.1016/j.amepre.2012.06.014 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 011UT UT WOS:000309191600005 PM 22992352 ER PT J AU Liu, Y Mack, KA Diekman, ST AF Liu, Ying Mack, Karin A. Diekman, Shane T. TI Smoke Alarm Giveaway and Installation Programs An Economic Evaluation SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS; UNITED-STATES; HOUSEHOLDS; FUNCTIONALITY; INTERVENTIONS; PREVENTION; PREVALENCE; HEALTH; HOMES AB Background: The burden of residential fire injury and death is substantial. Targeted smoke alarm giveaway and installation programs are popular interventions used to reduce residential fire mortality and morbidity. Purpose: To evaluate the cost effectiveness and cost benefit of implementing a giveaway or installation program in a small hypothetic community with a high risk of fire death and injury through a decision-analysis model. Methods: Model inputs included program costs; program effectiveness (life-years and qualityadjusted life-years saved); and monetized program benefits (medical cost, productivity, property loss and quality-of-life losses averted) and were identified through structured reviews of existing literature (done in 2011) and supplemented by expert opinion. Future costs and effectiveness were discounted at a rate of 3% per year. All costs were expressed in 2011 U.S. dollars. Results: Cost-effectiveness analysis (CEA) resulted in an average cost-effectiveness ratio (ACER) of $51,404 per quality-adjusted life-years (QALYs) saved and $45,630 per QALY for the giveaway and installation programs, respectively. Cost-benefit analysis (CBA) showed that both programs were associated with a positive net benefit with a benefit-cost ratio of 2.1 and 2.3, respectively. Smoke alarm functional rate, baseline prevalence of functional alarms, and baseline home fire death rate were among the most influential factors for the CEA and CBA results. Conclusions: Both giveaway and installation programs have an average cost-effectiveness ratio similar to or lower than the median cost-effectiveness ratio reported for other interventions to reduce fatal injuries in homes. Although more effort is required, installation programs result in lower cost per outcome achieved compared with giveaways. (Am J Prev Med 2012;43(4):385-391) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Liu, Ying; Mack, Karin A.; Diekman, Shane T.] CDC, NCIPC, Atlanta, GA 30333 USA. RP Diekman, ST (reprint author), 4770 Buford Hwy NE,Mailstop F62, Atlanta, GA 30341 USA. EM scd0@cdc.gov RI Mack, Karin/A-3263-2012 OI Mack, Karin/0000-0001-9274-3001 FU Intramural CDC HHS [CC999999] NR 40 TC 3 Z9 3 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD OCT PY 2012 VL 43 IS 4 BP 385 EP 391 DI 10.1016/j.amepre.2012.06.021 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 011UT UT WOS:000309191600009 PM 22992356 ER PT J AU Hostetler, DM Dwivedi, P Green, MD Fernandez, FM AF Hostetler, Dana M. Dwivedi, Prabha Green, Michael D. Fernandez, Facundo M. TI High throughput quantitation of artesunate and its degradation products by flow injection gradient ratio standard addition mass spectrometry (FI-GRSA-MS) SO ANALYTICAL METHODS LA English DT Article ID ATOMIC-ABSORPTION-SPECTROMETRY; ANTIMALARIAL-DRUG; CALIBRATION; MALARIA; ARTEMISININ; DIHYDROARTEMISININ AB There is a pressing need to equip post-marketing drug quality surveillance systems with higher throughput and robust analytical tools that can reinforce pharmaceutical quality control to ensure safety of patients and integrity of treatment practices. This manuscript reports the development of a flow injection analysis mass spectrometry-based gradient ratio standard addition (FI-GRSA-MS) method for quantification of artesunate, a common antimalarial active pharmaceutical ingredient in a simple, efficient, accurate, and high throughput manner. Dodecylamine (DDA) was evaluated as an electrospray modifier for improving the sensitivity of the GRSA quantitation method. The linear dynamic range and precision for artesunate quantification were found to be 7 ng to 86 pg artesunate and 2.1%, respectively. When compared to high performance liquid chromatography, results were found to be equivalent at the 95% confidence level. To identify chemical markers of improper drug storage and artesunate degradation, tablets were artificially exposed to heat for time periods ranging between 1 and 12 hours and the degradation products detected were identified via accurate mass and isotopic cluster abundance measurements. Moreover, degradation behavior of artesunate tablets from two different manufacturers under identical degradation conditions was investigated, indicating that tablet formulation plays a significant role in the shelf life of these valuable medicines. C1 [Hostetler, Dana M.; Dwivedi, Prabha; Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Hostetler, Dana M.; Green, Michael D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Fernandez, FM (reprint author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. EM facundo.fernandez@chemistry.gatech.edu RI Fernandez, Facundo/B-7015-2008 FU ACT consortium via Bill and Melinda Gates Foundation FX The authors are grateful to the ACT consortium for funding their project to assess the quality of drugs in Africa via an award from the Bill and Melinda Gates Foundation to the London School of Hygiene and Tropical Medicine. NR 24 TC 2 Z9 2 U1 1 U2 10 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1759-9660 J9 ANAL METHODS-UK JI Anal. Methods PD OCT PY 2012 VL 4 IS 10 BP 3392 EP 3398 DI 10.1039/c2ay25443c PG 7 WC Chemistry, Analytical; Food Science & Technology; Spectroscopy SC Chemistry; Food Science & Technology; Spectroscopy GA 012LS UT WOS:000309238300049 ER PT J AU Treanor, JJ Talbot, HK Ohmit, SE Coleman, LA Thompson, MG Cheng, PY Petrie, JG Lofthus, G Meece, JK Williams, JV Berman, L Hall, CB Monto, AS Griffin, MR Belongia, E Shay, DK AF Treanor, John J. Talbot, H. Keipp Ohmit, Suzanne E. Coleman, Laura A. Thompson, Mark G. Cheng, Po-Yung Petrie, Joshua G. Lofthus, Geraldine Meece, Jennifer K. Williams, John V. Berman, LaShondra Hall, Caroline Breese Monto, Arnold S. Griffin, Marie R. Belongia, Edward Shay, David K. CA US Flu-VE Network TI Effectiveness of Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine Strains SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID YOUNG-CHILDREN; HEALTHY-ADULTS; EFFICACY; PREVENTION; TRIVALENT; TRIAL AB Background. Influenza vaccines may be reformulated annually because of antigenic drift in influenza viruses. However, the relationship between antigenic characteristics of circulating viruses and vaccine effectiveness (VE) is not well understood. We conducted an assessment of the effectiveness of US influenza vaccines during the 2010-2011 season. Methods. We performed a case-control study comparing vaccination histories between subjects with acute respiratory illness with positive real-time reverse transcription polymerase chain reaction for influenza and influenza test-negative controls. Subjects with acute respiratory illness of <= 7 days duration were enrolled in hospitals, emergency departments, or outpatient clinics in communities in 4 states. History of immunization with the 2010-2011 vaccine was ascertained from vaccine registries or medical records. Vaccine effectiveness was estimated in logistic regression models adjusted for study community, age, race, insurance status, enrollment site, and presence of a high-risk medical condition. Results. A total of 1040 influenza-positive cases and 3717 influenza-negative controls were included from the influenza season, including 373 cases of influenza A(H1N1), 334 cases of influenza A(H3N2), and 333 cases of influenza B. Overall adjusted VE was 60% (95% confidence interval [CI], 53%-66%). Age-specific VE estimates ranged from 69% (95% CI, 56%-77%) in children aged 6 months-8 years to 38% (95% CI, -16% to 67%) in adults aged >= 65 years. Conclusions. The US 2010-2011 influenza vaccines were moderately effective in preventing medically attended influenza during a season when all 3 vaccine strains were antigenically similar to circulating viruses. Continued monitoring of influenza vaccines in all age groups is important, particularly as new vaccines are introduced. C1 [Treanor, John J.; Lofthus, Geraldine; Hall, Caroline Breese] Univ Rochester, Med Ctr, Dept Med, New York, NY USA. [Talbot, H. Keipp; Williams, John V.; Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Med & Pediat, Nashville, TN 37212 USA. [Williams, John V.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA. [Griffin, Marie R.] VA Tennessee Valley Hlth Care Syst, Mids Geriatr Res Educ & Clin Ctr, Nashville, TN USA. [Ohmit, Suzanne E.; Petrie, Joshua G.; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Coleman, Laura A.; Meece, Jennifer K.; Belongia, Edward] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI 54449 USA. [Thompson, Mark G.; Cheng, Po-Yung; Berman, LaShondra; Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Treanor, JJ (reprint author), Univ Rochester, Med Ctr, Rm 3-6209,601 Elmwood Ave, Rochester, NY 14642 USA. EM john_treanor@urmc.rochester.edu RI Williams, John/F-6962-2010; OI Williams, John/0000-0001-8377-5175; Irving, Stephanie/0000-0001-7437-6797; Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention (CDC); Marshfield Clinic Research Foundation [U01 IP000183]; University of Michigan [U01 IP000170]; University of Rochester [U01 IP000172]; Vanderbilt University [U01 IP000184]; NIAID [1K23AI074863-01]; Sanofi; GlaxoSmithKline (GSK); Protein Sciences; Vaxinnate; Sanofi Pasteur; Medimmune FX This study was funded by the Centers for Disease Control and Prevention (CDC) through cooperative agreements with the Marshfield Clinic Research Foundation (U01 IP000183), the University of Michigan (U01 IP000170), the University of Rochester (U01 IP000172), and Vanderbilt University (U01 IP000184). Internal CDC funds were used to support CDC investigators and to provide laboratory validation of RT-PCR methods at the enrolling site laboratories. As part of the cooperative agreement, CDC investigators participated in study design, analysis, decision to publish, and preparation of the manuscript. H. K. T. received salary support from the NIAID (1K23AI074863-01).; J. T. reports grant or clinical trial support from Sanofi, GlaxoSmithKline (GSK), Protein Sciences, and Vaxinnate, and is on the scientific advisory boards of Novartis and Immune Targeting Systems. H. K. T. has clinical trial support from Sanofi Pasteur. S. E. O. has clinical trial support and royalty income from Sanofi. J. V. W. is on the scientific advisory boards of MedImmune and Quidel. C. B. H. has performed consulting work for Medimmune and GSK. A. S. M. has grant support from Sanofi and is a consultant for GSK and Novartis. E. B. has grant support from Medimmune. All other authors: No potential conflicts. NR 21 TC 113 Z9 114 U1 1 U2 20 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2012 VL 55 IS 7 BP 951 EP 959 DI 10.1093/cid/cis574 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 002JI UT WOS:000308527500014 PM 22843783 ER PT J AU Mahamud, A Marin, M Nickell, SP Shoemaker, T Zhang, JX Bialek, SR AF Mahamud, Abdirahman Marin, Mona Nickell, Steven P. Shoemaker, Trevor Zhang, John X. Bialek, Stephanie R. TI Herpes Zoster-Related Deaths in the United States: Validity of Death Certificates and Mortality Rates, 1979-2007 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID CORONARY-HEART-DISEASE; OLDER-ADULTS; VARICELLA; ACCURACY; VACCINE; IMMUNIZATION; COMPLETION; HOSPITALS; TRENDS; IMPACT AB Background. Herpes zoster (HZ) vaccine was recommended in the United States to reduce HZ-associated morbidity. Vaccination may reduce HZ-associated mortality, but no strategy exists to monitor mortality trends. Methods. We validated HZ coding on death certificates from California, using hospital records as the gold standard, and applied the results to national-level data to estimate HZ mortality. Results. In the validation phase of the study, among 40 available hospital records listing HZ as the underlying cause of death, HZ was the underlying cause for 21 (52.5%) and a contributing cause for 5 (12.5%). Among the 21 hospital records listing HZ as the underlying cause of death, the median age of decedents was 84 years (range, 50-99); 60% had no contraindications for HZ vaccination. Of the 37 available records listing HZ as a contributing cause of death, HZ was a contributing cause for 2 (5.4%) and the underlying cause for 6 (16.2%). Nationally, in the 7 years preceding the HZ vaccination program, the average annual number of deaths in which HZ was reported as the underlying cause of death was 149; however, based on our validation study, we estimate the true number was 78 (range, 31-118). Conclusions. National death certificate data greatly overestimate deaths in which HZ is the underlying or contributing cause of death. The HZ vaccination program could prevent some HZ-related deaths, but the impact will be difficult to assess using national mortality data. C1 [Mahamud, Abdirahman; Marin, Mona; Zhang, John X.; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Med, Atlanta, GA 30333 USA. [Mahamud, Abdirahman] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Nickell, Steven P.; Shoemaker, Trevor] Calif Dept Publ Hlth, Immunizat Branch, Richmond, CA USA. RP Mahamud, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Med, 1600 Clifton Rd NE,MS A-47, Atlanta, GA 30333 USA. EM amahamud@cdc.gov FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. NR 26 TC 5 Z9 6 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2012 VL 55 IS 7 BP 960 EP 966 DI 10.1093/cid/cis575 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 002JI UT WOS:000308527500015 PM 22715169 ER PT J AU Kwan, CK Al-Samarrai, T Smith, LC Sabharwal, CJ Valente, KA Torian, LV McMurdo, LM Shepard, CW Brooks, JT Kuehnert, MJ AF Kwan, Candice K. Al-Samarrai, Teeb Smith, Lou C. Sabharwal, Charulata J. Valente, Kim A. Torian, Lucia V. McMurdo, Lisa M. Shepard, Colin W. Brooks, John T. Kuehnert, Matthew J. TI HIV Screening Practices for Living Organ Donors, New York State, 2010: Need for Standard Policies SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACID TESTING NAT; KIDNEY-TRANSPLANTATION; TRANSMISSION; RECIPIENTS; INFECTION; OUTCOMES AB Our survey of kidney and liver transplant centers in New York State found a wide variation among transplant centers in evaluation and screening for HIV risk and infection among prospective living donors. Survey results underscore the need to standardize practices. A recent transmission of human immunodeficiency virus (HIV) from a living donor to a kidney recipient revealed a possible limitation in existing screening protocols for HIV infection in living donors. We surveyed kidney and liver transplant centers (N = 18) in New York State to assess HIV screening protocols for living donors. Although most transplant centers evaluated HIV risk behaviors in living donors, evaluation practices varied widely, as did the extent of HIV testing and prevention counseling. All centers screened living donors for serologic evidence of HIV infection, either during initial evaluation or >= 1 month before surgery; however, only 50% of transplant centers repeated HIV testing within 14 days before surgery for all donors or donors with specific risk behaviors. Forty-four percent of transplant centers used HIV nucleic acid testing (NAT) to screen either all donors or donors with recognized risk behaviors, and 55% never performed HIV NAT. Results suggest the need to standardize evaluation of HIV risk behaviors and prevention counseling in New York State to prevent acquisition of HIV by prospective living organ donors, and to conduct HIV antibody testing and NAT as close to the time of donation as possible to prevent HIV transmission to recipients. C1 [Kwan, Candice K.; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Kwan, Candice K.; Al-Samarrai, Teeb] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Al-Samarrai, Teeb; Sabharwal, Charulata J.; Torian, Lucia V.; Shepard, Colin W.] New York City Dept Hlth & Mental Hyg, Albany, NY USA. [Smith, Lou C.; Valente, Kim A.; McMurdo, Lisa M.] New York State Dept Hlth, Albany, NY USA. [Kuehnert, Matthew J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Kwan, CK (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-45, Atlanta, GA 30333 USA. EM candicekwan@post.harvard.edu NR 16 TC 3 Z9 3 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2012 VL 55 IS 7 BP 990 EP 995 DI 10.1093/cid/cis555 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 002JI UT WOS:000308527500020 PM 22752517 ER PT J AU Cohen, C Simonsen, L Sample, J Kang, JW Miller, M Madhi, SA Campsmith, M Viboud, C AF Cohen, Cheryl Simonsen, Lone Sample, Jeannette Kang, Jong-Won Miller, Mark Madhi, Shabir A. Campsmith, Michael Viboud, Cecile TI Influenza-Related Mortality Among Adults Aged 25-54 Years With AIDS in South Africa and the United States of America SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; RESPIRATORY-TRACT INFECTIONS; PANDEMIC PREPAREDNESS; EXCESS MORTALITY; HIV-INFECTION; VACCINATION; PNEUMONIA; MORBIDITY; IMPACT; RECOMMENDATIONS AB Background. Data are limited on human immunodeficiency virus (HIV)-associated influenza burden in sub-Saharan Africa and the impact of highly active antiretroviral therapy (HAART). We compared influenza-related mortality in adults with AIDS in South Africa and the United States in the pre-HAART era and evaluated mortality trends after HAART introduction in the United States. Methods. Monthly all-cause and pneumonia and influenza (P&I) mortality rates were compiled for adults with AIDS aged 25-54 years in South Africa (1998-2005) and the United States (pre-HAART era, 1987-1994; HAART era, 1997-2005). We estimated influenza-related deaths as excess mortality above a model baseline during influenza epidemic periods. Influenza-related mortality rates in adults with AIDS were compared with rates for age peers in the general population and adults >= 65 years old. Results. In the United States before HAART, influenza-related mortality rates in adults with AIDS were 150 (95% confidence interval [CI], 49-460) and 208 (95% CI, 74-583) times greater than in the general population for all-cause and P&I deaths, respectively, and 2.5 (95% CI, 0.9-7.2) and 4.1 (95% CI, 1.4-13) times higher than in elderly adults. After HAART introduction, influenza-related mortality in adults with AIDS dropped 3-6-fold but remained elevated compared with the general population (all-cause relative risk [RR], 44 [95% CI, 16-121]); P& I RR, 73 [95% CI, 47-113]). Influenza-related mortality in South African adults with AIDS in recent years was similar to that in the United States in the pre-HAART era. Conclusions. Adults with AIDS experience substantially elevated influenza-associated mortality, which declines with widespread HAART introduction but does not disappear. These data support increased access to HAART and influenza vaccination for HIV-infected adults. C1 [Cohen, Cheryl] Univ Witwatersrand, Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa. [Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Madhi, Shabir A.] Univ Witwatersrand, Natl Res Fdn, Dept Sci & Technol, Johannesburg, South Africa. [Simonsen, Lone; Kang, Jong-Won; Miller, Mark; Viboud, Cecile] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Simonsen, Lone; Sample, Jeannette] George Washington Univ, Dept Global Hlth, Washington, DC USA. [Campsmith, Michael] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kang, Jong-Won] Chungbuk Natl Univ, Coll Med, Dept Prevent Med, Chonju, South Korea. RP Cohen, C (reprint author), Natl Inst Communicable Dis, Epidemiol & Surveillance Unit, Private Bag X4, ZA-2131 Johannesburg, Gauteng, South Africa. EM cherylc@nicd.ac.za OI Simonsen, Lone/0000-0003-1535-8526 FU RAPIDD program of the Science & Technology Directorate, Department of Homeland Security; Fogarty International Center; National Institutes of Health; Wyeth-Pfizer; SDI Health FX This work was supported in part by the RAPIDD program of the Science & Technology Directorate, Department of Homeland Security, and Fogarty International Center, National Institutes of Health (to L. S.). No other external funding was obtained for this publication. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; L. S. has received funding for a research study from Wyeth-Pfizer and consulting fees from SDI Health, a data warehouse business in Plymouth Meeting, Pennsylvania. All other authors report no potential conflicts. NR 36 TC 34 Z9 34 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2012 VL 55 IS 7 BP 996 EP 1003 DI 10.1093/cid/cis549 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 002JI UT WOS:000308527500021 PM 22715173 ER PT J AU Tourdjman, M Ibraheem, M Brett, M DeBess, E Progulske, B Ettestad, P McGivern, T Petersen, J Mead, P AF Tourdjman, Mathieu Ibraheem, Mam Brett, Meghan DeBess, Emilio Progulske, Barbara Ettestad, Paul McGivern, Teresa Petersen, Jeannine Mead, Paul TI Misidentification of Yersinia pestis by Automated Systems, Resulting in Delayed Diagnoses of Human Plague Infections-Oregon and New Mexico, 2010-2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article C1 [Tourdjman, Mathieu] Acute & Commun Dis Prevent, Oregon Publ Hlth Div, Oregon Hlth Author, Portland, OR 97232 USA. [Tourdjman, Mathieu; Ibraheem, Mam; Brett, Meghan] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Ibraheem, Mam; Ettestad, Paul] New Mexico Dept Hlth, Santa Fe, NM USA. [Brett, Meghan; Petersen, Jeannine; Mead, Paul] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Dis, Ft Collins, CO USA. [McGivern, Teresa] Oregon State Publ Hlth Lab, Hillsboro, OR USA. RP Tourdjman, M (reprint author), Acute & Commun Dis Prevent, Oregon Publ Hlth Div, Oregon Hlth Author, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA. EM mathieu.tourdjman@free.fr NR 9 TC 7 Z9 7 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD OCT 1 PY 2012 VL 55 IS 7 BP E58 EP E60 DI 10.1093/cid/cis578 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 002JI UT WOS:000308527500005 PM 22715170 ER PT J AU Haddad, L Gallo, MF Jamieson, DJ Macaluso, M AF Haddad, Lisa Gallo, Maria F. Jamieson, Denise J. Macaluso, Maurizio TI Condom type may influence sexual behavior and ejaculation and complicate the assessment of condom functionality SO CONTRACEPTION LA English DT Article DE Condoms; Effectiveness; Prostate-specific antigen, Ejaculation ID PROSTATE-SPECIFIC ANTIGEN; FEMALE CONDOM; POLYURETHANE CONDOM; LATEX CONDOM; VAGINAL INTERCOURSE; FAILURE; BREAKAGE; SEMEN; SLIPPAGE; EXPOSURE AB Background: Studies that evaluate condom effectiveness are affected by factors related to how the condom was used, and these factors may not be consistent between different types of condoms. Also, subjective assessments of the sexual act may be unreliable. Study Design: We performed a secondary data analysis of a randomized crossover trial of male and female condoms among 108 couples. Results: Self-reported duration and activeness of coital acts were significantly different for uses of the male condom compared to uses of the female condom. Fewer individuals reported ejaculation occurring with the female condom. Reliability of self-reports of ejaculation compared to a biological marker of semen detected inside the used male and female condoms was not strong. Conclusions: We found that sexual behaviors appear to differ by the type of condom used for the coital act. Studies should consider sexual behavior when evaluating condom effectiveness. Furthermore, studies would be strengthened by the use of a biological marker of semen to determine whether ejaculation, and therefore a true risk of exposure, occurred. (C) 2012 Elsevier Inc. All rights reserved. C1 [Haddad, Lisa] Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30303 USA. [Gallo, Maria F.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Macaluso, Maurizio] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA. RP Haddad, L (reprint author), Emory Univ, Sch Med, Dept Gynecol & Obstet, Atlanta, GA 30303 USA. EM lbhadda@emory.edu RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 FU Centers for Disease Control and Prevention [S0747-18/19]; Association of Schools of Public Health [S0747-18/19] FX This study was supported by cooperative agreement S0747-18/19 between the Centers for Disease Control and Prevention and the Association of Schools of Public Health. NR 28 TC 0 Z9 0 U1 3 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD OCT PY 2012 VL 86 IS 4 BP 391 EP 396 DI 10.1016/j.contraception.2012.01.016 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 011FO UT WOS:000309150600013 PM 22445432 ER PT J AU Oluoch, T Santas, X Kwaro, D Were, M Biondich, P Bailey, C Abu-Hanna, A de Keizer, N AF Oluoch, Tom Santas, Xenophon Kwaro, Daniel Were, Martin Biondich, Paul Bailey, Christopher Abu-Hanna, Ameen de Keizer, Nicolette TI The effect of electronic medical record-based clinical decision support on HIV care in resource-constrained settings: A systematic review SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS LA English DT Review DE Electronic medical records; Clinical decision support systems; HIV; Treatment guidelines; Developing countries; Systematic review ID FOLLOW-UP; QUALITY; MANAGEMENT; GUIDELINE; REMINDERS; IMPACT AB Background: It is estimated that one million people infected with HIV initiate anti-retroviral therapy (ART) in resource-constrained countries annually. This occurs against a background of overburdened health workers with limited skills to handle rapidly changing treatment standards and guidelines hence compromising quality of care. Electronic medical record (EMR)-based clinical decision support systems (CDSS) are considered a solution to improve quality of care. Little evidence, however, exists on the effectiveness of EMR-based CDSS on quality of HIV care and treatment in resource-constrained settings. Objective: The aim of this systematic review was to identify original studies on EMR-based CDSS describing process and outcome measures as well as reported barriers to their implementation in resource-constrained settings. We characterized the studies by guideline adherence, data and process, and barriers to CDSS implementation. Methods: Two reviewers independently assessed original articles from a search of the MEDLINE, EMBASE, CINAHL and Global Health Library databases until January 2012. The included articles were those that evaluated or described the implementation of EMR-based CDSS that were used in HIV care in low-income countries. Results: A total of 12 studies met the inclusion criteria, 10 of which were conducted in sub-Saharan Africa and 2 in the Caribbean. None of the papers described a strong (randomized controlled) evaluation design. Guideline adherence: One study showed that ordering rates for CD4 tests were significantly higher when reminders were used. Data and process: Studies reported reduction in data errors, reduction in missed appointments, reduction in missed CD4 results and reduction in patient waiting time. Two studies showed a significant increase in time spent by clinicians on direct patient care. Barriers to CDSS implementation: Technical infrastructure problems such as unreliable electric power and erratic Internet connectivity, clinicians' limited computer skills and failure by providers to comply with the reminders are key impediments to the implementation and effective use of CDSS. The limited number of evaluation studies, the basic and heterogeneous study designs, and varied outcome measures make it difficult to meaningfully conclude on the effectiveness of CDSS on quality of HIV care and treatment in resource-limited settings. High quality evaluation studies are needed. Factors specific to implementation of EMR-based CDSS in resource-limited setting should be addressed before such countries can demonstrate its full benefits. More work needs to be done to overcome the barriers to EMR and CDSS implementation in developing countries such as technical infrastructure and care providers' computer illiteracy. However, simultaneously evaluating and describing CDSS implementation strategies that work can further guide wise investments in their wider rollout. Published by Elsevier Ireland Ltd C1 [Oluoch, Tom] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Nairobi 00621, Kenya. [Santas, Xenophon] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. [Kwaro, Daniel] CDC Collaborat Program, Kenya Med Res Inst, Kisumu, Kenya. [Were, Martin; Biondich, Paul] Indiana Univ Sch Med, Regenstrief Inst Inc, Indianapolis, IN USA. [Bailey, Christopher] WHO, Knowledge Management Div, CH-1211 Geneva, Switzerland. [Abu-Hanna, Ameen; de Keizer, Nicolette] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. RP Oluoch, T (reprint author), US Ctr Dis Control & Prevent, Div Global HIV AIDS, POB 606, Nairobi 00621, Kenya. EM toluoch@ke.cdc.gov OI Oluoch, Tom/0000-0001-9621-5900 NR 38 TC 24 Z9 24 U1 3 U2 24 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 1386-5056 J9 INT J MED INFORM JI Int. J. Med. Inform. PD OCT PY 2012 VL 81 IS 10 BP E83 EP E92 DI 10.1016/j.ijmedinf.2012.07.010 PG 10 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA 008SE UT WOS:000308976000010 PM 22921485 ER PT J AU Schendel, DE DiGuiseppi, C Croen, LA Fallin, MD Reed, PL Schieve, LA Wiggins, LD Daniels, J Grether, J Levy, SE Miller, L Newschaffer, C Pinto-Martin, J Robinson, C Windham, GC Alexander, A Aylsworth, AS Bernal, P Bonner, JD Blaskey, L Bradley, C Collins, J Ferretti, CJ Farzadegan, H Giarelli, E Harvey, M Hepburn, S Herr, M Kaparich, K Landa, R Lee, LC Levenseller, B Meyerer, S Rahbar, MH Ratchford, A Reynolds, A Rosenberg, S Rusyniak, J Shapira, SK Smith, K Souders, M Thompson, PA Young, L Yeargin-Allsopp, M AF Schendel, Diana E. DiGuiseppi, Carolyn Croen, Lisa A. Fallin, M. Daniele Reed, Philip L. Schieve, Laura A. Wiggins, Lisa D. Daniels, Julie Grether, Judith Levy, Susan E. Miller, Lisa Newschaffer, Craig Pinto-Martin, Jennifer Robinson, Cordelia Windham, Gayle C. Alexander, Aimee Aylsworth, Arthur S. Bernal, Pilar Bonner, Joseph D. Blaskey, Lisa Bradley, Chyrise Collins, Jack Ferretti, Casara J. Farzadegan, Homayoon Giarelli, Ellen Harvey, Marques Hepburn, Susan Herr, Matthew Kaparich, Kristina Landa, Rebecca Lee, Li-Ching Levenseller, Brooke Meyerer, Stacey Rahbar, Mohammad H. Ratchford, Andria Reynolds, Ann Rosenberg, Steven Rusyniak, Julie Shapira, Stuart K. Smith, Karen Souders, Margaret Thompson, Patrick Aaron Young, Lisa Yeargin-Allsopp, Marshalyn TI The Study to Explore Early Development (SEED): A Multisite Epidemiologic Study of Autism by the Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE) Network SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism; Epidemiology; Study methods; Risk factors; Phenotype ID PERINATAL RISK-FACTORS; SOCIAL COMMUNICATION QUESTIONNAIRE; DIAGNOSTIC OBSERVATION SCHEDULE; HAZARDOUS AIR-POLLUTANTS; SPECTRUM DISORDERS; INFANTILE-AUTISM; TWIN PAIRS; CYTOMEGALOVIRUS-INFECTION; GASTROINTESTINAL SYMPTOMS; ENVIRONMENTAL-FACTORS AB The Study to Explore Early Development (SEED), a multisite investigation addressing knowledge gaps in autism phenotype and etiology, aims to: (1) characterize the autism behavioral phenotype and associated developmental, medical, and behavioral conditions and (2) investigate genetic and environmental risks with emphasis on immunologic, hormonal, gastrointestinal, and sociodemographic characteristics. SEED uses a case-control design with population-based ascertainment of children aged 2-5 years with an autism spectrum disorder (ASD) and children in two control groups-one from the general population and one with non-ASD developmental problems. Data from parent-completed questionnaires, interviews, clinical evaluations, biospecimen sampling, and medical record abstraction focus on the prenatal and early postnatal periods. SEED is a valuable resource for testing hypotheses regarding ASD characteristics and causes. C1 [Schendel, Diana E.; Croen, Lisa A.; Wiggins, Lisa D.; Alexander, Aimee; Harvey, Marques; Shapira, Stuart K.; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [DiGuiseppi, Carolyn] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Croen, Lisa A.; Collins, Jack] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Fallin, M. Daniele; Farzadegan, Homayoon; Lee, Li-Ching; Meyerer, Stacey] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Reed, Philip L.; Bonner, Joseph D.; Thompson, Patrick Aaron] Michigan State Univ, Clin & Translat Sci Inst, E Lansing, MI 48824 USA. [Daniels, Julie; Bradley, Chyrise; Herr, Matthew] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Daniels, Julie] Univ N Carolina, Dept Maternal & Child Hlth, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA. [Grether, Judith; Windham, Gayle C.; Smith, Karen] CA Dept Publ Hlth, Div Environm & Occupat Dis Control, Oakland, CA USA. [Levy, Susan E.; Blaskey, Lisa; Ferretti, Casara J.] Childrens Hosp Philadelphia, Ctr Autism, Philadelphia, PA 19104 USA. [Miller, Lisa; Ratchford, Andria] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Newschaffer, Craig] Drexel Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Philadelphia, PA 19104 USA. [Pinto-Martin, Jennifer; Giarelli, Ellen; Levenseller, Brooke; Souders, Margaret; Young, Lisa] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Pinto-Martin, Jennifer] Sch Med, Philadelphia, PA USA. [Robinson, Cordelia; Hepburn, Susan; Kaparich, Kristina; Reynolds, Ann; Rosenberg, Steven] Univ Colorado, Sch Med, Denver, CO USA. [Aylsworth, Arthur S.] Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC USA. [Aylsworth, Arthur S.] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC USA. [Bernal, Pilar] Kaiser Permanente No Calif, Autism Spectrum Disorders Ctr, San Jose Med Ctr, Oakland, CA USA. [Rahbar, Mohammad H.] Univ Texas Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA. [Landa, Rebecca; Rusyniak, Julie] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA. [Landa, Rebecca; Rusyniak, Julie] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD USA. RP Schendel, DE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM dschendel@cdc.gov OI Reynolds, Ann/0000-0002-0836-746X FU Intramural CDC HHS [CC999999]; NCBDD CDC HHS [U10DD000180, U10DD000181, U10DD000182, U10DD000183, U10DD000184, U10DD000498] NR 104 TC 18 Z9 19 U1 7 U2 34 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD OCT PY 2012 VL 42 IS 10 BP 2121 EP 2140 DI 10.1007/s10803-012-1461-8 PG 20 WC Psychology, Developmental SC Psychology GA 010ZR UT WOS:000309133600009 PM 22350336 ER PT J AU Hinkle, SN Sharma, AJ Swan, DW Schieve, LA Ramakrishnan, U Stein, AD AF Hinkle, Stefanie N. Sharma, Andrea J. Swan, Deanne W. Schieve, Laura A. Ramakrishnan, Usha Stein, Aryeh D. TI Excess Gestational Weight Gain Is Associated with Child Adiposity among Mothers with Normal and Overweight Prepregnancy Weight Status SO JOURNAL OF NUTRITION LA English DT Article ID BODY-MASS INDEX; BIRTH CERTIFICATE DATA; ENERGY-INTAKE; US CHILDREN; OFFSPRING ADIPOSITY; OBESITY; PREGNANCY; TRENDS; RISK; FOOD AB There are inconsistencies in the literature regarding the association between gestational weight gain (GWG) and child adiposity. GWG is hypothesized to act on child adiposity directly through intrauterine programming and indirectly through birth weight. It is unclear if the relative importance of these pathways differs by prepregnancy BMI status. We analyzed data from 3600 participants of the nationally representative Early Childhood Longitudinal Study-Birth Cohort. Child BMI Z-score was calculated from height and weight measured at 5 y. Using linear regression, controlling for sociodemographics and family lifestyle, we examined prepregnancy BMI-specific associations between GWG and child BMI Z-score. There was a nonlinear association among normal (P < 0.001) and overweight mothers only (P = 0.013), such that GWG beyond the midpoint of the 2009 Institute of Medicine recommendations was associated with a significant increase in child BMI Z-score. After the addition of birth-weight-for-gestational-age and breastfeeding to the model, the association remained among normal-weight mothers (P = 0.005) and was slightly attenuated among overweight mothers (P = 0.09). No significant association was observed between GWG and child BM) Z-score among underweight or obese mothers. We used path analysis to decompose the total effect into direct and indirect effects. This indicated the presence of a stronger direct than indirect effect. In conclusion, low GWG is not associated with BMI Z-score among any prepregnancy BMI group. Excess GWG is associated with an increase in child BMI Z-score among normal and overweight mothers only. Prevention of excess GWG may be a strategy to prevent childhood obesity. J. Nutr. 142: 1851-1858, 2012. C1 [Hinkle, Stefanie N.; Sharma, Andrea J.; Ramakrishnan, Usha; Stein, Aryeh D.] Emory Univ, Div Biol & Biomed Sci, Atlanta, GA 30322 USA. [Hinkle, Stefanie N.; Sharma, Andrea J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Sharma, Andrea J.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. [Swan, Deanne W.; Ramakrishnan, Usha; Stein, Aryeh D.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Schieve, Laura A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Sharma, AJ (reprint author), Emory Univ, Div Biol & Biomed Sci, Atlanta, GA 30322 USA. EM AJSharma@cdc.gov RI Hinkle, Stefanie/F-8253-2013; Ramakrishnan, Usha/L-8921-2016; OI Hinkle, Stefanie/0000-0003-4312-708X; Stein, Aryeh/0000-0003-1138-6458; Sharma, Andrea/0000-0003-0385-0011 FU CDC; Oak Ridge Institute for Science and Education [DE-AC05-06OR23100] FX Supported in part under an appointment to the CDC, administered by the Oak Ridge Institute for Science and Education under contract no. DE-AC05-06OR23100 between the U.S. Department of Energy and Oak Ridge Associated Universities. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. NR 55 TC 29 Z9 29 U1 2 U2 12 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD OCT PY 2012 VL 142 IS 10 BP 1851 EP 1858 DI 10.3945/jn.112.161158 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 009NH UT WOS:000309032000010 PM 22955516 ER PT J AU Asay, GRB Cho, BH Lorick, SA Tipton, ML Dube, NL Messonnier, ML AF Asay, Garrett R. Beeler Cho, Bo-Hyun Lorick, Suchita A. Tipton, Meredith L. Dube, Nancy L. Messonnier, Mark L. TI Coordination Costs for School-Located Influenza Vaccination Clinics, Maine, 2009 H1N1 Pandemic SO JOURNAL OF SCHOOL NURSING LA English DT Article DE influenza; vaccination; pandemic; H1N1; school nurse; economic evaluation; school-located vaccination clinics ID UNITED-STATES; CHILDREN AB School nurses played a key role in Maine's school-located influenza vaccination (SLV) clinics during the 2009-2010 pandemic season. The objective of this study was to determine, from the school district perspective, the labor hours and costs associated with outside-clinic coordination activities (OCA). The authors defined OCA as labor hours spent by staff outside of clinic operations. The authors surveyed a convenience sample of 10 school nurses from nine school districts. Eight nurses responded to the survey, representing seven districts, 45 schools and 84 SLV clinics that provided a total of 22,596 vaccine doses (H1N1 and seasonal combined) to children and adolescents. The mean total OCA time per clinic was 69 hours: out of total hours, 22 (36%) were spent outside regular clinic operation time. The authors estimated the mean cost of OCA to be $15.36 per dose. Survey respondents reported that costs would be lower during non-pandemic seasons and as schools become more proficient at planning clinics. C1 [Asay, Garrett R. Beeler; Lorick, Suchita A.; Messonnier, Mark L.] Ctr Dis Control & Prevent, Hlth Serv Res & Evaluat Branch, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Cho, Bo-Hyun] Carter Consulting Inc, Atlanta, GA USA. [Tipton, Meredith L.] Tipton Enterprizes Inc, Portland, ME USA. [Dube, Nancy L.] Maine Dept Educ, Augusta, ME USA. RP Asay, GRB (reprint author), Ctr Dis Control & Prevent, Hlth Serv Res & Evaluat Branch, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM hrp9@cdc.gov NR 26 TC 4 Z9 4 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1059-8405 J9 J SCH NURS JI J. Sch. Nurs. PD OCT PY 2012 VL 28 IS 5 BP 328 EP 335 DI 10.1177/1059840512448676 PG 8 WC Nursing SC Nursing GA 011CK UT WOS:000309140800002 PM 22691394 ER PT J AU Cho, BH Asay, GRB Lorick, SA Tipton, ML Dube, NL Messonnier, ML AF Cho, Bo-Hyun Asay, Garrett R. Beeler Lorick, Suchita A. Tipton, Meredith L. Dube, Nancy L. Messonnier, Mark L. TI Costs of School-Located Influenza Vaccination Clinics in Maine During the 2009-2010 H1N1 Pandemic SO JOURNAL OF SCHOOL NURSING LA English DT Article DE influenza vaccination; 2009 H1N1; pandemic; influenza; school nurse; cost evaluation; school-located vaccination clinics ID CHILDREN; IMMUNIZATION; ABSENTEEISM AB This study retrospectively estimated costs for a convenience sample of school-located vaccination (SLV) clinics conducted in Maine during the 2009-2010 influenza season. Surveys were developed to capture the cost of labor including unpaid volunteers as well as supplies and materials used in SLV clinics. Six nurses from different school districts completed a clinic day survey on staff time; four of the six also provided data for materials and supplies. For all clinics, average per-dose labor cost was estimated at $5.95. Average per-dose material cost, excluding vaccine, was $5.76. From the four complete clinic survey responses, total per-dose cost was estimated to be an average of $13.51 (range $4.91-$32.39). Use of donated materials and uncompensated volunteer staff could substantially reduce per-dose cost. Average per-dose cost could also be lowered by increasing the number of doses administered in a clinic. C1 [Cho, Bo-Hyun] Carter Consulting Inc, Atlanta, GA USA. [Asay, Garrett R. Beeler; Lorick, Suchita A.; Messonnier, Mark L.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Tipton, Meredith L.] Tipton Enterprises Inc, Portland, ME USA. [Dube, Nancy L.] Maine Dept Educ, Sch Nurse, Augusta, ME USA. [Asay, Garrett R. Beeler; Lorick, Suchita A.] Ctr Dis Control & Prevent, Hlth Serv Res & Evaluat Branch, Immunizat Serv Div, Atlanta, GA USA. [Messonnier, Mark L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Cho, BH (reprint author), 1600 Clifton Rd NE,Mailstop A19, Atlanta, GA 30333 USA. EM bcho@cdc.gov NR 24 TC 5 Z9 5 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1059-8405 J9 J SCH NURS JI J. Sch. Nurs. PD OCT PY 2012 VL 28 IS 5 BP 336 EP 343 DI 10.1177/1059840512457049 PG 8 WC Nursing SC Nursing GA 011CK UT WOS:000309140800003 PM 22914801 ER PT J AU Christensen, JJ Humiston, SG Long, CE Kennedy, AM DiMattia, K Kolasa, MS AF Christensen, Julie J. Humiston, Sharon G. Long, Christine E. Kennedy, Allison M. DiMattia, Kimberly Kolasa, Maureen S. TI Assessing the Acceptability and Feasibility of a School-Located Influenza Vaccination Program With Third-Party Billing in Elementary Schools SO JOURNAL OF SCHOOL NURSING LA English DT Article DE health/wellness; immunizations; community; elementary; coordinated school health program; program development /evaluation; school-based clinics; qualitative research ID YOUNG-CHILDREN; OUTPATIENT VISITS; IMMUNIZATION; HOSPITALIZATIONS; BURDEN AB This study qualitatively assesses the acceptability and feasibility of a school-located vaccination for influenza (SLIV) project that was conducted in New York State in 2009-2011, from the perspectives of project participants with different roles. Fourteen in-depth semistructured interviews with participating schools' personnel and the mass vaccinator were tape-recorded and transcribed. Interviewees were randomly selected from stratified lists and included five principals, five school nurses, two school administrators, and two lead personnel from the mass vaccinator. A content analysis of transcripts from the interviews was completed and several themes emerged. All participants generally found the SLIV project acceptable. School personnel and the vaccinator viewed the SLIV project process as feasible and beneficial. However, the vaccinator identified difficulties with third-party billing as a potential threat to sustainability. C1 [Humiston, Sharon G.] Childrens Mercy Hosp & Clin, Dept Pediat, Kansas City, MO USA. [Christensen, Julie J.] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA. [Long, Christine E.; DiMattia, Kimberly] Univ Rochester, Med Ctr, Ctr Community Hlth, Rochester, NY 14642 USA. [Kennedy, Allison M.; Kolasa, Maureen S.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Humiston, SG (reprint author), Childrens Mercy Hosp & Clin, Dept Pediat, Kansas City, MO USA. EM sghumiston@cmh.edu FU Centers for Disease Control and Prevention [GRANT00439262] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Centers for Disease Control and Prevention [Federal Identifier: GRANT00439262]. NR 15 TC 3 Z9 3 U1 2 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1059-8405 J9 J SCH NURS JI J. Sch. Nurs. PD OCT PY 2012 VL 28 IS 5 BP 344 EP 351 DI 10.1177/1059840512452667 PG 8 WC Nursing SC Nursing GA 011CK UT WOS:000309140800004 PM 22786984 ER PT J AU Davis, LL Wright, JS AF Davis, Leslie L. Wright, Janet S. TI The Million Hearts (TM) Initiative: How nurse practitioners can help lead SO JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS LA English DT Editorial Material C1 [Davis, Leslie L.] Univ N Carolina, Greensboro, NC 27412 USA. [Davis, Leslie L.] Univ N Carolina, Chapel Hill, NC USA. [Wright, Janet S.] CDC, Mill Hearts CMS Innovat Ctr, Baltimore, MD USA. RP Davis, LL (reprint author), Univ N Carolina, Greensboro, NC 27412 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1041-2972 J9 J AM ACAD NURSE PRAC JI J. Am. Acad. Nurse Pract. PD OCT PY 2012 VL 24 IS 10 BP 565 EP 568 DI 10.1111/j.1745-7599.2012.00774.x PG 4 WC Health Care Sciences & Services; Nursing SC Health Care Sciences & Services; Nursing GA 011TU UT WOS:000309188900001 PM 23006013 ER PT J AU Carter, SD Surtees, R Walter, CT Ariza, A Bergeron, E Nichol, ST Hiscox, JA Edwards, TA Barr, JN AF Carter, Stephen D. Surtees, Rebecca Walter, Cheryl T. Ariza, Antonio Bergeron, Eric Nichol, Stuart T. Hiscox, Julian A. Edwards, Thomas A. Barr, John N. TI Structure, Function, and Evolution of the Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein SO JOURNAL OF VIROLOGY LA English DT Article ID LASSA-VIRUS; NUCLEOPROTEIN REVEALS; SEQUENCE ALIGNMENT; GLYCOPROTEINS GN; CYTOPLASMIC TAIL; RNA-BINDING; CLUSTAL-W; CRYSTALLOGRAPHY; GC; MORPHOGENESIS AB Crimean-Congo hemorrhagic fever virus (CCHFV) is an emerging tick-borne virus of the Bunyaviridae family that is responsible for a fatal human disease for which preventative or therapeutic measures do not exist. We solved the crystal structure of the CCHFV strain Baghdad-12 nucleocapsid protein (N), a potential therapeutic target, at a resolution of 2.1 angstrom. N comprises a large globular domain composed of both N- and C-terminal sequences, likely involved in RNA binding, and a protruding arm domain with a conserved DEVD caspase-3 cleavage site at its apex. Alignment of our structure with that of the recently reported N protein from strain YL04057 shows a close correspondence of all folds but significant transposition of the arm through a rotation of 180 degrees and a translation of 40 angstrom. These observations suggest a structural flexibility that may provide the basis for switching between alternative N protein conformations during important functions such as RNA binding and oligomerization. Our structure reveals surfaces likely involved in RNA binding and oligomerization, and functionally critical residues within these domains were identified using a minigenome system able to recapitulate CCHFV-specific RNA synthesis in cells. Caspase-3 cleaves the polypeptide chain at the exposed DEVD motif; however, the cleaved N protein remains an intact unit, likely due to the intimate association of N- and C-terminal fragments in the globular domain. Structural alignment with existing N proteins reveals that the closest CCHFV relative is not another bunyavirus but the arenavirus Lassa virus instead, suggesting that current segmented negative-strand RNA virus taxonomy may need revision. C1 [Carter, Stephen D.; Surtees, Rebecca; Walter, Cheryl T.; Ariza, Antonio; Hiscox, Julian A.; Edwards, Thomas A.; Barr, John N.] Univ Leeds, Astbury Ctr Struct Mol Biol, Fac Biol Sci, Leeds, W Yorkshire, England. [Carter, Stephen D.; Surtees, Rebecca; Walter, Cheryl T.; Ariza, Antonio; Hiscox, Julian A.; Edwards, Thomas A.; Barr, John N.] Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds, W Yorkshire, England. [Surtees, Rebecca] Hlth Protect Agcy, Ctr Emergency Preparedness & Response, Salisbury, Wilts, England. [Bergeron, Eric; Nichol, Stuart T.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. RP Edwards, TA (reprint author), Univ Leeds, Astbury Ctr Struct Mol Biol, Fac Biol Sci, Leeds, W Yorkshire, England. EM T.A.Edwards@leeds.ac.uk; J.N.Barr@leeds.ac.uk RI Walter, Cheryl/K-2251-2012; OI Hiscox, Julian/0000-0002-6582-0275; Ariza, Antonio/0000-0003-4364-823X FU Jersey Government; Wellcome Trust FX This work was financially supported by a personal studentship to S. D. C. from The Jersey Government, by The Wellcome Trust, and by a generous donation from Jerry Knapp. NR 55 TC 38 Z9 39 U1 3 U2 23 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2012 VL 86 IS 20 BP 10914 EP 10923 DI 10.1128/JVI.01555-12 PG 10 WC Virology SC Virology GA 010SR UT WOS:000309114900001 PM 22875964 ER PT J AU Jeisy-Scott, V Kim, JH Davis, WG Cao, WP Katz, JM Sambhara, S AF Jeisy-Scott, Victoria Kim, Jin Hyang Davis, William G. Cao, Weiping Katz, Jacqueline M. Sambhara, Suryaprakash TI TLR7 Recognition Is Dispensable for Influenza Virus A Infection but Important for the Induction of Hemagglutinin-Specific Antibodies in Response to the 2009 Pandemic Split Vaccine in Mice SO JOURNAL OF VIROLOGY LA English DT Article ID TOLL-LIKE RECEPTORS; T-CELL RESPONSES; ADAPTIVE IMMUNE-RESPONSES; B-CELLS; INNATE IMMUNITY; YOUNG-CHILDREN; RNA VIRUSES; IN-VITRO; PATHWAYS; IMMUNIZATION AB Recognition of pathogen-associated molecular patterns by pattern recognition receptors of the innate immune system is crucial for the initiation of innate and adaptive responses and for immunological memory. We investigated the role of TLR7 in the induction of adaptive immunity and long-term memory following influenza virus infection and vaccination in C57BL/6 mice. During infection with influenza A/PR8/34 virus, the absence of either TLR7 or MyD88 leads to reduced virus-specific antibodies in the serum and antibody-secreting cells in their secondary lymphoid organs, particularly in bone marrow. In spite of this, the absence of TLR7/MyD88 signaling did not impair the production of protective antibodies. Following immunization with the 2009 pandemic inactivated split vaccine, TLR7(-/-) mice had significantly lower levels of germinal center formation, antibody-secreting cells, and circulating influenza virus-specific antibodies than control animals. Consequently, TLR7(-/-) mice failed to develop protective immunological memory upon challenge. Furthermore, the immunogenicity of the split vaccine was likely due to TLR7 recognition of virion RNA, as its removal from the split vaccine significantly reduced the levels of influenza virus-specific antibodies and compromised the vaccine protective efficacy in mice. Taken together, our data demonstrate that TLR7 plays an important role in vaccine-induced humoral immune responses to influenza virus through the interaction with viral RNA present in the split vaccine. C1 [Jeisy-Scott, Victoria; Kim, Jin Hyang; Davis, William G.; Cao, Weiping; Katz, Jacqueline M.; Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Jeisy-Scott, Victoria] Emory Univ, Atlanta, GA 30322 USA. RP Sambhara, S (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM ssambhara@cdc.gov FU Oak Ridge Institute for Science and Education FX We thank Kortney Gustin and Steve Lindstrom for the use of their reagents for this study. We also greatly appreciate Sanofi Pasteur for allowing us the use of their A/California/07/2009 X-179A (H1N1) monovalent split vaccine. V.J.-S. received a postgraduate stipend from the Oak Ridge Institute for Science and Education. NR 63 TC 20 Z9 20 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2012 VL 86 IS 20 BP 10988 EP 10998 DI 10.1128/JVI.01064-12 PG 11 WC Virology SC Virology GA 010SR UT WOS:000309114900007 PM 22837197 ER PT J AU Joshi, N Kissin, D Anderson, JE Session, D Macaluso, M Jamieson, DJ AF Joshi, Nikhil Kissin, Dmitry Anderson, John E. Session, Donna Macaluso, Maurizio Jamieson, Denise J. TI Trends and Correlates of Good Perinatal Outcomes in Assisted Reproductive Technology SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID IN-VITRO FERTILIZATION; LOW-BIRTH-WEIGHT; PRETERM BIRTH; CHILDREN BORN; PREGNANCIES; SINGLETON; COHORT; RISK; METAANALYSIS; INFERTILITY AB OBJECTIVE: To estimate trends in good perinatal outcomes (singleton live births at term with birthweight more than 2,500 g) among live births after assisted reproductive technology in the United States from 2000 to 2008, and associated factors among singletons in 2008. METHODS: Using retrospective cohort data from the National Assisted Reproductive Technology Surveillance System from 2000 to 2008, we calculated relative change and chi(2) tests for trend in the proportion of good perinatal outcomes among assisted reproductive technology live births (n=444,909) and liveborn singletons (n=222,500). We conducted univariable analyses followed by multiple logistic regression to estimate the effects of various characteristics on the outcome among singletons born in 2008 after fresh, nondonor assisted reproductive technology cycles (n=20,780). RESULTS: The proportion of good perinatal outcomes among all liveborn neonates increased from 38.6% in 2000 to 42.5% in 2008, whereas it declined marginally among singletons from 83.6% to 83.4%. One previous birth, transfer of fewer than three embryos, and the presence of fewer than three fetal hearts on 6-week ultrasound examination were associated with good perinatal outcome among singletons. Non-Hispanic black race, tubal factor infertility, uterine factor infertility, ovulatory disorder, and 5-day embryo culture were associated with reduced odds for a good outcome. The strongest association was the presence of one fetal heart compared with more than two (adjusted odds ratio 2.43, 95% confidence interval 1.73-3.42). CONCLUSION: From 2000 to 2008, good perinatal outcomes increased among assisted reproductive technology live births. Among singleton live births, odds for good outcome were greatest with the presence of a single fetal heart and lowest in women of non-Hispanic black race. C1 Emory Univ, Dept Gynecol & Obstet, Atlanta, GA 30322 USA. Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. Cincinnati Childrens Hosp, Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA. RP Joshi, N (reprint author), Glenn Bldg 4th Floor,69 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA. EM nvjoshi@emory.edu RI Macaluso, Maurizio/J-2076-2015 OI Macaluso, Maurizio/0000-0002-2977-9690 FU Intramural CDC HHS [CC999999] NR 34 TC 17 Z9 17 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2012 VL 120 IS 4 BP 843 EP 851 DI 10.1097/AOG.0b013e318269c0e9 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 012FN UT WOS:000309221200016 PM 22996102 ER PT J AU Patel, SJ Klinger, EJ O'Toole, D Schillinger, JA AF Patel, Sameer J. Klinger, Ellen J. O'Toole, Dana Schillinger, Julia A. TI Missed Opportunities for Preventing Congenital Syphilis Infection in New York City SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID INFANTS; MOTHERS; TEXAS AB OBJECTIVE: To describe health care providers' missed opportunities for preventing and treating congenital syphilis in New York City. METHODS: Review of congenital syphilis cases reported to the New York City Department of Health and Mental Hygiene from January 1, 2000 to December 31, 2009. Receipt and timing of prenatal care, serologic testing, and treatment of mothers and newborns were reviewed. Missed opportunities were defined as receipt of prenatal care plus one of the following: 1) lack of documented treatment for syphilis infection diagnosed before pregnancy; 2) absence of serologic testing during pregnancy; 3) late maternal treatment; 4) maternal treatment with a nonpenicillin regimen; or 5) lack of maternal treatment. RESULTS: In total, 195 newborns with congenital syphilis were born to 190 mothers with 191 pregnancies. Overall, 80% (95% confidence interval [CI] 74-86%, 152 of 190) of all mothers received prenatal care; 63% (95% CI 56-71%, 96 of 152) of these had one or more missed opportunities for prevention. Twelve mothers received inadequate treatment or no treatment during the case pregnancy for documented syphilis infection before pregnancy, and 42 mothers without previous syphilis diagnosis did not have serologic testing during the case pregnancy. Of 103 mothers with syphilis diagnosed before 30 weeks of gestation, 12 received late penicillin therapy, 27 received no therapy, and 3 received inappropriate (nonpenicillin) therapy. Seventeen percent (95% CI 12-22%, 33 of 193) of liveborn newborns received no treatment during their hospitalization. CONCLUSION: Providers missed well-defined opportunities to prevent congenital syphilis for the majority of cases. Combined efforts to prevent future cases include provider education and better integration of care between obstetricians and pediatricians. (Obstet Gynecol 2012; 120:882-8) DOI:http://10.1097/AOG.0b013e31826ac25f C1 Columbia Univ, Dept Pediat, New York, NY 10027 USA. New York City Dept Hlth & Mental Hyg, Bur Sexually Transmitted Dis Control, New York, NY USA. Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. RP Patel, SJ (reprint author), 622 W 168th St,PH 4W 475, New York, NY 10032 USA. EM sp2172@columbia.edu NR 13 TC 6 Z9 7 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2012 VL 120 IS 4 BP 882 EP 888 DI 10.1097/AOG.0b013e31826ac25f PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 012FN UT WOS:000309221200020 PM 22996106 ER PT J AU Su, JR Pillay, A Hook, EW Ghanem, KG Wong, W Jackson, D Smith, LD Pierce, E Philip, SS Wilson, S Golden, MR Workowski, KA Chi, KH Parrish, DD Chen, CY Weinstock, HS AF Su, John R. Pillay, Allan Hook, Edward W. Ghanem, Khalil G. Wong, William Jackson, Dawn Smith, Lewis D. Pierce, Elaine Philip, Susan S. Wilson, Steven Golden, Matthew R. Workowski, Kimberly A. Chi, Kai-Hua Parrish, Deidra D. Chen, Cheng Y. Weinstock, Hillard S. CA A2058G Prevalence Workgrp TI Prevalence of the 23S rRNA A2058G Point Mutation and Molecular Subtypes in Treponema pallidum in the United States, 2007 to 2009 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID PENICILLIN-G BENZATHINE; REAL-TIME PCR; MACROLIDE RESISTANCE; SECONDARY SYPHILIS; AZITHROMYCIN RESISTANCE; TREATMENT FAILURE; CLINICAL ISOLATE; SAN-FRANCISCO; EPIDEMIOLOGY; INFECTION AB Background: The 23S rRNA A2058G point mutation in Treponema pallidum is associated with macrolide antibiotic treatment failure. Its prevalence and potential association with a molecular subtype within the United States are unknown. Methods: During 2007 to 2009, 11 clinics across the United States sent samples from genital ulcers to the Centers for Disease Control and Prevention. Molecular techniques were used to identify T. pallidum DNA sequences, the A2058G mutation, and subtype of T. pallidum. Accompanying epidemiologic information was abstracted from medical records. Results: A total of 141 samples with T. pallidum were collected from individuals whose median age was 33 years (range, 13Y68 years): 118 were male (69% reported as men having sex with men [MSM]). The A2058G mutation was carried in 75 samples (53%) with T. pallidum, with samples from MSM (versus women and other men) more likely carrying the A2058G mutation (65/82 samples versus 8/57 samples; prevalence ratio, 5.7; 95% confidence interval, 2.9Y10.8). Of 98 strain-typed samples, 61 (62%) were the 14d9 subtype of T. pallidum, which was also associated with samples with T. pallidum from MSM (prevalence ratio, 3.5; 95% confidence interval, 1.9Y6.5). However, among T. pallidum from MSM, the A2058G mutation was not associated with the 14d9 subtype. Conclusions: The A2058G mutation and 14d9 subtype of T. pallidum were present throughout the United States. Both were more commonly found in T. pallidum from MSM compared with women or other men but were not associated with each other. Treating syphilis with azithromycin should be done cautiously and only when treatment with penicillin or doxycycline is not feasible. C1 [Su, John R.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Hook, Edward W.] Univ Alabama Birmingham, Birmingham, AL USA. [Hook, Edward W.] Jefferson Cty Dept Hlth, Birmingham, AL USA. [Ghanem, Khalil G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Wong, William] Chicago Dept Publ Hlth, Chicago, IL USA. [Jackson, Dawn] Detroit Dept Hlth & Wellness Promot, Detroit, MI USA. [Smith, Lewis D.] New Mexico Dept Hlth, Albuquerque, NM USA. [Pierce, Elaine] Cty San Diego Hlth & Human Serv Agcy, San Diego, CA USA. [Philip, Susan S.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Wilson, Steven] Dallas Cty Hlth & Human Serv, Dallas, TX USA. [Golden, Matthew R.] Univ Washington, Seattle, WA 98195 USA. [Workowski, Kimberly A.] Emory Univ, Atlanta, GA 30322 USA. [Parrish, Deidra D.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Su, JR (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E02, Atlanta, GA 30333 USA. EM ezu2@cdc.gov FU Centers for Disease Control and Prevention; Oak Ridge Institute for Science and Education FX Supported by the Centers for Disease Control and Prevention. D. D. P. was supported by the Oak Ridge Institute for Science and Education. NR 33 TC 19 Z9 19 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2012 VL 39 IS 10 BP 794 EP 798 DI 10.1097/OLQ.0b013e31826f36de PG 5 WC Infectious Diseases SC Infectious Diseases GA 012ES UT WOS:000309218900011 ER PT J AU White, RG Lansky, A Goel, S Wilson, D Hladik, W Hakim, A Frost, SDW AF White, Richard G. Lansky, Amy Goel, Sharad Wilson, David Hladik, Wolfgang Hakim, Avi Frost, Simon D. W. TI Respondent driven sampling-where we are and where should we be going? SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Editorial Material C1 [White, Richard G.] Univ London London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London WC1E 7HT, England. [Lansky, Amy] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Goel, Sharad] Microsoft Res, New York, NY USA. [Hladik, Wolfgang; Hakim, Avi] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA USA. [Frost, Simon D. W.] Univ Cambridge, Dept Vet Med, Cambridge, England. RP White, RG (reprint author), Univ London London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England. EM richard.white@lshtm.ac.uk RI White, Richard/D-5407-2009; Frost, Simon/F-3648-2010 OI White, Richard/0000-0003-4410-6635; Frost, Simon/0000-0002-5207-9879 FU Medical Research Council [G0802414]; NIDA NIH HHS [DA24998, R03 DA024998]; NINR NIH HHS [NR10961, R21 NR010961] NR 10 TC 30 Z9 31 U1 0 U2 8 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD OCT PY 2012 VL 88 IS 6 BP 397 EP 399 DI 10.1136/sextrans-2012-050703 PG 3 WC Infectious Diseases SC Infectious Diseases GA 012VX UT WOS:000309265800002 PM 23012492 ER PT J AU Kepka, D Berkowitz, Z Yabroff, KR Roland, K Saraiya, M AF Kepka, Deanna Berkowitz, Zahava Yabroff, K. Robin Roland, Katherine Saraiya, Mona TI Human papillomavirus vaccine practices in the USA: do primary care providers use sexual history and cervical cancer screening results to make HPV vaccine recommendations? SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Article AB Objectives Guidelines recommend against the use of Papanicolaou (Pap) or human papillomavirus (HPV) testing when determining eligibility for the HPV vaccine. Optimally, the HPV vaccine should be administered before sexual initiation. Guidelines recommend that age-eligible women with past exposure to HPV should still be vaccinated. Little is known about how primary care providers (PCPs) use sexual history and HPV and Pap tests in their HPV vaccine recommendations. Methods Data from the 2007 Cervical Cancer Screening Supplement (CCSS) administered with the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) were used to assess HPV vaccination recommendations. The CCSS investigates cervical cancer screening practices, HPV testing and HPV vaccine recommendations among PCPs. A summary measure of compliance with guidelines was defined as rarely or never using the number of sexual partners and HPV tests and Pap tests to determine vaccine receipt. A total of 421 PCPs completed the CCSS in 2007. Results Among NAMCS and NHAMCS providers who recommend the HPV vaccine, only 53% (95% CI 42% to 63%) reported making guideline-consistent recommendations. The majority reported sometimes to always recommending the HPV vaccine to women with a history of an abnormal Pap result (85%; 95% CI 75% to 91%) and a positive HPV test (79%; 95% CI 70% to 86%). Conclusions A large proportion of providers report practices that are inconsistent with guidelines. Providers may also be recommending the vaccine to women who may receive little benefit from the vaccine. Provider and system-level efforts to improve guideline-consistent practices are needed. C1 [Kepka, Deanna] NCI, Hlth Serv & Econ Branch, Appl Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Berkowitz, Zahava; Roland, Katherine; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Kepka, D (reprint author), NCI, Hlth Serv & Econ Branch, Appl Res Program, Div Canc Control & Populat Sci, Execut Plaza N,Room 4017,6130 Execut Blvd,MSC 734, Bethesda, MD 20892 USA. EM deanna.kepka@nih.gov OI Yabroff, K. Robin/0000-0003-0644-5572 FU Center for Cancer Training; Health Services and Economics Branch, Applied Research Program, Division of Cancer Control and Population Sciences of the National Cancer Institute, Bethesda, MD FX DLK acknowledges support from the Cancer Prevention Fellowship Program, Center for Cancer Training and the Health Services and Economics Branch, Applied Research Program, Division of Cancer Control and Population Sciences of the National Cancer Institute, Bethesda, MD. NR 9 TC 13 Z9 13 U1 0 U2 11 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD OCT PY 2012 VL 88 IS 6 BP 433 EP 435 DI 10.1136/sextrans-2011-050437 PG 3 WC Infectious Diseases SC Infectious Diseases GA 012VX UT WOS:000309265800010 PM 22522751 ER PT J AU Rostad, CA McElroy, AK Hilinski, JA Thompson, MP Drew, CP Denison, AM Zaki, SR Mahle, WT Rogers, J Abramowsky, CR Shehata, B AF Rostad, C. A. McElroy, A. K. Hilinski, J. A. Thompson, M. P. Drew, C. P. Denison, A. M. Zaki, S. R. Mahle, W. T. Rogers, J. Abramowsky, C. R. Shehata, B. TI Bartonella henselae-mediated disease in solid organ transplant recipients: two pediatric cases and a literature review SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE Bartonella henselae; bacillary angiomatosis; bacillary peliosis; solid organ transplant; pediatric ID CAT-SCRATCH DISEASE; LIVER-TRANSPLANT; IMMUNOCOMPROMISED HOST; BACILLARY ANGIOMATOSIS; DISSEMINATED INFECTION; ROCHALIMAEA-HENSELAE; PATIENT; PATHOGENESIS; REJECTION; PELIOSIS AB Bartonella henselae, the etiologic agent of cat-scratch disease, causes a well-defined, self-limited syndrome of fever and regional lymphadenopathy in immunocompetent hosts. In immunocompromised hosts, however, B. henselae can cause severe disseminated disease and pathologic vasoproliferation known as bacillary angiomatosis (BA) or bacillary peliosis. BA was first recognized in patients infected with human immunodeficiency virus. It has become more frequently recognized in solid organ transplant (SOT) recipients, but reports of pediatric cases remain rare. Our review of the literature revealed only one previously reported case of BA in a pediatric SOT recipient. We herein present 2 pediatric cases, one of which is the first reported case of BA in a pediatric cardiac transplant recipient, to our knowledge. In addition, we review and summarize the literature pertaining to all cases of B. henselae-mediated disease in SOT recipients. C1 [McElroy, A. K.; Hilinski, J. A.] Emory Univ, Div Infect Dis, Dept Pediat, Atlanta, GA 30322 USA. [Thompson, M. P.] Childrens Med Ctr, Dallas, TX 75235 USA. [Drew, C. P.; Denison, A. M.; Zaki, S. R.] Ctr Dis Control, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Mahle, W. T.] Emory Univ, Childrens Healthcare Atlanta, Dept Pediat, Atlanta, GA 30322 USA. [Rogers, J.; Abramowsky, C. R.; Shehata, B.] Emory Univ, Childrens Healthcare Atlanta, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. RP McElroy, AK (reprint author), Emory Univ, Div Infect Dis, Dept Pediat, 2015 Uppergate Dr Suite 500, Atlanta, GA 30322 USA. EM akmcelr@emory.edu NR 37 TC 8 Z9 8 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD OCT PY 2012 VL 14 IS 5 BP E71 EP E81 DI 10.1111/j.1399-3062.2012.00774.x PG 11 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA 012ME UT WOS:000309239500007 PM 22862881 ER PT J AU Hill, AN Becerra, JE Castro, KG AF Hill, A. N. Becerra, J. E. Castro, K. G. TI Modelling tuberculosis trends in the USA SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Incidence; mathematical modelling; tuberculosis ID INTRINSIC TRANSMISSION DYNAMICS; FOREIGN-BORN PERSONS; UNITED-STATES; POPULATION HEALTH; INFECTION; EPIDEMIOLOGY; IMMIGRATION; IMPACT; SENSITIVITY; UNCERTAINTY AB We present a mathematical transmission model of tuberculosis in the USA. The model is calibrated to recent trends of declining incidence in the US-born and foreign-born populations and is used in assessing relative impacts of treatment of latently infected individuals on elimination time, where elimination is defined as annual incidence <1 case/million. Provided current control efforts are maintained, elimination in the US-born population can be achieved before the end of this century. However, elimination in the foreign-born population is unlikely in this timeframe even with higher rates of targeted testing and treatment of residents of and immigrants to the USA with latent tuberculosis infection. Cutting transmission of disease as an interim step would shorten the time to elimination in the US-born population but foreign-born rates would remain above the elimination target. C1 [Hill, A. N.; Becerra, J. E.; Castro, K. G.] US Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. RP Hill, AN (reprint author), US Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA. EM ahill2@cdc.gov RI Becerra, Jose/C-4071-2014; Barley, Kamal/F-9579-2011 OI Barley, Kamal/0000-0003-1874-9813 NR 38 TC 31 Z9 31 U1 0 U2 20 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD OCT PY 2012 VL 140 IS 10 BP 1862 EP 1872 DI 10.1017/S095026881100286X PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 006UQ UT WOS:000308845100018 PM 22233605 ER PT J AU Hinkle, SN Sharma, AJ Kim, SY Park, S Dalenius, K Brindley, PL Grummer-Strawn, LM AF Hinkle, Stefanie N. Sharma, Andrea J. Kim, Shin Y. Park, Sohyun Dalenius, Karen Brindley, Patricia L. Grummer-Strawn, Laurence M. TI Prepregnancy Obesity Trends Among Low-Income Women, United States, 1999-2008 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Prepregnancy obesity; Body mass index; Obesity prevalence; Maternal obesity; Pregnancy nutrition surveillance system; Obesity trends ID BODY-MASS INDEX; GESTATIONAL WEIGHT-GAIN; HEALTH-CARE; PREGNANCY; OVERWEIGHT; POPULATION; PREVALENCE; MOTHERS; RISK; AGE AB There is limited data on prepregnancy obesity trends specifically among low-income women, a population at high risk for obstetric complications. Using the Pregnancy Nutrition Surveillance System, we assessed prepregnancy obesity [body mass index (BMI) a parts per thousand yen 30 kg/m(2)] trends among women who participated in the Supplemental Nutrition Program for Women, Infants, and Children in 1999, 2004, and 2008. Prepregnancy BMI was calculated using measured height and self-reported prepregnancy weight. We report unadjusted contributor (state, territory or Indian tribal organization) specific trends, and both unadjusted and adjusted overall trends, to account for changes in maternal age and race-ethnic distributions, using 1999 as the referent. Of the 27 contributors in 1999, 2 had a prepregnancy obesity prevalence < 20%, and 1 had a prevalence a parts per thousand yen30%. Of the 35 contributors in 2008, none had a prepregnancy obesity prevalence < 20%, and 14 had a prevalence a parts per thousand yen30%. From 1999 to 2008, the overall prevalence of prepregnancy obesity increased among all racial-ethnic groups, except among American Indian/Alaskan Natives, where it remained high, but stable. Overall prepregnancy obesity increased most rapidly among Hispanics, and remained stable from 2004 to 2008 among non-Hispanic blacks. In 2008, prevalence was highest among American Indian/Alaskan Natives (36.1%) and lowest among Asians/Pacific Islanders (10.8%). The adjusted prepregnancy obesity prevalence increased from 24.8% in 1999 to 28.3% in 2008, a relative increase of 14.1%. Prepregnancy obesity among low-income women increased from 1999 to 2008 and varied by race-ethnicity. These data can be used by obesity prevention programs to better target high-risk women. C1 [Hinkle, Stefanie N.; Sharma, Andrea J.; Kim, Shin Y.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Hinkle, Stefanie N.; Sharma, Andrea J.] Emory Univ, Grad Div Biol & Biomed Sci, Program Nutr & Hlth Sci, Atlanta, GA 30322 USA. [Park, Sohyun; Dalenius, Karen; Brindley, Patricia L.; Grummer-Strawn, Laurence M.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Sharma, AJ (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,MS-K23, Atlanta, GA 30341 USA. EM AJSharma@cdc.gov RI Hinkle, Stefanie/F-8253-2013; OI Hinkle, Stefanie/0000-0003-4312-708X; Sharma, Andrea/0000-0003-0385-0011 NR 34 TC 22 Z9 22 U1 4 U2 17 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2012 VL 16 IS 7 BP 1339 EP 1348 DI 10.1007/s10995-011-0898-2 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 006LT UT WOS:000308821400001 PM 22009444 ER PT J AU Qin, C Zhou, M Callaghan, WM Posner, SF Zhang, J Berg, CJ Zhao, GL AF Qin, Cheng Zhou, Min Callaghan, William M. Posner, Samuel F. Zhang, Jun Berg, Cynthia J. Zhao, Gengli TI Clinical Indications and Determinants of the Rise of Cesarean Section in Three Hospitals in Rural China SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Cesarean delivery rate; Cesarean indication; Rural China ID PREGNANCY OUTCOMES; DELIVERY; WOMEN AB This study investigated changes in cesarean delivery rate and cesarean indications in 3 county-level hospitals in rural China. Hospital delivery records in 1997 and 2003 were used to examine the reasons behind the changes. In Chengde County Hospital, the cesarean delivery rate increased from 28% in 1997 to 54% in 2003. The rate increased from 43% in 1997 to 65% in 2003 in Anxian County Hospital and Anxian Maternal and Child Health Hospital. The dramatic increase in cesarean delivery in the study hospitals was associated with a shift from more severe to mild or no clinical indications. The ratio of mild to moderate to severe hypertension increased substantially. More than half of the cephalopelvic disproportion cases were diagnosed prior to labor. The majority of nuchal cord cases were diagnosed without fetal distress. Maternal/family request was the number one cesarean indication in Anxian County Hospital and Anxian MCH Hospital in 2003. Ultrasound evidence of nuchal cord moved from the ninth ranked indication in 1997 to the second in 2003 in Chengde County Hospital. C1 [Qin, Cheng; Callaghan, William M.; Berg, Cynthia J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Zhou, Min; Zhao, Gengli] Peking Univ, Womens & Childrens Hlth Ctr, Beijing 100871, Peoples R China. [Zhang, Jun] NICHHD, NIH, Rockville, MD USA. RP Qin, C (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE MS K-23, Atlanta, GA 30341 USA. EM caq9@cdc.gov OI Posner, Samuel/0000-0003-1574-585X NR 21 TC 9 Z9 11 U1 1 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD OCT PY 2012 VL 16 IS 7 BP 1484 EP 1490 DI 10.1007/s10995-011-0913-7 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 006LT UT WOS:000308821400015 PM 22160744 ER PT J AU Bauer, D Krege, J Lane, N Leary, E Libanati, C Miller, P Myers, G Silverman, S Vesper, HW Lee, D Payette, M Randall, S AF Bauer, D. Krege, J. Lane, N. Leary, E. Libanati, C. Miller, P. Myers, G. Silverman, S. Vesper, H. W. Lee, D. Payette, M. Randall, S. TI National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Bone turnover markers; Position paper ID HORMONE REPLACEMENT THERAPY; RANDOMIZED CLINICAL-TRIAL; LONG-TERM RESPONSE; NO EASY TASK; BIOCHEMICAL MARKERS; ELDERLY-WOMEN; FRACTURE RISK; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; SERUM CTX AB This position paper reviews how the National Bone Health Alliance (NBHA) will execute a project to help assure health professionals of the clinical utility of bone turnover markers; the current clinical approaches concerning osteoporosis and the status and use of bone turnover markers in the USA; the rationale for focusing this effort around two specific bone turnover markers; the need to standardize bone marker sample collection procedures, reference ranges, and bone turnover marker assays in clinical laboratories; and the importance of harmonization for future research of bone turnover markers. Osteoporosis is a major global health problem, with the prevalence and incidence of osteoporosis for at-risk populations estimated to be 44 million Americans. The potential of bone markers as an additional tool for health care professionals to improve patient outcomes and impact morbidity and mortality is crucial in providing better health care and addressing rising health care costs. This need to advance the field of bone turnover markers has been recognized by a number of organizations, including the International Osteoporosis Foundation (IOF), National Osteoporosis Foundation, International Federation of Clinical Chemistry, and Laboratory Medicine (IFCC), and the NBHA. This position paper elucidates how this project will standardize bone turnover marker sample collection procedures in the USA, establish a USA reference range for one bone formation (serum procollagen type I N propeptide, s-PINP) and one bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) marker, and standardize bone turnover marker assays used in clinical laboratories. This effort will allow clinicians from the USA to have confidence in their use of bone turnover markers to help monitor osteoporosis treatment and assess future fracture risk. This project builds on the recommendations of the IOF/IFCC Bone Marker Standards Working Group by developing USA reference standards for s-PINP and s-CTX, the markers identified as most promising for use as reference markers. The goals of this project will be realized through the NBHA and will include its governmental, academic, for-profit, and non-profit sector stakeholders as well as major academic and commercial laboratories. Upon completion, a parallel effort will be pursued to make bone turnover marker measurements reliable and accepted by all health care professionals for facilitating treatment decisions and ultimately be reimbursed by all health insurance payers. Successful completion of this project will help assure health professionals from the USA of the clinical utility of bone turnover markers and ties in with the parallel effort of the IOF/IFCC to develop worldwide bone turnover reference ranges. C1 [Bauer, D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Krege, J.] Eli Lilly & Co Inc, Indianapolis, IN USA. [Lane, N.] Univ Calif Davis Hlth Syst, Sacramento, CA USA. [Leary, E.] Pacific Biomarkers, Seattle, WA USA. [Libanati, C.] Amgen Inc, Thousand Oaks, CA USA. [Miller, P.] Colorado Ctr Bone Res, Lakewood, CO USA. [Myers, G.] Amer Assoc Clin Chem, Washington, DC USA. [Silverman, S.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Vesper, H. W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lee, D.] Natl Bone Hlth Alliance, Washington, DC USA. [Payette, M.] Roche Diagnost, Indianapolis, IN USA. [Randall, S.] Natl Osteoporosis Fdn, Washington, DC USA. RP Bauer, D (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. EM dbauer@psg.ucsf.edu FU NIAMS NIH HHS [K24 AR051895] NR 51 TC 34 Z9 34 U1 3 U2 10 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD OCT PY 2012 VL 23 IS 10 BP 2425 EP 2433 DI 10.1007/s00198-012-2049-z PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 006KO UT WOS:000308818300003 PM 22797491 ER PT J AU O'Leary, A Jemmott, JB Jemmott, LS Bellamy, S Ngwane, Z Icard, L Gueits, L AF O'Leary, Ann Jemmott, John B., III Jemmott, Loretta Sweet Bellamy, Scarlett Ngwane, Zolani Icard, Larry Gueits, Lynnette TI Moderation and Mediation of an Effective HIV Risk-Reduction Intervention for South African Adolescents SO ANNALS OF BEHAVIORAL MEDICINE LA English DT Article DE HIV prevention; Behavioral intervention; Adolescents; South Africa; Moderation; Mediation ID RANDOMIZED CONTROLLED-TRIAL; CONDOM-USE INTENTIONS; PROBLEM BEHAVIOR; SEXUAL-BEHAVIOR; SELF-EFFICACY; HIV/STD RISK; WOMEN AB "Let Us Protect Our Future" is a sexual risk-reduction intervention for sixth-grade adolescents in South Africa. Tested in a cluster-randomized controlled trial, the intervention significantly reduced self-reported intercourse and unprotected intercourse during a 12-month follow-up period. The present analyses were conducted to identify moderators of the intervention's efficacy as well as, which theory-based variables mediated the intervention's effects. Intervention efficacy over the 3-, 6-, and 12-month follow-up was tested using generalized estimating equation models. Living with their father in the home, parental strictness, and religiosity moderated the efficacy of the intervention in reducing unprotected intercourse. Self-efficacy to avoid risky situations and expected parental disapproval of their having intercourse, derived from Social Cognitive Theory, significantly mediated the intervention's effect on abstinence. This is the first study to demonstrate that Social Cognitive variables mediate the efficacy of a sexual risk-reduction intervention among South African adolescents. C1 [O'Leary, Ann] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Jemmott, John B., III; Jemmott, Loretta Sweet; Bellamy, Scarlett; Gueits, Lynnette] Univ Penn, Philadelphia, PA 19104 USA. [Ngwane, Zolani] Haverford Coll, Haverford, PA 19041 USA. [Icard, Larry] Temple Univ, Philadelphia, PA 19122 USA. RP O'Leary, A (reprint author), Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA. EM aao0@cdc.gov FU NIMH NIH HHS [R01 MH065867] NR 34 TC 18 Z9 18 U1 0 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0883-6612 J9 ANN BEHAV MED JI Ann. Behav. Med. PD OCT PY 2012 VL 44 IS 2 BP 181 EP 191 DI 10.1007/s12160-012-9375-4 PG 11 WC Psychology, Multidisciplinary SC Psychology GA 006MI UT WOS:000308822900008 PM 22618963 ER PT J AU Hogben, M Kidd, S Burstein, GR AF Hogben, Matthew Kidd, Sarah Burstein, Gale R. TI Expedited partner therapy for sexually transmitted infections SO CURRENT OPINION IN OBSTETRICS & GYNECOLOGY LA English DT Review DE antimicrobial resistance; partner treatment; sexually transmitted disease/infection; STD prevention programs ID RESISTANT NEISSERIA-GONORRHOEAE; RANDOMIZED CONTROLLED-TRIAL; CHLAMYDIAL INFECTION; ORAL CEPHALOSPORINS; UNITED-STATES; NOTIFICATION; CEFIXIME; WOMEN; AZITHROMYCIN; UK AB Purpose of review In 2006, the Centers for Disease Control and Prevention recommended Expedited Partner Therapy (EPT) as a clinical option for assuring treatment of sex partners of persons infected with sexually transmitted infections. In this review, we provide an update on research, evaluation and efforts to increase EPT coverage. We also attend to EPT for gonorrhea in the context of antimicrobial resistance. Recent findings Controlled trials in the United States and United Kingdom have presented increasing variety in intervention approaches. Trials and program evaluations typically demonstrate increased partner treatment rates, although only some studies show reductions in follow-up infection rates. Coverage has increased substantially, with over 30 states permitting EPT for chlamydial infection, gonorrhea, or both. The prospect of cephalosporin-resistant gonorrhea, however, raises the prospect that EPT may become less feasible as a partner treatment approach for gonorrhea patients. Summary Clinicians should continue to be aware of the importance of partner managements for STD-infected patients, with EPT being an evidence-based intervention in that respect. The variety in EPT models provides alternatives that may suit some practices and venues. For clinicians seeing gonorrhea patients, effective counseling models - enhanced patient referral - should be closely examined in case oral treatment for gonorrhea becomes infeasible. C1 [Hogben, Matthew; Kidd, Sarah] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Burstein, Gale R.] SUNY Buffalo, Erie Cty Dept Hlth, Buffalo, NY 14260 USA. RP Hogben, M (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Mail Stop E-44, Atlanta, GA 30333 USA. EM mhogben@cdc.gov NR 42 TC 3 Z9 3 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-872X J9 CURR OPIN OBSTET GYN JI Curr. Opin. Obstet. Gynecol. PD OCT PY 2012 VL 24 IS 5 BP 299 EP 304 DI 10.1097/GCO.0b013e3283577e9d PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 007CK UT WOS:000308866200006 PM 22907483 ER PT J AU Stone, ND Ashraf, MS Calder, J Crnich, CJ Crossley, K Drinka, PJ Gould, CV Juthani-Mehta, M Lautenbach, E Loeb, M MacCannell, T Malani, PN Mody, L Mylotte, JM Nicolle, LE Roghmann, MC Schweon, SJ Simor, AE Smith, PW Stevenson, KB Bradley, SF AF Stone, Nimalie D. Ashraf, Muhammad S. Calder, Jennifer Crnich, Christopher J. Crossley, Kent Drinka, Paul J. Gould, Carolyn V. Juthani-Mehta, Manisha Lautenbach, Ebbing Loeb, Mark MacCannell, Taranisia Malani, Preeti N. Mody, Lona Mylotte, Joseph M. Nicolle, Lindsay E. Roghmann, Mary-Claire Schweon, Steven J. Simor, Andrew E. Smith, Philip W. Stevenson, Kurt B. Bradley, Suzanne F. CA Soc Healthcare Epidemiology Long-T TI Surveillance Definitions of Infections in Long-Term Care Facilities: Revisiting the McGeer Criteria SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID URINARY-TRACT-INFECTION; NURSING-HOME RESIDENTS; CLOSTRIDIUM-DIFFICILE; HEALTH-CARE; DISEASES SOCIETY; GASTROENTERITIS; MANAGEMENT; NOROVIRUS; OUTBREAKS; PREVENTION AB Infection surveillance definitions for long-term care facilities (ie, the McGeer Criteria) have not been updated since 1991. An expert consensus panel modified these definitions on the basis of a structured review of the literature. Significant changes were made to the criteria defining urinary tract and respiratory tract infections. New definitions were added for norovirus gastroenteritis and Clostridum difficile infections. Infect Control Hosp Epidemiol 2012;33(10):965-977 C1 [Stone, Nimalie D.; Gould, Carolyn V.; MacCannell, Taranisia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ashraf, Muhammad S.] E Carolina Univ, Greenville, NC USA. [Calder, Jennifer] New York Med Coll, Valhalla, NY 10595 USA. [Crnich, Christopher J.] Univ Wisconsin, Madison, WI USA. [Crnich, Christopher J.] William S Middleton VA Med Ctr, Madison, WI USA. [Crossley, Kent] Univ Minnesota, Minneapolis, MN USA. [Crossley, Kent] Minneapolis VA Med Ctr, Minneapolis, MN USA. [Drinka, Paul J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Juthani-Mehta, Manisha] Yale Univ, Sch Med, New Haven, CT USA. [Lautenbach, Ebbing] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Loeb, Mark] McMaster Univ, Hamilton, ON, Canada. [Malani, Preeti N.; Mody, Lona; Bradley, Suzanne F.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Malani, Preeti N.; Mody, Lona; Bradley, Suzanne F.] VA Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA. [Mylotte, Joseph M.] SUNY Buffalo, Sch Med & Biomed Sci, Buffalo, NY 14260 USA. [Nicolle, Lindsay E.] Univ Manitoba, Winnipeg, MB, Canada. [Roghmann, Mary-Claire] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Roghmann, Mary-Claire] Baltimore VA Med Ctr, Baltimore, MD USA. [Schweon, Steven J.] Pleasant Valley Manor Nursing Home, Stroudsburg, PA USA. [Simor, Andrew E.] Univ Toronto, Sch Med, Toronto, ON, Canada. [Smith, Philip W.] Univ Nebraska Med Ctr, Omaha, NE USA. [Stevenson, Kurt B.] Ohio State Univ Hosp, Columbus, OH 43210 USA. RP Stone, ND (reprint author), CDC, DHQP, 1600 Clifton Rd NE,Mailstop A-31, Atlanta, GA 30333 USA. EM nstone@cdc.gov RI Calder, Jennifer/F-4508-2015; OI Calder, Jennifer/0000-0003-4758-611X; Roghmann, Mary-Claire/0000-0003-1063-9257; Crnich, Christopher/0000-0002-9320-9262 FU NIA NIH HHS [R01 AG032298] NR 39 TC 71 Z9 71 U1 0 U2 15 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2012 VL 33 IS 10 BP 965 EP 977 DI 10.1086/667743 PG 13 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 004RR UT WOS:000308699300001 PM 22961014 ER PT J AU Chitnis, AS Caruthers, PS Rao, AK Lamb, J Lurvey, R De Rochars, VB Kitchel, B Cancio, M Torok, TJ Guh, AY Gould, CV Wise, ME AF Chitnis, Amit S. Caruthers, Pam S. Rao, Agam K. Lamb, JoAnne Lurvey, Robert De Rochars, Valery Beau Kitchel, Brandon Cancio, Margarita Toeroek, Thomas J. Guh, Alice Y. Gould, Carolyn V. Wise, Matthew E. TI Outbreak of Carbapenem-Resistant Enterobacteriaceae at a Long-Term Acute Care Hospital: Sustained Reductions in Transmission through Active Surveillance and Targeted Interventions SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID KLEBSIELLA-PNEUMONIAE; BETA-LACTAMASE; K. PNEUMONIAE; EPIDEMIOLOGY; INFECTIONS; FACILITIES; EMERGENCE; SYSTEM; IMPACT; SPREAD AB OBJECTIVE. To describe a Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacteriaceae (CRE) outbreak and interventions to prevent transmission. DESIGN, SETTING, AND PATIENTS. Epidemiologic investigation of a CRE outbreak among patients at a long-term acute care hospital (LTACH). METHODS. Microbiology records at LTACH A from March 2009 through February 2011 were reviewed to identify CRE transmission cases and cases admitted with CRE. CRE bacteremia episodes were identified during March 2009-July 2011. Biweekly CRE prevalence surveys were conducted during July 2010-July 2011, and interventions to prevent transmission were implemented, including education and auditing of staff and isolation and cohorting of CRE patients with dedicated nursing staff and shared medical equipment. Trends were evaluated using weighted linear or Poisson regression. CRE transmission cases were included in a case-control study to evaluate risk factors for acquisition. A real-time polymerase chain reaction assay was used to detect the bla(KPC) gene, and pulsed-field gel electrophoresis was performed to assess the genetic relatedness of isolates. RESULTS. Ninety-nine CRE transmission cases, 16 admission cases (from 7 acute care hospitals), and 29 CRE bacteremia episodes were identified. Significant reductions were observed in CRE prevalence (49% vs 8%), percentage of patients screened with newly detected CRE (44% vs 0%), and CRE bacteremia episodes (2.5 vs 0.0 per 1,000 patient-days). Cases were more likely to have received beta-lactams, have diabetes, and require mechanical ventilation. All tested isolates were KPC-producing K. pneumoniae, and nearly all isolates were genetically related. CONCLUSION. CRE transmission can be reduced in LTACHs through surveillance testing and targeted interventions. Sustainable reductions within and across healthcare facilities may require a regional public health approach. Infect Control Hosp Epidemiol 2012;33(10):984-992 C1 [Chitnis, Amit S.; Rao, Agam K.; Lurvey, Robert; Kitchel, Brandon; Guh, Alice Y.; Gould, Carolyn V.; Wise, Matthew E.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Chitnis, Amit S.; Rao, Agam K.; De Rochars, Valery Beau] CDC, Off Workforce & Career Dev, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Caruthers, Pam S.; Cancio, Margarita] Kindred Hosp Bay Area St Petersburg, Div Infect Prevent, St Petersburg, FL USA. [Lamb, JoAnne] Pinellas Cty Hlth Dept, Program Epidemiol, Dis Control Div, St Petersburg, FL USA. [Toeroek, Thomas J.] Bur Epidemiol, Div Dis Control, Florida Dept Hlth, Tallahassee, FL USA. [Toeroek, Thomas J.] CDC, Career Epidemiol Field Off Program, Off Publ Hlth Preparedness & Response, Atlanta, GA 30333 USA. RP Chitnis, AS (reprint author), 1600 Clifton Rd,MS A-24, Atlanta, GA 30333 USA. EM amit.chitnis@cdph.ca.gov FU US Department of Health and Human Services; Pinellas County Health Department; Florida Department of Health FX All funding and material support for this work was provided by the US Department of Health and Human Services, Pinellas County Health Department, and the Florida Department of Health. No commercial entity had any role in this work. NR 29 TC 37 Z9 39 U1 0 U2 24 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2012 VL 33 IS 10 BP 984 EP 992 DI 10.1086/667738 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 004RR UT WOS:000308699300004 PM 22961017 ER PT J AU Chitnis, AS Edwards, JR Ricks, PM Sievert, DM Fridkin, SK Gould, CV AF Chitnis, Amit S. Edwards, Jonathan R. Ricks, Phillip M. Sievert, Dawn M. Fridkin, Scott K. Gould, Carolyn V. TI Device-Associated Infection Rates, Device Utilization, and Antimicrobial Resistance in Long-Term Acute Care Hospitals Reporting to the National Healthcare Safety Network, 2010 SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID BLOOD-STREAM INFECTIONS; CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE; VENTILATOR-ASSOCIATED PNEUMONIA; KLEBSIELLA-PNEUMONIAE; UNITED-STATES; EMERGENCE AB OBJECTIVE. To evaluate national data on healthcare-associated infections (HAIs), device utilization, and antimicrobial resistance in long-term acute care hospitals (LTACHs). DESIGN AND SETTING. Comparison of data from LTACHs and from medical and medical-surgical intensive care units (ICUs) in short-stay acute care hospitals reporting to the National Healthcare Safety Network (NHSN) during 2010. METHODS. Rates of central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), and ventilator-associated pneumonia (VAP) as well as device utilization ratios were calculated. For each HAI, pathogen profiles and antimicrobial resistance prevalence were evaluated. Comparisons were made using Poisson regression and the Mood median and chi(2) tests. RESULTS. In 2010, 104 LTACHs reported CLABSIs and 57 reported CAUTIs and VAP to the NHSN. Median CLABSI rates in LTACHs (1.25 events per 1,000 device-days reported; range, 0.0-5.96) were comparable to rates in major teaching ICUs and were higher than those in other ICUs. CAUTI rates in LTACHs (median, 2.61; range, 0.0-9.92) were higher and VAP rates (median, 0.0; range, 0.0-3.29) were generally lower than those in ICUs. Central line utilization in LTACHs was higher than that in ICUs, whereas urinary catheter and ventilator utilization was lower. Methicillin resistance among Staphylococcus aureus CLABSIs (83%) and vancomycin resistance among Enterococcus faecalis CAUTIs (44%) were higher in LTACHs than in ICUs. Multidrug resistance among Pseudomonas aeruginosa CAUTIs (25%) was higher in LTACHs than in most ICUs. CONCLUSIONS. CLABSIs and CAUTIs associated with multidrug-resistant organisms present a challenge in LTACHs. Continued HAI surveillance with pathogen-level data can guide prevention efforts in LTACHs. Infect Control Hosp Epidemiol 2012;33(10):993-1000 C1 [Chitnis, Amit S.; Edwards, Jonathan R.; Ricks, Phillip M.; Sievert, Dawn M.; Fridkin, Scott K.; Gould, Carolyn V.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Chitnis, Amit S.] Ctr Dis Control & Prevent, Off Workforce & Career Dev, Epidem Intelligence Serv, Atlanta, GA USA. RP Gould, CV (reprint author), 1600 Clifton Rd,MS A-35, Atlanta, GA 30333 USA. EM cgould@cdc.gov FU US Department of Health and Human Services FX All funding and material support for this work was provided by the US Department of Health and Human Services. No commercial entity had any role in this work. NR 26 TC 15 Z9 15 U1 0 U2 14 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD OCT PY 2012 VL 33 IS 10 BP 993 EP 1000 DI 10.1086/667745 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 004RR UT WOS:000308699300005 PM 22961018 ER PT J AU Tyrrell, FC Budnick, GE Elliott, T Gillim-Ross, L Hildred, MV Mahlmeister, P Parrish, N Pentella, M Vanneste, J Wang, YF Starks, AM AF Tyrrell, Frances C. Budnick, Gary E. Elliott, Thor Gillim-Ross, Laura Hildred, Mary V. Mahlmeister, Peggy Parrish, Nicole Pentella, Michael Vanneste, Jolene Wang, Yun F. (Wayne) Starks, Angela M. TI Probability of Negative Mycobacterium tuberculosis Complex Cultures Based on Time to Detection of Positive Cultures: a Multicenter Evaluation of Commercial-Broth-Based Culture Systems SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID BACTEC MGIT 960; 1ST-LINE ANTITUBERCULOSIS DRUGS; LOWENSTEIN-JENSEN MEDIUM; CLINICAL SPECIMENS; RECOVERY; MB/BACT; IDENTIFICATION; THERAPY AB We conducted a multicenter study to determine whether Mycobacterium tuberculosis complex (MTBC) cultures in automated broth-based systems could reliably be considered negative sooner than 6 weeks. Laboratory sites used Bactec MGIT or BacT/Alert and tracked results of time to detection of all mycobacteria (TTD-all, n = 1547) and of MTBC (TTD-MTBC, n = 466) over 6-month periods from primarily (93%) respiratory specimens. Cumulative percentages by day detected and median TTD of initial and follow-up specimens were analyzed. The median TTD-MTBC for MGIT (n = 6 sites) was 14 days. For laboratories using standard processing procedures, 100% of MTBC were detected from initial and follow-up specimens in 28 and 35 days, respectively, and no yield of MTBC on solid or MGIT liquid media was observed after 5 weeks. The median TTD-MTBC for BacT/Alert (n = 3 sites) was 18 days, with 95% and 100% detected within 37 and 42 days, respectively. Analysis of TTD of positive MTBC cultures in broth can predict the probability of culture negativity at defined time points. Receipt of interim negative reports earlier than 6 weeks could assist clinicians in considering alternative diagnoses and could alter the timing and prioritization of public health interventions. Laboratories should analyze their own TTD data to inform protocol decisions. Laboratories using MGIT could issue reports of no growth of MTBC on initial specimens as early as 4 weeks and for patients undergoing treatment as early as 5 weeks postinoculation. C1 [Tyrrell, Frances C.; Starks, Angela M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Budnick, Gary E.] Connecticut Dept Publ Hlth, Hartford, CT USA. [Elliott, Thor] Kansas Dept Hlth & Environm, Topeka, KS USA. [Gillim-Ross, Laura] Colorado Dept Publ Hlth & Environm, Lab Serv Div, Denver, CO USA. [Hildred, Mary V.] Denver Hlth Med Ctr, Denver, CO USA. [Mahlmeister, Peggy] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Parrish, Nicole] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. [Pentella, Michael] State Hyg Lab, Coralville, IA USA. [Vanneste, Jolene] Michigan Dept Community Hlth, Lansing, MI USA. [Wang, Yun F. (Wayne)] Emory Univ, Sch Med, Atlanta, GA USA. [Wang, Yun F. (Wayne)] Grady Mem Hosp, Atlanta, GA USA. RP Tyrrell, FC (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM ftyrrell@cdc.gov NR 36 TC 6 Z9 7 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2012 VL 50 IS 10 BP 3275 EP 3282 DI 10.1128/JCM.01225-12 PG 8 WC Microbiology SC Microbiology GA 007DY UT WOS:000308870200020 PM 22837326 ER PT J AU Bunnell, R O'Neil, D Soler, R Payne, R Giles, WH Collins, J Bauer, U AF Bunnell, Rebecca O'Neil, Dara Soler, Robin Payne, Rebecca Giles, Wayne H. Collins, Janet Bauer, Ursula CA Communities Putting Prevention TI Fifty Communities Putting Prevention to Work: Accelerating Chronic Disease Prevention Through Policy, Systems and Environmental Change SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Chronic disease prevention; Obesity; Nutrition; Physical activity; Tobacco; Community; health; Policy; System; Environmental change ID SMOKING CESSATION COMMIT; OBESITY PREVENTION; INTERVENTION TRIAL; HEALTH; PREVALENCE; IMPACT AB The burden of preventable chronic diseases is straining our nation's health and economy. Diseases caused by obesity and tobacco use account for the largest portions of this preventable burden. CDC funded 50 communities in 2010 to implement policy, systems, and environmental (PSE) interventions in a 2-year initiative. Funded communities developed PSE plans to reduce obesity, tobacco use, and second-hand smoke exposure for their combined 55 million residents. Community outcome objectives and milestones were categorized by PSE interventions as they related to media, access, promotion, pricing, and social support. Communities estimated population reach based on their jurisdiction's census data and target populations. The average proportion of each community's population that was reached was calculated for each intervention category. Outcome objectives that were achieved within 12 months of program initiation were identified from routine program records. The average proportion of a community's jurisdictional population reached by a specific intervention varied across interventions. Mean population reach for obesity-prevention interventions was estimated at 35%, with 14 (26%) interventions covering over 50% of the jurisdictional populations. For tobacco prevention, mean population reach was estimated at 67%, with 16 (84%) interventions covering more than 50% of the jurisdictional populations. Within 12 months, communities advanced over one-third of their obesity and tobacco-use prevention strategies. Tobacco interventions appeared to have higher potential population reach than obesity interventions within this initiative. Findings on the progress and potential reach of this major initiative may help inform future chronic disease prevention efforts. C1 [Bunnell, Rebecca; Soler, Robin; Payne, Rebecca] Ctr Dis Control & Prevent, Div Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [O'Neil, Dara] ICF Int, Atlanta, GA 30329 USA. [Giles, Wayne H.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Bunnell, R (reprint author), Ctr Dis Control & Prevent, Div Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,MS K45, Atlanta, GA 30341 USA. EM rrb7@cdc.gov NR 36 TC 88 Z9 88 U1 0 U2 27 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 J9 J COMMUN HEALTH JI J. Community Health PD OCT PY 2012 VL 37 IS 5 BP 1081 EP 1090 DI 10.1007/s10900-012-9542-3 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 002MU UT WOS:000308537100021 PM 22323099 ER PT J AU Dorman, SE Goldberg, S Stout, JE Muzanyi, G Johnson, JL Weiner, M Bozeman, L Heilig, CM Feng, PJ Moro, R Narita, M Nahid, P Ray, S Bates, E Haile, B Nuermberger, EL Vernon, A Schluger, NW AF Dorman, Susan E. Goldberg, Stefan Stout, Jason E. Muzanyi, Grace Johnson, John L. Weiner, Marc Bozeman, Lorna Heilig, Charles M. Feng, Pei-Jean Moro, Ruth Narita, Masahiro Nahid, Payam Ray, Susan Bates, Edward Haile, Betial Nuermberger, Eric L. Vernon, Andrew Schluger, Neil W. CA TB Trials Consortium TI Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; DOSE PHARMACOKINETICS; MURINE TUBERCULOSIS; HEALTHY-VOLUNTEERS; MOXIFLOXACIN; REGIMENS; DRUGS; CHEMOTHERAPY; SINGLE; TWICE AB Methods. In total, 531 adults with sputum smear-positive pulmonary tuberculosis were randomized to rifapentine 10 mg/kg/dose or rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks (intensive phase), with isoniazid, pyrazinamide, and ethambutol. Coprimary outcomes were negative sputum culture on liquid and on solid media at completion of intensive phase. Results. Negative cultures on solid media occurred in 145 of 174 participants (83.3%) in the rifampin group and 171 of 198 participants (86.4%) in the rifapentine group (difference, 3.0%; 95% confidence interval [CI]: - 4.3, 10.5); negative cultures in liquid media occurred in 110 of 169 (65.1%) in the rifampin group and 133 of 196 (67.9%) in the rifapentine group (difference, 2.8%; 95% CI: -6.9, 12.4). Among 529 participants who received study therapy, 40 of 254 participants (15.7%) in the rifampin group and 40 of 275 participants (14.5%) in the rifapentine group prematurely discontinued treatment (P = .79). Conclusions. The rifapentine regimen was safe but not significantly more active than a standard rifampin regimen, by the surrogate endpoint of culture status at completion of intensive phase. Assessment of higher exposures to rifapentine for tuberculosis treatment is warranted. Clinical Trials registration. NCT00694629. C1 [Dorman, Susan E.] Johns Hopkins Univ, Ctr TB Res, Sch Med, Baltimore, MD 21231 USA. [Goldberg, Stefan; Bozeman, Lorna; Heilig, Charles M.; Feng, Pei-Jean; Moro, Ruth; Vernon, Andrew] Ctr Dis Control & Prevent, Atlanta, GA USA. [Stout, Jason E.] Duke Univ, Sch Med, Durham, NC USA. [Muzanyi, Grace; Johnson, John L.] Uganda Case Western Reserve Univ Res Collaborat, Kampala, Uganda. [Johnson, John L.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Weiner, Marc] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Narita, Masahiro] Univ Washington, Seattle, WA 98195 USA. [Nahid, Payam] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ray, Susan] Emory Univ, Sch Med, Atlanta, GA USA. [Weiner, Marc] S Texas VAMC, San Antonio, TX USA. [Bates, Edward] Univ N Texas, Denton, TX 76203 USA. [Haile, Betial] Westat Corp, Rockville, MD USA. [Schluger, Neil W.] Columbia Univ, Med Ctr, New York, NY USA. RP Dorman, SE (reprint author), Johns Hopkins Univ, Ctr TB Res, Sch Med, 1550 Orleans St,Rm 1M-12, Baltimore, MD 21231 USA. EM dsusan1@jhmi.edu RI Heilig, Charles/C-2753-2008; Alcaide, Fernando/B-4124-2015; OI Heilig, Charles/0000-0003-1075-1310; Mayanja-Kizza, Harriet/0000-0002-9297-6208; Joloba, Moses/0000-0002-0334-9983; Millet, Joan Pau/0000-0003-0200-2459; Stout, Jason/0000-0002-6698-8176; Alcaide, Fernando/0000-0002-4097-1499; Falco, Vicenc/0000-0001-9626-0023; de Souza Galvao, Maria Luiza/0000-0001-9703-989X FU US Government Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC); Sanofi-Aventis FX This work was supported by the US Government Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Sanofi-Aventis donated rifapentine and rifampin and donated over $1 million to the CDC Foundation to supplement available US federal funding for rifapentine research. NR 37 TC 49 Z9 51 U1 2 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2012 VL 206 IS 7 BP 1030 EP 1040 DI 10.1093/infdis/jis461 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 002JW UT WOS:000308529200007 PM 22850121 ER PT J AU Uzicanin, A Thompson, M Smith, P Chaves, SS Foster, L Dube, N Graitcer, S Jackson, R Ferdinands, J Gargiullo, P Mills, D Monto, AS Shay, DK AF Uzicanin, Amra Thompson, Mark Smith, Peter Chaves, Sandra S. Foster, Lydia Dube, Nancy Graitcer, Samuel Jackson, Rebel Ferdinands, Jill Gargiullo, Paul Mills, Dora Monto, Arnold S. Shay, David K. CA Maine 2009 Influenza A H1N1 TI Effectiveness of 1 Dose of Influenza A (H1N1) 2009 Monovalent Vaccines in Preventing Reverse-Transcription Polymerase Chain Reaction-Confirmed H1N1 Infection Among School-Aged Children in Maine SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID ANTIBODY-RESPONSE; UNITED-STATES; RISK GROUPS; VACCINATION AB Methods. A case-control evaluation of 2009 H1N1 vaccine effectiveness was conducted in schools in Cumberland County, Maine. A case was a child who had an acute respiratory illness during 2 November-18 December 2009, and who tested positive for pH1N1 by real-time reverse-transcription polymerase chain reaction (rRT-PCR). For each case, >= 4 event time-matched controls were sampled among classmates present in school during the study period who did not have an influenza-like illness. Vaccine effectiveness was calculated as (1 - adjusted odds ratio [aOR]) x 100%; aOR was estimated by using weighted logistic regression. Results. After adjusting for a diagnosis of asthma, 1 dose of 2009 H1N1 vaccine provided 69% protection (95% confidence interval (CI), 13-89) against rRT-PCR-confirmed H1N1 infection. Vaccine effectiveness estimates for live attenuated and inactivated vaccine were 81% (95% CI, -37 to 97), and 58% (95% CI: -39 to 87), respectively. Conclusions. One dose of monovalent pandemic vaccine provided substantial protection against pH1N1 infection among school-aged children. C1 [Uzicanin, Amra] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Thompson, Mark; Chaves, Sandra S.; Foster, Lydia; Graitcer, Samuel; Jackson, Rebel; Ferdinands, Jill; Gargiullo, Paul; Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Smith, Peter; Mills, Dora] Maine Ctr Dis Control & Prevent, Augusta, GA USA. [Dube, Nancy] Maine Dept Educ, Augusta, GA USA. [Monto, Arnold S.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA. RP Uzicanin, A (reprint author), Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, 1600 Clifton Rd,MS E-03, Atlanta, GA 30333 USA. EM aau5@cdc.gov OI Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention; sonofi-pasteur FX This work was supported by the Centers for Disease Control and Prevention.; A. S. M. served as consultant to Glaxosmithkline, Novartis, Novavax, and Roche and received grants from sonofi-pasteur. All other authors report no potential conflicts. NR 21 TC 12 Z9 12 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD OCT 1 PY 2012 VL 206 IS 7 BP 1059 EP 1068 DI 10.1093/infdis/jis441 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 002JW UT WOS:000308529200010 PM 22850120 ER PT J AU DeByle, C Bulkow, L Miernyk, K Chikoyak, L Hummel, KB Hennessy, T Singleton, R AF DeByle, Carolynn Bulkow, Lisa Miernyk, Karen Chikoyak, Lori Hummel, Kimberlee Boyd Hennessy, Thomas Singleton, Rosalyn TI Comparison of nasopharyngeal flocked swabs and nasopharyngeal wash collection methods for respiratory virus detection in hospitalized children using real-time polymerase chain reaction SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Real-time PCR; Nasopharyngeal flocked swabs; Respiratory virus detection; Clinical setting ID TRANSCRIPTION-PCR ASSAY; RT-PCR; MOLECULAR-DETECTION; SYNCYTIAL VIRUS; NASAL SWAB; SPECIMENS; INFECTIONS; RECIPIENTS; DIAGNOSIS; TODDLERS AB This paper describes the molecular detection of respiratory viruses from nasopharyngeal flocked swabs (flocked swabs) and nasopharyngeal washes (washes) in a clinical setting. Washes and flocked swabs collected from children <3 years old hospitalized with a lower respiratory tract infection were tested for parainfluenza virus 1-3, respiratory syncytial virus, influenza A and B and metapneumovirus (Group 1) and adenovirus, rhinovirus and coronavirus (Group 2) using real-time reverse transcriptase PCR (rRT-PCR). A consensuses standard was used to determine sensitivity and compare cycle thresholds (C-T) of washes and flocked swabs for each virus and group of viruses. Sensitivities ranged from 79 to 89% and 69 to 94% for flocked swabs and washes, respectively, excluding AdV which had a sensitivity of 35% for flocked swabs. When the flocked swabs and washes of Group 1 viruses were collected on the day of admission, the sensitivity of both sample types was 100%. Wash specimens had a lower C-T value and higher sensitivity than flocked swabs; however there was no statistical difference in the sensitivity of a flocked swab (89%) versus wash (93%) for the detection of Group 1 viruses, particularly when samples were collected on the same day. Flocked swabs may be a useful alternative to washes for detection of respiratory viruses in clinical settings. Published by Elsevier B.V. C1 [DeByle, Carolynn; Bulkow, Lisa; Miernyk, Karen; Hummel, Kimberlee Boyd; Hennessy, Thomas; Singleton, Rosalyn] Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, Anchorage, AK 99508 USA. [Miernyk, Karen; Singleton, Rosalyn] Alaska Native Tribal Hlth Consortium, Anchorage, AK 99508 USA. [Chikoyak, Lori] Yukon Kuskokwim Hlth Corp, Bethel, AK 99559 USA. RP DeByle, C (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Div Preparedness & Emerging Infect, Natl Ctr Emerging & Zoonot Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM cdebyle@cdc.gov FU Intramural CDC HHS [CC999999] NR 26 TC 17 Z9 17 U1 1 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD OCT PY 2012 VL 185 IS 1 BP 89 EP 93 DI 10.1016/j.jviromet.2012.06.009 PG 5 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 990FC UT WOS:000307615400013 PM 22728277 ER PT J AU Beutin, L Hammerl, JA Strauch, E Reetz, J Dieckmann, R Kelner-Burgos, Y Martin, A Miko, A Strockbine, NA Lindstedt, BA Horn, D Monse, H Huettel, B Muller, I Stuber, K Reinhardt, R AF Beutin, Lothar Hammerl, Jens Andre Strauch, Eckhard Reetz, Jochen Dieckmann, Ralf Kelner-Burgos, Ylanna Martin, Annett Miko, Angelika Strockbine, Nancy A. Lindstedt, Bjorn Arne Horn, Detlef Monse, Hella Huettel, Bruno Mueller, Ines Stueber, Kurt Reinhardt, Richard TI Spread of a Distinct Stx2-Encoding Phage Prototype among Escherichia coli O104:H4 Strains from Outbreaks in Germany, Norway, and Georgia SO JOURNAL OF VIROLOGY LA English DT Article ID HEMOLYTIC-UREMIC SYNDROME; SHIGA TOXIN 2; GENOMIC SEQUENCE; GENE; BACTERIOPHAGE; O157-H7; VARIANTS; ASSOCIATION; EXPRESSION; INFECTION AB Shiga toxin 2 (Stx2)-producing Escherichia coli (STEC) O104:H4 caused one of the world's largest outbreaks of hemorrhagic colitis and hemolytic uremic syndrome in Germany in 2011. These strains have evolved from enteroaggregative E. coli (EAEC) by the acquisition of the Stx2 genes and have been designated enteroaggregative hemorrhagic E. coli. Nucleotide sequencing has shown that the Stx2 gene is carried by prophages integrated into the chromosome of STEC O104: H4. We studied the properties of Stx2-encoding bacteriophages which are responsible for the emergence of this new type of E. coli pathogen. For this, we analyzed Stx bacteriophages from STEC O104: H4 strains from Germany (in 2001 and 2011), Norway (2006), and the Republic of Georgia (2009). Viable Stx2-encoding bacteriophages could be isolated from all STEC strains except for the Norwegian strain. The Stx2 phages formed lysogens on E. coli K-12 by integration into the wrbA locus, resulting in Stx2 production. The nucleotide sequence of the Stx2 phage P13374 of a German STEC O104: H4 outbreak was determined. From the bioinformatic analyses of the prophage sequence of 60,894 bp, 79 open reading frames were inferred. Interestingly, the Stx2 phages from the German 2001 and 2011 outbreak strains were found to be identical and closely related to the Stx2 phages from the Georgian 2009 isolates. Major proteins of the virion particles were analyzed by mass spectrometry. Stx2 production in STEC O104: H4 strains was inducible by mitomycin C and was compared to Stx2 production of E. coli K-12 lysogens. C1 [Beutin, Lothar; Hammerl, Jens Andre; Strauch, Eckhard; Reetz, Jochen; Dieckmann, Ralf; Kelner-Burgos, Ylanna; Miko, Angelika] Fed Inst Risk Assessment, Dept Biol Safety, Berlin, Germany. [Martin, Annett] Fed Inst Risk Assessment, Epidemiol Serv, Berlin, Germany. [Martin, Annett] Fed Inst Risk Assessment, Biostat & Math Modelling Serv, Berlin, Germany. [Martin, Annett] Fed Inst Risk Assessment, Sci Serv, Berlin, Germany. [Strockbine, Nancy A.] Ctr Dis Control & Prevent, Escherichia & Shigella Reference Unit, Atlanta, GA USA. [Lindstedt, Bjorn Arne] Norwegian Inst Publ Hlth, Dept Foodborne Infect, Oslo, Norway. [Horn, Detlef; Monse, Hella] Chem & Vet Untersuchungsamt Rhein Ruhr Wupper, CVUA RRW, Krefeld, Germany. [Huettel, Bruno; Mueller, Ines; Stueber, Kurt; Reinhardt, Richard] Max Planck Genomzentrum, Cologne, Germany. RP Beutin, L (reprint author), Fed Inst Risk Assessment, Dept Biol Safety, Berlin, Germany. EM lothar.beutin@bfr.bund.de; jens-andre.hammerl@bfr.bund.de OI Hammerl, Jens Andre/0000-0002-6930-4358 FU BMBF FX J. A. Hammerl was supported by a grant of the BMBF-funded project SiLeBAT. NR 55 TC 14 Z9 14 U1 0 U2 21 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2012 VL 86 IS 19 BP 10444 EP 10455 DI 10.1128/JVI.00986-12 PG 12 WC Virology SC Virology GA 005HE UT WOS:000308740700019 PM 22811533 ER PT J AU Bergeron, E Chakrabarti, AK Bird, BH Dodd, KA McMullan, LK Spiropoulou, CF Nichol, ST Albarino, CG AF Bergeron, Eric Chakrabarti, Ayan K. Bird, Brian H. Dodd, Kim A. McMullan, Laura K. Spiropoulou, Christina F. Nichol, Stuart T. Albarino, Cesar G. TI Reverse Genetics Recovery of Lujo Virus and Role of Virus RNA Secondary Structures in Efficient Virus Growth SO JOURNAL OF VIROLOGY LA English DT Article ID LYMPHOCYTIC CHORIOMENINGITIS VIRUS; TRANSCRIPTION TERMINATION; TACARIBE VIRUS; SEQUENCE CONSERVATION; PICHINDE ARENAVIRUS; GENOME REPLICATION; HEMORRHAGIC-FEVER; INTERGENIC REGION; MESSENGER-RNAS; LASSA-VIRUS AB Arenaviruses are rodent-borne viruses with a bisegmented RNA genome. A genetically unique arenavirus, Lujo virus, was recently discovered as the causal agent of a nosocomial outbreak of acute febrile illness with hemorrhagic manifestations in Zambia and South Africa. The outbreak had a case fatality rate of 80%. A reverse genetics system to rescue infectious Lujo virus from cDNA was established to investigate the biological properties of this virus. Sequencing the genomic termini showed unique nucleotides at the 3' terminus of the S segment promoter element. While developing this system, we discovered that reconstructing infectious Lujo virus using the previously reported L segment intergenic region (IGR), comprising the arenaviral transcription termination signal, yielded an attenuated Lujo virus. Resequencing revealed that the correct L segment IGR was 36 nucleotides longer, and incorporating it into the reconstructed Lujo virus restored the growth rate to that of the authentic clinical virus isolate. These additional nucleotides were predicted to more than double the free energy of the IGR main stem-loop structure. In addition, incorporating the newly determined L-IGR into a replicon reporter system enhanced the expression of a luciferase reporter L segment. Overall, these results imply that an extremely stable secondary structure within the L-IGR is critical for Lujo virus propagation and viral protein production. The technology for producing recombinant Lujo virus now provides a method to precisely investigate the molecular determinants of virulence of this newly identified pathogen. C1 [Bergeron, Eric; Chakrabarti, Ayan K.; Bird, Brian H.; Dodd, Kim A.; McMullan, Laura K.; Spiropoulou, Christina F.; Nichol, Stuart T.; Albarino, Cesar G.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. RP Bergeron, E (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Atlanta, GA 30329 USA. EM ebergeron@cdc.gov NR 38 TC 9 Z9 9 U1 2 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD OCT PY 2012 VL 86 IS 19 BP 10759 EP 10765 DI 10.1128/JVI.01144-12 PG 7 WC Virology SC Virology GA 005HE UT WOS:000308740700051 PM 22837210 ER PT J AU Gong, F Castaneda, D Zhang, X Stock, L Ayala, L Baron, S AF Gong, Fang Castaneda, Diego Zhang, Xu Stock, Laura Ayala, Linda Baron, Sherry TI Using the Associative Imagery Technique in Qualitative Health Research: The Experiences of Homecare Workers and Consumers SO QUALITATIVE HEALTH RESEARCH LA English DT Article DE focus groups; occupational health; relationships, research; research, qualitative ID CARE WORKERS; JOB STRESS; COMPREHENSION; PICTURES AB The associative imagery technique is a qualitative tool with which researchers use carefully selected photographs or images to trigger participants' responses to explain difficult behavioral and social concepts. In this article, we describe the development and implementation of the associative imagery method in focus groups to understand the complex relationships between homecare workers and their clients as part of a larger health and safety intervention project conducted by the National Institute for Occupational Safety and Health. A total of 116 homecare workers and clients were recruited for the study. We found that participants used images mainly in two ways. First, the images served to remind participants of specific persons, events, and/or objects. Second, the images facilitated recollections and reflections that allowed participants to metaphorically describe their experiences, feelings, and emotions. Both usages of imagery generated comments that answered the research question in a more relevant, descriptive, and vivid way. C1 [Gong, Fang] Ball State Univ, Dept Sociol, Muncie, IN 47306 USA. [Castaneda, Diego] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Ayala, Linda] Alameda Alliance Hlth, Alameda, CA USA. [Baron, Sherry] NIOSH, Cincinnati, OH 45226 USA. [Stock, Laura] Univ Calif Berkeley, Labor Occupat Hlth Program, Berkeley, CA 94720 USA. RP Gong, F (reprint author), Ball State Univ, Dept Sociol, Muncie, IN 47306 USA. EM fgong@bsu.edu NR 20 TC 1 Z9 1 U1 0 U2 3 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-7323 J9 QUAL HEALTH RES JI Qual. Health Res. PD OCT PY 2012 VL 22 IS 10 SI SI BP 1414 EP 1424 DI 10.1177/1049732312452935 PG 11 WC Information Science & Library Science; Social Sciences, Interdisciplinary; Social Sciences, Biomedical SC Information Science & Library Science; Social Sciences - Other Topics; Biomedical Social Sciences GA 995SL UT WOS:000308032800010 PM 22851495 ER PT J AU Krishnarao, A de Leon, L Bright, R Leleiko, N Sands, B Shah, S Merrick, M Flowers, N AF Krishnarao, Anita de Leon, Lauren Bright, Renee Leleiko, Neil Sands, Bruce Shah, Samir Merrick, Marjorie Flowers, Nicole TI Low Rate of Clostridium difficile Infection Testing in Patients with Newly Diagnosed Inflammatory Bowel Disease and Diarrhea SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract C1 [Krishnarao, Anita] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [de Leon, Lauren; Bright, Renee; Shah, Samir] Rhode Isl Hosp, Providence, RI USA. [Leleiko, Neil] Hasbro Childrens Hosp, Providence, RI USA. [Sands, Bruce] Mt Sinai Hosp, New York, NY 10029 USA. [Merrick, Marjorie] Crohns & Colitis Fdn Amer, New York, NY USA. [Flowers, Nicole] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2012 VL 107 SU 1 MA 1631 BP S659 EP S660 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA V30UA UT WOS:000208839702515 ER PT J AU Biggerstaff, M Jhung, M Kamimoto, L Balluz, L Finelli, L AF Biggerstaff, Matthew Jhung, Michael Kamimoto, Laurie Balluz, Lina Finelli, Lyn TI Self-Reported Influenza-Like Illness and Receipt of Influenza Antiviral Drugs During the 2009 Pandemic, United States, 2009-2010 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article AB Objectives. The purpose of our study was to more accurately characterize people reporting influenza-like illness (ILI) and evaluate trends in health care seeking and influenza diagnosis and treatment during the 2009 influenza pandemic. Methods. From September 2009 to March 2010, we ascertained ILI (fever with cough or sore throat), health care seeking, and clinical diagnosis and treatment of influenza with influenza antiviral drugs among adults in 51 jurisdictions, and ILI and health care seeking among children in 41 jurisdictions. Results. Among 216 431 adults and 43 511 children, 8.1% and 28.4% reported ILI, respectively. ILI peaked during November interviews and was higher among young people and American Indian/Alaska Natives. Of those with ILI, 40% of adults and 56% of children reported seeking health care; 26% of adults who sought care reported receiving a diagnosis of influenza. Of adults reporting an influenza diagnosis, 36% were treated with influenza antiviral drugs; treatment was highest among adults aged 18 to 49 years. Conclusions. Analysis of ILI data from the Behavioral Risk Factor Surveillance System enabled a better understanding of the factors associated with self-reported ILI, health care seeking, and clinical influenza diagnosis and treatment, and will help inform year-to-year influenza trends. C1 [Biggerstaff, Matthew; Jhung, Michael; Kamimoto, Laurie; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Balluz, Lina] Ctr Dis Control & Prevent, Div Behav Surveillance, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Biggerstaff, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE MS A-32, Atlanta, GA 30333 USA. EM mbiggerstaff@cdc.gov NR 23 TC 15 Z9 15 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2012 VL 102 IS 10 BP E21 EP E26 DI 10.2105/AJPH.2012.300651 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V41XH UT WOS:000209578400009 PM 22897525 ER PT J AU Scutchfield, FD Michener, JL Thacker, SB AF Scutchfield, F. Douglas Michener, J. Lloyd Thacker, Stephen B. TI INTEGRATING PRIMARY CARE AND PUBLIC HEALTH RESPOND SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter C1 [Scutchfield, F. Douglas] Univ Kentucky, Coll Publ Hlth, Lexington, KY 40506 USA. [Scutchfield, F. Douglas] Univ Kentucky, Coll Med, Lexington, KY 40506 USA. [Michener, J. Lloyd] Duke Univ, Med Ctr, Dept Community & Family Med, Box 2914 DUMC, Durham, NC 27710 USA. [Thacker, Stephen B.] Ctr Dis Control & Prevent, Surveillance Serv, Atlanta, GA USA. [Thacker, Stephen B.] Ctr Dis Control & Prevent, Epidemiol Serv, Atlanta, GA USA. [Thacker, Stephen B.] Ctr Dis Control & Prevent, Lab Serv, Atlanta, GA USA. RP Michener, JL (reprint author), Duke Univ, Med Ctr, Dept Community & Family Med, Box 2914 DUMC, Durham, NC 27710 USA. EM miche001@mc.duke.edu NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD OCT PY 2012 VL 102 IS 10 BP E1 EP E2 DI 10.2105/AJPH.2012.301012 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V41XH UT WOS:000209578400002 ER PT J AU Blanck, HM Allen, D Bashir, Z Gordon, N Goodman, A Merriam, D Rutt, C AF Blanck, Heidi M. Allen, Diana Bashir, Zarnaaz Gordon, Nina Goodman, Alyson Merriam, Dee Rutt, Candace TI Let's Go to the Park Today: The Role of Parks in Obesity Prevention and Improving the Public's Health SO CHILDHOOD OBESITY LA English DT Article AB Let's go to the park today! This familiar phrase is heard routinely throughout the year in many U. S. households. Access to parks, trails, open spaces, and recreational facilities not only provides increased opportunities for children and adults to play and be physically active, but these venues also influence other behaviors. As the health and wellbeing of our children are impacted by the daily environment in which they live, learn, and play, the use of parks and other recreation spaces as a healthful venue is important to consider in a comprehensive view of childhood and family obesity prevention. This article briefly summarizes some of the obesity-related benefits of parks across the local, state, and national park systems and highlights specific initiatives as examples of the commitment by park agencies to benefit the public's health and play a role in obesity and chronic disease prevention. C1 [Blanck, Heidi M.; Goodman, Alyson; Rutt, Candace] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Allen, Diana] Natl Pk Serv, Off Publ Hlth, Hlth Promot Branch, Washington, DC 20240 USA. [Bashir, Zarnaaz] Natl Recreat & Pk Assoc, Hlth Initiat, Ashburn, VA USA. [Gordon, Nina] Calif State Pk, Sacramento, CA USA. [Goodman, Alyson] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Merriam, Dee] Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, Hlth Community Design Initiat, Atlanta, GA USA. RP Blanck, HM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, 4770 Buford Highway NE,MS K-26, Atlanta, GA 30341 USA. EM hblanck@cdc.gov NR 31 TC 14 Z9 14 U1 3 U2 12 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-2168 EI 2153-2176 J9 CHILD OBES JI Child Obes. PD OCT PY 2012 VL 8 IS 5 BP 423 EP 428 DI 10.1089/chi.2012.0085.blan PG 6 WC Pediatrics SC Pediatrics GA V32JK UT WOS:000208947300003 PM 23061497 ER PT J AU An, Y Gregg, E Zhang, P Wang, J Gong, Q Engelgau, M Roglic, G Bennett, PH Li, G AF An, Y. Gregg, E. Zhang, P. Wang, J. Gong, Q. Engelgau, M. Roglic, G. Bennett, P. H. Li, G. TI Long-duration diabetes reduces physical function in Chinese adults: Da Qing IGT and diabetes study SO DIABETOLOGIA LA English DT Meeting Abstract C1 [An, Y.; Gong, Q.] Fuwai Hosipital, Endocrine Dept, Beijing, Peoples R China. [Gregg, E.; Zhang, P.; Engelgau, M.] CDC, Atlanta, GA 30333 USA. [Wang, J.] DaQing First Hosp, Daqing, Peoples R China. [Roglic, G.] WHO, CH-1211 Geneva, Switzerland. [Bennett, P. H.] NIDDK, Phoenix, AZ USA. [Li, G.] China Japan Friendship Hosp, Beijing, Peoples R China. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD OCT PY 2012 VL 55 SU 1 MA 1204 BP S489 EP S489 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA V30OY UT WOS:000208826502519 ER PT J AU Hall, AJ Eisenbart, VG Etingue, AL Gould, LH Lopman, BA Parashar, UD AF Hall, Aron J. Eisenbart, Valerie G. Etinguee, Amy Lehman Gould, L. Hannah Lopman, Ben A. Parashar, Umesh D. TI Epidemiology of Foodborne Norovirus Outbreaks, United States, 2001-2008 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID DISEASE OUTBREAKS; NORWALK VIRUS; FELINE CALICIVIRUS; MURINE NOROVIRUS; GII.4 NOROVIRUS; GASTROENTERITIS; SURVEILLANCE; PREVALENCE; EXCRETION; INFECTION AB Noroviruses are the leading cause of foodborne illness in the United States. To better guide interventions, we analyzed 2,922 foodborne disease outbreaks for which norovirbs was the suspected or confirmed cause, which had been reported to the Foodborne Disease Outbreak Surveillance System of the Centers for Disease Control and Prevention during 2001-2008. On average, 365 foodborne norovirus outbreaks were reported annually, resulting in an estimated 10,324 illnesses, 1,247 health care provider visits, 156 hospitalizations, and 1 death. In 364 outbreaks attributed to a single commodity, leafy vegetables (33%), fruits/nuts (16%), and mollusks (13%) were implicated most commonly. Infected food handlers were the source of 53% of outbreaks and may have contributed to 82% of outbreaks. Most foods were likely contaminated during preparation and service, except for mollusks, and occasionally, produce was contaminated during production and processing. Interventions to reduce the frequency of foodborne norovirus outbreaks should focus on food workers and production of produce and shellfish. C1 [Hall, Aron J.; Eisenbart, Valerie G.; Etinguee, Amy Lehman; Gould, L. Hannah; Lopman, Ben A.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Eisenbart, Valerie G.] Univ Illinois, Urbana, IL 61801 USA. [Etinguee, Amy Lehman] N Carolina State Univ, Raleigh, NC 27695 USA. RP Hall, AJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30333 USA. EM ajhall@cdc.gov FU Agriculture and Food Research Initiative Competitive Grant from the US Department of Agriculture, National Institute of Food and Agriculture [2011-68003-30395] FX This project was supported in part by Agriculture and Food Research Initiative Competitive Grant no. 2011-68003-30395 from the US Department of Agriculture, National Institute of Food and Agriculture. NR 39 TC 87 Z9 89 U1 3 U2 33 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2012 VL 18 IS 10 BP 1566 EP 1573 DI 10.3201/eid1810.120833 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LP UT WOS:000328172500002 PM 23017158 ER PT J AU Diack, AB Ritchie, D Bishop, M Pinion, V Brandel, JP Haik, S Tagliavini, F Van Duijn, C Belay, ED Gambetti, P Schonberger, LB Piccardo, P Will, RG Manson, JC AF Diack, Abigail B. Ritchie, Diane Bishop, Matthew Pinion, Victoria Brandel, Jean-Philippe Haik, Stephane Tagliavini, Fabrizio Van Duijn, Cornelia Belay, Ermias D. Gambetti, Pierluigi Schonberger, Lawrence B. Piccardo, Pedro Will, Robert G. Manson, Jean C. TI Constant Transmission Properties of Variant Creutzfeldt-Jakob Disease in 5 Countries SO EMERGING INFECTIOUS DISEASES LA English DT Article ID UNITED-KINGDOM; SCRAPIE; AGENT; MICE; STRAINS; FRANCE; BSE AB Variant Creutzfeldt-Jakob disease (vCJD) has been reported in 12 countries. We hypothesized that a common strain of agent is responsible for all vCJD cases, regardless of geographic origin. To test this hypothesis, we inoculated strain-typing panels of wild-type mice with brain material from human vCJD case-patients from France, the Netherlands, Italy, and the United States. Mice were assessed for clinical disease, neuropathologic changes, and glycoform profile; results were compared with those for 2 reference vCJD cases from the United Kingdom. Transmission to mice occurred from each sample tested, and data were similar between non-UK and UK cases, with the exception of the ranking of mean clinical incubation times of mouse lines. These findings support the hypothesis that a single strain of infectious agent is responsible for all vCJD infections. However, differences in incubation times require further subpassage in mice to establish any true differences in strain properties between cases. C1 [Diack, Abigail B.; Pinion, Victoria; Manson, Jean C.] Roslin Inst, Easter Bush, Scotland. [Ritchie, Diane; Bishop, Matthew; Will, Robert G.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Brandel, Jean-Philippe; Haik, Stephane] Univ Paris 06, INSERM, Paris, France. [Brandel, Jean-Philippe; Haik, Stephane] CNRS, Paris, France. [Tagliavini, Fabrizio] Fdaz IRCCS Ist Neurol Carlo Besta, Milan, Italy. [Van Duijn, Cornelia] Erasmus Univ, Sch Med, Rotterdam, Netherlands. [Belay, Ermias D.; Schonberger, Lawrence B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gambetti, Pierluigi] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Piccardo, Pedro] US FDA, Rockville, MD 20857 USA. RP Manson, JC (reprint author), Univ Edinburgh, Roslin Inst, Easter Bush EH25 9RG, Midlothian, Scotland. EM jean.manson@roslin.ed.ac.uk FU Neuroprion; Department of Health (England) FX This project was funded by Neuroprion and the Department of Health (England). NR 14 TC 6 Z9 6 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2012 VL 18 IS 10 BP 1574 EP 1579 DI 10.3201/eid1810.120792 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LP UT WOS:000328172500003 PM 23017202 ER PT J AU Ye, JB Xiao, LH Ma, JB Guo, MJ Liu, LL Feng, YY AF Ye, Jianbin Xiao, Lihua Ma, Jingbo Guo, Meijin Liu, Lili Feng, Yaoyu TI Anthroponotic Enteric Parasites in Monkeys in Public Park, China SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ENTEROCYTOZOON-BIENEUSI; GIARDIA-DUODENALIS AB Cryptosporidium spp., Giardia duodenalis, and Enterocytozoon bieneusi were detected in 45, 35, and 116 of 411 free-range rhesus monkeys, respectively, in a popular public park in the People's Republic of China. Most genotypes and subtypes detected were anthroponotic, indicating these animals might be reservoirs for human cryptosporidiosis, giardiasis, and microsporidiosis. C1 [Ye, Jianbin; Ma, Jingbo; Guo, Meijin; Liu, Lili; Feng, Yaoyu] E China Univ Sci & Technol, Shanghai 200237, Peoples R China. [Ye, Jianbin; Xiao, Lihua] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Resources & Environm Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31110103901, 31229005, 41001316]; National Basic Research Program of China (973 Project) [2011CB200903]; Fundamental Research Funds for the Central Universities; State Key Laboratory of Veterinary Etiological Biology at the Lanzhou Veterinary Research Institute; State Key Laboratory of Bioreactor Engineering at East China University of Science and Technology FX This work was supported in part by the National Natural Science Foundation of China (31110103901, 31229005, 41001316), the National Basic Research Program of China (973 Project) (2011CB200903), Fundamental Research Funds for the Central Universities, and Open Funding Projects of the State Key Laboratory of Veterinary Etiological Biology at the Lanzhou Veterinary Research Institute and State Key Laboratory of Bioreactor Engineering at East China University of Science and Technology. NR 9 TC 43 Z9 47 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2012 VL 18 IS 10 BP 1640 EP 1643 DI 10.3201/eid1810.120653 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LP UT WOS:000328172500014 PM 23017776 ER PT J AU Cohen, NJ Slaten, DD Marano, N Tappero, JW Wellman, M Albert, RJ Hill, VR Espey, D Handzel, T Henry, A Tauxe, RV AF Cohen, Nicole J. Slaten, Douglas D. Marano, Nina Tappero, Jordan W. Wellman, Michael Albert, Ryan J. Hill, Vincent R. Espey, David Handzel, Thomas Henry, Ariel Tauxe, Robert V. TI Preventing Maritime Transfer of Toxigenic Vibrio cholerae SO EMERGING INFECTIOUS DISEASES LA English DT Article ID WATER; PATHOGENS; BALLAST AB Organisms, including Vibrio cholerae, can be transferred between harbors in the ballast water of ships. Zones in the Caribbean region where distance from shore and water depth meet International Maritime Organization guidelines for ballast water exchange are extremely limited. Use of ballast water treatment systems could mitigate the risk for organism transfer. C1 [Cohen, Nicole J.; Slaten, Douglas D.; Marano, Nina; Tappero, Jordan W.; Wellman, Michael; Hill, Vincent R.; Espey, David; Handzel, Thomas; Tauxe, Robert V.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Albert, Ryan J.] US EPA, Washington, DC 20460 USA. [Henry, Ariel] Haitian Minist Publ Hlth & Populat, Portau Prince, Haiti. RP Cohen, NJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E03, Atlanta, GA 30333 USA. EM hei1@cdc.gov NR 15 TC 6 Z9 6 U1 0 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2012 VL 18 IS 10 BP 1680 EP 1682 DI 10.3201/eid1810.120676 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LP UT WOS:000328172500025 PM 23017338 ER PT J AU Flett, K Youngster, I Huang, J McAdam, A Sandora, TJ Rennick, M Smole, S Rogers, SL Nix, WA Oberste, MS Gellis, S Ahmed, AA AF Flett, Kelly Youngster, Ilan Huang, Jennifer McAdam, Alexander Sandora, Thomas J. Rennick, Marcus Smole, Sandra Rogers, Shannon L. Nix, W. Allan Oberste, M. Steven Gellis, Stephen Ahmed, Asim A. TI Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID OUTBREAK; ONYCHOMADESIS C1 [Flett, Kelly; Youngster, Ilan; Huang, Jennifer; McAdam, Alexander; Sandora, Thomas J.; Gellis, Stephen; Ahmed, Asim A.] Childrens Hosp, Boston, MA 02115 USA. [Rennick, Marcus] Boston Publ Hlth Commiss, Boston, MA USA. [Smole, Sandra] Massachusetts Dept Publ Hlth, Jamaica Plain, MA USA. [Rogers, Shannon L.; Nix, W. Allan; Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ahmed, AA (reprint author), Childrens Hosp Boston Infect Dis, 300 Longwood Ave, Boston, MA 02115 USA. EM asim.ahmed@childrens.harvard.edu RI Youngster, Ilan/J-5047-2014 OI Youngster, Ilan/0000-0001-5233-1213 FU NIAID NIH HHS [K08 AI093676-02, K08 AI093676] NR 10 TC 42 Z9 49 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2012 VL 18 IS 10 BP 1702 EP 1704 DI 10.3201/eid1810.120813 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LP UT WOS:000328172500035 PM 23017893 ER PT J AU Ferrari, FAG Goddard, J Paddock, CD Varela-Stokes, AS AF Ferrari, Flavia A. G. Goddard, Jerome Paddock, Christopher D. Varela-Stokes, Andrea S. TI Rickettsia parkeri and Candidatus Rickettsia andeanae in Gulf Coast Ticks, Mississippi, USA SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID AMBLYOMMA-MACULATUM; UNITED-STATES; IDENTIFICATION; VIRGINIA C1 [Ferrari, Flavia A. G.; Goddard, Jerome; Varela-Stokes, Andrea S.] Mississippi State Univ, Mississippi State, MS 39762 USA. [Paddock, Christopher D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Varela-Stokes, AS (reprint author), Mississippi State Univ, Wise Ctr, 240 Wise Ctr Dr, Mississippi State, MS 39762 USA. EM stokes@cvm.msstate.edu NR 9 TC 21 Z9 21 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD OCT PY 2012 VL 18 IS 10 BP 1705 EP 1707 DI 10.3201/eid1810.120250 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 268LP UT WOS:000328172500037 PM 23018026 ER PT J AU Ferguson, B Baden, D AF Ferguson, Bill Baden, Dan TI An Interview with Dan Baden, MD SO GAMES FOR HEALTH JOURNAL LA English DT Editorial Material C1 [Baden, Dan] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Baden, Dan] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Off State Tribal Local & Terr Support, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2161-783X EI 2161-7856 J9 GAMES HEALTH J JI Games Health J. PD OCT PY 2012 VL 1 IS 5 BP 323 EP 325 DI 10.1089/g4h.2012.0059 PG 3 WC Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA V40YR UT WOS:000209514400002 ER PT J AU Sinha, DN Rinchen, S Palipudi, KM Shein, NNN de Silva, P Khadka, BB Pednekar, M Singh, G Pitayarangsarit, S Bhattad, VB Lee, KA Asma, S Singh, PK AF Sinha, D. N. Rinchen, S. Palipudi, K. M. Shein, Nang Naing Naing de Silva, P. Khadka, B. B. Pednekar, M. Singh, G. Pitayarangsarit, S. Bhattad, V. B. Lee, K. A. Asma, S. Singh, P. K. TI Tobacco use, exposure to second-hand smoke, and cessation training among the third-year medical and dental students in selected Member States of South-East Asia region: A trend analysis on data from the Global Health Professions Student Survey, 2005-2011 SO INDIAN JOURNAL OF CANCER LA English DT Article DE Cessation training; health professionals; medical and dental students; tobacco use AB Background: The Medical and Dental Global Health Professions Student Surveys (GHPSS) are surveys based in schools that collect self-administered data from students on the prevalence of tobacco use, exposure to second-hand smoke, and tobacco cessation training, among the third-year medical and dental students. Materials and Methods: Two rounds of medical and dental GHPSS have been conducted in Bangladesh, India, Myanmar, Nepal, Sri Lanka, and Thailand, among the third-year medical and dental students, between 2005 and 2006 and 2009 and 2011. Results: The prevalence of any tobacco use among third-year male and female medical students did not change in Bangladesh, India, and Nepal between 2005 and 2006 and 2009 and 2011; however, it reduced significantly among females in Myanmar (3.3% in 2006 to 1.8% in 2009) and in Sri Lanka (2.5% in 2006 to 0.6% in 2011). The prevalence of any tobacco use among third-year male dental students did not change in Bangladesh, India, Nepal, and Thailand between 2005 and 2006 and 2009 and 2011; however, in Myanmar, the prevalence increased significantly (35.6% in 2006 to 49.5% in 2009). Among the third-year female students, a significant increase in prevalence was noticed in Bangladesh (4.0% in 2005 to 22.2% in 2009) and Thailand (0.7% in 2006 to 2.1% in 2011). It remained unchanged in the other three countries. Prevalence of exposure to second-hand smoke (SHS) both at home and in public places, among medical students, decreased significantly in Myanmar and Sri Lanka between 2006 and 2009 and in 2011. Among dental students, the prevalence of SHS exposure at home reduced significantly in Bangladesh, India, and Myanmar, and in public places in India. However, there was an increase of SHS exposure among dental students in Nepal, both at home and in public places, between 2005 and 2011. Medical students in Myanmar, Nepal, and Sri Lanka reported a declining trend in schools, with a smoking ban policy in place, between 2005 and 2006 and 2009 and 2011, while proportions of dental students reported that schools with a smoking ban policy have increased significantly in Bangladesh and Myanmar. Ever receiving cessation training increased significantly among medical students in Sri Lanka only, whereas, among dental students, it increased in India, Nepal, and Thailand. Conclusion: Trends of tobacco use and exposure to SHS among medical and dental students in most countries of the South-East Asia Region had changed only relatively between the two rounds of GHPSS (2005-2006 and 2009-2011). No significant improvement was observed in the trend in schools with a policy banning smoking in school buildings and clinics. Almost all countries in the SEA Region that participated in GHPSS showed no significant change in ever having received formal training on tobacco cessation among medical and dental students. C1 [Sinha, D. N.; Rinchen, S.; Bhattad, V. B.; Singh, P. K.] WHO, Reg Off South East Asia, New Delhi, India. [Palipudi, K. M.; Lee, K. A.; Asma, S.] US Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Shein, Nang Naing Naing] Minist Hlth, Dept Hlth, Nay Pyi Taw, Myanmar. [de Silva, P.] Minist Healthcare & Nutr, Colombo, Sri Lanka. [Khadka, B. B.] Natl Hlth Educ Informat & Commun Ctr, Kathmandu, Nepal. [Pednekar, M.] Healis Sekhsaria Inst Publ Hlth, Bombay, Maharashtra, India. [Singh, G.] Sch Prevent Oncol, Patna, Bihar, India. [Pitayarangsarit, S.] Tobacco Control Res & Knowledge Management Ctr, Bangkok, Thailand. RP Sinha, DN (reprint author), WHO, Reg Off South East Asia, New Delhi, India. EM sinhad@who.int RI yan, liu/A-1822-2015 OI yan, liu/0000-0001-8517-1084 NR 16 TC 1 Z9 1 U1 0 U2 5 PU INDIAN CANCER SOC PI MUMBAI PA C/O DR D J JUSSAWALLA, EDITOR-IN-CHIEF, 74 JERBAI WADIA RD, PAREL, MUMBAI, 00000, INDIA SN 0019-509X EI 1998-4774 J9 INDIAN J CANCER JI Indian J. Cancer PD OCT-DEC PY 2012 VL 49 IS 4 BP 379 EP 386 DI 10.4103/0019-509X.107743 PG 8 WC Oncology SC Oncology GA V33KT UT WOS:000209018400011 PM 23442402 ER PT J AU Palipudi, KM Sinha, DN Choudhury, S Zaman, MM Asma, S Andes, L Dube, S AF Palipudi, K. M. Sinha, D. N. Choudhury, S. Zaman, M. M. Asma, S. Andes, L. Dube, S. TI Predictors of tobacco smoking and smokeless tobacco use among adults in Bangladesh SO INDIAN JOURNAL OF CANCER LA English DT Article DE Bangladesh; global adult tobacco survey; social determinants tobacco use; smokeless tobacco; use tobacco smoking AB Introduction: To examine predictors of current tobacco smoking and smokeless tobacco use among the adult population in Bangladesh. Materials and Methods: We used data from the 2009 Global Adult Tobacco Survey (GATS) in Bangladesh consisting of 9,629 adults aged ?15 years. Differences in and predictors of prevalence for both smoking and smokeless tobacco use were analyzed using selected socioeconomic and demographic characteristics that included gender, age, place of residence, education, occupation, and an index of wealth. Results: The prevalence of smoking is high among males (44.7%, 95% confidence interval [CI]: 42.5-47.0) as compared to females (1.5%, 95% CI: 1.1-2.1), whereas the prevalence of smokeless tobacco is almost similar among both males (26.4%, 95% CI: 24.2-28.6) and females (27.9%, 95% CI: 25.9-30.0). Correlates of current smoking are male gender (odds ratio [OR] = 41.46, CI = 23.8-73.4), and adults in older age (ORs range from 1.99 in 24-35 years age to 5.49 in 55-64 years age), less education (ORs range from 1.47 in less than secondary to 3.25 in no formal education), and lower socioeconomic status (ORs range from 1.56 in high wealth index to 2.48 in lowest wealth index. Predictors of smokeless tobacco use are older age (ORs range from 2.54in 24-35 years age to 12.31 in 55-64 years age), less education (ORs range from 1.44 in less than secondary to 2.70 in no formal education), and the low (OR = 1.34, CI = 1.0-1.7) or lowest (OR = 1.43, CI = 1.1-1.9) socioeconomic status. Conclusion: Implementation of tobacco control strategies needs to bring special attention on disadvantaged group and cover all types of tobacco product as outlined in the WHO Framework Convention on Tobacco Control (FCTC) and WHO MPOWER to protect peoples health and prevent premature death. C1 [Palipudi, K. M.; Asma, S.; Andes, L.] Ctr Dis Control & Prevent, Global Tobacco Control Branch, Off Smoking & Hlth, Atlanta, GA 30333 USA. [Sinha, D. N.] WHO, Surveillance Tobacco Control Tobacco Free Initiat, South East Asia Reg Off, New Delhi, India. [Choudhury, S.] WHO, Dept Epidemiol & Res, Natl Heart Fdn Hosp & Res Inst, Dhaka, Bangladesh. [Zaman, M. M.] WHO, Country Off Bangladesh, Dhaka, Bangladesh. [Dube, S.] Ctr Dis Control & Prevent, Epidemiol Branch, Off Smoking & Hlth, Atlanta, GA USA. RP Palipudi, KM (reprint author), Ctr Dis Control & Prevent, Global Tobacco Control Branch, Off Smoking & Hlth, Atlanta, GA 30333 USA. EM kpalipudi@cdc.gov FU Bloomberg Initiative to Reduce Tobacco Use, a program of Bloomberg Philanthropies FX Funding for GATS was provided by the Bloomberg Initiative to Reduce Tobacco Use, a program of Bloomberg Philanthropies. NR 21 TC 6 Z9 7 U1 0 U2 3 PU INDIAN CANCER SOC PI MUMBAI PA C/O DR D J JUSSAWALLA, EDITOR-IN-CHIEF, 74 JERBAI WADIA RD, PAREL, MUMBAI, 00000, INDIA SN 0019-509X EI 1998-4774 J9 INDIAN J CANCER JI Indian J. Cancer PD OCT-DEC PY 2012 VL 49 IS 4 BP 387 EP 392 DI 10.4103/0019-509X.107745 PG 6 WC Oncology SC Oncology GA V33KT UT WOS:000209018400012 PM 23442403 ER PT J AU Gupta, PC Ray, CS Narake, SS Palipudi, KM Sinha, DN Asma, S Blutcher-Nelson, G AF Gupta, P. C. Ray, C. S. Narake, S. S. Palipudi, K. M. Sinha, D. N. Asma, S. Blutcher-Nelson, G. TI Profile of dual tobacco users in India: An analysis from Global Adult Tobacco Survey, 2009-10 SO INDIAN JOURNAL OF CANCER LA English DT Article DE Cessation; dual; mixed tobacco users; India; initiation; national survey; socio-demographic profile AB Introduction: Individuals who use both smoked and smokeless tobacco products (dual tobacco users) form a special group about which little is known. This group is especially relevant to India, where smokeless tobacco use is very common. The aim of this study was to characterise the profile of dual users, study their pattern of initiation to the second product, their attitudes toward quittingas well as their cessation profile. Methods and Materials: The GATS dataset for India was analyzed using SPSS; . Results: In India, dual tobacco users (42.3 million; 5.3% of all adults; 15.4% of all tobacco users) have a profile similar to that of smokers. Some 52.6% of dual users started both practices within 2 years. The most prevalent product combination was bidi-khaini (1.79%) followed by bidi-gutka (1.50%), cigarette-khaini (1.28%), and cigarette-gutka (1.22%). Among daily users, the correlation between the daily frequencies of the use of each product was very high for most product combinations. While 36.7% of dual users were interested in quitting, only 5.0% of dual users could do so. The prevalence of ex-dual users was 0.4%. Conclusion: Dual users constitute a large, high-risk group that requires special attention. C1 [Gupta, P. C.; Ray, C. S.; Narake, S. S.] Healis Sekhsaria Inst Publ Hlth, Navi Mumbai, Maharashtra, India. [Palipudi, K. M.; Asma, S.; Blutcher-Nelson, G.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Sinha, D. N.] WHO, Reg Off South East Asia, New Delhi, India. RP Ray, CS (reprint author), Healis Sekhsaria Inst Publ Hlth, Navi Mumbai, Maharashtra, India. EM raycs@healis.org FU South-East Asia Regional Office of the World Health Organization FX South-East Asia Regional Office of the World Health Organization. NR 13 TC 9 Z9 9 U1 0 U2 0 PU INDIAN CANCER SOC PI MUMBAI PA C/O DR D J JUSSAWALLA, EDITOR-IN-CHIEF, 74 JERBAI WADIA RD, PAREL, MUMBAI, 00000, INDIA SN 0019-509X EI 1998-4774 J9 INDIAN J CANCER JI Indian J. Cancer PD OCT-DEC PY 2012 VL 49 IS 4 BP 393 EP 400 DI 10.4103/0019-509X.107746 PG 8 WC Oncology SC Oncology GA V33KT UT WOS:000209018400013 PM 23442404 ER PT J AU Surani, NS Pednekar, MS Sinha, DN Singh, G Warren, CW Asma, S Gupta, PC Singh, PK AF Surani, N. S. Pednekar, M. S. Sinha, D. N. Singh, G. Warren, C. W. Asma, S. Gupta, P. C. Singh, P. K. TI Tobacco use and cessation counseling in India-data from the Global Health Professions Students Survey, 2005-09 SO INDIAN JOURNAL OF CANCER LA English DT Article DE Cessation training; health professionals; tobacco use AB Context: Tobacco use by health professionals reflects the failure of healthcare systems in protecting not only beneficiaries of the system but also those involved in health care delivery. Aim: The aim of this study was to report findings from the Global Health Professions Students Survey (GHPSS) conducted in medical, dental, nursing and pharmacy schools in India. Settings and Design: A cross-sectional survey was conducted in Indian dental and medical schools (in 2009), nursing (in 2007), and pharmacy (in 2008) schools. Materials and Methods: Anonymous, self-administered GHPSS questionnaire covering demographics, tobacco use prevalence, secondhand smoke (SHS) exposure, desire to quit smoking and training received to provide cessation counseling to patients was used. Statistical Analysis: Proportions and prevalence were computed using SUDAAN and SPSS 15.0. Results: Current cigarette smoking and other tobacco use ranged from 3.4-13.4% and 4.5-11.6% respectively, in the four health professional schools, with the highest numbers for medical schools and males. Enforcement of smoking ban in medical schools was low (53%) compared to nursing (86.4%), pharmacy (85.5%), and dental (90.8%) schools. Ninety percent students thought health professionals have a role in giving smoking cessation advice to their patients. Three out of five current smokers wanted to quit. However, one out of two reported receiving help/advice to quit. Although all expressed the need, 29.1-54.8% students received cessation training in their schools. Conclusion: Tobacco control policy, cessation training and initiatives to help students quit smoking should be undertaken. C1 [Surani, N. S.; Pednekar, M. S.; Gupta, P. C.] Healis Sekhsaria Inst Publ Hlth, Navi Mumbai, India. [Sinha, D. N.; Singh, P. K.] WHO, Reg Off South East Asia, New Delhi, India. [Singh, G.] Sch Prevent Oncol, Patna, Bihar, India. [Warren, C. W.; Asma, S.] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Pednekar, MS (reprint author), Healis Sekhsaria Inst Publ Hlth, Navi Mumbai, India. EM pednekarm@healis.org NR 13 TC 3 Z9 3 U1 0 U2 1 PU INDIAN CANCER SOC PI MUMBAI PA C/O DR D J JUSSAWALLA, EDITOR-IN-CHIEF, 74 JERBAI WADIA RD, PAREL, MUMBAI, 00000, INDIA SN 0019-509X EI 1998-4774 J9 INDIAN J CANCER JI Indian J. Cancer PD OCT-DEC PY 2012 VL 49 IS 4 BP 425 EP 430 DI 10.4103/0019-509X.107751 PG 6 WC Oncology SC Oncology GA V33KT UT WOS:000209018400017 PM 23442408 ER PT J AU Chew, GL AF Chew, Ginger L. TI Assessment of Environmental Cockroach Allergen Exposure SO CURRENT ALLERGY AND ASTHMA REPORTS LA English DT Review DE Cockroach allergen; Exposure; Bla g 1; Bla g 2; Environment; Housing; Schools; Indoor air; House dust; Allergy; Asthma; Assessment ID INNER-CITY CHILDREN; NEW-YORK-CITY; RISK-FACTORS; PROTEASE ACTIVITY; INDOOR ALLERGENS; ASTHMA MORBIDITY; SUBURBAN HOMES; UNITED-STATES; SENSITIZATION; DUST AB In the past, cockroach allergen exposure assessment mainly focused on settled dust in homes in low-income urban cities in the United States. That choice was not wrong; without measureable levels of cockroach allergen, it is difficult to show associations with any home characteristics, much less with health outcomes (e.g., allergy, asthma). However, recent studies in other suburban areas, schools, and other countries have elucidated the importance of cockroach allergen in these environments too. In addition, characterizing the underlying factors that give rise to cockroach allergen exposure (or protect against it) can lead to more targeted public health interventions. This review discusses different approaches to sampling indoor environments, interprets recent asthma and allergy studies, compares cockroach allergen levels from past studies with those of recent studies, and describes strategies for decreasing exposures. C1 Ctr Dis Control & Prevent CDC, Off Noncommunicable Dis Injury & Environm Hlth, Div Emergency & Environm Hlth Serv, Healthy Homes & Lead Poisoning Prevent Branch, Atlanta, GA 30341 USA. RP Chew, GL (reprint author), Ctr Dis Control & Prevent CDC, Off Noncommunicable Dis Injury & Environm Hlth, Div Emergency & Environm Hlth Serv, Healthy Homes & Lead Poisoning Prevent Branch, 4770 Buford Highway,MS F-60, Atlanta, GA 30341 USA. EM gjc0@cdc.gov FU Intramural CDC HHS [CC999999] NR 48 TC 6 Z9 6 U1 1 U2 9 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1529-7322 J9 CURR ALLERGY ASTHM R JI Curr. Allergy Asthma Rep. PD OCT PY 2012 VL 12 IS 5 BP 456 EP 464 DI 10.1007/s11882-012-0287-y PG 9 WC Allergy; Immunology SC Allergy; Immunology GA 999CG UT WOS:000308286100011 PM 22825884 ER PT J AU Pohl, HR Ruiz, P Scinicariello, F Mumtaz, MM AF Pohl, H. R. Ruiz, P. Scinicariello, F. Mumtaz, M. M. TI Joint toxicity of alkoxyethanol mixtures: Contribution of in silico applications SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE Alkoxyethanols; Alcohol dehydrogenase; Aldehyde dehydrogenase; Mixtures toxicity; QSAR modeling; Genetic variability ID ALDEHYDE DEHYDROGENASES; ALCOHOL-CONSUMPTION; BUTOXYACETIC ACID; DRINKING-WATER; TOLUENE; EXPOSURE; 2-BUTOXYETHANOL; METABOLISM; ETHERS; RATS AB Exposure to chemicals occurs often as mixtures. Presented in this paper is information on alkoxyethanols and the impact they might have on human health in combination with some commonly found aliphatic and aromatic compounds. Our studies to evaluate the joint toxicity of these chemicals among themselves and in combination with other chemicals reveal a variety of possible outcomes depending on the exposure scenario. The interactions are predominantly based on metabolic pathways and are common among several solvents and organic compounds. Quantitative structure activity relationship (QSAR) analysis can be used with high confidence to identify chemicals that will interact to influence overall joint toxicity. Potential human exposure to a combination of alkoxyethanol, toluene and substituted benzenes may increase reproductive and developmental disease conditions. Inheritable gene alterations result in changes in the enzyme function in different subpopulations causing variations in quantity and/or quality of particular isoenzymes. These changes are responsible for differential metabolism of chemicals in species, genders, and life stages and are often the basis of a population's susceptibility. Unique genotypes introduced as a function of migration can alter the genetic makeup of any given population. Hence special consideration should be given to susceptible populations while conducting chemical health risk assessments. Published by Elsevier Inc. C1 [Pohl, H. R.; Ruiz, P.; Scinicariello, F.; Mumtaz, M. M.] US Dept HHS, Agcy Toxic Subst & Dis Registry, Atlanta, GA USA. RP Pohl, HR (reprint author), US Dept HHS, Agcy Toxic Subst & Dis Registry, Atlanta, GA USA. EM hpohl@cdc.gov NR 58 TC 3 Z9 3 U1 2 U2 25 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 EI 1096-0295 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD OCT PY 2012 VL 64 IS 1 BP 134 EP 142 DI 10.1016/j.yrtph.2012.06.008 PG 9 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA 998WF UT WOS:000308270400016 PM 22749914 ER PT J AU Toms, LML Guerra, P Eljarrat, E Barcelo, D Harden, FA Hobson, P Sjodin, A Ryan, E Mueller, JF AF Toms, Leisa-Maree L. Guerra, Paula Eljarrat, Ethel Barcelo, Damia Harden, Fiona A. Hobson, Peter Sjodin, Andreas Ryan, Elizabeth Mueller, Jochen F. TI Brominated flame retardants in the Australian population: 1993-2009 SO CHEMOSPHERE LA English DT Article DE HBCD; Hexabromocyclododecane; PBDEs; Brominated flame retardants; Blood serum; Breast milk ID POLYBROMINATED DIPHENYL ETHERS; HUMAN BREAST-MILK; TETRABROMOBISPHENOL-A; POLYCHLORINATED-BIPHENYLS; EXPOSURE ASSESSMENT; UNITED-STATES; MOTHERS MILK; TIME-TREND; PBDES; HEXABROMOCYCLODODECANE AB Brominated flame retardants, including hexabromocyclododecane (HBCD) and polybrominated diphenyl ethers (PBDEs) are used to reduce the flammability of a multitude of electrical and electronic products, textiles and foams. The use of selected PBDEs has ceased, however, use of decaBDE and HBCD continues. While elevated concentrations of PBDEs in humans have been observed in Australia, no data is available on other BFRs such as HBCD. This study aimed to provide background HBCD concentrations from a representative sample of the Australian population and to assess temporal trends of HBCD and compare with PBDE concentrations over a 16 year period. Samples of human milk collected in Australia from 1993 to 2009, primarily from primiparae mothers were combined into 12 pools from 1993 (2 pools); 2001; 2002/2003 (4 pools); 2003/2004; 2006; 2007/2008 (2 pools); and 2009. Concentrations of Sigma HBCD ranged from not quantified (nq) to 19 ng g(-1) lipid while alpha-HBCD and gamma-HBCD ranged from nq to 10 ng g(-1) lipid and nq to 9.2 ng g(-1) lipid. beta-HBCD was detected in only one sample at 3.6 ng g(-1) lipid while Sigma 4PBDE ranged from 2.5 to 15.8 ng g(-1) lipid. No temporal trend was apparent in HBCD concentrations in human milk collected in Australia from 1993 to 2009. In comparison, PBDE concentrations in human milk show a peak around 2002/03 (mean Sigma 4PBDEs = 9.6 ng g(-1) lipid) and 2003/04 (12.4 ng g(-1) lipid) followed by a decrease in 2007/08 (2.7 ng g(-1) lipid) and 2009 (2.6 ng g(-1) lipid). In human blood serum samples collected from the Australian population, PBDE concentrations did not vary greatly (p = 0.441) from 2002/03 to 2008/09. Continued monitoring including both human milk and serum for HBCD and PBDEs is required to observe trends in human body burden of HBCD and PBDEs body burden following changes to usage. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Toms, Leisa-Maree L.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia. [Ryan, Elizabeth; Mueller, Jochen F.] Univ Queensland, Natl Res Ctr Environm Toxicol Entox, Brisbane, Qld, Australia. [Guerra, Paula; Eljarrat, Ethel; Barcelo, Damia] CSIC, Dept Environm Chem, IDAEA, Barcelona, Spain. [Hobson, Peter] Sullivan Nicolaides Pathol, Brisbane, Qld, Australia. [Sjodin, Andreas] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Toms, LML (reprint author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia. EM leisamaree.toms@qut.edu.au RI Mueller, Jochen/C-6241-2008; Sjodin, Andreas/F-2464-2010; Toms, Leisa-Maree/C-9530-2009; Harden, Fiona/C-2450-2011; OI Toms, Leisa-Maree/0000-0002-1444-1638; Harden, Fiona/0000-0003-4831-2292; ELJARRAT, ETHEL/0000-0002-0814-6579; Mueller, Jochen/0000-0002-0000-1973 FU Queensland Health; Department of Sustainability, Environment, Water, Population and Communities FX The authors would like to thank: all of the mothers and babies who donated or attempted to donate their precious time and milk samples for this study; all of the local coordinators who assisted in the recruitment of participants and the subsequent collection and return of samples: all laboratory staff at Sullivan Nicolaides Pathology and the CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The National Research Centre for Environmental Toxicology is co-funded by Queensland Health. This study was partly funded by the Department of Sustainability, Environment, Water, Population and Communities. NR 53 TC 25 Z9 27 U1 4 U2 72 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 J9 CHEMOSPHERE JI Chemosphere PD OCT PY 2012 VL 89 IS 4 BP 398 EP 403 DI 10.1016/j.chemosphere.2012.05.053 PG 6 WC Environmental Sciences SC Environmental Sciences & Ecology GA 990JE UT WOS:000307626000006 PM 22748388 ER PT J AU Masciotra, S Khamadi, S Bile, E Puren, A Fonjungo, P Nguyen, S Girma, M Downing, R Ramos, A Subbarao, S Ellenberger, D AF Masciotra, Silvina Khamadi, Samoel Bile, Ebi Puren, Adrian Fonjungo, Peter Nguyen, Shon Girma, Mulu Downing, Robert Ramos, Artur Subbarao, Shambavi Ellenberger, Dennis TI Evaluation of blood collection filter papers for HIV-1 DNA PCR SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE HIV-1; DNA; DBS; Blood collection papers; PCR; Early diagnosis ID HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 DRUG-RESISTANCE; RESOURCE-LIMITED SETTINGS; POLYMERASE-CHAIN-REACTION; DRIED SERUM SPOTS; SUBTYPE-B DNA; WHOLE-BLOOD; RURAL TANZANIA; DIAGNOSIS; INFANTS AB Background: The collection of dried blood spots (DBS) on Whatman 903 cards has facilitated for years the detection of HIV-1 in infants by DNA PCR as early as 4-6 weeks after birth in resource-limited settings (RLS), but alternate blood collection devices are proving to be necessary. Objectives: The qualitative detection of HIV-1 DNA by PCR from DBS prepared on three commercially available blood collection cards was evaluated at the Centers for Disease Control and Prevention (CDC) and in four laboratories in Africa. Study design: DBS were prepared on Ahlstrom grade 226, Munktell TFN and Whatman 903, and stored under a variety of conditions. DBS were stored at ambient temperature (RT), 37 degrees C with high humidity, and -20 degrees C for varying lengths of time. The presence of HIV-1 DNA was tested using Roche Amplicor HIV-1 DNA (v 1.5) weekly for 4 weeks and at weeks 8 and 12 (RT and 37 degrees C), at weeks 4, 8, and 18 (-20 degrees C) of storage. DBS specimens were also tested after international shipment at RT. In addition, after nearly 3 years storage at -20 degrees C, DBS were also evaluated independently using the COBAS Ampliprep/TaqMan HIV-1 Qual and Abbott RealTime HIV-1 Qualitative tests. Results: HIV-1 DNA was detected equally well on the three blood collection cards regardless of storage conditions and PCR assay. Conclusions: Ahlstrom 226 and Munktell TFN papers were comparable to Whatman 903 for HIV-1 DNA detection and may be considered as optional blood collection devices in resource-limited countries. Published by Elsevier B.V. C1 [Ellenberger, Dennis] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Int Lab Branch, Atlanta, GA 30333 USA. [Khamadi, Samoel] Kenya Govt Med Res Ctr, Ctr Virus Res Inst, Nairobi, Kenya. [Bile, Ebi] CDC BOTUSA, Global AIDS Program Ethiopia, Gaborone, Botswana. [Fonjungo, Peter] US Ctr Dis Control, Global AIDS Program Ethiopia, Addis Ababa, Ethiopia. [Girma, Mulu] EHNRI, Natl HIV Lab, Addis Ababa, Ethiopia. [Downing, Robert] US Ctr Dis Control & Prevent, Global AIDS Program Uganda, Entebbe, Uganda. RP Ellenberger, D (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Int Lab Branch, 1600 Clifton Rd,MS G-19, Atlanta, GA 30333 USA. EM dellenberger@cdc.gov FU U.S. President's Emergency Plan for AISD Relief (PEPFAR) FX This study was supported by the U.S. President's Emergency Plan for AISD Relief (PEPFAR). NR 43 TC 8 Z9 8 U1 2 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD OCT PY 2012 VL 55 IS 2 BP 101 EP 106 DI 10.1016/j.jcv.2012.06.010 PG 6 WC Virology SC Virology GA 995HC UT WOS:000307997800003 PM 22776163 ER EF